0001171843-23-001729.txt : 20230316 0001171843-23-001729.hdr.sgml : 20230316 20230316153756 ACCESSION NUMBER: 0001171843-23-001729 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 101 CONFORMED PERIOD OF REPORT: 20221231 FILED AS OF DATE: 20230316 DATE AS OF CHANGE: 20230316 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Anika Therapeutics, Inc. CENTRAL INDEX KEY: 0000898437 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 043145961 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-14027 FILM NUMBER: 23738582 BUSINESS ADDRESS: STREET 1: 32 WIGGINS AVENUE CITY: BEDFORD STATE: MA ZIP: 01730 BUSINESS PHONE: (781) 457-9000 MAIL ADDRESS: STREET 1: 32 WIGGINS AVENUE CITY: BEDFORD STATE: MA ZIP: 01730 FORMER COMPANY: FORMER CONFORMED NAME: ANIKA THERAPEUTICS INC DATE OF NAME CHANGE: 19970114 FORMER COMPANY: FORMER CONFORMED NAME: ANIKA RESEARCH INC DATE OF NAME CHANGE: 19930309 10-K 1 anik20221231_10k.htm FORM 10-K anik20221231_10k.htm
0000898437 Anika Therapeutics, Inc. false --12-31 FY 2022 0.01 0.01 1,250 1,250 0 0 0 0 0.01 0.01 90,000 90,000 14,625 14,625 14,441 14,441 0 0 5 16 1 0 0 0 0 5 0 0 1 4 10 0.5 3 4 10 1.28 4.28 0.29 1.00 0.21 1.59 0.0 0.0 3 4 3 0 0 2019 2020 2021 2022 00008984372022-01-012022-12-31 iso4217:USD 00008984372022-06-30 xbrli:shares 00008984372023-03-08 thunderdome:item 00008984372022-12-31 00008984372021-12-31 iso4217:USDxbrli:shares 00008984372021-01-012021-12-31 00008984372020-01-012020-12-31 0000898437us-gaap:CommonStockMember2019-12-31 0000898437us-gaap:AdditionalPaidInCapitalMember2019-12-31 0000898437us-gaap:RetainedEarningsMember2019-12-31 0000898437us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-31 00008984372019-12-31 0000898437us-gaap:CommonStockMember2020-01-012020-12-31 0000898437us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-31 0000898437us-gaap:RetainedEarningsMember2020-01-012020-12-31 0000898437us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-31 0000898437us-gaap:RestrictedStockUnitsRSUMemberus-gaap:CommonStockMember2020-01-012020-12-31 0000898437us-gaap:RestrictedStockUnitsRSUMemberus-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-31 0000898437us-gaap:RestrictedStockUnitsRSUMemberus-gaap:RetainedEarningsMember2020-01-012020-12-31 0000898437us-gaap:RestrictedStockUnitsRSUMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-12-31 0000898437us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-12-31 0000898437us-gaap:CommonStockMember2020-12-31 0000898437us-gaap:AdditionalPaidInCapitalMember2020-12-31 0000898437us-gaap:RetainedEarningsMember2020-12-31 0000898437us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-31 00008984372020-12-31 0000898437us-gaap:CommonStockMember2021-01-012021-12-31 0000898437us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-31 0000898437us-gaap:RetainedEarningsMember2021-01-012021-12-31 0000898437us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-31 0000898437us-gaap:CommonStockMember2021-12-31 0000898437us-gaap:AdditionalPaidInCapitalMember2021-12-31 0000898437us-gaap:RetainedEarningsMember2021-12-31 0000898437us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-31 0000898437us-gaap:CommonStockMember2022-01-012022-12-31 0000898437us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-31 0000898437us-gaap:RetainedEarningsMember2022-01-012022-12-31 0000898437us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-31 0000898437us-gaap:CommonStockMember2022-12-31 0000898437us-gaap:AdditionalPaidInCapitalMember2022-12-31 0000898437us-gaap:RetainedEarningsMember2022-12-31 0000898437us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-31 0000898437us-gaap:AccountingStandardsUpdate201602Member2022-01-012022-12-31 0000898437us-gaap:AccountingStandardsUpdate201602Member2021-01-012021-12-31 0000898437us-gaap:AccountingStandardsUpdate201602Member2020-01-012020-12-31 xbrli:pure 0000898437us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberanik:DepuyMitekIncMember2022-01-012022-12-31 0000898437us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberanik:DepuyMitekIncMember2021-01-012021-12-31 0000898437us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberanik:DepuyMitekIncMember2020-01-012020-12-31 0000898437us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberanik:DepuyMitekIncMember2022-01-012022-12-31 0000898437us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberanik:DepuyMitekIncMember2021-01-012021-12-31 utr:Y 0000898437anik:ComputerEquipmentAndSoftwareMembersrt:MinimumMember2022-01-012022-12-31 0000898437anik:ComputerEquipmentAndSoftwareMembersrt:MaximumMember2022-01-012022-12-31 0000898437us-gaap:FurnitureAndFixturesMembersrt:MinimumMember2022-01-012022-12-31 0000898437us-gaap:FurnitureAndFixturesMembersrt:MaximumMember2022-01-012022-12-31 0000898437us-gaap:EquipmentMembersrt:MinimumMember2022-01-012022-12-31 0000898437us-gaap:EquipmentMembersrt:MaximumMember2022-01-012022-12-31 00008984372022-01-012022-11-30 0000898437srt:MinimumMember2022-01-012022-12-31 0000898437srt:MaximumMember2022-01-012022-12-31 0000898437anik:ParcusMedicalMember2020-01-242020-01-24 0000898437anik:ParcusMedicalMember2021-09-30 0000898437anik:ParcusMedicalMember2020-01-012020-03-31 0000898437anik:ParcusMedicalMember2020-01-24 0000898437anik:ParcusMedicalMemberus-gaap:DevelopedTechnologyRightsMember2020-01-24 0000898437anik:ParcusMedicalMemberus-gaap:TradeNamesMember2020-01-24 0000898437anik:ParcusMedicalMemberus-gaap:CustomerRelationshipsMember2020-01-24 0000898437anik:ParcusMedicalMemberus-gaap:DevelopedTechnologyRightsMember2020-01-242020-01-24 0000898437anik:ParcusMedicalMemberus-gaap:CustomerRelationshipsMember2020-01-242020-01-24 0000898437anik:ParcusMedicalMemberus-gaap:TradeNamesMember2020-01-242020-01-24 0000898437anik:ArthrosurfaceMember2020-02-032020-02-03 0000898437anik:ArthrosurfaceMember2020-10-012020-10-31 0000898437anik:ArthrosurfaceMember2021-07-012021-07-31 0000898437anik:ArthrosurfaceMember2020-01-012020-03-31 0000898437anik:ArthrosurfaceMember2020-02-03 0000898437anik:ArthrosurfaceMemberus-gaap:DevelopedTechnologyRightsMember2020-02-03 0000898437anik:ArthrosurfaceMemberus-gaap:TradeNamesMember2020-02-03 0000898437anik:ArthrosurfaceMemberus-gaap:CustomerRelationshipsMember2020-02-03 0000898437anik:ArthrosurfaceMemberus-gaap:InProcessResearchAndDevelopmentMember2020-02-03 0000898437anik:ArthrosurfaceMemberus-gaap:DevelopedTechnologyRightsMember2020-02-032020-02-03 0000898437anik:ArthrosurfaceMemberus-gaap:CustomerRelationshipsMember2020-02-032020-02-03 0000898437anik:ArthrosurfaceMemberus-gaap:TradeNamesMember2020-02-032020-02-03 0000898437anik:ArthrosurfaceMemberus-gaap:InProcessResearchAndDevelopmentMember2022-12-31 0000898437us-gaap:MoneyMarketFundsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-31 0000898437us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-31 0000898437us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-31 0000898437us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-31 0000898437us-gaap:MoneyMarketFundsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-31 0000898437us-gaap:MoneyMarketFundsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-31 0000898437us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-31 0000898437us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-31 0000898437us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-31 0000898437us-gaap:MoneyMarketFundsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-12-31 0000898437us-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-31 0000898437us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-31 0000898437us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-31 0000898437us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2021-12-31 0000898437us-gaap:CarryingReportedAmountFairValueDisclosureMember2021-12-31 0000898437anik:ContingentConsiderationMember2021-12-31 0000898437anik:ContingentConsiderationMember2020-12-31 0000898437anik:ContingentConsiderationMember2022-01-012022-12-31 0000898437anik:ContingentConsiderationMember2021-01-012021-12-31 0000898437anik:ContingentConsiderationMember2022-12-31 0000898437anik:ParcusMedicalAndArthrosurfaceAcquisitionsMember2022-01-012022-12-31 0000898437anik:ParcusMedicalAndArthrosurfaceAcquisitionsMemberus-gaap:MeasurementInputDiscountRateMembersrt:MinimumMember2022-12-31 0000898437anik:ParcusMedicalAndArthrosurfaceAcquisitionsMemberus-gaap:MeasurementInputDiscountRateMembersrt:MaximumMember2022-12-31 0000898437anik:ParcusMedicalMemberanik:MeasurementInputWeightedAverageCostOfCapitalMember2020-12-31 0000898437anik:ParcusMedicalMemberanik:MeasurementInputWeightedAverageCostOfCapitalMember2021-12-31 0000898437anik:ArthrosurfaceMemberanik:MeasurementInputWeightedAverageCostOfCapitalMember2020-12-31 0000898437anik:ParcusMedicalMember2021-12-31 0000898437anik:ArthrosurfaceMember2021-06-012021-06-30 0000898437anik:ArthrosurfaceMember2021-01-012021-12-31 0000898437anik:ArthrosurfaceMember2020-01-012020-12-31 0000898437anik:EquipmentAndSoftwareMember2022-12-31 0000898437anik:EquipmentAndSoftwareMember2021-12-31 0000898437us-gaap:FurnitureAndFixturesMember2022-12-31 0000898437us-gaap:FurnitureAndFixturesMember2021-12-31 0000898437us-gaap:LeaseholdImprovementsMember2022-12-31 0000898437us-gaap:LeaseholdImprovementsMember2021-12-31 0000898437us-gaap:ConstructionInProgressMember2022-12-31 0000898437us-gaap:ConstructionInProgressMember2021-12-31 0000898437us-gaap:DevelopedTechnologyRightsMember2022-12-31 0000898437us-gaap:DevelopedTechnologyRightsMember2022-01-012022-12-31 0000898437us-gaap:InProcessResearchAndDevelopmentMember2022-12-31 0000898437us-gaap:InProcessResearchAndDevelopmentMember2022-01-012022-12-31 0000898437us-gaap:CustomerRelationshipsMember2022-12-31 0000898437us-gaap:CustomerRelationshipsMember2022-01-012022-12-31 0000898437us-gaap:DistributionRightsMember2022-12-31 0000898437us-gaap:DistributionRightsMember2022-01-012022-12-31 0000898437us-gaap:PatentsMember2022-12-31 0000898437us-gaap:PatentsMember2022-01-012022-12-31 0000898437us-gaap:TradeNamesMember2022-12-31 0000898437us-gaap:TradeNamesMember2022-01-012022-12-31 0000898437us-gaap:DevelopedTechnologyRightsMember2021-12-31 0000898437us-gaap:DevelopedTechnologyRightsMember2021-01-012021-12-31 0000898437us-gaap:InProcessResearchAndDevelopmentMember2021-12-31 0000898437us-gaap:InProcessResearchAndDevelopmentMember2021-01-012021-12-31 0000898437us-gaap:CustomerRelationshipsMember2021-12-31 0000898437us-gaap:CustomerRelationshipsMember2021-01-012021-12-31 0000898437us-gaap:DistributionRightsMember2021-12-31 0000898437us-gaap:DistributionRightsMember2021-01-012021-12-31 0000898437us-gaap:PatentsMember2021-12-31 0000898437us-gaap:PatentsMember2021-01-012021-12-31 0000898437us-gaap:TradeNamesMember2021-12-31 0000898437us-gaap:TradeNamesMember2021-01-012021-12-31 0000898437anik:AcquisitionsOfParcusMedicalAndArthrosurfaceMemberus-gaap:ResearchAndDevelopmentExpenseMember2021-10-012021-12-31 0000898437anik:ParcusMedicalAndArthrosurfaceMemberus-gaap:ResearchAndDevelopmentExpenseMember2020-10-012020-12-31 0000898437us-gaap:DevelopedTechnologyRightsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-12-31 0000898437anik:ParcusMedicalAndArthrosurfaceMember2022-01-012022-12-31 0000898437anik:LegacyAnikaReportingUnitMember2021-01-012021-11-30 0000898437anik:LegacyAnikaReportingUnitMember2020-01-012020-03-31 0000898437anik:LegacyAnikaReportingUnitMember2020-01-012020-12-31 0000898437anik:ParcusMedicalAndArthrosurfaceMember2020-01-012020-03-31 0000898437anik:ParcusMedicalAndArthrosurfaceMember2020-10-012020-12-31 0000898437anik:ParcusMedicalAndArthrosurfaceMember2020-01-012020-12-31 0000898437anik:ParcusMedicalAndArthrosurfaceMember2020-12-31 0000898437anik:LiabilitiesMember2022-12-31 0000898437anik:AccruedExpensesAndOtherCurrentLiabilitiesMember2022-12-31 0000898437anik:AccruedExpensesAndOtherCurrentLiabilitiesMember2021-12-31 0000898437us-gaap:RevolvingCreditFacilityMember2021-11-12 0000898437us-gaap:RevolvingCreditFacilityMembersrt:MinimumMember2021-11-122021-11-12 0000898437us-gaap:RevolvingCreditFacilityMembersrt:MaximumMember2021-11-122021-11-12 0000898437us-gaap:RevolvingCreditFacilityMember2021-11-122021-11-12 0000898437us-gaap:RevolvingCreditFacilityMember2022-12-31 0000898437us-gaap:RevolvingCreditFacilityMember2021-12-31 0000898437us-gaap:RevolvingCreditFacilityMember2020-04-082020-04-08 0000898437us-gaap:RevolvingCreditFacilityMember2020-04-08 0000898437us-gaap:RevolvingCreditFacilityMember2022-01-012022-12-31 0000898437us-gaap:RevolvingCreditFacilityMember2021-01-012021-12-31 0000898437us-gaap:RevolvingCreditFacilityMember2020-01-012020-12-31 0000898437anik:OAPainManagementMember2022-01-012022-12-31 0000898437anik:OAPainManagementMember2021-01-012021-12-31 0000898437anik:OAPainManagementMember2020-01-012020-12-31 0000898437anik:JointPreservationAndRestorationMember2022-01-012022-12-31 0000898437anik:JointPreservationAndRestorationMember2021-01-012021-12-31 0000898437anik:JointPreservationAndRestorationMember2020-01-012020-12-31 0000898437anik:NonorthopedicMember2022-01-012022-12-31 0000898437anik:NonorthopedicMember2021-01-012021-12-31 0000898437anik:NonorthopedicMember2020-01-012020-12-31 0000898437anik:VeterinaryMemberanik:OAPainManagementMember2022-01-012022-12-31 0000898437anik:VeterinaryMemberanik:OAPainManagementMember2021-01-012021-12-31 0000898437anik:VeterinaryMemberanik:OAPainManagementMember2020-01-012020-12-31 0000898437country:US2022-01-012022-12-31 0000898437country:US2021-01-012021-12-31 0000898437country:US2020-01-012020-12-31 0000898437srt:EuropeMember2022-01-012022-12-31 0000898437srt:EuropeMember2021-01-012021-12-31 0000898437srt:EuropeMember2020-01-012020-12-31 0000898437anik:OtherLocationMember2022-01-012022-12-31 0000898437anik:OtherLocationMember2021-01-012021-12-31 0000898437anik:OtherLocationMember2020-01-012020-12-31 0000898437country:US2022-12-31 0000898437country:US2021-12-31 0000898437country:IT2022-12-31 0000898437country:IT2021-12-31 0000898437anik:The2017PlanMember2017-06-13 0000898437anik:The2017PlanMember2022-12-31 0000898437anik:The2021InducementPlanMember2021-11-04 0000898437anik:The2021InducementPlanMember2022-12-31 0000898437anik:The2017PlanMembersrt:MinimumMember2022-01-012022-12-31 0000898437anik:The2017PlanMembersrt:MaximumMember2022-01-012022-12-31 0000898437anik:The2017PlanMember2022-01-012022-12-31 0000898437us-gaap:CostOfSalesMember2022-01-012022-12-31 0000898437us-gaap:CostOfSalesMember2021-01-012021-12-31 0000898437us-gaap:CostOfSalesMember2020-01-012020-12-31 0000898437us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-12-31 0000898437us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-12-31 0000898437us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-12-31 0000898437us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-12-31 0000898437us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-12-31 0000898437us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-12-31 0000898437us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-03-31 0000898437anik:PremiumPricedEmployeeStockOptionsMember2022-01-012022-12-31 0000898437us-gaap:EmployeeStockOptionMembersrt:MinimumMember2022-01-012022-12-31 0000898437us-gaap:EmployeeStockOptionMembersrt:MaximumMember2022-01-012022-12-31 0000898437us-gaap:EmployeeStockOptionMember2022-01-012022-12-31 0000898437anik:TotalShareholderReturnTsrsOptionsMember2022-01-012022-12-31 0000898437anik:TotalShareholderReturnTsrsOptionsMembersrt:MinimumMember2022-01-012022-12-31 0000898437anik:TotalShareholderReturnTsrsOptionsMembersrt:MaximumMember2022-01-012022-12-31 0000898437anik:TotalShareholderReturnTsrsOptionsMember2022-12-31 0000898437srt:MinimumMember2021-01-012021-12-31 0000898437srt:MaximumMember2021-01-012021-12-31 0000898437srt:MinimumMember2020-01-012020-12-31 0000898437srt:MaximumMember2020-01-012020-12-31 0000898437us-gaap:EmployeeStockOptionMember2022-12-31 0000898437us-gaap:RestrictedStockUnitsRSUMembersrt:MinimumMember2022-01-012022-12-31 0000898437us-gaap:RestrictedStockUnitsRSUMembersrt:MaximumMember2022-01-012022-12-31 0000898437us-gaap:RestrictedStockUnitsRSUMember2021-12-31 0000898437us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-31 0000898437us-gaap:RestrictedStockUnitsRSUMember2022-12-31 0000898437us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-31 0000898437us-gaap:PerformanceSharesMembersrt:MinimumMember2022-01-012022-12-31 0000898437anik:GrantedIn2019Memberus-gaap:PerformanceSharesMember2019-12-31 0000898437anik:GrantedIn2019Memberus-gaap:PerformanceSharesMember2022-12-31 0000898437anik:GrantedIn2020Memberus-gaap:PerformanceSharesMember2021-12-31 0000898437anik:GrantedIn2020Memberus-gaap:PerformanceSharesMember2022-12-31 0000898437us-gaap:PerformanceSharesMember2021-12-31 0000898437us-gaap:PerformanceSharesMember2022-01-012022-12-31 0000898437us-gaap:PerformanceSharesMember2022-12-31 0000898437us-gaap:PerformanceSharesMember2021-01-012021-12-31 0000898437us-gaap:PerformanceSharesMember2020-01-012020-12-31 0000898437anik:EmployeeStockPurchasePlanESPPMember2021-03-17 0000898437us-gaap:DomesticCountryMemberus-gaap:InternalRevenueServiceIRSMember2022-12-31 0000898437us-gaap:StateAndLocalJurisdictionMember2022-12-31 0000898437us-gaap:ForeignCountryMemberus-gaap:MinistryOfEconomicAffairsAndFinanceItalyMember2022-12-31 0000898437us-gaap:DomesticCountryMemberus-gaap:InternalRevenueServiceIRSMemberus-gaap:ResearchMember2022-12-31 0000898437us-gaap:StateAndLocalJurisdictionMemberus-gaap:ResearchMember2022-12-31 0000898437us-gaap:InProcessResearchAndDevelopmentMemberus-gaap:DomesticCountryMember2022-01-012022-12-31 0000898437us-gaap:InProcessResearchAndDevelopmentMemberus-gaap:ForeignCountryMember2022-01-012022-12-31 0000898437us-gaap:ForeignCountryMemberus-gaap:MinistryOfEconomicAffairsAndFinanceItalyMember2022-01-012022-12-31 0000898437us-gaap:ForeignCountryMember2022-12-31
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 10-K

 

(Mark One)

 

☒

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2022

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                          to                  

 

Commission File Number 001-14027

 

Anika Therapeutics, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

(State or Other Jurisdiction of Incorporation or Organization)

04-3145961

(IRS Employer Identification No.)

 

32 Wiggins Avenue, Bedford, Massachusetts 01730

(Address of Principal Executive Offices) (Zip Code)

 

(781) 457-9000

(Registrant’s Telephone Number, Including Area Code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

Trading Symbol

Name of Each Exchange on Which Registered

Common Stock, par value $0.01 per share

ANIK

NASDAQ Global Select Market

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒  No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐

Accelerated filer ☒

Non-accelerated filer ☐

Smaller reporting company ☐

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 
 

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

The aggregate market value of voting common stock held by non-affiliates of the registrant as of June 30, 2022, the last day of the registrant’s most recently completed second fiscal quarter, was $321,805,229 computed by reference to the closing price of common stock on such date. The registrant does not have any non-voting stock outstanding.

 

At March 8, 2023, there were 14,632,910 shares of the registrant’s common stock outstanding.

 

 

Documents Incorporated By Reference

 

Portions of the registrant’s proxy statement for its 2023 annual meeting of stockholders are incorporated by reference in Part III of this Annual Report on Form 10-K.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
 

 

 

ANIKA THERAPEUTICS, INC.

TABLE OF CONTENTS

 

     

Page
       
   

Cautionary Note Regarding Forward-Looking Statements

 4

Part I

    
 

Item 1.

Business

 7
 

Item 1A.

Risk Factors

 22
 

Item 2.

Properties

 39
 

Item 3.

Legal Proceedings

 39

 

Item 4.

Mine Safety Disclosures

 39

Part II

    
 

Item 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 40
 

Item 6.

[Reserved]

 41
 

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 41
 

Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

 56
 

Item 8.

Financial Statements and Supplementary Data

 57
 

Item 9.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosures

 89
 

Item 9A.

Controls and Procedures

 89
 

Item 9B.

Other information 

 93
 

Item 9C.

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

 93

Part III

    
 

Item 10.

Directors, Executive Officers and Corporate Governance

 94
 

Item 11.

Executive Compensation

 94
 

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 94
 

Item 13.

Certain Relationships and Related Transactions, and Director Independence

 94
 

Item 14.

Principal Accountant Fees and Services

 94

Part IV

    
 

Item 15.

Exhibits and Financial Statement Schedules

 95
 

Item 16.

Form 10-K Summary

 97

Signatures

 98
 

 

References in this Annual Report on Form 10-K to “we,” “us,” “our,” “our company,” and other similar references refer to Anika Therapeutics, Inc. and its subsidiaries unless the context otherwise indicates.

 

ANIKA, ANIKA THERAPEUTICS, ANIKAVISC, ARTHROSURFACE, CINGAL, HYAFF, HYVISC, MONOVISC, ORTHOVISC, OVOMOTION, PARCUS MEDICAL, REVOMOTION, TACTOSET, WRISTMOTION, and X-TWIST are trademarks or registered trademarks of Anika Therapeutics, Inc. or its subsidiaries that appear in this Annual Report on Form 10-K. For convenience, these trademarks appear in this Annual Report on Form 10-K without ® and ™ symbols, but that practice does not mean that we will not assert, to the fullest extent under applicable law, our rights to the trademarks. This Annual Report on Form 10-K may also contain trademarks and trade names that are the property of other companies, including certain trademarks licensed to us. The use of third-party trademarks does not constitute an endorsement or imply a relationship or other affiliation.

 

 
 

 

FORM 10-K

ANIKA THERAPEUTICS, INC.

For Fiscal Year Ended December 31, 2022

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This Annual Report on Form 10-K contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 concerning our business, consolidated financial condition, and results of operations. The Securities and Exchange Commission, or SEC, encourages companies to disclose forward-looking statements so that investors can better understand a company’s future prospects and make informed investment decisions. Forward-looking statements are subject to risks and uncertainties, many of which are outside our control, which could cause actual results to differ materially from these statements. Therefore, you should not rely on any of these forward-looking statements. Forward-looking statements can be identified by such words as "will," "likely," "may," "believe," "expect," "anticipate," "intend," "seek," "designed," "develop," "would," "future," "can," "could," and other expressions that are predictions of or indicate future events and trends and that do not relate to historical matters. All statements other than statements of historical facts included in this Annual Report regarding our strategies, prospects, financial condition, operations, costs, plans, and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements regarding expected future operating results, expectations regarding the timing and receipt of regulatory results, anticipated levels of capital expenditures, and expectations of the effect on our financial condition of claims, litigation, and governmental and regulatory proceedings.

 

Please refer to "Item 1A. Risk Factors" for important factors that we believe could cause actual results to differ materially from those in our forward-looking statements. Any forward-looking statement made by us in this Annual Report on Form 10-K is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise.

 

 

 

 

 

 

 

 

 

 

 

 

4
 

 

RISK FACTOR SUMMARY

 

The risk factors detailed in Item 1A entitled “Risk Factors” in this Annual Report on Form 10-K are the risks that we believe are material to our investors and a reader should carefully consider them. Those risks are not all of the risks we face and other factors not presently known to us or that we currently believe are immaterial may also affect our business if they occur. The following is a summary of the risk factors detailed in Item 1A:

 

 

●

Our financial performance depends on sales growth and increasing demand for our legacy and acquired product portfolios, and we may not be able to successfully manage the recent, and future, expansion of our operations.
 

●

Substantial competition could materially affect our financial performance.
 

●

Our business may be adversely affected if consolidation in the healthcare industry leads to demand for price concessions or if we are excluded from being a supplier by a group purchasing organization or similar entity.
 

●

A significant portion of our OA Pain Management revenues are derived from a small number of customers, the loss of which could materially adversely affect our business, financial condition and results of operations.
 

●

We experience quarterly sales volume variation, which makes our future results difficult to predict and makes period-to-period comparisons potentially not meaningful.
 

●

We rely on a small number of suppliers for certain key raw materials and a small number of suppliers for a number of other materials required for the manufacturing and delivery of our products, and disruption could materially adversely affect our business, financial condition, and results of operations.
 

●

Our manufacturing processes involve inherent risks, and disruption could materially adversely affect our business, financial condition, and results of operations.
 

●

Failure to comply with current or future national, international, federal or state laws and regulations, regulatory guidance and industry standards relating to data protection, privacy and information security, including restrictive European regulations, could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business.
 

●

We are increasingly dependent on sophisticated information technology and if we fail to effectively maintain or protect our information systems or data, including from data breaches, our business could be adversely affected.
 

●

We may require additional capital in the future. We cannot give any assurance that such capital will be available at all or on terms acceptable to us, and if it is available, additional capital raised by us could dilute your ownership interest or the value of your shares.
 

●

Our license agreements with Mitek provide substantial control of Monovisc and Orthovisc in the United States to Mitek, and Mitek’s actions could have a material impact on our business, financial condition and results of operations.
 

●

We may not succeed in our integration and buildout of our direct sales channel in the United States, and our failure to do so could negatively impact our business and financial results.
 

●

We are dependent upon marketing and distribution partners and the failure to maintain strategic alliances on acceptable terms will have a material adverse effect on our business, financial condition, and results of operations.
 

●

Sales of our products are largely dependent upon third-party health insurance coverage and reimbursement and our performance may be harmed by health care cost containment initiatives or decisions of individual third-party payers.
 

●

We are facing a longer than expected pathway to commercialize our Cingal product in the United States, and we may face other unforeseen difficulties in achieving regulatory approval for Cingal, which could affect our business and financial results.
 

●

Failure to obtain, or any delay in obtaining, FDA or other U.S. and foreign governmental clearances or approvals for our products may have a material adverse effect on our business, financial condition and results of operations.
 

●

Once obtained, we cannot guarantee that the FDA or international product clearances or approvals will not be withdrawn or that relevant agencies will not require other corrective action, and any withdrawal or corrective action could materially affect our business and financial results.
 

●

Our operations and products are subject to extensive regulation, compliance with which is costly and time consuming, and our failure to comply may result in substantial penalties, including recalls of our products.
 

●

Any changes in the FDA or international regulations related to product approval or approval renewal, including those currently under consideration by the FDA or those that apply retroactively, could adversely affect our competitive position and materially affect our business and financial results.
 

●

Notices of inspectional observations or deficiencies from the FDA or other regulatory bodies require us to undertake corrective and preventive actions or other actions to address the FDA’s or other regulatory bodies' concerns. These actions could be expensive and time-consuming to complete and could impose an additional burden on us.
 

●

We may rely on third parties to support certain aspects of our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory clearance or approval or commercialize our products, and our business could be substantially harmed.
 

●

We may have difficulty managing our growth.
 

●

We may not generate the expected benefits of our acquisitions, and the ongoing integration of those acquisitions could disrupt our ongoing business, distract our management and increase our expenses.

 

5
 

 

 

●

We expect to continue to actively explore inorganic growth as a part of our future growth strategy, which exposes us to a variety of risks that could adversely affect our business operations.
 

●

As our international sales and operations grow, we could become increasingly subject to additional economic, political, and other risks that could harm our business.
 

●

We may be unable to adequately protect our intellectual property rights, which could have a material impact on our business and future financial results.
 

●

Our operations are located in areas impacted by the COVID-19 pandemic, and those operations have been, and may continue to be, adversely affected by the COVID-19 pandemic.
 

●

The COVID-19 pandemic resulted in a significant reduction in the number of elective surgeries being performed since 2020 and the lingering impact of the pandemic has slowed the pace of new product approvals by current and potential customers, which has decreased the usage of, and revenue from, certain of our products.
 

●

Our stock price may be highly volatile, and we cannot assure you that market making in our common stock will continue.
 

●

Our charter documents contain anti-takeover provisions that may prevent or delay an acquisition of our company.
 

●

We have been, and may continue to be, subject to the actions of activist stockholders, which could cause us to incur substantial costs, divert management’s and the board’s attention and resources, and have an adverse effect on our business and stock price.

 

This section contains forward-looking statements. You should refer to the explanation of the qualifications and limitations on forward-looking statements beginning on page 4.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

6
 

 

PART I

 

ITEM 1. BUSINESS

 

Overview

 

Founded in 1992, Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Based on our collaborations with clinicians to understand what they need most to treat their patients, we develop minimally invasive products that restore active living for people around the world. We are committed to leading in high opportunity spaces within orthopedics, including osteoarthritis, or OA pain management, regenerative solutions, sports medicine and Arthrosurface joint solutions (previously Bone Preserving Joint Solutions).

 

We have over thirty years of global expertise developing, manufacturing and commercializing products based on our hyaluronic acid, or HA, technology platform. HA is a naturally occurring polymer found throughout the body that is vital for proper joint health and tissue function. Our proprietary technologies for modifying the HA molecule allow product properties to be tailored specifically to multiple uses, including enabling longer residence time to support OA pain management and creating a solid form of HA called Hyaff, which is the platform for some of our regenerative solutions portfolio.

 

In early 2020, we expanded our overall technology platform, product portfolio, and significantly expanded our commercial infrastructure, especially in the United States, through our strategic acquisitions of Parcus Medical, LLC, or Parcus Medical, a sports medicine and instrumentation solutions provider, and Arthrosurface, Inc., or Arthrosurface, a company specializing in bone preserving partial and total joint replacement solutions. These acquisitions have ignited the transformation of our company by augmenting our HA-based OA pain management and regenerative products with a broad suite of products and capabilities focused on early intervention joint preservation primarily in upper and lower extremities such as shoulder, foot/ankle, knee and hand/wrist.

 

overview.jpg

Note: Illustration of available treatments does not reflect Anika’s full product portfolio

 

7
 

 

Strategy

 

Beginning in 2020, we launched our transformational strategy to diversify our revenue in the global joint preservation markets, expanding our addressable global market from the over $1 billion global OA pain management market to the over $8 billion global joint preservation market (which includes faster growing regenerative medicine, sports medicine and extremities segments). This multi-year journey, which accelerated with the acquisitions of Arthrosurface and Parcus Medical, through which we entered into the sports medicine and bone preserving joint technology markets with a hybrid direct sales model that also expanded the commercial capabilities for our regenerative solutions portfolio, leverages our existing leadership position and expertise in the HA-based OA pain management market, and has included strengthening our team and infrastructure with investments in people, systems and processes. The combination of Anika with Arthrosurface and Parcus Medical enhances the value to the clinician and their patient through a unique product portfolio suited to early intervention orthopedics that leverages HA’s regenerative attributes for natural, faster healing. In the upcoming years, we will continue to invest in our research and development pipeline and strengthen our commercial capabilities to position our product portfolio for the needs of clinicians that practice in ambulatory surgical centers, or ASCs, and hospitals, as well as expand into new geographic areas to drive accelerated growth and profitability. As our pipeline evolves, we intend to expand our HA expertise by selectively developing and offering solutions for joint preservation and regenerative solutions targeted at procedures that are performed in the ASCs and to focus on completing clinical development for key products we sell outside the United States, (i.e. Cingal and Hyalofast), to gain approval for entry into the large U.S. market.

 

As we look forward, our business is positioned to capture value within our target markets in joint preservation. We believe our future success will be driven by our:

 

 

●

Decades of experience in HA-based regenerative solutions and early intervention orthopedics combined under new seasoned leadership with a strong financial foundation for future investment in meaningful solutions for our customers and their patients;
     
 

●

Utilizing HA-based technology and manufacturing expertise to provide new and differentiated solutions for the faster growing joint preservation and regenerative medicine markets;
     
 

●

Robust network of stakeholders in our target markets that will allow us to identify evolving unmet patient treatment needs;
     
 

●

Prioritized investment in a differentiated pipeline of regenerative solutions, bone preserving implants and sports medicine solutions;
     
 

●

Global commercial expertise, which we will leverage to drive growth across our product portfolio, including an intentional site of care focus in ASCs in the United States and continued international expansion;
     
 

●

Pursuit of strategic inorganic growth opportunities, including potential partnerships and smaller acquisitions and technology licensing, by leveraging our strong financial foundation and operational capabilities; and
     
 

●

Energized and experienced team focused on strong values, talent, and culture.

 

 

 

8
 

 

Products

 

OA Pain Management

 

Our OA Pain Management product family consists of:

 

 

●

Monovisc and Orthovisc, our single- and multi-injection, HA-based viscosupplement product offerings indicated to provide pain relief from OA conditions solely for use in the knee. Our OA Pain Management products are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by DePuy Synthes Mitek Sports Medicine, part of the Johnson & Johnson Medical Companies, or Mitek. In December 2011, we entered into a fifteen-year licensing agreement with Mitek to exclusively market Monovisc in the United States through December 2026. In December 2003, we entered into a ten-year licensing agreement to exclusively market Orthovisc in the United States. Mitek extended this agreement for additional five-year terms in 2007, 2012, 2017 and most recently in August 2022. The current agreement expires in December 2028 unless extended at the option of Mitek. The Monovisc and Orthovisc products have been the market leaders, based on combined overall revenue in the viscosupplement market, since 2018. Internationally, we market our OA Pain Management products directly through a worldwide network of commercial distributors.
     
 

●

Cingal, our novel, next-generation, single-injection OA Pain Management product consisting of our proprietary cross-linked HA material combined with a fast-acting steroid, designed to provide both short- and long-term pain relief. Cingal is CE marked and for several years has been sold outside the United States directly in over 35 countries through our network of distributors. In the United States, Cingal is a pipeline product not yet approved for commercial sale; for additional information please see the section captioned “Item 1. Business—Research and Development.”
     
 

●

Hyvisc, our high molecular weight injectable HA veterinary product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine OA.

 

Joint Preservation and Restoration

 

Our Joint Preservation and Restoration product family, consists of:

 

 

●

Regenerative Solutions. Our portfolio of orthopedic regenerative solutions leveraging our proprietary technologies based on HA and Hyaff, which is a solid form of HA. These products include Tactoset Injectable Bone Substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and for augmenting hardware fixation, such as suture anchors, and Hyalofast, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery. Tactoset is commercialized principally in the United States, whereas Hyalofast is currently available outside the United States in over 30 countries within Europe, South America, Asia, and certain other international markets. In the United States, Hyalofast is a pipeline product under a pivotal Investigational Device Exemption, or IDE, clinical trial and is not available for commercial sale. For additional information, please see the section captioned “Item 1. Business—Research and Development.”
     
 

●

Sports Medicine. Our line of soft tissue repair solutions is used by surgeons to repair and reconstruct damaged ligaments and tendons resulting from sports injuries, trauma and disease. These more traditional sports medicine solutions include screws, sutures, suture anchors, grafts and other surgical systems that facilitate surgical procedures on the shoulder, knee, hip, upper and lower extremities, and other soft tissues. Our X-Twist Fixation System, launched in September of 2022 for limited use and fully launched in early 2023 for broad market use in the United States and certain international markets, is a platform of knotless and knotted suture anchors designed for soft tissue repairs in the shoulder and other extremities.
     
 

●

 Arthrosurface Joint Solutions. Our portfolio of more than 150 bone preserving joint solutions, including partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants, is designed to treat upper and lower extremity orthopedic conditions as well as knee and hip conditions caused by arthritic disease, trauma and injury. These products span multiple joints including OVOMotion with Inlay Glenoid for the shoulder, WristMotion wrist arthroplasty system, as well as foot and ankle, and knee products generally intended to restore a patient’s natural anatomy and movement. Our recently launched RevoMotion Reverse Shoulder Arthroplasty System (limited launch beginning early 2023), is a differentiated reverse shoulder implant system addressing the largest portion of the shoulder replacement market. These products often are used to treat patients with OA progression beyond where our OA Pain Management products can allow the patients to retain an active lifestyle when early surgical intervention becomes preferable.

 

9
 

 

We currently commercialize our Joint Preservation and Restoration products principally by selling to hospitals and ASCs, through an independent network of sales representatives and distributors.

 

Non-Orthopedic 

 

Our Non-Orthopedic product family consists of legacy HA-based products that are marketed principally for non-orthopedic applications. These products include Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries, Hyalomatrix, used for the treatment of complex wounds such as burns and ulcers, as well as products used in connection with the treatment of ears, nose and throat disorders, and ophthalmic products, including injectable, high molecular weight HA products such as Anikavisc and Nuvisc, used as viscoelastic agents in ophthalmic surgical procedures such as cataract extraction and intraocular lens implantation. These Non-Orthopedic products are sold through commercial sales and marketing partners around the world.

 

Sales Channels

 

A majority of our products are used by clinicians and surgeons in one of three environments: office-based procedures usually focused on injections, hospital operating rooms and ASCs, which are clinics outside of a normal hospital setting that are often at least partially physician-owned. These medical care delivery environments typically require different commercial approaches and have distinct call points, which requires diversity in our sales approach. For instance, our OA Pain Management product family and certain products in our Non-Orthopedic category are almost entirely utilized in an office-based setting while our Joint Preservation and Restoration and certain of our Non-Orthopedic products are almost exclusively consumed in hospital operating rooms or ASCs.

 

As a result of these distinctions, we employ multiple sales models in the United States to ensure that we are meeting the needs of our customers and other healthcare system stakeholders. For many years, we have maintained a mutually beneficial commercial partnership with Mitek, which sells Monovisc and Orthovisc in the United States. For this arrangement with Mitek, we sell the Monovisc and Orthovisc products that we manufacture to Mitek, and we also receive from Mitek a royalty on their end user sales of these products in the United States. We have U.S. commercial partnerships for other products in our OA Pain Management and Non-Orthopedic product families. Under these commercial partnerships, we sell our products directly to our partners, who perform downstream sales and marketing activities to customers and end-users. In addition to a transfer price, we may also structure our arrangements to receive a royalty on end user sales.

 

With our expanded commercial infrastructure as a result of the Parcus Medical and Arthrosurface acquisitions, we sell our Joint Preservation and Restoration family directly to clinicians, including hospitals and ASCs, through our Anika sales team and large network of independent third-party distributors. Since the acquisitions, we integrated our U.S. commercial organization, including cross training our sales team to sell the consolidated Joint Preservation and Restoration product portfolio. Within this framework, we employ selling models that seek to maximize the benefit for our company and customers, including in certain instances, contracts with group purchasing organizations and certain fixed-price delivery models.

 

Outside of the United States, we principally market and sell our products using a worldwide network of commercial partners, along with a small number of direct sales representatives, to provide a solid foundation for future revenue growth and territorial expansion. Our relationships with these partners are generally structured such that we sell our products to these partners directly while they, with global support from our team, perform the in-country sales and marketing activities to drive growth and adoption of our products locally. We expect to generally maintain this model for the foreseeable future, while also selectively evaluating other options and being opportunistic about adopting other sales models, including direct sales, in certain jurisdictions.

 

We believe that our overall sales approach provides our business with a strong base to drive revenue growth as we continue to grow and scale our commercial infrastructure. We will continue to focus on expanding our own commercial capabilities, including with respect to market access, innovative sales and delivery models, and improved logistics management.

 

Manufacturing

 

We manufacture all of our HA-based products, including all our OA Pain Management products and certain additional products, at our facility in Bedford, Massachusetts, where we have developed significant manufacturing expertise around procedures such as homogenized mixing and filling of highly viscous liquids and manipulation of solid HA into scaffolds or other presentations. We manufacture much of our sports medicine soft tissue repair products at our facility in Sarasota, Florida and we manufacture our bone preserving joint products and certain elements of our soft tissue repair portfolio utilizing third-party contract manufacturing organizations.

 

10
 

 

The raw materials necessary to manufacture our products are generally available from multiple sources. However, we rely on a small number of suppliers for certain key raw materials and a small number of suppliers for certain other materials, components, parts and disposables required for the manufacturing and delivery of these products. The downstream effects of the COVID-19 pandemic has impacted our supply chain as the companies that produce our products, product components or otherwise support our manufacturing processes, the distribution centers where we manage our inventory, or the operations of our logistics and other service providers, including third parties that sterilize and store our products, are disrupted, temporarily close or experience worker shortages or expanded lead-times for deliveries for a sustained period of time. Any prolonged interruption of operations or significant reduction in the capacity or performance capability of any of our manufacturing facilities, or with any of our key suppliers, could have a material adverse effect on our operations. For additional information on the impact of the COVID-19 pandemic on our manufacturing operations, please refer to the section captioned “Item 1A. Risk Factors—Risks related to the COVID-19 Pandemic. “Our operations are located in areas impacted by the COVID-19 pandemic, and those operations have been, and may continue to be, adversely affected by the COVID-19 pandemic”, and “Our global supply chain may be materially adversely impacted due to the COVID-19 pandemic.”

 

Research and Development

 

Our research and development efforts consist of the development of new medical applications for our technology platforms, including new implant designs, the development of intellectual property with respect to our technology platforms and new products, the management of clinical trials for certain product candidates, the preparation and processing of applications for regulatory clearances and approvals, and process development and scale-up manufacturing activities for our existing and new product development initiatives. For 2022, 2021, and 2020, research and development expenses were $28.2 million, $27.3 million and $23.4 million, respectively. The increase in 2022 was primarily due to costs to ensure compliance with growing regulatory requirements globally and new product development in our research and development pipeline. We anticipate that we will continue to commit significant resources to research and development activities, primarily for new product development, regulatory compliance, scale-up manufacturing activities, and pre-clinical and clinical activities.

 

Our new product development efforts focus on products in four large and growing orthopedic markets to drive long-term growth: OA pain management, regenerative solutions, sports medicine soft tissue repair and Arthrosurface joint solutions. In order to better inform and target our research and development investment, we routinely interact with key external stakeholders, including clinicians, to encompass customer and patient insights in our development process that help ensure we bring needed solutions to the market. As we move forward, we plan to continue to invest in novel and meaningful new products for our target markets based on our core capabilities, including further expanding our regenerative HA technology platform.

 

Our development focus for OA Pain Management will continue to be on bringing Cingal, our next-generation, single-injection HA-based viscosupplement product combined with a fast-acting steroid, to the U.S. market. In 2022, we completed a third Phase III clinical trial for Cingal, which achieved its primary endpoint. We will engage with the U.S. Food and Drug Administration, or the FDA, in 2023 on next steps for U.S. regulatory approval. In parallel, we are exploring the potential to advance Cingal through commercial partnerships in the U.S. and select Asian markets. These efforts will inform next steps, including if and how to proceed with another clinical trial in the United States.

 

Development for our Joint Preservation and Restoration product family is focused in several key areas. We are developing novel solutions and line extensions across our regenerative solutions, sports medicine soft tissue repair and Arthrosurface joint solutions product families, largely targeting the faster-growing extremities segments such as the shoulder. These include enhancements to existing regenerative solutions such as our fast-growing Tactoset Injectable Bone Substitute, which received an additional 510(k) clearance in 2021 for hardware augmentation, along with new soft tissue fixation and extremities products like our X-Twist Fixation System that achieved 510(k) clearance from the FDA in 2022 (with a limited market launch that began in September 2022) and our RevoMotion Reverse Shoulder Arthroplasty System, which received 510(k) clearance in 2021 (with a limited market launch that began in early 2023), as well as continued progress on a regenerative solution product targeted at rotator cuff repair utilizing our proprietary solid HA technology. We also made significant progress in 2022 on our clinical trial to support approval in the United States for Hyalofast, our single stage, off the shelf, cartilage repair therapy, currently sold only outside the United States. To date, we have enrolled 199 of the 200 patients targeted in the trial. This pivotal trial has a two-year follow-up protocol before regulatory submission.

 

Intellectual Property

 

We seek patent and trademark protection for our key technologies, products and product improvements, both in the U.S. and in select foreign countries. When determined appropriate, we enforce and plan to enforce and defend our patent and trademark rights. While we rely on our patent and trademark portfolio to provide us with competitive advantages as it relates to our existing and future product lines, it is not our sole source of protection in the development and manufacture of our products. We also rely upon trade secrets and continuing technological innovations to develop and maintain our competitive position.

 

11
 

 

Competition

 

We compete with many companies including large pharmaceutical firms and large and specialized medical device companies across our product lines. For our OA Pain Management products, our principal competitors include Sanofi Genzyme, Zimmer Biomet, Inc., Bioventus Inc., Avanos Medical, Inc., and Ferring Pharmaceuticals, as well as other companies that are commercializing or developing competitive products. Our key competitors for our Joint Preservation and Restoration products include Arthrex, Inc., the DePuy Synthes Companies of Johnson & Johnson, Smith & Nephew PLC., Stryker Corporation, and Zimmer Biomet, Inc., as well as certain smaller organizations that focus on subsets of the larger industry, such as Catalyst OrthoScience, Enovis Corporation and Shoulder Innovations. Many of the larger companies have substantially greater financial resources, larger research and development staffs, more extensive marketing and manufacturing organizations, and more experience in regulatory processes than we have. We also compete with academic institutions, government agencies, and other research organizations that may be involved in the research and development and commercialization of products. Many of our competitors also compete against us in securing relationships with collaborators for their research and development, manufacturing and supply, and distribution and commercialization programs.

 

We compete with other market participants primarily on the efficacy of our products, our products’ reputation for safety, and the breadth of our overall product portfolio. Other factors that impact competition in our industry are the timing and scope of regulatory approvals, the availability of manufacturing supplies, raw materials and finished product supply, marketing and sales capability, reimbursement coverage, product pricing, and patent protection. Some of the principal factors that may affect our ability to compete in our target markets include:

 

 

●

The quality and breadth of our continued development of our product portfolio;
     
 

●

Our ability to complete successful clinical studies and obtain FDA marketing and foreign regulatory clearances/approvals;
     
 

●

Our ability to successfully source raw materials and components from suppliers at price points that are in-line with our financial objectives, as well as deliver them on schedule to meet the needs of our operational and commercial organizations;
     
 

●

Our ability to continue to build our commercial infrastructure, integrate our sales channels and execute our sales strategies;
     
 

●

The execution by our key partners of their commercial strategies for our products and our ability to manage our relationships with those key partners;
     
 

●

Our ability to recruit and retain skilled employees; and
     
 

●

The availability of capital resources to fund strategic activities related to the significant expansion of our business or product portfolio, including through acquisitions of third parties or certain assets.

 

We are aware of several companies that are developing and/or marketing competitive products. In some cases, competitors have already obtained product approvals, submitted applications for approval, or commenced human clinical studies, either in the United States or in certain foreign countries. All our products face substantial competition. There is a risk that we will be unable to compete effectively against our current or future competitors. Additionally, legislation and regulation aimed at curbing rising healthcare costs has resulted in a consolidation trend in the healthcare industry to create larger companies, including hospitals, with greater market power. In turn, this has led to greater and more intense competition in the provision of products and services to market participants. Important market makers, like group purchasing organizations and integrated delivery networks, have increased their negotiating leverage, and if these market makers demand significant price concessions or if we are excluded as a supplier by these market makers, our product revenue could be adversely impacted.

 

12
 

 

Governmental Regulation

 

The clinical development, manufacturing, and marketing of our products are subject to governmental regulation in the United States, the European Union, and other territories worldwide, including pursuant to the Federal Food, Drug, and Cosmetic Act, or FDCA, in the United States. Medical products regulated by the FDA and other regulatory authorities are generally classified as drugs, biologics, or medical devices, and the current classification standards for our current or future products may be altered over time due to new regulations or augmented interpretation of data or current regulations.

 

Regulation of Medical Devices

 

Medical devices intended for human use are classified into three categories (Class I, II or III) based on the controls deemed reasonably necessary by the FDA to assure their safety and effectiveness. Class I and II devices are subject to the 510(k) premarket notification process in order to be commercially distributed, unless exempt Class III devices must obtain FDA approval of their premarket approval applications, or PMAs, in order to be commercially distributed.

 

Some of our current products are subject to premarket notification and clearance under section 510(k) of the FDCA. To obtain 510(k) clearance, a company must submit to the FDA a premarket notification, or 510(k), demonstrating that the proposed device is “substantially equivalent” to a legally marketed device, known as a “predicate device.” A device is substantially equivalent if, with respect to the predicate device, it has the same intended use and has either (i) the same technological characteristics, or (ii) different technological characteristics, but the information provided in the 510(k) submission demonstrates that the device does not raise new questions of safety and effectiveness and is at least as safe and effective as the predicate device.

 

The FDA aims to review and issue a determination on a 510(k) submission within 90 calendar days. As a practical matter, 510(k) clearance often takes longer. The FDA may require additional information, including clinical data, to make a determination regarding substantial equivalence.

 

If the FDA agrees that the device is substantially equivalent, it will grant 510(k) clearance to commercially market the device. If the FDA determines that the device is ‘‘not substantially equivalent’’ to a predicate device, the device is automatically designated as a Class III device. The device sponsor must then fulfill more rigorous PMA requirements or may be able to request a risk-based classification determination for the device in accordance with the ‘‘de novo’’ process, which is a route to market for novel medical devices that are low to moderate risk and are not substantially equivalent to a predicate device.

 

After a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change or modification in its intended use, will require a new 510(k) clearance or, depending on the modification, PMA approval. The determination as to whether a modification could significantly affect the device’s safety or effectiveness is initially left to the manufacturer using available FDA guidance. Many minor modifications are accomplished by a ‘‘letter to file’’, in which the manufacturer documents the rationale for the change and why a new 510(k) submission is not required. However, the FDA may review such letters to file to evaluate the regulatory status of the modified device at any time and may require the manufacturer to cease marketing and recall the modified device until 510(k) clearance or PMA approval is obtained.

 

Some of our devices are Class III devices that require PMA approval before they can be marketed. In a PMA, the manufacturer must demonstrate that the device is reasonably safe and effective, and the PMA must be supported by extensive data, including data from preclinical studies and clinical trials. The PMA must also contain a full description of the device and its components, a full description of the methods, facilities and controls used for manufacturing, and proposed labeling. If the FDA accepts the application for review, it has 180 days under the FDCA to complete its review of a PMA, although in practice, the FDA’s review often takes significantly longer, and can take up to several years. An advisory committee of experts from outside the FDA may be convened to review and evaluate the application and provide recommendations to the FDA as to the approvability of the device. The FDA may or may not accept the advisory committee’s recommendation. In addition, the FDA will generally conduct a pre-approval inspection of the applicant or its third-party manufacturers’ or suppliers’ manufacturing facility or facilities to ensure compliance with the QSR.

 

The FDA will approve the new device for commercial distribution if it determines that the data and information in the PMA constitute valid scientific evidence and that there is reasonable assurance that the device is safe and effective for its intended use(s). Certain changes to an approved device that affect the safety or effectiveness of the device, require submission of a PMA supplement or in some cases a new PMA.

 

Regulation of a Drug

 

In order to be marketed, new drugs require FDA approval of a New Drug Application, or NDA. Satisfaction of the FDA approval requirements for drugs typically takes several years and the actual time required may vary substantially based on the type, complexity and novelty of the product. None of our products are currently approved under an NDA.

 

The steps for obtaining FDA approval of an NDA to market a drug in the United States include:

 

13
 

 

 

●

completion of preclinical laboratory tests, animal studies and formulation studies under the FDA’s Good Laboratory Practices regulations;         

 

 

●

submission to the FDA of an Investigational New Drug Application, or IND, for human clinical testing, which must become effective before human clinical trials may begin and Institutional Review Board, or IRB, approval at each clinical site before the trials may be initiated;        

 

 

●

performance of adequate and well-controlled clinical trials in accordance with Good Clinical Practices to establish the safety and efficacy of the product for each indication;         

 

 

●

submission to the FDA of a user fee (unless a fee waiver applies) and an NDA, which contains detailed information about the Chemistry, Manufacturing and Control, or CMC, for the product, reports of the outcomes and full data sets of the preclinical testing and clinical trials, and proposed labeling and packaging for the product;         

 

 

●

satisfactory review of the contents of the NDA by the FDA, including the satisfactory resolution of any questions raised during the review;

 

 

●

satisfactory completion of an FDA advisory committee review, if applicable;         

 

 

●

satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with current Good Manufacturing Practices, or cGMP, regulations, to assure that the facilities, methods and controls are adequate to ensure the product’s identity, strength, quality and purity; and      

 

 

●

FDA approval of the NDA including agreement on post-marketing commitments, if applicable.    

 

After the NDA submission is accepted for filing, the FDA reviews the NDA to determine, among other things, whether the proposed product is safe and effective for its intended use, and has an acceptable purity profile. A drug-drug combination product must meet the FDA’s fixed combination rule and thus demonstrate the contribution of each component to the therapeutic effect.

 

If the FDA determines the application, the manufacturing process or manufacturing facilities are not acceptable, it will either not approve the NDA or issue a complete response letter in which it will outline the deficiencies in the NDA. If a complete response letter is issued, the applicant may either resubmit the NDA to address all deficiencies identified in the letter, withdraw the application, or request a hearing. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the NDA does not satisfy the regulatory criteria for approval.

 

The FDA seeks to review standard NDAs in 10 months and priority NDAs in six months, whereupon a review decision is to be made. The FDA does not always meet its goal dates for standard and priority NDAs and its review goals are subject to change from time to time.

 

Clinical Trials

 

Clinical trials are typically required to support a PMA and an NDA and are sometimes required to support a 510(k) submission. All clinical trials must be approved by, and conducted under the oversight of an IRB for each clinical site.  Clinical investigators must obtain informed consent from all study subjects. After a trial begins, we, the FDA or the IRB could suspend or terminate a clinical trial at any time for various reasons, including a belief that the risks to study subjects outweigh the anticipated benefits. Information about certain clinical studies must be submitted with specific timeframes to the National Institutes of Health for public dissemination at www.clinicaltrials.gov. All clinical investigations of devices to determine safety and effectiveness must be conducted in accordance with the FDA’s investigational device exemption, or IDE, regulations which govern investigational device labeling, prohibit promotion of the investigational device, and specify an array of recordkeeping, reporting and monitoring responsibilities of study sponsors and study investigators. If the device presents a ‘‘significant risk’’ as defined by the FDA, to human health, the FDA requires the device sponsor to submit an IDE application to the FDA, which must be approved prior to commencing human clinical trials. A significant risk device is one that presents a potential for serious risk to the health, safety or welfare of a patient and either is implanted, purported or represented to be used in supporting or sustaining human life, is for a use that is substantially important in diagnosing, curing, mitigating or treating disease or otherwise preventing impairment of human health, or otherwise presents a potential for serious risk to a subject. A clinical trial may begin 30 days after receipt of the IDE by the FDA unless the FDA notifies the company that the investigation may not begin.

 

14
 

 

If an IDE application is approved by the FDA and one or more IRBs, human clinical trials may begin at a specific number of investigational sites with a specific number of patients, as approved by the FDA. If the device is considered a ‘‘non-significant risk’’ IDE submission to the FDA is not required. Instead, only approval from the IRB overseeing the investigation at each clinical trial site is required.

 

For a new drug, an IND application must be submitted prior to the initiation of the clinical study and contain information on animal pharmacology and toxicology studies, manufacturing, and clinical protocols and investigator information.

 

Some preclinical testing may continue after the IND application is submitted. The IND must become effective before human clinical trials may begin. An IND will automatically become effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions about issues such as the conduct of the trials and/or supporting preclinical data as outlined in the IND application and places the trial on clinical hold. In that case, the IND sponsor and the FDA must resolve any outstanding FDA concerns or questions before clinical trials can proceed.

 

For purposes of NDA approval, human clinical trials are typically conducted in three sequential phases that may overlap:

 

 

●

Phase 1—The investigational product is initially introduced into healthy human subjects and tested for safety. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients. These trials may also provide early evidence of their effectiveness.

 

 

●

Phase 2—These trials are conducted in a limited number of patients in the target population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.

 

 

●

Phase 3—Phase 3 trials are undertaken to provide statistically significant evidence of clinical efficacy and to further evaluate dosage, potency, and safety in an expanded patient population at multiple clinical trial sites. They are performed after preliminary evidence suggesting effectiveness of the product has been obtained and are intended to establish the overall benefit-risk relationship of the investigational product, and to provide an adequate basis for product approval and physician labeling.

 

Typically, if a product is intended to treat a chronic disease, safety and efficacy data must be gathered over an extended period, which can range from six months to three years or more.

 

During all phases of clinical development, the FDA requires extensive monitoring and auditing of all clinical activities, clinical data, and clinical trial investigators. Annual progress reports detailing the results of the clinical trials and reports of serious adverse events must be submitted to the FDA.

 

Post-Approval Requirements

 

Products manufactured or distributed pursuant to FDA clearances or approvals are subject to continuing regulation by the FDA, including, among other things, requirements relating to monitoring, record-keeping, advertising and promotion, reporting of adverse experiences, and limitations on industry-sponsored scientific and educational activities.

 

15
 

 

FDA regulations require that PMA and NDA approved products be manufactured in specific facilities and all devices and drugs must be manufactured in accordance with the QSR and cGMP regulations, respectively. Manufacturers and other entities involved in the manufacture and distribution of cleared or approved devices or drugs are required to register their establishments and list their products with the FDA and certain state agencies. Manufacturers are subject to periodic announced and unannounced inspections by the FDA and certain state agencies for compliance with regulatory requirements. The discovery of violative conditions, including failure to conform to the QSR and cGMP regulations, could result in enforcement actions.

 

Products may be promoted only for the cleared or approved indications and in accordance with the provisions of the label. The FDA does not regulate behavior of physicians in their choice of treatments and physicians may legally prescribe available products for uses that are not described in the product’s labeling and that differ from those approved or cleared by the FDA. However, the FDA does restrict an applicant’s communications about off-label use of its products. The FDA and other agencies actively enforce the laws prohibiting the marketing and promotion of off-label uses, and a company that is found to have improperly marketed or promoted off-label use may be subject to significant liability, including criminal and civil penalties under the FDCA and False Claims Act, exclusion from participation in federal healthcare programs, and mandatory compliance programs.

 

The FDA also may require post-marketing testing and surveillance to monitor the effects of a marketed product. Discovery of previously unknown problems with a product or the failure to comply with applicable FDA requirements can have negative consequences, including adverse publicity, restrictions on a product, and judicial or administrative enforcement. The FDA has broad regulatory compliance and enforcement powers. If the FDA determines that we failed to comply with applicable regulatory requirements, it can take a variety of compliance or enforcement actions, including, without limitation, issuing a Form FDA 483 notice of inspectional observations or a warning letter or untitled letter, imposing civil money penalties, suspending or delaying issuance of clearances or approvals or refusing to grant clearances or approve pending premarket applications, requiring or requesting product recall, imposing a total or partial shutdown of production, withdrawal of approvals or clearances already granted, pursuing product seizures, consent decrees or other injunctive relief, or criminal prosecution through the Department of Justice. The FDA can also require us to repair, replace, or refund the cost of devices that we manufactured or distributed. Outside the United States, regulatory agencies may exert a range of similar powers.

 

EU Regulation

 

In the European Union, medical devices must be CE marked in order to be marketed. CE marking a device involves working with a Notified Body (or in some cases, for the lowest risk class devices, the manufacturer can self-certify) to demonstrate that the device meets all applicable requirements of the EU medical devices legislation and that the Quality Management System is compliant. The EU’s Medical Device Directive, or MDD, has been replaced by the EU Medical Device Regulation, or EU MDR, enacted in 2017, and which became effective on May 26, 2021. EU MDR requirements will phase in on a product-by-product basis as certifications issued under the MDD lapse and will require all products to undergo review and approval under these new regulations.  The timing for this transition has been extended from no later than May 26, 2024 to December 2027 or December 2028, depending on device classification, provided certain conditions are met with regard to the new regulation, one of which being that all submissions are filed by May 26, 2024. The EU MDR will generally require increased levels of clinical data as compared to MDD requirements, and all product technical data must comply to the latest standards regardless of when the product was initially developed.

 

Drug approval in the European Union follows one of several possible processes: (i) a centralized procedure involving members of the European Medicines Agency’s Committee for Medicinal Products for Human Use; (ii) a “mutual recognition procedure” in which an individual country's regulatory agency approves the product followed by “mutual recognition” of this approval by regulatory agencies of other countries; (iii) a decentralized procedure in which the approval is sought through the regulatory agencies of multiple countries at the same time; or (iv) a national procedure in which the approval is sought through the regulatory agency of one country.

 

UK Regulation

 

The UK formally left the EU on January 31, 2020. The EU and the UK have concluded a trade and cooperation agreement, or TCA, which was provisionally applicable since January 1, 2021 and has been formally applicable since May 1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP documents issued, but does not foresee wholesale mutual recognition of UK and EU pharmaceutical regulations. At present, Great Britain has implemented EU legislation on the marketing, promotion and sale of medicinal products through the Human Medicines Regulations 2012 (as amended) (under the Northern Ireland Protocol, the EU regulatory framework will continue to apply in Northern Ireland). The regulatory regime in Great Britain therefore currently aligns with EU regulations in many ways, however it is possible that these regimes will diverge more significantly in the future now that Great Britain’s regulatory system is independent from the EU.

 

16
 

 

In respect of medical devices, since the end of the Brexit transitional period on January 1, 2021, new regulations require medical devices to be registered with the Medicines and Healthcare products Regulatory Agency, or MHRA (the UK medicines and medical devices regulator) before being placed on the Great Britain market. The MHRA will only register devices where the manufacturer or their United Kingdom Responsible Person has a registered place of business in the United Kingdom. By July 1, 2023, in Great Britain, all medical devices will require a UKCA (UK Conformity Assessed) mark but CE marks issued by EU notified bodies will remain valid until December 2024. Manufacturers may choose to use the UKCA mark on a voluntary basis until June 30, 2023. UCKA marking will, however, not be recognized in the EU. The rules for placing medical devices on the market in Northern Ireland, which is part of the United Kingdom, differ from those in the rest of the United Kingdom.

 

Other Health Care Laws 

 

The delivery of our products is subject to regulation by the U.S. Department of Health and Human services and other state and non-U.S. government agencies responsible for reimbursement and regulation of health care items and services. U.S. laws and regulations are imposed primarily in connection with government-funded health care programs, such as Medicare and Medicaid, as well as the government’s interest in regulating the quality and cost of health care. Other governments also impose regulations in connection with their health care reimbursement programs and the delivery of health care items and services. 

 

We are subject to various U.S. federal and state laws pertaining to health care fraud and abuse, including anti-kickback, false claims, self-referrals, and other health care fraud. In addition, we are subject to U.S. federal and state transparency laws, such as the U.S. Physician Payments Sunshine Act, which require us to annually disclose certain payments and other transfers of value we make to U.S.-licensed health care practitioners (like physicians, nurse practitioners, advanced practice registered nurses, and others) and others. Similar laws and regulations pertaining to sales, marketing and advertising practices exist in the other geographic areas where we operate.

 

Coverage and Reimbursement

 

Sales of any medical product depend, in part, on the extent to which such product (or procedures using such product) will be covered by third-party payers, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product or procedure by third-party payers. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. These third-party payers are increasingly reducing reimbursements for medical products and related procedures.

 

Factors that payers consider in determining reimbursement are based on whether the product or procedure is:

 

 

●

a covered benefit under its health plan;

 

 

●

safe, effective and medically necessary;

 

 

●

appropriate for the specific patient;

 

 

●

cost-effective; and

 

 

●

neither experimental nor investigational.

 

17
 

 

No uniform policy for coverage and reimbursement for medical products or procedures that use medical products exists among third-party payers in the U.S. Therefore, coverage and reimbursement for products or their procedures can differ significantly from payer to payer. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payer separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases on short notice, and we believe that changes in these rules and regulations are likely.

 

In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or procedure that uses our products or a decision by a third-party payer not to cover a product or related procedure could reduce physician usage and patient demand for the product or procedure and also have a material adverse effect on sales.

 

Health Care Reform

 

The Affordable Care Act of 2010, or the ACA, substantially changed the way healthcare is financed by both governmental and private insurers, and significantly affected the pharmaceutical and medical device industry. The ACA contained a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement adjustments and changes to fraud and abuse laws as well as Medicare provisions aimed at decreasing costs, comparative effectiveness research, an independent payment advisory board and pilot programs to evaluate alternative payment methodologies. Since its enactment, there have been ongoing judicial and Congressional efforts to modify or repeal certain aspects of the ACA. For example, the Further Consolidated Appropriations Act, 2020, repealed the Cadillac tax, the health insurance provider tax, and the medical device excise tax. It is impossible to determine whether similar taxes could be instated in the future or how future healthcare reform measures or other efforts, if any, to challenge repeal or replace the ACA, will impact our business.

 

Data Privacy and Security Laws

 

We are also subject to various laws and regulations concerning data privacy in the United States, Europe, and elsewhere, including the General Data Protection Regulation, or GDPR, in the European Union and the United Kingdom. These legal requirements impose stringent requirements on the processing, administration, security, and confidentiality of personal data and empower enforcement agencies to impose large penalties for noncompliance. In addition, various jurisdictions around the world continue to propose new laws that regulate the privacy and/or security of certain types of personal data. Complying with these laws, if enacted, would require significant resources and leave us vulnerable to possible fines, penalties, litigation, and reputational harm if we are unable to comply.

 

Environmental Laws

 

We believe that we are in compliance with all foreign, federal, state, and local environmental regulations with respect to our manufacturing facilities. The cost of ongoing compliance with such environmental regulations does not have a material effect on our operations.

 

18
 

 

Seasonality

 

Our OA Pain Management and Non-Orthopedic product families are generally less seasonal in nature due to the nature of our product mix and sales channels and strategies. In Joint Preservation and Restoration, procedure volumes are normally higher in the fourth quarter due to several factors including the satisfaction by patients of insurance deductible limits and the time of year patients prefer to have elective procedures. The ongoing effects of the COVID-19 pandemic have also somewhat changed the historic seasonality of our Joint Preservation and Restoration business. These effects have included periodic restrictions on the performance of elective surgical procedures throughout the U.S. and global markets, the unavailability of physicians and/or changes to their treatment prioritizations, reductions in the levels of healthcare facility staffing and, in certain instances, the willingness or ability of patients to seek treatment. The impact of seasonality on our business could continue to evolve based on factors such as patient behavior and attitudes towards vacations, the emergence of COVID-19 variants, and supply chain and staffing challenges.

 

Environmental, Social and Governance

 

In 2021, we began a process to develop a foundational Environmental, Social and Governance, or ESG, framework for our organization. This framework integrates our six key corporate values: People, Quality, Integrity, Accountability, Innovation and Teamwork. The initial step in our ESG journey included the completion of a “materiality assessment” based on the Sustainability Accounting Standards Board, or SASB, framework. Our materiality assessment was a research-intensive and stakeholder-inclusive process and included guidance and insight from external advisors, and crucial feedback from key internal and external stakeholders, including investors, customers, suppliers, employees and our board of directors.  

 

As a result of the materiality assessment, we identified the themes that are most important to our stakeholders and our business within traditional environmental, social and governance pillars. Most immediately, our materiality assessment enabled us to select our six key focus areas, with a goal to be aligned with SASB standards for the medical device industry. We will continue to assess and update our ESG initiatives as our business grows and as we implement processes and improvements over time.

 

Human Capital Management

 

We believe that creating a diverse, talented, and inclusive workplace is a central aspect to our culture, employee recruitment, retention and engagement, innovation, operational excellence and overall performance. In turn, this culture and drive for performance is an important factor in our ability to attract and retain key talent. Our culture is centered around our fundamental values of:

 

 

●

People: We engage and invest in each other in a community that values diversity and inclusion.
     
 

●

Innovation: We are agile and entrepreneurial in developing and delivering meaningful solutions to our healthcare stakeholders within our target markets.
     
 

●

Quality: We strive for the highest quality and compliance in everything we do.
     
 

●

Teamwork: We operate with mutual respect and trust and are collaborative as we grow together.
     
 

●

Integrity: We live up to our promises and do the right thing, every day.
     
 

●

Accountability: We are empowered and accountable to deliver results and value to all of our stakeholders.

 

19
 

 

Talent Acquisition and Management

 

Our industry requires complex processes for product development and commercialization, each of which requires deep expertise and experience across a broad array of disciplines. Medical device companies therefore compete for a limited number of qualified applicants to fill specialized positions. This requires competitive compensation and benefits packages and an attractive culture in order to attract and retain skilled employees to support the growth and success of the company.

 

As of December 31, 2022, we employed 345 full-time employees in the United States and Europe. We expect to continue to add employees in 2023 and beyond as we grow our business.

 

We believe that our employees’ understanding of how their work contributes to our overall strategy and performance is key to our success. In order to communicate with respect to these important topics in a manner that is engaging to our team, we utilize a variety of channels. These include all-employee town hall meetings with senior management, regular email updates from our chief executive officer and other key members of the executive team, as well as presentations to our employees by invited clinicians, who use our products, participate and share their experiences from a customer’s perspective. In addition, to assess employee perceptions in areas such as inclusion, professional development/training, reward/recognition, equity, engagement and overall organizational satisfaction, we conduct company-wide employee engagement surveys using an external survey platform. Our management team evaluates the results and identifies potential opportunities for improvement. As a result of employee feedback, we have established an employee communications taskforce chartered with improving communications and employee engagement across the business and introduced new e-learning programs to expand employee development.

 

Diversity, Equity and Inclusion

 

We are committed to a diverse, equitable and inclusive workplace where all employees, regardless of their gender, race, ethnicity, national origin, age, sexual orientation or identity, education or disability are valued, respected and supported. Beginning in 2021, we made a commitment to comply with key elements of the MassBio CEO Pledge for a More Equitable and Inclusive Life Science Industry. We are working on a multi-year approach at providing the key deliverables to meet our commitment. This included the development and communication of a corporate Diversity, Equity and Inclusion Policy Statement as well as the creation of a Diversity Dashboard. The Diversity Dashboard tracks the current diversity within the organization and is shared with the board of directors to provide engagement and oversight at the highest levels of the organization. We have also conducted employee surveys and employee focus groups to discuss diversity and inclusion. We will continue to enhance the diversity of our workforce through focused talent acquisition goals and development plans.

 

Employee Development

 

The ongoing development of our employees continues to be a catalyst for our growth and success as a company. Many of our employees have obtained advanced degrees in their professions. We support our employees’ further development with individualized development plans, mentoring, coaching, group training, conference attendance. We also provide financial support, including tuition reimbursement for qualified programs, as well as access to a broad-based learning management platform for self-directed learning and improvement.

 

Competitive Pay and Benefits

 

To attract and retain qualified employees and key talent, we offer our employees total rewards packages consisting of base salary, a cash bonus, and a comprehensive benefit package. We also provide equity compensation for certain employees based on various criteria, including their level within our company. All employees globally are eligible to participate in the annual incentive cash bonus plan or a sales incentive plan which are aligned to both corporate and individual performance. Bonus opportunity and equity compensation increase as a percentage of total compensation based on level of responsibility. Our Employee Stock Purchase Plan, introduced in 2021, gives eligible employees the opportunity to purchase shares in Anika at a discounted rate. Bravo, our global online employee recognition program, provides the opportunity for both peer to peer and manager to employee recognition, and has been well received by our employees.

 

20
 

 

Health and Safety

 

We remain focused on promoting the total wellness of our employees including resources, programs and services to support their physical, mental and financial wellness. As a result of the COVID-19 pandemic, we augmented certain of our normal business practices to ensure that we promote health and safety for our employees. A cross functional COVID-19 Pandemic Task Force was put in place since the start of the pandemic. We established safety policies and protocols, and we regularly update our employees with respect to any changes. We adjusted attendance policies to encourage those who may be ill to stay home. To further protect our on-site employees, we have provided personal protective equipment and cleaning supplies. Additionally, we engaged a third-party firm to conduct a proactive facility assessment and upgraded our air filtration systems to be more effective against COVID-19 transmission, thus enhancing the safety of our workforce while on the job. We have also provided general information updates and support for our employees to ensure that they have resources and information to protect their health and that of those around them, including their families and co-workers.

 

 

Product Liability

 

The testing, marketing, and sale of human health care products entail an inherent risk of allegations of product liability, and we cannot assure that substantial product liability claims will not be asserted against us. Although we have not received any material product liability claims to date, we cannot assure that if material claims arise in the future, our insurance will be adequate to cover all situations. Moreover, we cannot assure that such insurance, or additional insurance, if required, will be available in the future or, if available, will be available on commercially reasonable terms. Any product liability claim, if successful, could have a material adverse effect on our business, financial condition, and results of operations.

 

Available Information

 

We are required to file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC maintains a website at www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.

 

Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, proxy statements, and other information, including amendments and exhibits to such reports, filed or furnished pursuant to the Securities Exchange Act of 1934 are available free of charge in the “SEC Filings” section of our website located at http://www.anika.com, as soon as reasonably practicable after the reports are electronically filed with or furnished to the SEC. The information on our website is not part of this Annual Report on Form 10-K.

 

 

 

 

 

 

 

 

 

21
 

 

ITEM 1A. RISK FACTORS

 

Our operating results and financial condition have varied in the past and could vary significantly in the future depending on a number of factors. You should consider carefully the risks and uncertainties described below, in addition to the other information contained in this Annual Report on Form 10-K, before deciding whether to purchase our common stock. If any of the following risks actually occur, our business, financial condition, results of operations, and future prospects could be materially and adversely affected. In that event, the trading price of our common stock could decline, and stockholders could lose part or all of their investment.

 

Risks Related to Our Business and Industry

 

Our financial performance depends on sales growth and increasing demand for our legacy and acquired product portfolios, and we may not be able to successfully manage the recent, and future, expansion of our operations.

 

Through our acquisitions of Parcus Medical and Arthrosurface in early 2020, we significantly broadened our technology and development platforms and commercialization infrastructure and expanded our addressable market from the global OA pain management market to the substantially larger global joint preservation market. Our future success depends on growth in sales of both our legacy and acquired products. There can be no assurance that such growth can be achieved or, if achieved, sustained. There can be no assurance that, even if substantial growth in product sales and the demand for our products is achieved, we will be able to:

 

 

●

Gain acceptance of our broadened portfolio of existing products, as well as future products, by the medical community, hospitals, physicians, other health care providers, third-party payers, and end-users, which acceptance may depend upon the extent to which the medical community and end-users perceive our products as safer, more effective or more cost-competitive than other similar products.
 

●

Maintain, manage, and develop the necessary manufacturing capabilities and inventory management practices;
 

●

Develop, implement, and integrate the mix of appropriate sales channels needed to generate increased sales across our expanded product platform and to develop marketing partners and viable commercial strategies for the distribution of our expanded mix of products;
 

●

Attract, retain, and integrate required key personnel; and
 

●

Implement the financial, accounting, and management systems needed to manage our expanded business and growing demand for our products.

 

There can be no assurance that our current and future products will achieve significant market acceptance on a timely basis, or at all. The failure of some or all of our products to achieve significant market acceptance, or our failure to successfully manage future growth, could have a material adverse effect on our business, financial condition, and results of operations.

 

Substantial competition could materially affect our financial performance.

 

We compete with many companies, including large pharmaceutical companies and large and specialized medical devices companies, across all our product lines. For our OA Pain Management products, our principal competitors include Sanofi Genzyme, Zimmer Biomet, Inc., Bioventus Inc., Avanos Medical, Inc., and Ferring Pharmaceuticals, as well as other companies that are commercializing or developing competitive products. Our key competitors for our Joint Preservation and Restoration products include Arthrex, Inc., the DePuy Synthes Companies of Johnson & Johnson, Smith & Nephew PLC., Stryker Corporation, and Zimmer Biomet, Inc., as well as certain smaller organizations that focus on subsets of the larger industry, such as Catalyst OrthoScience, Enovis Corporation and Shoulder Innovations. Many of these companies have substantially greater financial resources, larger research and development staffs, more extensive marketing and manufacturing organizations, and more experience in the regulatory process than us. We also compete with academic institutions, government agencies, and other research organizations that are involved in the research and development and commercialization of products similar to our own. Many of our competitors also compete against us in securing relationships with collaborators for their research and development and commercialization programs.

 

Because a number of companies are developing or have developed products for similar applications as our products and have received FDA clearance or approval, the successful commercialization of a particular product will depend in part upon our ability to complete clinical studies and/or obtain the FDA marketing and foreign regulatory clearance or approvals prior to our competitors, or, if regulatory clearance or approval is not obtained prior to our competitors, to identify markets for our products that may be sufficient to permit meaningful sales of our products. Additionally, legislation and regulation aimed at curbing rising healthcare costs has resulted in a consolidation trend in the healthcare industry to create larger companies, including hospitals, with greater market power. In turn, this has led to greater and more intense competition in the provision of products and services to market participants. Important market makers, like group purchasing organizations and integrated delivery networks, have increased their negotiating leverage, and if these market makers demand significant price concessions or if we are excluded as a supplier by these market makers, our product revenue could be adversely impacted. There can be no assurance that we will be able to compete against current or future competitors or that competition will not have a material adverse effect on our business, financial condition, and results of operations. 

 

22
 

 

Our business may be adversely affected if consolidation in the healthcare industry leads to demand for price concessions or if we are excluded from being a supplier by a group purchasing organization or similar entity.

 

Because healthcare costs have risen significantly over the past decade, numerous initiatives and reforms have been launched by legislators, regulators, and third-party payers to curb these costs. As a result, there has been a consolidation trend in the healthcare industry to create larger companies, including hospitals, with greater market power. As the healthcare industry consolidates, competition to provide products and services to industry participants has become and may continue to become more intense. This may result in greater pricing pressures and the exclusion of certain suppliers from important markets as group purchasing organizations, independent delivery networks, and large single accounts continue to use their market power to consolidate purchasing decisions. If a group purchasing organization excludes us from being one of their suppliers, our net sales could be adversely impacted. We expect that market demand, government regulation, third-party reimbursement policies, and societal pressures will continue to change the worldwide healthcare industry, which may exert further downward pressure on the prices of our products.

 

A significant portion of our OA Pain Management revenues are derived from a small number of customers, the loss of which could materially adversely affect our business, financial condition and results of operations.

 

We have historically derived most of our OA Pain Management revenues from a small number of customers who resell our products to end-users. Many of these customers are significantly larger companies than us. In 2022, Mitek accounted for 43% of our total revenue. While we have started to diversify our sales channels, including through the implementation of a direct commercial model in the United States for our Joint Preservation and Restoration products, we expect to continue to be dependent on a small number of large customers for a substantial portion of our business. The failure of key customers to purchase our products in the amounts they historically have or in amounts that we expect would seriously harm our business.

 

In addition, if present and future customers terminate their purchasing arrangements with us, significantly reduce or delay their orders, or seek to renegotiate their agreements on terms less favorable to us, our business, financial condition, and results of operations will be adversely affected. If we accept terms less favorable than the terms of the current agreements, such renegotiations may have a material adverse effect on our business, financial condition, and/or results of operations. Furthermore, in any future negotiations we may be subject to the perceived or actual leverage that these customers may have given their relative size and importance to us. Any termination, change, reduction, or delay in orders could seriously harm our business, financial condition, and results of operations. The loss of any one of our major customers, the delay of significant orders from such customers or our inability to timely supply product to these customers (including due to production and shipping delays attributable to supply or staffing shortages), even if only temporary, could reduce or delay our recognition of revenues, harm our reputation in the industry, and reduce our ability to accurately predict cash flow, and, as a consequence, could seriously harm our business, financial condition, and results of operations.

 

We experience quarterly sales volume variation, which makes our future results difficult to predict and makes period-to-period comparisons potentially not meaningful.

 

We experience quarterly fluctuations in our product sales as a result of multiple factors, many of which are outside of our control including our arrangement with Mitek which performs most of the downstream sales and marketing activities to customers and end-users for Monovisc and Orthovisc in the United States. Therefore, we are subject to fluctuations in our customers’ sales patterns and corresponding ordering patterns, including Mitek. These quarterly fluctuations create uncertainty as to the volume of sales that we may achieve in a given period. As a result, comparing our operating results on a period-to-period basis might not be meaningful. You should not rely on our past results as an indication of our future performance. Our operating results could be disproportionately affected by a reduction in revenue because a proportionately smaller amount of our expenses varies with our revenue. As a result, our quarterly operating results are difficult to predict, even in the near term.

 

We rely on a small number of suppliers for certain key raw materials and a small number of suppliers for a number of other materials required for the manufacturing and delivery of our products, and disruption could materially adversely affect our business, financial condition, and results of operations.

 

Although we believe that alternative sources for many of these and other components and raw materials that we use in our manufacturing processes are available, we cannot be certain that the supply of key raw materials will continue to be available at current levels or will be sufficient to meet our future needs. The COVID-19 pandemic has impacted, and the lingering effects of the pandemic may continue to impact, our supply chain as the companies that produce our products, product components or otherwise support our manufacturing processes, the distribution centers where we manage our inventory, or the operations of our logistics and other service providers, including third parties that sterilize and store our products, are, or may be disrupted, temporarily closed or experience worker shortages for a sustained period of time. For example, for the manufacture of Arthrosurface joint solutions products, we engage a single third-party organization as a contract manufacturer. This contract manufacturer has noted that there could be lead times up to a year or more to deliver certain products. Any supply interruption could harm our ability to manufacture our products until a new source of supply is identified and qualified. We may not be able to find sufficient alternative suppliers in a reasonable time period, or on commercially reasonable terms, if at all, and our ability to produce and supply our products could be impaired.

 

23
 

 

Our manufacturing processes involve inherent risks, and disruption could materially adversely affect our business, financial condition, and results of operations.

 

The operation of biomedical manufacturing plants involves many risks, including the risks of breakdown, failure, substandard performance of equipment, the inability of production runs to pass internal quality standards, the need to comply with the requirements of directives of government agencies, including the FDA, and the occurrence of natural and other disasters. Such occurrences could have a material adverse effect on our business, financial condition, and results of operations during the period of such operational difficulties and beyond.

 

We could become subject to product liability claims, which, if successful, could materially adversely affect our business, financial condition, and results of operations.

 

The testing, marketing, and sale of human health care products include an inherent risk of allegations of product liability, and there can be no assurance that substantial product liability claims will not be asserted against us. Although we have not received any material product liability claims to date and we believe that we have adequate insurance coverage to cover such product liability claims should they arise, there can be no assurance that material claims will not arise in the future or that our insurance will be adequate to cover all situations. Moreover, there can be no assurance that such insurance, or additional insurance, if required, will be available in the future or, if available, will be available on commercially reasonable terms. Any product liability claim, if successful, could have a material adverse effect on our business, financial condition, and results of operations.

 

Failure to comply with current or future national, international, federal or state laws and regulations, regulatory guidance and industry standards relating to data protection, privacy and information security, including restrictive European regulations, could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business.

 

We and our third-party providers are subject to national, international, federal or state laws and regulations, regulatory guidance and industry standards relating to data protection, privacy and information security. This includes the European Union, or EU, GDPR, as well as other national data protection legislation in force in relevant EU member states (including the GDPR in such form as incorporated into the law of England and Wales, Scotland and Northern Ireland by virtue of the European Union (Withdrawal) Act 2018 and any regulations thereunder and the UK Data Protection Act 2018, or UK GDPR.

 

The GDPR and UK GDPR are wide-ranging in scope and impose numerous additional requirements on companies that process personal data, including imposing special requirements in respect of the processing of health and other sensitive data, requiring that consent of individuals to whom the personal data relates is obtained in certain circumstances, requiring additional disclosures to individuals regarding data processing activities, requiring that safeguards are implemented to protect the security and confidentiality of personal data, creating mandatory data breach notification requirements in certain circumstances, requiring data protection impact assessments for high risk processing and requiring that certain measures (including contractual requirements) are put in place when engaging third-party processors. The GDPR and the UK GDPR also provide individuals with various rights in respect of their personal data. The GDPR and UK GDPR define personal data to include pseudonymized or coded data and requires different informed consent practices and more detailed notices for clinical trial participants and investigators than applies to clinical trials conducted in the United States. We are required to apply GDPR and UK GDPR standards to any clinical trials that our EU and UK established businesses carry out anywhere in the world.

 

Significantly, the GDPR and the UK GDPR impose strict rules on the transfer of personal data out of the EU or the UK to the U.S. or other regions that have not been deemed to offer “adequate” privacy protections. Currently, we rely mainly on Standard Contractual Clauses approved by the European Commission, or SCCs, to legitimize transfers of personal data out of the EU and International Transfer Agreements approved in the UK for transfers of personal data out of the UK, however, there continue to be concerns about whether the SCCs and other mechanisms will face additional legal challenges. Any inability to transfer personal data from the EU to the U.S. in compliance with data protection laws may impede our ability to conduct trials and may adversely affect our business and financial position.

 

The GDPR and UK GDPR have increased our responsibilities and may increase our liability in relation to personal data that we process where such processing is subject to the GDPR and UK GDPR. While we have taken steps to comply with the GDPR and UK GDPR, and implementing legislation in applicable EU member states and the UK, including by seeking to establish appropriate lawful bases for the various processing activities we carry out, reviewing our security procedures and those of our service providers, and entering into data processing agreements with relevant service providers we cannot be certain that our efforts to achieve and remain in compliance have been, and/or will continue to be, fully successful. Given the breadth and depth of changes in data protection obligations, complying with the GDPR and UK GDPR and similar laws’ requirements are rigorous and time intensive and require significant resources and a review of our technologies, systems and practices, as well as those of any third-party service providers, contractors or consultants that process or transfer personal data.

 

24
 

 

In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws and federal and state consumer protection laws that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our collaborators and third-party providers. For example, California has enacted the California Consumer Privacy Act, or the CCPA, which became effective on January 1, 2020. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. At this time, we do not collect personal data on residents of California but should we begin to do so, and in the context of doing so, become subject to the CCPA, the CCPA will impose new and burdensome privacy compliance obligations on our business and will raise new risks for potential fines and class actions.

 

In addition a California ballot initiative, the California Privacy Rights Act, or CPRA, was passed in November 2020. As of January 1, 2023, the CPRA imposes additional obligations on companies covered by the legislation and will significantly modify the CCPA, including by expanding consumers’ rights with respect to certain sensitive personal information. The CPRA also creates a new state agency that will be vested with authority to implement and enforce the CCPA, as modified by the CPRA. The effects of the CCPA are potentially significant and may require us to modify our data collection or processing practices and policies and to incur substantial costs and expenses in an effort to comply and increase our potential exposure to regulatory enforcement and/or litigation.

 

Some observers have noted that the CCPA could mark the beginning of a trend toward more stringent privacy legislation in the United States, which could increase our potential liability and adversely affect our business. New consumer privacy laws enter into force in Connecticut, Colorado, Virginia and Utah in 2023. In addition, many other states have proposed new privacy laws, some of which are similar to the above discussed recently passed laws. Such proposed legislation, if enacted, may add additional complexity, variation in requirements, restrictions and potential legal risk, require additional investment of resources in compliance programs, impact strategies and the availability of previously useful data and could result in increased compliance costs and/or changes in business practices and policies. The existence of comprehensive privacy laws in different states in the country would make our compliance obligations more complex and costly and may increase the likelihood that we may be subject to enforcement actions or otherwise incur liability for noncompliance.

 

In addition, many jurisdictions around the world have adopted legislation that regulates how businesses operate online and enforces information security, including measures relating to privacy, data security and data breaches. Many of these laws require businesses to notify data breaches to the regulators and/or data subjects. These laws are not consistent, and compliance in the event of a widespread data breach is costly and burdensome.

 

In many jurisdictions, enforcement actions and consequences for non-compliance with protection, privacy and information security laws and regulations are rising. In the EU and the UK, data protection authorities may impose large penalties for violations of the data protection laws, including potential fines of up to €20 million (£17.5 million in the UK) or 4% of annual global revenue, whichever is greater. The authorities have shown a willingness to impose significant fines and issue orders preventing the processing of personal data on non-compliant businesses. Data subjects also have a private right of action, as do consumer associations, to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of applicable data protection laws. In the United States, possible consequences for non-compliance include enforcement actions in response to rules and regulations promulgated under the authority of federal agencies and state attorneys general and legislatures and consumer protection agencies.

 

The risk of our being found in violation of these laws is increased by the fact that the interpretation and enforcement of them is not entirely clear. EU Member States have adopted implementing national laws to implement the GDPR which may partially deviate from the GDPR and the competent authorities in the EU Member States may interpret GDPR obligations slightly differently from country to country, so that we do not expect to operate in a uniform legal landscape in the EU. In addition, the UK has announced plans to reform the country’s data protection legal framework in its Data Reform Bill, but these have been put on hold. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance and/or reporting requirements increases the possibility that a healthcare company may run afoul of one or more of the requirements.

 

25
 

 

Compliance with data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. It could also require us to change our business practices and put in place additional compliance mechanisms, which may interrupt or delay our development, regulatory and commercialization activities and increase our cost of doing business. Failure by us or our and third-party providers to comply with data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties and orders preventing us from processing personal data), private litigation and result in significant fines and penalties against us. Claims that we have violated individuals’ privacy rights, failed to comply with data protection laws or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend, could result in adverse publicity and could have a material adverse effect on our business, financial condition, results of operations and prospects.

 

We are increasingly dependent on sophisticated information technology and if we fail to effectively maintain or protect our information systems or data, including from data breaches, our business could be adversely affected.

 

We are increasingly dependent on sophisticated information technology for our products and infrastructure. As a result of technology initiatives, recently enacted regulations, changes in our system platforms and integration of new business acquisitions, we have been consolidating and integrating the number of systems we operate and have upgraded and expanded our information systems capabilities. We also have outsourced elements of our operations to third parties, and, as a result, we manage a few third-party suppliers who may or could have access to our confidential intellectual property or business information.

 

Our information systems, and those of third-party suppliers with whom we contract, require an ongoing commitment of significant resources to maintain, protect and enhance existing systems and develop new systems to keep pace with continuing changes in information technology, evolving systems and regulatory standards and the increasing need to protect patient and customer information. In addition, given their size and complexity, these systems could be vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by our employees, third-party suppliers and/or business partners, or from cyber-attacks by malicious third parties attempting to gain unauthorized access to our products, systems or Confidential Information.

 

The risk of a security breach or disruption, particularly through cyberattacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. Cyberattacks could include wrongful conduct by hostile foreign governments, industrial espionage, wire fraud and other forms of cyber fraud, the deployment of harmful malware, denial-of-service, social engineering fraud or other means to threaten data security, confidentiality, integrity and availability. If such an event were to occur, it could result in the theft or destruction of intellectual property, data or other misappropriation of assets, or otherwise compromise our confidential or proprietary information and result in a material disruption of our development programs and our business operations.

 

Although we devote resources to protect our information systems, we realize that cyberattacks are a threat, and there can be no assurance that our efforts will prevent information security breaches that would result in business, legal, financial or reputational harm to us, or would have a material adverse effect on our business, financial condition, results of operations and prospects.

 

Likewise, we rely on third parties for various operations, including the manufacture of our products and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. We rely on our third-party providers to implement effective security measures and identify and correct for any such failures, deficiencies or breaches. Any breach in our or our third-party providers’ information technology systems could lead to the unauthorized access, disclosure and use of non-public information, including protected health information and other personally identifiable information which is protected by HIPAA, and other laws. Any such access, disclosure, or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, damage to our reputation and the further development and commercialization of our products could be delayed. If we or our third-party providers fail to maintain or protect our information technology systems and data integrity effectively or fail to anticipate, plan for or manage significant disruptions to our information technology systems, we or our third-party providers could have difficulty preventing, detecting and controlling such cyberattacks and any such attacks could result in losses described above as well as disputes with physicians, participants and our partners, regulatory sanctions or penalties, increases in operating expenses, expenses or lost revenues or other adverse consequences, any of which could have a material adverse effect on our business, results of operations, financial condition, prospects and cash flows. If we are unable to prevent or mitigate the impact of such security or data privacy breaches, we could be exposed to litigation and governmental investigations, which could lead to a potential disruption to our business.

 

Any compromise to our information security or that of our third party service providers or contractors could result in an interruption in our operations, the unauthorized publication of our confidential business or proprietary information, the unauthorized release, use, disclosure and/or dissemination of customer, vendor, or employee data, the violation of privacy and/or data protection laws, including under the GDPR, in the European Union or the United Kingdom, or other laws and exposure to litigation, any of which could harm our business and operating results.

 

26
 

 

We may face circumstances in the future that will result in impairment charges, including, but not limited to, goodwill impairment and in-process research and development charges.

 

As of December 31, 2022, we had long-lived assets in the amount of $130.2 million. If the fair value of any of our long-lived assets, including those that we acquired in the acquisitions of Arthrosurface and Parcus Medical, decrease as a result of an economic slowdown, a downturn in the markets where we sell products and services, a downturn in our financial performance or future outlook, or other reasons, we may be required to record an impairment charge on such assets. We are required to test intangible assets with indefinite life periods for potential impairment annually and on an interim basis if there are indicators of a potential impairment. We also are required to evaluate amortizable intangible assets and fixed assets for impairment if there are indicators of a possible impairment. Impairment charges could have a negative impact on our results of operations and financial position, as well as on the market price of our common stock.

 

Our business is dependent upon hiring and retaining qualified management, operations, commercial and technical personnel.

 

We are highly dependent on the members of our management, operations, commercial and technical staff, the loss of one or more of whom could have a material adverse effect on us. We have experienced a number of management changes in recent years, and there can be no assurances that any future management changes will not adversely affect our business. We believe that our future success will depend in large part upon our ability to attract and retain technical and highly skilled executive, managerial, professional, and technical personnel. We face significant competition for such personnel from competitive companies, research and academic institutions, government entities, and other organizations. There can be no assurance that we will be successful in hiring or retaining the personnel we require. The failure to hire and retain such personnel could have a material adverse effect on our business, financial condition, and results of operations.

 

We may require additional capital in the future. We cannot give any assurance that such capital will be available at all or on terms acceptable to us, and if it is available, additional capital raised by us could dilute your ownership interest or the value of your shares.

 

We may need to raise capital in the future depending on numerous factors, including:

 

 

●

Market acceptance of our existing and future products;
 

●

The success and sales of our products under various distributor agreements and other appropriate commercial strategies, including the ability of our partners to achieve third party reimbursement for our products;
 

●

The successful commercialization of products in development through appropriate commercial models and marketing channels;
 

●

Progress in our product development efforts;
 

●

The magnitude and scope of such product development efforts;
 

●

Any potential acquisitions of products, technologies, or businesses;
 

●

Progress with preclinical studies, clinical trials, and product approvals and clearances by the FDA and other agencies;
  ● Requirement to conduct additional preclinical studies and clinical trials for future products; 
 

●

The cost and timing of our efforts to manage our manufacturing capabilities and related costs;
 

●

The cost of filing, prosecuting, defending, and enforcing patent claims and other intellectual property rights and the cost of defending any other legal proceeding;
 

●

Competing technological and market developments;
 

●

The development of strategic alliances for the marketing of certain of our products;
 

●

The terms of such strategic alliances, including provisions (and our ability to satisfy such provisions) that provide upfront and/or milestone payments to us;
 

●

The cost of maintaining adequate inventory levels to meet current and future product demand; and
 

●

Further expanding our business in international markets.

 

To the extent funds generated from our operations, together with our existing capital resources, are insufficient to meet future requirements, we will be required to obtain additional funds through equity or debt financings, through strategic alliances with corporate partners and others, or through other sources. The terms of any future equity financing may be dilutive to our investors and the terms of any debt financing may contain restrictive covenants, which limit our ability to pursue certain courses of action. Our ability to obtain financing is dependent on the status of our future business prospects as well as conditions prevailing in the relevant capital markets at the time, we seek financing. No assurance can be given that any additional financing will be made available to us or will be available on acceptable terms should such a need arise.

 

27
 

 

If we succeed in raising additional funds through the issuance of equity or convertible securities, then the issuance could result in substantial dilution to existing stockholders. Furthermore, the holders of these new securities or debt may have rights, preferences and privileges senior to those of the holders of common stock. In addition, any preferred equity issuance or debt financing that we may obtain in the future could have restrictive covenants relating to our capital raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities, including potential acquisitions.

 

Changes in tax law could adversely affect our business and financial condition.

 

The rules dealing with U.S. federal, state, and local and non-U.S. taxation are constantly under review by persons involved in the legislative process, the Internal Revenue Service, the U.S. Treasury Department and other taxing authorities. Changes to tax laws or tax rulings, or changes in interpretations of existing laws (which changes may have retroactive application), could adversely affect us or the holders of our common stock. These changes could subject us to additional income-based taxes and non-income taxes (such as payroll, sales, use, value-added, net worth, property, and goods and services taxes), which in turn could materially affect our financial position and results of operations. Additionally, new, changed, modified, or newly interpreted or applied tax laws could increase our customers’ and our compliance, operating and other costs, as well as the costs of our products. In recent years, many such changes have been made, and changes are likely to continue to occur in the future. As we expand the scale of our business activities, any changes in the U.S. and non-U.S. taxation of such activities may increase our effective tax rate and harm our business, financial condition, and results of operations.

 

Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults, or non-performance by financial institutions or transactional counterparties, could adversely affect the Company’s current and projected business operations and its financial condition and results of operations.

 

Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. If any of our customers, suppliers or other parties with whom we conduct business are unable to access funds pursuant to lending arrangements with financial institutions, such parties’ ability to pay their obligations to us or to enter into new commercial arrangements requiring additional payments to us could be adversely affected.

 

Although we assess our banking and customer relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect the Company, the financial institutions with which the Company has credit agreements or arrangements directly, or the financial services industry or economy in general.  These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry.  These factors could involve financial institutions or financial services industry companies with which the Company has financial or business relationships, but could also include factors involving financial markets or the financial services industry generally.

 

The results of events or concerns that involve one or more of these factors could include a variety of material and adverse impacts on our current and projected business operations and our financial condition and results of operations. These could include, but may not be limited to, the following:

 

28
 

 

 

●

Delayed access to deposits or other financial assets or the uninsured loss of deposits or other financial assets;
 

●

Delayed or lost access to, or reductions in borrowings available under revolving existing credit facilities or other working capital sources and/or delays, inability or reductions in the company’s ability to refund, roll over or extend the maturity of, or enter into new credit facilities or other working capital resources;
 

●

Potential or actual breach of contractual obligations that require the Company to maintain letters of credit or other credit support arrangements;
 

●

Potential or actual breach of financial covenants in our credit agreements or credit arrangements;
 

●

Potential or actual cross-defaults in other credit agreements, credit arrangements or operating or financing agreements; or
 

●

Termination of cash management arrangements and/or delays in accessing or actual loss of funds subject to cash management arrangements.

 

Risks Related to Our Commercialization Activities

 

Our license agreements with Mitek provide substantial control of Monovisc and Orthovisc in the United States to Mitek, and Mitek’s actions could have a material impact on our business, financial condition and results of operations.

 

Our license and distribution agreements with Mitek related to Monovisc and Orthovisc provide Mitek with, among other things, the exclusive right to market and sell Monovisc and Orthovisc in the United States, unilateral decision-making authority over the sale, price, and promotion of Monovisc and Orthovisc in the United States, substantial control over the future development of Monovisc and Orthovisc related to the treatment of pain associated with osteoarthritis, a license to manufacture and have manufactured such products in the event that we are unable to supply Mitek with Monovisc or Orthovisc in accordance with the terms of the relevant agreement, and certain rights of first refusal with respect to future products we develop for the treatment of pain associated with osteoarthritis. In exchange, Mitek pays us a transfer price calculated with reference to historical end-user prices in the market and a fixed royalty rate per product on their net product sales. As Mitek accounts for a large percentage of our yearly revenue and has unilateral decision-making authority over in-market activities, including end-user pricing and discounts, reimbursement strategy, and overall promotion strategy, actions taken by Mitek could impact our ability to predict and generate revenue and have a material impact on our business, financial condition, and results of operations.

 

We may not succeed in our integration and buildout of our direct sales channel in the United States, and our failure to do so could negatively impact our business and financial results.

 

Beginning in 2019, and with our expanded commercial infrastructure, as a result of the Parcus Medical and Arthrosurface acquisitions in 2020, we now sell our Joint Preservation and Restoration family of products directly to customers, including hospitals and ASCs, through our direct Anika sales team and large network of independent third-party distributors. This approach was a departure from our historical distribution model in the United States, and we cannot be certain that we will be successful in implementing and executing on this commercial approach or that, even if we are able to implement it, the approach will be successful at scale. We may not be able to attract or retain the sophisticated personnel required for our approach, to identify or negotiate favorable or acceptable terms with distribution agents and ensure that they dedicate time and focus to our products, to achieve in-market pricing at the levels we have targeted, to develop and tailor our product portfolio to be specifically desired by clinicians who practice in ASCs, or to timely execute on our strategies for market penetration generally. Our failure to successfully implement and execute this commercial approach could have a material adverse effect on our business, financial condition, and results of operations.

 

We are dependent upon marketing and distribution partners and the failure to maintain strategic alliances on acceptable terms will have a material adverse effect on our business, financial condition, and results of operations.

 

Our success is dependent, in part, upon the efforts of our marketing, distribution, and logistics partners, including our sales agent partners in the United States, and the terms and conditions of our relationships with such partners. We cannot assure you that our commercial partners, including Mitek, will not seek to renegotiate their current agreements on terms less favorable to us or terminate such agreements. A failure to maintain relationships with our commercial partners on terms satisfactory to us, or at all, could result in a material adverse effect on our operating results.

 

29
 

 

We continue to seek to establish long-term partnerships in regions and countries not covered by existing agreements, and we may need to obtain the assistance of additional marketing partners to bring new and existing products to market and to replace certain marketing partners. There can be no assurance that we will be able to identify or engage appropriate distribution or collaboration partners or effectively transition to any such new partnerships. The failure to establish strategic partnerships for the marketing and distribution of our products on acceptable terms and within our planned timeframes could have a material adverse effect on our business, financial condition, and results of operations.

 

Sales of our products are largely dependent upon third-party health insurance coverage and reimbursement and our performance may be harmed by health care cost containment initiatives or decisions of individual third-party payers.

 

In the United States and other foreign markets, health care providers, such as hospitals and physicians, that purchase health care products, such as our products, generally rely on third-party payers, including Medicare, Medicaid, and other health insurance and managed care plans, to provide coverage and to reimburse for all or part of the cost of the health care product or procedures that use such products. Coverage and reimbursement by third-party payers, both in the United States and internationally, may depend on several factors, including the individual payer’s determination that our products or procedures that use our products are clinically useful and cost-effective, medically necessary, and not experimental or investigational. Since insurance coverage determinations and reimbursement decisions are made by each payer individually, seeking positive coverage and reimbursement decisions can be a time consuming and costly process, which could require us or our marketing partners to provide supporting scientific, clinical, and cost-effectiveness data for the use of our products to each payer separately. Significant uncertainty exists as to the insurance coverage and reimbursement status of newly approved health care products or procedures that use such products, and any failure or delay in obtaining reimbursement approvals can negatively impact sales of our new products. In addition, we cannot be certain that payers who currently provide reimbursement for our products or procedures that use our products will continue to provide such reimbursement in the future, and such payer decisions could negatively impact the sales of our current or future products.

 

In addition, third party payers are increasingly attempting to contain the costs of health care products and services by limiting both coverage and the level of reimbursement for new therapeutic products and by refusing, in some cases, to provide coverage for uses of approved products for disease indications for which the FDA, or the applicable foreign regulatory agency, has granted marketing approval. Also, the U.S. Congress, certain state legislatures, and certain foreign governments and regulatory agencies have considered reforms, including, among other items, any material changes to the ACA or the potential repeal of reference drug pricing in the United States, which may affect current reimbursement practices and create additional uncertainty about the pricing of our products, including the potential implementation of controls on health care spending through limitations on the growth of Medicare and Medicaid spending. For example, in 2010, the ACA was enacted and was intended to expand access to health insurance coverage and improve the quality of health care over time. There has been ongoing litigation and congressional efforts to modify or repeal all or certain provisions of the ACA. There may be uncertainties that result from modification or repeal of any of the provisions of the ACA, including as a result of current and future executive orders and legislative actions. We cannot predict what other health care programs and regulations will ultimately be implemented at the federal or state level or the effect that any future legislation or regulation in the United States may have on our business. There can be no assurance that third party coverage will be available or that reimbursement will be adequate for any products or services developed by us or procedures using our products or services.

 

Outside the United States, the success of our products is also dependent in part upon the availability of reimbursement and health care payment systems. Domestic and international reimbursement laws and regulations may change from time to time. Lack of adequate coverage and reimbursement provided by governments and other third-party payers for our products and services, including continuing coverage for Monovisc and Orthovisc in the United States, and any change of classification by the Centers for Medicare and Medicaid Services for reimbursement of Orthovisc and Monovisc, could have a material adverse effect on our business, financial condition, and results of operations.

 

30
 

 

Risks Related to Our Product Development and Regulatory Compliance

 

We are facing a longer than expected pathway to commercialize our Cingal product in the United States, and we may face other unforeseen difficulties in achieving regulatory approval for Cingal, which could affect our business and financial results.

 

In 2018, we received and analyzed the results of our second Phase III clinical trial for Cingal and found that the data did not meet the primary study endpoint of demonstrating a statistically significant difference in pain reduction between Cingal and the approved steroid component of Cingal at the six-month time point. After discussions, the FDA indicated that an additional Phase III clinical trial would be necessary to support U.S. marketing approval for Cingal. In 2019, we began the design of our third Phase III clinical trial to enable us to evaluate our full-scale Phase III clinical trial design, including patient and site selection criteria, and increase the probability of success for the Phase III trial. In 2020 the first patient was enrolled in the pilot study and in 2022, we completed this third Phase III clinical trial, which achieved its primary endpoint. Together with previous clinical studies, Cingal has demonstrated superiority over each of its active ingredients and placebo over 26 weeks for long-acting pain relief. We will engage with the FDA in the first half of 2023 on next steps for U.S. regulatory approval. In parallel, we are exploring the potential to advance Cingal through commercial partnerships in the U.S. and select Asian markets. These efforts will inform next steps, including if and how to proceed with another clinical trial in the United States. We cannot guarantee the success of any additional future clinical trials for Cingal. Because the results of any additional clinical trials, or other unforeseen future developments, could have a substantial negative impact on the timeline for and the cost associated with a potential Cingal regulatory approval, our overall business condition, financial results, and competitive position could be affected.

 

Failure to obtain, or any delay in obtaining, FDA or other U.S. and foreign governmental clearances or approvals for our products may have a material adverse effect on our business, financial condition and results of operations.

 

Several of our current products under development, and certain future products we may develop, will require clinical trials to determine their safety and efficacy for marketing approval by regulatory bodies, including the FDA. Product development and clearance or approval within the FDA and international regulatory frameworks takes several years and involves the expenditure of substantial resources. There can be no assurance that the FDA or other regulatory authorities will accept submissions related to our new products or the expansion of the indications of our current products, and, even if submissions are accepted, there can be no guarantee that the FDA or other regulatory authorities will grant clearance or approval for our new products, on a timely basis, if at all. In addition to regulations enforced by the FDA, we are subject to other existing and future federal, state, local, and foreign regulations applicable to product clearance or approval, which may vary significantly across jurisdictions. Additional clearance or approval of existing products may be required when changes to such products may affect the safety and effectiveness, including for new indications for use, labeling changes, process or manufacturing changes, the use of a different facility to manufacture, process or package the product, and changes in performance or design specifications. For our devices that are subject to 510(k) clearances, the FDA requires device manufacturers to make a determination of whether a modification requires a clearance; however, the FDA can review a manufacturer’s decision not to submit for additional clearances. We cannot provide any assurance that the FDA will agree with our decisions not to seek clearances for particular device modifications. If the FDA disagrees, and requires new clearances or approvals for any modifications, and we fail to obtain such approvals or clearances or fail to secure approvals or clearances in a timely manner, we may be required to recall and to stop the manufacturing and marketing of the modified device until we obtain the FDA approval or clearance, and we may be subject to significant regulatory fines or penalties. Failure to obtain regulatory clearance or approvals of our products, including any changes to existing products, could have an adverse material impact on our business, financial condition, and results of operations.

 

Even if ultimately granted, the FDA and international regulatory clearances or approvals may be subject to significant, unanticipated delays throughout the regulatory review process. Internally, we make assumptions regarding product clearance or approval timelines, both in the United States and internationally, in our business planning, and any delay in clearance or approval could materially affect our competitive position in the relevant product market and our projections related to future business results.

 

We cannot be certain that product clearance or approvals, both in the United States and internationally, will not include significant limitations on the product indications, and other claims sought for use, under which the products may be marketed. The relevant approval or clearance may also include other significant conditions such as post-market testing, tracking, or surveillance requirements. Any of these factors could significantly impact our competitive position in relation to such products and could have a negative impact on the sales of such products. 

 

31
 

 

Once obtained, we cannot guarantee that the FDA or international product clearances or approvals will not be withdrawn or that relevant agencies will not require other corrective action, and any withdrawal or corrective action could materially affect our business and financial results.

 

Once obtained, marketing approval can be withdrawn by the FDA or comparable foreign regulatory agencies for a number of reasons, including the failure to comply with ongoing regulatory requirements or the occurrence of unforeseen problems following initial approval. Regulatory authorities could also limit or prevent the manufacture or distribution of our products. Any regulatory limitations on the use of our products or any withdrawal or suspension of approval or rescission of approval or reclassification by the FDA or a comparable foreign regulatory agency could have a material adverse effect on our business, financial condition, and results of operations.

 

Our operations and products are subject to extensive regulation, compliance with which is costly and time consuming, and our failure to comply may result in substantial penalties, including recalls of our products.

 

The FDA and foreign regulatory bodies impose extensive regulations applicable to our operations and products, including regulations governing product and sterilization standards, packaging requirements, labeling requirements, adverse event reporting, quality system and manufacturing requirements, import restrictions, tariff regulations, duties, and tax requirements. The FDA and other foreign regulatory bodies worldwide conduct periodic inspections of our facilities to determine compliance with the FDA’s requirements and all comparable foreign regulations. We cannot assure you that we will be able to achieve and maintain compliance required for the FDA, CE marking, or other foreign regulatory clearances or approvals for any or all our operations and products or that we will be able to produce our products in a timely and profitable manner while complying with applicable requirements.

 

Failure to comply with applicable regulatory requirements could result in substantial penalties, including warning letters, fines, injunctions, civil penalties, seizure of products, total or partial suspension of production, refusal to grant pre-market clearance or pre-market approval for devices or drugs, withdrawal of approvals, and criminal prosecution. Additionally, regulatory authorities have the power to require the recall of our products. It also might be necessary for us, in applicable circumstances, to initiate a voluntary recall per regulatory requirements of one or several of our products. The imposition of any of the foregoing penalties, whether voluntarily or involuntary, could have a material negative impact on our business, financial condition, and results of operations.

 

Any changes in the FDA or international regulations related to product approval or approval renewal, including those currently under consideration by the FDA or those that apply retroactively, could adversely affect our competitive position and materially affect our business and financial results.

 

The FDA and foreign regulations depend heavily on administrative interpretation, and we cannot assure you that future interpretations made by the FDA or other regulatory bodies, with possible retroactive effects, will not adversely affect us. Additionally, any changes, whether in interpretation or substance, in existing regulations or policies, or any future adoption of new regulations or policies by relevant regulatory bodies, could prevent or delay approval of our products. In the event our future, or current, products, including HA generally, are classified, or re-classified, as human drugs, combination products, or biologics by the FDA or an applicable international regulatory body, the applicable review process-related to such products is typically substantially longer and substantially more expensive than the review process to which they are currently subject as medical devices. In 2018, the FDA publicly indicated its intent to consider HA products for certain indications for regulation as a drug and has indicated that industry should submit new products or indication expansions to its Office of Combination Products to designate the appropriate FDA office for review. There exists uncertainty with respect to the final interpretation, implementation, and consequences of this development, and this or any other potential regulatory changes in approach or interpretation similar in substance to those mentioned in this paragraph and affecting our products could materially impact our competitive position, business, and financial results.

 

Additionally, the implementation of the new EU MDR which was put into effect in 2021, has changed several aspects of the medical device regulatory framework in the EU. Specifically, the EU MDR requires (i) changes in the clinical evidence required for medical devices, (ii) post-market clinical follow-up evidence, (iii) annual reporting of safety information for Class III and Class IIb products, and reporting every two years for Class IIa products, (iv) Unique Device Identification, or UDI, for all products and submission of core data elements to an EU UDI database prior to placement of a device on the market, (v) reclassification of some medical devices, and (vi) multiple other labeling changes. Approvals for certain of our currently marketed products could be curtailed or withdrawn as a result of the implementation of the EU MDR, and acquiring approvals for new products could be more challenging and costly. The EU MDR requires all devices to undergo review and approval for compliance to EU MDR.  The original compliance date of May 26, 2024 is being reconsidered in response to concerns raised about notified body capacity and the ability for devices to be re-certified within such time period. The European Commission’s proposal is to December 2027 or December 2028, depending on the risk class of the device. This proposal has been approved by the Council of the European Union, and is awaiting publication in the Official Journal to be made effective, which is expected to occur in March 2023. We have reviewed our products that are sold in the EU market and have completed the product rationalization exercise to identify the products that we will continue to market in the EU. Products we intend to continue marketing will require substantial submissions to be made to the notified bodies no later than May 26, 2024, for the MDR extension timelines to apply. Compliance with this and any other requirements is time consuming and costly, and our failure to comply may subject us to significant liabilities, which could have a material adverse effect on our business, financial condition, and results of operations.

 

32
 

 

Notices of inspectional observations or deficiencies from the FDA or other regulatory bodies require us to undertake corrective and preventive actions or other actions to address the FDA’s or other regulatory bodies' concerns. These actions could be expensive and time-consuming to complete and could impose an additional burden on us.

 

We are subject to periodic inspections by the FDA and other regulatory bodies related to regulatory requirements that apply to products designed and manufactured, and clinical trials sponsored, by us. If we receive a notice of inspectional observations or deficiencies from the FDA or other regulatory bodies following an inspection, we may be required to undertake corrective and protective actions or other actions in order to address the FDA or other regulatory bodies concerns which could be expensive and time-consuming to complete and could impose additional burdens and expenses. We have previously received notices of observations or deficiencies from the FDA. Failure to adequately address the FDA’s or other regulatory bodies’ concerns could expose us to enforcement or administrative actions.

 

We may rely on third parties to support certain aspects of our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory clearance or approval or commercialize our products, and our business could be substantially harmed.

 

We have hired experienced clinical development and regulatory staff, and we have also retained the services of knowledgeable external service providers, including consultants and clinical research organizations, to develop and supervise our clinical trials and regulatory processes. Despite our internal investment in staffing, we will remain dependent upon these third-party contract research organizations and consultants to carry out portions of our clinical and preclinical research studies and regulatory filing assistance for the foreseeable future. As a result, we have had and will have less control over the conduct of the clinical trials, the timing and completion of the trials, the required reporting of adverse events, and the management of data developed through the trials than would be the case if we were relying entirely on our own staff. Outside parties may have staffing difficulties, may undergo changes in priorities or may become financially distressed, adversely affecting their willingness or ability to conduct our trials. Failure by these third parties to comply with regulatory requirements or to meet timing expectations may require us to repeat clinical trials or preclinical studies, which would delay the regulatory clearance or approval process, or require substantial unexpected expenditures.

 

If we are found to have improperly promoted our products for off-label uses, we may become subject to significant fines and other liability.

 

The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about medical devices and drugs. For example, devices cleared under section 510(k) cannot be marketed for any intended use that is outside of the FDA’s substantial equivalence determination for such devices. Physicians nevertheless may use our products on their patients in a manner that is inconsistent with the intended use cleared by the FDA. If we are found to have promoted such “off-label” uses, we may become subject to significant government fines and other related liability. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.

 

We are subject to various healthcare laws and regulations, and any failure to comply with applicable laws could subject us to significant liability and harm our business.

 

The sales, marketing and pricing of products and the relationships that medical products companies have with healthcare providers such as physicians, hospitals, ASCs, and others are under increased scrutiny. Our industry is subject to various laws and regulations pertaining to healthcare fraud and abuse, as well as other laws that impose extensive tracking and reporting related to all transfers of value provided to certain health care providers and others. These laws include the False Claims Act, the Anti-Kickback Statute, the Stark law, the Physician Payments Sunshine Act, the FDCA, and similar laws and regulations in the U.S. and around the world. These laws and regulations are broad in scope and are subject to evolving interpretation. We could be required to incur substantial costs to investigate, audit, and monitor compliance or to alter our practices, to the extent that we are subject to government scrutiny under these laws. In addition, we are subject to various laws concerning anti-corruption and anti-bribery matters (including the Foreign Corrupt Practices Act), sales to countries or persons subject to economic sanctions and other matters affecting our international operations. Violations of these laws are punishable by criminal and/or civil sanctions, including, in some instances, fines, imprisonment and, within the United States, exclusion from participation in government healthcare programs, including Medicare, Medicaid and Veterans Administration health programs. These laws are administered by, among others, the U.S. Department of Justice, the U.S. Department of Health and Human Services Office of Inspector General, the Securities and Exchange Commission, the Office of Foreign Access Control, the Bureau of Industry and Security of the U.S. Department of Commerce, and state attorneys general. Any failure to comply with these laws could subject us to significant liabilities, which could have a material adverse effect on our business, financial condition, and results of operations.

 

33
 

 

We are subject to environmental regulations and any failure to comply with applicable laws could subject us to significant liabilities and harm our business.

 

We are subject to a variety of local, state, federal, and foreign government regulations relating to the storage, discharge, handling, emission, generation, manufacture, and disposal of toxic or other hazardous substances used in the manufacture of our products. Any failure by us to control the use, disposal, removal, or storage of hazardous chemicals or toxic substances could subject us to significant liabilities, which could have a material adverse effect on our business, financial condition, and results of operations.

 

Risks Related to Our Growth Initiatives

 

We may have difficulty managing our growth.

 

As a result of our activities, we have experienced substantial growth in the number of our employees, the scope of our product portfolio and pipeline, the size of our operating and financial systems, and the geographic area of our operations. This growth has resulted in increased responsibilities for our management. To manage our growth effectively, we must continue to expand our management team, attract, motivate and retain employees, and improve our operating and financial systems. There can be no assurance that our current management systems will be adequate or that we will be able to manage our recent or future growth successfully. Any failure to do so could have a material adverse effect on our business, operating results and financial condition. 

 

We may not generate the expected benefits of our acquisitions, and the ongoing integration of those acquisitions could disrupt our ongoing business, distract our management and increase our expenses.

 

Through our acquisitions of Parcus Medical and Arthrosurface, we expanded our product portfolio and pipeline, diversified our business, expanded our commercial infrastructure, entered new markets, and increased the scope of our operations and the number of our employees. The continued successful integration of these other companies into our operations is critical to our future financial performance. This will require that we continue to integrate more closely the companies’ product offerings and research and development capabilities, retain key employees, assimilate diverse corporate cultures, further integrate management and financial information systems, consolidate the acquired operations and manage geographically dispersed operations, among other things, each of which could pose significant challenges. The difficulty of combining the acquired companies with our company may be increased by the need to integrate personnel, and changes effected in the combination may cause key employees to leave. To succeed in the market for joint preservation and restoration, we must also invest additional resources, primarily in the areas of sales and marketing, to extend name recognition and increase market share.

 

The integration of the two acquired companies into our operations has taken longer than originally anticipated and has required more effort and expense than was originally planned. This has resulted, and may continue to result, in the loss of valuable employees, additional expenses, the disruption of our ongoing business, processes and systems, or inconsistencies in standards, controls, procedures, practices, policies and compensation arrangements, any of which could adversely affect our ability to achieve the anticipated benefits of the acquisitions. There may be increased risk due to the ongoing integration of financial reporting and internal control systems. Any diversion of the attention of management created by the integration process, any disruptions or other difficulties encountered in the integration process, and unforeseen liabilities or unanticipated problems with the acquired businesses could have a material adverse effect on our business, operating results and financial condition. We are working diligently to complete integration activities, minimize employee disruptions and improve manufacturing and operations processes and communication as we continue to integrate the Arthrosurface and Parcus Medical businesses. It has been more challenging than anticipated to effectively and timely complete our integration goals. We recorded an impairment to goodwill in 2020 and a reduction in the fair value of contingent consideration in connection with the acquisitions that was driven in part by the significant effect that COVID-19 has had on the business industry.

 

There can be no assurance that these acquisitions will provide the benefits we expect or that we will be able to integrate and develop the operations of Parcus Medical and Arthrosurface successfully. Any failure to do so could have a material adverse effect on our business, operating results and financial condition.

 

We expect to continue to actively explore inorganic growth as a part of our future growth strategy, which exposes us to a variety of risks that could adversely affect our business operations.

 

Our business and future growth strategy includes as an important component the acquisition of businesses, technologies, services, assets or products that we believe are a strategic fit with or otherwise provide value to our business. We may fund these acquisitions by utilizing our cash, incurring debt, issuing additional shares of our common stock, or by other means. Completed transactions may expose us to a number of risks and expenses, including unanticipated liabilities, amortization expenses related to intangible assets with definite lives, or risks associated with entering new markets with which we have limited experience or where commercial alliances with experienced partners or existing sales channels are not available. Whether or not completed, transactions may result in diversion of management resources otherwise available for ongoing development of our business and significant expenditures.

 

34
 

 

Customer and employee uncertainty about the effects of any acquisitions could harm us.

 

Customers of any companies or technologies that we acquire may, in response to the consummation of the acquisitions, delay or defer purchasing decisions, which could adversely affect the success of our acquired businesses. Similarly, employees of acquired companies may experience uncertainty about their future roles, which may adversely affect our ability to attract and retain key management, sales, marketing, and technical personnel following an acquisition. 

 

As our international sales and operations grow, we could become increasingly subject to additional economic, political, and other risks that could harm our business.

 

Since we manufacture our products for sale worldwide, our business is subject to risks associated with doing business internationally. During 2022, 2021, and 2020, 24%, 23%, and 21%, respectively, of our product sales were to international customers. We continue to be subject to a variety of risks, which could cause fluctuations in the results of our international and domestic operations. These risks include:

 

 

●

The impact of recessions, inflation and other economic conditions in economies, including the impact of the COVID-19 pandemic, outside the United States;
 

●

Instability of foreign economic, political, and labor conditions;
 

●

Fluctuations in foreign currency exchange rates relative to the U.S. dollar;
 

●

Unfavorable labor regulations applicable to our European operations, such as severance and the unenforceability of non-competition agreements in the European Union;
 

●

The impact of strikes, work stoppages, work slowdowns, grievances, complaints, claims of unfair labor practices, or other collective bargaining disputes;
 

●

Difficulties in complying with restrictions imposed by regulatory or market requirements, tariffs, or other trade barriers or by U.S. export laws;
 

●

Imposition of government controls limiting the volume of international sales;
 

●

Longer accounts receivable payment cycles;
 

●

Potentially adverse tax consequences, including, if required or applicable, difficulties transferring funds generated in non-U.S. jurisdictions to the United States in a tax efficient manner;
 

●

Difficulties in protecting intellectual property, especially in international jurisdictions;
 

●

Difficulties in managing international operations; and
 

●

Burdens of complying with a wide variety of foreign laws, including the EU MDR and GDPR among others.

 

Our success depends, in part, on our ability to anticipate and address these and any new risks. We cannot guarantee that these or other factors will not adversely affect our business or operating results.

 

Risks Related to Our Intellectual Property

 

We may be unable to adequately protect our intellectual property rights, which could have a material impact on our business and future financial results.

 

Our efforts to enforce our intellectual property rights may not be successful. We rely on a combination of copyright, trademark, patent, and trade secret laws, confidentiality procedures, and contractual provisions to protect our proprietary rights. Our success will depend, in part, on our ability to obtain and enforce patents and trademarks, to protect trade secrets, to obtain licenses to technology owned by third parties when necessary, and to conduct our business without infringing on the valid proprietary rights of others. The patent positions of pharmaceutical, medical product, and biotechnology firms, including ours, can be uncertain and involve complex legal and factual questions. There can be no assurance that any patent applications will result in the issuance of patents or, if any patents are issued, that they will provide significant proprietary protection or commercial advantage or will not be circumvented by others. Filing and prosecution of patent applications, litigation to establish the validity and scope of patents, assertion of patent infringement claims against others, and the defense of patent infringement claims by others can be expensive and time consuming. There can be no assurance that, in the event that any claims with respect to any of our patents, if issued, are challenged by one or more third parties, any court or patent authority ruling on such challenge will determine that such patent claims are valid and enforceable. An adverse outcome in such litigation or patent review process could cause us to lose exclusivity covered by the disputed rights. If a third party is found to have rights covering products or processes used by us, we could be forced to cease using the technologies or marketing the products covered by such rights, we could be subject to significant liabilities to such third party, and we could be required to license technologies from such third party in order to continue production of the products. Furthermore, even if our patents are determined to be valid, enforceable, and broad in scope, there can be no assurance that competitors will not be able to design around such patents and compete with us using the resulting alternative technology. We have a policy of seeking patent protection for patentable aspects of our proprietary technology. We intend to seek patent protection with respect to products and processes developed in the course of our activities when we believe such protection is in our best interest and when the cost of seeking such protection is appropriate. However, no assurance can be given that any patent application will be filed, that any filed applications will result in issued patents, or that any issued patents will provide us with a competitive advantage or will not be successfully challenged by third parties. The protections afforded by patents will depend upon their scope and validity, and others may be able to design around our patents. 

 

35
 

 

We also rely upon trade secrets and proprietary know-how for certain non-patented aspects of our technology. To protect such information, we have a policy requiring all employees, consultants, and licensees to enter into confidentiality agreements limiting the disclosure and use of such information. There can be no assurance that these agreements provide meaningful protection or that they will not be breached, that we would have adequate remedies for any such breach, or that our trade secrets, proprietary know-how, and our technological advances will not otherwise become known to others. In addition, there can be no assurance that, despite precautions taken by us, others have not and will not obtain access to our proprietary technology. Further, there can be no assurance that third parties will not independently develop substantially equivalent or better technology.

 

There can be no assurance that we will not infringe upon the intellectual property rights of others, which could have a significant impact on our business and financial results.

 

Other entities have filed patent applications for, or have been issued patents concerning, various products or processes in the segments in which we do business. There can be no assurance that the products or processes developed by us will not infringe on the patent rights of others in the future. The cost of defending infringement suits is typically large, and there is no guarantee that any future defense would be successful. In addition, infringement could lead to substantial damages payouts or our inability to produce or market certain of our current or future products. As a result, any such infringement may have a material adverse effect on our business, financial condition, and results of operations.

 

Risks Related to the COVID-19 Pandemic

 

Our operations are located in areas impacted by the COVID-19 pandemic, and those operations have been, and may continue to be, adversely affected by the COVID-19 pandemic.

 

The coronavirus has impacted the social and economic framework globally. Our administrative, research and development, and manufacturing operations are principally performed at our U.S. facilities in Massachusetts and Florida. Though our Italian operations represent a relatively small percentage of our consolidated business, we conduct commercial activity, product development, sales, logistics, inventory management and supply chain activities, and other services in our office in Padova, Italy. Our business operations in the United States and Italy are subject to potential business interruptions arising from protective measures that have been or may be taken by Italian, U.S., Massachusetts and Florida regulators and other government agencies due to COVID-19 or its variants. Business disruptions elsewhere in the world could also negatively affect the sources and availability of components and materials that are essential to the operation of our business in both the United States and Italy. Our commercial day-to-day operations have been, and may in the future be, significantly impacted by cancellations or delays of elective procedures in hospitals and ASCs, and timelines associated with certain clinical studies and research and development programs have been delayed.

 

Stay-at-home orders, business closures, travel restrictions, supply chain disruptions, employee illness or quarantines, our or our suppliers’ ability to hire employees and other extended periods of interruption to our business have resulted in disruptions to our operations, caused us to cease or delay operations, and prevented our customers from receiving shipments or processing payments. All these impacts could continue as new variants of COVID-19 could continue to impact our business. If a number of our essential employees become sick or otherwise unable to continue working during the current or any future epidemic, our operations may be harmed. Also, the remote work environment made necessary by the COVID-19 pandemic may exacerbate various cybersecurity risks to our business, including an increased demand for information technology resources, an increased risk of phishing and other cybersecurity attacks, and an increased risk of unauthorized dissemination of sensitive personal information or proprietary or confidential information. Extended periods of interruption to our corporate, development or manufacturing facilities due to the COVID-19 pandemic have caused or could cause us to lose revenue and market share, which has depressed and could continue to depress our financial performance and may be difficult to recapture. Employee disruptions and remote working environments related to the COVID-19 pandemic have impacted, and are continuing to impact, the efficiency and pace with which we work and develop our product candidates and our manufacturing capabilities.

 

36
 

 

In addition, the COVID-19 pandemic and related economic uncertainties have increased challenges associated with hiring highly skilled and experienced employees and may continue to create challenges and/or adversely impact employee retention due to the additional financial, family, and health burdens that many employees or potential employees may be experiencing. Our industry’s highly competitive market for skilled workers and leaders may negatively affect our ability to retain qualified employees. Losing members of our senior management and other highly skilled personnel could prevent us from achieving our business objectives or divert management’s attention to seeking qualified replacements and ensuring seamless transitions.

 

The COVID-19 pandemic resulted in a significant reduction in the number of elective surgeries being performed since 2020 and the lingering impact of the pandemic has slowed the pace of new product approvals by current and potential customers, which has decreased the usage of, and revenue from, certain of our products.

 

A significant portion of the demand for our products results from the usage of our products in elective surgeries. Since 2020, we have experienced a significant decline in procedure volume in the U.S. compared to previous levels, as healthcare systems diverted resources to meet the increasing demands of managing COVID-19 and subsequently encountered significant staffing challenges when trying to support procedures.

 

In addition, primarily as a result of the impacts of COVID-19 including stay-at-home orders and other attempts to limit in-person meetings, and ongoing staffing challenges, hospitals and ASCs at times delayed having meetings of their committees to review and approve the introduction of new products into their facilities. As we are focused on growing our business by introducing new products to existing and new hospital and ASC customers, the inability to have our products timely reviewed and approved by these customers has also negatively impacted our revenue and operating results as delays in product approvals impact and draw out product adoption timelines. It is uncertain whether elective surgeries or product review and approval processes will be negatively impacted or halted again in the future by a resurgence of COVID-19.

 

The COVID-19 pandemic, its variants or other similar pandemics could adversely impact our development activities, preclinical studies and clinical trials, which could significantly impair our long-term business plans and operating results.

 

The timely initiation and completion of our preclinical and development activities and clinical trials depend upon the availability of facility access, preclinical study and clinical trial sites, researchers and investigators, regulatory agency personnel, and materials, all of which may be adversely affected by the COVID-19 pandemic, its variants or other similar pandemics. The timing of our clinical trials depends on our ability to recruit patients to participate as well as the completion of required follow-up periods. The COVID-19 pandemic has had and may continue to have a sustained impact on our ability to recruit, enroll, treat and follow-up with patients either due to renewed restrictions on travel or shelter-in-place orders or policies, or due to changes in patient willingness to participate in trials or travel to study sites during a pandemic. The timeline for recruiting patients, conducting trials and obtaining regulatory approval of our product candidates have been and may in the future be delayed, which could result in increased costs, delays in advancing our product candidates, delays in testing the effectiveness of our product candidates or termination of the clinical trials altogether. Factors resulting from the COVID-19 pandemic, its variants or other similar pandemics that could delay or otherwise adversely affect the completion of our preclinical activities and the planned activities related to our clinical trials, as well as our business generally, include: 

 

 

●

the potential diversion of healthcare resources away from the conduct of preclinical activities and clinical trials to focus on pandemic concerns, including the availability of necessary materials and the attention of physicians serving as our clinical trial investigators, hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our prospective clinical trials;

 

 

●

limitations on travel that could interrupt key preclinical and clinical activities, such as clinical trial site initiations and monitoring, domestic and international travel by employees, contractors or patients to clinical trial sites, including any government-imposed travel restrictions or quarantines that will impact the ability or willingness of patients, employees or contractors to travel to our research, manufacturing and clinical trial sites or secure visas or entry permissions, any of which could delay or adversely impact the conduct or progress of our prospective clinical trials;

 

37
 

 

 

●

interruption or delays in the operations of the FDA and comparable foreign regulatory agencies, which may impact review, inspection, clearance and approval timelines;

 

 

●

interruption in global shipping affecting the transport of clinical trial materials, such as patient samples, product candidates and supplies, to be used in our prospective clinical trials;

 

 

●

limitations on our business operations by government authorities that could impact our ability to conduct our preclinical or clinical activities; and

 

 

●

business disruptions caused by potential workplace, laboratory and office closures and an increased reliance on employees working from home, disruptions to or delays in ongoing laboratory experiments and operations, staffing shortages, travel limitations, cyber security and data accessibility, or communication or mass transit disruptions, any of which could adversely impact our business operations or delay necessary interactions with local regulators, ethics committees, manufacturing sites, research or clinical trial sites, and other important agencies and contractors.

 

Our global supply chain may be materially adversely impacted due to the ongoing impacts of the COVID-19 pandemic, its variants or other pandemics.

 

We rely upon the facilities of our global suppliers to support our business. The COVID-19 pandemic resulted in significant governmental measures being implemented in many countries to control the spread of COVID-19, including restrictions on manufacturing and the movement of employees. As a result of COVID-19 and the measures designed to contain its spread, certain of our suppliers did not have the materials, staffing, capacity, or capability to supply our needed materials and other supplies that we require to manufacture our products according to our schedule and specifications. It is uncertain whether and to what extent these supply chain challenges will continue or fully recover following the direct and indirect impacts of COVID-19. Further, logistics issues, including our ability and our supply chain’s ability to quickly ramp up production, and transportation demands may cause delays. If our suppliers’ operations are curtailed, we may need to seek alternate sources of supply, which may be more expensive or require approval from regulatory agencies which could cause further delays. Alternate sources may not be available or may result in delays in shipments to us from our supply chain and subsequently to our customers, each of which would affect our results of operations. If the duration of the production and supply chain disruptions continue for an extended period of time, the impact on our supply chain could have a material adverse effect on our results of operations and cash flows.

 

Risks Related to Ownership of Our Common Stock

 

Our stock price may be highly volatile, and we cannot assure you that market making in our common stock will continue.

 

The market price of shares of our common stock may be highly volatile. Factors such as announcements of new commercial products or technological innovations by us or our competitors, disclosure of results of clinical testing or regulatory proceedings, government regulation and approvals, developments in patent or other proprietary rights, public concern as to the safety of products developed by us, and general market conditions may have a significant effect on the market price of our common stock. We have highlighted to investors increased volatility and uncertainty in the global macroeconomic environment and the changing dynamics associated with staffing shortages, supply chain disruption, inflation and other direct and indirect impacts of the COVID pandemic. These actions, as well as general investor uncertainty, could create volatility and unpredictability in our stock price. The trading price of our common stock could also be subject to wide fluctuations in response to quarter-to-quarter variations in our operating results, material announcements by us or our competitors, governmental regulatory action, conditions in the health care industry generally or in the medical products industry specifically, or other events or factors, many of which are beyond our control. In addition, the stock market has experienced extreme price and volume fluctuations, which have particularly affected the market prices of many medical products companies, and which often have been unrelated to the operating performance of such companies. Our operating results in future quarters may be below the expectations of equity research analysts and investors. In such an event, the price of our common stock would likely decline, perhaps substantially. 

 

Our charter documents contain anti-takeover provisions that may prevent or delay an acquisition of our company.

 

Our charter documents contain anti-takeover provisions that could prevent or delay an acquisition of our company. The provisions include, among others, a classified board of directors, advance notice to the board of stockholder proposals, limitations on the ability of stockholders to remove directors and to call stockholder meetings, and a provision that allows vacancies on the Board of Directors to be filled by vote of a majority of the remaining directors. We are also subject to Section 203 of the Delaware General Corporate Law which, subject to certain exceptions, prohibits a Delaware corporation from engaging in any of a broad range of business combinations with any “interested stockholder” for a period of three years following the date that such stockholder becomes an interested stockholder. Those provisions could have the effect of discouraging a third party from pursuing a non-negotiated takeover of our company at a price considered attractive by many stockholders and could have the effect of preventing or delaying a potential acquirer from acquiring control of our company.

 

38
 

 

If securities or industry analysts do not publish or cease publishing research or reports about us, our business, or our market, or if they adversely change their recommendations regarding our stock, our stock price and trading volume could decline.

 

The trading market for our common stock is influenced by the research and reports that securities or industry analysts may publish about us, our business, our market, or our competitors. No person is under any obligation to publish research or reports on us, and any person publishing research or reports on us may discontinue doing so at any time without notice. If adequate research coverage is not maintained on our company or if any of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business or provide relatively more favorable recommendations about our competitors, our stock price would likely decline. If any analysts who cover us were to cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.

 

We have been, and may continue to be, subject to the actions of activist stockholders, which could cause us to incur substantial costs, divert management’s and the board’s attention and resources, and have an adverse effect on our business and stock price.

 

From time to time, we may be subject to proposals by activist stockholders urging us to take certain corporate actions or to nominate certain individuals to our board of directors. In February 2023, Caligan Partners LP, or Caligan, indicated that it intends to consider all available options, including nominating a slate of directors for election to the board of directors at our 2023 annual meeting of stockholders. If activist stockholder activities, such as those by Caligan or other stockholders, ensue, our business could be adversely affected, as responding to proxy contests and reacting to other actions by activist stockholders can be costly and time-consuming, disrupt our operations and divert the attention of management and our board of directors. For example, we have retained the services of various professionals to advise us on activist stockholder matters, including legal, financial, and communications advisors, the costs of which negatively impact our financial results and we may be required to retain additional services in the future, which could have a further negative impact on our financial results. In addition, perceived uncertainties as to our future direction, strategy or leadership created as a consequence of activist stockholder initiatives may result in the loss of potential business opportunities, harm our ability to attract new investors, customers, and employees, and cause our stock price to experience periods of volatility or stagnation.

 

ITEM 1B. UNRESOLVED STAFF COMMENTS

 

[None].

 

ITEM 2. PROPERTIES

 

We maintain leases on six facilities, including our corporate headquarters location in Bedford, Massachusetts, where we lease approximately 134,000 square feet of administrative, research and development, and manufacturing space. The lease on this facility contains multiple extension options that allow us to extend the term through October 2038. Our other lease locations are in Franklin, Massachusetts, Sarasota, Florida, Warsaw, Indiana and Padova, Italy. These additional facilities provide us with an aggregate of over 80,000 square feet of additional space and have terms expiring between 2022 and 2032, subject to certain renewal provisions contained within the lease agreements.

 

See Note 9, Leases, to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K for additional information regarding our specific leaseholds.

 

ITEM 3. LEGAL PROCEEDINGS

 

We are involved from time-to-time in various legal proceedings arising in the normal course of business. Although the outcomes of these legal proceedings are inherently difficult to predict, we do not expect the resolution of these proceedings to have a material adverse effect on our financial position, results of operations, or cash flows.

 

On October 21, 2021, we received notice that the former unitholders of Parcus Medical had filed a request for arbitration regarding the earnout provisions agreed to in the Parcus Medical Merger Agreement. We have engaged in the arbitration process and do not anticipate a resolution during the first half of 2023. We are unable to estimate the potential liability with respect to this matter at this time. There are numerous factors that make it difficult to estimate reasonably possible loss or range of loss at this stage of the matter, including the significant number of legal and factual issues still to be resolved in the arbitration process. We intend to vigorously defend against the claims, and we believe that we have strong defenses to the claims asserted.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

39
 

 

PART II

 

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

 

Common Stock Information

 

Our common stock has traded on the NASDAQ Global Select Market since November 25, 1997, under the symbol “ANIK.” At December 31, 2022, the closing price per share of our common stock was $29.60 as reported on the NASDAQ Global Select Market, and there were 111 holders of record. We believe that the number of beneficial owners of our common stock at that date was substantially greater, due to shares being held by intermediaries.

 

We have never declared or paid any cash dividends on our common stock. We currently intend to retain earnings, if any, for use in our business and do not anticipate paying cash dividends on our common stock in the foreseeable future. Payment of future dividends, if any, on our common stock will be at the discretion of our Board of Directors after considering various factors, including our financial condition, operating results, anticipated cash needs, and plans for expansion.

 

Performance Graph

 

Set forth below is a graph comparing the total returns of our company, the NASDAQ Composite Index, and the NASDAQ Biotechnology Index. The graph assumes $100 is invested on December 31, 2017, in our common stock and each of the indices. Past performance is not indicative of future results.

 

perf.jpg

 

 

   

Dec-17

    

Dec-18

    

Dec-19

    

Dec-20

    

Dec-21

    

Dec-22

  

Anika Therapeutics, Inc.

   $ 100.00     $ 62.34     $ 96.18     $ 83.95     $ 66.46     $ 54.91  

NASDAQ Composite Index

   $ 100.00     $ 96.12     $ 129.97     $ 186.69     $ 226.63     $ 151.61  

NASDAQ Biotechnology Index

   $ 100.00     $ 90.68     $ 112.81     $ 141.78     $ 140.88     $ 125.52  

 

40
 

 

Issuer Purchases of Equity Securities

 

On May 2, 2019, we announced that our Board of Directors approved a $50.0 million share repurchase program with $30.0 million to be utilized for an accelerated share repurchase program, which was completed in January 2020, and $20.0 million reserved for open market repurchases which represents the maximum value of shares that may yet be purchased. No open market repurchases were made during the years ended December 31, 2021 and 2022.

 

Securities Authorized for Issuance Under Equity Compensation Plans

 

For information regarding securities authorized for issuance under our employee stock-based compensation plans, see Part III. Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

 

ITEM 6. [RESERVED]

 

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following section contains statements that are not statements of historical fact and are forward-looking statements within the meaning of the federal securities laws. These statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievement to differ materially from anticipated results, performance, or achievement, expressed or implied in such forward-looking statements. These statements reflect our current views with respect to future events, are based on assumptions, and are subject to risks and uncertainties. We discuss many of these risks and uncertainties at the beginning of this Annual Report on Form 10-K and under the sections captioned “Business” and “Risk Factors.” The following discussion should also be read in conjunction with the consolidated financial statements and the Notes thereto appearing elsewhere in this Annual Report on Form 10-K. 

 

Management Overview

 

We are a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Based on our collaborations with clinicians to understand what they need most to treat their patients, we develop minimally invasive products that restore active living for people around the world. We are committed to leading in high opportunity spaces within orthopedics, including OA, pain management, regenerative solutions, sports medicine and Arthrosurface joint solutions (previously Bone Preserving Joint Solutions).

 

We have thirty years of global expertise developing, manufacturing and commercializing products based on our HA technology platform. HA is a naturally occurring polymer found throughout the body that is vital for proper joint health and tissue function. Our proprietary technologies for modifying the HA molecule allow product properties to be tailored specifically to multiple uses, including enabling longer residence time to support OA pain management and creating a solid form of HA called Hyaff, which is a platform utilized in our regenerative solutions portfolio.

 

In early 2020, we expanded our overall technology platform, product portfolio, and significantly expanded our commercial infrastructure, especially in the United States, through our strategic acquisitions of Parcus Medical, LLC, a sports medicine and instrumentation solutions provider, and Arthrosurface, Inc., a company specializing in bone preserving partial and total joint replacement solutions. These acquisitions, have ignited the transformation of our company by augmenting our HA-based OA pain management and regenerative products with a broad suite of products and capabilities focused on early intervention joint preservation primarily in upper and lower extremities such as shoulder, foot/ankle, knee and hand/wrist.

 

As we look towards the future, our business is positioned to capture value within our target market of joint preservation. We believe our success will be driven by our:

 

 

●

Decades of experience in HA-based regenerative solutions and early intervention orthopedics combined under new seasoned leadership with a strong financial foundation for future investment in meaningful solutions for our customers and their patients;

 

41
 

 

 

●

Robust network of stakeholders in our target markets to identify evolving unmet patient treatment needs;

 

 

●

Prioritized investment in differentiated pipeline of regenerative solutions, bone preserving implants and sports medicine products;

 

 

●

Leveraging our global commercial expertise to drive growth across the portfolio, with an intentional site of care focus on ASCs in the United States;

 

 

●

Opportunity to pursue strategic inorganic growth opportunities, including potential partnerships and smaller acquisitions, technology licensing, and leveraging our strong financial foundation and operational capabilities; and

 

 

●

Energized and experienced team focused on strong values, talent, and culture.

 

For additional information regarding our business, please refer to “Item 1. Business” of this Annual Report on Form 10-K.

 

Key Developments during the Year Ended December 31, 2022

 

 

o

Strengthened #1 U.S. market share position for 2022 in OA Pain Management with single-injection Monovisc and multi-injection Orthovisc (SmartTRAK 2022 data). In August 2022, DePuy Mitek extended our license and supply agreement for Orthovisc for another 5-year term through December 2028.
 

o

Continued accelerated growth of Tactoset, Anika’s regenerative solution for insufficiency fractures and soft tissue hardware augmentation, with multiple planned 510(k)s targeting further expansion.
 

o

Cingal, Anika’s next generation, non-opioid, single-injection HA-based product combined with fast-acting steroid, successfully achieved its primary endpoint in a third Phase III clinical trial, Cingal 19-01, which demonstrated the superiority of Cingal over steroid alone, for OA pain relief at 26 weeks. Together with previous studies, Cingal has shown superiority over each of its active ingredients and placebo, consistently demonstrating strong and durable pain relief in OA patients. Engaging with the FDA regarding next steps for U.S. regulatory approval and exploring the potential to advance Cingal through commercial partnerships in the U.S. and select Asian markets.
 

o

Submitted multiple 510(k)s for a new innovative HA-based regenerative rotator cuff system, which will further build upon Anika's growing and differentiated shoulder portfolio.
 

o

Hyalofast has been designated as a Breakthrough Device by the FDA, allowing prioritized interaction and review. Approaching full enrollment in pivotal Phase III clinical trial with 199 of 200 subjects enrolled.  Company expects to be on track to file for a Premarket Approval (PMA) with the FDA in 2025.
 

o

Completed development of RevoMotion Reverse Shoulder Arthroplasty System, with limited market release initiated and first surgeries performed in Q1 2023. RevoMotion’s differentiated bone preserving design expands Anika’s shoulder arthroplasty portfolio in the over $800 million U.S. reverse shoulder market and offers the industry’s smallest diameter threaded glenoid baseplate.
 

o

Received 510(k) clearance and launched new X-Twist Fixation System, Anika’s cornerstone suture anchor system, with full market launch in early 2023 following successful limited launch in the second half of 2022. X-Twist is a key addition to Anika’s portfolio and is uniquely positioned to address the needs of surgeons performing high volume soft tissue repair procedures such as rotator cuff repair and ankle stabilization surgeries.

 

42
 

 

Impact of COVID-19 Pandemic

 

In March 2020, the World Health Organization declared the spread of the COVID-19 virus a pandemic. This pandemic caused an economic downturn globally, which created volatility in our results due to the worldwide cancellation or delay of elective procedures, staffing shortages and supply chain disruptions, as well as the impact on timelines associated with certain clinical studies. Please see the section captioned “Part I. Item 1A. Risk Factors” of this Annual Report on Form 10-K for additional information with respect to the risks faced by our business in light of the COVID-19 pandemic. While the impact has been limited to these items to date, we caution that there continues to be a possibility for potential future implementation of certain additional restrictions or other challenges associated with infections, staffing shortages or supply chain disruptions due to COVID-19 and current or new variants in certain jurisdictions. The impact of these challenges is currently unknown but could be significant and we continue to take precautions so as not to disrupt our business.

 

Products

 

OA Pain Management

 

Our OA Pain Management product family consists of Monovisc and  Orthovisc, our injectable, HA-based viscosupplement offerings that are indicated to provide pain relief from osteoarthritis conditions; Cingal, our novel, next-generation, single-injection OA Pain Management product consisting of our proprietary cross-linked HA material combined with a fast-acting steroid, designed to provide both short- and long-term pain relief, which is currently sold outside the United States in over 35 countries; and Hyvisc, our high molecular weight injectable HA veterinary product.

 

Joint Preservation and Restoration

 

Our Joint Preservation and Restoration product family consists of: (a) our portfolio of over 150 bone preserving joint technology products, including partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants, designed to treat upper and lower extremity orthopedic conditions caused by trauma, injury and arthritic disease; (b) our line of sports medicine solutions used to repair and reconstruct damaged ligaments and tendons due to sports injuries, trauma and disease; and (c) our orthopedic regenerative solutions products, including Hyalofast and Tactoset.

 

Non-Orthopedic

 

Our Non-Orthopedic product family consists of legacy HA-based products that are marketed principally for non-orthopedic applications, including our adhesion barrier product, advanced wound care products, our ear, nose and throat products, and our ophthalmic products.

 

For additional information with respect to our products, including information related to how they are sold and new product development initiatives, please see the sections captioned “Products,” “Sales Channels,” and “Research and Development” contained within “Part I. Item I. Business” of this Annual Report on Form 10-K.

 

43
 

 

Results of Operations

 

Year ended December 31, 2022 compared to year ended December 31, 2021

 

Statement of Operations Detail

 

   

Years Ended December 31,

 
   

2022

    

2021

    

$ Change

    

% Change

  
   

(in thousands, except percentages)

  

Revenue

   $ 156,236     $ 147,794     $ 8,442       6 %

Cost of revenue

     62,660       64,851       (2,191 )     (3% )

Gross profit

     93,576       82,943       10,633       13 %

Gross margin

     60 %     56 %                

Operating expenses:

                                

Research & development

     28,182       27,327       855       3 %

Selling, general & administrative

     84,794       74,096       10,698       14 %

Change in fair value of contingent consideration

     -       (21,095

)

     21,095       (100% )

Total operating expenses

     112,976       80,328       32,648       41 %

(Loss) income from operations

     (19,400 )     2,615       (22,015

)

     (842% )

Interest and other expense, net

     654       (188

)

     842       (448% )

(Loss) income before income taxes

     (18,746 )     2,427       (21,173 )     (872% )

Benefit from income taxes

     (3,887 )     (1,707

)

     (2,180 )     128 %

Net (loss) income

   $ (14,859 )   $ 4,134     $ (18,993 )     (459% )

 

Revenue

 

The following table presents revenue by product family for fiscal years 2022 and 2021 (dollars in thousands): 

 

   

Years Ended December 31,

  
   

2022

    

2021

    

$ Change

    

% Change

  
                                 

OA Pain Management

   $ 97,887     $ 89,503     $ 8,384       9 %

Joint Preservation and Restoration

     50,402       48,588       1,814       4 %

Non-Orthopedic

     7,947       9,703       (1,756 )     (18% )
    $ 156,236     $ 147,794     $ 8,442       6 %

 

Revenue for the year ended December 31, 2022 was $156.2 million, an increase of $8.4 million, or 6%, compared to the prior year. The increase in revenue was driven by recovery outside the U.S. from the initial impact of the COVID-19 pandemic on sales volumes and related strategic partner ordering patterns, as well as from growing global commercial adoption of our products.

 

Revenue from our OA Pain Management product family increased 9% for the year ended December 31, 2022, as compared to prior year, due primarily to higher international sales on recovery from the initial impact of the COVID-19 pandemic, favorable ordering patterns and growth in adoption of our products globally. The increase was also a result of growth in Mitek revenues as well as higher veterinary sales on favorable order patterns and COVID-19 recovery. 

 

Revenue from our Joint Preservation and Restoration product family increased 4% for the year ended December 31, 2022, as compared to prior year, due to improving elective procedure volumes and rapidly growing commercial adoption of our newest products.

 

44
 

 

Revenue from our Non-Orthopedic product family decreased 18% for the year ended December 31, 2022, as compared to prior year, primarily due to timing of distributor sales as well as last-time purchases of legacy products during 2021.

 

Gross Profit and Margin

 

Gross profit for the year ended December 31, 2022 was $93.6 million, or gross margin of 60%, as compared with $82.9 million, or gross margin of 56%, for the year ended December 31, 2021. The increase in gross profit for the year ended December 31, 2022, primarily resulted from higher revenue growth and the conclusion of the amortization of inventory step-up costs related to the 2020 Arthrosurface and Parcus Medical acquisitions. This increase was partially offset by higher product rationalization charges, as well as higher manufacturing-related costs. Gross margin includes acquisition-related amortization expenses and the impact of inventory step-up costs associated with the Arthrosurface and Parcus Medical acquisitions. These expenses together increased cost of revenue by $6.2 million, or 7 points of gross margin, for the year ended December 31, 2022, as compared to increased cost of revenue of $12.7 million, or 9 points of gross margin for the same periods in 2021.

 

Research and Development

 

Research and development expenses for the year ended December 31, 2022 were $28.2 million, an increase of $0.9 million, or 3%, as compared to the prior year, primarily due to increased costs to ensure compliance with growing regulatory requirements globally as well as new product development associated with our research and development pipeline. Also included in research and development expenses are clinical costs. We completed a third Phase III clinical trial for Cingal in 2022, which achieved its primary endpoint, and made significant progress in completing enrollment in our Hyalofast clinical trial.

 

For additional information on our research and development activities, please see the section captioned “Part I. Item 1. Business—Research and Development” in this Annual Report on Form 10-K.

 

Selling, General and Administrative

 

Selling, general and administrative, or SG&A, expenses for the year ended December 31, 2022 were $84.8 million, an increase of $10.7 million, or 14%, as compared to the prior year. The increase in SG&A expenses for the year ended December 31, 2022 was primarily related to the expansion of our commercial capability in the United States, including increased marketing, medical education and other operational capabilities to support our growing business needs, as well as increased commissions on higher sales. The growth in SG&A expenses also reflects the increase in certain activities that were curtailed in the early stages of the COVID-19 pandemic, such as travel, as well as higher stock-based compensation expense driven by the growth in personnel to support Anika’s strategic transformation, and higher general corporate costs.

 

Contingent Consideration Fair Value Change

 

In the year ended December 31, 2021, we recorded a $21.1 million net benefit related to the change in fair value of our contingent consideration liabilities incurred associated with the acquisitions of Parcus Medical and Arthrosurface in 2020. The liability for contingent consideration is remeasured at each reporting period until the contingency is resolved. The decrease in fair value of the contingent consideration was due primarily to the decrease in the likelihood that certain contingent milestones would be achieved or because certain contingent milestones were not achieved. In July 2021, we made a regulatory milestone payment in connection with the Arthrosurface acquisition in the amount of $10.0 million upon obtaining a regulatory clearance for a reverse shoulder implant system. In September 2022, we made a milestone payment in connection with the Parcus Medical acquisition in the amount of $4.3 million. As of December 31, 2022, we do not expect that any additional milestones associated with the Parcus Medical and Arthrosurface acquisitions to be achieved.

 

Income Taxes

 

The benefit from income taxes was $3.9 million for the year ended December 31, 2022, resulting in an effective tax rate of 20.7%. The benefit from income taxes was $1.7 million for the year ended December 31, 2021, resulting in an effective tax rate of (70.4%). The increase in our effective rate for the year ended December 31, 2022 as compared to the year ended December 31, 2021 is primarily due to the change in fair value of contingent consideration and the release of the valuation allowance related to the net deferred tax assets in Italy during 2021.

 

Net Income (Loss)

 

For the year ended December 31, 2022, net loss was $14.9 million, or $1.02 per diluted share, compared to net income of $4.1 million, or $0.28 per diluted share, for the prior year. The decrease in net income and diluted earnings per share was primarily due to the net of tax benefit of $17.0 million recorded in 2021 related to the reduction in fair value of contingent consideration, as well as higher operating expenses in 2022 primarily driven by increased spending to expand our commercial capability and development of new products, partially offset by higher revenues and favorable gross profit in 2022.

 

45
 

 

Non-GAAP Financial Measures

 

We present certain information with respect to adjusted gross profit and adjusted gross margin, adjusted Earnings Before Interest, Tax, Depreciation and Amortization, or EBITDA, adjusted net income, adjusted diluted earnings per share or adjusted Earnings Per Share, or EPS, which are financial measures not based on any standardized methodology prescribed by accounting principles generally accepted in the United States, or GAAP, and is not necessarily comparable to similarly titled measures presented by other companies.

 

We have presented adjusted gross profit and adjusted gross margin, adjusted EBITDA, adjusted net income, adjusted EPS, because they are key measures used by our management and board of directors to understand and evaluate our operating performance and to develop operational goals for managing our business. We believe these financial measures help identify underlying trends in our business that could otherwise be masked by the effect of the expenses that we exclude. We believe that the exclusion of these items in calculating these measures can provide a useful tool for period-to-period comparisons of our core operating performance. Accordingly, we believe that these measures provide useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and future prospects and allowing for greater transparency with respect to key financial metrics used by our management in their financial and operational decision-making. 

 

Adjusted Gross Profit and Adjusted Gross Margin

 

We define adjusted gross profit as our gross profit excluding amortization of certain acquired intangible assets, the impact of inventory fair-value step up associated with our recent acquisitions and certain product rationalization charges. The amortized assets contribute to revenue generation, and the amortization of such assets will likely continue in future periods until such assets are fully amortized. These assets include the fair value of certain identified assets acquired in acquisitions, including developed technology and acquired trade names. We define adjusted gross margin as adjusted gross profit divided by total revenue.

 

The following is a reconciliation of adjusted gross profit to gross profit for the years ended December 30, 2022 and 2021, respectively:

 

   

Years Ended December 31,

  
   

2022

    

2021

  

Gross profit

   $ 93,576     $ 82,943  

Product rationalization charges

     3,199       2,445  

Acquisition related intangible asset amortization

     6,240       6,248  

Acquisition related inventory step up

     -       6,465  

Adjusted gross profit

   $ 103,015     $ 98,101  

Adjusted gross margin

     66 %     66 %

 

Adjusted gross profit for the year ended December 31, 2022 increased $4.9 million to $103.0 million representing 66% of revenue. Adjusted gross profit for the year ended December 31, 2021 was $98.1 million, or 66% of revenue. The increase in adjusted gross profit for the year ended December 31, 2022 as compared to 2021, primarily resulted from the growth of revenue. There was no change in adjusted gross margin for the year ended December 31, 2022 as compared to 2021, as the benefits of higher revenue and related production volumes were offset by increased costs and the continued impact of global supply chain and staffing challenges that arose following the COVID-19 pandemic.

 

Adjusted EBITDA

 

We present information below with respect to adjusted EBITDA, which we define as our net income (loss) excluding interest and other income, net, income tax benefit (expense), depreciation and amortization, stock-based compensation, product rationalization charges, and acquisition-related expenses. We have also excluded the impact changes in the fair value of contingent consideration associated with our acquisition transactions in early 2020.

 

Adjusted EBITDA is not prepared in accordance with U.S. GAAP, and should not be considered in isolation of, or as an alternative to, measures prepared in accordance with U.S. GAAP. There are a number of limitations related to the use of adjusted EBITDA rather than net income (loss), which is the nearest U.S. GAAP equivalent. Some of these limitations are:

 

46
 

 

 

•

adjusted EBITDA excludes depreciation and amortization, and, although these are non-cash expenses, the assets being depreciated or amortized may have to be replaced in the future, the cash requirements for which are not reflected in adjusted EBITDA;

 

 

•

we exclude stock-based compensation expense from adjusted EBITDA although (a) it has been, and will continue to be for the foreseeable future, a significant recurring expense for our business and an important part of our employee compensation strategy and (b) if we did not pay out a portion of our compensation in the form of stock-based compensation, the cash salary and bonus expense included in operating expenses likely would be higher, which would affect our cash position;

 

 

•

we exclude acquisition related expenses, including transaction costs and other related expenses, amortization and depreciation of acquired assets in recent acquisitions, and the impact of inventory fair-value step up on cost of goods sold;

 

 

•

we exclude certain impairment charges, including impairment related to In-Process Research and Development, or IPR&D, assets, certain product rationalization charges, the impact of COVID-19 and changing regulatory requirements;

 

 

•

we exclude goodwill impairment charges and changes in the fair value of contingent consideration;

 

 

•

the expenses and other items that we exclude in our calculation of adjusted EBITDA may differ from the expenses and other items, if any, that other companies may exclude from adjusted EBITDA when they report their operating results;

 

 

•

adjusted EBITDA does not reflect changes in, or cash requirements for, working capital needs;

 

 

•

adjusted EBITDA does not reflect provision for (benefit from) income taxes or the cash requirements to pay taxes; and

 

 

•

adjusted EBITDA does not reflect historical cash expenditures or future requirements for capital expenditures or contractual commitments.

 

The following is a reconciliation of adjusted EBITDA to net income (loss) for the years ended December 31, 2022 and 2021 respectively:

 

   

Years Ended December 31,

  
   

2022

    

2021

  

Net (loss) income

   $ (14,859 )   $ 4,134  

Interest and other expense, net

     (654 )     188  

Benefit from income taxes

     (3,887 )     (1,707

)

Depreciation and amortization

     7,340       7,169  

Stock-based compensation

     14,315       11,085  

Product rationalization charges

     3,199       2,445  

IPR&D impairment

     -       600  

Acquisition related intangible asset amortization

     7,147       7,148  

Acquisition related inventory step up

     -       6,465  

Change in fair value of contingent consideration

     -       (21,095

)

Adjusted EBITDA

   $ 12,601     $ 16,432  

 

Adjusted EBITDA for year ended December 31, 2022, decreased $3.8 million as compared to 2021. The decrease in adjusted EBITDA was primarily due to an increase in operating expenses largely attributable to expansion of our commercial capability in the United States and an increase in product development costs, partially offset by an increase in revenue.

 

47
 

 

Adjusted Net Income (Loss) and Adjusted EPS

 

We present information below with respect to adjusted net income (loss) and adjusted EPS. We define adjusted net income (loss) as our net income (loss) excluding amortization and depreciation of acquired assets, the impact of inventory fair-value step up on cost of revenue, changes in the fair value of contingent consideration, as well as certain impairment charges, including impairment related to IPR&D assets and non-cash product rationalization charges, each on a tax effected basis. Acquisition-related expenses are those that we would not have incurred except as a direct result of acquisition transactions. The amortized assets contribute to revenue generation and the amortization of such assets will recur in future periods until such assets are fully amortized. These assets include the estimated fair value of certain identified assets acquired in acquisitions, including in-process research and development, or IPR&D, developed technology, customer relationships and acquired trade names. We define adjusted EPS as U.S. GAAP diluted earnings per share excluding the above adjustments to net income (loss) used in calculating adjusted net income (loss), each on a per share and tax effected basis.

 

The following is a reconciliation of adjusted net income (loss) to net income (loss) for the years ended December 31, 2022 and 2021, respectively:

 

   

Years Ended December 31,

  
   

2022

    

2021

  

Net (loss) income

   $ (14,859 )   $ 4,134  

Product rationalization charges, tax effected

     2,410       1,830  

IPR&D impairment, tax effected

     -       448  

Acquisition related intangible asset amortization, tax effected

     5,386       5,386  

Acquisition related inventory step up, tax effected

     -       4,810  

Change in fair value of contingent consideration, tax effected

     -       (16,979

)

Adjusted net loss

   $ (7,063 )   $ (371 )

 

The following is a reconciliation of adjusted EPS to diluted earnings (loss) per share for the years ended December 31, 2022 and 2021, respectively (in thousands, expect per share data):

 

   

Years Ended December 31,

  
   

2022

    

2021

  

Diluted (loss) earnings per share

   $ (1.02 )   $ 0.28  

Product rationalization charges, tax effected

     0.17       0.13  

IPR&D impairment, tax effected

     -       0.03  

Acquisition related intangible asset amortization, tax effected

     0.36       0.37  

Acquisition related inventory step up

     -       0.33  

Change in fair value contingent consideration, tax effected

     -       (1.16

)

Adjusted diluted loss per share

   $ (0.49 )   $ (0.02 )

 

Adjusted net loss in 2022, increased by $6.7 million as compared to 2021. The increase in adjusted net loss for the period was primarily due to an increase in selling and marketing expenses to support our commercial capability in the United States, an increase in research and development expenses and an increase in stock-based compensation expense.

 

48
 

 

Results of Operations

 

Year ended December 31, 2021 compared to year ended December 31, 2020

 

Statement of Operations Detail

 

   

Years Ended December 31,

 
   

2021

    

2020

    

$ Change

    

% Change

  
   

(in thousands, except percentages)

  

Revenue

   $ 147,794     $ 130,457     $ 17,337       13 %

Cost of revenue

     64,851       61,431       3,420       6 %

Gross profit

     82,943       69,026       13,917       20 %

Gross margin

     56 %     53 %                

Operating expenses:

                                

Research & development

     27,327       23,431       3,896       17 %

Selling, general & administrative

     74,096       60,063       14,033       23 %

Goodwill impairment

     -       42,520       (42,520 )     (100% )

Change in fair value of contingent consideration

     (21,095 )     (28,666

)

     7,571       (26% )

Total operating expenses

     80,328       97,348       (17,020 )     (17% )

Income (loss) from operations

     2,615       (28,322

)

     30,937       109 %

Interest and other expense, net

     (188 )     (302

)

     114       (38% )

Income (loss) before income taxes

     2,427       (28,624

)

     31,051       108 %

Benefit from income taxes

     (1,707 )     (4,642

)

     2,935       (63% )

Net income (loss)

   $ 4,134     $ (23,982

)

   $ 28,116       117 %

 

Revenue

 

The following table presents product revenue by product family for fiscal years 2021 and 2020 (dollars in thousands):

 

   

Years Ended December 31,

  
   

2021

    

2020

    

$ Change

    

% Change

  
                                 

OA Pain Management

   $ 89,503     $ 83,029     $ 6,474       8 %

Joint Preservation and Restoration

     48,588       39,368       9,220       23 %

Non-orthopedic

     9,703       8,060       1,643       20 %
    $ 147,794     $ 130,457     $ 17,337       13 %

 

Revenue for the year ended December 31, 2021 was $147.8 million, an increase of $17.3 million, or 13%, compared to the prior year. The increase in revenue was primarily driven by partial recovery from the initial impact of the COVID-19 pandemic on sales volumes and related strategic partner ordering patterns as well as from growing commercial adoption of new products. The increase for 2021 was also in part due to inclusion of full first quarter results of Parcus Medical and Arthrosurface, which we acquired on January 24, 2020 and February 3, 2020, respectively.

 

Revenue from our OA Pain Management product family increased 8% for the year ended December 31, 2021, as compared to prior year, due primarily to partial recovery from the initial impact of the COVID-19 pandemic on sales volumes and related strategic partner ordering patterns. 

 

Revenue from our Joint Preservation and Restoration product family increased 23% for the year ended December 31, 2021, as compared to prior year, due primarily to organic growth as the initial impact of the COVID-19 pandemic on elective procedures begins to lift in various worldwide jurisdictions, especially in the United States during 2021. We also saw rapidly growing commercial adoption of new regenerative, soft tissue and bone sparing joint products introduced in 2019, 2020 and 2021. The increase was also due in part to the inclusion of full year results from Parcus Medical and Arthrosurface which were acquired in the first quarter of 2020.

 

49
 

 

Revenue from our non-orthopedic product family increased 20% for the year ended December 31, 2021, as compared to the prior year, primarily due to the timing of distributor sales as well as due to higher revenues from legacy products during the first quarter.

 

Gross Profit and Margin

 

Gross profit for the year ended December 31, 2021 was $82.9 million, or gross margin of 56%, as compared with $69.0 million, or gross margin of 53%, for the year ended December 31, 2020. The increase in gross profit for the year ended December 31, 2021, primarily resulted from revenue growth and lower amortization of inventory step up costs related to the Arthrosurface and Parcus Medical acquisitions. This increase was partially offset by higher product rationalization charges, as well as lower production levels and increased reserves caused in part by staffing and supply chain challenges resulting from the COVID-19 pandemic. Gross margin includes the impact of inventory step-up associated with the Arthrosurface and Parcus Medical acquisitions, as well as acquisition-related amortization expenses. These expenses together increased cost of revenue by $12.7 million, or 9 points of gross margin, for the year ended December 31, 2021 as compared to increased cost of revenue of $16.9 million, or 13 points of gross margin for the same periods in 2020.

 

Research and Development

 

Research and development expenses for the year ended December 31, 2021 were $27.3 million, an increase of $3.9 million, or 17%, as compared to the prior year, primarily due to product development activities associated with the development of new product candidates in our research and development pipeline, execution of the third Cingal Phase III clinical study and Hyalofast clinical trial.

 

Selling, General and Administrative

 

Selling, general and administrative, or SG&A, expenses for the year ended December 31, 2021 were $74.1 million, an increase of $14.0 million, or 23%, as compared to the prior year. The increase in SG&A expenses for the year ended December 31, 2021 was primarily related to full period expenses from Parcus Medical and Arthrosurface, expansion of our commercial capability in the United States and expanded marketing activities and other operational capabilities to support the growing business needs, higher stock based compensation expense, and a non-cash loss on disposal of fixed assets, partially offset by the absence of transaction costs incurred in 2020 related to acquisitions of Parcus Medical and Arthrosurface. Certain activities were curtailed in the year ended December 31, 2020 due to cost optimization in light of the early stages of the COVID-19 pandemic.

 

Goodwill Impairment Charge

 

We assess goodwill for impairment annually, or, under certain circumstances, more frequently, such as when events or changes in circumstances indicate there may be impairment. U.S. government policy responses to the COVID-19 pandemic and the resulting changes in healthcare guidelines caused a temporary suspension of domestic elective surgical procedures. As a result of these events during 2020, we experienced decreases in immediate term revenue and related cash flows which directly impacted the Parcus Medical and Arthrosurface reporting unit. The results of the interim and annual impairment tests indicated that the estimated fair value of this reporting unit was less than its carrying value. Consequently, a non-cash goodwill impairment charge of $42.5 million was recorded in 2020. There were no goodwill impairment charges during 2021.

 

Contingent Consideration Fair Value Change

 

In the year ended December 31, 2021, we recorded a $21.1 million net benefit related to the change in fair value of our contingent consideration liabilities incurred associated with the acquisition of Parcus Medical and Arthrosurface in 2020. The liability for contingent consideration is remeasured at each reporting period until the contingency is resolved. The decrease in fair value of the contingent consideration was due primarily to the decrease in the likelihood that certain contingent milestones would be achieved or because certain contingent milestones were not achieved. In July 2021, we made a regulatory milestone payment in connection with the Arthrosurface acquisition in the amount of $10.0 million upon obtaining a regulatory clearance for a reverse shoulder implant system.

 

Income Taxes

 

The benefit from income taxes was $1.7 million for the year ended December 31, 2021, resulting in an effective tax rate of (70.4%). The benefit from income taxes was $4.6 million for the year ended December 31, 2020, resulting in an effective tax rate of 16.2%. The net change in the effective tax rate for the year ended December 31, 2021, as compared to the prior year, was primarily due to lower income before tax in 2021, favorable state tax apportionment, a $0.9 million tax benefit on the decrease in the fair value of contingent consideration and the release of a valuation allowance initially recorded in 2020 in the amount of $0.9 million due to increased likelihood regarding the realizability of certain net deferred tax assets in Italy.

 

50
 

 

Net Income (Loss)

 

For the year ended December 31, 2021, net income was $4.1 million, or $0.28 per diluted share, compared to net loss of $24.0 million, or $1.69 per diluted share, for the prior year. The increase in net income and diluted earnings per share was primarily due to increased revenue, reduction in the fair value of contingent consideration and the absence of goodwill impairment charges, partially offset by higher operating expenses primarily driven by increased spending to expand our commercial capability in the United States and development of new products and clinical trial activity.

 

Concentration of Risk

 

We have historically derived the majority of our revenue from a small number of customers, most of whom resell our products to end-users and are significantly larger companies than us. For the year ended December 31, 2022, Mitek accounted for 43% of revenue, as compared to 45% in prior year. While we believe that our expanded commercial infrastructure has been and will continue to diversify our revenue base, we expect to continue to be dependent on a small number of large customers, especially Mitek, for a sizeable portion of our revenues in the near-term future. The failure of these customers to purchase our products in the amounts they historically have or in amounts that we expect could materially impact our business.

 

In addition, if present and future customers terminate their purchasing arrangements with us, significantly reduce or delay their orders, or seek to renegotiate their agreements on terms less favorable to us, our business, financial condition, and results of operations will be adversely affected. If we accept terms less favorable than the terms of the current agreements, such renegotiations may have a material adverse effect on our business, financial condition, and/or results of operations. Furthermore, in any future negotiations we may be subject to the perceived or actual leverage that these customers may have given their relative size and importance to us. Any termination, change, reduction, or delay in orders could seriously harm our business, financial condition, and results of operations. Accordingly, unless and until we diversify and expand our customer base, our future success will significantly depend upon the timing and size of future purchases by our largest customers and the financial and operational success of these customers. The loss of any one of our major customers or the delay of significant orders from such customers, even if only temporary, could reduce or delay our recognition of revenues, harm our reputation in the industry, and reduce our ability to accurately predict cash flow, and, consequently, it could seriously harm our business, financial condition, and results of operations.

 

See Note 13, Revenue by Product Family, by Significant Customer and by Geographic Location; Geographic Information, to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K for information regarding significant customers.

 

Liquidity and Capital Resources

 

We require cash to fund our operating activities and to make capital expenditures and other investments in the business. We expect that our requirements for cash to fund these uses will increase as our operations expand. We continue to generate cash from operating activities, and we believe that our operating cash flows, cash currently on our balance sheet and availability under our credit facility will be sufficient to allow us to continue to invest in our existing business, to manage our capital structure on a short and long-term basis, and to meet our anticipated operating cash needs. Cash, cash equivalents, and investments aggregated $86.3 million and $94.4 million, and working capital totaled $141.6 million and $138.7 million, at December 31, 2022 and 2021, respectively. 

 

We entered into a Third Amendment to Credit Agreement, on November 12, 2021, with Bank of America N.A. as administrative agent, which amended our existing revolving line of credit agreement dated October 24, 2017 and provides up to $75.0 million in the form of a senior revolving line of credit. Subject to certain conditions, we may request up to an additional $75.0 million for a maximum aggregate commitment of $150.0 million. As a precautionary measure at the beginning of the COVID-19 pandemic, we executed a drawdown of $50.0 million in April 2020, all of which we repaid during the year ended December 31, 2020. As of December 31, 2022, and 2021, there were no outstanding borrowings, and we are in compliance with the terms of the credit facility.

 

Summary of Cash Flows (in thousands):

 

   

Years Ended December 31,

  
   

2022

    

2021

    

2020

  

Cash provided by (used in)

                        

Operating activities

   $ 4,409     $ 8,397     $ 13,065  

Investing activities

     (7,486 )     (3,118

)

     (71,264 )

Financing activities

     (4,852 )     (6,779

)

     (3,774

)

Effect of exchange rate changes on cash

     (130 )     69       327  

Net decrease in cash and cash equivalents

   $ (8,059 )   $ (1,431

)

   $ (61,646 )

 

51
 

 

The following changes contributed to the net change in cash and cash equivalents from 2021 to 2022.

 

Operating Activities

 

Cash provided by operating activities was $4.4 million, $8.4 million, $13.1 million for 2022, 2021 and 2020. The change in 2022 was primarily attributable to an increase in operating spending largely attributable to expansion of our commercial capability in the United States and an increase in product development costs, partially offset by an increase in product sales. We also made a payment of contingent consideration in July 2021, in which we paid contingent consideration in the amount of $10.0 million, $2.8 million of which was classified within operating activities and the remaining $7.2 million was classified within financing activities.

 

For the foreseeable future, we expect to continue to invest substantial resources in research and development for new products and clinical trials as well as continued investment in our commercial infrastructure to support our growth strategy. These costs will be funded with a combination of cash on hand and cash expected to be generated from future operations.

 

Investing Activities

 

Investing activities used $7.5 million, $3.1 million, $71.3 million in 2022, 2021 and 2020. The significant use of cash from investing activities in 2020 was primarily due to the $94.6 million of consideration paid, net of cash acquired, for the acquisitions of Parcus Medical and Arthrosurface. Capital expenditures totaled $7.5 million, $5.1 million, and $1.6 million for 2022, 2021 and 2020, respectively.

 

Financing Activities

 

Cash used in financing activities was $4.9 million, $6.8 million and $3.8 million for 2022, 2021 and 2020. The change in 2022 was primarily due to lower payments of contingent consideration compared to 2021. 

 

For a discussion of our liquidity and capital resources as of December 31, 2021, and our cash flow activities for the fiscal year ended December 31, 2021, see “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our annual report on Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC on March 10, 2022, which is incorporated by reference in this Report.

 

Contractual Obligations and Other Commercial Commitments 

 

The table below summarizes our non-cancelable operating leases, purchase commitments, and contractual obligations related to future periods which are not reflected in our consolidated balance sheet at December 31, 2022. Purchase commitments relate primarily to non-cancellable inventory commitments and capital expenditures entered in the normal course of business:

 

   

Payments due by period (in thousands)

  
           

Less than

                    

More than

  
   

Total

     1 year    

1 - 3 years

    

3 - 5 years

     5 years  

Operating Leases

   $ 39,924     $ 3,170     $ 6,121     $ 5,403     $ 25,230  

Year Ended December 31, 2022

   $ 39,924     $ 3,170     $ 6,121     $ 5,403     $ 25,230  

 

We also have purchase orders and commitments for materials and other day-to-day business requirements in which there are no material commitments greater than one year.

 

Critical Accounting Policies and Estimates

 

Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements included elsewhere in this Annual Report on Form 10-K, which consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and the related disclosure of contingent assets and liabilities. We monitor our estimates on an ongoing basis for changes in facts and circumstances, and material changes in these estimates could occur in the future. Changes in estimates are recorded in the period in which they become known. We base our estimates on historical experience and other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from our estimates if past experience or other assumptions do not turn out to be substantially accurate.

 

52
 

 

We have identified the policies below as critical to our business operations and the understanding of our results of operations. The impact and any associated risks related to these policies on our business operations are discussed throughout this section captioned “Management’s Discussion and Analysis of Financial Condition and Results of Operations” where such policies affect our reported and expected financial results. For a detailed discussion on the application of these and other accounting policies, see Note 2 to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K.

 

Business Combinations and Contingent Consideration

 

Amounts paid for acquisitions are allocated to the intangible and tangible assets acquired and liabilities assumed, if any, based on their fair values at the dates of acquisition. This purchase price allocation process requires management to make significant estimates and assumptions with respect to intangible assets and deferred revenue obligations. Critical estimates include, but are not limited to, future expected cash flows, including projected revenues and expenses, and the applicable discount rates. The fair value of identifiable intangible assets is based on detailed valuations that use information and assumptions determined by management. Any excess of purchase price over the fair value of the net tangible and intangible assets acquired is allocated to goodwill. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date as well as any contingent consideration, where applicable, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Upon conclusion of the measurement period or final determination of the values of assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recorded to our consolidated statements of comprehensive income. The fair value of contingent consideration includes estimates and judgments made by management regarding the probability that future contingent payments will be made.

 

We use the income approach to determine the fair value of certain identifiable intangible assets including developed technology and IPR&D. This approach determines fair value by estimating after-tax cash flows attributable to these assets over their respective useful lives and then discounting these after-tax cash flows back to a present value. The estimated economic lives were determined using a variety of indicators including historical usage, evolutionary changes and other observable market data. We base our assumptions on estimates of future cash flows, expected growth rates and expected trends in technology. We base the discount rate used to arrive at the present value used in this method as of the date of acquisition on the time value of money and certain industry-specific risk factors. We use the relief-from-royalty method of the income approach to determine the fair value of trade names. This approach determines fair value by estimating the after-tax royalty savings attributable to owning the intangible asset and then discounting these after-tax royalty savings back to a present value. We base our assumptions on the estimated revenue attributable to the trade name and the estimated royalty rate attributable to the trade name. We use the avoided costs/lost profits method to determine the fair value of customer relationships. This approach determines fair value by estimating the projected revenues related to the asset and estimated costs to recreate the intangible asset. We believe the estimated purchased customer relationships, developed technologies, trade name, and in process research and development amounts so determined represent the fair value at the date of acquisition and do not exceed the amount a third party would pay for the assets. If the subsequent actual results and updated projections of the underlying business activity change compared with the assumptions and projections used to develop these values, we could experience impairment charges which could be material. In addition, estimated economic lives of certain acquired assets are used to calculate depreciation and amortization expense. If our estimates of the economic lives change, depreciation or amortization expenses could be accelerated or slowed.

 

We used the comparative sales method to determine the fair value of work-in-process, or WIP, and finished goods inventory acquired and ultimately the inventory step- up required. The fair value of WIP inventory was estimated as the selling price less the sum of (a) costs to complete, (b) costs of disposal, and (c) a reasonable profit allowance for the selling effort of the acquiring entity based on profit for similar products. The fair value of finished goods inventory was estimated as the selling price less the sum of (a) costs of disposal and (b) a reasonable profit allowance for the selling effort of the acquiring entity based on profit for similar products.

 

For contingent consideration, we update these estimates and the related fair value of contingent consideration at each reporting period based on the estimated probability of achieving the earn-out targets and applying a discount rate that measures the risk associated with the expected contingent payments. Under the Parcus Medical and Arthrosurface merger agreements, there are contingent consideration milestones totaling up to $100 million payable from 2020 to 2022. Parcus Medical has net sales milestones annually from 2020 to 2022, while Arthrosurface had both regulatory and net sales milestones in 2020 and 2021. As of December 31, 2022, there were no more remaining regulatory or net sales milestones related to Parcus Medical or Arthrosurface expected to be achieved. The fair value of the Parcus Medical contingent consideration was estimated using a Monte Carlo simulation. Changes in the fair value can result from changes pertaining to the achievement of the defined milestones and changes in assumed discount rates. Changes in the fair value of contingent consideration are recorded in our consolidated statements of operations. As of December 31, 2022, there was no contingent consideration for Parcus Medical or Arthrosurface.

 

53
 

 

Revenue Recognition – General

 

Pursuant to ASC 606, we recognize revenue when a customer obtains control of promised goods or services. The amount of revenue that is recorded reflects the consideration that we expect to receive in exchange for those goods or services. We apply the following five-step model in order to determine this amount: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are capable of being distinct or distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) we satisfy each performance obligation.

 

We generate sales principally through three types of customers: (i) commercial partnerships (ii) hospitals and ASCs, and (iii) distributors, referred to as distribution model.

 

For commercial partnership sales, we sell our products directly to these partners, who perform most of the downstream sales and marketing activities to customers and end-users. These arrangements may include the grant of certain licenses, performance of development services, and the supply of product. Our largest such customer, Mitek, represented 43% of total revenues for the year ended December 31, 2022. We recognize revenue from product sales when the customer obtains control of our product, which typically occurs upon shipment to the customer. Commercial partnership agreements may also include sales-based royalties and milestones. As we considered the license to be the predominant item to which the royalties relate for these agreements, sales-based royalties and milestones are only recognized when the later of the underlying sale occurs or the performance obligation to which some or all of the sales-based royalty has been satisfied (or partially satisfied). This is generally in the same period that our licensees complete their product sales in their territory, for which we are contractually entitled to a percentage-based royalty. We record royalty revenues based on estimated net sales of licensed products as reported to us by our commercial partners. The differences between actual and estimated royalty revenues have not been material and are typically adjusted in the following quarter when the actual amounts are known. Revenue from sales-based royalties is included in revenues in our consolidated statement of operations.

 

For sales to hospitals and ASCs, which generally pairs in-house sales representatives with local or regional distributors, the inventory is generally consigned so that products are available when needed for surgical procedures. No revenue is recognized upon the placement of inventory into consignment, as we retain the ability to control the inventory. Revenue is recognized typically as of the date of surgical implantation of the product.

 

For distributor sales, we sell our products to our distributors, generally outside the United States, who subsequently resell the products to sub-distributors and health care providers, among others. We recognize revenue from product sales when the distributor obtains control of our product, which typically occurs upon shipment to the distributor, in return for agreed-upon, fixed-price consideration. Performance obligations are generally settled quickly after purchase order acceptance; therefore, the value of unsatisfied performance obligations at the end of any reporting period is generally insignificant. We sell to a diversified base of distributors and, therefore, we believe there is no material concentration of credit risk.

 

Certain of our supply agreements contain terms that represent a promise to deliver product at the customer’s discretion that are considered distributor options. We assess if these options provide a material right to the licensee, and if so, they are accounted for as separate performance obligations. Our supply agreements do not provide options that are considered material rights.

 

Our payment terms are consistent with prevailing practice in the respective markets in which we do business. Most of our customers make payments based on contract terms, which are not affected by contingent events that could impact the transaction price. Payment terms fall within the one-year guidance for the practical expedient, which allows us to forgo adjustment of the contractual payment amount of consideration for the effects of a significant financing component.

 

Some of our distributor agreements have volume-based discounts with tiered pricing which are generally prospective in nature. These prospective discounts together with any free-of-charge sample units offered are evaluated as potential material rights. If the prospective discounts or free-of-charge sample units are considered material rights, these would be separate performance obligations and a portion of the sales transaction price is allocated to the material right. Revenue allocated to the material right is recognized when the additional goods are transferred to the customer or when the option expires. During 2022, the consideration allocated to material rights was not significant.

 

We receive payments from our customers based on billing schedules established in each contract. Up-front payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until we perform our obligations under these arrangements. Amounts are recorded as accounts receivable when our right to consideration is unconditional. Deferred revenue was $0 and $1.0 million as of December 31, 2022 and 2021, respectively.

 

54
 

 

Generally, customer contracts contain Free on Board, or FOB, or Ex-Works shipping point terms where the customer pays the shipping company directly for all shipping and handling costs. In those contracts in which we pay for the shipping and handling, the associated costs are generally recorded along with the product sale at the time of shipment in cost of revenue when control over the products has transferred to the customer. Value-add and other taxes we collected concurrently with revenue-producing activities are excluded from revenue. Our general product warranty does not extend beyond an assurance that the product or services delivered will be consistent with stated contractual specifications, which does not create a separate performance obligation. We recognize the incremental costs of obtaining contracts as an expense when incurred as the amortization period of the assets that we otherwise would have recognized is one year or less in accordance with the practical expedient in paragraph ASC 340-40-25-4. These costs are included in selling, general and administrative expenses.

 

Inventories

 

Inventories are primarily stated at the lower of standard cost and net realizable value, with approximate cost determined using the first-in, first-out method. Work-in-process and finished goods inventories include materials, labor, and manufacturing overhead. Manufacturing variances attributable to abnormally low production are expensed in the period incurred. Inventory costs associated with product candidates that have not yet received regulatory approval are capitalized if we believe there is probable future commercial use and future economic benefit.

 

Our policy is to write down inventory when conditions exist that suggest inventory may be in excess of anticipated demand or is obsolete based upon assumptions about future demand for our products and market conditions. We regularly evaluate the ability to realize the value of inventory based on a combination of factors including, but not limited to, historical usage rates, forecasted sales or usage, product end of life dates, and estimated current or future market values. Inventory needs and alternative usage avenues are explored within these processes to mitigate inventory exposure

 

When recorded, inventory write-downs are intended to reduce the carrying value of inventory to its net realizable value. If actual demand for our products deteriorates, or if market conditions are less favorable than those projected, additional inventory write-downs may be required. Other long-term assets include inventory expected to remain on hand beyond one year.

 

Goodwill and In-Process Research and Development

 

Goodwill is the amount by which the purchase price of acquired net assets in a business combination exceeded the fair values of net identifiable assets on the date of acquisition. Goodwill is not amortized but is subject to impairment test annually or more frequently if events or changes in circumstances suggest that the carrying value of goodwill may not be recoverable, utilizing either the qualitative or quantitative method.

 

We test goodwill for impairment at the reporting unit level on an annual basis as of November 30 or more frequently if we believe indicators of impairment exist. We have two reporting units: the legacy Anika reporting unit and a reporting unit established in 2020 upon the acquisitions of Parcus Medical and Arthrosurface. The remaining goodwill as of December 31, 2022 pertains to the legacy Anika reporting unit, as the goodwill with respect to the Parcus Medical and Arthrosurface reporting unit was fully impaired in 2020.

 

We have the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. When using the qualitative method in 2022, we considered several factors, including the following:

 

 

●

the amount by which the fair value of the reporting unit exceeded its carrying value as of the date of the most recent quantitative impairment analysis, which indicated there would need to be substantial negative developments in the markets in which the reporting unit operates for there to be potential impairment;
 

●

the carrying value of the reporting unit as of the assessment date compared to their previously calculated fair value as of the date of the most recent quantitative impairment analysis;
 

●

the current forecasts as compared to the forecasts included in the most recent quantitative impairment analysis;
 

●

public information from competitors and other industry information to determine if there were any significant adverse trends in our competitors' businesses;
 

●

changes in the value of major U.S. stock indices that could suggest declines in overall market stability that could impact the valuation of our reporting unit;
 

●

whether there had been any significant increases in the weighted-average cost of capital rates for the reporting unit, which could materially lower our prior valuation conclusions under a discounted cash flow approach.

 

55
 

 

Significant assumptions utilized in the impairment analysis included valuation multiple with respect to revenue and weighted-average cost of capital. Based on sensitivity analysis performed on key assumptions at November 30, 2022, a 10% decrease in valuation multiples or a 10% increase in the weighted average cost of capital assumption would not have resulted in a fair value below the reporting unit’s carrying value. Accordingly, we determined it was not more likely than not that the fair value of the legacy Anika reporting unit is less than its carrying amount and thus goodwill was not impaired as of November 30, 2022.

 

IPR&D represents the fair value assigned to research and development assets that we acquire that have not been completed at the date of acquisition or are pending regulatory approval in certain jurisdictions. We conduct annual impairment tests of IPR&D, by comparing the fair value of each IPR&D project to its carrying value. If the carrying value exceeds its fair value, we record an impairment loss to the extent that the carrying value of the IPR&D project exceeds its fair value. We estimate the fair value for IPR&D using the income approach which incorporates significant estimates and assumptions related to the forecasted results including revenues, expenses, expected economic life of the asset, contributory asset charges and discount rates to estimate future cash flows. During 2021, we decided not to further invest in certain of our projects and recorded an impairment charge in the amount of $0.6 million in 2021, in research and development expenses in the consolidated statements of operations. Based on a sensitivity analysis performed on key assumptions at November 30, 2022 with respect to the remaining IPR&D, a 10% decrease in the long-term growth factor assumption, or 10% increase in the weighted average cost of capital assumption would not have resulted in a fair value below the IPR&D carrying value.

 

Recent Accounting Pronouncements

 

A discussion of recent accounting pronouncements is included in Note 2 to the consolidated financial statements in this Annual Report on Form 10-K.

 

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Interest Rate Risk

 

We manage our investment portfolio in accordance with our investment policy. The primary objectives of our investment policy are to preserve principal, maintain a high degree of liquidity to meet operating and other needs, and obtain competitive returns subject to prevailing market conditions without significantly increasing risk. To achieve this objective, we maintain our portfolio of cash equivalents and investments in a variety of high-quality securities, including money market funds and U.S. treasury bills. The investments are classified as available-for-sale and consequently are recorded at fair value with unrealized gains or losses reported as a separate component of accumulated other comprehensive income (loss). Our portfolio of cash equivalents and investments is subject to interest rate fluctuations, changes in credit quality of the issuer, and other factors.

 

Foreign Currency Exchange Risk

 

Foreign currency risk arises from our investments in subsidiaries owned and operated in non-U.S. countries. Such risk is also a result of transactions with customers in countries outside the United States. Approximately $8.6 million of our revenue was denominated in foreign currencies (primarily the Euro) for the year ended December 31, 2022. Gains and losses arising from transactions denominated in foreign currencies are primarily related to intercompany accounts that have been determined to be temporary in nature and cash, accounts payable, and accounts receivable denominated in non-functional currencies. We also utilize clinical vendors that are located in various countries outside of the United States and invoice us in their local currency and we have one major supplier contract denominated in a foreign currency. We do not engage in foreign currency hedging arrangements for these transactions, and, consequently, foreign currency fluctuations may adversely affect our earnings. Unfavorable fluctuations in exchange rates would have a negative impact on our financial statements. The impact of currency exchange rate fluctuations related to our international subsidiaries on our financial statements were insignificant in 2022. We recognize foreign currency gains or losses arising from our operations in the period incurred. 

 

56
 
 

 

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

 

ANIKA THERAPEUTICS, INC. AND SUBSIDIARIES

 

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

 

Report of Independent Registered Public Accounting Firm (PCAOB ID No. 34)

58
Consolidated Balance Sheets as of December 31, 2022 and 202160

Consolidated Statements of Operations and Comprehensive Income (Loss) for the Years Ended December 31, 2022, 2021 and 2020

61

Consolidated Statements of Stockholders’ Equity for the Years Ended December 31, 2022, 2021 and 2020

62

Consolidated Statements of Cash Flows for the Years Ended December 31, 2022, 2021 and 2020

63

Notes to Consolidated Financial Statements

64

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

57
 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 

 

To the Board of Directors and Stockholders of Anika Therapeutics, Inc.

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of Anika Therapeutics, Inc. and subsidiaries (the "Company") as of December 31, 2022 and 2021, the related consolidated statements of operations and comprehensive income (loss), stockholders’ equity and cash flows for each of the three years in the period ended December 31, 2022, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America (GAAP).

 

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated March 16, 2023, expressed an adverse opinion on the Company's internal control over financial reporting.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matter

 

The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

 

58
 

 

Inventories — Refer to Notes 2 and 5 to the financial statements

 

Critical Audit Matter Description

 

The Company evaluates inventory each reporting period for excess quantities and obsolescence, establishing reserves, when necessary, based upon historical experience, assessment of economic conditions, and expected demand. Once recorded, these reserves are considered permanent adjustments to the carrying value of inventory. As of December 31, 2022, the Company has total inventories of $56.5 million, net of excess quantities and obsolescence reserves.

 

We identified the reserve for excess quantities and obsolete inventory as a critical audit matter because of the significant estimates and assumptions management makes to quantify and to record the reserve, including the determination of expected demand. This required a high degree of auditor judgment and an increased extent of effort when performing audit procedures to evaluate the methodology and the reasonableness of assumptions including expected demand.

 

How the Critical Audit Matter Was Addressed in the Audit

 

Our audit procedures related to the reserve for excess quantities and obsolete inventory including management’s estimate of expected demand, included the following, among others:

 

 

•

We tested the effectiveness of controls over inventory, including those over the estimation of reserves for excess quantities and obsolescence.

 

 

•

We evaluated the reasonableness of the Company's excess and obsolete inventory policy, considering historical experience and the underlying assumptions.

 

 

•

We tested the calculation of the excess and obsolescence reserve pursuant to the Company's policy, on a sample basis, including the completeness and accuracy of the data used in the calculation.

 

 

•

We performed procedures to evaluate management’s ability to accurately forecast by comparing the historical expiring inventory estimates to subsequent inventory destructions and expirations.

 

 

•

We performed a retrospective review by comparing management’s prior year projections of future demand by product, with actual sales in the current year to identify potential bias in the inventory reserve.

 

 

•

We made inquiries of senior financial and operating management to determine whether any strategic, regulatory, or operational changes in the business were consistent with the projections of future demand that were utilized as the basis for the excess and obsolescence reserve recorded.

 

 

•

We considered the existence of contradictory evidence based on consideration of internal communications to management and the board of directors, Company press releases, and analysts' reports, as well as any changes within the business.

 

/s/ Deloitte & Touche LLP

 

Boston, Massachusetts
March 16, 2023

 

We have served as the Company’s auditor since 2017.

 

59
 
 

 

Anika Therapeutics, Inc. and Subsidiaries

Consolidated Balance Sheets

(in thousands, except per share data)

       

  

As of December 31,

 

ASSETS

 

2022

  

2021

 

Current assets:

        

Cash and cash equivalents

 $86,327  $94,386 

Accounts receivable, net

  34,627   29,843 

Inventories

  39,765   36,010 

Prepaid expenses and other current assets

  8,828   8,289 

Total current assets

  169,547   168,528 

Property and equipment, net

  48,279   47,602 

Right-of-use assets

  30,696   20,957 

Other long-term assets

  17,219   20,285 

Deferred tax assets

  1,449   - 

Intangible assets, net

  74,599   82,382 

Goodwill

  7,339   7,781 

Total assets

 $349,128  $347,535 
         

LIABILITIES AND STOCKHOLDERS’ EQUITY

        

Current liabilities:

        

Accounts payable

 $9,074  $7,633 

Accrued expenses and other current liabilities

  18,840   17,847 

Contingent consideration

  -   4,315 

Total current liabilities

  27,914   29,795 

Other long-term liabilities

  398   1,258 

Deferred tax liability

  6,436   10,157 

Lease liabilities

  28,817   19,240 

Commitments and contingencies (Note 12)

          

Stockholders’ equity:

        

Preferred stock, $0.01 par value; 1,250 shares authorized, no shares issued and outstanding at December 31, 2022 and 2021, respectively

  -   - 

Common stock, $.01 par value; 90,000 shares authorized, 14,625 and 14,441 shares issued and outstanding at December 31, 2022 and 2021, respectively

  146   144 

Additional paid-in-capital

  81,141   67,081 

Accumulated other comprehensive loss

  (6,443)  (5,718

)

Retained earnings

  210,719   225,578 

Total stockholders’ equity

  285,563   287,085 

Total liabilities and stockholders’ equity

 $349,128  $347,535 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

60
 
 

 

Anika Therapeutics, Inc. and Subsidiaries

Consolidated Statements of Operations and Comprehensive Income (Loss)

(in thousands, except per share data)

           

   

Years Ended December 31,

  
   

2022

    

2021

    

2020

  

Revenue

   $ 156,236     $ 147,794     $ 130,457  

Cost of revenue

     62,660       64,851       61,431  

Gross profit

     93,576       82,943       69,026  
                         

Operating expenses:

                        

Research & development

     28,182       27,327       23,431  

Selling, general & administrative

     84,794       74,096       60,063  

Goodwill impairment charge

     -       -       42,520  

Change in fair value of contingent consideration

     -       (21,095

)

     (28,666 )

Total operating expenses

     112,976       80,328       97,348  

(Loss) income from operations

     (19,400 )     2,615       (28,322 )

Interest and other income (expense) , net

     654       (188

)

     (302 )

(Loss) income before income taxes

     (18,746 )     2,427       (28,624 )

Benefit from for income taxes

     (3,887 )     (1,707

)

     (4,642 )

Net (loss) income

   $ (14,859 )   $ 4,134     $ (23,982 )
                         

Net income (loss) per share:

                        

Basic

   $ (1.02 )   $ 0.29     $ (1.69 )

Diluted

   $ (1.02 )   $ 0.28     $ (1.69 )
                         

Weighted average common shares outstanding:

                        

Basic

     14,561       14,401       14,222  

Diluted

     14,561       14,634       14,222  
                         

Net (loss) income

   $ (14,859 )   $ 4,134     $ (23,982 )

Foreign currency translation adjustment

     (725 )     (1,176 )     1,356  

Comprehensive (loss) income

   $ (15,584 )   $ 2,958     $ (22,626 )

 

The accompanying notes are an integral part of these consolidated financial statements.

 

61
 
 

Anika Therapeutics, Inc. and Subsidiaries

Consolidated Statements of Stockholders' Equity

(in thousands, except per share data)

 

                                   

Accumulated

          
   

Common Stock

            

Other

    

Total

  
   

Number of

    

$.01 Par

    

Additional Paid

    

Retained

    

Comprehensive

    

Stockholders'

  
   

Shares

    

Value

    

in Capital

    

Earnings

    

Loss

    

Equity

  

Balance, December 31, 2019

     14,308     $ 143     $ 48,707     $ 245,426     $ (5,898

)

   $ 288,378  

Issuance of common stock for equity awards

     123       1       1,523       –       –       1,524  

Vesting of restricted stock units

     54       –       –       –       –       –  

Forfeiture of restricted stock awards

     (9

)

     –       –       –       –       –  

Stock-based compensation expense

     –       –       5,386       –       –       5,386  

Retirement of common stock for minimum tax withholdings

     (8

)

     –       (262

)

     –       –       (262

)

Repurchase of common stock

     (139

)

     (1

)

     1       –       –       -  

Net loss

     –       –       –       (23,982 )     –       (23,982 )

Other comprehensive income

     –       –       –       –       1,356       1,356  

Balance, December 31, 2020

     14,329     $ 143     $ 55,355     $ 221,444     $ (4.542

)

   $ 272,400  

Issuance of common stock for equity awards

     32       -       1,128       -       -       1,128  

Vesting of restricted stock units

     92       1       (1 )     -       -       -  

Stock-based compensation expense

     -       -       11,085       -       -       11,085  

Retirement of common stock for minimum tax withholdings

     (12 )     -       (486 )     -       -       (486 )

Net income

     -       -       -       4,134       -       4,134  

Other comprehensive loss

     -       -       -       -       (1,176 )     (1,176 )

Balance, December 31, 2021

     14,441     $ 144     $ 67,081     $ 225,578     $ (5,718

)

   $ 287,085  

Issuance of common stock for equity awards

     -       -       16       -       -       16  

Vesting of restricted stock units

     184       2       (2 )     -       -       -  

Issuance of common stock from employee purchase plan

     35       -       665       -       -       665  

Stock-based compensation expense

     -       -       14,315       -       -       14,315  

Retirement of common stock for minimum tax withholdings

     (35 )     -       (934 )     -       -       (934 )

Net loss

     -       -       -       (14,859 )     -       (14,859 )

Other comprehensive loss

     -       -       -       -       (725 )     (725 )

Balance, December 31, 2022

     14,625     $ 146     $ 81,141     $ 210,719     $ (6,443 )   $ 285,563  

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

62
 
 

Anika Therapeutics, Inc. and Subsidiaries

Consolidated Statements of Cash Flows

(in thousands)

 

   

Years Ended December 31,

  
   

2022

    

2021

    

2020

  

Cash flows from operating activities:

                        

Net (loss) income

   $ (14,859 )   $ 4,134     $ (23,982 )

Adjustments to reconcile net income (loss) to net cash provided by operating activities:

                        

Depreciation

     6,704       6,480       6,083  

Amortization of acquisition related intangible assets

     7,783       7,837       7,381  

Amortization of acquisition related inventory step-up

     -       6,465       11,082  

Non-cash operating lease cost

     1,850       1,708       1.531  

Goodwill impairment charge

     -       -       42,520  

Change in fair value of contingent consideration

     -       (21,095

)

     (28,666 )

Loss on disposal of fixed assets

     -       993       265  

Loss on impairment of intangible asset

     -       600       2,439  

Stock-based compensation expense

     14,315       11,085       5,386  

Deferred income taxes

     (5,270 )     (1,766

)

     (3,543 )

Provision for doubtful accounts

     378       64       549  

Provision for inventory

     5,329       6,628       5,490  

Other

     -       (18 )     (12

)

Changes in operating assets and liabilities:

                        

Accounts receivable

     (5,630 )     (6.216 )     5,855  

Inventories

     (6,873 )     (6,619

)

     (14,177

)

Prepaid expenses, other current and long-term assets

     (792 )     1,424       (1,783

)

Accounts payable

     1,965       (1,100 )     822  

Operating lease liabilities

     (1,485 )     (1,626

)

     (1,439

)

Accrued expenses, other current and long-term liabilities

     (443 )     3,510       (142 )

Income taxes

     1,437       (1,311

)

     (2,072

)

Payments of contingent consideration

     -       (2,780

)

     (522 )

Net cash provided by operating activities

     4,409       8,397       13,065  
                         

Cash flows from investing activities:

                        

Acquisition of Parcus Medical and Arthrosurface, net of cash acquired

     -       (476

)

     (94,601 )

Proceeds from maturities of investments

     -       2,501       45,000  

Purchases of investments

     -       -       (20.035

)

Purchases of property and equipment

     (7,486 )     (5,143

)

     (1,628

)

Net cash (used in) provided by investing activities

     (7,486 )     (3,118

)

     (71,264 )
                         

Cash flows from financing activities:

                        

Payments made on finance leases

     (284 )     (201

)

     (208 )

Proceeds from long-term debt

     -       -       50,000  

Repayments of long-term debt

     -       -       (50,350 )

Proceeds from employee stock purchase program

     665       -       -  

Cash paid for tax withheld on vested restricted stock awards

     (934 )     (486

)

     (262

)

Proceeds from exercises of equity awards

     16       1,128       1,524  

Payments of contingent consideration

     (4,315 )     (7,220

)

     (4,478 )

Net cash used by financing activities

     (4,852 )     (6,779

)

     (3,774

)
                         

Exchange rate impact on cash

     (130 )     69       327  
                         

Decrease in cash and cash equivalents

     (8,059 )     (1,431

)

     (61,646 )

Cash and cash equivalents at beginning of period

     94,386       95,817       157,463  

Cash and cash equivalents at end of period

   $ 86,327     $ 94,386     $ 95,817  

Supplemental disclosure of cash flow information:

                        

Cash paid for income taxes, net of refunds

   $ 106     $ 1,233     $ 993  

Right-of-use assets obtained in exchange for operating lease liabilities

   $ 11,703     $ 220     $ -  

Non-cash investing activities:

                        

Purchases of property and equipment included in accounts payable and accrued expenses

   $ 108     $ 15     $ 17  

Consideration for acquisitions included in accounts payable and accrued expenses

   $ -      $ -     $ 476  

Contingent consideration fair value on acquisition date

     0       0       69,076  

 

The accompanying notes are an integral part of these consolidated financial statements.

 

63
 

 

Anika Therapeutics, Inc. and Subsidiaries

Notes to Consolidated Financial Statements

(amounts in thousands, except share and per share amounts or as otherwise noted)

 

1. Nature of Business

 

Anika Therapeutics, Inc. (“the Company”) is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care, including in the areas of osteoarthritis (“OA”) pain management, regenerative solutions, sports medicine and bone preserving joint solutions.

 

In early 2020, the Company expanded its overall technology platform through its strategic acquisitions of Parcus Medical, LLC (“Parcus Medical”), a sports medicine implant and instrumentation company, and Arthrosurface Inc. (“Arthrosurface”), a company specializing in less invasive, bone preserving partial and total joint replacement solutions. These acquisitions broadened the Company's product portfolio, developed over its 30 years of expertise in hyaluronic acid technology, into joint preservation and restoration, added higher-growth revenue streams, increased its commercial capabilities, diversified its revenue base, and expanded its product pipeline and research and development expertise.

 

The Company is subject to risks common to companies in the life sciences industry including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with U.S. Food and Drug Administration (“FDA”) and foreign regulations and approval requirements, as well as the ability to grow the Company’s business through appropriate commercial strategies.

 

Since the global COVID pandemic began in 2020, there also continues to be increased volatility and uncertainty in the global macroeconomic environment, including staffing shortages, supply chain disruption, inflation and other direct and indirect impacts of the pandemic.

 

 

2. Summary of Significant Accounting Policies

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America (“US GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Principles of Consolidation

 

The accompanying consolidated financial statements include the accounts of Anika Therapeutics, Inc. and its wholly owned subsidiaries, Anika Securities, Inc., Anika Therapeutics S.r.l. (“Anika S.r.l.”), Anika Therapeutics Limited, Parcus Medical and Arthrosurface. All intercompany balances and transactions have been eliminated in consolidation.

 

Foreign Currency Translation

 

The functional currency of Anika S.r.l. is the Euro, and the functional currency of Anika Therapeutics Limited is the British Pound Sterling. Assets and liabilities of the foreign subsidiaries are translated using the exchange rate existing on each respective balance sheet date. Revenues and expenses are translated using the average exchange rates for the period. The translation adjustments resulting from this process are included in stockholders’ equity as a component of accumulated other comprehensive income (loss) which resulted in a gain (loss) from foreign currency translation of ($0.7) million, ($1.2) million, and $1.3 million for the years ended December 31, 2022, 2021, and 2020, respectively.

 

Gains and losses resulting from foreign currency transactions are recognized in the consolidated statements of operations. Recorded balances that are denominated in a currency other than the functional currency are remeasured to the functional currency using the exchange rate at the balance sheet date and gains or losses are recorded in the statements of operations. The Company recognized a gain (loss) from foreign currency transactions of ($0.5) million, ($0.4) million, and $0.3 million during the years ended December 31, 2022, 2021, and 2020, respectively

 

64
 
 

Accounts Receivable

 

The Company estimates an allowance for credit losses with its accounts receivable resulting from the inability of its customers to make required payments, which is included in selling, general and administrative expenses in the accompanying consolidated statements of operations. In determining the adequacy of the allowance, management specifically analyzes individual accounts receivable, historical bad debts, customer concentrations, customer creditworthiness, current and reasonable and supportable forecasts of future economic conditions, accounts receivable aging trends, and changes in the Company’s customer payment terms.

 

The components of the Company’s accounts receivables are as follows:

 

  

As of December 31,

 
  

2022

  

2021

 

Accounts Receivable

 $36,235  $31,285 

Allowance for credit losses

  1,608   1,442 

Net balance, end of the year

  34,627   29,843 

 

A summary of activity in the allowance for credit losses is as follows:

 

  

As of December 31,

 
  

2022

  

2021

  

2020

 

Balance, beginning of the year

 $1,442  $1,523  $962 

Amounts provided

  554   156   635 

Amounts recovered

  (180)  (92

)

  (86

)

Amounts written off

  (158)  (73

)

  (78

)

Translation adjustments

  (50)  (72)  90 

Balance, end of the year

 $1,608  $1,442  $1,523 

 

Revenue Recognition

 

Pursuant to Accounting Standard Codification 606, Revenue from Contracts with Customers (“ASC 606”), the Company recognizes revenue when a customer obtains control of promised goods or services. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are capable of being distinct or distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.

 

Revenue

 

The Company generates sales principally through three types of customers: (i) commercial partnerships (ii) hospitals and ambulatory surgical centers (“ASCs”), and (iii) distributors, referred to as the distribution model.

 

For commercial partnership sales, the Company sells its products directly to these partners, who perform most of the downstream sales and marketing activities to customers and end-users. These arrangements may include the grant of certain licenses, performance of development services, and the supply of product. The Company’s largest such customer, DePuy Synthes Mitek Sports Medicine, a division of DePuy Orthopedics, Inc., part of the Johnson & Johnson Medical Companies (“Mitek”), represented 43%, 45% and 49% of total revenues for the years-ended December 31, 2022, 2021 and 2020 respectively. The Company completed the performance obligations related to granted licenses and development services under the agreements with Mitek prior to 2016 and has no remaining material performance obligations. The Company recognizes revenue from product sales when the customer obtains control of the Company’s product, which typically occurs upon shipment to the customer. Commercial partnership agreements may also include sales-based royalties and milestones. As the Company considered the license to be the predominant item to which the royalties relate for these agreements, sales-based royalties and milestones are only recognized when the later of the underlying sale occurs or the performance obligation to which the sales-based royalty has been satisfied (or partially satisfied). This is generally in the same period that the Company’s licensees complete their product sales in their territory, for which the Company is contractually entitled to a percentage-based royalty. The Company records royalty revenues based on estimated net sales of licensed products as reported to the Company by its commercial partners. The differences between actual and estimated royalty revenues have not been material and are typically adjusted in the following quarter when the actual amounts are known. Revenue from sales-based royalties is included in revenue in the consolidated statement of operations. The Company’s certain supply agreements represent a promise to deliver products at the customer’s discretion that are considered distributor options. The Company assesses if these options provide a material right to the licensee, and if so, they are accounted for as separate performance obligations. Substantially all of the Company’s supply agreements do not provide options that are considered material rights.

 

65
 
 

For sales to hospitals and ASCs, which generally pairs in-house sales representatives with local or regional distributors, the inventory is generally consigned so that products are available when needed for surgical procedures. No revenue is recognized upon the placement of inventory into consignment, as the Company retains the ability to control the inventory. Revenue is typically recognized as of the date of surgical implantation of the product.

 

For distributor sales, the Company sells its products principally to distributors, generally outside the United States, who subsequently resell the products to sub-distributors and health care providers, among others. The Company recognizes revenue from product sales when the distributor obtains control of the Company’s product, which typically occurs upon shipment to the distributor, in return for agreed-upon, fixed-price consideration. Performance obligations are generally settled quickly after purchase order acceptance; therefore, the value of unsatisfied performance obligations at the end of any reporting period is generally insignificant. The Company sells to a diversified base of distributors and, therefore, believes there is no material concentration of credit risk.

 

The Company’s payment terms are consistent with prevailing practice in the respective markets in which the Company does business. Most of the Company’s customers make payments based on contract terms, which are not affected by contingent events that could impact the transaction price. Payment terms fall within the one-year guidance for the practical expedient, which allows the Company to forgo adjustment of the contractual payment amount of consideration for the effects of a significant financing component.

 

Some of the Company’s distributor agreements have volume-based discounts with tiered pricing which are generally prospective in nature. These prospective discounts together with any free-of-charge sample units offered are evaluated as potential material rights. If the prospective discounts or free-of-charge sample units are considered material rights, these would be separate performance obligations and a portion of the sales transaction price is allocated to the material right. Revenue allocated to the material right is recognized when the additional goods are transferred to the customer or when the option expires. During 2022 and 2021, the consideration allocated to material rights was not significant.

 

The Company receives payments from its customers based on billing schedules established in each contract. Up-front payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when its right to consideration is unconditional. Deferred revenue was $0 and $1.0 million as of December 31, 2022 and 2021, respectively.

 

Generally, customer contracts contain Free on Board (“FOB”) or Ex-Works shipping point terms where the customer pays the shipping company directly for all shipping and handling costs. In those contracts in which the Company pays for the shipping and handling, the associated costs are generally recorded along with the product sale at the time of shipment in cost of revenue when control over the products has transferred to the customer. Value-add and other taxes collected by the Company concurrently with revenue-producing activities are excluded from revenue. The Company’s general product warranty does not extend beyond an assurance that the product or services delivered will be consistent with stated contractual specifications, which does not create a separate performance obligation. The Company recognizes the incremental costs of obtaining contracts as an expense when incurred as the amortization period of the assets that the Company otherwise would have recognized is one year or less in accordance with the practical expedient in paragraph ASC 340-40-25-4. These costs are included in selling, general and administrative expenses.

 

Licensing, Milestone and Contract Revenue

 

The agreements with Mitek include variable consideration such as contingent development and regulatory milestones. Since 2016, there have been no remaining regulatory milestones related to the Mitek agreements. In general, variable consideration is included in the transaction price only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable to occur.

 

Cash and Cash Equivalents

 

The Company considers only those investments which are highly liquid, readily convertible to cash, and that mature within 90 days from the date of purchase to be cash equivalents. The Company’s cash equivalents consist of money market funds.

 

66
 
 

Investments

 

All of the Company’s investments are classified as available-for-sale which consist of U.S. treasury bills and are carried at fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income (loss), net of related income taxes. For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. Realized gains and losses on the sale of investments are recorded in interest and other income, net. Interest is recorded when earned. Investments with original maturities greater than approximately three months and remaining maturities less than one year are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments. The Company had no investments as of December 31, 2022 or December 31, 2021.

 

All of the Company’s investments are subject to a periodic impairment review. For available-for-sale debt securities in an unrealized loss position, the Company first assesses whether (i) the Company intends to sell, or (ii) it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either case is affirmative, any previously recognized allowances are charged-off and the security's amortized cost is written down to fair value through earnings. If neither case is affirmative, the security is evaluated to determine whether the decline in fair value has resulted from credit losses or other factors.

 

Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income. Adjustments to the allowance are reported in the consolidated statement of operations as a component of credit loss expense. Available-for-sale securities are charged-off against the allowance or, in the absence of any allowance, written down through earnings when deemed uncollectible by management or when either of the criteria regarding intent or requirement to sell is met.

 

During the years ended  December 31, 2022, 2021 and 2020, the Company did not record any impairment charges on its available-for-sale securities because it is not more likely than not that the Company will be required to sell these securities before the recovery of their cost basis.

 

Concentration of Credit Risk

 

The Company has no significant off-balance sheet risks related to foreign exchange contracts, option contracts, or other foreign hedging arrangements. The Company’s cash equivalents and investments are held with two major international financial institutions.

 

The Company, by policy, routinely assesses the financial strength of its customers. As a result, the Company believes that its accounts receivable credit risk exposure is limited.

 

As of December 31, 2022 and 2021, Mitek represented 47% and 41%, respectively, of the Company’s accounts receivable balance. No other single customer accounted for more than 10% of accounts receivable in either period.

 

Inventories

 

Inventories are primarily stated at the lower of standard cost and net realizable value, with cost determined using the first-in, first-out method. Work-in-process and finished goods inventories include materials, labor, and certain manufacturing overhead. Manufacturing variances attributable to abnormally low production are expensed in the period incurred.  

 

The Company’s policy is to write down inventory when conditions exist that suggest inventory may be in excess of anticipated demand or is obsolete based upon assumptions about future demand for the Company’s products and market conditions. The Company regularly evaluates the ability to realize the value of inventory based on a combination of factors including, but not limited to, historical usage rates, forecasted sales or usage, product end of life dates, and estimated current or future market values. Purchasing requirements and alternative usage avenues are explored within these processes to mitigate inventory exposure.

 

When recorded, inventory write-downs are intended to reduce the carrying value of inventory to its net realizable value. If actual demand for the Company’s products deteriorates, or if market conditions are less favorable than those projected, additional inventory write-downs may be required. Other long-term assets include inventory expected to remain on hand beyond one year.

 

Leases

 

At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the circumstances present and evaluates whether the lease is an operating lease or a finance lease at the commencement date. Operating and finance leases with a term greater than one year are recognized on the consolidated balance sheet as right-of-use assets, lease liabilities, and, if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease in the lease term where it is reasonably certain that it will exercise these options. Operating and finance lease liabilities and the corresponding right-of-use assets are recorded based on the present values of lease payments over the lease terms. The Company elected an accounting policy to combine the non-lease components (which include common area maintenance, taxes and insurance) with the related lease component. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a similar economic environment. Variable payments that do not depend on a rate or index are not included in the lease liability and are recognized as incurred. Lease contracts do not include residual value guarantees nor do they include restrictions or other covenants. Certain adjustments to the right-of-use assets may be required for items such as initial direct costs paid, incentives received or lease prepayments. If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure the finance and operating lease liabilities by using revised inputs as of the reassessment date, and adjust the right-of-use asset. Operating lease expense is recognized on a straight-line basis over the lease term. Finance lease expense is recognized based on the effective-interest method over the lease term.

 

67
 
 

Property and Equipment

 

Property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives, which are typically:

 

Asset

 

Estimated useful life
(in years)

 

Computer equipment and software

  3   -   10 

Furniture and fixtures

  5   -   7 

Equipment

  5   -   20 

Leasehold improvements

     

Shorter of useful life or term of lease

     

 

Maintenance and repairs are charged to expense when incurred; additions and improvements are capitalized. Fully depreciated assets are retained in the accounts until they are no longer used and no further charge for depreciation is made in respect of these assets. When an item is sold, retired or removed from service, the cost and related accumulated depreciation is relieved, and the resulting gain or loss, if any, is recognized in income.

 

Construction-in-process assets are stated at cost, which includes the cost of construction and other direct costs attributable to the construction. Construction-in-process assets are not depreciated until such time as the relevant assets are completed and put into use.

 

Goodwill and IPR&D Assets

 

Goodwill is the amount by which the purchase price of acquired net assets in a business combination exceeded the fair values of net identifiable assets on the date of acquisition. Acquired In-Process Research and Development (“IPR&D”) represents the fair value assigned to research and development assets that the Company acquires that have not been completed at the date of acquisition or are pending regulatory approval in certain jurisdictions. The value assigned to the acquired IPR&D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenue from the projects, and discounting the net cash flows to present value.  

 

Goodwill and IPR&D are not amortized but are evaluated for impairment annually or more frequently if events or changes in circumstances indicate that the asset might be impaired. The goodwill impairment assessment is performed by reporting unit. A reporting unit is the operating segment, or a business one level below that operating segment (the component level) if discrete financial information is prepared and regularly reviewed by segment management. However, components are aggregated as a single reporting unit if they have similar economic characteristics. The Company has two reporting units: the legacy Anika reporting unit, which specializes in therapies based on its hyaluronic acid, or HA, technology platform, and a newly formed reporting unit established in 2020 upon the acquisitions of Parcus Medical and Arthrosurface. Factors that the Company considers important, on an overall company basis, that could trigger an impairment review include significant underperformance relative to historical or projected future operating results, significant changes in the Company’s use of the acquired assets or the strategy for its overall business, significant negative industry or economic trends, a significant decline in the Company’s stock price for a sustained period, or a reduction of its market capitalization relative to net book value.

 

68
 
 

Under U.S. GAAP, the Company has the option to perform a qualitative assessment to determine if it is necessary to perform the impairment test. If the Company concludes, based on a qualitative assessment, it is not more likely than not that the Goodwill or the IPR&D asset is impaired, the Company is not required to perform the quantitative test. The Company has an unconditional option to bypass the qualitative assessment in any period and proceed directly to the quantitative impairment test.

 

To conduct quantitative impairment tests of goodwill, the fair value of the reporting unit is compared to its carrying value. If the reporting unit’s carrying value exceeds its fair value, the Company records an impairment loss to the extent that the carrying value of goodwill exceeds its implied fair value, not to exceed the recorded amount of goodwill. The Company recorded a non-cash goodwill impairment charge with respect to the newly formed reporting unit amounted to $42.5 million for the year ended December 31, 2020. Please see Note 8, Goodwill for further details.

 

The Company performed a qualitative annual assessment for impairment of the remaining goodwill with respect to legacy Anika reporting unit as of November 30, 2022, including consideration of (i) general macroeconomic factors, (ii) industry and market conditions, and (iii) the extent of the excess of the fair value over the carrying value indicated in prior impairment testing. Accordingly, the Company determined it was not more likely than not that the fair value of the legacy Anika reporting unit is less than its carrying amount and thus goodwill was not impaired as of November 30, 2022.

 

To conduct impairment tests of IPR&D, the fair value of the IPR&D project is compared to its carrying value. If the carrying value exceeds its fair value, the Company records an impairment loss to the extent that the carrying value of the IPR&D project exceeds its fair value. The Company estimates the fair value for IPR&D using the income approach, which is based on the Multi-Period Excess Earnings Method (“MPEEM”). MPEEM measures economic benefit indirectly by calculating the income attributable to an asset after appropriate returns are paid to complementary assets used in conjunction with the subject asset to produce the earnings associated with the subject asset, commonly referred to as contributory asset charges. This approach incorporates significant estimates and assumptions related to the forecasted results including revenues, expenses, expected economic life of the asset, contributory asset charges and discount rates to estimate future cash flows.

 

Long-Lived Assets

 

Long-lived assets primarily include property and equipment and intangible assets with finite lives. The Company’s intangible assets are comprised of purchased developed technologies, patents, trade names, customer relationships and distributor relationships. These intangible assets are carried at cost, net of accumulated amortization. Amortization is recorded on a straight-line basis over the intangible assets' useful lives, which range from approximately five to sixteen years. The Company reviews long-lived assets for impairment when events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful lives of those assets are no longer appropriate. Each impairment test is based on a comparison of the undiscounted cash flows to the recorded value of the asset. If impairment is indicated, the asset is written down to its estimated fair value based on a discounted cash flow analysis.

 

In determining the useful lives of intangible assets, the Company considers the expected use of the assets and the effects of obsolescence, demand, competition, anticipated technological advances, changes in surgical techniques, market influences and other economic factors. For technology-based intangible assets, the Company considers the expected life cycles of products, absent unforeseen technological advances, which incorporate the corresponding technology.

 

Fair Value Measurements

 

Fair value is defined as the price that would be received from selling an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of non-performance. The accounting standard establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

 

A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Three levels of inputs that may be used to measure fair value are:

 

 

•

Level 1 – Valuation is based upon quoted prices for identical instruments traded in active markets. Level 1 instruments include securities traded on active exchange markets, such as the New York Stock Exchange.

 

 

•

Level 2 – Valuation is based upon quoted prices, unadjusted, for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are directly observable in the market.

 

69
 
 
 

•

Level 3 – Valuation is generated from model-based techniques that use significant assumptions not observable in the market. These unobservable assumptions reflect the Company’s own estimates of assumptions market participants would use in pricing the instrument.

 

The Company’s financial assets have been classified as Level 1. The Company’s financial assets (which include cash equivalents and investments) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third party pricing services. The Company’s financial liabilities have been classified as Level 3. The Company’s financial liabilities (which include contingent considerations as discussed in Note 4 – Fair Value Measurements) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing a third-party valuation specialist.

 

Research and Development

 

Research and development costs consist primarily of salaries and related expenses for personnel, clinical trial expenses and fees paid to outside consultants and outside service providers. Research and development costs are expensed as incurred.

 

Stock-Based Compensation

 

The Company has stock-based compensation plans under which it grants various types of equity-based awards, the cost of which is based on the grant-date fair value of the underlying award and recognized over the period during which an employee is required to provide service in exchange for the award, which is generally the vesting period.

 

For performance-equity awards with market-based conditions, compensation cost is measured at the date of the award and is recorded over the vesting period, regardless of the likelihood of achievement of the market-based performance criteria. For performance-based equity awards with financial and business milestone achievement targets, compensation cost is based on the probable outcome of the performance conditions. Changes to the probability assessment and the estimated shares expected to vest will result in adjustments to the related stock-based compensation expense that will be recorded in the period of the change. If the performance targets are not achieved, no compensation cost is recognized, and any previously recognized compensation cost is reversed.

 

See Note 14, Equity Incentive Plan, for a description of the types of stock-based awards granted, the compensation expense related to such awards, and detail of equity-based awards outstanding.

 

Income Taxes

 

We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets, or DTAs, and deferred tax liabilities, or DTLs, for the expected future tax consequences of events that have been included in the financial statements. Under this method, we determine DTAs and DTLs based on the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on DTAs and DTLs is recognized in income in the period that includes the enactment date.

 

We recognize DTAs to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, carryback potential if permitted under the tax law, and results of recent operations.

 

We record uncertain tax positions in accordance with ASC 740, Income Taxes, on the basis of a two-step process in which (1) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. Interest and penalties associated with income tax filings are recorded in income tax expense.

 

Comprehensive Income (Loss)

 

Comprehensive income (loss) consists of net income (loss) and other comprehensive income (loss), which includes foreign currency translation adjustments. For the purposes of comprehensive income (loss) disclosures, the Company does not record tax provisions or benefits for the net changes in the foreign currency translation adjustment, as it intends to indefinitely reinvest undistributed earnings of its foreign subsidiary. Accumulated other comprehensive income (loss) is reported as a component of stockholders' equity.

 

Segment Information

 

Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is its President and Chief Executive Officer as of December 31, 2022. Based on the criteria established by ASC 280, Segment Reporting, the Company has one operating and reportable segment.

 

Contingencies

 

In the normal course of business, the Company is involved from time-to-time in various legal proceedings and other matters such as contractual disputes, which are complex in nature and have outcomes that are difficult to predict. The Company records accruals for loss contingencies to the extent that it concludes that it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. The Company considers all relevant factors when making assessments regarding these contingencies. Although the outcomes of any potential legal proceedings are inherently difficult to predict, the Company does not expect the resolution of any potential legal proceedings to have a material adverse effect on its financial position, results of operations, or cash flow.

 

70
 
 

Recent Issued Accounting Pronouncements

 

No new accounting pronouncements issued or effective during the period had, or are expected to have, a material impact on the consolidated financial statements.

 

 

3. Business Combinations

 

Parcus Medical, LLC

 

On January 24, 2020, the Company completed the acquisition of Parcus Medical pursuant to the terms of the Agreement and Plan of Merger, dated as of January 4, 2020 (the “Parcus Medical Merger Agreement”), by and among the Company, Parcus Medical, the Unitholder Representative, and Sunshine Merger Sub LLC, a Wisconsin limited liability company and a wholly owned subsidiary of the Company. At the closing date, Parcus Medical became a wholly owned subsidiary of the Company. Parcus Medical is a sports medicine implant and instrumentation solutions provider focused on surgical repair and reconstruction of soft tissue.

 

The acquisition of Parcus Medical has been accounted for as a business combination under ASC 805, Business Combinations (“ASC 805”). Under ASC 805, assets acquired and liabilities assumed in a business combination are recorded at their fair value as of the acquisition date. The Company’s consolidated financial statements include results of operations for Parcus Medical from the January 24, 2020 acquisition date.

 

Consideration Transferred

 

Pursuant to the Parcus Medical Merger Agreement, the Company acquired all outstanding equity of Parcus Medical for estimated total purchase consideration of $75.1 million, as of January 24, 2020 which consisted of:

 

Cash consideration

 $32,794 

Deferred consideration

  1,642 

Estimated fair value of contingent consideration

  40,700 

Estimated total purchase consideration

 $75,136 

 

71
 
 

Pursuant to the Parcus Medical Merger Agreement, contingent consideration represents additional payments that the Company may be required to make in the future could total up to $60.0 million depending on the level of net sales of Parcus Medical products generated from 2020 through 2022.

 

The fair value of contingent consideration related to net sales as of January 24, 2020 was determined based on a Monte Carlo simulation model in an option pricing framework at the acquisition date, whereby a range of possible scenarios were simulated. There also was deferred consideration related to certain purchase price holdbacks, which was resolved within one year of the acquisition date in accordance with the Parcus Merger. The liability for contingent and deferred consideration is included in current and long-term liabilities on the consolidated balance sheets and will be remeasured at each reporting period until the contingency is resolved. During the three months ended September 30, 2022, the Company paid contingent consideration of $4.3 million related to net sales of Parcus Medical products earned in 2021 that was recorded in contingent consideration at December 31, 2021. As of December 31, 2022, there were no milestones remaining.

 

Acquisition-related costs are not included as a component of consideration transferred but are expensed in the periods in which the costs are incurred. The Company incurred approximately $1.9 million in transaction costs related to the Parcus Medical acquisition during the three-month period ending March 31, 2020. The transaction costs have been included in selling, general and administrative expenses in the consolidated statements of operations.

 

Fair Value of Net Assets Acquired

 

The estimate of fair value as of the acquisition date required the use of significant assumptions and estimates. Critical estimates included, but were not limited to, future expected cash flows, including projected revenues and expenses, and the applicable discount rates. These estimates were based on assumptions that the Company believes to be reasonable, however, actual results may differ from these estimates.

 

The allocation of purchase price to the identifiable assets acquired and liabilities assumed was based on estimates of fair value as of January 24, 2020, and is as follows:

 

Recognized identifiable assets acquired and liabilities assumed:

    

Cash and cash equivalents

 $196 

Accounts receivable

  2,029 

Inventories

  10,968 

Prepaid expenses and other current assets

  364 

Property and equipment, net

  1,099 

Right-of-use assets

  944 

Intangible assets

  44,000 

Accounts payable, accrued expenses and other current liabilities

  (2,763

)

Other long-term liabilities

  (594

)

Lease liabilities

  (735

)

Net assets acquired

  55,508 

Goodwill

  19,628 

Estimated total purchase consideration

 $75,136 

 

The acquired intangible assets based on estimates of fair value as of January 24, 2020 are as follows:

 

Developed technology

 $41,100 

Trade name

  1,800 

Customer relationships

  1,100 

Total acquired intangible assets

 $44,000 

 

The fair value of the developed technology intangible assets has been estimated using the multi-period excess earnings method, which is based on the principle that the value of an intangible asset is equal to the present value of the incremental after-tax cash flows attributable to the asset, after charges for other assets employed by the business. The fair value of the customer relationships has been estimated using the avoided costs/lost profits method, which is based on the principle that the value of an intangible asset is based on consideration of the total costs that would be avoided by having this asset in place. The fair value of the trade name has been estimated using the relief from royalty method of the income approach, which is based on the principle that the value of an intangible asset is equal to the present value of the after-tax royalty savings attributable to owning the intangible asset. Key estimates and assumptions used in these models are projected revenues and expenses related to the asset, estimated contributory asset charges, estimated costs to recreate the asset, and a risk-adjusted discount rate used to calculate the present value of the future expected cash inflows or cash outflows avoided from the asset.

 

72
 
 

The fair value of developed technology will be amortized over a useful life of 15 years, the fair value of customer relationships over 10 years, and the fair value of the trade name over 5 years.

 

The excess of the purchase price over the fair value of the net assets acquired was recorded as goodwill and assigned to the reporting unit for Parcus Medical and Arthrosurface. The goodwill is attributable to the workforce of the business and the value of future technologies expected to arise after the acquisition. Goodwill will not be amortized and is expected to be deductible for income tax purposes as the acquisition of the limited liability company is an asset purchase for tax purposes. See Note 8, Goodwill, for further discussion.

 

Arthrosurface, Inc.

 

On February 3, 2020, the Company completed the acquisition of Arthrosurface pursuant to the terms of the Agreement and Plan of Merger, dated as of January 4, 2020 (the “Arthrosurface Merger Agreement”), by and among the Company, Arthrosurface, the Stockholder Representative, and Button Merger Sub, a Delaware corporation and a wholly owned subsidiary of the Company. At the closing date, Arthrosurface became a wholly owned subsidiary of the Company. Arthrosurface is a joint preservation technology company specializing in less invasive, bone-preserving partial and total joint replacement solutions.

 

The acquisition of Arthrosurface has been accounted for as a business combination under ASC 805. Under ASC 805, assets acquired and liabilities assumed in a business combination are recorded at their fair values as of the acquisition date. Anika’s consolidated financial statements include results of operations for Arthrosurface from the February 3, 2020 acquisition date.

 

Consideration Transferred

 

Pursuant to the Arthrosurface Merger Agreement, the Company acquired all outstanding equity of Arthrosurface for estimated total purchase consideration of $90.3 million, as of February 3, 2020 which consisted of:

 

Cash consideration

 $61,909 

Estimated fair value of contingent consideration

  28,376 

Estimated total purchase consideration

 $90,285 

 

Pursuant to the Arthrosurface Merger Agreement, the Company could be required to make future payments of up to $40.0 million depending on the achievement of regulatory milestones and the level of net sales of Arthrosurface products from 2020 through 2021. The fair value of contingent consideration related to regulatory milestones as of February 3, 2020 was determined through a scenario-based discounted cash flow analysis using scenario probabilities and regulatory milestone dates. The fair value of contingent consideration related to net sales achievement as of February 3, 2020 was determined based upon a Monte Carlo simulation approach at acquisition date, whereby a range of possible scenarios were simulated. The Company paid $5.0 million in October 2020 and $10.0 million in July 2021 based upon the achievement of two distinct regulatory milestones. As of December 31, 2022, there were no milestones remaining.

 

Acquisition-related costs are not included as a component of consideration transferred but are expensed in the periods in which the costs are incurred. The Company incurred approximately $2.2 million in transaction costs related to the Arthrosurface acquisition during the three-month period ending March 31, 2020. The transaction costs have been included in selling, general and administrative expenses in the consolidated statements of operations.

 

Fair Value of Net Assets Acquired

 

The estimate of fair value required the use of significant assumptions and estimates. Critical estimates included, but were not limited to, future expected cash flows, including projected revenues and expenses, and the applicable discount rates. These estimates were based on assumptions that the Company believes to be reasonable. However, actual results may differ from these estimates.

 

73
 
 

The allocation of purchase price to the identifiable assets acquired and liabilities assumed was based on estimates of fair value as of February 3, 2020, as follows:

 

Recognized identifiable assets acquired and liabilities assumed:

    

Cash and cash equivalents

 $1,072 

Accounts receivable

  5,368 

Inventories

  15,652 

Prepaid expenses and other current assets

  535 

Property, plant and equipment

  3,394 

Other long-term assets

  7,548 

Intangible assets

  48,900 

Accounts payable, accrued expenses and other liabilities

  (3,929

)

Deferred tax liabilities

  (11,147

)

Net assets acquired

  67,393 

Goodwill

  22,892 

Estimated total purchase consideration

 $90,285 

 

Intangible assets acquired consist of:

    

Developed technology

 $37,000 

Trade name

  3,400 

Customer relationships

  7,900 

IPR&D

  600 

Total acquired intangible assets

 $48,900 

 

The fair value of the developed technology intangible assets has been estimated using the multi-period excess earnings method, which is based on the principle that the value of an intangible asset is equal to the present value of the incremental after-tax cash flow attributable to the asset, after charges for other assets employed by the business. The fair value of the customer relationships has been estimated using the avoided costs/lost profits method, which is based on the principle that the value of an intangible asset is based on consideration of the total costs that would be avoided by having this asset in place. The fair value of the trade name has been estimated using the relief from royalty method of the income approach, which is based on the principle that the value of an intangible asset is equal to the present value of the after-tax royalty savings attributable to owning the intangible asset. Key estimates and assumptions used in these models are projected revenues and expenses related to the asset, estimated contributory asset charges, estimated costs to recreate the asset, and a risk-adjusted discount rate used to calculate the present value of the future expected cash inflows or cash outflows avoided from the asset.

 

The fair value of developed technology that will be amortized over an estimated useful life of 15 years, the fair value of customer relationships over 10 years, and the fair value of trade names over 5 years. A total of $0.6 million represents the fair value of IPR&D with an indefinite useful life which was impaired during the quarter ended December 31, 2021. See Note 7, Acquired Intangible Assets, Net, for further discussion.

 

The excess of the purchase price over the fair value of the net assets acquired was recorded as goodwill and assigned to the newly established reporting unit for Parcus Medical and Arthrosurface. The goodwill is attributable to the workforce of the business and the value of future technologies expected to arise after the acquisition. Goodwill will not be amortized and is not expected to be deductible for income tax purposes as the acquisition of the corporation is a stock purchase for tax purposes. See Note 8, Goodwill, for further discussion.

 

Pro forma Information

 

The Parcus Medical and Arthrosurface acquisitions were both completed in the first quarter of 2020. Both acquired companies have similar businesses with all of their products in the Joint Preservation and Restoration product family, serving orthopedic surgeons, ambulatory surgical centers and hospitals. The Company has combined legacy Anika, Parcus Medical and Arthrosurface pro forma supplemental information as follows.

 

The unaudited pro forma information for the year ended December 31, 2020 was calculated after applying the Company’s accounting policies and the impact of acquisition date fair value adjustments. The pro forma financial information presents the combined results of operations of Anika, Parcus Medical and Arthrosurface as if the acquisitions had occurred on January 1, 2019 after giving effect to certain pro forma adjustments. The pro forma adjustments reflected herein include only those adjustments that are factually supportable and directly attributable to the acquisitions.

 

These pro forma adjustments include: (i) a net increase in amortization expense to record amortization expense for the aforementioned acquired identifiable intangible assets, (ii) an adjustment to cost of revenue based on the preliminary inventory step-up and the anticipated inventory turnover, (iii) a net decrease in interest expense as a result of eliminating interest expense and interest income related to borrowings that were settled in accordance with the respective Parcus Medical Merger Agreement and Arthrosurface Merger Agreement, (iv) an adjustment to record the acquisition-related transaction costs in the period required, and (v) the tax effect of the pro forma adjustments using the anticipated effective tax rate. The effective tax rate of the combined company could be materially different from the effective rate presented in this unaudited pro forma combined financial information. As a result of the transaction, the combined company may be subject to annual limitations on its ability to utilize pre-acquisition net operating loss carryforwards to offset future taxable income. The amount of the annual limitation is determined based on the value of Anika immediately prior to the acquisition. As further information becomes available, any such adjustment described above could be material to the amounts presented in the unaudited pro forma combined financial statements. The pro forma information does not purport to be indicative of the results of operations that actually would have resulted had the combination occurred at the beginning of each period presented, or of future results of the consolidated entities.

 

74
 
 

The following table presents unaudited supplemental pro forma information:

 

  

Year Ended December 31,

2020

 

Total revenue

 $134,410 

Net loss

 $(22,984)

 

 

4. Fair Value Measurements

 

There were no available-for-sale securities as of December 31, 2022 and 2021.

 

The Company’s investments are all classified within Levels 1 of the fair value hierarchy and are valued based on quoted prices in active markets. For cash, current receivables, accounts payable, and interest accrual, the carrying amounts approximate fair value, because of the short maturity of these instruments, and therefore fair value information is not included in the table below. Contingent consideration related to the previously described business combinations are classified within Level 3 of the fair value hierarchy as the determination of fair value uses considerable judgement and represents the Company’s best estimate of an amount that could be realized in a market exchange for the asset or liability. 

 

The classification of the Company’s cash equivalents and investments within the fair value hierarchy is as follows:

 

      

Active Markets

  

Significant Other

  

Significant

     
      

for Identical Assets

  

Observable Inputs

  

Unobservable Inputs

     
  

December 31, 2022

  

(Level 1)

  

(Level 2)

  

(Level 3)

  

Amortized Cost

 

Cash equivalents:

                    

Money Market Funds

 $67,801  $67,801  $-  $-  $67,801 

 

      

Active Markets

  

Significant Other

  

Significant

     
      

for Identical Assets

  

Observable Inputs

  

Unobservable Inputs

     
  

December 31, 2021

  

(Level 1)

  

(Level 2)

  

(Level 3)

  

Amortized Cost

 

Cash equivalents:

                    

Money Market Funds

 $67,046  $67,046  $-  $-  $67,046 
                     

Other current and long-term liabilities:

                    

Contingent Consideration - Short Term

 $4,315  $-  $-  $4,315  $- 

 

There were no transfers between fair value levels in 2022 or 2021.

 

 

75
 
 

Contingent Consideration

 

The following table provides a roll forward of the contingent consideration related to business acquisitions discussed in Note 3, Business Combinations.

 

  

Years Ended December 31

 
  

2022

  

2021

 

Balance, beginning January 1

 $4,315  $35,410 

Additions

  -   - 

Payments

  (4,315

)

  (10,000

)

Change in fair value

  -   (21,095

)

Balance, ending December 31

 $-  $4,315 

 

Under the Parcus Medical Merger Agreement and Arthrosurface Merger Agreement, there were earn-out milestones totaling up to $100 million payable from 2020 to 2022. Parcus Medical had net sales earn-out milestones annually from 2020 to 2022, while Arthrosurface had both regulatory and net sales earn-out milestones annually in 2020 and 2021.

 

In order to determine the fair value of contingent consideration at each reporting date, the projected contingent payment amounts were discounted back to the current period using a discounted cash flow model or a Monte Carlo simulation approach. The unobservable inputs used in the fair value measurement of the Company’s contingent consideration are the probabilities of successful achievement, the net sales estimates, the weighted average cost of capital used for the Monte Carlo simulation, discount rate and the periods in which the milestones are expected to be achieved. The discount rates used for the net sales earn-out milestone ranged from 3.1% - 3.4%. The weighted average cost of capital for Parcus Medical decreased from 11.4% as of December 31, 2020 to 11.3% as of December 31, 2021. The weighted average cost of capital for Arthrosurface was 11.4% as of December 31, 2020. Increases or decreases in the discount rate would result in a lower or higher fair value measurement, respectively.

 

As of December 31, 2021, a net sales growth milestone with respect to the Parcus Merger Agreement was achieved for 2021, and a liability in the amount of $4.3 million was recorded in current liabilities. This amount was paid in September 2022. In June 2021, the Company received regulatory clearance for a reverse shoulder implant system, which triggered a $10.0 million regulatory milestone payment per the terms of the Arthrosurface Merger Agreement. This amount was paid in July 2021. As of December 31, 2022, there were no milestones remaining.

 

The overall fair value of the contingent consideration decreased by $21.1 million and $28.7 million during the years ended December 31, 2021 and 2020, respectively, due primarily to the decrease in the likelihood that certain contingent milestones would be achieved.

 

 

5. Inventories

 

Total inventories included in the balance sheet consist of the following:

 

   

As of December 31,

  
   

2022

    

2021

  

Raw materials

   $ 20,535     $ 16,881  

Work-in-process

     10,648       11,442  

Finished goods

     25,306       26,731  

Total

   $ 56,489     $ 55,054  
                 

Inventories

   $ 39,765     $ 36,010  

Other long-term assets

     16,724       19,044  
Total   $ 56,489     $ 55,054  

 

Inventories are stated net of inventory reserves of approximately $9.9 million and $9.1 million, as of December 31, 2022 and 2021, respectively.

 

76
 

 

 

6. Property and Equipment

 

Property and equipment is stated at cost and consists of the following:

 

   

As of December 31,

  
   

2022

    

2021

  

Equipment and software

   $ 52,112     $ 48,804  

Furniture and fixtures

     2,413       2,389  

Leasehold improvements

     34,916       34,614  

Construction in progress

     5,021       1,378  

Subtotal

     94,462       87,185  

Less accumulated depreciation

     (46,183 )     (39,583

)

Total

   $ 48,279     $ 47,602  

 

Depreciation expense was $6.7 million, $6.5 million, and $6.1 million for the years ended December 31, 2022, 2021, and 2020, respectively.

 

 

7. Acquired Intangible Assets, Net

 

Intangible assets consist of the following:

 

      

Year Ended December 31, 2022

 
  

Gross Cost

  

Less: Accumulated

Currency Translation

Adjustment

  

Less: Current Period

Impairment Charge

  

Less: Accumulated

Amortization

  

Net Book Value

  

Weighted

Average Useful

Life (in Years)

 

Developed technology

 $89,580  $(1,608) $-  $(23,686) $64,286   15 

IPR&D

  2,656   (1,006)  -   -   1,650  

Indefinite

 

Customer relationships

  9,000   -   -   (2,627)  6,373   10 

Distributor relationships

  4,700   (415)  -   (4,285)  -   5 

Patents

  1,000   (189)  -   (680)  131   16 

Tradenames

  5,200   -   -   (3,041)  2,159   5 

Total

 $112,136  $(3,218) $-  $(34,319) $74,599   13 

 

      

Year Ended December 31, 2021

 
  

Gross Cost

  

Less: Accumulated

Currency Translation

Adjustment

  

Less: Current Period

Impairment Charge

  

Less: Accumulated

Amortization

  

Net Book Value

  

Weighted

Average Useful

Life

 

Developed technology

 $89,580  $(1,608

)

 $-  $(17,891

)

 $70,081   15 

IPR&D

  3,256   (1,006

)

  (600

)

  -   1,650  

Indefinite

 

Customer relationships

  9,000   -   -   (1,727

)

  7,273   10 

Distributor relationships

  4,700   (415

)

  -   (4,285

)

  -   5 

Patents

  1,000   (189

)

  -   (632

)

  179   16 

Tradenames

  5,200   -   -   (2,001

)

  3,199   5 

Total

 $112,736  $(3,218

)

 $(600

)

 $(26,536

)

 $82,382   13 

 

77
 
 

Total amortization expense with respect to the definite lived acquired intangible assets was $7.8 million for each of the years ended December 31, 2022 and 2021 and $7.4 million for the year ended December 31, 2020.

 

During the fourth quarter of 2021, the Company decided not to further invest in a joint technology IPR&D project, as it is no longer aligned with the Company’s core strategic focus. As a result, the Company recorded an impairment charge in the amount of $0.6 million in research and development expenses in the Company’s consolidated statements of operations.

 

During the fourth quarter of 2020, the Company decided not to further invest in its Hyalobone and Hyalonect IPR&D projects as they were no longer aligned with the Company’s core strategic focus. As a result, the Company recorded an impairment charge in the period totaling $1.4 million recorded in research and development expenses in the Company’s consolidated statements of operations.

 

The Company performed its annual assessment of the remaining IPR&D intangible asset as of November 30, 2022. The Company estimated the fair value of the IPR&D intangible assets using the income approach which is based on the Multi-Period Excess Earnings Method (“MPEEM”). MPEEM measures economic benefit indirectly by calculating the income attributable to an asset after appropriate returns are paid to complementary assets used in conjunction with the subject asset to produce the earnings associated with the subject asset, commonly referred to as contributory asset charges. This approach incorporates significant estimates and assumptions related to the forecasted results including revenues, expenses, expected economic life of the asset, contributory asset charges and discount rates to estimate future cash flows. While assumptions utilized are subject to a high degree of judgment and complexity, the Company made its best estimate of future cash flows under a high degree of economic uncertainty that existed as of November 30, 2022. In developing its assumptions, the Company also considered observed trends of its industry participants. No impairment existed as the estimated fair value of the remaining IPR&D intangible asset was greater than its carrying value.

 

During 2020, the Company determined that it would not pursue CE mark renewals for certain of its legacy products, which resulted in an impairment of certain developed technology related assets in the amount of $1.0 million in 2020. This impairment charge was recorded in selling, general and administrative expenses on the Company’s consolidated statements of operations.

 

 

8. Goodwill

 

The following table provides a roll forward of goodwill for the years ended December 31, 2022 and 2021:

 

  

Years Ended December 31

 
  

2022

  

2021

 

Balance, beginning January 1

 $7,781  $8,413 

Effect of foreign currency adjustments

  (442)  (632)

Balance, ending December 31

 $7,339  $7,781 

 

In the first quarter of 2020, the Company acquired Parcus Medical and Arthrosurface, as further discussed in Note 3, Business Combinations. As a result of the acquisitions, the Company determined that it had two reporting units. It created a reporting unit in 2020 that included Parcus Medical and Arthrosurface, which share similar economic and qualitative characteristics. This reporting unit produces sports medicine surgical products, instruments and joint repair implants. The Company also has another reporting unit that comprises the legacy Anika business, which specializes in therapies based on its hyaluronic acid, or HA, technology platform. The Company impaired the Parcus Medical and Arthrosurface reporting unit in 2020. The remaining goodwill balance at December 31, 2022 and 2021 was related to the legacy Anika reporting unit.

 

As part of its annual impairment testing as of November 30 each year for the goodwill related to the legacy Anika reporting unit, the Company performed a qualitative assessment including consideration of (i) general macroeconomic factors, (ii) industry and market conditions, and (iii) the extent of the excess of the fair value over the carrying value indicated in prior impairment testing. The Company determined it was not more likely than not that the fair value of the legacy Anika reporting unit is less than its carrying amount and thus goodwill was not impaired as of November 30, 2022.

 

Government policy responses to the COVID-19 pandemic and the resulting changes in healthcare guidelines caused a temporary suspension of global elective surgical procedures. As a result, the widespread economic volatility triggered impairment testing in the first quarter of 2020, and accordingly, the Company performed interim impairment testing on the goodwill balances of its reporting units. The Company also performed its annual impairment testing in the fourth quarter of 2020.

 

78
 
 

The Company estimated the fair value of the reporting units using a discounted cash flow method, which is based on the present value of projected cash flows and a terminal value, which represents the expected normalized cash flows of the reporting units beyond the cash flows from the discrete projection period. The Company determined that a discounted cash flow model provided the best approximation of fair value of the reporting units for the purpose of performing the impairment test. This approach incorporates significant estimates and assumptions related to the forecasted results including revenues, expenses, the achievement of certain cost synergies, terminal growth rates and discount rates to estimate future cash flows. While assumptions utilized are subject to a high degree of judgment and complexity, the Company made its best estimate of future cash flows under a high degree of economic uncertainty that existed as of November 30, 2020. In developing its assumptions, the Company also considered observed trends of its industry participants.

 

For the legacy Anika reporting unit, the Company performed a qualitative assessment including consideration of (i) general macroeconomic factors, (ii) industry and market conditions, and (iii) the extent of the excess of the fair value over the carrying value indicated in prior impairment testing. The Company determined it was not more likely than not that the fair value of the legacy Anika reporting unit is less than its carrying amount and thus goodwill was not impaired as of March 31, 2020. As part of its annual impairment testing, the Company decided to perform a quantitative assessment related to the legacy Anika reporting unit as of November 30, 2020, due to the expectation that the economic recovery will take longer than expected to materialize. The results of the impairment test indicated that the estimated fair value of the legacy Anika reporting unit was greater than its carrying value, therefore the Company did not record any impairment charges related to the legacy Anika reporting unit for the year ended December 31, 2020.

 

For its newly created reporting unit, which includes Parcus Medical and Arthrosurface, the Company performed an interim quantitative assessment of goodwill impairment as of March 31, 2020. The Company estimated the fair value of the reporting unit using a discounted cash flow method. The results of the interim impairment test indicated that the estimated fair value of the reporting unit was less than its carrying value. This was primarily due to decreases in near term revenue and related cash flows as a result of the temporary suspension of domestic elective procedures, primarily due to the COVID-19 pandemic which directly impacted the reporting unit. Consequently, a non-cash goodwill impairment charge was recorded in the amount of $18.1 million during the first quarter of 2020. As part of its annual impairment testing, the Company performed a quantitative assessment related to the newly created reporting unit as of November 30, 2020. The results of the annual impairment test indicated that the estimated fair value of the reporting unit was less than its carrying value. This was primarily due to a decline in projected net cash flows as a result of the continued impact of COVID-19 on revenue and related cash flows, the expectation that the economic recovery will take longer than expected to materialize, and additional projected investment to support future growth. Consequently, a non-cash goodwill impairment charge was recorded in the amount of $24.4 million during the fourth quarter of 2020. The total non-cash goodwill impairment charge with respect to the reporting unit amounted to $42.5 million for the year ended December 31, 2020. There was no remaining goodwill with respect to the newly created reporting unit as of December 31, 2020.

 

 

9. Leases

 

The Company leases its buildings and manufacturing facilities under operating leases. As of December 31, 2022, the Company had real estate leases in Bedford, Massachusetts, Franklin, Massachusetts, Sarasota, Florida, Warsaw, Indiana and Padova, Italy.

 

In June 2022, the Company finalized a renewal option to extend the current term for its operating headquarters and manufacturing facility in Bedford through 2027. There are also lease renewal options into 2038. The current term of the Padova lease extends to 2032, with a right to terminate at the Company’s option in 2026 without penalty.

 

As a result of the acquisition of Parcus Medical and Arthrosurface, the Company acquired operating and finance leases for corporate offices, manufacturing and warehouse facilities and machinery. The operating leases consist of one real estate lease in Franklin, Massachusetts (Franklin lease) and two real estate leases in Sarasota, Florida (Sarasota lease). In October 2022, the Company entered into an option to extend the current term of the Franklin lease through 2024. In June 2022, the Company finalized an option to extend the current term of the two Sarasota leases through 2027. The finance leases include equipment utilized in the Company’s manufacturing facility in Sarasota, Florida and were terminated in September 2022.

 

The significant assumptions in recognizing the right-of-use asset and lease liability are as follows:

 

Incremental borrowing rate. The Company derives its incremental borrowing rate from information available at the lease commencement date in determining the present value of lease payments. The incremental borrowing rate represents a collateralized rate of interest the Company would have to pay to borrow over a similar term an amount equal to the lease payments in a similar economic environment. The Company’s lease agreements do not provide implicit rates. As the Company did not have any external borrowings at either the transition or subsequent renewal dates with comparable terms to its lease agreements, the Company estimated its incremental borrowing rate based on its credit quality, line of credit agreement and by comparing interest rates available in the market for similar borrowings, and adjusting this amount based on the impact of collateral over the term of the lease. The weighted average discount rate at December 31, 2022 was 3.6% for operating leases.

 

79
 
 

Lease term. The lease term begins at the lease commencement date and is determined on that date based on the non-cancelable term of the lease together with periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, or periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option.

 

The components of lease expense and other information are as follows: 

 

  Years Ended December 31 
  

2022

  

2021

  

2020

 

Finance lease amortization of right-of-use assets

 $121  $143  $185 

Interest on finance lease liabilities

  11   19   25 

Finance lease expense

  132   162   210 

Operating lease expense

  2,839   2,468   2,383 

Short-term lease expense

  17   2   - 

Variable lease expense

  413   319   264 

Total lease expense

 $3,401  $2,951  $2,857 

 

  

Years Ended December 31

 
  

2022

  

2021

 

Weighted Average Remaining Lease Term (in years)

        

Operating leases

  14.8   15.3 

Financing leases

  -   2.3 

Weighted Average Discount Rate

        

Operating leases

  3.6

%

  4.1

%

Financing leases

  -   4.9

%

Other information

        

Operating cash flows from operating leases

 $2,471  $2,392 

Operating cash flows from financing leases

 $121  $136 

 

Future commitments due under these lease agreements as of December 31, 2022 are as follows:

 

Years ended December 31,

 

Operating Leases

 
     

2023

 $3,170 

2024

  3,055 

2025

  3,066 

2026

  2,760 

2027

  2,643 

Thereafter

  25,230 

Present value adjustment

  (9,034)

Present value of lease payments

  30,890 

Less current portion included in accrued expenses and other current liabilities

  (2,073)

Total lease liabilities

 $28,817 

 
 

10. Accrued Expenses

 

Accrued expenses consist of the following:

 

   

As of December 31,

  
   

2022

    

2021

  
                 

Compensation and related expenses

   $ 11,303     $ 9,523  

Professional fees

     3,145       3,590  

Operating lease liability- current

     2,073       1,526  

Clinical trial costs

     999       1,961  

Finance lease liability - current

     -       188  

Income taxes payable

     810       -  

Other

     510       1,059  

Total

   $ 18,840     $ 17,847  

 
80
 

 

 

11. Revolving Credit Agreement

 

On November 12, 2021, the Company, entered into a “Third Amendment to Credit Agreement” amending the existing revolving line of credit agreement dated October 24, 2017 with Bank of America, N.A., as administrative agent, swingline lender and issuer of letters of credit, for a $75.0 million senior revolving line of credit (the “Credit Agreement”). Subject to certain conditions, the Company may request up to an additional $75.0 million in commitments for a maximum aggregate commitment of $150.0 million, which requests must be approved by the Revolving Lenders (as defined in the Credit Agreement). Loans under the Credit Agreement generally bear interest at a rate equal to (a) the Bloomberg Short-Term Bank Yield Index, (“BSBY”), rate plus (b) an additional percentage that will range from 0.25% to 1.00%, based on the Company’s consolidated leverage ratio at the time of the borrowings. The Company is required to pay a commitment fee in an amount that is equal to 0.20% to 0.30% per annum, based on the Company’s consolidated leverage ratio, on the actual daily unused amount of the credit facility and that is due and payable quarterly in arrears. Loan origination costs are included as assets on the balance sheet and are being amortized over the five-year term of the Credit Agreement. As of December 31, 2022 and 2021, there were no outstanding borrowings under the Credit Agreement and the Company is in compliance with the terms of the Credit Agreement. 

 

The Credit Agreement contains customary representations, warranties, affirmative and negative covenants, including financial covenants, events of default, and indemnification provisions in favor of the Lenders. These include restrictive covenants that require the Company not to exceed certain maximum leverage and interest coverage ratios, limit its incurrence of liens and indebtedness, and its entry into certain merger and acquisition transactions or dispositions and place additional restrictions on other matters, all subject to certain exceptions. The Revolving Lenders has been granted a first priority lien and security interest in substantially all of the Company’s assets, except for certain intangible assets.

 

In April 2020, the Company borrowed $50.0 million available under the previous credit facility, with an initial applicable interest rate of 2.08%, all of which were repaid during the year ended December 31, 2020. Interest expense for the years ended December 31, 2022, 2021 and 2020 was $0, $0, and $0.8 million, respectively.

 

 

12. Commitments and Contingencies

 

In certain of its contracts, the Company warrants to its customers that the products it manufactures conform to the product specifications as in effect at the time of delivery of the specific product. The Company may also warrant that the products it manufactures do not infringe, violate or breach any U.S. or international patent or intellectual property rights, trade secret, or other proprietary information of any third party. On occasion, the Company contractually indemnifies its customers against any and all losses arising out of, or in any way connected with, any claim or claims of breach of its warranties or any actual or alleged defect in any product caused by the negligent acts or omissions of the Company. The Company maintains a products liability insurance policy that limits its exposure to these risks. Based on the Company’s historical activity, in combination with its liability insurance coverage, the Company believes the estimated fair value of these indemnification agreements is immaterial. The Company had no accrued warranties at December 31, 2022 or 2021, respectively, and has no history of claims paid.  

 

The Company is also involved from time-to-time in various legal proceedings arising in the normal course of business. Although the outcomes of these legal proceedings are inherently difficult to predict, the Company does not expect the resolution of these occasional legal proceedings to have a material adverse effect on its financial position, results of operations, or cash flows.

 

On October 21, 2021, the Company received notice that the former unitholders of Parcus Medical had filed a request for arbitration regarding the earnout provisions agreed to in the Parcus Medical Merger Agreement. The Company has engaged in the arbitration process and does not anticipate a resolution during the first half of 2023. The Company is unable to estimate the potential liability with respect to this matter at this time. There are numerous factors that make it difficult to estimate reasonably possible loss or range of loss at this stage of the matter, including the significant number of legal and factual issues still to be resolved in the arbitration process. The Company intends to vigorously defend against the claims and believes it has strong defenses to the claims asserted.

 

 

13. Revenue and Geographic Information

 

The Company categorizes its product portfolio into three product families: OA Pain Management, Joint Preservation and Restoration, and Non-Orthopedic. Anika’s consolidated financial statements include results of operations for Parcus Medical from the January 24, 2020 acquisition date and Arthrosurface from the February 3, 2020 acquisition date.

 

81
 
 

Product revenue by product family is as follows:

 

  

Years Ended December 31,

 
  

2022

  

2021

  

2020

 
  

Revenue

  

Percentage of
Product
Revenue

  

Revenue

  

Percentage of
Product
Revenue

  

Revenue

  

Percentage of
Product
Revenue

 

OA Pain Management

 $97,887   63

%

 $89,503   61

%

 $83,029   64

%

Joint Preservation and Restoration

  50,402   32

%

  48,588   33

%

  39,368   30

%

Non-Orthopedic

  7,947   5

%

  9,703   6

%

  8,060   6

%

Total

 $156,236   100

%

 $147,794   100

%

 $130,457   100

%

 

Effective January 1, 2023, the Company will begin to report revenue from product sales to veterinary customers within the Non-Orthopedic product family whereas such revenue had been reported within the OA Pain Management revenue product family. Revenue from product sales to veterinary customers amounted to $5.9 million, $4.4 million and $3.8 million for 2022, 2021 and 2020, respectively.

 

Product revenue from the Company’s sole significant customer, Mitek, as a percentage of the Company’s total product revenue was 43%, 45%, and 49% for the years ended December 31, 2022, 2021, and 2020, respectively.

 

Total revenue by geographic location based on the location of the customer in total and as a percentage of total revenue are as follows:

 

  

Years Ended December 31,

 
  

2022

  

2021

  

2020

 
  

Total

  

Percentage of

  

Total

  

Percentage of

  

Total

  

Percentage of

 
  

Revenue

  

Revenue

  

Revenue

  

Revenue

  

Revenue

  

Revenue

 

Geographic Location:

                        

United States

 $119,151   76% $113,833   77

%

 $103,182   79

%

Europe

  20,639   13%  19,580   13

%

  14,179   11

%

Other

  16,446   11%  14,381   10

%

  13,096   10

%

Total

 $156,236   100% $147,794   100

%

 $130,457   100

%

 

Net long-lived assets, consisting primarily of net property and equipment, are subject to geographic risks because they are generally difficult to move and to effectively utilize in another geographic area in a reasonable time period and because they are relatively illiquid. Net tangible long-lived assets by principal geographic areas are as follows:

 

  

Years Ended December 31,

 
  

2022

  

2021

 

United States

 $47,068  $46,068 

Italy

  1,211   1,534 

Total

 $48,279  $47,602 

 
82
 

 

 

14. Equity Incentive Plan

 

Equity Incentive Plan

 

The Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan (the “2017 Plan”) was approved by the Company’s stockholders on June 13, 2017 and subsequently amended on June 18, 2019, June 16, 2020 and June 16, 2021. The 2017 Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights (“SARs”), restricted stock awards (“RSAs”), performance restricted stock units (“PSUs”), restricted stock units (“RSUs”), total shareholder return options (“TSRs”) and performance options that may be settled in cash, stock, or other property. In accordance with the 2017 Plan approved by the Company’s stockholders, including the amendments thereto, each share award other than stock options or SAR’s will reduce the number of total shares available for grant by two shares. Subject to adjustment for specified types of changes in the Company’s capitalization, no more than 4.6 million shares of common stock may be issued under the 2017 Plan. There are 1.2 million shares available for future grant at December 31, 2022 under the 2017 Plan.

 

The Anika Therapeutics, Inc. 2021 Inducement Plan (the “Inducement Plan”) was adopted by the Company’s board of directors on November 4, 2021. The Inducement Plan reserves 125,000 shares of common stock for issuance pursuant to equity-based awards granted under the Inducement Plan. Such awards may be granted only to an individual who was not previously the Company’s employee or director with the Company. The Inducement Plan provides for the grant of awards under terms substantially similar to the 2017 Plan (as amended). There are 4,883 shares available for future grant at December 31, 2022 under the Inducement Plan.

 

The Company may satisfy the awards upon exercise, or upon fulfillment of the vesting requirements for other equity-based awards, with either newly issued shares or shares reacquired by the Company. Stock-based awards are granted with an exercise price equal to or greater than the market price of the Company’s stock on the date of grant. Awards contain service conditions or service and performance conditions, and they generally become exercisable ratably over one to four years with a maximum contractual term of ten years.

 

The Company presents the expenses related to stock-based compensation awards in the same expense line items as cash compensation paid to each of its employees. For the year ended December 31, 2022, the tax benefit associated with stock-based compensation was $1.1 million. A summary of the stock-based compensation in the Company’s statements of operations is as follows (in thousands):

 

 

  

Years Ended December 31,

 
  

2022

  

2021

  

2020

 

Cost of revenue

 

$

820

  

$

716

  

$

719

 

Research and development

  

1,646

   

1,233

   

713

 

Selling, general and administrative

  

11,849

   

9,136

   

3,954

 

Total stock-based compensation expense

 

$

14,315

  

$

11,085

  

$

5,386

 

 

For the years ended December 31, 2022, 2021 and 2020, windfall tax benefits (expense) of $(0.5) million, $0.1 million and $0.2 million, respectively, are associated with the stock-based compensation expense above.

 

The Company’s former President and Chief Executive Officer, Joseph Darling, passed away unexpectedly in January 2020. According to the terms of Mr. Darling’s equity award grants and the 2017 Plan, the unvested portion of his stock-based compensation was forfeited upon his death, resulting in a one-time benefit of $1.8 million that was fully recognized during the three-month period ended March 31, 2020 within selling, general and administrative expenses.

 

Stock Options

 

Stock options are granted to purchase common shares at prices that are equal to the fair market value of the shares on the date the options are granted or, in the case of premium options, are granted with an exercise price at 110% of the market price of the Company’s common stock on the date of grant. Options generally vest in equal annual installments over a period of three to four years and expire 10 years after the date of grant. The grant-date fair value of options is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period.

 

83
 
 

The following summarizes the activity under the Company’s stock option plans:

 

  

Number of Options

  

Weighted Average Exercise Price

  

Weighted Average

Remaining

Contractual

Term (in years)

  

Aggregate Intrinsic

Value

(in thousands)

 

Outstanding as of December 31, 2021

  1,175,993  $39.56         

Granted

  553,827  $28.07         

Exercised

  (433) $8.83      $10 

Forfeited and canceled

  (198,684) $43.24         

Outstanding as of December 31, 2022

  1,530,703  $34.93   8.1  $1,050 

Vested, December 31, 2022

  640,056  $40.08   7.2  $12 

Vested or expected to vest, December 31, 2022

  1,530,703  $34.93   8.1  $1,050 

 

The aggregate intrinsic value of options exercised for the years ended December 31, 2021 and 2020 was $0.3 million and $2.8 million, respectively.

 

The Company granted 553,827 stock options during the year ended December 31, 2022, of which 398,314 shares were premium-priced options.

 

The Company uses the Black-Scholes pricing model to determine the fair value of options granted. The calculation of the fair value of stock options is affected by the stock price on the grant date, the expected volatility of the Company’s common stock over the expected term of the award, the expected life of the award, the risk-free interest rate and the dividend yield. The Company estimated the fair value of TSRs using Monte-Carlo simulation model where the expected volatility assumption is evaluated over 6.3 years. The actual number of TSR options that may be earned ranges from 0% to 150% of the target number, depending on the total shareholder return of the Company relative to the peer group over the vesting period of 2.7 years. The Company completed its evaluation of the TSR award and vested 139,168 TSRs as of December 31, 2022.

 

The assumptions used in the Black-Scholes pricing model for options granted during the years ended December 31, 2022 2021 and 2020, along with the weighted-average grant-date fair values, were as follows:

 

 

2022

 

2021

 

2020

Risk-free interest rate

1.28%

-

4.28%

 

0.29%

-

1.00%

 

0.21%

-

1.59%

Expected stock price volatility

53.80%

-

55.55%

 

54.80%

-

56.35%

 

46.48%

-

54.06%

Expected life of options (in years)

 

4.5

   

4.0

   

4.0

 

Expected dividend yield

 

0.0%

   

0.0%

   

-%

 

Fair value per option

 

11.45

   

14.80

   

16.31

 

 

As of December 31, 2022, there was $7.4 million of unrecognized compensation cost related to unvested stock options. This expense is expected to be recognized over a weighted average period of 1.8 years.

 

84
 
 

Restricted Stock Units

 

RSUs generally vest in equal annual installments over a three- or four-year periods. The grant-date fair value of RSUs is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The Company determines the fair value of restricted stock units based on the closing price of its common stock on the date of grant.

 

RSU activity for the year ended December 31, 2022 is as follows:

 

  

Number of Shares

  

Weighted Average Fair Value

 

Outstanding as of December 31, 2021

 $412,658  $36.33 

Granted

  507,524  $25.14 

Vested

  (164,167) $36.77 

Forfeited and cancelled

  (80,610) $(31.40)

Outstanding as of December 31, 2022

 $675,405  $28.40 

 

The weighted-average grant-date fair value per share of RSUs granted was $25.14, $35.88 and $38.20 for the years ended December 31, 2022, 2021 and 2020, respectively. The total fair value of RSUs vested was $6.0 million, $3.7 million and $2.2 million for the years ended December 31, 2022, 2021 and 2020, respectively.

 

As of December 31, 2022, there was $12.3 million of unrecognized compensation cost related to time-based RSUs, which is expected to be recognized over a weighted-average period of 1.8 years.

 

Performance Stock Units

 

PSUs generally vest over a three-year period from the grant date and include both a service and performance component. The PSUs granted to employees in 2019 contained performance conditions with business and financial targets. The business target, amounting to 30% of the total performance condition awards, was measured and achieved in the 2019 fiscal year. One of the financial targets, amounting to 55% of the total performance condition awards, was measured and achieved in the 2022 fiscal year, while the remaining financial target, amounting to 15% of the total performance condition awards, was not achieved. The PSUs granted to employees in 2020 contained performance conditions with business and financial targets. One of the business targets, amounting to 20% of the total performance condition awards, was not achieved in the 2021 fiscal year, while the remaining business target related to a certain timely regulatory approval, amounting to 20% of the total performance condition awards, was not achieved in the 2022 fiscal year. The financial targets, amounting to 60% of the total performance condition awards, were not achieved in the 2022 fiscal year.

 

PSU activity for the year ended December 31, 2022 is as follows:

 

  

Number of Shares

  

Weighted Average Fair Value

 

Outstanding as of December 31, 2021

  158,297  $37.44 

Granted

  2,125  $32.53 

Vested

  (19,125) $32.53 

Forfeited and cancelled

  (23,400) $41.86 

Outstanding as of December 31, 2022

  117,897  $34.98 

 

The weighted-average grant-date fair value per share of PSUs granted was $32.53, $0 and $36.93 for the years ended December 31, 2022, 2021 and 2020, respectively. The total fair value of PSUs vested was $0.6 million, $0 and $0 for the years ended December 31, 2022, 2021 and 2020, respectively. As of December 31, 2022, there was no unrecognized compensation cost related to PSUs in which milestones are expected to be achieved.

 

Employee Stock Purchase Plan

 

On March 17, 2021, the Company adopted the 2021 Employee Stock Purchase Plan (“ESPP”). The ESPP is authorized to issue up to 200,000 shares of common stock to participating employees. Employees that participate in the Company’s ESPP may purchase up to a maximum of 800 shares per six-month offering period or $25,000 worth of common stock per calendar year by authorizing payroll deductions of up to 10% of their base salary. The purchase price for each share purchased is 85% of the lower of the fair market value of the common stock on the first or last day of the offering period.

 

85
 

 

 

15. Employee Benefit Plan

 

The Company’s U.S. employees are eligible to participate in the Company’s 401(k) savings plan. Employees may elect to contribute a percentage of their compensation to the plan, and the Company will make 140% matching contributions up to a limit of 5% of an employee’s eligible compensation. In addition, the Company may make annual discretionary contributions. The Company made matching contributions of $2.3 million, $2.0 million, and $1.7 million for the years ended December 31, 2022, 2021, and 2020, respectively.

 

 

16. Income Taxes 

 

Income Tax Expense

 

The components of the Company’s income (loss) before income taxes and its provision for (benefit from) income taxes consist of the following:

 

  

Years ended December 31,

 
  

2022

  

2021

  

2020

 

(Loss) income before income taxes

            

Domestic

 $(19,080) $(2,529

)

 $(25,722)

Foreign

  334   4,956   (2,902

)

  $(18,746) $2,427  $(28,624)

 

  

Years ended December 31,

 
  

2022

  

2021

  

2020

 

Provision for (benefit from) income taxes:

            

Current:

            

Federal

 $1,005  $494  $357 

State

  285   (635

)

  (1,970)

Foreign

  96   167   49 

Total current

  1,386   26   (1,564)

Deferred:

            

Federal

  (3,243)  (553

)

  (1,980)

State

  (1,256)  (426

)

  (1,070)

Foreign

  (774)  (754

)

  (28)

Total deferred

  (5,273)  (1,733

)

  (3,078)

Total benefit from income taxes

 $(3,887) $(1,707

)

 $(4,642)

 

86
 
 

Deferred Tax Assets and Liabilities

 

Significant components of the Company’s deferred tax assets and liabilities consist of the following:

 

  

As of December 31,

 
  

2022

  

2021

 

Deferred tax assets:

        

Lease liability

 $7,468  $4,684 

Capitalized research expenditures

  5,451   - 

Stock-based compensation expense

  2,795   2,782 

Inventory reserves

  2,763   2,453 

Compensation accrual

  1,635   1,236 

Net operating loss carry forwards

  1,551   2,822 

Tax credits

  741   3,022 

Accrued expenses

  519   491 

Foreign currency exchange

  221   282 

Deferred tax assets

 $23,144  $17,772 

 

  

As of December 31,

 
  

2022

  

2021

 

Deferred tax liabilities:

        

Acquisition-related intangible asset

 $(12,075) $(14,770

)

Depreciation

  (8,804)  (8,509

)

Right of use asset

  (7,252)  (4,650

)

Deferred tax liabilities

 $(28,131) $(27,929

)

         

Net deferred tax liabilities

 $(4,987) $(10,157

)

 

As of December 31, 2022, the Company had no Federal net operating loss (“NOL”) carryforwards and state net NOL carryforwards of $3.1 million that will begin to expire in 2026. The Company also had NOL carryforwards in Italy of $6.1 million that do not expire but are limited to 80% of taxable income. As of December 31, 2022, the Company had federal and state research and development tax credit carryforwards of $0.4 million and $0.5 million, respectively, that will begin expiring in 2023.

 

The Tax Cuts and Jobs Act (“TCJA”) requires taxpayers to capitalize and amortize research and experimental (“R&D”) expenditures for tax years beginning after December 31, 2021. This rule became effective for the Company during the year ended December 31, 2022 and resulted in the capitalization of R&D costs of $23.4 million. The Company will amortize these costs for tax purposes over 5 years if the R&D was performed in the U.S. and over 15 years if the R&D was performed outside the U.S.

 

The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, carryback potential if permitted under the tax law, and results of recent operations. Based upon future reversals of existing taxable temporary differences, the Company believes it is more likely than not that it will realize its domestic deferred tax assets. Based upon future reversals of existing taxable temporary differences and projected future taxable income, the Company believes it is more likely than not it will realize its foreign deferred tax assets.

 

During the year ended December 31, 2021, the Company released the valuation allowance recorded related to the net deferred tax assets in Italy in the amount of $0.9 million. 

 

Undistributed earnings of certain of the Company’s foreign subsidiaries amounted to approximately $0.5 million at December 31, 2022. The Company expects to be able to take a 100% dividend received deduction to offset any U.S. federal income tax liability on the undistributed earnings. Determination of the amount of unrecognized state and local deferred income tax liability is not practicable due to the complexities associated with its hypothetical calculation.

 

87
 
 

Effective Tax Rate

 

The reconciliation between the U.S. federal statutory rate and the Company’s effective rate is summarized as follows:

 

  

Years ended December 31,

 
  

2022

  

2021

  

2020

 

Statutory federal income tax rate

  21.0%  21.0

%

  21.0

%

State tax expense, net of federal benefit

  1.4%  (3.2

%)

  1.5

%

Stock compensation

  (4.7%)  22.3

%

  (2.2

%)

Section 162(m) limitation

  (8.2%)  8.7

%

  - 

Goodwill impairment

  -   -

 

  (16.8

%)

Change in fair value of contingent consideration

  -   (36.7

%)

  6.7

%

Change in tax rates and state apportionment

  1.2%  (29.8

%)

  4.9

%

Federal, state and foreign tax credits

  5.1%  (28.4

%)

  2.2

%

Valuation allowance

  -   (35.3

%)

  (3.0

%)

Return to provision adjustments

  5.0%  -

 

  -

 

Other permanent items

  (0.1

)%

  11.0

%

  1.9

%

Effective income tax rate

  20.7%  (70.4

%)

  16.2

%

 

Accounting for Uncertainty in Income Taxes

 

The Company had no unrecognized tax benefits for the years ended December 31, 2022 and 2021, respectively. The Company does not anticipate experiencing any significant increase or decrease in its unrecognized tax benefits within the twelve months following December 31, 2022.

 

In the normal course of business, Anika and its subsidiaries may be periodically examined by various taxing authorities. The Company files income tax returns in the United States on a federal basis, in certain U.S. states, and in certain foreign jurisdictions. The associated tax filings remain subject to examination by applicable tax authorities for a certain length of time following the tax year to which those filings relate. With a few exceptions, the Company is no longer subject to income tax examinations for years prior to 2019.

 

 

17. Earnings per Share (“EPS”)

 

Basic EPS is calculated by dividing net income (loss) by the weighted average number of shares outstanding during the period. Unvested restricted shares, although legally issued and outstanding, are not considered outstanding for purposes of calculating basic EPS. Diluted EPS is calculated by dividing net income by the weighted average number of shares outstanding plus the dilutive effect, if any, of outstanding share-based awards using the treasury stock method.

 

The following table provides share information used in the calculation of the Company's basic and diluted EPS (in thousands):

 

  

Years Ended December 31,

 
  

2022

  

2021

  

2020

 

Shares used in the calculation of basic EPS

  14,561   14,401   14,222 

Effect of dilutive securities:

            

Share based awards

  -   233   - 

Diluted shares used in the calculation of EPS

  14,561   14,634   14,222 

 

Stock options of 1.1 million shares were outstanding for the year ended December 31, 2021 and were not included in the computation of diluted EPS because the awards’ impact on EPS would have been anti-dilutive. The Company was in a loss position during the years ended December 31, 2022 and 2020, therefore all potential common shares would have been anti-dilutive and accordingly were excluded from the computation of diluted EPS.

 

88
 
 

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 

[None].

 

ITEM 9A. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2022. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosures. Based on the evaluation of our disclosure controls and procedures as of December 31, 2022, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were not effective to provide reasonable assurance due to material weaknesses in internal control over financial reporting described below.

 

Management’s Annual Report on Internal Control over Financial Reporting

 

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, the company’s principal executive and principal financial officers and effected by the company’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:

 

 

●

pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company;

 

 

●

provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and

 

 

●

provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company’s assets that could have a material effect on the financial statements.

 

An effective internal control system, no matter how well designed, has inherent limitations, including the possibility of human error or overriding of controls, and limitations therefore can provide only reasonable assurance with respect to reliable financial reporting. Because of its inherent limitations, our internal control over financial reporting may not prevent or detect all misstatements, including the possibility of human error, the circumvention or overriding of controls, or fraud. Effective internal controls can provide only reasonable assurance with respect to the preparation and fair presentation of financial statements.

 

Our management assessed the effectiveness of the Company’s internal control over financial reporting as of December 31, 2022. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control — Integrated Framework (2013).  Based on this assessment, our management concluded that as of December 31, 2022, material weaknesses were identified in March 2023 as described below, and, as a result, our internal control over financial reporting was not effective as of December 31, 2022.

 

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.

 

89
 

 

Material Weaknesses

 

In March 2023, we identified material weaknesses in the Company’s internal control over financial reporting as of December 31, 2022 resulting from a misappropriation of assets under a legacy credit card program utilized by a limited number of our employees affiliated with one of our subsidiaries. Specifically, in March 2023, during the process of retiring this credit card program, the Company determined that a mid-level accounting employee had charged approximately $4,000 in personal expenses on his corporate credit card, and that certain non-accounting employees also charged personal expenses of an immaterial amount in aggregate. This accounting employee had roles in the Company’s system of internal control over financial reporting, including controls for this subsidiary’s corporate credit card program. As a result, there were individually and in the aggregate deficiencies that represent material weaknesses including: (i) inadequate segregation of duties; (ii) a failure to identify fraud risks; and (iii) a failure in the design and operating effectiveness of control activities for which the accounting employee’s competent authority was compromised.

 

In response, the Company performed additional analyses, reconciliations and other post-closing procedures to ensure that our consolidated financial statements included in this Form 10-K were prepared in accordance with U.S. generally accepted accounting principles (“GAAP”).

 

These control deficiencies did not have any material impact on our current or prior period consolidated annual or interim financial statements, but could have resulted in material misstatements to the annual or interim financial statements that would not have been prevented or detected. Accordingly, management concluded that the control deficiencies were material weaknesses in the Company’s internal control over financial reporting.

 

Deloitte & Touche LLP, our independent registered public accounting firm that audited the consolidated financial statements, has issued an audit report on our internal control over financial reporting as of December 31, 2022, which is included in Item 8 of this Annual Report on Form 10-K.

 

Changes in Internal Control over Financial Reporting

 

Except for the material weaknesses discussed above, there were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Securities Exchange Act) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting during the fourth quarter of our fiscal year ended December 31, 2022.

 

Remediation of Material Weaknesses

 

Our management, under the oversight of the Audit Committee, is in the process of remediating the material weaknesses in our internal control over financial reporting as noted above. We have already implemented and will continue to implement measures designed to directly address, or contribute to, the remediation of our material weaknesses and the enhancement of our internal control over financial reporting, including:

 

 

●

Termination of the mid-level accounting employee referenced above and reassignment of this employee’s roles and responsibilities within impacted control activities.

 

 

●

Complete the transition of all employees from the legacy subsidiary credit card program to the Company’s established credit card program, which is subject to centralized review, approval, monitoring, and reconciliation processes and controls.

 

 

●

Enhancement of our fraud risk assessment in order to more fully tailor the design of internal control over financial reporting to ensure appropriate segregation of duties and mitigate the risk of material misstatement caused by fraud.

 

 

●

Enhancement of training for employees on compliance with the Company’s travel and entertainment policy and Code of Conduct, as well as its internal control over financial reporting.

 

The material weaknesses will not be considered remediated until management completes its remediation plan and the enhanced controls operate for a sufficient period of time and management has concluded, through testing, that the related controls are effective. The Company will monitor the effectiveness of its remediation plan and will refine its remediation plan as appropriate.

 

90
 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and Stockholders of Anika Therapeutics, Inc.

 

Opinion on Internal Control over Financial Reporting

 

We have audited the internal control over financial reporting of Anika Therapeutics, Inc. and subsidiaries (the “Company”) as of December 31, 2022, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, because of the effect of the material weaknesses identified below on the achievement of the objectives of the control criteria, the Company has not maintained effective internal control over financial reporting as of December 31, 2022, based on criteria established in Internal Control — Integrated Framework (2013) issued by COSO.

 

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, 2022, of the Company and our report dated March 16, 2023, expressed an unqualified opinion on those financial statements.

 

Basis for Opinion

 

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

 

Definition and Limitations of Internal Control over Financial Reporting

 

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

91
 

 

Material Weaknesses

 

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements will not be prevented or detected on a timely basis.  Management’s assessment identified that there were individually and in the aggregate deficiencies that represent material weaknesses including:

 

 

i.

inadequate segregation of duties
 

ii.

failure to identify fraud risks; and
 

iii.

a failure in the design and operating effectiveness of control activities for which the accounting employee’s competent authority was compromised.

 

These material weaknesses were considered in determining the nature, timing, and extent of audit tests applied in our audit of the consolidated financial statements as of and for the year ended December 31, 2022, of the Company, and this report does not affect our report on such financial statements.

 

/s/ Deloitte & Touche LLP

 

Boston, Massachusetts

March 16, 2023

 

 

 

 

 

 

 

 

 

 

 

 

 

92
 

 

ITEM 9B. OTHER INFORMATION

 

[None].

 

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS

 

Not applicable.

 

 

 

 

 

 

 

 

 

 

 

 

 

93
 

 

PART III

 

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 

The information required under this item is incorporated herein by reference to our definitive proxy statement pursuant to Regulation 14A, which proxy statement will be filed with the SEC not later than 120 days after the close of our fiscal year ended December 31, 2022.

 

ITEM 11. EXECUTIVE COMPENSATION

 

The information required under this item is incorporated herein by reference to our definitive proxy statement pursuant to Regulation 14A, which proxy statement will be filed with the SEC not later than 120 days after the close of our fiscal year ended December 31, 2022.

 

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 

The information required under this item and Item 5 of this Annual Report on Form 10-K under the heading “Equity Compensation Plan Information” is incorporated herein by reference to our definitive proxy statement pursuant to Regulation 14A, which proxy statement will be filed with the SEC not later than 120 days after the close of our fiscal year ended December 31, 2022.

 

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 

The information required under this item is incorporated herein by reference to our definitive proxy statement pursuant to Regulation 14A, which proxy statement will be filed with the SEC not later than 120 days after the close of our fiscal year ended December 31, 2022.

 

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

 

The information required under this item is incorporated herein by reference to our definitive proxy statement pursuant to Regulation 14A, which proxy statement will be filed with the SEC not later than 120 days after the close of our fiscal year ended December 31, 2022.

 

 

 

 

94
 

 

PART IV

 

ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

 

(a)

Documents filed as part of Form 10-K.

  
     
 

(1)            Financial Statements

  
     
 

Report of Independent Registered Public Accounting Firm

 58
 

Consolidated Balance Sheets

 60
 

Consolidated Statements of Operations and Comprehensive Income

 61
 

Consolidated Statements of Stockholders’ Equity

 62
 

Consolidated Statements of Cash Flows

 63
 

Notes to Consolidated Financial Statements

 64
     
 

(2)            Schedules

  

 

Schedules have been omitted as all required information has been disclosed in the financial statements and related footnotes. 

 

 

(3)            Exhibits

  

 

Exhibit
Number

  

Description
     

+2.1

  

Agreement and Plan of Merger, dated January 4, 2020, by and between Anika Therapeutics, Inc., Arthrosurface, Inc., Button Merger Sub, Inc. and Boston Millennia Partners Button Shareholder Representation, Inc.

+2.2

  

Agreement and Plan of Merger, dated January 4, 2020, by and between Anika Therapeutics, Inc., Parcus Medical, LLC, Sunshine Merger Sub, LLC and Philip Mundy

3.1

  

Certificate of Incorporation of Anika Therapeutics, Inc.

3.2

  

Bylaws of Anika Therapeutics, Inc., effective as of June 6, 2018

****4.1

  

Description of Securities of Anika Therapeutics, Inc.

10.1a

  

Lease, dated January 3, 2007, between Anika Therapeutics, Inc. and Farley White Wiggins, LLC, relating to 32 Wiggins Avenue, Bedford, Massachusetts

10.1b

  

Amendment No. 1 to Lease, dated February 1, 2007, between Anika Therapeutics, Inc. and Farley White Wiggins, LLC, relating to 32 Wiggins Avenue, Bedford, Massachusetts

10.2a

  

Translation of Lease Agreement, dated October 9, 2015, between Anika Therapeutics S.r.l. and Consorzio Zona Industriale E Porto Fluviale di Padova relating to Land Registry of the Municipality of Padova, Page 148, cadastral map 516 and 517

10.2b

  

Translation of Amendment No. 1 to Lease Agreement, dated February 2, 2017, between Anika Therapeutics S.r.l. and Consorzio Zona Industriale E Porto Fluviale di Padova relating to Land Registry of the Municipality of Padova, Page 148, cadastral map 516 and 517

10.3a

  

Lease Agreement, dated November 26, 2012, between High Properties and Parcus Medical LLC relating to 6423 Parkland Drive, Suites 101 and 102, Sarasota, FL

10.3b

  

Amendment #1 to the Lease, Renewal Amendement, dated January 4, 2018, between High Properties and Parcus Medical LLC relating to 6423 Parkland Drive, Suites 101 and 102, Sarasota, FL

10.3c

  

Lease Agreement, dated May 25, 2017, between High Properties and Parcus Medical, LLC relating to 6455 Parkland Drive, Suite 101, Sarasota, FL

10.4a

  

Credit Agreement, dated as of October 24, 2017, among Anika Therapeutics, Inc., certain subsidiaries of Anika Therapeutics, Inc. as are or may from time to time become parties to the Credit Agreement, Bank of America, N.A., as administrative agent, swingline lender and issuer of letters of credit, and the lenders party thereto

10.4b

  

Security and Pledge Agreement, dated as of October 24, 2017, among Anika Therapeutics, Inc., certain subsidiaries of Anika Therapeutics, Inc. listed on the signature pages thereto, and Bank of America, N.A., as administrative agent

10.4c

  

First Amendment effective August 13, 2019, with respect to the Credit Agreement dated as of October 24, 2017 and the Security and Pledge Agreement dated as of October 24, 2017

 

95
 

 

10.4d

  

Second Amendment effective May 14, 2020, with respect to the Credit Agreement dated as of October 24, 2017 and First Amendment to the Security and Pledge Agreement dated as of October 24, 2017

10.4e

  

Third Amendment to Credit Agreement dated as of November 12, 2021, by and among Anika Therapeutics, Inc., the Subsidiary Guarantors party thereto, the Lenders party thereto, Bank of America, N.A., as administrative agent, L/C Issuer and Swingline Lender, and the other parties thereto

*10.5

  

License Agreement, dated as of December 20, 2003, by and between Anika Therapeutics, Inc. and Ortho Biotech Products, L.P.

*10.6

  

License Agreement, dated as of December 21, 2011, by and between Anika Therapeutics, Inc. and DePuy Mitek, Inc.

†10.7

  

Anika Therapeutics, Inc. Senior Executive Incentive Compensation Plan

†10.8

  

Anika Therapeutics, Inc. Non-Employee Director Compensation Policy (restated as of February 9, 2022)

†10.9a

  

Second Amended and Restated 2003 Stock Option and Incentive Plan (adopted April 5, 2011)

†10.9b

  

Amendment to Second Amended and Restated 2003 Stock Option and Incentive Plan (adopted April 11, 2013)

†10.9c

  

Form of Incentive Stock Option Agreement under Second Amended and Restated 2003 Stock Option and Incentive Plan  

†10.9d

  

Form of Non-Qualified Stock Option Agreement for Non-Employee Directors under Second Amended and Restated 2003 Stock Option and Incentive Plan

†10.10a

  

Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan (as amended effective June 8, 2022)

†10.10b

  

Form of Notice of Grant of Incentive Stock Option, including Terms and Conditions of Stock Option, granted under Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan.

†10.10c

  

Form of Notice of Grant of Nonqualified Stock Option, including Terms and Conditions of Stock Option, granted under Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan

†10.10d

  

Form of Notice of Grant of Restricted Stock Award, including Terms and Conditions of Restricted Stock Award, granted under Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan.

†10.10e

  

Form of Notice of Grant of Restricted Stock Units, including Terms and Conditions of Restricted Stock Units, granted under Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan

†10.10f

  

Form of Notice of Grant of Deferred Stock Awards Units, including Terms and Conditions of Deferred Stock Units, granted under Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan

†10.10g

  

Anika Therapeutics, Inc. 2021 Employee Stock Purchase Plan (adopted March 17, 2021)

†10.10h

  

Anika Therapeutics, Inc. 2021 Inducement Plan (adopted November 4, 2021)

†10.10i

  

Form of Notice of Grant of Nonqualified Stock Option, including Terms and Conditions of Stock Option, granted under Anika Therapeutics, Inc. 2021 Inducement Plan

†10.10j

  

Form of Notice of Grant of Restricted Stock Units Award, including Terms and Conditions of Restricted Stock Award, granted under Anika Therapeutics, Inc. 2021 Inducement Plan

†10.10k

  

Form of Notice of Grant of Deferred Stock Awards Units, including Terms and Conditions of Deferred Stock Units, granted under Anika Therapeutics, Inc. 2021 Inducement Plan

†10.11

  

Employment Agreement, dated April 23, 2020, by and between Anika Therapeutics, Inc., and Dr. Cheryl R. Blanchard

†10.12

  

Executive Retention Agreement, dated August 10, 2020, by and between Anika Therapeutics, Inc. and Michael Levitz

****†10.13

  

Executive Retention Agreement, dated March 9, 2020, by and between Anika Therapeutics, Inc. and David Colleran

10.14

  

Fixed Dollar Accelerated Share Repurchase Transaction Confirmation entered into as of May 24, 2018 by and between Morgan Stanley & Co. LLC and Anika Therapeutics, Inc.

10.15

  

Fixed Dollar Accelerated Share Repurchase Transaction Confirmation entered into as of May 7, 2019 by and between Morgan Stanley & Co. LLC and Anika Therapeutics, Inc.

****21.1

  

List of Subsidiaries of Anika Therapeutics, Inc.

****23.1

  

Consent of Deloitte & Touche LLP

****31.1

  

Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

****31.2

  

Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

**32.1

  

Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

***101

   The following materials from the Annual Report on Form 10-K of Anika Therapeutics, Inc. for the fiscal year ended December 31, 2022, formatted in Inline XBRL:  (i) Consolidated Balance Sheets as of December 31, 2022 and December 31, 2021; (ii) Consolidated Statements of Operations and Comprehensive Income for the Years Ended December 31, 2022, December 31, 2021, and December 31, 2020; (iii) Consolidated Statements of Stockholders’ Equity for the Years Ended December 31, 2022, December 31, 2021, and December 31, 2020; (iv) Consolidated Statements of Cash Flows for the Years Ended December 31, 2022, December 31, 2021, and December 31, 2020; and (v) Notes to Consolidated Financial Statements

 

 

96
 

 

104

  

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

+

Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(b)(2). The omitted information is not material and would likely cause competitive harm to the Company if publicly disclosed.

†

Management contract or compensatory plan or arrangement.

*

Certain portions of this document have been omitted pursuant to a confidential treatment request filed with the Securities and Exchange Commission. The omitted portions have been filed separately with the Commission.

**

The certification attached as Exhibit 32.1 that accompanies this Form 10-K is not deemed filed with the SEC and is not to be incorporated by reference into any filing of Anika Therapeutics, Inc. under the Securities Act of 1933 or the Securities Exchange Act of 1934, whether made before or after the date of this Form 10-K, irrespective of any general incorporation language contained in such filing.

***

Pursuant to Rule 406T of Regulation S-T, XBRL (Extensible Business Reporting Language) information is deemed not filed or a part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934 and otherwise is not subject to liability under these sections.
**** Filed or furnished herewith

 

 

 

ITEM 16. FORM 10-K SUMMARY

 

Not applicable.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

97
 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

ANIKA THERAPEUTICS, INC.

  
       

Date: March 16, 2023

By: 

/s/ CHERYL BLANCHARD

  
   

Cheryl R. Blanchard, Ph.D.

  
   

Chief Executive Officer

  

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Signature

  

Title

  

Date
         
         

/s/ CHERYL BLANCHARD

  

President and Chief Executive Officer

    

Cheryl R. Blanchard, Ph.D.

  

(Principle Executive Officer)

  

March 16, 2023
         

/s/ MICHAEL LEVITZ

  

Executive Vice President, Chief Financial Officer

and Treasurer

    

Michael Levitz

  

(Principal Financial Officer)

  

March 16, 2023
         

/s/ IAN MCLEOD

  

Vice President, Chief Accounting Officer

    

Ian McLeod

  

(Principal Accounting Officer)

  

March 16, 2023
         

/s/ JEFFERY S. THOMPSON

  

Director, Chairman of the Board

    

Jeffery S. Thompson

      

March 16, 2023
         

/s/ SHERYL L. CONLEY

  

Director

    

Sheryl L. Conley

      

March 16, 2023
         

/s/ JOHN HENNEMAN

  

Director

    

John Henneman

      

March 16, 2023
         

/s/ GLENN R. LARSEN, PH.D.

  

Director

    

Glenn R. Larsen, Ph.D.

      

March 16, 2023
         

/s/ STEPHEN RICHARD

  

Director

    

Stephen Richard

      

March 16, 2023
         

/s/ SUSAN N. VOGT

  

Director

    

Susan N. Vogt

      

March 16, 2023
         

 

98
EX-4.1 2 ex_487320.htm EXHIBIT 4.1 ex_487320.htm

Exhibit 4.1

 

 

DESCRIPTION OF SECURITIES

Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

 

We have one class of securities registered under Section 12 of the Securities Exchange Act of 1934 (the “Exchange Act”): common stock, $0.01 par value per share (“Common Stock”).

 

Authorized Capital Stock

 

We are authorized to issue two classes of capital stock to be designated as the Common Stock and as preferred stock, par value $0.01 per share (“Preferred Stock”). The total number of shares of capital stock that we are authorized to issue is 91,250,000, of which 90,000,000 shares shall be Common Stock and 1,250,000 shares shall be Preferred Stock.

 

Description of Common Stock

 

The following is a description of the material terms and provisions relating to Common Stock. Because it is a summary, the following description is not complete and is subject to and qualified in its entirety by reference to our Certificate of Incorporation, our Bylaws and provisions of Delaware General Corporation Law (the “DGCL”) that define the rights of our stockholders.

 

Voting Rights

 

Under our Certificate of Incorporation, each holder of Common Stock will be entitled to one vote for each share held on matters submitted to a vote of stockholders. Under the DGCL and our Certificate of Incorporation, the holders of Common Stock will not have cumulative voting rights in the election of directors.

 

Dividends

 

Under our Bylaws, dividends on Common Stock may be declared by the board of directors and are subject to any preferential dividend or other rights of any then-outstanding Preferred Stock and to applicable requirements of the DGCL.

 

Liquidation

 

Upon our dissolution or liquidation, holders of Common Stock will be entitled to receive all assets of our company available for distribution to its stockholders, subject to any preferential rights of then-outstanding Preferred Stock.

 

Number and Classification of Directors

 

Our Certificate of Incorporation and Bylaws provide that the board of directors is to be divided into three classes, with the classes serving for staggered three-year terms and until successors are elected and qualified. Pursuant to our Certificate of Incorporation and Bylaws, the number of directors will not be less than three nor more than nine, as determined by a majority of the authorized directors, and may be decreased either by the stockholders or a majority of the board of directors, but only to eliminate vacancies.

 

Other Rights and Preferences

 

Other than as described herein, holders of Common Stock have no preemptive, conversion or subscription rights, and there are no redemption or sinking fund provisions applicable to Common Stock. The rights, preferences and privileges of the holders of Common Stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of Preferred Stock that we may designate and issue.

 

Description of Preferred Stock

 

Our Certificate of Incorporation provides that the board of directors is authorized to fix the designation and number of any series of Preferred Stock and to determine the rights, powers, preferences, qualifications, limitations, restrictions, voting powers, and the relative, participating, optional or other special rights of such Preferred Stock.

 

 
 

 

Nasdaq Global Select Market

 

Common Stock is traded on The Nasdaq Global Select Market under the symbol “ANIK.”

 

Transfer Agent and Registrar

 

The transfer agent and registrar for the Common Stock is American Stock Transfer & Trust Co.

 

Anti-Takeover Effects of Provisions of Our Certificate of Incorporation, Our Bylaws and the DGCL

 

Certain provisions of our Certificate of Incorporation and Bylaws and the DGCL contain provisions that may delay, defer or discourage another party from acquiring control of our company. We expect that these provisions, which are summarized below, will discourage coercive takeover practices or inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with the board of directors, which we believe may result in an improvement of the terms of any such acquisition in favor of our stockholders. However, they also give the board of directors the power to discourage acquisitions that some stockholders may favor.

 

Authorized but Unissued Shares

 

The authorized but unissued shares of Common Stock and Preferred Stock are available for future issuance without stockholder approval, subject to any limitations imposed by the listing standards of The Nasdaq Stock Market LLC. These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved Common Stock and Preferred Stock could make more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise.

 

Staggered Board of Directors

 

Our Certificate of Incorporation provides that our board of directors will be classified into three classes of directors of approximately equal size. As a result, in most circumstances, a person can gain control of the board of directors only by successfully engaging in a proxy contest at two or more annual meetings.

 

Delaware Law

 

Section 203 of the DGCL prevents some Delaware corporations from engaging, under some circumstances, in a business combination that includes a merger or sale of at least 10% of a corporation’s assets with any interested stockholder, meaning a stockholder who, together with affiliates and associates, owns (or, within three years prior to the determination of interested stockholder status, owned) 15% or more of the corporation’s outstanding voting stock, unless:

 

 

•

the transaction is approved by the board of directors prior to the time that the interested stockholder becomes an interested stockholder;

 

 

•

upon consummation of the transaction that resulted in the stockholder’s becoming an interested stockholder, the interested stockholder owned at least 85% of the corporation’s voting stock outstanding at the time the transaction commenced, excluding stock owned by directors who are also officers of the corporation; or

 

 

•

subsequent to the time the stockholder became an interested stockholder, the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders by at least two-thirds of the outstanding voting stock that is not owned by the interested stockholder.

 

A Delaware corporation may “opt out” of these provisions with an express provision in its original certificate of incorporation or an express provision in its certificate of incorporation or bylaws resulting from a stockholders’ amendment approved by at least a majority of the outstanding voting shares. We have not opted out of these provisions. As a result, mergers or other takeover or change in control attempts of us may be discouraged or prevented.

 

 
 

 

Stockholder Action by Written Consent

 

Pursuant to Section 228 of the DGCL, any action required to be taken at any annual or special meeting of the stockholders may be taken without a meeting, without prior notice and without a vote if a consent or consents in writing, setting forth the action so taken, is signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares of our stock entitled to vote thereon were present and voted, unless the corporation’s certificate of incorporation provides otherwise. Our Certificate of Incorporation prohibits stockholder action by written consent (and, thus, requires that all stockholder actions be taken at a meeting of our stockholders).

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
 EX-10.13 3 ex_489371.htm EXHIBIT 10.13 Image Exhibit

Exhibit 10.13

 

ANIKA THERAPEUTICS, INC.

 

EXECUTIVE RETENTION AGREEMENT

 

Anika Therapeutics, Inc., a Massachusetts corporation (the “Company”), and [David Colleran] (the “Executive”) enter into this Executive Retention Agreement (the “Agreement”) dated as of March 9th, 2020 (the “Effective Date”).

 

Whereas, the Company desires to provide and the Executive desires to accept the severance protections provided herein in the event of the Executive’s involuntary or constructive termination, including in connection with a change in control of the Company.

 

Now, Therefore, in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

 

 

1.

Key Definitions. As used herein, the following terms shall have the following respective meanings:

 

 

(a)

“Cause” shall be defined as that term is defined in the Executive’s offer letter, employment agreement, or other similar agreement; or if there is no such definition, “Cause” means, as determined by the Company in its sole discretion, any of the following:

 

 

(i)

substantial and continuing neglect or inattention to the Executive’s duties;
     
 

(ii)

willful misconduct or gross negligence in connection with the performance of such duties;
     
 

(iii)

the commission of an act of embezzlement, fraud, or deliberate disregard of the rules or policies of the Company, which results in economic loss, damage, or injury to the Company;
     
 

(iv)

the unauthorized disclosure of any trade secret or confidential information of the Company or any third party who has a business relationship with the Company or the violation of any non-competition obligation to the Company;
     
 

(v)

the commission of an act that induces any customer or prospective customer of the Company to break a contract with the Company or to decline to do business with the Company;
     
 

(vi)

the commission of an act that induces any investor or prospective investor in any investment entity affiliated with or managed by the Company to break a contract with such investment entity or to decline to invest in such investment entity;
     
 

(vii)

the conviction of a felony involving any financial impropriety or which would materially interfere with the performance of services or otherwise be injurious to the Company; or
     
 

(viii)

the failure to perform in a material respect the Executive’s services or duties without proper cause.

 

 
 

 

 

(b)

“Change in Control” shall mean any of the following:

 

 
 

(i)

any “person,” as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the “Act”) (other than the Company, any of its subsidiaries, or any trustee, fiduciary or other person or entity holding securities under any employee benefit plan or trust of the Company or any of its subsidiaries), together with all “affiliates” and “associates” (as such terms are defined in Rule 12b-2 under the Act) of such person, shall become the “beneficial owner” (as such term is defined in Rule 13d-3 under the Act), directly or indirectly, of securities of the Company representing more than 50 percent of the combined voting power of the Company’s then outstanding securities having the right to vote in an election of the Board (“Voting Securities”) (in such case other than as a result of an acquisition of securities directly from the Company); or
     
 

(ii)

the date a majority of the members of the Board is replaced during the longer of (a) any 12-month period or (b) the period covering two consecutive annual meetings of the Company’s stockholders, in either case by directors whose appointment or election is not endorsed by a majority of the members of the Board before the date of the appointment or election (other than an endorsement that occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consent by or on behalf of a person other than the Board); or
     
 

(iii)

the consummation of (A) any consolidation or merger of the Company where the stockholders of the Company, immediately prior to the consolidation or merger, would not, immediately after the consolidation or merger, beneficially own (as such term is defined in Rule 13d-3 under the Act), directly or indirectly, shares representing in the aggregate more than 50 percent of the voting shares of the Company issuing cash or securities in the consolidation or merger (or of its ultimate parent corporation, if any), or (B) any sale or other transfer (in one transaction or a series of transactions contemplated or arranged by any party as a single plan) of all or substantially all of the assets of the Company.

 

Notwithstanding the foregoing, a “Change in Control” shall not be deemed to have occurred for purposes of the foregoing clause (i) solely as the result of an acquisition of securities by the Company which, by reducing the number of shares of Voting Securities outstanding, increases the proportionate number of Voting Securities beneficially owned by any person to more than 50 percent of the combined voting power of all of the then outstanding Voting Securities; provided, however, that if any person referred to in this sentence shall thereafter become the beneficial owner of any additional shares of Voting Securities (other than pursuant to a stock split, stock dividend, or similar transaction or as a result of an acquisition of securities directly from the Company) and immediately thereafter beneficially owns more than 50 percent of the combined voting power of all of the then outstanding Voting Securities, then a “Change in Control” shall be deemed to have occurred for purposes of the foregoing clause (i).

 

 

(c)

“Disability” means inability to perform the essential functions of the Executive’s then existing position or positions under this Agreement with or without reasonable accommodation for a period of 180 days (which need not be consecutive) in any 12-month period.
     
 

(d)

“Good Reason” shall mean that the Executive has complied with the Good Reason Process (hereinafter defined) following the occurrence of any of the following events: (i) a material diminution in the Executive’s responsibilities, authority or duties; (ii) a material diminution in the Executive’s annual base salary except for across-the-board salary reductions based on the Company’s financial performance similarly affecting all or substantially all senior management employees of the Company; (iii) a material change in the geographic location at which the Executive provides services to the Company, which is a relocation of more than 75 miles from the Company’s Bedford, Massachusetts headquarters; or (iv) the material breach of this Agreement by the Company.

 

2
 

 

 

(e)

“Good Reason Process” shall mean that (i) the Executive reasonably determines in good faith that a “Good Reason” condition has occurred; (ii) the Executive notifies the Company in writing of the occurrence of the Good Reason condition within 60 days of the occurrence of such condition; (iii) the Executive cooperates in good faith with the Company’s efforts, for a period not less than 30 days following such notice (the “Cure Period”), to remedy the condition; (iv) notwithstanding such efforts, the Good Reason condition continues to exist; and (v) the Executive terminates his employment within 60 days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.
     
 

(f)

“Qualifying Termination” shall mean (i) a termination of the Executive’s employment by the Company without Cause within 3 months prior to or 12 months after a Change in Control, or (ii) a termination of the Executive’s employment by the Executive for Good Reason within 12 months after a Change in Control.

 

 

2.

Term of Agreement. This Agreement shall take effect upon the Effective Date and shall expire upon the first to occur of (a) the expiration of the Term (as defined below) if a Change in Control has not occurred during the Term, (b) the date 12 months after the Change in Control Date, if the Executive is still employed by the Company as of such later date, or (c) the fulfillment by the Company of all of its obligations under Sections 4 and 5 if the Executive’s employment with the Company terminates during the Term or within 12 months following the Change in Control Date. “Term” shall mean the period commencing as of the Effective Date and continuing in effect through December 31, 2019; provided, however, that commencing on January 1, 2020 and each January 1 thereafter, the Term shall be automatically extended for one additional year unless, not later than 90 days prior to the scheduled expiration of the Term (or any extension thereof), the Company shall have given the Executive written notice that the Term will not be extended.
     
 

3.

Date of Termination.

 

 

(a)

Termination by Company for Cause. The Company may terminate the Executive’s employment for Cause at any time, subject to any applicable notice or cure requirement related to the specific event triggering Cause.
     
 

(b)

Termination Without Cause. Any termination by the Company of the Executive’s employment that does not constitute a termination for Cause or a termination due to the death or Disability of the Executive shall be deemed a termination without Cause.
     
 

(c)

Termination by Executive for Good Reason. In order to terminate employment for Good Reason, the Executive must comply with the Good Reason Process.
     
 

(d)

Notice of Termination. Except for termination due to the Executive’s death, any termination of the Executive’s employment by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto. For purposes of this Agreement, a “Notice of Termination” shall mean a notice that indicated the specific termination provision in this Agreement relied upon.

 

3
 

 

 

(e)

Date of Termination. “Date of Termination” shall mean: (i) if the Executive’s employment is terminated by the Company without Cause, the date specified in the Notice of Termination (not earlier than the date the Notice of Termination is given); (ii) if the Executive’s employment is terminated by the Executive without Good Reason, the date specified in the Notice of Termination (not earlier than the date the Notice of Termination is given); and (iii) if the Executive’s employment is terminated by the Executive for Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period. Notwithstanding the foregoing, in the event that the Executive gives a Notice of Termination to the Company, the Company may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this Agreement.

 

 

4.

Compensation Upon Termination.

 

 

(a)

Termination Generally. If the Executive’s employment with the Company is terminated for any reason during the Term, the Company shall pay or provide to the Executive (or to his authorized representative or estate) any earned but unpaid base salary, incentive compensation earned but not yet paid, unpaid expense reimbursements, accrued but unused vacation and any vested benefits the Executive may have under any employee benefit plan of the Company (the “Accrued Benefit”) within 30 days of the Executive’s Date of Termination.
     
 

(b)

Termination by Company Without Cause. If the Executive’s employment is terminated by the Company without Cause, then the Company shall, through the Date of Termination, pay the Executive his Accrued Benefit. If the Executive signs a general release of claims in a form and manner satisfactory to the Company (the “Release”) within 45 days of the receipt of the Release (which shall be provided no later than within two business days after the Date of Termination) and does not revoke such Release during the seven-day revocation period,

 

 

(i)

the Company shall pay the Executive an amount (the “Severance Amount”) equal to the Executive’s annual base salary for the fiscal year in which the Date of Termination occurs. The Severance Amount shall be paid out in substantially equal installments in accordance with the Company’s payroll practice over 12 months, beginning within 60 days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, the Severance Amount commence to be paid in the second calendar year. Solely for purposes of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), each installment payment is considered a separate payment. Notwithstanding the foregoing, if the Executive breaches any of the obligations contained in Section 7 of this Agreement, all payments of the Severance Amount shall immediately cease; and
     
 

(ii)

subject to the Executive’s copayment of premium amounts at the active employees’ rate, the Executive may continue to participate in the Company’s group health, dental and vision program for 12 months; provided, however, that the continuation of health benefits under this Section shall reduce and count against the Executive’s rights under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”); provided, however, that if the Company determines necessary to avoid any adverse tax or other consequences for the Executive or the Company, the Company may instead pay to the Executive on a monthly basis during the period covered by this Section 4(b)(ii) an amount equal to the difference between the applicable COBRA premium and the applicable active employees’ rate for the coverage.

 

4
 

 

 

5.

Change in Control. The provisions of this Section set forth certain terms of an agreement reached between the Executive and the Company regarding the Executive’s rights and obligations upon the occurrence of a Change in Control of the Company. These provisions are intended to assure and encourage in advance the Executive’s continued attention and dedication to his assigned duties and his objectivity during the pendency and after the occurrence of any such event. These provisions shall apply in lieu of, and expressly supersede, the provisions of Section 4(b) regarding severance pay and benefits upon a termination of employment, if such termination of employment occurs within 3 months prior to or 12 months after the occurrence of the first event constituting a Change in Control, provided that such first event occurs during the Term. These provisions shall terminate and be of no further force or effect beginning 12 months after the occurrence of a Change in Control, in which case the provisions of Section 4(b) shall once again become applicable.

 

 

(a)

Change in Control Benefits.

 

 

(i)

If the Executive incurs a Qualifying Termination, then:

 

 

(A)

Subject to the signing of the Release by the Executive within 45 days of the receipt of the Release (which shall be provided no later than two business days after the Date of Termination) and not revoking the Release during the seven-day revocation period, the Company shall pay the Executive a lump sum in cash in an amount (the “Change in Control Severance Amount”) equal to the sum of (I) the Executive’s current annual base salary (or the Executive’s annual base salary in effect immediately prior to the Change in Control, if higher) plus (II) the Executive’s target annual bonus for the current fiscal year (or if higher, the target annual bonus for the fiscal year immediately prior to the Change in Control). The Change in Control Severance Amount shall be paid to the Executive by the 60th day after the later of the date of the Change in Control and the Date of Termination; provided, however, that (x) if the Date of Termination occurs during the three-month period before the Change in Control, the payment under this Section 5(a)(i)(A) shall be reduced by any payments made under Section 4(b)(i) before the date of the Change in Control; and (y) to the extent that the Company determines necessary to comply with Section 409A of the Code, all or a portion of the payments under this Section 5(a)(i)(A) shall be made on the schedule set forth in Section 4(b)(i) rather than in a lump sum.

 

 

(B)

The Company shall pay to the Executive in a cash lump sum by the 60th day after the later of the date of the Change in Control and the Date of Termination, an amount equal to 12 times the excess of (I) the monthly premium payable by former employees for continued coverage under COBRA for the same level of coverage, including dependents, provided to the Executive under the Company’s group health benefit plans in which the Executive participates immediately prior to the Date of Termination over (II) the monthly premium paid by active employees for the same coverage immediately prior to the Notice of Termination.

 

 

(ii)

Notwithstanding anything to the contrary in any applicable option agreement or stock-based award agreement:

 

5
 

 

 

(A)

All stock options and other stock-based awards held by the Executive that were granted before January 29, 2019 shall immediately accelerate and become fully exercisable or nonforfeitable as of the effective date of such Change in Control. If any such award includes a performance-based vesting condition, vesting shall be based on the greater of assumed target performance or actual performance measured through the date of the Change in Control; and
     
 

(B)

All stock options and other stock-based awards held by the Executive that are granted on or after January 29, 2019, (I) if assumed or continued by the successor in the Change in Control (as set forth in Section 15.2.1(b) of the Company’s 2017 Omnibus Incentive Plan, or any similar provision in any predecessor or successor plan), and the Executive incurs a Qualifying Termination, shall only immediately accelerate and become fully exercisable or nonforfeitable upon the later of the Date of Termination or the effective date of the Change in Control, and (II) if not assumed or continued by the successor in the Change in Control, shall become fully vested and exercisable upon the effective date of the Change in Control as provided in Section 6(a)(ii)(A).  In that regard, for any such award that includes a performance-based vesting condition, vesting shall be based on the greater of assumed target performance or actual performance measured through the date of accelerated vesting.

 

For the avoidance of any doubt, the provisions of this Section 5(a)(ii) shall supersede the provisions contained in the applicable award agreements, provided that the provisions of the award agreements will control to the extent such provisions are more favorable to the Executive.

 

 

(b)

Section 280G. If any of the payments or benefits received or to be received by the Executive (including, without limitation, any payment or benefits received in connection with a Change in Control or the Executive’s termination of employment, whether pursuant to the terms of this Agreement or any other plan, arrangement or agreement, or otherwise) (all such payments collectively referred to herein as the “280G Payments”) constitute “parachute payments” within the meaning of Section 280G of the Code and would, but for this Section 6(b), be subject to the excise tax imposed under Section 4999 of the Code (the “Excise Tax”), then prior to making the 280G Payments, a calculation shall be made comparing (i) the Net Benefit (as defined below) to the Executive of the 280G Payments after payment of the Excise Tax to (ii) the Net Benefit to the Executive if the 280G Payments are limited to the extent necessary to avoid being subject to the Excise Tax. Only if the amount calculated under (i) above is less than the amount under (ii) above will the 280G Payments be reduced to the minimum extent necessary to ensure that no portion of the 280G Payments is subject to the Excise Tax. “Net Benefit” shall mean the present value of the 280G Payments net of all federal, state, local, and foreign income, employment, and excise taxes. Any reduction made pursuant to this Section 5(b) shall be made in a manner determined by the Company that is consistent with the requirements of Section 409A of the Code.

 

 

6.

Section 409A.

 

 

(a)

Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive’s separation from service within the meaning of Section 409A of the Code, the Company determines that the Executive is a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that the Executive becomes entitled to under this Agreement would be considered deferred compensation subject to the 20 percent additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (i) six months and one day after the Executive’s separation from service, or (ii) the Executive’s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule. Any such delayed cash payment shall earn interest at an annual rate equal to the applicable federal short-term rate published by the Internal Revenue Service for the month in which the date of separation from service occurs, from such date of separation from service until the payment.

 

6
 

 

 

(b)

The parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.
     
 

(c)

The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-1(h). To the extent required by Section 409A of the Code, each reimbursement or in-kind benefit provided under the Agreement shall be provided in accordance with the following: (i) the amount of expenses eligible for reimbursement, or in-kind benefits provided, during each calendar year cannot affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other calendar year, (ii) any reimbursement of an eligible expense shall be paid to the Executive on or before the last day of the calendar year following the calendar year in which the expense was incurred, and (iii) any right to reimbursements or in-kind benefits under the Agreement shall not be subject to liquidation or exchange for another benefit.
     
 

(d)

The Company makes no representation or warranty and shall have no liability to the Executive or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.

 

 

7.

Confidentiality and Non-Competition Agreement. Nothing in this Agreement supersedes the terms of the Confidentiality and Non-Competition Agreement between the Executive and the Company. Any and all obligations of the Company under this Agreement are contingent upon the Executive’s compliance with the Executive’s obligations under the Confidentiality and Non-Competition Agreement.
     
 

8.

Arbitration of Disputes. Except for any request by the Company or by the Executive for temporary, preliminary, or permanent injunctive relief from a court of competent jurisdiction to enforce or enjoin any portion of the Confidentiality and Non-Competition Agreement (which right shall remain in full force and effect following the termination of the Executive’s employment with the Company), in the event of any dispute, controversy, or claim arising out of or relating to this Agreement, the Executive’s employment with the Company, or the termination of the Executive’s employment, including but not limited to, any claims arising out of M.G.L. ch.151B, Title VII of the Civil Rights Act of 1964, the Americans with Disabilities Act, the Age Discrimination in Employment Act, the Family and Medical Leave Act, the Small Necessities Leave Act, the Massachusetts Civil Rights Act (M.G.L. ch. 12), or any other federal, state, or local statute, regulation, or ordinance that provides protection against employment discrimination, harassment, or retaliation; any claims under the Fair Labor Standards Act or M.G.L. ch. 149 or any other federal, state, or local statute, regulation, or ordinance that provides protection against wage and hour and/or wage payment violations; any claims under the federal or state equal pay act; any tort and/or privacy claims, including those under the Massachusetts Privacy Statute (M.G.L. ch. 214), that dispute, controversy, or claim shall, to the fullest extent permitted by law, be settled by binding arbitration before an arbitrator experienced in employment law. Said arbitration will be conducted in accordance with the Employment Dispute Resolution Rules and Mediation Procedures of the American Arbitration Association (“AAA”) in Boston, Massachusetts, including, but not limited to, the rules and procedures applicable to the selection of arbitrators (or alternatively, in any other forum or in any other form agreed upon by the parties). In the event that any person or entity other than the Executive or Anika may be a party with regard to any such controversy or claim, such controversy or claim shall be submitted to arbitration subject to such other person or entity’s agreement. Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. This provision shall be specifically enforceable. Arbitration as provided in this section shall be the exclusive, final, and binding remedy for any such dispute and will be used instead of any court action, which is hereby expressly waived. The Federal Arbitration Act shall govern the interpretation and enforcement of such arbitration proceeding. The Executive acknowledges and understands that by agreeing to arbitrate, the Executive is waiving any right to bring an action against the Company in a court of law, either state or federal, and the right to a trial by jury, except as otherwise expressively set forth in this Agreement.

 

 

7
 

 

 

9.

Consent to Jurisdiction. To the extent that any court action is permitted consistent with or to enforce Section 7 of this Agreement, the parties hereby consent to the jurisdiction of the Superior Court of the Commonwealth of Massachusetts and the United States District Court for the District of Massachusetts. Accordingly, with respect to any such court action, the Executive (a) submits to the personal jurisdiction of such courts; (b) consents to service of process; and (c) waives any other requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process.
     
 

10.

Integration; Non-Duplication. This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements, including any severance provisions under an offer letter, employment agreement, or other similar agreement.  In no event shall the Executive be eligible for severance benefits under both this Agreement and any other agreement with the Company or under and statutory requirements under applicable law.
     
 

11.

Withholding. All payments made by the Company to the Executive under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law.
     
 

12.

Successor to Executive. This Agreement shall inure to the benefit of and be enforceable by the Executive’s personal representatives, executors, administrators, heirs, distributees, devisees, and legatees. In the event of the Executive’s death after his termination of employment but prior to the completion by the Company of all payments due him under this Agreement, the Company shall continue such payments to the Executive’s beneficiary designated in writing to the Company prior to his death (or to his estate, if the Executive fails to make such designation).
     
 

13.

Enforceability. If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.
     
 

14.

Waiver. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.

 

8
 

 

 

15.

Notices. Any notices, requests, demands, and other communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing with the Company or, in the case of the Company, at its main offices, attention of the Board.
     
 

16.

Amendment. This Agreement may be amended or modified only by a written instrument signed by the Executive and by a duly authorized representative of the Company.
     
 

17.

Governing Law. This is a Massachusetts contract and shall be construed under and be governed in all respects by the laws of the Commonwealth of Massachusetts, without giving effect to the conflict of laws principles of such Commonwealth. With respect to any disputes concerning federal law, such disputes shall be determined in accordance with the law as it would be interpreted and applied by the United States Court of Appeals for the First Circuit.
     
 

18.

Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document.
     
 

19.

Successor to Company. The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and agree to perform this Agreement to the same extent that the Company would be required to perform it if no succession had taken place. Failure of the Company to obtain an assumption of this Agreement at or prior to the effectiveness of any succession shall be a material breach of this Agreement.
     
 

20.

Gender Neutral. Wherever used herein, a pronoun in the masculine gender shall be considered as including the feminine gender unless the context clearly indicates otherwise.
     
 

21.

At-Will Employment. The Executive acknowledges that the Executive’s employment remains at-will. Nothing in this Agreement shall be construed otherwise.

 

 

 

In Witness Whereof, the parties hereby execute this Agreement as of the date first written above.

 

  Anika Therapeutics, Inc.
   
   
  By:   /s/ Cheryl Blanchard 
          Name:  Cheryl Blanchard
          Title:    Interim Chief Executive Officer
   
  [Name]
   
   
  /s/ David Colleran
  David Colleran

 

9
 EX-21.1 4 ex_489365.htm EXHIBIT 21.1 HTML Editor

Exhibit 21.1

 

 SUBSIDIARIES OF THE REGISTRANT

 

Name of Subsidiary

Jurisdiction of Formation
   

Anika Securities, Inc.

Massachusetts
   

Anika Therapeutics Limited

United Kingdom
   

Anika Therapeutics S.r.l.

(Formerly: Fidia Advanced Biopolymers S.r.l.)

Italy
   

ArthroSurface Incorporated

Delaware
   

Parcus Medical, LLC

Wisconsin

 

 

 

 
 EX-23.1 5 ex_487324.htm EXHIBIT 23.1 HTML Editor

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 

  

We consent to the incorporation by reference in Registration Statements on Form S-8 (Nos. 333-110326, 333-160102, 333-176103, 333-190597, 333-219190, 333-232254, 333-239304, 333-258529, 333-258530, 333-260821, and 333-266550) of our reports dated March 16, 2023, relating to the financial statements of Anika Therapeutics, Inc. (the “Company”), and the effectiveness of the Company's internal control over financial reporting, appearing in this Annual Report on Form 10-K of Anika Therapeutics, Inc. for the year ended December 31, 2022. 

  

/s/ Deloitte & Touche LLP 

  

Boston, Massachusetts 

March 16, 2023 

 

 

 EX-31.1 6 ex_487325.htm EXHIBIT 31.1 HTML Editor

Exhibit 31.1 

 

CERTIFICATION

 

I, Cheryl Blanchard, certify that:

 

 

1.

I have reviewed this annual report on Form 10-K for the year ended December 31, 2022 of Anika Therapeutics, Inc.;
     
 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
 

4.

The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d- 15(f)) for the registrant and have:

 

 

a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
 

b.

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
 

c.

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
 

d.

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

 

5.

The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

 

a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
     
 

b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Date: March 16, 2023

  
 

/s/ Cheryl Blanchard
 

President and Chief Executive Officer
 

(Principal Executive Officer) 
   

 

 
 EX-31.2 7 ex_487326.htm EXHIBIT 31.2 HTML Editor

Exhibit 31.2 

 

CERTIFICATION

 

I, Michael Levitz, certify that:

 

 

1.

I have reviewed this annual report on Form 10-K for the year ended December 31, 2022 of Anika Therapeutics, Inc.;
     
 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
 

4.

The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d- 15(f)) for the registrant and have:

 

 

a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
 

b.

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
 

c.

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
 

d.

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

 

5.

The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

 

a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
     
 

b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

 

Date: March 16, 2023

  
 

/s/ Michael Levitz
 

Executive Vice President, Chief Financial Officer and Treasurer
 

(Principal Financial Officer) 
   

 

 
 EX-32.1 8 ex_487327.htm EXHIBIT 32.1 HTML Editor

Exhibit 32.1

 

CERTIFICATION

 

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), each of the undersigned officers of Anika Therapeutics, Inc., a Delaware corporation (the "Company"), does hereby certify, to such officer's knowledge, that:

 

The Annual Report on Form 10-K for the year ended December 31, 2022 (the "Form 10-K") of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: March 16, 2023

  
 

/s/ Cheryl Blanchard
 

President and Chief Executive Officer
 

(Principal Executive Officer)
   
   
 

/s/ Michael Levitz
 

Executive Vice President, Chief Financial Officer and Treasurer
 

(Principal Financial Officer) 

 

 

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

 
 EX-101.SCH 9 anik-20221231.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Consolidated Balance Sheets link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Consolidated Balance Sheets (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Consolidated Statements of Stockholders' Equity link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 1 - Nature of Business link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 2 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 3 - Business Combinations link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 4 - Fair Value Measurements link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 5 - Inventories link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 6 - Property and Equipment link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 7 - Acquired Intangible Assets, Net link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 8 - Goodwill link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 9 - Leases link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 10 - Accrued Expenses and Other Liabilities link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 11 - Revolving Credit Agreement link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 12 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 13 - Revenue and Geographic Information link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 14 - Equity Incentive Plan link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 15 - Employee Benefit Plan link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 16 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 17- Earnings Per Share ("EPS") link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 3 - Business Combinations (Tables) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 4 - Fair Value Measurements (Tables) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 5 - Inventories (Tables) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 6 - Property and Equipment (Tables) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 7 - Acquired Intangible Assets, Net (Tables) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 8 - Goodwill (Tables) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 9 - Leases (Tables) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 10 - Accrued Expenses and Other Liabilities (Tables) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 13 - Revenue and Geographic Information (Tables) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 14 - Equity Incentive Plan (Tables) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 16 - Income Taxes (Tables) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 17- Earnings Per Share ("EPS") (Tables) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Allowance for Doubtful Accounts (Details) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Details) link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note 3 - Business Combinations (Details Textual) link:calculationLink link:definitionLink link:presentationLink 041 - Disclosure - Note 3 - Business Combinations - Consideration Transferred (Details) link:calculationLink link:definitionLink link:presentationLink 042 - Disclosure - Note 3 - Business Combinations - Fair Value of Net Assets Acquired (Details) link:calculationLink link:definitionLink link:presentationLink 043 - Disclosure - Note 3 - Business Combinations - Intangible Assets Acquired (Details) link:calculationLink link:definitionLink link:presentationLink 044 - Disclosure - Note 3 - Business Combinations - Pro Forma Information (Details) link:calculationLink link:definitionLink link:presentationLink 045 - Disclosure - Note 4 - Fair Value Measurements (Details Textual) link:calculationLink link:definitionLink link:presentationLink 046 - Disclosure - Note 4 - Fair Value Measurements - Fair Value of Financial Instruments (Details) link:calculationLink link:definitionLink link:presentationLink 047 - Disclosure - Note 4 - Fair Value Measurements - Contingent Consideration (Details) link:calculationLink link:definitionLink link:presentationLink 048 - Disclosure - Note 5 - Inventories (Details Textual) link:calculationLink link:definitionLink link:presentationLink 049 - Disclosure - Note 5 - Inventories - Summary of Inventories (Details) link:calculationLink link:definitionLink link:presentationLink 050 - Disclosure - Note 6 - Property and Equipment (Details Textual) link:calculationLink link:definitionLink link:presentationLink 051 - Disclosure - Note 6 - Property and Equipment - Property and Equipment at Cost (Details) link:calculationLink link:definitionLink link:presentationLink 052 - Disclosure - Note 7 - Acquired Intangible Assets, Net (Details Textual) link:calculationLink link:definitionLink link:presentationLink 053 - Disclosure - Note 7 - Acquired Intangible Assets, Net - Summary of Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 054 - Disclosure - Note 8 - Goodwill (Details Textual) link:calculationLink link:definitionLink link:presentationLink 055 - Disclosure - Note 8 - Goodwill - Changes in the Carrying Value of Goodwill (Details) link:calculationLink link:definitionLink link:presentationLink 056 - Disclosure - Note 9 - Leases (Details Textual) link:calculationLink link:definitionLink link:presentationLink 057 - Disclosure - Note 9 - Leases - Lease Expense and Other Information (Details) link:calculationLink link:definitionLink link:presentationLink 058 - Disclosure - Note 9 - Leases - Future Minimum Rental Payments for Leases (Details) link:calculationLink link:definitionLink link:presentationLink 059 - Disclosure - Note 10 - Accrued Expenses and Other Liabilities - Summary of Accrued Expenses (Details) link:calculationLink link:definitionLink link:presentationLink 060 - Disclosure - Note 11 - Revolving Credit Agreement (Details Textual) link:calculationLink link:definitionLink link:presentationLink 061 - Disclosure - Note 12 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 062 - Disclosure - Note 13 - Revenue and Geographic Information (Details Textual) link:calculationLink link:definitionLink link:presentationLink 063 - Disclosure - Note 13 - Revenue and Geographic Information - Disaggregated Revenues (Details) link:calculationLink link:definitionLink link:presentationLink 064 - Disclosure - Note 13 - Revenue and Geographic Information - Total Revenue by Geographic Location (Details) link:calculationLink link:definitionLink link:presentationLink 065 - Disclosure - Note 13 - Revenue and Geographic Information - Net Tangible Long-lived Assets by Principal Geographic Areas (Details) link:calculationLink link:definitionLink link:presentationLink 066 - Disclosure - Note 14 - Equity Incentive Plan (Details Textual) link:calculationLink link:definitionLink link:presentationLink 067 - Disclosure - Note 14 - Equity Incentive Plan - Total Stock-based Compensation Expense (Details) link:calculationLink link:definitionLink link:presentationLink 068 - Disclosure - Note 14 - Equity Incentive Plan - Stock Options (Details) link:calculationLink link:definitionLink link:presentationLink 069 - Disclosure - Note 14 - Equity Incentive Plan - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details) link:calculationLink link:definitionLink link:presentationLink 070 - Disclosure - Note 14 - Equity Incentive Plan - Restricted Stock Activity (Details) link:calculationLink link:definitionLink link:presentationLink 071 - Disclosure - Note 14 - Equity Incentive Plan - Performance Stock Units (Details) link:calculationLink link:definitionLink link:presentationLink 072 - Disclosure - Note 15 - Employee Benefit Plan (Details Textual) link:calculationLink link:definitionLink link:presentationLink 073 - Disclosure - Note 16 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 074 - Disclosure - Note 16 - Income Taxes - Components of Income Before Taxes and Provision for (Benefit from) Income Taxes (Details) link:calculationLink link:definitionLink link:presentationLink 075 - Disclosure - Note 16 - Income Taxes - Significant Components of Company's Deferred Tax Assets and Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 076 - Disclosure - Note 16 - Income Taxes - Reconciliation Between U.S. Federal Statutory Rate and Effective Rate (Details) link:calculationLink link:definitionLink link:presentationLink 077 - Disclosure - Note 17- Earnings Per Share ("EPS") (Details Textual) link:calculationLink link:definitionLink link:presentationLink 078 - Disclosure - Note 17 - Earnings Per Share ("EPS") - Basic and Diluted Earnings Per Share (Details) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 10 anik-20221231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 11 anik-20221231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 12 anik-20221231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Intangible assets us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles Expected dividend yield Intangible assets us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Note To Financial Statement Details Textual Significant Accounting Policies Note 2 - Summary of Significant Accounting Policies Note 3 - Business Combinations Risk-free interest rate Note 4 - Fair Value Measurements Note 5 - Inventories Note 6 - Property and Equipment Note 7 - Acquired Intangible Assets, Net Note 8 - Goodwill Prepaid expenses and other current assets us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets Note 9 - Leases Accounts receivable us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables Income Tax Disclosure [Text Block] Note 10 - Accrued Expenses and Other Liabilities Other permanent items anik_EffectiveIncomeTaxReconciliationNondeductibleExpensesPermanentItemsPercent Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent items including nondeductible expenses. Note 13 - Revenue and Geographic Information Note 14 - Equity Incentive Plan Cash and cash equivalents us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents Contingent consideration Business Combination, Contingent Consideration, Liability, Current Note 16 - Income Taxes Expected stock price volatility Inventories us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory Note 17- Earnings Per Share ("EPS") us-gaap_LiabilitiesCurrent Total current liabilities Note 2 - Summary of Significant Accounting Policies - Allowance for Doubtful Accounts (Details) Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Details) Note 3 - Business Combinations - Consideration Transferred (Details) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year) Note 3 - Business Combinations - Fair Value of Net Assets Acquired (Details) Note 3 - Business Combinations - Intangible Assets Acquired (Details) Note 3 - Business Combinations - Pro Forma Information (Details) Estimated total purchase consideration Business Combination, Consideration Transferred, Total Note 4 - Fair Value Measurements - Fair Value of Financial Instruments (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Note 4 - Fair Value Measurements - Contingent Consideration (Details) Note 5 - Inventories - Summary of Inventories (Details) Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Note 6 - Property and Equipment - Property and Equipment at Cost (Details) Note 7 - Acquired Intangible Assets, Net - Summary of Intangible Assets (Details) Estimated fair value of contingent consideration Note 8 - Goodwill - Changes in the Carrying Value of Goodwill (Details) Note 9 - Leases - Lease Expense and Other Information (Details) Note 9 - Leases - Future Minimum Rental Payments for Leases (Details) Share-Based Payment Arrangement, Option, Activity [Table Text Block] Note 10 - Accrued Expenses and Other Liabilities - Summary of Accrued Expenses (Details) Note 13 - Revenue and Geographic Information - Disaggregated Revenues (Details) Granted, weighted average grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) Foreign currency translation adjustment Note 13 - Revenue and Geographic Information - Total Revenue by Geographic Location (Details) Vested, weighted average grant date fair value (in dollars per share) Proceeds from maturities of investments Note 13 - Revenue and Geographic Information - Net Tangible Long-lived Assets by Principal Geographic Areas (Details) Forfeited and cancelled, weighted average grant date fair value (in dollars per share) Forfeited and cancelled, weighted average grant date fair value (in dollars per share) Note 14 - Equity Incentive Plan - Total Stock-based Compensation Expense (Details) Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Note 14 - Equity Incentive Plan - Stock Options (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Outstanding, weighted average grant date fair value (in dollars per share) Outstanding, weighted average grant date fair value (in dollars per share) Note 14 - Equity Incentive Plan - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Forfeited and cancelled, shares (in shares) Note 14 - Equity Incentive Plan - Restricted Stock Activity (Details) us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Outstanding, shares (in shares) Outstanding, shares (in shares) Note 14 - Equity Incentive Plan - Performance Stock Units (Details) Note 16 - Income Taxes - Components of Income Before Taxes and Provision for (Benefit from) Income Taxes (Details) Note 16 - Income Taxes - Significant Components of Company's Deferred Tax Assets and Liabilities (Details) Note 16 - Income Taxes - Reconciliation Between U.S. Federal Statutory Rate and Effective Rate (Details) Granted (in shares) Note 17 - Earnings Per Share ("EPS") - Basic and Diluted Earnings Per Share (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Vested, shares (in shares) Vested, shares (in shares) Notes To Financial Statements Vested and expected to vest, Weighted Average Remaining Contractual Term (Year) Notes To Financial Statements [Abstract] Schedule of Nonvested Performance-Based Units Activity [Table Text Block] anik_CapitalizedCostsResearchAndDevelopment Capitalized Costs, Research and Development Represent the capitalization of research and development. Vested and expected to vest, shares (in shares) Vested and expected to vest, Weighted Average Exercise Price (in dollars per share) anik_DeferredTaxAssetsCapitalizedResearchExpenditures Capitalized research expenditures Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research expenditures. Other comprehensive income (loss) Vested and expected to vest, Aggregate Intrinsic Value Return to provision adjustments Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to returning provision adjustments. Net loss us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss Vested, Weighted Average Remaining Contractual Term (Year) Vested, Aggregate Intrinsic Value Exercised, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Business Acquisition, Pro Forma Information [Table Text Block] Total revenue us-gaap_BusinessAcquisitionsProFormaRevenue Outstanding, Weighted Average Remaining Contractual Term (Year) Outstanding, Aggregate Intrinsic Value Granted, Weighted Average Exercise Price (in dollars per share) anik_SharebasedCompensationPerformanceSharesMeasuredByFinancialTargetsNotAchieved Share-based Compensation, Performance Shares Measured by Financial Targets, Not Achieved The percent of performance shares in a share based compensation arrangement measured by financial targets not achieved. Vested, Weighted Average Exercise Price (in dollars per share) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue Outstanding, Weighted Average Exercise Price (in dollars per share) Granted in 2019 [Member] Represents granted in 2019. Vested, shares (in shares) Granted in 2020 [Member] Represents granted in 2020. anik_LineOfCreditFacilityAdditionalBorrowingCapacity Line of Credit Facility, Additional Borrowing Capacity Amount of additional borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed. us-gaap_PaymentsToAcquireMarketableSecurities Purchases of investments us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput Business Combination, Contingent Consideration, Liability, Measurement Input anik_SharebasedCompensationPerformanceSharesMeasuredByBusinessTargetsNotAchieved Share-based Compensation, Performance Shares Measured by Business Targets, Not Achieved The percent of performance shares in a share based compensation arrangement measured by financial targets that was not achieved. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Outstanding, Weighted Average Exercise (in dollars per share) Reporting Unit [Axis] Reporting Unit [Domain] Forfeited and canceled, Weighted Average Exercise Price (in dollars per share) Goodwill and Intangible Assets Disclosure [Text Block] Schedule of Goodwill [Table Text Block] Exercised, Weighted Average Exercise Price (in dollars per share) Compensation and related expenses us-gaap_EmployeeRelatedLiabilitiesCurrent Income taxes payable us-gaap_AccruedIncomeTaxesCurrent Section 162(m) limitation anik_EffectiveIncomeTaxRateReconciliationShareBasedCompensationSection162mLimitationExcessTaxBenefitPercent Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) of section 162(m) limitation computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement. Fair value per option Represents fair value per option related to share based compensation arrangement by share based payment award. Accounts payable Revolving Credit Facility [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) Outstanding, shares (in shares) Outstanding, shares (in shares) Provision for doubtful accounts The amount of expense credit loss on accounts receivable, net of recoveries. Purchases of property and equipment included in accounts payable and accrued expenses Credit Facility [Axis] Credit Facility [Domain] Employee Stock Purchase Plan (ESPP) [Member] Represents Employee Stock Purchase Plan (ESPP). Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Other us-gaap_OtherAccruedLiabilitiesCurrent us-gaap_PolicyTextBlockAbstract Accounting Policies Trade Names [Member] Parcus Medical and Arthrosurface Acquisitions [Member] Represents acquisitions of Parcus Medical and Arthrosurface. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) Professional fees us-gaap_AccruedProfessionalFeesCurrent anik_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPerOfferingPeriod Share Based Compensation Arrangement by Share Based Payment Award Number of Shares Authorized per Offering Period (in shares) Represents share based compensation arrangement by share based payment award number of shares authorized per offering period. anik_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueAuthorized Share Based Compensation Arrangement by Share Based Payment Award, Value Authorized Represents share based compensation arrangement by share based payment award, value authorized. OA Pain Management [member] Represents QA pain management. us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchases of property and equipment Non-Orthopedic [Member] Represents non-orthopedic. us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) anik_RepresentsShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionPercentage Represents Share Based Compensation Arrangement by Share Based Payment Award, Payroll Deduction percentage Represents share based compensation arrangement by share based payment award, payroll deduction. Cash paid for income taxes, net of refunds anik_RepresentsShareBasedCompensationArrangementByShareBasedPaymentAwardThePurchasePriceForEachSharePurchasedPercentage Represents Share Based Compensation Arrangement by Share Based Payment Award, the Purchase Price for Each Share Purchased, Percentage Represents share based compensation arrangement by share based payment award, the purchase price for each share purchased, percentage. Goodwill Disclosure [Text Block] Current liabilities: Developed Technology Rights [Member] us-gaap_Assets Total assets Supplemental disclosure of cash flow information: Patents [Member] Plan Name [Axis] Plan Name [Domain] Compensation and Employee Benefit Plans [Text Block] In Process Research and Development [Member] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) Customer Relationships [Member] Distribution Rights [Member] us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense Share-Based Payment Arrangement, Expense, Tax Benefit Deferred tax assets Finite-Lived Intangible Assets by Major Class [Axis] Share-Based Payment Arrangement [Text Block] Finite-Lived Intangible Assets, Major Class Name [Domain] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation Retirement of common stock for minimum tax withholdings Property, Plant and Equipment Estimated Useful Lives [Table Text Block] Tabular disclosure of the estimated useful lives of physical assets used in the normal conduct of business and not intended for resale. Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Premium-Priced Employee Stock Options [Member] Information pertaining to premium priced employee stock options. Award Type [Domain] Award Date [Axis] Award Date [Domain] Award Type [Axis] Net (loss) income Net (loss) income us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Accumulated Amortization Intangible assets, net Net book value Restricted Stock Units (RSUs) [Member] Performance Shares [Member] Share-Based Payment Arrangement, Option [Member] us-gaap_GoodwillForeignCurrencyTranslationGainLoss Effect of foreign currency adjustments Computer Equipment and Software [Member] Information related to computer equipment and software. Business Combination Disclosure [Text Block] Commitments and Contingencies Disclosure [Text Block] us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Less accumulated depreciation Schedule of Business Acquisitions, by Acquisition [Table Text Block] Property and equipment, net Total Goodwill Goodwill, Ending Balance Balance Balance anik_RevenuesFromAgreementsAsPercentOfTotalRevenue Revenues From Agreements as Percent of Total Revenue The percent of total revenue that revenue from agreements comprises. Property, plant and equipment, gross anik_SharebasedCompensationArrangementBySharebasedPaymentAwardPercentageOfTargetNumber Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Target Number Represents percentage of target market for actual number of shares that may be earned for share-based compensation. Cash flows from investing activities: us-gaap_AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale, Total anik_EffectiveIncomeTaxRateReconciliationSharebasedCompensationWindfallTaxBenefitAmount Effective Income Tax Rate Reconciliation, Share-based Compensation, Windfall Tax Benefit, Amount Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to windfall tax benefit for share-based compensation. Earnings Per Share [Text Block] Income taxes Schedule of Revenue and Operating Income by Geographical Areas [Table Text Block] Represents schedule of revenue and operating income, by geographical areas. Other Location [Member] Represents other location. Percent of revenue Represents the percentage of net revenue. Total Shareholder Return ("TSRs") Options [Member] Represents information related to total shareholder return ("TSRs") options. Accrued expenses, other current and long-term liabilities Total benefit from income taxes Benefit from for income taxes Accounts payable us-gaap_IncreaseDecreaseInAccountsPayable The 2021 Inducement Plan [Member] Represents the 2021 Inducement Plan. us-gaap_DebtInstrumentTerm Debt Instrument, Term (Year) Consideration for acquisitions included in accounts payable and accrued expenses Amount of consideration for acquisitions included in accounts payable and accrued expenses. Contingent consideration fair value on acquisition date Amount of acquisition related contingent consideration. us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch Defined Contribution Plan, Employer Matching Contribution, Percent of Match anik_FinanceLeaseExpense Finance lease expense Amount of finance lease expense. Lessee, Operating Leases and Finance Leases [Text Block] The entire disclosure for operating leases and finance leases of lessee. Lessee, Operating Lease and Finance Lease, Liability, Maturity [Table Text Block] Tabular disclosure of undiscounted cash flows of lessee's operating lease and finance lease liability. Cash and cash equivalents Translation adjustments Amount of translation adjustments affecting the allowance for doubtful accounts receivable. Stock-based compensation expense us-gaap_AllocatedShareBasedCompensationExpense us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings Change in fair value Amortization of acquisition related inventory step-up Amount of amortization expenses related to the acquisition inventory step-up. Amendment Flag us-gaap_ComprehensiveIncomeNetOfTax Comprehensive (loss) income City Area Code Use of Estimates, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures Forfeiture of restricted stock awards Parcus Medical and Arthrosurface [Member] Represents Parcus Medical and Arthrosurface. anik_SharebasedCompensationArrangementBySharebasedPaymentAwardPremiumPricedOptionsExercisePriceAsPercentageOfMarketPrice Share-based Compensation Arrangement by Share-based Payment Award, Premium Priced Options, Exercise Price as Percentage of Market Price The exercise price of premium priced options granted during the reporting period represented as percentage of market price. us-gaap_GainLossOnSaleOfPropertyPlantEquipment Loss on disposal of fixed assets us-gaap_SharesOutstanding Balance (in shares) Balance (in shares) Common stock, shares outstanding (in shares) Preferred stock, shares outstanding (in shares) ITALY Current Fiscal Year End Date us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Debt Instrument, Basis Spread on Variable Rate us-gaap_DebtInstrumentInterestRateStatedPercentage Debt Instrument, Interest Rate, Stated Percentage Amortization of acquisition related intangible assets Amount of amortization expenses related to the acquisition related intangible assets. Variable lease expense us-gaap_LeaseCost Total lease expense us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses, other current and long-term assets us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent Cash equivalents anik_CashEquivalentsFairValueDisclosure Represents the fair value disclosure for cash equivalents as of the balance sheet date. Document Fiscal Period Focus Operating lease expense Document Fiscal Year Focus Consolidation, Policy [Policy Text Block] Short-term lease expense Lease, Cost [Table Text Block] Operating cash flows from financing leases Document Period End Date Right-of-use assets obtained in exchange for operating lease liabilities us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Operating leases (Year) Entity File Number Entity Emerging Growth Company Document Type Entity Small Business Entity Shell Company Document Information [Line Items] anik_NumberOfSharesAvailableForGrantReducedByEachShareAwardIssuedOtherThanOptionsOrSARs Number of Shares Available for Grant Reduced By Each Share Award Issued Other Than Options or SARs (in shares) Represents the number of shares by which shares available for grant is reduced for each share award issued after a specified date other than options or stock appreciation rights. Document Information [Table] us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Balance Balance Entity Public Float us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements Payments Entity Filer Category Entity Current Reporting Status Entity Voluntary Filers us-gaap_BusinessCombinationAcquisitionRelatedCosts Business Combination, Acquisition Related Costs Entity Well-known Seasoned Issuer Loss on impairment of intangible asset Impairment of Intangible Assets, Finite-lived Current period impairment charge Additions Schedule of Finite-Lived and Indefinite-Lived Intangible Assets by Major Class [Table Text Block] Tabular disclosure of finite-lived and indefinite-lived intangible assets by major class. Equipment and Software [Member] Represents equipment and software. us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Goodwill impairment charge Goodwill, Impairment Loss us-gaap_ConcentrationRiskPercentage1 Concentration Risk, Percentage us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable Entity Tax Identification Number Entity Central Index Key Depreciation Entity Registrant Name Liability Class [Axis] Fair Value by Liability Class [Domain] Entity [Domain] Customer Concentration Risk [Member] Legal Entity [Axis] Entity Address, Address Line One Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] anik_AccumulatedCurrencyTranslationAdjustment Accumulated Currency Translation Adjustment Represents the amount of the accumulated currency translation adjustment. us-gaap_AmortizationOfIntangibleAssets Amortization of Intangible Assets, Total Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Concentration Risk Type [Axis] Concentration Risk Type [Domain] us-gaap_AllowanceForDoubtfulAccountsReceivable Balance, beginning of the year Balance, end of the year us-gaap_StockRepurchasedDuringPeriodShares Repurchase of common stock (in shares) Entity Common Stock, Shares Outstanding Clinical trial costs anik_AccruedClinicalTrialCostsCurrent Represents accrued clinical trial costs current. us-gaap_StockRepurchasedDuringPeriodValue Repurchase of common stock Revenue Benchmark [Member] Accounts Receivable [Member] Measurement Input, Weighted Average Cost of Capital [Member] Related to the weighted average cost of capital. us-gaap_IncreaseDecreaseInInventories Inventories Trading Symbol Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Nature of Operations [Text Block] Local Phone Number us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Exercised, shares (in shares) us-gaap_TableTextBlock Notes Tables Issuance of common stock from employee purchase plan us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited Forfeiture of restricted stock awards (in shares) us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Line of Credit Facility, Maximum Borrowing Capacity Vesting of restricted stock units (in shares) us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity Line of Credit Facility, Current Borrowing Capacity Vesting of restricted stock units us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Issuance of common stock for equity awards (in shares) Selling, general & administrative us-gaap_ProvisionForDoubtfulAccounts Amounts provided Issuance of common stock for equity awards Granted, shares (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Forfeited and canceled, shares (in shares) Veterinary [Member] Represents veterinary. Raw materials us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and stockholders’ equity Finished goods Work-in-process Reported Value Measurement [Member] UNITED STATES Retained earnings Research & development Accumulated other comprehensive loss DePuy Mitek Inc [Member] The DePuy Mitek Inc. Money Market Funds [Member] Measurement Input, Discount Rate [Member] Debt Disclosure [Text Block] us-gaap_InterestExpenseDebt Interest Expense, Debt, Total Changes in operating assets and liabilities: us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements us-gaap_OtherNoncashIncomeExpense Other Inventory Disclosure [Text Block] Lease liabilities Total lease liabilities, operating leases Schedule of Inventory, Current [Table Text Block] Present value of lease payments, operating leases us-gaap_OperatingLeaseLiability Operating lease liability- current us-gaap_OperatingLeaseLiabilityCurrent Less current portion included in Accrued expenses and other current liabilities, operating leases anik_DeferredIncomeTaxExpenseBenefitForeignAndDomesticNet Total deferred Amount of global net deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. Finance lease liability - current us-gaap_FinanceLeaseLiabilityCurrent Gross value Right-of-use assets us-gaap_FinanceLeasePrincipalPayments Payments made on finance leases us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Present value adjustment, operating leases Deferred income taxes Measurement Input Type [Axis] us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree 2025, operating leases Measurement Input Type [Domain] us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour 2026, operating leases us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive 2027, operating leases us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Thereafter Fair Value Measurement, Policy [Policy Text Block] us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths 2023, operating leases us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo 2024, operating leases Segment Reporting, Policy [Policy Text Block] Foreign Currency Transactions and Translations Policy [Policy Text Block] Other long-term assets us-gaap_ShareBasedCompensation Stock-based compensation expense Lessee, Leases [Policy Text Block] Useful life (Year) Finite-Lived Intangible Asset, Useful Life (Year) Operating expenses: Comprehensive Income, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Research and Development Expense, Policy [Policy Text Block] us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent Debt Securities, Available-for-Sale, Noncurrent us-gaap_Depreciation Depreciation, Total us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation Retirement of common stock for minimum tax withholdings (in shares) us-gaap_InventoryNoncurrent Other long-term assets us-gaap_AssetsCurrent Total current assets Share-Based Payment Arrangement [Policy Text Block] Change in fair value of contingent consideration anik_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentConsiderationPercent Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in fair value of contingent consideration. Change in tax rates and state apportionment Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to change in state apportionment. Legacy Anika Reporting Unit [Member] Information related to the legacy Anika reporting unit. Goodwill impairment anik_EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to goodwill impairment. Change in fair value of contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Payments of contingent consideration Amount of increase (decrease) in the value of a contingent consideration liability. Interest and other income (expense) , net Common stock, $.01 par value; 90,000 shares authorized, 14,625 and 14,441 shares issued and outstanding at December 31, 2022 and 2021, respectively Adjustments to reconcile net income (loss) to net cash provided by operating activities: Common stock, shares authorized (in shares) Common stock, shares issued (in shares) Common stock, par value (in dollars per share) anik_DefinedContributionPlanEmployerMatchingContributionAmount Defined Contribution Plan, Employer Matching Contribution, Amount Amount of employer matching contributions made by an employer to a defined contribution plan. us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Revenue from Contract with Customer [Policy Text Block] us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance (in shares) Statistical Measurement [Domain] Maximum [Member] Commitments and Contingencies, Policy [Policy Text Block] Minimum [Member] Product and Service [Axis] Product and Service [Domain] us-gaap_DeferredTaxAssetsNet Deferred tax assets Statistical Measurement [Axis] Preferred stock, $0.01 par value; 1,250 shares authorized, no shares issued and outstanding at December 31, 2022 and 2021, respectively us-gaap_NumberOfReportingUnits Number of Reporting Units Preferred stock, shares issued (in shares) Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] Property, Plant and Equipment Disclosure [Text Block] Geographical [Axis] Property, Plant and Equipment [Table Text Block] Geographical [Domain] Preferred stock, shares authorized (in shares) us-gaap_DeferredIncomeTaxLiabilities Deferred tax liabilities Europe [Member] Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Inventories Inventories Portion at Fair Value Measurement [Member] [Default] Preferred stock, par value (in dollars per share) Estimate of Fair Value Measurement [Member] us-gaap_InventoryValuationReserves Inventory Valuation Reserves Measurement Basis [Axis] Fair Value, Inputs, Level 3 [Member] Revenue from External Customers by Products and Services [Table Text Block] us-gaap_ForeignCurrencyTransactionGainLossBeforeTax Foreign Currency Transaction Gain (Loss), before Tax, Total Foreign currency exchange Fair Value Hierarchy and NAV [Domain] Customer [Axis] us-gaap_DeferredTaxAssetsInventory Inventory reserves Customer [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value Hierarchy and NAV [Axis] Accrued expenses Estimated useful life (Year) Property, Plant and Equipment, Useful Life (Year) Construction in Progress [Member] Cash flows from operating activities: Revenue [Policy Text Block] Statement [Line Items] Accounts Receivable Allowance for credit losses us-gaap_NumberOfOperatingSegments Number of Operating Segments Furniture and Fixtures [Member] us-gaap_AccountsReceivableNetCurrent Net balance, end of the year us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Stock-based compensation expense Compensation accrual Accounts receivable, net Additional paid-in-capital AOCI Attributable to Parent [Member] Stockholders’ equity: Leasehold Improvements [Member] Property, Plant and Equipment, Policy [Policy Text Block] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Domain] Tax credits Net operating loss carry forwards Current assets: Fair Value Disclosures [Text Block] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Inventory, Policy [Policy Text Block] Exchange rate impact on cash us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Decrease in cash and cash equivalents us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash used by financing activities Commitments and contingencies (Note 12) us-gaap_OperatingIncomeLoss (Loss) income from operations us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash provided by operating activities Prepaid expenses and other current assets us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash (used in) provided by investing activities us-gaap_DeferredTaxLiabilities Net deferred tax liabilities us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets Acquisition-related intangible asset us-gaap_GrossProfit Gross profit Cost of revenue Deferred tax liability Provision for inventory anik_IncreaseDecreaseInLeaseLiabilities Operating lease liabilities The increase (decrease) during the reporting period in the lease liabilities. us-gaap_ContractWithCustomerLiability Contract with Customer, Liability, Total Accounting Standards Update 2016-02 [Member] us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings Deferred Tax Liabilities, Undistributed Foreign Earnings Investment, Policy [Policy Text Block] us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities Payment for Contingent Consideration Liability, Financing Activities Payments of contingent consideration Accounting Standards Update [Domain] Concentration Risk, Credit Risk, Policy [Policy Text Block] us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Cash paid for tax withheld on vested restricted stock awards us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment Depreciation Accounting Standards Update [Axis] us-gaap_ProductWarrantyAccrual Standard and Extended Product Warranty Accrual, Ending Balance Accrued Expenses and Other Current Liabilities [Member] Related to accrued expenses and other current liabilities. Liabilities [Member] Related to liabilities. us-gaap_CostsAndExpenses Total operating expenses Proceeds from employee stock purchase program Retained Earnings [Member] anik_InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal Total The aggregate carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of raw materials, work in process and finished goods. Revenue Revenue from Contract with Customer, Excluding Assessed Tax Proceeds from exercises of equity awards us-gaap_CurrentStateAndLocalTaxExpenseBenefit State us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit State us-gaap_CurrentForeignTaxExpenseBenefit Foreign us-gaap_DeferredForeignIncomeTaxExpenseBenefit Foreign Additional Paid-in Capital [Member] us-gaap_CurrentFederalTaxExpenseBenefit Federal Common Stock [Member] us-gaap_DeferredFederalIncomeTaxExpenseBenefit Federal Equity Components [Axis] Equity Component [Domain] us-gaap_CurrentIncomeTaxExpenseBenefit Total current Foreign us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest (Loss) income before income taxes Domestic ICFR Auditor Attestation Flag Ministry of Economic Affairs and Finance, Italy [Member] anik_SharebasedCompensationPerformanceSharesMeasuredByBusinessTargets Share-based Compensation, Performance Shares Measured by Business Targets The percent of performance shares in a share based compensation arrangement measured by business targets. us-gaap_LineOfCredit Long-Term Line of Credit, Total Parcus Medical [Member] Related to Parcus Medical. anik_SharebasedCompensationPerformanceSharesMeasuredByFinancialTargets Share-based Compensation, Performance Shares Measured by Financial Targets The percent of performance shares in a share based compensation arrangement measured by financial targets. The 2017 Plan [Member] Represents the Anika Therapeutics, Inc. Omnibus Incentive Plan (the “2017 Plan”). State and Local Jurisdiction [Member] Income Tax Authority, Name [Axis] Right-of-use assets anik_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets Amount of operating lease, right of use assets acquired at the acquisition date. Income Tax Authority, Name [Domain] Internal Revenue Service (IRS) [Member] Income Tax Authority [Axis] Income Tax Authority [Domain] Domestic Tax Authority [Member] Arthrosurface [Member] Related to Arthrosurface. Foreign Tax Authority [Member] us-gaap_RepaymentsOfLongTermDebt Repayments of long-term debt Equipment [Member] Revenue from Contract with Customer [Text Block] Document Annual Report Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Entity Incorporation, State or Country Code us-gaap_UnrecognizedTaxBenefits Unrecognized Tax Benefits, Ending Balance Accounting Policies [Abstract] Significant Accounting Policies [Text Block] us-gaap_OpenTaxYear Open Tax Year Document Transition Report Selling, General and Administrative Expenses [Member] Entity Interactive Data Current us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries Amounts recovered Security Exchange Name Title of 12(b) Security us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs Amounts written off Proceeds from long-term debt Cost of Sales [Member] Research and Development Expense [Member] us-gaap_ProceedsFromLongTermLinesOfCredit Proceeds from Long-term Lines of Credit Income Statement Location [Axis] Income Statement Location [Domain] Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Auditor Name Accrued expenses and other current liabilities Total Auditor Firm ID Auditor Location Share based awards (in shares) Research Tax Credit Carryforward [Member] us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) Diluted (in shares) Diluted shares used in the calculation of EPS (in shares) Acquisitions of Parcus Medical and Arthrosurface [Member] Represents acquisitions of Parcus Medical and Arthrosurface. Tax Credit Carryforward [Axis] Tax Credit Carryforward, Name [Domain] Joint Preservation and Restoration [Member] Represents Joint Preservation and Restoration. us-gaap_OperatingLossCarryforwards Operating Loss Carryforwards Asset Class [Axis] Asset Class [Domain] Statement [Table] Statement of Financial Position [Abstract] us-gaap_EarningsPerShareDiluted Diluted (in dollars per share) Basic (in shares) Stock compensation anik_DeferredTaxLiabilitiesRightOfUseAsset Right of use asset Amount of deferred tax liability attributable to taxable temporary differences from right of use asset. Accounts Payable and Accrued Liabilities Disclosure [Text Block] Lease liability Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liability. us-gaap_EffectiveIncomeTaxRateContinuingOperations Effective income tax rate Business Acquisition [Axis] us-gaap_EarningsPerShareBasic Basic (in dollars per share) Business Acquisition, Acquiree [Domain] Valuation allowance us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Statement of Cash Flows [Abstract] us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High Statement of Stockholders' Equity [Abstract] Income Statement [Abstract] Schedule of Accrued Liabilities [Table Text Block] Interest on finance lease liabilities Finance lease amortization of right-of-use assets Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent Financing leases us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits Federal, state and foreign tax credits State tax expense, net of federal benefit us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Fair Value, Assets Measured on Recurring Basis [Table Text Block] Deferred consideration Amount of deferred consideration by the acquirer as part of consideration transferred in a business combination. us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1 Financing leases (Year) Cash flows from financing activities: Contingent Consideration [Member] Represents the information pertaining to the contingent consideration. anik_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseLiabilities Lease liabilities Amount of operating lease right-of-use liabilities assumed at the acquisition date. Other long-term liabilities Statutory federal income tax rate anik_APICSharebasedPaymentArrangementIncreaseDecreaseForCostRecognitionBenefit Stock-based compensation expense Amount of increase (decrease) to additional paid-in capital (APIC) for recognition of cost (benefit) for award under share-based payment arrangement. Net assets acquired us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet Estimated total purchase consideration us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet us-gaap_StockholdersEquity Total stockholders’ equity Balance Balance Non-cash operating lease cost us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther Other long-term liabilities us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired Acquisition of Parcus Medical and Arthrosurface, net of cash acquired Class of Stock [Axis] us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities Deferred tax liabilities Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Cash consideration us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable Accounts payable, accrued expenses and other current liabilities Property and equipment, net us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment Other long-term assets us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets EX-101.PRE 13 anik-20221231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 14 overview.jpg begin 644 overview.jpg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end GRAPHIC 15 perf.jpg begin 644 perf.jpg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end XML 16 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Document And Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2022
Mar. 08, 2023
Jun. 30, 2022
Document Information [Line Items]      
Entity Central Index Key 0000898437    
Entity Registrant Name Anika Therapeutics, Inc.    
Amendment Flag false    
Current Fiscal Year End Date --12-31    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2022    
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2022    
Document Transition Report false    
Entity File Number 001-14027    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 04-3145961    
Entity Address, Address Line One 32 Wiggins Avenue    
Entity Address, City or Town Bedford    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 01730    
City Area Code 781    
Local Phone Number 457-9000    
Title of 12(b) Security Common Stock, par value $0.01 per share    
Trading Symbol ANIK    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Entity Shell Company false    
Entity Public Float     $ 321,805,229
Entity Common Stock, Shares Outstanding   14,632,910  
Auditor Firm ID 34    
Auditor Name Deloitte & Touche LLP    
Auditor Location Boston, Massachusetts    
XML 17 R2.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 86,327 $ 94,386
Accounts receivable, net 34,627 29,843
Inventories 39,765 36,010
Prepaid expenses and other current assets 8,828 8,289
Total current assets 169,547 168,528
Property and equipment, net 48,279 47,602
Right-of-use assets 30,696 20,957
Other long-term assets 17,219 20,285
Deferred tax assets 1,449 0
Intangible assets, net 74,599 82,382
Goodwill 7,339 7,781
Total assets 349,128 347,535
Current liabilities:    
Accounts payable 9,074 7,633
Accrued expenses and other current liabilities 18,840 17,847
Contingent consideration 0 4,315
Total current liabilities 27,914 29,795
Other long-term liabilities 398 1,258
Deferred tax liability 6,436 10,157
Lease liabilities 28,817 19,240
Commitments and contingencies (Note 12)
Stockholders’ equity:    
Preferred stock, $0.01 par value; 1,250 shares authorized, no shares issued and outstanding at December 31, 2022 and 2021, respectively 0 0
Common stock, $.01 par value; 90,000 shares authorized, 14,625 and 14,441 shares issued and outstanding at December 31, 2022 and 2021, respectively 146 144
Additional paid-in-capital 81,141 67,081
Accumulated other comprehensive loss (6,443) (5,718)
Retained earnings 210,719 225,578
Total stockholders’ equity 285,563 287,085
Total liabilities and stockholders’ equity $ 349,128 $ 347,535
XML 18 R3.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Balance Sheets (Parentheticals) - $ / shares
shares in Thousands
Dec. 31, 2022
Dec. 31, 2021
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 1,250 1,250
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 90,000 90,000
Common stock, shares issued (in shares) 14,625 14,441
Common stock, shares outstanding (in shares) 14,625 14,441
XML 19 R4.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenue $ 156,236 $ 147,794 $ 130,457
Cost of revenue 62,660 64,851 61,431
Gross profit 93,576 82,943 69,026
Operating expenses:      
Research & development 28,182 27,327 23,431
Selling, general & administrative 84,794 74,096 60,063
Goodwill impairment charge 0 0 42,520
Change in fair value of contingent consideration 0 (21,095) (28,666)
Total operating expenses 112,976 80,328 97,348
(Loss) income from operations (19,400) 2,615 (28,322)
Interest and other income (expense) , net 654 (188) (302)
(Loss) income before income taxes (18,746) 2,427 (28,624)
Benefit from for income taxes (3,887) (1,707) (4,642)
Net (loss) income $ (14,859) $ 4,134 $ (23,982)
Basic (in dollars per share) $ (1.02) $ 0.29 $ (1.69)
Diluted (in dollars per share) $ (1.02) $ 0.28 $ (1.69)
Basic (in shares) 14,561 14,401 14,222
Diluted (in shares) 14,561 14,634 14,222
Net (loss) income $ (14,859) $ 4,134 $ (23,982)
Foreign currency translation adjustment (725) (1,176) 1,356
Comprehensive (loss) income $ (15,584) $ 2,958 $ (22,626)
XML 20 R5.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Stockholders' Equity - USD ($)
shares in Thousands
Restricted Stock Units (RSUs) [Member]
Common Stock [Member]
Restricted Stock Units (RSUs) [Member]
Additional Paid-in Capital [Member]
Restricted Stock Units (RSUs) [Member]
Retained Earnings [Member]
Restricted Stock Units (RSUs) [Member]
AOCI Attributable to Parent [Member]
Restricted Stock Units (RSUs) [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Total
Balance (in shares) at Dec. 31, 2019           14,308        
Balance at Dec. 31, 2019           $ 143,000 $ 48,707,000 $ 245,426,000 $ (5,898,000) $ 288,378,000
Issuance of common stock for equity awards (in shares)           123        
Issuance of common stock for equity awards           $ 1,000 1,523,000 0 0 1,524,000
Vesting of restricted stock units (in shares) 54                  
Vesting of restricted stock units $ 0 $ 0 $ 0 $ 0 $ 0          
Forfeiture of restricted stock awards (in shares)           (9)        
Forfeiture of restricted stock awards           $ 0 0 0 0 0
Stock-based compensation expense           $ 0 5,386,000 0 0 5,386,000
Retirement of common stock for minimum tax withholdings (in shares)           (8)        
Retirement of common stock for minimum tax withholdings           $ 0 (262,000) 0 0 (262,000)
Repurchase of common stock (in shares)           (139)        
Repurchase of common stock           $ (1,000) 1,000 0 0 0
Net (loss) income           0 0 (23,982,000) 0 (23,982,000)
Other comprehensive income (loss)           $ 0 0 0 1,356,000 1,356,000
Balance (in shares) at Dec. 31, 2020           14,329        
Balance at Dec. 31, 2020           $ 143,000 55,355,000 221,444,000 (4,542) 272,400,000
Issuance of common stock for equity awards (in shares)           32        
Issuance of common stock for equity awards           $ 0 1,128,000 0 0 1,128,000
Vesting of restricted stock units (in shares)           92        
Vesting of restricted stock units           $ 1,000 (1,000) 0 0 0
Stock-based compensation expense           $ 0 11,085,000 0 0 11,085,000
Retirement of common stock for minimum tax withholdings (in shares)           (12)        
Retirement of common stock for minimum tax withholdings           $ 0 (486,000) 0 0 (486,000)
Net (loss) income           0 0 4,134,000 0 4,134,000
Other comprehensive income (loss)           $ 0 0 0 (1,176,000) (1,176,000)
Balance (in shares) at Dec. 31, 2021           14,441        
Balance at Dec. 31, 2021           $ 144,000 67,081,000 225,578,000 (5,718,000) 287,085,000
Issuance of common stock for equity awards           $ 0 16,000 0 0 16,000
Vesting of restricted stock units (in shares)           184        
Vesting of restricted stock units           $ 2,000 (2,000) 0 0 0
Stock-based compensation expense           0 14,315,000 0 0 14,315,000
Retirement of common stock for minimum tax withholdings           0 (934,000) 0 0 (934,000)
Net (loss) income           0 0 (14,859,000) 0 (14,859,000)
Other comprehensive income (loss)           0 0 0 (725,000) (725,000)
Issuance of common stock from employee purchase plan           $ 0 665,000 0 0 665,000
Balance (in shares) at Dec. 31, 2022           14,625        
Balance at Dec. 31, 2022           $ 146,000 $ 81,141,000 $ 210,719,000 $ (6,443,000) $ 285,563,000
XML 21 R6.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Cash flows from operating activities:      
Net (loss) income $ (14,859,000) $ 4,134,000 $ (23,982,000)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:      
Depreciation 6,704,000 6,480,000 6,083,000
Amortization of acquisition related intangible assets 7,783,000 7,837,000 7,381,000
Amortization of acquisition related inventory step-up 0 6,465,000 11,082,000
Non-cash operating lease cost 1,850,000 1,708,000 1,531
Goodwill impairment charge 0 0 42,520,000
Change in fair value of contingent consideration 0 (21,095,000) (28,666,000)
Loss on disposal of fixed assets 0 993,000 265,000
Loss on impairment of intangible asset 0 600,000 2,439,000
Stock-based compensation expense 14,315,000 11,085,000 5,386,000
Deferred income taxes (5,270,000) (1,766,000) (3,543,000)
Provision for doubtful accounts 378,000 64,000 549,000
Provision for inventory 5,329,000 6,628,000 5,490,000
Other 0 (18,000) (12,000)
Changes in operating assets and liabilities:      
Accounts receivable (5,630,000) (6,216) 5,855,000
Inventories (6,873,000) (6,619,000) (14,177,000)
Prepaid expenses, other current and long-term assets (792,000) 1,424,000 (1,783,000)
Accounts payable 1,965,000 (1,100,000) 822,000
Operating lease liabilities (1,485,000) (1,626,000) (1,439,000)
Accrued expenses, other current and long-term liabilities (443,000) 3,510,000 (142,000)
Income taxes 1,437,000 (1,311,000) (2,072,000)
Payments of contingent consideration 0 (2,780,000) (522,000)
Net cash provided by operating activities 4,409,000 8,397,000 13,065,000
Cash flows from investing activities:      
Acquisition of Parcus Medical and Arthrosurface, net of cash acquired 0 (476,000) (94,601,000)
Proceeds from maturities of investments 0 2,501,000 45,000,000
Purchases of investments 0 0 (20,035.000)
Purchases of property and equipment (7,486,000) (5,143,000) (1,628,000)
Net cash (used in) provided by investing activities (7,486,000) (3,118,000) (71,264,000)
Cash flows from financing activities:      
Payments made on finance leases (284,000) (201,000) (208,000)
Proceeds from long-term debt 0 0 50,000,000
Repayments of long-term debt 0 0 (50,350,000)
Proceeds from employee stock purchase program 665,000 0 0
Cash paid for tax withheld on vested restricted stock awards (934,000) (486,000) (262,000)
Proceeds from exercises of equity awards 16,000 1,128,000 1,524,000
Payments of contingent consideration (4,315,000) (7,220,000) (4,478,000)
Net cash used by financing activities (4,852,000) (6,779,000) (3,774,000)
Exchange rate impact on cash (130,000) 69,000 327,000
Decrease in cash and cash equivalents (8,059,000) (1,431,000) (61,646,000)
Cash and cash equivalents at beginning of period 94,386,000 95,817,000 157,463,000
Cash and cash equivalents at end of period 86,327,000 94,386,000 95,817,000
Supplemental disclosure of cash flow information:      
Cash paid for income taxes, net of refunds 106,000 1,233,000 993,000
Right-of-use assets obtained in exchange for operating lease liabilities 2,471,000 2,392,000  
Purchases of property and equipment included in accounts payable and accrued expenses 108,000 15,000 17,000
Consideration for acquisitions included in accounts payable and accrued expenses 0 0 476,000
Contingent consideration fair value on acquisition date 0 0 69,076,000
Accounting Standards Update 2016-02 [Member]      
Supplemental disclosure of cash flow information:      
Right-of-use assets obtained in exchange for operating lease liabilities $ 11,703,000 $ 220,000 $ 0
XML 22 R7.htm IDEA: XBRL DOCUMENT v3.22.4
Note 1 - Nature of Business
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Nature of Operations [Text Block]

1. Nature of Business

 

Anika Therapeutics, Inc. (“the Company”) is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care, including in the areas of osteoarthritis (“OA”) pain management, regenerative solutions, sports medicine and bone preserving joint solutions.

 

In early 2020, the Company expanded its overall technology platform through its strategic acquisitions of Parcus Medical, LLC (“Parcus Medical”), a sports medicine implant and instrumentation company, and Arthrosurface Inc. (“Arthrosurface”), a company specializing in less invasive, bone preserving partial and total joint replacement solutions. These acquisitions broadened the Company's product portfolio, developed over its 30 years of expertise in hyaluronic acid technology, into joint preservation and restoration, added higher-growth revenue streams, increased its commercial capabilities, diversified its revenue base, and expanded its product pipeline and research and development expertise.

 

The Company is subject to risks common to companies in the life sciences industry including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with U.S. Food and Drug Administration (“FDA”) and foreign regulations and approval requirements, as well as the ability to grow the Company’s business through appropriate commercial strategies.

 

Since the global COVID pandemic began in 2020, there also continues to be increased volatility and uncertainty in the global macroeconomic environment, including staffing shortages, supply chain disruption, inflation and other direct and indirect impacts of the pandemic.
XML 23 R8.htm IDEA: XBRL DOCUMENT v3.22.4
Note 2 - Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Significant Accounting Policies [Text Block]

2. Summary of Significant Accounting Policies

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America (“US GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Principles of Consolidation

 

The accompanying consolidated financial statements include the accounts of Anika Therapeutics, Inc. and its wholly owned subsidiaries, Anika Securities, Inc., Anika Therapeutics S.r.l. (“Anika S.r.l.”), Anika Therapeutics Limited, Parcus Medical and Arthrosurface. All intercompany balances and transactions have been eliminated in consolidation.

 

Foreign Currency Translation

 

The functional currency of Anika S.r.l. is the Euro, and the functional currency of Anika Therapeutics Limited is the British Pound Sterling. Assets and liabilities of the foreign subsidiaries are translated using the exchange rate existing on each respective balance sheet date. Revenues and expenses are translated using the average exchange rates for the period. The translation adjustments resulting from this process are included in stockholders’ equity as a component of accumulated other comprehensive income (loss) which resulted in a gain (loss) from foreign currency translation of ($0.7) million, ($1.2) million, and $1.3 million for the years ended December 31, 2022, 2021, and 2020, respectively.

 

Gains and losses resulting from foreign currency transactions are recognized in the consolidated statements of operations. Recorded balances that are denominated in a currency other than the functional currency are remeasured to the functional currency using the exchange rate at the balance sheet date and gains or losses are recorded in the statements of operations. The Company recognized a gain (loss) from foreign currency transactions of ($0.5) million, ($0.4) million, and $0.3 million during the years ended December 31, 2022, 2021, and 2020, respectively

 

Accounts Receivable

 

The Company estimates an allowance for credit losses with its accounts receivable resulting from the inability of its customers to make required payments, which is included in selling, general and administrative expenses in the accompanying consolidated statements of operations. In determining the adequacy of the allowance, management specifically analyzes individual accounts receivable, historical bad debts, customer concentrations, customer creditworthiness, current and reasonable and supportable forecasts of future economic conditions, accounts receivable aging trends, and changes in the Company’s customer payment terms.

 

The components of the Company’s accounts receivables are as follows:

 

  

As of December 31,

 
  

2022

  

2021

 

Accounts Receivable

 $36,235  $31,285 

Allowance for credit losses

  1,608   1,442 

Net balance, end of the year

  34,627   29,843 

 

A summary of activity in the allowance for credit losses is as follows:

 

  

As of December 31,

 
  

2022

  

2021

  

2020

 

Balance, beginning of the year

 $1,442  $1,523  $962 

Amounts provided

  554   156   635 

Amounts recovered

  (180)  (92

)

  (86

)

Amounts written off

  (158)  (73

)

  (78

)

Translation adjustments

  (50)  (72)  90 

Balance, end of the year

 $1,608  $1,442  $1,523 

 

Revenue Recognition

 

Pursuant to Accounting Standard Codification 606, Revenue from Contracts with Customers (“ASC 606”), the Company recognizes revenue when a customer obtains control of promised goods or services. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are capable of being distinct or distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.

 

Revenue

 

The Company generates sales principally through three types of customers: (i) commercial partnerships (ii) hospitals and ambulatory surgical centers (“ASCs”), and (iii) distributors, referred to as the distribution model.

 

For commercial partnership sales, the Company sells its products directly to these partners, who perform most of the downstream sales and marketing activities to customers and end-users. These arrangements may include the grant of certain licenses, performance of development services, and the supply of product. The Company’s largest such customer, DePuy Synthes Mitek Sports Medicine, a division of DePuy Orthopedics, Inc., part of the Johnson & Johnson Medical Companies (“Mitek”), represented 43%, 45% and 49% of total revenues for the years-ended December 31, 2022, 2021 and 2020 respectively. The Company completed the performance obligations related to granted licenses and development services under the agreements with Mitek prior to 2016 and has no remaining material performance obligations. The Company recognizes revenue from product sales when the customer obtains control of the Company’s product, which typically occurs upon shipment to the customer. Commercial partnership agreements may also include sales-based royalties and milestones. As the Company considered the license to be the predominant item to which the royalties relate for these agreements, sales-based royalties and milestones are only recognized when the later of the underlying sale occurs or the performance obligation to which the sales-based royalty has been satisfied (or partially satisfied). This is generally in the same period that the Company’s licensees complete their product sales in their territory, for which the Company is contractually entitled to a percentage-based royalty. The Company records royalty revenues based on estimated net sales of licensed products as reported to the Company by its commercial partners. The differences between actual and estimated royalty revenues have not been material and are typically adjusted in the following quarter when the actual amounts are known. Revenue from sales-based royalties is included in revenue in the consolidated statement of operations. The Company’s certain supply agreements represent a promise to deliver products at the customer’s discretion that are considered distributor options. The Company assesses if these options provide a material right to the licensee, and if so, they are accounted for as separate performance obligations. Substantially all of the Company’s supply agreements do not provide options that are considered material rights.

 

For sales to hospitals and ASCs, which generally pairs in-house sales representatives with local or regional distributors, the inventory is generally consigned so that products are available when needed for surgical procedures. No revenue is recognized upon the placement of inventory into consignment, as the Company retains the ability to control the inventory. Revenue is typically recognized as of the date of surgical implantation of the product.

 

For distributor sales, the Company sells its products principally to distributors, generally outside the United States, who subsequently resell the products to sub-distributors and health care providers, among others. The Company recognizes revenue from product sales when the distributor obtains control of the Company’s product, which typically occurs upon shipment to the distributor, in return for agreed-upon, fixed-price consideration. Performance obligations are generally settled quickly after purchase order acceptance; therefore, the value of unsatisfied performance obligations at the end of any reporting period is generally insignificant. The Company sells to a diversified base of distributors and, therefore, believes there is no material concentration of credit risk.

 

The Company’s payment terms are consistent with prevailing practice in the respective markets in which the Company does business. Most of the Company’s customers make payments based on contract terms, which are not affected by contingent events that could impact the transaction price. Payment terms fall within the one-year guidance for the practical expedient, which allows the Company to forgo adjustment of the contractual payment amount of consideration for the effects of a significant financing component.

 

Some of the Company’s distributor agreements have volume-based discounts with tiered pricing which are generally prospective in nature. These prospective discounts together with any free-of-charge sample units offered are evaluated as potential material rights. If the prospective discounts or free-of-charge sample units are considered material rights, these would be separate performance obligations and a portion of the sales transaction price is allocated to the material right. Revenue allocated to the material right is recognized when the additional goods are transferred to the customer or when the option expires. During 2022 and 2021, the consideration allocated to material rights was not significant.

 

The Company receives payments from its customers based on billing schedules established in each contract. Up-front payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when its right to consideration is unconditional. Deferred revenue was $0 and $1.0 million as of December 31, 2022 and 2021, respectively.

 

Generally, customer contracts contain Free on Board (“FOB”) or Ex-Works shipping point terms where the customer pays the shipping company directly for all shipping and handling costs. In those contracts in which the Company pays for the shipping and handling, the associated costs are generally recorded along with the product sale at the time of shipment in cost of revenue when control over the products has transferred to the customer. Value-add and other taxes collected by the Company concurrently with revenue-producing activities are excluded from revenue. The Company’s general product warranty does not extend beyond an assurance that the product or services delivered will be consistent with stated contractual specifications, which does not create a separate performance obligation. The Company recognizes the incremental costs of obtaining contracts as an expense when incurred as the amortization period of the assets that the Company otherwise would have recognized is one year or less in accordance with the practical expedient in paragraph ASC 340-40-25-4. These costs are included in selling, general and administrative expenses.

 

Licensing, Milestone and Contract Revenue

 

The agreements with Mitek include variable consideration such as contingent development and regulatory milestones. Since 2016, there have been no remaining regulatory milestones related to the Mitek agreements. In general, variable consideration is included in the transaction price only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable to occur.

 

Cash and Cash Equivalents

 

The Company considers only those investments which are highly liquid, readily convertible to cash, and that mature within 90 days from the date of purchase to be cash equivalents. The Company’s cash equivalents consist of money market funds.

 

Investments

 

All of the Company’s investments are classified as available-for-sale which consist of U.S. treasury bills and are carried at fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income (loss), net of related income taxes. For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. Realized gains and losses on the sale of investments are recorded in interest and other income, net. Interest is recorded when earned. Investments with original maturities greater than approximately three months and remaining maturities less than one year are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments. The Company had no investments as of December 31, 2022 or December 31, 2021.

 

All of the Company’s investments are subject to a periodic impairment review. For available-for-sale debt securities in an unrealized loss position, the Company first assesses whether (i) the Company intends to sell, or (ii) it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either case is affirmative, any previously recognized allowances are charged-off and the security's amortized cost is written down to fair value through earnings. If neither case is affirmative, the security is evaluated to determine whether the decline in fair value has resulted from credit losses or other factors.

 

Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income. Adjustments to the allowance are reported in the consolidated statement of operations as a component of credit loss expense. Available-for-sale securities are charged-off against the allowance or, in the absence of any allowance, written down through earnings when deemed uncollectible by management or when either of the criteria regarding intent or requirement to sell is met.

 

During the years ended  December 31, 2022, 2021 and 2020, the Company did not record any impairment charges on its available-for-sale securities because it is not more likely than not that the Company will be required to sell these securities before the recovery of their cost basis.

 

Concentration of Credit Risk

 

The Company has no significant off-balance sheet risks related to foreign exchange contracts, option contracts, or other foreign hedging arrangements. The Company’s cash equivalents and investments are held with two major international financial institutions.

 

The Company, by policy, routinely assesses the financial strength of its customers. As a result, the Company believes that its accounts receivable credit risk exposure is limited.

 

As of December 31, 2022 and 2021, Mitek represented 47% and 41%, respectively, of the Company’s accounts receivable balance. No other single customer accounted for more than 10% of accounts receivable in either period.

 

Inventories

 

Inventories are primarily stated at the lower of standard cost and net realizable value, with cost determined using the first-in, first-out method. Work-in-process and finished goods inventories include materials, labor, and certain manufacturing overhead. Manufacturing variances attributable to abnormally low production are expensed in the period incurred.  

 

The Company’s policy is to write down inventory when conditions exist that suggest inventory may be in excess of anticipated demand or is obsolete based upon assumptions about future demand for the Company’s products and market conditions. The Company regularly evaluates the ability to realize the value of inventory based on a combination of factors including, but not limited to, historical usage rates, forecasted sales or usage, product end of life dates, and estimated current or future market values. Purchasing requirements and alternative usage avenues are explored within these processes to mitigate inventory exposure.

 

When recorded, inventory write-downs are intended to reduce the carrying value of inventory to its net realizable value. If actual demand for the Company’s products deteriorates, or if market conditions are less favorable than those projected, additional inventory write-downs may be required. Other long-term assets include inventory expected to remain on hand beyond one year.

 

Leases

 

At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the circumstances present and evaluates whether the lease is an operating lease or a finance lease at the commencement date. Operating and finance leases with a term greater than one year are recognized on the consolidated balance sheet as right-of-use assets, lease liabilities, and, if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease in the lease term where it is reasonably certain that it will exercise these options. Operating and finance lease liabilities and the corresponding right-of-use assets are recorded based on the present values of lease payments over the lease terms. The Company elected an accounting policy to combine the non-lease components (which include common area maintenance, taxes and insurance) with the related lease component. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a similar economic environment. Variable payments that do not depend on a rate or index are not included in the lease liability and are recognized as incurred. Lease contracts do not include residual value guarantees nor do they include restrictions or other covenants. Certain adjustments to the right-of-use assets may be required for items such as initial direct costs paid, incentives received or lease prepayments. If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure the finance and operating lease liabilities by using revised inputs as of the reassessment date, and adjust the right-of-use asset. Operating lease expense is recognized on a straight-line basis over the lease term. Finance lease expense is recognized based on the effective-interest method over the lease term.

 

Property and Equipment

 

Property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives, which are typically:

 

Asset

 

Estimated useful life
(in years)

 

Computer equipment and software

  3   -   10 

Furniture and fixtures

  5   -   7 

Equipment

  5   -   20 

Leasehold improvements

     

Shorter of useful life or term of lease

     

 

Maintenance and repairs are charged to expense when incurred; additions and improvements are capitalized. Fully depreciated assets are retained in the accounts until they are no longer used and no further charge for depreciation is made in respect of these assets. When an item is sold, retired or removed from service, the cost and related accumulated depreciation is relieved, and the resulting gain or loss, if any, is recognized in income.

 

Construction-in-process assets are stated at cost, which includes the cost of construction and other direct costs attributable to the construction. Construction-in-process assets are not depreciated until such time as the relevant assets are completed and put into use.

 

Goodwill and IPR&D Assets

 

Goodwill is the amount by which the purchase price of acquired net assets in a business combination exceeded the fair values of net identifiable assets on the date of acquisition. Acquired In-Process Research and Development (“IPR&D”) represents the fair value assigned to research and development assets that the Company acquires that have not been completed at the date of acquisition or are pending regulatory approval in certain jurisdictions. The value assigned to the acquired IPR&D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenue from the projects, and discounting the net cash flows to present value.  

 

Goodwill and IPR&D are not amortized but are evaluated for impairment annually or more frequently if events or changes in circumstances indicate that the asset might be impaired. The goodwill impairment assessment is performed by reporting unit. A reporting unit is the operating segment, or a business one level below that operating segment (the component level) if discrete financial information is prepared and regularly reviewed by segment management. However, components are aggregated as a single reporting unit if they have similar economic characteristics. The Company has two reporting units: the legacy Anika reporting unit, which specializes in therapies based on its hyaluronic acid, or HA, technology platform, and a newly formed reporting unit established in 2020 upon the acquisitions of Parcus Medical and Arthrosurface. Factors that the Company considers important, on an overall company basis, that could trigger an impairment review include significant underperformance relative to historical or projected future operating results, significant changes in the Company’s use of the acquired assets or the strategy for its overall business, significant negative industry or economic trends, a significant decline in the Company’s stock price for a sustained period, or a reduction of its market capitalization relative to net book value.

 

Under U.S. GAAP, the Company has the option to perform a qualitative assessment to determine if it is necessary to perform the impairment test. If the Company concludes, based on a qualitative assessment, it is not more likely than not that the Goodwill or the IPR&D asset is impaired, the Company is not required to perform the quantitative test. The Company has an unconditional option to bypass the qualitative assessment in any period and proceed directly to the quantitative impairment test.

 

To conduct quantitative impairment tests of goodwill, the fair value of the reporting unit is compared to its carrying value. If the reporting unit’s carrying value exceeds its fair value, the Company records an impairment loss to the extent that the carrying value of goodwill exceeds its implied fair value, not to exceed the recorded amount of goodwill. The Company recorded a non-cash goodwill impairment charge with respect to the newly formed reporting unit amounted to $42.5 million for the year ended December 31, 2020. Please see Note 8, Goodwill for further details.

 

The Company performed a qualitative annual assessment for impairment of the remaining goodwill with respect to legacy Anika reporting unit as of November 30, 2022, including consideration of (i) general macroeconomic factors, (ii) industry and market conditions, and (iii) the extent of the excess of the fair value over the carrying value indicated in prior impairment testing. Accordingly, the Company determined it was not more likely than not that the fair value of the legacy Anika reporting unit is less than its carrying amount and thus goodwill was not impaired as of November 30, 2022.

 

To conduct impairment tests of IPR&D, the fair value of the IPR&D project is compared to its carrying value. If the carrying value exceeds its fair value, the Company records an impairment loss to the extent that the carrying value of the IPR&D project exceeds its fair value. The Company estimates the fair value for IPR&D using the income approach, which is based on the Multi-Period Excess Earnings Method (“MPEEM”). MPEEM measures economic benefit indirectly by calculating the income attributable to an asset after appropriate returns are paid to complementary assets used in conjunction with the subject asset to produce the earnings associated with the subject asset, commonly referred to as contributory asset charges. This approach incorporates significant estimates and assumptions related to the forecasted results including revenues, expenses, expected economic life of the asset, contributory asset charges and discount rates to estimate future cash flows.

 

Long-Lived Assets

 

Long-lived assets primarily include property and equipment and intangible assets with finite lives. The Company’s intangible assets are comprised of purchased developed technologies, patents, trade names, customer relationships and distributor relationships. These intangible assets are carried at cost, net of accumulated amortization. Amortization is recorded on a straight-line basis over the intangible assets' useful lives, which range from approximately five to sixteen years. The Company reviews long-lived assets for impairment when events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful lives of those assets are no longer appropriate. Each impairment test is based on a comparison of the undiscounted cash flows to the recorded value of the asset. If impairment is indicated, the asset is written down to its estimated fair value based on a discounted cash flow analysis.

 

In determining the useful lives of intangible assets, the Company considers the expected use of the assets and the effects of obsolescence, demand, competition, anticipated technological advances, changes in surgical techniques, market influences and other economic factors. For technology-based intangible assets, the Company considers the expected life cycles of products, absent unforeseen technological advances, which incorporate the corresponding technology.

 

Fair Value Measurements

 

Fair value is defined as the price that would be received from selling an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of non-performance. The accounting standard establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

 

A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Three levels of inputs that may be used to measure fair value are:

 

 

•

Level 1 – Valuation is based upon quoted prices for identical instruments traded in active markets. Level 1 instruments include securities traded on active exchange markets, such as the New York Stock Exchange.

 

 

•

Level 2 – Valuation is based upon quoted prices, unadjusted, for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are directly observable in the market.

 

 

•

Level 3 – Valuation is generated from model-based techniques that use significant assumptions not observable in the market. These unobservable assumptions reflect the Company’s own estimates of assumptions market participants would use in pricing the instrument.

 

The Company’s financial assets have been classified as Level 1. The Company’s financial assets (which include cash equivalents and investments) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third party pricing services. The Company’s financial liabilities have been classified as Level 3. The Company’s financial liabilities (which include contingent considerations as discussed in Note 4 – Fair Value Measurements) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing a third-party valuation specialist.

 

Research and Development

 

Research and development costs consist primarily of salaries and related expenses for personnel, clinical trial expenses and fees paid to outside consultants and outside service providers. Research and development costs are expensed as incurred.

 

Stock-Based Compensation

 

The Company has stock-based compensation plans under which it grants various types of equity-based awards, the cost of which is based on the grant-date fair value of the underlying award and recognized over the period during which an employee is required to provide service in exchange for the award, which is generally the vesting period.

 

For performance-equity awards with market-based conditions, compensation cost is measured at the date of the award and is recorded over the vesting period, regardless of the likelihood of achievement of the market-based performance criteria. For performance-based equity awards with financial and business milestone achievement targets, compensation cost is based on the probable outcome of the performance conditions. Changes to the probability assessment and the estimated shares expected to vest will result in adjustments to the related stock-based compensation expense that will be recorded in the period of the change. If the performance targets are not achieved, no compensation cost is recognized, and any previously recognized compensation cost is reversed.

 

See Note 14, Equity Incentive Plan, for a description of the types of stock-based awards granted, the compensation expense related to such awards, and detail of equity-based awards outstanding.

 

Income Taxes

 

We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets, or DTAs, and deferred tax liabilities, or DTLs, for the expected future tax consequences of events that have been included in the financial statements. Under this method, we determine DTAs and DTLs based on the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on DTAs and DTLs is recognized in income in the period that includes the enactment date.

 

We recognize DTAs to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, carryback potential if permitted under the tax law, and results of recent operations.

 

We record uncertain tax positions in accordance with ASC 740, Income Taxes, on the basis of a two-step process in which (1) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. Interest and penalties associated with income tax filings are recorded in income tax expense.

 

Comprehensive Income (Loss)

 

Comprehensive income (loss) consists of net income (loss) and other comprehensive income (loss), which includes foreign currency translation adjustments. For the purposes of comprehensive income (loss) disclosures, the Company does not record tax provisions or benefits for the net changes in the foreign currency translation adjustment, as it intends to indefinitely reinvest undistributed earnings of its foreign subsidiary. Accumulated other comprehensive income (loss) is reported as a component of stockholders' equity.

 

Segment Information

 

Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is its President and Chief Executive Officer as of December 31, 2022. Based on the criteria established by ASC 280, Segment Reporting, the Company has one operating and reportable segment.

 

Contingencies

 

In the normal course of business, the Company is involved from time-to-time in various legal proceedings and other matters such as contractual disputes, which are complex in nature and have outcomes that are difficult to predict. The Company records accruals for loss contingencies to the extent that it concludes that it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. The Company considers all relevant factors when making assessments regarding these contingencies. Although the outcomes of any potential legal proceedings are inherently difficult to predict, the Company does not expect the resolution of any potential legal proceedings to have a material adverse effect on its financial position, results of operations, or cash flow.

 

Recent Issued Accounting Pronouncements

 

No new accounting pronouncements issued or effective during the period had, or are expected to have, a material impact on the consolidated financial statements.
XML 24 R9.htm IDEA: XBRL DOCUMENT v3.22.4
Note 3 - Business Combinations
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Business Combination Disclosure [Text Block]

3. Business Combinations

 

Parcus Medical, LLC

 

On January 24, 2020, the Company completed the acquisition of Parcus Medical pursuant to the terms of the Agreement and Plan of Merger, dated as of January 4, 2020 (the “Parcus Medical Merger Agreement”), by and among the Company, Parcus Medical, the Unitholder Representative, and Sunshine Merger Sub LLC, a Wisconsin limited liability company and a wholly owned subsidiary of the Company. At the closing date, Parcus Medical became a wholly owned subsidiary of the Company. Parcus Medical is a sports medicine implant and instrumentation solutions provider focused on surgical repair and reconstruction of soft tissue.

 

The acquisition of Parcus Medical has been accounted for as a business combination under ASC 805, Business Combinations (“ASC 805”). Under ASC 805, assets acquired and liabilities assumed in a business combination are recorded at their fair value as of the acquisition date. The Company’s consolidated financial statements include results of operations for Parcus Medical from the January 24, 2020 acquisition date.

 

Consideration Transferred

 

Pursuant to the Parcus Medical Merger Agreement, the Company acquired all outstanding equity of Parcus Medical for estimated total purchase consideration of $75.1 million, as of January 24, 2020 which consisted of:

 

Cash consideration

 $32,794 

Deferred consideration

  1,642 

Estimated fair value of contingent consideration

  40,700 

Estimated total purchase consideration

 $75,136 

 

Pursuant to the Parcus Medical Merger Agreement, contingent consideration represents additional payments that the Company may be required to make in the future could total up to $60.0 million depending on the level of net sales of Parcus Medical products generated from 2020 through 2022.

 

The fair value of contingent consideration related to net sales as of January 24, 2020 was determined based on a Monte Carlo simulation model in an option pricing framework at the acquisition date, whereby a range of possible scenarios were simulated. There also was deferred consideration related to certain purchase price holdbacks, which was resolved within one year of the acquisition date in accordance with the Parcus Merger. The liability for contingent and deferred consideration is included in current and long-term liabilities on the consolidated balance sheets and will be remeasured at each reporting period until the contingency is resolved. During the three months ended September 30, 2022, the Company paid contingent consideration of $4.3 million related to net sales of Parcus Medical products earned in 2021 that was recorded in contingent consideration at December 31, 2021. As of December 31, 2022, there were no milestones remaining.

 

Acquisition-related costs are not included as a component of consideration transferred but are expensed in the periods in which the costs are incurred. The Company incurred approximately $1.9 million in transaction costs related to the Parcus Medical acquisition during the three-month period ending March 31, 2020. The transaction costs have been included in selling, general and administrative expenses in the consolidated statements of operations.

 

Fair Value of Net Assets Acquired

 

The estimate of fair value as of the acquisition date required the use of significant assumptions and estimates. Critical estimates included, but were not limited to, future expected cash flows, including projected revenues and expenses, and the applicable discount rates. These estimates were based on assumptions that the Company believes to be reasonable, however, actual results may differ from these estimates.

 

The allocation of purchase price to the identifiable assets acquired and liabilities assumed was based on estimates of fair value as of January 24, 2020, and is as follows:

 

Recognized identifiable assets acquired and liabilities assumed:

    

Cash and cash equivalents

 $196 

Accounts receivable

  2,029 

Inventories

  10,968 

Prepaid expenses and other current assets

  364 

Property and equipment, net

  1,099 

Right-of-use assets

  944 

Intangible assets

  44,000 

Accounts payable, accrued expenses and other current liabilities

  (2,763

)

Other long-term liabilities

  (594

)

Lease liabilities

  (735

)

Net assets acquired

  55,508 

Goodwill

  19,628 

Estimated total purchase consideration

 $75,136 

 

The acquired intangible assets based on estimates of fair value as of January 24, 2020 are as follows:

 

Developed technology

 $41,100 

Trade name

  1,800 

Customer relationships

  1,100 

Total acquired intangible assets

 $44,000 

 

The fair value of the developed technology intangible assets has been estimated using the multi-period excess earnings method, which is based on the principle that the value of an intangible asset is equal to the present value of the incremental after-tax cash flows attributable to the asset, after charges for other assets employed by the business. The fair value of the customer relationships has been estimated using the avoided costs/lost profits method, which is based on the principle that the value of an intangible asset is based on consideration of the total costs that would be avoided by having this asset in place. The fair value of the trade name has been estimated using the relief from royalty method of the income approach, which is based on the principle that the value of an intangible asset is equal to the present value of the after-tax royalty savings attributable to owning the intangible asset. Key estimates and assumptions used in these models are projected revenues and expenses related to the asset, estimated contributory asset charges, estimated costs to recreate the asset, and a risk-adjusted discount rate used to calculate the present value of the future expected cash inflows or cash outflows avoided from the asset.

 

The fair value of developed technology will be amortized over a useful life of 15 years, the fair value of customer relationships over 10 years, and the fair value of the trade name over 5 years.

 

The excess of the purchase price over the fair value of the net assets acquired was recorded as goodwill and assigned to the reporting unit for Parcus Medical and Arthrosurface. The goodwill is attributable to the workforce of the business and the value of future technologies expected to arise after the acquisition. Goodwill will not be amortized and is expected to be deductible for income tax purposes as the acquisition of the limited liability company is an asset purchase for tax purposes. See Note 8, Goodwill, for further discussion.

 

Arthrosurface, Inc.

 

On February 3, 2020, the Company completed the acquisition of Arthrosurface pursuant to the terms of the Agreement and Plan of Merger, dated as of January 4, 2020 (the “Arthrosurface Merger Agreement”), by and among the Company, Arthrosurface, the Stockholder Representative, and Button Merger Sub, a Delaware corporation and a wholly owned subsidiary of the Company. At the closing date, Arthrosurface became a wholly owned subsidiary of the Company. Arthrosurface is a joint preservation technology company specializing in less invasive, bone-preserving partial and total joint replacement solutions.

 

The acquisition of Arthrosurface has been accounted for as a business combination under ASC 805. Under ASC 805, assets acquired and liabilities assumed in a business combination are recorded at their fair values as of the acquisition date. Anika’s consolidated financial statements include results of operations for Arthrosurface from the February 3, 2020 acquisition date.

 

Consideration Transferred

 

Pursuant to the Arthrosurface Merger Agreement, the Company acquired all outstanding equity of Arthrosurface for estimated total purchase consideration of $90.3 million, as of February 3, 2020 which consisted of:

 

Cash consideration

 $61,909 

Estimated fair value of contingent consideration

  28,376 

Estimated total purchase consideration

 $90,285 

 

Pursuant to the Arthrosurface Merger Agreement, the Company could be required to make future payments of up to $40.0 million depending on the achievement of regulatory milestones and the level of net sales of Arthrosurface products from 2020 through 2021. The fair value of contingent consideration related to regulatory milestones as of February 3, 2020 was determined through a scenario-based discounted cash flow analysis using scenario probabilities and regulatory milestone dates. The fair value of contingent consideration related to net sales achievement as of February 3, 2020 was determined based upon a Monte Carlo simulation approach at acquisition date, whereby a range of possible scenarios were simulated. The Company paid $5.0 million in October 2020 and $10.0 million in July 2021 based upon the achievement of two distinct regulatory milestones. As of December 31, 2022, there were no milestones remaining.

 

Acquisition-related costs are not included as a component of consideration transferred but are expensed in the periods in which the costs are incurred. The Company incurred approximately $2.2 million in transaction costs related to the Arthrosurface acquisition during the three-month period ending March 31, 2020. The transaction costs have been included in selling, general and administrative expenses in the consolidated statements of operations.

 

Fair Value of Net Assets Acquired

 

The estimate of fair value required the use of significant assumptions and estimates. Critical estimates included, but were not limited to, future expected cash flows, including projected revenues and expenses, and the applicable discount rates. These estimates were based on assumptions that the Company believes to be reasonable. However, actual results may differ from these estimates.

 

The allocation of purchase price to the identifiable assets acquired and liabilities assumed was based on estimates of fair value as of February 3, 2020, as follows:

 

Recognized identifiable assets acquired and liabilities assumed:

    

Cash and cash equivalents

 $1,072 

Accounts receivable

  5,368 

Inventories

  15,652 

Prepaid expenses and other current assets

  535 

Property, plant and equipment

  3,394 

Other long-term assets

  7,548 

Intangible assets

  48,900 

Accounts payable, accrued expenses and other liabilities

  (3,929

)

Deferred tax liabilities

  (11,147

)

Net assets acquired

  67,393 

Goodwill

  22,892 

Estimated total purchase consideration

 $90,285 

 

Intangible assets acquired consist of:

    

Developed technology

 $37,000 

Trade name

  3,400 

Customer relationships

  7,900 

IPR&D

  600 

Total acquired intangible assets

 $48,900 

 

The fair value of the developed technology intangible assets has been estimated using the multi-period excess earnings method, which is based on the principle that the value of an intangible asset is equal to the present value of the incremental after-tax cash flow attributable to the asset, after charges for other assets employed by the business. The fair value of the customer relationships has been estimated using the avoided costs/lost profits method, which is based on the principle that the value of an intangible asset is based on consideration of the total costs that would be avoided by having this asset in place. The fair value of the trade name has been estimated using the relief from royalty method of the income approach, which is based on the principle that the value of an intangible asset is equal to the present value of the after-tax royalty savings attributable to owning the intangible asset. Key estimates and assumptions used in these models are projected revenues and expenses related to the asset, estimated contributory asset charges, estimated costs to recreate the asset, and a risk-adjusted discount rate used to calculate the present value of the future expected cash inflows or cash outflows avoided from the asset.

 

The fair value of developed technology that will be amortized over an estimated useful life of 15 years, the fair value of customer relationships over 10 years, and the fair value of trade names over 5 years. A total of $0.6 million represents the fair value of IPR&D with an indefinite useful life which was impaired during the quarter ended December 31, 2021. See Note 7, Acquired Intangible Assets, Net, for further discussion.

 

The excess of the purchase price over the fair value of the net assets acquired was recorded as goodwill and assigned to the newly established reporting unit for Parcus Medical and Arthrosurface. The goodwill is attributable to the workforce of the business and the value of future technologies expected to arise after the acquisition. Goodwill will not be amortized and is not expected to be deductible for income tax purposes as the acquisition of the corporation is a stock purchase for tax purposes. See Note 8, Goodwill, for further discussion.

 

Pro forma Information

 

The Parcus Medical and Arthrosurface acquisitions were both completed in the first quarter of 2020. Both acquired companies have similar businesses with all of their products in the Joint Preservation and Restoration product family, serving orthopedic surgeons, ambulatory surgical centers and hospitals. The Company has combined legacy Anika, Parcus Medical and Arthrosurface pro forma supplemental information as follows.

 

The unaudited pro forma information for the year ended December 31, 2020 was calculated after applying the Company’s accounting policies and the impact of acquisition date fair value adjustments. The pro forma financial information presents the combined results of operations of Anika, Parcus Medical and Arthrosurface as if the acquisitions had occurred on January 1, 2019 after giving effect to certain pro forma adjustments. The pro forma adjustments reflected herein include only those adjustments that are factually supportable and directly attributable to the acquisitions.

 

These pro forma adjustments include: (i) a net increase in amortization expense to record amortization expense for the aforementioned acquired identifiable intangible assets, (ii) an adjustment to cost of revenue based on the preliminary inventory step-up and the anticipated inventory turnover, (iii) a net decrease in interest expense as a result of eliminating interest expense and interest income related to borrowings that were settled in accordance with the respective Parcus Medical Merger Agreement and Arthrosurface Merger Agreement, (iv) an adjustment to record the acquisition-related transaction costs in the period required, and (v) the tax effect of the pro forma adjustments using the anticipated effective tax rate. The effective tax rate of the combined company could be materially different from the effective rate presented in this unaudited pro forma combined financial information. As a result of the transaction, the combined company may be subject to annual limitations on its ability to utilize pre-acquisition net operating loss carryforwards to offset future taxable income. The amount of the annual limitation is determined based on the value of Anika immediately prior to the acquisition. As further information becomes available, any such adjustment described above could be material to the amounts presented in the unaudited pro forma combined financial statements. The pro forma information does not purport to be indicative of the results of operations that actually would have resulted had the combination occurred at the beginning of each period presented, or of future results of the consolidated entities.

 

The following table presents unaudited supplemental pro forma information:

 

  

Year Ended December 31,

2020

 

Total revenue

 $134,410 

Net loss

 $(22,984)
XML 25 R10.htm IDEA: XBRL DOCUMENT v3.22.4
Note 4 - Fair Value Measurements
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Fair Value Disclosures [Text Block]

4. Fair Value Measurements

 

There were no available-for-sale securities as of December 31, 2022 and 2021.

 

The Company’s investments are all classified within Levels 1 of the fair value hierarchy and are valued based on quoted prices in active markets. For cash, current receivables, accounts payable, and interest accrual, the carrying amounts approximate fair value, because of the short maturity of these instruments, and therefore fair value information is not included in the table below. Contingent consideration related to the previously described business combinations are classified within Level 3 of the fair value hierarchy as the determination of fair value uses considerable judgement and represents the Company’s best estimate of an amount that could be realized in a market exchange for the asset or liability. 

 

The classification of the Company’s cash equivalents and investments within the fair value hierarchy is as follows:

 

      

Active Markets

  

Significant Other

  

Significant

     
      

for Identical Assets

  

Observable Inputs

  

Unobservable Inputs

     
  

December 31, 2022

  

(Level 1)

  

(Level 2)

  

(Level 3)

  

Amortized Cost

 

Cash equivalents:

                    

Money Market Funds

 $67,801  $67,801  $-  $-  $67,801 

 

      

Active Markets

  

Significant Other

  

Significant

     
      

for Identical Assets

  

Observable Inputs

  

Unobservable Inputs

     
  

December 31, 2021

  

(Level 1)

  

(Level 2)

  

(Level 3)

  

Amortized Cost

 

Cash equivalents:

                    

Money Market Funds

 $67,046  $67,046  $-  $-  $67,046 
                     

Other current and long-term liabilities:

                    

Contingent Consideration - Short Term

 $4,315  $-  $-  $4,315  $- 

 

There were no transfers between fair value levels in 2022 or 2021.

 

 

Contingent Consideration

 

The following table provides a roll forward of the contingent consideration related to business acquisitions discussed in Note 3, Business Combinations.

 

  

Years Ended December 31

 
  

2022

  

2021

 

Balance, beginning January 1

 $4,315  $35,410 

Additions

  -   - 

Payments

  (4,315

)

  (10,000

)

Change in fair value

  -   (21,095

)

Balance, ending December 31

 $-  $4,315 

 

Under the Parcus Medical Merger Agreement and Arthrosurface Merger Agreement, there were earn-out milestones totaling up to $100 million payable from 2020 to 2022. Parcus Medical had net sales earn-out milestones annually from 2020 to 2022, while Arthrosurface had both regulatory and net sales earn-out milestones annually in 2020 and 2021.

 

In order to determine the fair value of contingent consideration at each reporting date, the projected contingent payment amounts were discounted back to the current period using a discounted cash flow model or a Monte Carlo simulation approach. The unobservable inputs used in the fair value measurement of the Company’s contingent consideration are the probabilities of successful achievement, the net sales estimates, the weighted average cost of capital used for the Monte Carlo simulation, discount rate and the periods in which the milestones are expected to be achieved. The discount rates used for the net sales earn-out milestone ranged from 3.1% - 3.4%. The weighted average cost of capital for Parcus Medical decreased from 11.4% as of December 31, 2020 to 11.3% as of December 31, 2021. The weighted average cost of capital for Arthrosurface was 11.4% as of December 31, 2020. Increases or decreases in the discount rate would result in a lower or higher fair value measurement, respectively.

 

As of December 31, 2021, a net sales growth milestone with respect to the Parcus Merger Agreement was achieved for 2021, and a liability in the amount of $4.3 million was recorded in current liabilities. This amount was paid in September 2022. In June 2021, the Company received regulatory clearance for a reverse shoulder implant system, which triggered a $10.0 million regulatory milestone payment per the terms of the Arthrosurface Merger Agreement. This amount was paid in July 2021. As of December 31, 2022, there were no milestones remaining.

 

The overall fair value of the contingent consideration decreased by $21.1 million and $28.7 million during the years ended December 31, 2021 and 2020, respectively, due primarily to the decrease in the likelihood that certain contingent milestones would be achieved.
XML 26 R11.htm IDEA: XBRL DOCUMENT v3.22.4
Note 5 - Inventories
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Inventory Disclosure [Text Block]

5. Inventories

 

Total inventories included in the balance sheet consist of the following:

 

   

As of December 31,

  
   

2022

    

2021

  

Raw materials

   $ 20,535     $ 16,881  

Work-in-process

     10,648       11,442  

Finished goods

     25,306       26,731  

Total

   $ 56,489     $ 55,054  
                 

Inventories

   $ 39,765     $ 36,010  

Other long-term assets

     16,724       19,044  
Total   $ 56,489     $ 55,054  

 

Inventories are stated net of inventory reserves of approximately $9.9 million and $9.1 million, as of December 31, 2022 and 2021, respectively.
XML 27 R12.htm IDEA: XBRL DOCUMENT v3.22.4
Note 6 - Property and Equipment
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Property, Plant and Equipment Disclosure [Text Block]

6. Property and Equipment

 

Property and equipment is stated at cost and consists of the following:

 

   

As of December 31,

  
   

2022

    

2021

  

Equipment and software

   $ 52,112     $ 48,804  

Furniture and fixtures

     2,413       2,389  

Leasehold improvements

     34,916       34,614  

Construction in progress

     5,021       1,378  

Subtotal

     94,462       87,185  

Less accumulated depreciation

     (46,183 )     (39,583

)

Total

   $ 48,279     $ 47,602  

 

Depreciation expense was $6.7 million, $6.5 million, and $6.1 million for the years ended December 31, 2022, 2021, and 2020, respectively.
XML 28 R13.htm IDEA: XBRL DOCUMENT v3.22.4
Note 7 - Acquired Intangible Assets, Net
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Goodwill and Intangible Assets Disclosure [Text Block]

7. Acquired Intangible Assets, Net

 

Intangible assets consist of the following:

 

      

Year Ended December 31, 2022

 
  

Gross Cost

  

Less: Accumulated

Currency Translation

Adjustment

  

Less: Current Period

Impairment Charge

  

Less: Accumulated

Amortization

  

Net Book Value

  

Weighted

Average Useful

Life (in Years)

 

Developed technology

 $89,580  $(1,608) $-  $(23,686) $64,286   15 

IPR&D

  2,656   (1,006)  -   -   1,650  

Indefinite

 

Customer relationships

  9,000   -   -   (2,627)  6,373   10 

Distributor relationships

  4,700   (415)  -   (4,285)  -   5 

Patents

  1,000   (189)  -   (680)  131   16 

Tradenames

  5,200   -   -   (3,041)  2,159   5 

Total

 $112,136  $(3,218) $-  $(34,319) $74,599   13 

 

      

Year Ended December 31, 2021

 
  

Gross Cost

  

Less: Accumulated

Currency Translation

Adjustment

  

Less: Current Period

Impairment Charge

  

Less: Accumulated

Amortization

  

Net Book Value

  

Weighted

Average Useful

Life

 

Developed technology

 $89,580  $(1,608

)

 $-  $(17,891

)

 $70,081   15 

IPR&D

  3,256   (1,006

)

  (600

)

  -   1,650  

Indefinite

 

Customer relationships

  9,000   -   -   (1,727

)

  7,273   10 

Distributor relationships

  4,700   (415

)

  -   (4,285

)

  -   5 

Patents

  1,000   (189

)

  -   (632

)

  179   16 

Tradenames

  5,200   -   -   (2,001

)

  3,199   5 

Total

 $112,736  $(3,218

)

 $(600

)

 $(26,536

)

 $82,382   13 

 

Total amortization expense with respect to the definite lived acquired intangible assets was $7.8 million for each of the years ended December 31, 2022 and 2021 and $7.4 million for the year ended December 31, 2020.

 

During the fourth quarter of 2021, the Company decided not to further invest in a joint technology IPR&D project, as it is no longer aligned with the Company’s core strategic focus. As a result, the Company recorded an impairment charge in the amount of $0.6 million in research and development expenses in the Company’s consolidated statements of operations.

 

During the fourth quarter of 2020, the Company decided not to further invest in its Hyalobone and Hyalonect IPR&D projects as they were no longer aligned with the Company’s core strategic focus. As a result, the Company recorded an impairment charge in the period totaling $1.4 million recorded in research and development expenses in the Company’s consolidated statements of operations.

 

The Company performed its annual assessment of the remaining IPR&D intangible asset as of November 30, 2022. The Company estimated the fair value of the IPR&D intangible assets using the income approach which is based on the Multi-Period Excess Earnings Method (“MPEEM”). MPEEM measures economic benefit indirectly by calculating the income attributable to an asset after appropriate returns are paid to complementary assets used in conjunction with the subject asset to produce the earnings associated with the subject asset, commonly referred to as contributory asset charges. This approach incorporates significant estimates and assumptions related to the forecasted results including revenues, expenses, expected economic life of the asset, contributory asset charges and discount rates to estimate future cash flows. While assumptions utilized are subject to a high degree of judgment and complexity, the Company made its best estimate of future cash flows under a high degree of economic uncertainty that existed as of November 30, 2022. In developing its assumptions, the Company also considered observed trends of its industry participants. No impairment existed as the estimated fair value of the remaining IPR&D intangible asset was greater than its carrying value.

 

During 2020, the Company determined that it would not pursue CE mark renewals for certain of its legacy products, which resulted in an impairment of certain developed technology related assets in the amount of $1.0 million in 2020. This impairment charge was recorded in selling, general and administrative expenses on the Company’s consolidated statements of operations.
XML 29 R14.htm IDEA: XBRL DOCUMENT v3.22.4
Note 8 - Goodwill
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Goodwill Disclosure [Text Block]

8. Goodwill

 

The following table provides a roll forward of goodwill for the years ended December 31, 2022 and 2021:

 

  

Years Ended December 31

 
  

2022

  

2021

 

Balance, beginning January 1

 $7,781  $8,413 

Effect of foreign currency adjustments

  (442)  (632)

Balance, ending December 31

 $7,339  $7,781 

 

In the first quarter of 2020, the Company acquired Parcus Medical and Arthrosurface, as further discussed in Note 3, Business Combinations. As a result of the acquisitions, the Company determined that it had two reporting units. It created a reporting unit in 2020 that included Parcus Medical and Arthrosurface, which share similar economic and qualitative characteristics. This reporting unit produces sports medicine surgical products, instruments and joint repair implants. The Company also has another reporting unit that comprises the legacy Anika business, which specializes in therapies based on its hyaluronic acid, or HA, technology platform. The Company impaired the Parcus Medical and Arthrosurface reporting unit in 2020. The remaining goodwill balance at December 31, 2022 and 2021 was related to the legacy Anika reporting unit.

 

As part of its annual impairment testing as of November 30 each year for the goodwill related to the legacy Anika reporting unit, the Company performed a qualitative assessment including consideration of (i) general macroeconomic factors, (ii) industry and market conditions, and (iii) the extent of the excess of the fair value over the carrying value indicated in prior impairment testing. The Company determined it was not more likely than not that the fair value of the legacy Anika reporting unit is less than its carrying amount and thus goodwill was not impaired as of November 30, 2022.

 

Government policy responses to the COVID-19 pandemic and the resulting changes in healthcare guidelines caused a temporary suspension of global elective surgical procedures. As a result, the widespread economic volatility triggered impairment testing in the first quarter of 2020, and accordingly, the Company performed interim impairment testing on the goodwill balances of its reporting units. The Company also performed its annual impairment testing in the fourth quarter of 2020.

 

The Company estimated the fair value of the reporting units using a discounted cash flow method, which is based on the present value of projected cash flows and a terminal value, which represents the expected normalized cash flows of the reporting units beyond the cash flows from the discrete projection period. The Company determined that a discounted cash flow model provided the best approximation of fair value of the reporting units for the purpose of performing the impairment test. This approach incorporates significant estimates and assumptions related to the forecasted results including revenues, expenses, the achievement of certain cost synergies, terminal growth rates and discount rates to estimate future cash flows. While assumptions utilized are subject to a high degree of judgment and complexity, the Company made its best estimate of future cash flows under a high degree of economic uncertainty that existed as of November 30, 2020. In developing its assumptions, the Company also considered observed trends of its industry participants.

 

For the legacy Anika reporting unit, the Company performed a qualitative assessment including consideration of (i) general macroeconomic factors, (ii) industry and market conditions, and (iii) the extent of the excess of the fair value over the carrying value indicated in prior impairment testing. The Company determined it was not more likely than not that the fair value of the legacy Anika reporting unit is less than its carrying amount and thus goodwill was not impaired as of March 31, 2020. As part of its annual impairment testing, the Company decided to perform a quantitative assessment related to the legacy Anika reporting unit as of November 30, 2020, due to the expectation that the economic recovery will take longer than expected to materialize. The results of the impairment test indicated that the estimated fair value of the legacy Anika reporting unit was greater than its carrying value, therefore the Company did not record any impairment charges related to the legacy Anika reporting unit for the year ended December 31, 2020.

 

For its newly created reporting unit, which includes Parcus Medical and Arthrosurface, the Company performed an interim quantitative assessment of goodwill impairment as of March 31, 2020. The Company estimated the fair value of the reporting unit using a discounted cash flow method. The results of the interim impairment test indicated that the estimated fair value of the reporting unit was less than its carrying value. This was primarily due to decreases in near term revenue and related cash flows as a result of the temporary suspension of domestic elective procedures, primarily due to the COVID-19 pandemic which directly impacted the reporting unit. Consequently, a non-cash goodwill impairment charge was recorded in the amount of $18.1 million during the first quarter of 2020. As part of its annual impairment testing, the Company performed a quantitative assessment related to the newly created reporting unit as of November 30, 2020. The results of the annual impairment test indicated that the estimated fair value of the reporting unit was less than its carrying value. This was primarily due to a decline in projected net cash flows as a result of the continued impact of COVID-19 on revenue and related cash flows, the expectation that the economic recovery will take longer than expected to materialize, and additional projected investment to support future growth. Consequently, a non-cash goodwill impairment charge was recorded in the amount of $24.4 million during the fourth quarter of 2020. The total non-cash goodwill impairment charge with respect to the reporting unit amounted to $42.5 million for the year ended December 31, 2020. There was no remaining goodwill with respect to the newly created reporting unit as of December 31, 2020.
XML 30 R15.htm IDEA: XBRL DOCUMENT v3.22.4
Note 9 - Leases
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Lessee, Operating Leases and Finance Leases [Text Block]

9. Leases

 

The Company leases its buildings and manufacturing facilities under operating leases. As of December 31, 2022, the Company had real estate leases in Bedford, Massachusetts, Franklin, Massachusetts, Sarasota, Florida, Warsaw, Indiana and Padova, Italy.

 

In June 2022, the Company finalized a renewal option to extend the current term for its operating headquarters and manufacturing facility in Bedford through 2027. There are also lease renewal options into 2038. The current term of the Padova lease extends to 2032, with a right to terminate at the Company’s option in 2026 without penalty.

 

As a result of the acquisition of Parcus Medical and Arthrosurface, the Company acquired operating and finance leases for corporate offices, manufacturing and warehouse facilities and machinery. The operating leases consist of one real estate lease in Franklin, Massachusetts (Franklin lease) and two real estate leases in Sarasota, Florida (Sarasota lease). In October 2022, the Company entered into an option to extend the current term of the Franklin lease through 2024. In June 2022, the Company finalized an option to extend the current term of the two Sarasota leases through 2027. The finance leases include equipment utilized in the Company’s manufacturing facility in Sarasota, Florida and were terminated in September 2022.

 

The significant assumptions in recognizing the right-of-use asset and lease liability are as follows:

 

Incremental borrowing rate. The Company derives its incremental borrowing rate from information available at the lease commencement date in determining the present value of lease payments. The incremental borrowing rate represents a collateralized rate of interest the Company would have to pay to borrow over a similar term an amount equal to the lease payments in a similar economic environment. The Company’s lease agreements do not provide implicit rates. As the Company did not have any external borrowings at either the transition or subsequent renewal dates with comparable terms to its lease agreements, the Company estimated its incremental borrowing rate based on its credit quality, line of credit agreement and by comparing interest rates available in the market for similar borrowings, and adjusting this amount based on the impact of collateral over the term of the lease. The weighted average discount rate at December 31, 2022 was 3.6% for operating leases.

 

Lease term. The lease term begins at the lease commencement date and is determined on that date based on the non-cancelable term of the lease together with periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, or periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option.

 

The components of lease expense and other information are as follows: 

 

  Years Ended December 31 
  

2022

  

2021

  

2020

 

Finance lease amortization of right-of-use assets

 $121  $143  $185 

Interest on finance lease liabilities

  11   19   25 

Finance lease expense

  132   162   210 

Operating lease expense

  2,839   2,468   2,383 

Short-term lease expense

  17   2   - 

Variable lease expense

  413   319   264 

Total lease expense

 $3,401  $2,951  $2,857 

 

  

Years Ended December 31

 
  

2022

  

2021

 

Weighted Average Remaining Lease Term (in years)

        

Operating leases

  14.8   15.3 

Financing leases

  -   2.3 

Weighted Average Discount Rate

        

Operating leases

  3.6

%

  4.1

%

Financing leases

  -   4.9

%

Other information

        

Operating cash flows from operating leases

 $2,471  $2,392 

Operating cash flows from financing leases

 $121  $136 

 

Future commitments due under these lease agreements as of December 31, 2022 are as follows:

 

Years ended December 31,

 

Operating Leases

 
     

2023

 $3,170 

2024

  3,055 

2025

  3,066 

2026

  2,760 

2027

  2,643 

Thereafter

  25,230 

Present value adjustment

  (9,034)

Present value of lease payments

  30,890 

Less current portion included in accrued expenses and other current liabilities

  (2,073)

Total lease liabilities

 $28,817 

 
XML 31 R16.htm IDEA: XBRL DOCUMENT v3.22.4
Note 10 - Accrued Expenses and Other Liabilities
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Accounts Payable and Accrued Liabilities Disclosure [Text Block]

10. Accrued Expenses

 

Accrued expenses consist of the following:

 

   

As of December 31,

  
   

2022

    

2021

  
                 

Compensation and related expenses

   $ 11,303     $ 9,523  

Professional fees

     3,145       3,590  

Operating lease liability- current

     2,073       1,526  

Clinical trial costs

     999       1,961  

Finance lease liability - current

     -       188  

Income taxes payable

     810       -  

Other

     510       1,059  

Total

   $ 18,840     $ 17,847  

 
XML 32 R17.htm IDEA: XBRL DOCUMENT v3.22.4
Note 11 - Revolving Credit Agreement
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Debt Disclosure [Text Block]

11. Revolving Credit Agreement

 

On November 12, 2021, the Company, entered into a “Third Amendment to Credit Agreement” amending the existing revolving line of credit agreement dated October 24, 2017 with Bank of America, N.A., as administrative agent, swingline lender and issuer of letters of credit, for a $75.0 million senior revolving line of credit (the “Credit Agreement”). Subject to certain conditions, the Company may request up to an additional $75.0 million in commitments for a maximum aggregate commitment of $150.0 million, which requests must be approved by the Revolving Lenders (as defined in the Credit Agreement). Loans under the Credit Agreement generally bear interest at a rate equal to (a) the Bloomberg Short-Term Bank Yield Index, (“BSBY”), rate plus (b) an additional percentage that will range from 0.25% to 1.00%, based on the Company’s consolidated leverage ratio at the time of the borrowings. The Company is required to pay a commitment fee in an amount that is equal to 0.20% to 0.30% per annum, based on the Company’s consolidated leverage ratio, on the actual daily unused amount of the credit facility and that is due and payable quarterly in arrears. Loan origination costs are included as assets on the balance sheet and are being amortized over the five-year term of the Credit Agreement. As of December 31, 2022 and 2021, there were no outstanding borrowings under the Credit Agreement and the Company is in compliance with the terms of the Credit Agreement. 

 

The Credit Agreement contains customary representations, warranties, affirmative and negative covenants, including financial covenants, events of default, and indemnification provisions in favor of the Lenders. These include restrictive covenants that require the Company not to exceed certain maximum leverage and interest coverage ratios, limit its incurrence of liens and indebtedness, and its entry into certain merger and acquisition transactions or dispositions and place additional restrictions on other matters, all subject to certain exceptions. The Revolving Lenders has been granted a first priority lien and security interest in substantially all of the Company’s assets, except for certain intangible assets.

 

In April 2020, the Company borrowed $50.0 million available under the previous credit facility, with an initial applicable interest rate of 2.08%, all of which were repaid during the year ended December 31, 2020. Interest expense for the years ended December 31, 2022, 2021 and 2020 was $0, $0, and $0.8 million, respectively.
XML 33 R18.htm IDEA: XBRL DOCUMENT v3.22.4
Note 12 - Commitments and Contingencies
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Commitments and Contingencies Disclosure [Text Block]

12. Commitments and Contingencies

 

In certain of its contracts, the Company warrants to its customers that the products it manufactures conform to the product specifications as in effect at the time of delivery of the specific product. The Company may also warrant that the products it manufactures do not infringe, violate or breach any U.S. or international patent or intellectual property rights, trade secret, or other proprietary information of any third party. On occasion, the Company contractually indemnifies its customers against any and all losses arising out of, or in any way connected with, any claim or claims of breach of its warranties or any actual or alleged defect in any product caused by the negligent acts or omissions of the Company. The Company maintains a products liability insurance policy that limits its exposure to these risks. Based on the Company’s historical activity, in combination with its liability insurance coverage, the Company believes the estimated fair value of these indemnification agreements is immaterial. The Company had no accrued warranties at December 31, 2022 or 2021, respectively, and has no history of claims paid.  

 

The Company is also involved from time-to-time in various legal proceedings arising in the normal course of business. Although the outcomes of these legal proceedings are inherently difficult to predict, the Company does not expect the resolution of these occasional legal proceedings to have a material adverse effect on its financial position, results of operations, or cash flows.

 

On October 21, 2021, the Company received notice that the former unitholders of Parcus Medical had filed a request for arbitration regarding the earnout provisions agreed to in the Parcus Medical Merger Agreement. The Company has engaged in the arbitration process and does not anticipate a resolution during the first half of 2023. The Company is unable to estimate the potential liability with respect to this matter at this time. There are numerous factors that make it difficult to estimate reasonably possible loss or range of loss at this stage of the matter, including the significant number of legal and factual issues still to be resolved in the arbitration process. The Company intends to vigorously defend against the claims and believes it has strong defenses to the claims asserted.
XML 34 R19.htm IDEA: XBRL DOCUMENT v3.22.4
Note 13 - Revenue and Geographic Information
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Revenue from Contract with Customer [Text Block]

13. Revenue and Geographic Information

 

The Company categorizes its product portfolio into three product families: OA Pain Management, Joint Preservation and Restoration, and Non-Orthopedic. Anika’s consolidated financial statements include results of operations for Parcus Medical from the January 24, 2020 acquisition date and Arthrosurface from the February 3, 2020 acquisition date.

 

Product revenue by product family is as follows:

 

  

Years Ended December 31,

 
  

2022

  

2021

  

2020

 
  

Revenue

  

Percentage of
Product
Revenue

  

Revenue

  

Percentage of
Product
Revenue

  

Revenue

  

Percentage of
Product
Revenue

 

OA Pain Management

 $97,887   63

%

 $89,503   61

%

 $83,029   64

%

Joint Preservation and Restoration

  50,402   32

%

  48,588   33

%

  39,368   30

%

Non-Orthopedic

  7,947   5

%

  9,703   6

%

  8,060   6

%

Total

 $156,236   100

%

 $147,794   100

%

 $130,457   100

%

 

Effective January 1, 2023, the Company will begin to report revenue from product sales to veterinary customers within the Non-Orthopedic product family whereas such revenue had been reported within the OA Pain Management revenue product family. Revenue from product sales to veterinary customers amounted to $5.9 million, $4.4 million and $3.8 million for 2022, 2021 and 2020, respectively.

 

Product revenue from the Company’s sole significant customer, Mitek, as a percentage of the Company’s total product revenue was 43%, 45%, and 49% for the years ended December 31, 2022, 2021, and 2020, respectively.

 

Total revenue by geographic location based on the location of the customer in total and as a percentage of total revenue are as follows:

 

  

Years Ended December 31,

 
  

2022

  

2021

  

2020

 
  

Total

  

Percentage of

  

Total

  

Percentage of

  

Total

  

Percentage of

 
  

Revenue

  

Revenue

  

Revenue

  

Revenue

  

Revenue

  

Revenue

 

Geographic Location:

                        

United States

 $119,151   76% $113,833   77

%

 $103,182   79

%

Europe

  20,639   13%  19,580   13

%

  14,179   11

%

Other

  16,446   11%  14,381   10

%

  13,096   10

%

Total

 $156,236   100% $147,794   100

%

 $130,457   100

%

 

Net long-lived assets, consisting primarily of net property and equipment, are subject to geographic risks because they are generally difficult to move and to effectively utilize in another geographic area in a reasonable time period and because they are relatively illiquid. Net tangible long-lived assets by principal geographic areas are as follows:

 

  

Years Ended December 31,

 
  

2022

  

2021

 

United States

 $47,068  $46,068 

Italy

  1,211   1,534 

Total

 $48,279  $47,602 

 
XML 35 R20.htm IDEA: XBRL DOCUMENT v3.22.4
Note 14 - Equity Incentive Plan
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Share-Based Payment Arrangement [Text Block]

14. Equity Incentive Plan

 

Equity Incentive Plan

 

The Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan (the “2017 Plan”) was approved by the Company’s stockholders on June 13, 2017 and subsequently amended on June 18, 2019, June 16, 2020 and June 16, 2021. The 2017 Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights (“SARs”), restricted stock awards (“RSAs”), performance restricted stock units (“PSUs”), restricted stock units (“RSUs”), total shareholder return options (“TSRs”) and performance options that may be settled in cash, stock, or other property. In accordance with the 2017 Plan approved by the Company’s stockholders, including the amendments thereto, each share award other than stock options or SAR’s will reduce the number of total shares available for grant by two shares. Subject to adjustment for specified types of changes in the Company’s capitalization, no more than 4.6 million shares of common stock may be issued under the 2017 Plan. There are 1.2 million shares available for future grant at December 31, 2022 under the 2017 Plan.

 

The Anika Therapeutics, Inc. 2021 Inducement Plan (the “Inducement Plan”) was adopted by the Company’s board of directors on November 4, 2021. The Inducement Plan reserves 125,000 shares of common stock for issuance pursuant to equity-based awards granted under the Inducement Plan. Such awards may be granted only to an individual who was not previously the Company’s employee or director with the Company. The Inducement Plan provides for the grant of awards under terms substantially similar to the 2017 Plan (as amended). There are 4,883 shares available for future grant at December 31, 2022 under the Inducement Plan.

 

The Company may satisfy the awards upon exercise, or upon fulfillment of the vesting requirements for other equity-based awards, with either newly issued shares or shares reacquired by the Company. Stock-based awards are granted with an exercise price equal to or greater than the market price of the Company’s stock on the date of grant. Awards contain service conditions or service and performance conditions, and they generally become exercisable ratably over one to four years with a maximum contractual term of ten years.

 

The Company presents the expenses related to stock-based compensation awards in the same expense line items as cash compensation paid to each of its employees. For the year ended December 31, 2022, the tax benefit associated with stock-based compensation was $1.1 million. A summary of the stock-based compensation in the Company’s statements of operations is as follows (in thousands):

 

 

  

Years Ended December 31,

 
  

2022

  

2021

  

2020

 

Cost of revenue

 

$

820

  

$

716

  

$

719

 

Research and development

  

1,646

   

1,233

   

713

 

Selling, general and administrative

  

11,849

   

9,136

   

3,954

 

Total stock-based compensation expense

 

$

14,315

  

$

11,085

  

$

5,386

 

 

For the years ended December 31, 2022, 2021 and 2020, windfall tax benefits (expense) of $(0.5) million, $0.1 million and $0.2 million, respectively, are associated with the stock-based compensation expense above.

 

The Company’s former President and Chief Executive Officer, Joseph Darling, passed away unexpectedly in January 2020. According to the terms of Mr. Darling’s equity award grants and the 2017 Plan, the unvested portion of his stock-based compensation was forfeited upon his death, resulting in a one-time benefit of $1.8 million that was fully recognized during the three-month period ended March 31, 2020 within selling, general and administrative expenses.

 

Stock Options

 

Stock options are granted to purchase common shares at prices that are equal to the fair market value of the shares on the date the options are granted or, in the case of premium options, are granted with an exercise price at 110% of the market price of the Company’s common stock on the date of grant. Options generally vest in equal annual installments over a period of three to four years and expire 10 years after the date of grant. The grant-date fair value of options is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period.

 

The following summarizes the activity under the Company’s stock option plans:

 

  

Number of Options

  

Weighted Average Exercise Price

  

Weighted Average

Remaining

Contractual

Term (in years)

  

Aggregate Intrinsic

Value

(in thousands)

 

Outstanding as of December 31, 2021

  1,175,993  $39.56         

Granted

  553,827  $28.07         

Exercised

  (433) $8.83      $10 

Forfeited and canceled

  (198,684) $43.24         

Outstanding as of December 31, 2022

  1,530,703  $34.93   8.1  $1,050 

Vested, December 31, 2022

  640,056  $40.08   7.2  $12 

Vested or expected to vest, December 31, 2022

  1,530,703  $34.93   8.1  $1,050 

 

The aggregate intrinsic value of options exercised for the years ended December 31, 2021 and 2020 was $0.3 million and $2.8 million, respectively.

 

The Company granted 553,827 stock options during the year ended December 31, 2022, of which 398,314 shares were premium-priced options.

 

The Company uses the Black-Scholes pricing model to determine the fair value of options granted. The calculation of the fair value of stock options is affected by the stock price on the grant date, the expected volatility of the Company’s common stock over the expected term of the award, the expected life of the award, the risk-free interest rate and the dividend yield. The Company estimated the fair value of TSRs using Monte-Carlo simulation model where the expected volatility assumption is evaluated over 6.3 years. The actual number of TSR options that may be earned ranges from 0% to 150% of the target number, depending on the total shareholder return of the Company relative to the peer group over the vesting period of 2.7 years. The Company completed its evaluation of the TSR award and vested 139,168 TSRs as of December 31, 2022.

 

The assumptions used in the Black-Scholes pricing model for options granted during the years ended December 31, 2022 2021 and 2020, along with the weighted-average grant-date fair values, were as follows:

 

 

2022

 

2021

 

2020

Risk-free interest rate

1.28%

-

4.28%

 

0.29%

-

1.00%

 

0.21%

-

1.59%

Expected stock price volatility

53.80%

-

55.55%

 

54.80%

-

56.35%

 

46.48%

-

54.06%

Expected life of options (in years)

 

4.5

   

4.0

   

4.0

 

Expected dividend yield

 

0.0%

   

0.0%

   

-%

 

Fair value per option

 

11.45

   

14.80

   

16.31

 

 

As of December 31, 2022, there was $7.4 million of unrecognized compensation cost related to unvested stock options. This expense is expected to be recognized over a weighted average period of 1.8 years.

 

Restricted Stock Units

 

RSUs generally vest in equal annual installments over a three- or four-year periods. The grant-date fair value of RSUs is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The Company determines the fair value of restricted stock units based on the closing price of its common stock on the date of grant.

 

RSU activity for the year ended December 31, 2022 is as follows:

 

  

Number of Shares

  

Weighted Average Fair Value

 

Outstanding as of December 31, 2021

 $412,658  $36.33 

Granted

  507,524  $25.14 

Vested

  (164,167) $36.77 

Forfeited and cancelled

  (80,610) $(31.40)

Outstanding as of December 31, 2022

 $675,405  $28.40 

 

The weighted-average grant-date fair value per share of RSUs granted was $25.14, $35.88 and $38.20 for the years ended December 31, 2022, 2021 and 2020, respectively. The total fair value of RSUs vested was $6.0 million, $3.7 million and $2.2 million for the years ended December 31, 2022, 2021 and 2020, respectively.

 

As of December 31, 2022, there was $12.3 million of unrecognized compensation cost related to time-based RSUs, which is expected to be recognized over a weighted-average period of 1.8 years.

 

Performance Stock Units

 

PSUs generally vest over a three-year period from the grant date and include both a service and performance component. The PSUs granted to employees in 2019 contained performance conditions with business and financial targets. The business target, amounting to 30% of the total performance condition awards, was measured and achieved in the 2019 fiscal year. One of the financial targets, amounting to 55% of the total performance condition awards, was measured and achieved in the 2022 fiscal year, while the remaining financial target, amounting to 15% of the total performance condition awards, was not achieved. The PSUs granted to employees in 2020 contained performance conditions with business and financial targets. One of the business targets, amounting to 20% of the total performance condition awards, was not achieved in the 2021 fiscal year, while the remaining business target related to a certain timely regulatory approval, amounting to 20% of the total performance condition awards, was not achieved in the 2022 fiscal year. The financial targets, amounting to 60% of the total performance condition awards, were not achieved in the 2022 fiscal year.

 

PSU activity for the year ended December 31, 2022 is as follows:

 

  

Number of Shares

  

Weighted Average Fair Value

 

Outstanding as of December 31, 2021

  158,297  $37.44 

Granted

  2,125  $32.53 

Vested

  (19,125) $32.53 

Forfeited and cancelled

  (23,400) $41.86 

Outstanding as of December 31, 2022

  117,897  $34.98 

 

The weighted-average grant-date fair value per share of PSUs granted was $32.53, $0 and $36.93 for the years ended December 31, 2022, 2021 and 2020, respectively. The total fair value of PSUs vested was $0.6 million, $0 and $0 for the years ended December 31, 2022, 2021 and 2020, respectively. As of December 31, 2022, there was no unrecognized compensation cost related to PSUs in which milestones are expected to be achieved.

 

Employee Stock Purchase Plan

 

On March 17, 2021, the Company adopted the 2021 Employee Stock Purchase Plan (“ESPP”). The ESPP is authorized to issue up to 200,000 shares of common stock to participating employees. Employees that participate in the Company’s ESPP may purchase up to a maximum of 800 shares per six-month offering period or $25,000 worth of common stock per calendar year by authorizing payroll deductions of up to 10% of their base salary. The purchase price for each share purchased is 85% of the lower of the fair market value of the common stock on the first or last day of the offering period.
XML 36 R21.htm IDEA: XBRL DOCUMENT v3.22.4
Note 15 - Employee Benefit Plan
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Compensation and Employee Benefit Plans [Text Block]

15. Employee Benefit Plan

 

The Company’s U.S. employees are eligible to participate in the Company’s 401(k) savings plan. Employees may elect to contribute a percentage of their compensation to the plan, and the Company will make 140% matching contributions up to a limit of 5% of an employee’s eligible compensation. In addition, the Company may make annual discretionary contributions. The Company made matching contributions of $2.3 million, $2.0 million, and $1.7 million for the years ended December 31, 2022, 2021, and 2020, respectively.
XML 37 R22.htm IDEA: XBRL DOCUMENT v3.22.4
Note 16 - Income Taxes
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Income Tax Disclosure [Text Block]

16. Income Taxes 

 

Income Tax Expense

 

The components of the Company’s income (loss) before income taxes and its provision for (benefit from) income taxes consist of the following:

 

  

Years ended December 31,

 
  

2022

  

2021

  

2020

 

(Loss) income before income taxes

            

Domestic

 $(19,080) $(2,529

)

 $(25,722)

Foreign

  334   4,956   (2,902

)

  $(18,746) $2,427  $(28,624)

 

  

Years ended December 31,

 
  

2022

  

2021

  

2020

 

Provision for (benefit from) income taxes:

            

Current:

            

Federal

 $1,005  $494  $357 

State

  285   (635

)

  (1,970)

Foreign

  96   167   49 

Total current

  1,386   26   (1,564)

Deferred:

            

Federal

  (3,243)  (553

)

  (1,980)

State

  (1,256)  (426

)

  (1,070)

Foreign

  (774)  (754

)

  (28)

Total deferred

  (5,273)  (1,733

)

  (3,078)

Total benefit from income taxes

 $(3,887) $(1,707

)

 $(4,642)

 

Deferred Tax Assets and Liabilities

 

Significant components of the Company’s deferred tax assets and liabilities consist of the following:

 

  

As of December 31,

 
  

2022

  

2021

 

Deferred tax assets:

        

Lease liability

 $7,468  $4,684 

Capitalized research expenditures

  5,451   - 

Stock-based compensation expense

  2,795   2,782 

Inventory reserves

  2,763   2,453 

Compensation accrual

  1,635   1,236 

Net operating loss carry forwards

  1,551   2,822 

Tax credits

  741   3,022 

Accrued expenses

  519   491 

Foreign currency exchange

  221   282 

Deferred tax assets

 $23,144  $17,772 

 

  

As of December 31,

 
  

2022

  

2021

 

Deferred tax liabilities:

        

Acquisition-related intangible asset

 $(12,075) $(14,770

)

Depreciation

  (8,804)  (8,509

)

Right of use asset

  (7,252)  (4,650

)

Deferred tax liabilities

 $(28,131) $(27,929

)

         

Net deferred tax liabilities

 $(4,987) $(10,157

)

 

As of December 31, 2022, the Company had no Federal net operating loss (“NOL”) carryforwards and state net NOL carryforwards of $3.1 million that will begin to expire in 2026. The Company also had NOL carryforwards in Italy of $6.1 million that do not expire but are limited to 80% of taxable income. As of December 31, 2022, the Company had federal and state research and development tax credit carryforwards of $0.4 million and $0.5 million, respectively, that will begin expiring in 2023.

 

The Tax Cuts and Jobs Act (“TCJA”) requires taxpayers to capitalize and amortize research and experimental (“R&D”) expenditures for tax years beginning after December 31, 2021. This rule became effective for the Company during the year ended December 31, 2022 and resulted in the capitalization of R&D costs of $23.4 million. The Company will amortize these costs for tax purposes over 5 years if the R&D was performed in the U.S. and over 15 years if the R&D was performed outside the U.S.

 

The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, carryback potential if permitted under the tax law, and results of recent operations. Based upon future reversals of existing taxable temporary differences, the Company believes it is more likely than not that it will realize its domestic deferred tax assets. Based upon future reversals of existing taxable temporary differences and projected future taxable income, the Company believes it is more likely than not it will realize its foreign deferred tax assets.

 

During the year ended December 31, 2021, the Company released the valuation allowance recorded related to the net deferred tax assets in Italy in the amount of $0.9 million. 

 

Undistributed earnings of certain of the Company’s foreign subsidiaries amounted to approximately $0.5 million at December 31, 2022. The Company expects to be able to take a 100% dividend received deduction to offset any U.S. federal income tax liability on the undistributed earnings. Determination of the amount of unrecognized state and local deferred income tax liability is not practicable due to the complexities associated with its hypothetical calculation.

 

Effective Tax Rate

 

The reconciliation between the U.S. federal statutory rate and the Company’s effective rate is summarized as follows:

 

  

Years ended December 31,

 
  

2022

  

2021

  

2020

 

Statutory federal income tax rate

  21.0%  21.0

%

  21.0

%

State tax expense, net of federal benefit

  1.4%  (3.2

%)

  1.5

%

Stock compensation

  (4.7%)  22.3

%

  (2.2

%)

Section 162(m) limitation

  (8.2%)  8.7

%

  - 

Goodwill impairment

  -   -

 

  (16.8

%)

Change in fair value of contingent consideration

  -   (36.7

%)

  6.7

%

Change in tax rates and state apportionment

  1.2%  (29.8

%)

  4.9

%

Federal, state and foreign tax credits

  5.1%  (28.4

%)

  2.2

%

Valuation allowance

  -   (35.3

%)

  (3.0

%)

Return to provision adjustments

  5.0%  -

 

  -

 

Other permanent items

  (0.1

)%

  11.0

%

  1.9

%

Effective income tax rate

  20.7%  (70.4

%)

  16.2

%

 

Accounting for Uncertainty in Income Taxes

 

The Company had no unrecognized tax benefits for the years ended December 31, 2022 and 2021, respectively. The Company does not anticipate experiencing any significant increase or decrease in its unrecognized tax benefits within the twelve months following December 31, 2022.

 

In the normal course of business, Anika and its subsidiaries may be periodically examined by various taxing authorities. The Company files income tax returns in the United States on a federal basis, in certain U.S. states, and in certain foreign jurisdictions. The associated tax filings remain subject to examination by applicable tax authorities for a certain length of time following the tax year to which those filings relate. With a few exceptions, the Company is no longer subject to income tax examinations for years prior to 2019.
XML 38 R23.htm IDEA: XBRL DOCUMENT v3.22.4
Note 17- Earnings Per Share ("EPS")
 12 Months Ended
Dec. 31, 2022
Notes to Financial Statements  
Earnings Per Share [Text Block]

17. Earnings per Share (“EPS”)

 

Basic EPS is calculated by dividing net income (loss) by the weighted average number of shares outstanding during the period. Unvested restricted shares, although legally issued and outstanding, are not considered outstanding for purposes of calculating basic EPS. Diluted EPS is calculated by dividing net income by the weighted average number of shares outstanding plus the dilutive effect, if any, of outstanding share-based awards using the treasury stock method.

 

The following table provides share information used in the calculation of the Company's basic and diluted EPS (in thousands):

 

  

Years Ended December 31,

 
  

2022

  

2021

  

2020

 

Shares used in the calculation of basic EPS

  14,561   14,401   14,222 

Effect of dilutive securities:

            

Share based awards

  -   233   - 

Diluted shares used in the calculation of EPS

  14,561   14,634   14,222 

 

Stock options of 1.1 million shares were outstanding for the year ended December 31, 2021 and were not included in the computation of diluted EPS because the awards’ impact on EPS would have been anti-dilutive. The Company was in a loss position during the years ended December 31, 2022 and 2020, therefore all potential common shares would have been anti-dilutive and accordingly were excluded from the computation of diluted EPS.
XML 39 R24.htm IDEA: XBRL DOCUMENT v3.22.4
Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
Use of Estimates, Policy [Policy Text Block]

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America (“US GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 
Consolidation, Policy [Policy Text Block]

Principles of Consolidation

 

The accompanying consolidated financial statements include the accounts of Anika Therapeutics, Inc. and its wholly owned subsidiaries, Anika Securities, Inc., Anika Therapeutics S.r.l. (“Anika S.r.l.”), Anika Therapeutics Limited, Parcus Medical and Arthrosurface. All intercompany balances and transactions have been eliminated in consolidation.

 
Foreign Currency Transactions and Translations Policy [Policy Text Block]

Foreign Currency Translation

 

The functional currency of Anika S.r.l. is the Euro, and the functional currency of Anika Therapeutics Limited is the British Pound Sterling. Assets and liabilities of the foreign subsidiaries are translated using the exchange rate existing on each respective balance sheet date. Revenues and expenses are translated using the average exchange rates for the period. The translation adjustments resulting from this process are included in stockholders’ equity as a component of accumulated other comprehensive income (loss) which resulted in a gain (loss) from foreign currency translation of ($0.7) million, ($1.2) million, and $1.3 million for the years ended December 31, 2022, 2021, and 2020, respectively.

 

Gains and losses resulting from foreign currency transactions are recognized in the consolidated statements of operations. Recorded balances that are denominated in a currency other than the functional currency are remeasured to the functional currency using the exchange rate at the balance sheet date and gains or losses are recorded in the statements of operations. The Company recognized a gain (loss) from foreign currency transactions of ($0.5) million, ($0.4) million, and $0.3 million during the years ended December 31, 2022, 2021, and 2020, respectively

 
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]

Accounts Receivable

 

The Company estimates an allowance for credit losses with its accounts receivable resulting from the inability of its customers to make required payments, which is included in selling, general and administrative expenses in the accompanying consolidated statements of operations. In determining the adequacy of the allowance, management specifically analyzes individual accounts receivable, historical bad debts, customer concentrations, customer creditworthiness, current and reasonable and supportable forecasts of future economic conditions, accounts receivable aging trends, and changes in the Company’s customer payment terms.

 

The components of the Company’s accounts receivables are as follows:

 

  

As of December 31,

 
  

2022

  

2021

 

Accounts Receivable

 $36,235  $31,285 

Allowance for credit losses

  1,608   1,442 

Net balance, end of the year

  34,627   29,843 

 

A summary of activity in the allowance for credit losses is as follows:

 

  

As of December 31,

 
  

2022

  

2021

  

2020

 

Balance, beginning of the year

 $1,442  $1,523  $962 

Amounts provided

  554   156   635 

Amounts recovered

  (180)  (92

)

  (86

)

Amounts written off

  (158)  (73

)

  (78

)

Translation adjustments

  (50)  (72)  90 

Balance, end of the year

 $1,608  $1,442  $1,523 

 
Revenue [Policy Text Block]

Revenue Recognition

 

Pursuant to Accounting Standard Codification 606, Revenue from Contracts with Customers (“ASC 606”), the Company recognizes revenue when a customer obtains control of promised goods or services. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are capable of being distinct or distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.

 
Revenue from Contract with Customer [Policy Text Block]

Revenue

 

The Company generates sales principally through three types of customers: (i) commercial partnerships (ii) hospitals and ambulatory surgical centers (“ASCs”), and (iii) distributors, referred to as the distribution model.

 

For commercial partnership sales, the Company sells its products directly to these partners, who perform most of the downstream sales and marketing activities to customers and end-users. These arrangements may include the grant of certain licenses, performance of development services, and the supply of product. The Company’s largest such customer, DePuy Synthes Mitek Sports Medicine, a division of DePuy Orthopedics, Inc., part of the Johnson & Johnson Medical Companies (“Mitek”), represented 43%, 45% and 49% of total revenues for the years-ended December 31, 2022, 2021 and 2020 respectively. The Company completed the performance obligations related to granted licenses and development services under the agreements with Mitek prior to 2016 and has no remaining material performance obligations. The Company recognizes revenue from product sales when the customer obtains control of the Company’s product, which typically occurs upon shipment to the customer. Commercial partnership agreements may also include sales-based royalties and milestones. As the Company considered the license to be the predominant item to which the royalties relate for these agreements, sales-based royalties and milestones are only recognized when the later of the underlying sale occurs or the performance obligation to which the sales-based royalty has been satisfied (or partially satisfied). This is generally in the same period that the Company’s licensees complete their product sales in their territory, for which the Company is contractually entitled to a percentage-based royalty. The Company records royalty revenues based on estimated net sales of licensed products as reported to the Company by its commercial partners. The differences between actual and estimated royalty revenues have not been material and are typically adjusted in the following quarter when the actual amounts are known. Revenue from sales-based royalties is included in revenue in the consolidated statement of operations. The Company’s certain supply agreements represent a promise to deliver products at the customer’s discretion that are considered distributor options. The Company assesses if these options provide a material right to the licensee, and if so, they are accounted for as separate performance obligations. Substantially all of the Company’s supply agreements do not provide options that are considered material rights.

 

For sales to hospitals and ASCs, which generally pairs in-house sales representatives with local or regional distributors, the inventory is generally consigned so that products are available when needed for surgical procedures. No revenue is recognized upon the placement of inventory into consignment, as the Company retains the ability to control the inventory. Revenue is typically recognized as of the date of surgical implantation of the product.

 

For distributor sales, the Company sells its products principally to distributors, generally outside the United States, who subsequently resell the products to sub-distributors and health care providers, among others. The Company recognizes revenue from product sales when the distributor obtains control of the Company’s product, which typically occurs upon shipment to the distributor, in return for agreed-upon, fixed-price consideration. Performance obligations are generally settled quickly after purchase order acceptance; therefore, the value of unsatisfied performance obligations at the end of any reporting period is generally insignificant. The Company sells to a diversified base of distributors and, therefore, believes there is no material concentration of credit risk.

 

The Company’s payment terms are consistent with prevailing practice in the respective markets in which the Company does business. Most of the Company’s customers make payments based on contract terms, which are not affected by contingent events that could impact the transaction price. Payment terms fall within the one-year guidance for the practical expedient, which allows the Company to forgo adjustment of the contractual payment amount of consideration for the effects of a significant financing component.

 

Some of the Company’s distributor agreements have volume-based discounts with tiered pricing which are generally prospective in nature. These prospective discounts together with any free-of-charge sample units offered are evaluated as potential material rights. If the prospective discounts or free-of-charge sample units are considered material rights, these would be separate performance obligations and a portion of the sales transaction price is allocated to the material right. Revenue allocated to the material right is recognized when the additional goods are transferred to the customer or when the option expires. During 2022 and 2021, the consideration allocated to material rights was not significant.

 

The Company receives payments from its customers based on billing schedules established in each contract. Up-front payments and fees are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when its right to consideration is unconditional. Deferred revenue was $0 and $1.0 million as of December 31, 2022 and 2021, respectively.

 

Generally, customer contracts contain Free on Board (“FOB”) or Ex-Works shipping point terms where the customer pays the shipping company directly for all shipping and handling costs. In those contracts in which the Company pays for the shipping and handling, the associated costs are generally recorded along with the product sale at the time of shipment in cost of revenue when control over the products has transferred to the customer. Value-add and other taxes collected by the Company concurrently with revenue-producing activities are excluded from revenue. The Company’s general product warranty does not extend beyond an assurance that the product or services delivered will be consistent with stated contractual specifications, which does not create a separate performance obligation. The Company recognizes the incremental costs of obtaining contracts as an expense when incurred as the amortization period of the assets that the Company otherwise would have recognized is one year or less in accordance with the practical expedient in paragraph ASC 340-40-25-4. These costs are included in selling, general and administrative expenses.

 

Licensing, Milestone and Contract Revenue

 

The agreements with Mitek include variable consideration such as contingent development and regulatory milestones. Since 2016, there have been no remaining regulatory milestones related to the Mitek agreements. In general, variable consideration is included in the transaction price only to the extent a significant reversal in the amount of cumulative revenue recognized is not probable to occur.

 
Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

 

The Company considers only those investments which are highly liquid, readily convertible to cash, and that mature within 90 days from the date of purchase to be cash equivalents. The Company’s cash equivalents consist of money market funds.

 
Investment, Policy [Policy Text Block]

Investments

 

All of the Company’s investments are classified as available-for-sale which consist of U.S. treasury bills and are carried at fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income (loss), net of related income taxes. For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. Realized gains and losses on the sale of investments are recorded in interest and other income, net. Interest is recorded when earned. Investments with original maturities greater than approximately three months and remaining maturities less than one year are classified as short-term investments. Investments with remaining maturities greater than one year are classified as long-term investments. The Company had no investments as of December 31, 2022 or December 31, 2021.

 

All of the Company’s investments are subject to a periodic impairment review. For available-for-sale debt securities in an unrealized loss position, the Company first assesses whether (i) the Company intends to sell, or (ii) it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either case is affirmative, any previously recognized allowances are charged-off and the security's amortized cost is written down to fair value through earnings. If neither case is affirmative, the security is evaluated to determine whether the decline in fair value has resulted from credit losses or other factors.

 

Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income. Adjustments to the allowance are reported in the consolidated statement of operations as a component of credit loss expense. Available-for-sale securities are charged-off against the allowance or, in the absence of any allowance, written down through earnings when deemed uncollectible by management or when either of the criteria regarding intent or requirement to sell is met.

 

During the years ended  December 31, 2022, 2021 and 2020, the Company did not record any impairment charges on its available-for-sale securities because it is not more likely than not that the Company will be required to sell these securities before the recovery of their cost basis.

 
Concentration Risk, Credit Risk, Policy [Policy Text Block]

Concentration of Credit Risk

 

The Company has no significant off-balance sheet risks related to foreign exchange contracts, option contracts, or other foreign hedging arrangements. The Company’s cash equivalents and investments are held with two major international financial institutions.

 

The Company, by policy, routinely assesses the financial strength of its customers. As a result, the Company believes that its accounts receivable credit risk exposure is limited.

 

As of December 31, 2022 and 2021, Mitek represented 47% and 41%, respectively, of the Company’s accounts receivable balance. No other single customer accounted for more than 10% of accounts receivable in either period.

 
Inventory, Policy [Policy Text Block]

Inventories

 

Inventories are primarily stated at the lower of standard cost and net realizable value, with cost determined using the first-in, first-out method. Work-in-process and finished goods inventories include materials, labor, and certain manufacturing overhead. Manufacturing variances attributable to abnormally low production are expensed in the period incurred.  

 

The Company’s policy is to write down inventory when conditions exist that suggest inventory may be in excess of anticipated demand or is obsolete based upon assumptions about future demand for the Company’s products and market conditions. The Company regularly evaluates the ability to realize the value of inventory based on a combination of factors including, but not limited to, historical usage rates, forecasted sales or usage, product end of life dates, and estimated current or future market values. Purchasing requirements and alternative usage avenues are explored within these processes to mitigate inventory exposure.

 

When recorded, inventory write-downs are intended to reduce the carrying value of inventory to its net realizable value. If actual demand for the Company’s products deteriorates, or if market conditions are less favorable than those projected, additional inventory write-downs may be required. Other long-term assets include inventory expected to remain on hand beyond one year.

 
Lessee, Leases [Policy Text Block]

Leases

 

At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the circumstances present and evaluates whether the lease is an operating lease or a finance lease at the commencement date. Operating and finance leases with a term greater than one year are recognized on the consolidated balance sheet as right-of-use assets, lease liabilities, and, if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease in the lease term where it is reasonably certain that it will exercise these options. Operating and finance lease liabilities and the corresponding right-of-use assets are recorded based on the present values of lease payments over the lease terms. The Company elected an accounting policy to combine the non-lease components (which include common area maintenance, taxes and insurance) with the related lease component. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a similar economic environment. Variable payments that do not depend on a rate or index are not included in the lease liability and are recognized as incurred. Lease contracts do not include residual value guarantees nor do they include restrictions or other covenants. Certain adjustments to the right-of-use assets may be required for items such as initial direct costs paid, incentives received or lease prepayments. If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure the finance and operating lease liabilities by using revised inputs as of the reassessment date, and adjust the right-of-use asset. Operating lease expense is recognized on a straight-line basis over the lease term. Finance lease expense is recognized based on the effective-interest method over the lease term.

 
Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment

 

Property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives, which are typically:

 

Asset

 

Estimated useful life
(in years)

 

Computer equipment and software

  3   -   10 

Furniture and fixtures

  5   -   7 

Equipment

  5   -   20 

Leasehold improvements

     

Shorter of useful life or term of lease

     

 

Maintenance and repairs are charged to expense when incurred; additions and improvements are capitalized. Fully depreciated assets are retained in the accounts until they are no longer used and no further charge for depreciation is made in respect of these assets. When an item is sold, retired or removed from service, the cost and related accumulated depreciation is relieved, and the resulting gain or loss, if any, is recognized in income.

 

Construction-in-process assets are stated at cost, which includes the cost of construction and other direct costs attributable to the construction. Construction-in-process assets are not depreciated until such time as the relevant assets are completed and put into use.

 
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]

Goodwill and IPR&D Assets

 

Goodwill is the amount by which the purchase price of acquired net assets in a business combination exceeded the fair values of net identifiable assets on the date of acquisition. Acquired In-Process Research and Development (“IPR&D”) represents the fair value assigned to research and development assets that the Company acquires that have not been completed at the date of acquisition or are pending regulatory approval in certain jurisdictions. The value assigned to the acquired IPR&D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenue from the projects, and discounting the net cash flows to present value.  

 

Goodwill and IPR&D are not amortized but are evaluated for impairment annually or more frequently if events or changes in circumstances indicate that the asset might be impaired. The goodwill impairment assessment is performed by reporting unit. A reporting unit is the operating segment, or a business one level below that operating segment (the component level) if discrete financial information is prepared and regularly reviewed by segment management. However, components are aggregated as a single reporting unit if they have similar economic characteristics. The Company has two reporting units: the legacy Anika reporting unit, which specializes in therapies based on its hyaluronic acid, or HA, technology platform, and a newly formed reporting unit established in 2020 upon the acquisitions of Parcus Medical and Arthrosurface. Factors that the Company considers important, on an overall company basis, that could trigger an impairment review include significant underperformance relative to historical or projected future operating results, significant changes in the Company’s use of the acquired assets or the strategy for its overall business, significant negative industry or economic trends, a significant decline in the Company’s stock price for a sustained period, or a reduction of its market capitalization relative to net book value.

 

Under U.S. GAAP, the Company has the option to perform a qualitative assessment to determine if it is necessary to perform the impairment test. If the Company concludes, based on a qualitative assessment, it is not more likely than not that the Goodwill or the IPR&D asset is impaired, the Company is not required to perform the quantitative test. The Company has an unconditional option to bypass the qualitative assessment in any period and proceed directly to the quantitative impairment test.

 

To conduct quantitative impairment tests of goodwill, the fair value of the reporting unit is compared to its carrying value. If the reporting unit’s carrying value exceeds its fair value, the Company records an impairment loss to the extent that the carrying value of goodwill exceeds its implied fair value, not to exceed the recorded amount of goodwill. The Company recorded a non-cash goodwill impairment charge with respect to the newly formed reporting unit amounted to $42.5 million for the year ended December 31, 2020. Please see Note 8, Goodwill for further details.

 

The Company performed a qualitative annual assessment for impairment of the remaining goodwill with respect to legacy Anika reporting unit as of November 30, 2022, including consideration of (i) general macroeconomic factors, (ii) industry and market conditions, and (iii) the extent of the excess of the fair value over the carrying value indicated in prior impairment testing. Accordingly, the Company determined it was not more likely than not that the fair value of the legacy Anika reporting unit is less than its carrying amount and thus goodwill was not impaired as of November 30, 2022.

 

To conduct impairment tests of IPR&D, the fair value of the IPR&D project is compared to its carrying value. If the carrying value exceeds its fair value, the Company records an impairment loss to the extent that the carrying value of the IPR&D project exceeds its fair value. The Company estimates the fair value for IPR&D using the income approach, which is based on the Multi-Period Excess Earnings Method (“MPEEM”). MPEEM measures economic benefit indirectly by calculating the income attributable to an asset after appropriate returns are paid to complementary assets used in conjunction with the subject asset to produce the earnings associated with the subject asset, commonly referred to as contributory asset charges. This approach incorporates significant estimates and assumptions related to the forecasted results including revenues, expenses, expected economic life of the asset, contributory asset charges and discount rates to estimate future cash flows.

 
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]

Long-Lived Assets

 

Long-lived assets primarily include property and equipment and intangible assets with finite lives. The Company’s intangible assets are comprised of purchased developed technologies, patents, trade names, customer relationships and distributor relationships. These intangible assets are carried at cost, net of accumulated amortization. Amortization is recorded on a straight-line basis over the intangible assets' useful lives, which range from approximately five to sixteen years. The Company reviews long-lived assets for impairment when events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful lives of those assets are no longer appropriate. Each impairment test is based on a comparison of the undiscounted cash flows to the recorded value of the asset. If impairment is indicated, the asset is written down to its estimated fair value based on a discounted cash flow analysis.

 

In determining the useful lives of intangible assets, the Company considers the expected use of the assets and the effects of obsolescence, demand, competition, anticipated technological advances, changes in surgical techniques, market influences and other economic factors. For technology-based intangible assets, the Company considers the expected life cycles of products, absent unforeseen technological advances, which incorporate the corresponding technology.

 
Fair Value Measurement, Policy [Policy Text Block]

Fair Value Measurements

 

Fair value is defined as the price that would be received from selling an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of non-performance. The accounting standard establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

 

A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Three levels of inputs that may be used to measure fair value are:

 

 

•

Level 1 – Valuation is based upon quoted prices for identical instruments traded in active markets. Level 1 instruments include securities traded on active exchange markets, such as the New York Stock Exchange.

 

 

•

Level 2 – Valuation is based upon quoted prices, unadjusted, for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are directly observable in the market.

 

 

•

Level 3 – Valuation is generated from model-based techniques that use significant assumptions not observable in the market. These unobservable assumptions reflect the Company’s own estimates of assumptions market participants would use in pricing the instrument.

 

The Company’s financial assets have been classified as Level 1. The Company’s financial assets (which include cash equivalents and investments) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing third party pricing services. The Company’s financial liabilities have been classified as Level 3. The Company’s financial liabilities (which include contingent considerations as discussed in Note 4 – Fair Value Measurements) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing a third-party valuation specialist.

 
Research and Development Expense, Policy [Policy Text Block]

Research and Development

 

Research and development costs consist primarily of salaries and related expenses for personnel, clinical trial expenses and fees paid to outside consultants and outside service providers. Research and development costs are expensed as incurred.

 
Share-Based Payment Arrangement [Policy Text Block]

Stock-Based Compensation

 

The Company has stock-based compensation plans under which it grants various types of equity-based awards, the cost of which is based on the grant-date fair value of the underlying award and recognized over the period during which an employee is required to provide service in exchange for the award, which is generally the vesting period.

 

For performance-equity awards with market-based conditions, compensation cost is measured at the date of the award and is recorded over the vesting period, regardless of the likelihood of achievement of the market-based performance criteria. For performance-based equity awards with financial and business milestone achievement targets, compensation cost is based on the probable outcome of the performance conditions. Changes to the probability assessment and the estimated shares expected to vest will result in adjustments to the related stock-based compensation expense that will be recorded in the period of the change. If the performance targets are not achieved, no compensation cost is recognized, and any previously recognized compensation cost is reversed.

 

See Note 14, Equity Incentive Plan, for a description of the types of stock-based awards granted, the compensation expense related to such awards, and detail of equity-based awards outstanding.

 
Income Tax, Policy [Policy Text Block]

Income Taxes

 

We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets, or DTAs, and deferred tax liabilities, or DTLs, for the expected future tax consequences of events that have been included in the financial statements. Under this method, we determine DTAs and DTLs based on the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on DTAs and DTLs is recognized in income in the period that includes the enactment date.

 

We recognize DTAs to the extent that we believe that these assets are more likely than not to be realized. In making such a determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, carryback potential if permitted under the tax law, and results of recent operations.

 

We record uncertain tax positions in accordance with ASC 740, Income Taxes, on the basis of a two-step process in which (1) we determine whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. Interest and penalties associated with income tax filings are recorded in income tax expense.

 
Comprehensive Income, Policy [Policy Text Block]

Comprehensive Income (Loss)

 

Comprehensive income (loss) consists of net income (loss) and other comprehensive income (loss), which includes foreign currency translation adjustments. For the purposes of comprehensive income (loss) disclosures, the Company does not record tax provisions or benefits for the net changes in the foreign currency translation adjustment, as it intends to indefinitely reinvest undistributed earnings of its foreign subsidiary. Accumulated other comprehensive income (loss) is reported as a component of stockholders' equity.

 
Segment Reporting, Policy [Policy Text Block]

Segment Information

 

Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is its President and Chief Executive Officer as of December 31, 2022. Based on the criteria established by ASC 280, Segment Reporting, the Company has one operating and reportable segment.

 
Commitments and Contingencies, Policy [Policy Text Block]

Contingencies

 

In the normal course of business, the Company is involved from time-to-time in various legal proceedings and other matters such as contractual disputes, which are complex in nature and have outcomes that are difficult to predict. The Company records accruals for loss contingencies to the extent that it concludes that it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. The Company considers all relevant factors when making assessments regarding these contingencies. Although the outcomes of any potential legal proceedings are inherently difficult to predict, the Company does not expect the resolution of any potential legal proceedings to have a material adverse effect on its financial position, results of operations, or cash flow.

 
New Accounting Pronouncements, Policy [Policy Text Block]

Recent Issued Accounting Pronouncements

 

No new accounting pronouncements issued or effective during the period had, or are expected to have, a material impact on the consolidated financial statements.
XML 40 R25.htm IDEA: XBRL DOCUMENT v3.22.4
Note 2 - Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]
  

As of December 31,

 
  

2022

  

2021

 

Accounts Receivable

 $36,235  $31,285 

Allowance for credit losses

  1,608   1,442 

Net balance, end of the year

  34,627   29,843 
  

As of December 31,

 
  

2022

  

2021

  

2020

 

Balance, beginning of the year

 $1,442  $1,523  $962 

Amounts provided

  554   156   635 

Amounts recovered

  (180)  (92

)

  (86

)

Amounts written off

  (158)  (73

)

  (78

)

Translation adjustments

  (50)  (72)  90 

Balance, end of the year

 $1,608  $1,442  $1,523 
Property, Plant and Equipment Estimated Useful Lives [Table Text Block]

Asset

 

Estimated useful life
(in years)

 

Computer equipment and software

  3   -   10 

Furniture and fixtures

  5   -   7 

Equipment

  5   -   20 

Leasehold improvements

     

Shorter of useful life or term of lease

     
XML 41 R26.htm IDEA: XBRL DOCUMENT v3.22.4
Note 3 - Business Combinations (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Business Acquisitions, by Acquisition [Table Text Block]

Cash consideration

 $32,794 

Deferred consideration

  1,642 

Estimated fair value of contingent consideration

  40,700 

Estimated total purchase consideration

 $75,136 

Cash consideration

 $61,909 

Estimated fair value of contingent consideration

  28,376 

Estimated total purchase consideration

 $90,285 
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

Recognized identifiable assets acquired and liabilities assumed:

    

Cash and cash equivalents

 $196 

Accounts receivable

  2,029 

Inventories

  10,968 

Prepaid expenses and other current assets

  364 

Property and equipment, net

  1,099 

Right-of-use assets

  944 

Intangible assets

  44,000 

Accounts payable, accrued expenses and other current liabilities

  (2,763

)

Other long-term liabilities

  (594

)

Lease liabilities

  (735

)

Net assets acquired

  55,508 

Goodwill

  19,628 

Estimated total purchase consideration

 $75,136 

Recognized identifiable assets acquired and liabilities assumed:

    

Cash and cash equivalents

 $1,072 

Accounts receivable

  5,368 

Inventories

  15,652 

Prepaid expenses and other current assets

  535 

Property, plant and equipment

  3,394 

Other long-term assets

  7,548 

Intangible assets

  48,900 

Accounts payable, accrued expenses and other liabilities

  (3,929

)

Deferred tax liabilities

  (11,147

)

Net assets acquired

  67,393 

Goodwill

  22,892 

Estimated total purchase consideration

 $90,285 
Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]

Developed technology

 $41,100 

Trade name

  1,800 

Customer relationships

  1,100 

Total acquired intangible assets

 $44,000 

Intangible assets acquired consist of:

    

Developed technology

 $37,000 

Trade name

  3,400 

Customer relationships

  7,900 

IPR&D

  600 

Total acquired intangible assets

 $48,900 
Business Acquisition, Pro Forma Information [Table Text Block]
  

Year Ended December 31,

2020

 

Total revenue

 $134,410 

Net loss

 $(22,984)
XML 42 R27.htm IDEA: XBRL DOCUMENT v3.22.4
Note 4 - Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Fair Value, Assets Measured on Recurring Basis [Table Text Block]
      

Active Markets

  

Significant Other

  

Significant

     
      

for Identical Assets

  

Observable Inputs

  

Unobservable Inputs

     
  

December 31, 2022

  

(Level 1)

  

(Level 2)

  

(Level 3)

  

Amortized Cost

 

Cash equivalents:

                    

Money Market Funds

 $67,801  $67,801  $-  $-  $67,801 
      

Active Markets

  

Significant Other

  

Significant

     
      

for Identical Assets

  

Observable Inputs

  

Unobservable Inputs

     
  

December 31, 2021

  

(Level 1)

  

(Level 2)

  

(Level 3)

  

Amortized Cost

 

Cash equivalents:

                    

Money Market Funds

 $67,046  $67,046  $-  $-  $67,046 
                     

Other current and long-term liabilities:

                    

Contingent Consideration - Short Term

 $4,315  $-  $-  $4,315  $- 
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
  

Years Ended December 31

 
  

2022

  

2021

 

Balance, beginning January 1

 $4,315  $35,410 

Additions

  -   - 

Payments

  (4,315

)

  (10,000

)

Change in fair value

  -   (21,095

)

Balance, ending December 31

 $-  $4,315 
XML 43 R28.htm IDEA: XBRL DOCUMENT v3.22.4
Note 5 - Inventories (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Inventory, Current [Table Text Block]
   

As of December 31,

  
   

2022

    

2021

  

Raw materials

   $ 20,535     $ 16,881  

Work-in-process

     10,648       11,442  

Finished goods

     25,306       26,731  

Total

   $ 56,489     $ 55,054  
                 

Inventories

   $ 39,765     $ 36,010  

Other long-term assets

     16,724       19,044  
Total   $ 56,489     $ 55,054  
XML 44 R29.htm IDEA: XBRL DOCUMENT v3.22.4
Note 6 - Property and Equipment (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Property, Plant and Equipment [Table Text Block]
   

As of December 31,

  
   

2022

    

2021

  

Equipment and software

   $ 52,112     $ 48,804  

Furniture and fixtures

     2,413       2,389  

Leasehold improvements

     34,916       34,614  

Construction in progress

     5,021       1,378  

Subtotal

     94,462       87,185  

Less accumulated depreciation

     (46,183 )     (39,583

)

Total

   $ 48,279     $ 47,602  
XML 45 R30.htm IDEA: XBRL DOCUMENT v3.22.4
Note 7 - Acquired Intangible Assets, Net (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Finite-Lived and Indefinite-Lived Intangible Assets by Major Class [Table Text Block]
      

Year Ended December 31, 2022

 
  

Gross Cost

  

Less: Accumulated

Currency Translation

Adjustment

  

Less: Current Period

Impairment Charge

  

Less: Accumulated

Amortization

  

Net Book Value

  

Weighted

Average Useful

Life (in Years)

 

Developed technology

 $89,580  $(1,608) $-  $(23,686) $64,286   15 

IPR&D

  2,656   (1,006)  -   -   1,650  

Indefinite

 

Customer relationships

  9,000   -   -   (2,627)  6,373   10 

Distributor relationships

  4,700   (415)  -   (4,285)  -   5 

Patents

  1,000   (189)  -   (680)  131   16 

Tradenames

  5,200   -   -   (3,041)  2,159   5 

Total

 $112,136  $(3,218) $-  $(34,319) $74,599   13 
      

Year Ended December 31, 2021

 
  

Gross Cost

  

Less: Accumulated

Currency Translation

Adjustment

  

Less: Current Period

Impairment Charge

  

Less: Accumulated

Amortization

  

Net Book Value

  

Weighted

Average Useful

Life

 

Developed technology

 $89,580  $(1,608

)

 $-  $(17,891

)

 $70,081   15 

IPR&D

  3,256   (1,006

)

  (600

)

  -   1,650  

Indefinite

 

Customer relationships

  9,000   -   -   (1,727

)

  7,273   10 

Distributor relationships

  4,700   (415

)

  -   (4,285

)

  -   5 

Patents

  1,000   (189

)

  -   (632

)

  179   16 

Tradenames

  5,200   -   -   (2,001

)

  3,199   5 

Total

 $112,736  $(3,218

)

 $(600

)

 $(26,536

)

 $82,382   13 
XML 46 R31.htm IDEA: XBRL DOCUMENT v3.22.4
Note 8 - Goodwill (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Goodwill [Table Text Block]
  

Years Ended December 31

 
  

2022

  

2021

 

Balance, beginning January 1

 $7,781  $8,413 

Effect of foreign currency adjustments

  (442)  (632)

Balance, ending December 31

 $7,339  $7,781 
XML 47 R32.htm IDEA: XBRL DOCUMENT v3.22.4
Note 9 - Leases (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Lease, Cost [Table Text Block]
  Years Ended December 31 
  

2022

  

2021

  

2020

 

Finance lease amortization of right-of-use assets

 $121  $143  $185 

Interest on finance lease liabilities

  11   19   25 

Finance lease expense

  132   162   210 

Operating lease expense

  2,839   2,468   2,383 

Short-term lease expense

  17   2   - 

Variable lease expense

  413   319   264 

Total lease expense

 $3,401  $2,951  $2,857 
  

Years Ended December 31

 
  

2022

  

2021

 

Weighted Average Remaining Lease Term (in years)

        

Operating leases

  14.8   15.3 

Financing leases

  -   2.3 

Weighted Average Discount Rate

        

Operating leases

  3.6

%

  4.1

%

Financing leases

  -   4.9

%

Other information

        

Operating cash flows from operating leases

 $2,471  $2,392 

Operating cash flows from financing leases

 $121  $136 
Lessee, Operating Lease and Finance Lease, Liability, Maturity [Table Text Block]

Years ended December 31,

 

Operating Leases

 
     

2023

 $3,170 

2024

  3,055 

2025

  3,066 

2026

  2,760 

2027

  2,643 

Thereafter

  25,230 

Present value adjustment

  (9,034)

Present value of lease payments

  30,890 

Less current portion included in accrued expenses and other current liabilities

  (2,073)

Total lease liabilities

 $28,817 
XML 48 R33.htm IDEA: XBRL DOCUMENT v3.22.4
Note 10 - Accrued Expenses and Other Liabilities (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Accrued Liabilities [Table Text Block]
   

As of December 31,

  
   

2022

    

2021

  
                 

Compensation and related expenses

   $ 11,303     $ 9,523  

Professional fees

     3,145       3,590  

Operating lease liability- current

     2,073       1,526  

Clinical trial costs

     999       1,961  

Finance lease liability - current

     -       188  

Income taxes payable

     810       -  

Other

     510       1,059  

Total

   $ 18,840     $ 17,847  
XML 49 R34.htm IDEA: XBRL DOCUMENT v3.22.4
Note 13 - Revenue and Geographic Information (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Revenue from External Customers by Products and Services [Table Text Block]
  

Years Ended December 31,

 
  

2022

  

2021

  

2020

 
  

Revenue

  

Percentage of
Product
Revenue

  

Revenue

  

Percentage of
Product
Revenue

  

Revenue

  

Percentage of
Product
Revenue

 

OA Pain Management

 $97,887   63

%

 $89,503   61

%

 $83,029   64

%

Joint Preservation and Restoration

  50,402   32

%

  48,588   33

%

  39,368   30

%

Non-Orthopedic

  7,947   5

%

  9,703   6

%

  8,060   6

%

Total

 $156,236   100

%

 $147,794   100

%

 $130,457   100

%
Schedule of Revenue and Operating Income by Geographical Areas [Table Text Block]
  

Years Ended December 31,

 
  

2022

  

2021

  

2020

 
  

Total

  

Percentage of

  

Total

  

Percentage of

  

Total

  

Percentage of

 
  

Revenue

  

Revenue

  

Revenue

  

Revenue

  

Revenue

  

Revenue

 

Geographic Location:

                        

United States

 $119,151   76% $113,833   77

%

 $103,182   79

%

Europe

  20,639   13%  19,580   13

%

  14,179   11

%

Other

  16,446   11%  14,381   10

%

  13,096   10

%

Total

 $156,236   100% $147,794   100

%

 $130,457   100

%
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]
  

Years Ended December 31,

 
  

2022

  

2021

 

United States

 $47,068  $46,068 

Italy

  1,211   1,534 

Total

 $48,279  $47,602 
XML 50 R35.htm IDEA: XBRL DOCUMENT v3.22.4
Note 14 - Equity Incentive Plan (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
  

Years Ended December 31,

 
  

2022

  

2021

  

2020

 

Cost of revenue

 

$

820

  

$

716

  

$

719

 

Research and development

  

1,646

   

1,233

   

713

 

Selling, general and administrative

  

11,849

   

9,136

   

3,954

 

Total stock-based compensation expense

 

$

14,315

  

$

11,085

  

$

5,386

 
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
  

Number of Options

  

Weighted Average Exercise Price

  

Weighted Average

Remaining

Contractual

Term (in years)

  

Aggregate Intrinsic

Value

(in thousands)

 

Outstanding as of December 31, 2021

  1,175,993  $39.56         

Granted

  553,827  $28.07         

Exercised

  (433) $8.83      $10 

Forfeited and canceled

  (198,684) $43.24         

Outstanding as of December 31, 2022

  1,530,703  $34.93   8.1  $1,050 

Vested, December 31, 2022

  640,056  $40.08   7.2  $12 

Vested or expected to vest, December 31, 2022

  1,530,703  $34.93   8.1  $1,050 
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
 

2022

 

2021

 

2020

Risk-free interest rate

1.28%

-

4.28%

 

0.29%

-

1.00%

 

0.21%

-

1.59%

Expected stock price volatility

53.80%

-

55.55%

 

54.80%

-

56.35%

 

46.48%

-

54.06%

Expected life of options (in years)

 

4.5

   

4.0

   

4.0

 

Expected dividend yield

 

0.0%

   

0.0%

   

-%

 

Fair value per option

 

11.45

   

14.80

   

16.31

 
Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]
  

Number of Shares

  

Weighted Average Fair Value

 

Outstanding as of December 31, 2021

 $412,658  $36.33 

Granted

  507,524  $25.14 

Vested

  (164,167) $36.77 

Forfeited and cancelled

  (80,610) $(31.40)

Outstanding as of December 31, 2022

 $675,405  $28.40 
Schedule of Nonvested Performance-Based Units Activity [Table Text Block]
  

Number of Shares

  

Weighted Average Fair Value

 

Outstanding as of December 31, 2021

  158,297  $37.44 

Granted

  2,125  $32.53 

Vested

  (19,125) $32.53 

Forfeited and cancelled

  (23,400) $41.86 

Outstanding as of December 31, 2022

  117,897  $34.98 
XML 51 R36.htm IDEA: XBRL DOCUMENT v3.22.4
Note 16 - Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]
  

Years ended December 31,

 
  

2022

  

2021

  

2020

 

(Loss) income before income taxes

            

Domestic

 $(19,080) $(2,529

)

 $(25,722)

Foreign

  334   4,956   (2,902

)

  $(18,746) $2,427  $(28,624)
  

Years ended December 31,

 
  

2022

  

2021

  

2020

 

Provision for (benefit from) income taxes:

            

Current:

            

Federal

 $1,005  $494  $357 

State

  285   (635

)

  (1,970)

Foreign

  96   167   49 

Total current

  1,386   26   (1,564)

Deferred:

            

Federal

  (3,243)  (553

)

  (1,980)

State

  (1,256)  (426

)

  (1,070)

Foreign

  (774)  (754

)

  (28)

Total deferred

  (5,273)  (1,733

)

  (3,078)

Total benefit from income taxes

 $(3,887) $(1,707

)

 $(4,642)
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
  

As of December 31,

 
  

2022

  

2021

 

Deferred tax assets:

        

Lease liability

 $7,468  $4,684 

Capitalized research expenditures

  5,451   - 

Stock-based compensation expense

  2,795   2,782 

Inventory reserves

  2,763   2,453 

Compensation accrual

  1,635   1,236 

Net operating loss carry forwards

  1,551   2,822 

Tax credits

  741   3,022 

Accrued expenses

  519   491 

Foreign currency exchange

  221   282 

Deferred tax assets

 $23,144  $17,772 
  

As of December 31,

 
  

2022

  

2021

 

Deferred tax liabilities:

        

Acquisition-related intangible asset

 $(12,075) $(14,770

)

Depreciation

  (8,804)  (8,509

)

Right of use asset

  (7,252)  (4,650

)

Deferred tax liabilities

 $(28,131) $(27,929

)

         

Net deferred tax liabilities

 $(4,987) $(10,157

)
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
  

Years ended December 31,

 
  

2022

  

2021

  

2020

 

Statutory federal income tax rate

  21.0%  21.0

%

  21.0

%

State tax expense, net of federal benefit

  1.4%  (3.2

%)

  1.5

%

Stock compensation

  (4.7%)  22.3

%

  (2.2

%)

Section 162(m) limitation

  (8.2%)  8.7

%

  - 

Goodwill impairment

  -   -

 

  (16.8

%)

Change in fair value of contingent consideration

  -   (36.7

%)

  6.7

%

Change in tax rates and state apportionment

  1.2%  (29.8

%)

  4.9

%

Federal, state and foreign tax credits

  5.1%  (28.4

%)

  2.2

%

Valuation allowance

  -   (35.3

%)

  (3.0

%)

Return to provision adjustments

  5.0%  -

 

  -

 

Other permanent items

  (0.1

)%

  11.0

%

  1.9

%

Effective income tax rate

  20.7%  (70.4

%)

  16.2

%
XML 52 R37.htm IDEA: XBRL DOCUMENT v3.22.4
Note 17- Earnings Per Share ("EPS") (Tables)
 12 Months Ended
Dec. 31, 2022
Notes Tables  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
  

Years Ended December 31,

 
  

2022

  

2021

  

2020

 

Shares used in the calculation of basic EPS

  14,561   14,401   14,222 

Effect of dilutive securities:

            

Share based awards

  -   233   - 

Diluted shares used in the calculation of EPS

  14,561   14,634   14,222 
XML 53 R38.htm IDEA: XBRL DOCUMENT v3.22.4
Note 2 - Summary of Significant Accounting Policies (Details Textual)
$ in Thousands
 11 Months Ended 12 Months Ended
Nov. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total   $ (700) $ (1,200) $ 1,300
Foreign Currency Transaction Gain (Loss), before Tax, Total   (500) (400) 300
Contract with Customer, Liability, Total   0 1,000  
Debt Securities, Available-for-Sale, Noncurrent   $ 0 0  
Number of Reporting Units   2    
Goodwill, Impairment Loss $ 0 $ 0 $ 0 $ 42,520
Number of Operating Segments   1    
Minimum [Member]        
Property, Plant and Equipment, Useful Life (Year)   5 years    
Maximum [Member]        
Property, Plant and Equipment, Useful Life (Year)   16 years    
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | DePuy Mitek Inc [Member]        
Concentration Risk, Percentage   43.00% 45.00% 49.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | DePuy Mitek Inc [Member]        
Concentration Risk, Percentage   47.00% 41.00%  
XML 54 R39.htm IDEA: XBRL DOCUMENT v3.22.4
Note 2 - Summary of Significant Accounting Policies - Allowance for Doubtful Accounts (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Accounts Receivable $ 36,235 $ 31,285  
Allowance for credit losses 1,608 1,442  
Net balance, end of the year 34,627 29,843  
Balance, beginning of the year 1,442 1,523 $ 962
Amounts provided 554 156 635
Amounts recovered (180) (92) (86)
Amounts written off (158) (73) (78)
Translation adjustments (50) (72) 90
Balance, end of the year $ 1,608 $ 1,442 $ 1,523
XML 55 R40.htm IDEA: XBRL DOCUMENT v3.22.4
Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Details)
 12 Months Ended
Dec. 31, 2022
Minimum [Member]  
Estimated useful life (Year) 5 years
Maximum [Member]  
Estimated useful life (Year) 16 years
Computer Equipment and Software [Member] | Minimum [Member]  
Estimated useful life (Year) 3 years
Computer Equipment and Software [Member] | Maximum [Member]  
Estimated useful life (Year) 10 years
Furniture and Fixtures [Member] | Minimum [Member]  
Estimated useful life (Year) 5 years
Furniture and Fixtures [Member] | Maximum [Member]  
Estimated useful life (Year) 7 years
Equipment [Member] | Minimum [Member]  
Estimated useful life (Year) 5 years
Equipment [Member] | Maximum [Member]  
Estimated useful life (Year) 20 years
XML 56 R41.htm IDEA: XBRL DOCUMENT v3.22.4
Note 3 - Business Combinations (Details Textual) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 12 Months Ended
Feb. 03, 2020
Jan. 24, 2020
Jul. 31, 2021
Jun. 30, 2021
Oct. 31, 2020
Mar. 31, 2020
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Sep. 30, 2021
Business Combination, Contingent Consideration, Liability, Current             $ 0 $ 4,315    
Finite-Lived Intangible Asset, Useful Life (Year)             13 years 13 years    
Payment for Contingent Consideration Liability, Financing Activities             $ 4,315 $ 7,220 $ 4,478  
Developed Technology Rights [Member]                    
Finite-Lived Intangible Asset, Useful Life (Year)             15 years 15 years    
Customer Relationships [Member]                    
Finite-Lived Intangible Asset, Useful Life (Year)             10 years 10 years    
Trade Names [Member]                    
Finite-Lived Intangible Asset, Useful Life (Year)             5 years 5 years    
Parcus Medical [Member]                    
Business Combination, Consideration Transferred, Total   $ 75,136                
Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High   60,000                
Business Combination, Contingent Consideration, Liability, Current               $ 4,300   $ 4,300
Business Combination, Acquisition Related Costs           $ 1,900        
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles   $ 44,000                
Parcus Medical [Member] | Developed Technology Rights [Member]                    
Finite-Lived Intangible Asset, Useful Life (Year)   15 years                
Parcus Medical [Member] | Customer Relationships [Member]                    
Finite-Lived Intangible Asset, Useful Life (Year)   10 years                
Parcus Medical [Member] | Trade Names [Member]                    
Finite-Lived Intangible Asset, Useful Life (Year)   5 years                
Arthrosurface [Member]                    
Business Combination, Consideration Transferred, Total $ 90,285                  
Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High 40,000                  
Business Combination, Acquisition Related Costs           $ 2,200        
Payment for Contingent Consideration Liability, Financing Activities     $ 10,000 $ 10,000 $ 5,000          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles $ 48,900                  
Arthrosurface [Member] | Developed Technology Rights [Member]                    
Finite-Lived Intangible Asset, Useful Life (Year) 15 years                  
Arthrosurface [Member] | Customer Relationships [Member]                    
Finite-Lived Intangible Asset, Useful Life (Year) 10 years                  
Arthrosurface [Member] | Trade Names [Member]                    
Finite-Lived Intangible Asset, Useful Life (Year) 5 years                  
Arthrosurface [Member] | In Process Research and Development [Member]                    
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles             $ 600      
XML 57 R42.htm IDEA: XBRL DOCUMENT v3.22.4
Note 3 - Business Combinations - Consideration Transferred (Details) - USD ($)
$ in Thousands
Feb. 03, 2020
Jan. 24, 2020
Parcus Medical [Member]    
Cash consideration   $ 32,794
Deferred consideration   1,642
Estimated fair value of contingent consideration   40,700
Estimated total purchase consideration   $ 75,136
Arthrosurface [Member]    
Cash consideration $ 61,909  
Estimated fair value of contingent consideration 28,376  
Estimated total purchase consideration $ 90,285  
XML 58 R43.htm IDEA: XBRL DOCUMENT v3.22.4
Note 3 - Business Combinations - Fair Value of Net Assets Acquired (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Feb. 03, 2020
Jan. 24, 2020
Goodwill $ 7,339 $ 7,781 $ 8,413    
Parcus Medical [Member]          
Cash and cash equivalents         $ 196
Accounts receivable         2,029
Inventories         10,968
Prepaid expenses and other current assets         364
Property and equipment, net         1,099
Right-of-use assets         944
Intangible assets         44,000
Accounts payable, accrued expenses and other current liabilities         (2,763)
Other long-term liabilities         (594)
Lease liabilities         (735)
Net assets acquired         55,508
Goodwill         19,628
Estimated total purchase consideration         $ 75,136
Arthrosurface [Member]          
Cash and cash equivalents       $ 1,072  
Accounts receivable       5,368  
Inventories       15,652  
Prepaid expenses and other current assets       535  
Property and equipment, net       3,394  
Intangible assets       48,900  
Accounts payable, accrued expenses and other current liabilities       (3,929)  
Net assets acquired       67,393  
Goodwill       22,892  
Estimated total purchase consideration       90,285  
Other long-term assets       7,548  
Deferred tax liabilities       $ (11,147)  
XML 59 R44.htm IDEA: XBRL DOCUMENT v3.22.4
Note 3 - Business Combinations - Intangible Assets Acquired (Details) - USD ($)
$ in Millions
Feb. 03, 2020
Jan. 24, 2020
Parcus Medical [Member]    
Intangible assets   $ 44.0
Arthrosurface [Member]    
Intangible assets $ 48.9  
Developed Technology Rights [Member] | Parcus Medical [Member]    
Intangible assets   41.1
Developed Technology Rights [Member] | Arthrosurface [Member]    
Intangible assets 37.0  
Trade Names [Member] | Parcus Medical [Member]    
Intangible assets   1.8
Trade Names [Member] | Arthrosurface [Member]    
Intangible assets 3.4  
Customer Relationships [Member] | Parcus Medical [Member]    
Intangible assets   $ 1.1
Customer Relationships [Member] | Arthrosurface [Member]    
Intangible assets 7.9  
In Process Research and Development [Member] | Arthrosurface [Member]    
Intangible assets $ 0.6  
XML 60 R45.htm IDEA: XBRL DOCUMENT v3.22.4
Note 3 - Business Combinations - Pro Forma Information (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
USD ($)
Total revenue $ 134,410
Net loss $ (22,984)
XML 61 R46.htm IDEA: XBRL DOCUMENT v3.22.4
Note 4 - Fair Value Measurements (Details Textual)
$ in Thousands
 1 Months Ended 12 Months Ended
Feb. 03, 2020
USD ($)
Jan. 24, 2020
USD ($)
Jul. 31, 2021
USD ($)
Jun. 30, 2021
USD ($)
Oct. 31, 2020
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Sep. 30, 2021
USD ($)
Debt Securities, Available-for-sale, Total           $ 0      
Business Combination, Contingent Consideration, Liability, Current           0 $ 4,315    
Payment for Contingent Consideration Liability, Financing Activities           4,315 7,220 $ 4,478  
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability           0 (21,095) $ (28,666)  
Parcus Medical and Arthrosurface Acquisitions [Member]                  
Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High           $ 100,000      
Parcus Medical and Arthrosurface Acquisitions [Member] | Minimum [Member] | Measurement Input, Discount Rate [Member]                  
Business Combination, Contingent Consideration, Liability, Measurement Input           3.1      
Parcus Medical and Arthrosurface Acquisitions [Member] | Maximum [Member] | Measurement Input, Discount Rate [Member]                  
Business Combination, Contingent Consideration, Liability, Measurement Input           3.4      
Parcus Medical [Member]                  
Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High   $ 60,000              
Business Combination, Contingent Consideration, Liability, Current             $ 4,300   $ 4,300
Parcus Medical [Member] | Measurement Input, Weighted Average Cost of Capital [Member]                  
Business Combination, Contingent Consideration, Liability, Measurement Input             11.3 11.4  
Arthrosurface [Member]                  
Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High $ 40,000                
Payment for Contingent Consideration Liability, Financing Activities     $ 10,000 $ 10,000 $ 5,000        
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability             $ 21,100 $ 28,700  
Arthrosurface [Member] | Measurement Input, Weighted Average Cost of Capital [Member]                  
Business Combination, Contingent Consideration, Liability, Measurement Input               11.4  
XML 62 R47.htm IDEA: XBRL DOCUMENT v3.22.4
Note 4 - Fair Value Measurements - Fair Value of Financial Instruments (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Business Combination, Contingent Consideration, Liability, Current $ 0 $ 4,315
Estimate of Fair Value Measurement [Member]    
Business Combination, Contingent Consideration, Liability, Current   4,315
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member]    
Business Combination, Contingent Consideration, Liability, Current   0
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]    
Business Combination, Contingent Consideration, Liability, Current   0
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member]    
Business Combination, Contingent Consideration, Liability, Current   4,315
Reported Value Measurement [Member]    
Business Combination, Contingent Consideration, Liability, Current   0
Money Market Funds [Member] | Estimate of Fair Value Measurement [Member]    
Cash equivalents 67,801 67,046
Money Market Funds [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 1 [Member]    
Cash equivalents 67,801 67,046
Money Market Funds [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]    
Cash equivalents 0 0
Money Market Funds [Member] | Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 3 [Member]    
Cash equivalents 0 0
Money Market Funds [Member] | Reported Value Measurement [Member]    
Cash equivalents $ 67,801 $ 67,046
XML 63 R48.htm IDEA: XBRL DOCUMENT v3.22.4
Note 4 - Fair Value Measurements - Contingent Consideration (Details) - Contingent Consideration [Member] - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Balance $ 4,315 $ 35,410
Additions 0 0
Payments (4,315) (10,000)
Change in fair value 0 (21,095)
Balance $ 0 $ 4,315
XML 64 R49.htm IDEA: XBRL DOCUMENT v3.22.4
Note 5 - Inventories (Details Textual) - USD ($)
$ in Millions
Dec. 31, 2022
Dec. 31, 2021
Inventory Valuation Reserves $ 9.9 $ 9.1
XML 65 R50.htm IDEA: XBRL DOCUMENT v3.22.4
Note 5 - Inventories - Summary of Inventories (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Raw materials $ 20,535 $ 16,881
Work-in-process 10,648 11,442
Finished goods 25,306 26,731
Total 56,489 55,054
Inventories 39,765 36,010
Other long-term assets $ 16,724 $ 19,044
XML 66 R51.htm IDEA: XBRL DOCUMENT v3.22.4
Note 6 - Property and Equipment (Details Textual) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Depreciation, Total $ 6.7 $ 6.5 $ 6.1
XML 67 R52.htm IDEA: XBRL DOCUMENT v3.22.4
Note 6 - Property and Equipment - Property and Equipment at Cost (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Property, plant and equipment, gross $ 94,462 $ 87,185
Less accumulated depreciation (46,183) (39,583)
Total 48,279 47,602
Equipment and Software [Member]    
Property, plant and equipment, gross 52,112 48,804
Furniture and Fixtures [Member]    
Property, plant and equipment, gross 2,413 2,389
Leasehold Improvements [Member]    
Property, plant and equipment, gross 34,916 34,614
Construction in Progress [Member]    
Property, plant and equipment, gross $ 5,021 $ 1,378
XML 68 R53.htm IDEA: XBRL DOCUMENT v3.22.4
Note 7 - Acquired Intangible Assets, Net (Details Textual) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Amortization of Intangible Assets, Total     $ 7,800 $ 7,400  
Impairment of Intangible Assets, Finite-lived     0 600 $ 2,439
In Process Research and Development [Member]          
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)     0    
Impairment of Intangible Assets, Finite-lived     (0) 600  
Developed Technology Rights [Member]          
Impairment of Intangible Assets, Finite-lived     $ (0) $ (0)  
Selling, General and Administrative Expenses [Member] | Developed Technology Rights [Member]          
Impairment of Intangible Assets, Finite-lived         $ 1,000
Acquisitions of Parcus Medical and Arthrosurface [Member] | Research and Development Expense [Member]          
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) $ 600        
Parcus Medical and Arthrosurface [Member] | Research and Development Expense [Member]          
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)   $ 1,400      
XML 69 R54.htm IDEA: XBRL DOCUMENT v3.22.4
Note 7 - Acquired Intangible Assets, Net - Summary of Intangible Assets (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Gross value $ 112,136 $ 112,736  
Accumulated Currency Translation Adjustment (3,218) (3,218)  
Current period impairment charge 0 (600) $ (2,439)
Accumulated Amortization (34,319) (26,536)  
Net book value $ 74,599 $ 82,382  
Useful life (Year) 13 years 13 years  
Developed Technology Rights [Member]      
Gross value $ 89,580 $ 89,580  
Accumulated Currency Translation Adjustment (1,608) (1,608)  
Current period impairment charge 0 0  
Accumulated Amortization (23,686) (17,891)  
Net book value $ 64,286 $ 70,081  
Useful life (Year) 15 years 15 years  
In Process Research and Development [Member]      
Gross value $ 2,656 $ 3,256  
Accumulated Currency Translation Adjustment (1,006) (1,006)  
Current period impairment charge 0 (600)  
Accumulated Amortization 0 0  
Net book value 1,650 1,650  
Customer Relationships [Member]      
Gross value 9,000 9,000  
Accumulated Currency Translation Adjustment 0 0  
Current period impairment charge 0 0  
Accumulated Amortization (2,627) (1,727)  
Net book value $ 6,373 $ 7,273  
Useful life (Year) 10 years 10 years  
Distribution Rights [Member]      
Gross value $ 4,700 $ 4,700  
Accumulated Currency Translation Adjustment (415) (415)  
Current period impairment charge 0 0  
Accumulated Amortization (4,285) (4,285)  
Net book value $ 0 $ 0  
Useful life (Year) 5 years 5 years  
Patents [Member]      
Gross value $ 1,000 $ 1,000  
Accumulated Currency Translation Adjustment (189) (189)  
Current period impairment charge 0 0  
Accumulated Amortization (680) (632)  
Net book value $ 131 $ 179  
Useful life (Year) 16 years 16 years  
Trade Names [Member]      
Gross value $ 5,200 $ 5,200  
Accumulated Currency Translation Adjustment 0 0  
Current period impairment charge 0 0  
Accumulated Amortization (3,041) (2,001)  
Net book value $ 2,159 $ 3,199  
Useful life (Year) 5 years 5 years  
XML 70 R55.htm IDEA: XBRL DOCUMENT v3.22.4
Note 8 - Goodwill (Details Textual)
$ in Thousands
 3 Months Ended 11 Months Ended 12 Months Ended
Dec. 31, 2020
USD ($)
Mar. 31, 2020
USD ($)
Nov. 30, 2022
USD ($)
Nov. 30, 2021
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Number of Reporting Units         2    
Goodwill, Impairment Loss     $ 0   $ 0 $ 0 $ 42,520
Goodwill, Ending Balance $ 8,413       $ 7,339 $ 7,781 8,413
Parcus Medical and Arthrosurface [Member]              
Number of Reporting Units         2    
Goodwill, Impairment Loss 24,400 $ 18,100         42,500
Goodwill, Ending Balance $ 0           0
Legacy Anika Reporting Unit [Member]              
Goodwill, Impairment Loss   $ 0   $ 0     $ 0
XML 71 R56.htm IDEA: XBRL DOCUMENT v3.22.4
Note 8 - Goodwill - Changes in the Carrying Value of Goodwill (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Balance $ 7,781 $ 8,413
Effect of foreign currency adjustments (442) (632)
Balance $ 7,339 $ 7,781
XML 72 R57.htm IDEA: XBRL DOCUMENT v3.22.4
Note 9 - Leases (Details Textual)
Dec. 31, 2022
Dec. 31, 2021
Operating Lease, Weighted Average Discount Rate, Percent 3.60% 4.10%
XML 73 R58.htm IDEA: XBRL DOCUMENT v3.22.4
Note 9 - Leases - Lease Expense and Other Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Finance lease amortization of right-of-use assets $ 121 $ 143 $ 185
Interest on finance lease liabilities 11 19 25
Finance lease expense 132 162 210
Operating lease expense 2,839 2,468 2,383
Short-term lease expense 17 2 0
Variable lease expense 413 319 264
Total lease expense $ 3,401 $ 2,951 $ 2,857
Operating leases (Year) 14 years 9 months 18 days 15 years 3 months 18 days  
Financing leases (Year)   2 years 3 months 18 days  
Operating Lease, Weighted Average Discount Rate, Percent 3.60% 4.10%  
Financing leases 0.00% 4.90%  
Right-of-use assets obtained in exchange for operating lease liabilities $ 2,471 $ 2,392  
Operating cash flows from financing leases $ 121 $ 136  
XML 74 R59.htm IDEA: XBRL DOCUMENT v3.22.4
Note 9 - Leases - Future Minimum Rental Payments for Leases (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
2023, operating leases $ 3,170  
2024, operating leases 3,055  
2025, operating leases 3,066  
2026, operating leases 2,760  
2027, operating leases 2,643  
Thereafter 25,230  
Present value adjustment, operating leases (9,034)  
Total lease liabilities, operating leases 28,817 $ 19,240
Liabilities [Member]    
Present value of lease payments, operating leases 30,890  
Accrued Expenses and Other Current Liabilities [Member]    
Less current portion included in Accrued expenses and other current liabilities, operating leases $ (2,073) $ (1,526)
XML 75 R60.htm IDEA: XBRL DOCUMENT v3.22.4
Note 10 - Accrued Expenses and Other Liabilities - Summary of Accrued Expenses (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Compensation and related expenses $ 11,303 $ 9,523
Professional fees 3,145 3,590
Clinical trial costs 999 1,961
Income taxes payable 810 0
Other 510 1,059
Total 18,840 17,847
Accrued Expenses and Other Current Liabilities [Member]    
Operating lease liability- current 2,073 1,526
Finance lease liability - current $ 0 $ 188
XML 76 R61.htm IDEA: XBRL DOCUMENT v3.22.4
Note 11 - Revolving Credit Agreement (Details Textual) - Revolving Credit Facility [Member] - USD ($)
$ in Thousands
 12 Months Ended
Nov. 12, 2021
Apr. 08, 2020
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Line of Credit Facility, Current Borrowing Capacity $ 75,000        
Line of Credit Facility, Additional Borrowing Capacity 75,000        
Line of Credit Facility, Maximum Borrowing Capacity $ 150,000        
Debt Instrument, Term (Year) 5 years        
Long-Term Line of Credit, Total     $ 0 $ 0  
Proceeds from Long-term Lines of Credit   $ 50,000      
Debt Instrument, Interest Rate, Stated Percentage   2.08%      
Interest Expense, Debt, Total     $ 0 $ 0 $ 800
Minimum [Member]          
Debt Instrument, Basis Spread on Variable Rate 0.25%        
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage 0.20%        
Maximum [Member]          
Debt Instrument, Basis Spread on Variable Rate 1.00%        
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage 0.30%        
XML 77 R62.htm IDEA: XBRL DOCUMENT v3.22.4
Note 12 - Commitments and Contingencies (Details Textual) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Standard and Extended Product Warranty Accrual, Ending Balance $ 0 $ 0
XML 78 R63.htm IDEA: XBRL DOCUMENT v3.22.4
Note 13 - Revenue and Geographic Information (Details Textual) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenue from Contract with Customer, Excluding Assessed Tax $ 156,236 $ 147,794 $ 130,457
Revenues From Agreements as Percent of Total Revenue 43.00% 45.00% 49.00%
OA Pain Management [member]      
Revenue from Contract with Customer, Excluding Assessed Tax $ 97,887 $ 89,503 $ 83,029
Veterinary [Member] | OA Pain Management [member]      
Revenue from Contract with Customer, Excluding Assessed Tax $ 5,900 $ 4,400 $ 3,800
XML 79 R64.htm IDEA: XBRL DOCUMENT v3.22.4
Note 13 - Revenue and Geographic Information - Disaggregated Revenues (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenue $ 156,236 $ 147,794 $ 130,457
Percent of revenue 100.00% 100.00% 100.00%
OA Pain Management [member]      
Revenue $ 97,887 $ 89,503 $ 83,029
Percent of revenue 63.00% 61.00% 64.00%
Joint Preservation and Restoration [Member]      
Revenue $ 50,402 $ 48,588 $ 39,368
Percent of revenue 32.00% 33.00% 30.00%
Non-Orthopedic [Member]      
Revenue $ 7,947 $ 9,703 $ 8,060
Percent of revenue 5.00% 6.00% 6.00%
XML 80 R65.htm IDEA: XBRL DOCUMENT v3.22.4
Note 13 - Revenue and Geographic Information - Total Revenue by Geographic Location (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenue $ 156,236 $ 147,794 $ 130,457
Percent of revenue 100.00% 100.00% 100.00%
UNITED STATES      
Revenue $ 119,151 $ 113,833 $ 103,182
Percent of revenue 76.00% 77.00% 79.00%
Europe [Member]      
Revenue $ 20,639 $ 19,580 $ 14,179
Percent of revenue 13.00% 13.00% 11.00%
Other Location [Member]      
Revenue $ 16,446 $ 14,381 $ 13,096
Percent of revenue 11.00% 10.00% 10.00%
XML 81 R66.htm IDEA: XBRL DOCUMENT v3.22.4
Note 13 - Revenue and Geographic Information - Net Tangible Long-lived Assets by Principal Geographic Areas (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Property and equipment, net $ 48,279 $ 47,602
UNITED STATES    
Property and equipment, net 47,068 46,068
ITALY    
Property and equipment, net $ 1,211 $ 1,534
XML 82 R67.htm IDEA: XBRL DOCUMENT v3.22.4
Note 14 - Equity Incentive Plan (Details Textual) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2020
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Nov. 04, 2021
Mar. 17, 2021
Dec. 31, 2019
Jun. 13, 2017
Share-Based Payment Arrangement, Expense, Tax Benefit   $ 1,100,000            
Effective Income Tax Rate Reconciliation, Share-based Compensation, Windfall Tax Benefit, Amount   (500,000) $ 100,000 $ 200,000        
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value   $ 10,000 $ 300,000 $ 2,800,000        
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)   553,827            
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)   1,530,703 1,175,993          
Premium-Priced Employee Stock Options [Member]                
Share-based Compensation Arrangement by Share-based Payment Award, Premium Priced Options, Exercise Price as Percentage of Market Price   110.00%            
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)   398,314            
Share-Based Payment Arrangement, Option [Member]                
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)   10 years            
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total   $ 7,400,000            
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)   1 year 9 months 18 days            
Total Shareholder Return ("TSRs") Options [Member]                
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)   2 years 8 months 12 days            
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)   6 years 3 months 18 days            
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)   139,168            
Restricted Stock Units (RSUs) [Member]                
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total   $ 12,300,000            
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)   1 year 9 months 18 days            
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)   $ 25.14 $ 35.88 $ 38.20        
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value   $ 6,000,000.0 $ 3,700,000 $ 2,200,000        
Performance Shares [Member]                
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)   $ 32.53 $ 0 $ 36.93        
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value   $ 600,000 $ 0 $ 0        
Performance Shares [Member] | Granted in 2019 [Member]                
Share-based Compensation, Performance Shares Measured by Business Targets             30.00%  
Share-based Compensation, Performance Shares Measured by Financial Targets   55.00%            
Share-based Compensation, Performance Shares Measured by Financial Targets, Not Achieved   15.00%            
Performance Shares [Member] | Granted in 2020 [Member]                
Share-based Compensation, Performance Shares Measured by Financial Targets, Not Achieved   60.00%            
Share-based Compensation, Performance Shares Measured by Business Targets, Not Achieved   20.00% 20.00%          
Selling, General and Administrative Expenses [Member]                
Share-Based Payment Arrangement, Expense, Tax Benefit $ 1,800,000              
Minimum [Member] | Share-Based Payment Arrangement, Option [Member]                
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)   3 years            
Minimum [Member] | Total Shareholder Return ("TSRs") Options [Member]                
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Target Number   0.00%            
Minimum [Member] | Restricted Stock Units (RSUs) [Member]                
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)   3 years            
Minimum [Member] | Performance Shares [Member]                
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)   3 years            
Maximum [Member] | Share-Based Payment Arrangement, Option [Member]                
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)   4 years            
Maximum [Member] | Total Shareholder Return ("TSRs") Options [Member]                
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Target Number   150.00%            
Maximum [Member] | Restricted Stock Units (RSUs) [Member]                
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)   4 years            
The 2017 Plan [Member]                
Number of Shares Available for Grant Reduced By Each Share Award Issued Other Than Options or SARs (in shares)               2
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)               4,600,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)   1,200,000            
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)   10 years            
The 2017 Plan [Member] | Minimum [Member]                
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)   1 year            
The 2017 Plan [Member] | Maximum [Member]                
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)   4 years            
The 2021 Inducement Plan [Member]                
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)   4,883            
Common Stock, Capital Shares Reserved for Future Issuance (in shares)         125,000      
Employee Stock Purchase Plan (ESPP) [Member]                
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)           200,000    
Share Based Compensation Arrangement by Share Based Payment Award Number of Shares Authorized per Offering Period (in shares)           800    
Share Based Compensation Arrangement by Share Based Payment Award, Value Authorized           $ 25,000    
Represents Share Based Compensation Arrangement by Share Based Payment Award, Payroll Deduction percentage           10.00%    
Represents Share Based Compensation Arrangement by Share Based Payment Award, the Purchase Price for Each Share Purchased, Percentage           85.00%    
XML 83 R68.htm IDEA: XBRL DOCUMENT v3.22.4
Note 14 - Equity Incentive Plan - Total Stock-based Compensation Expense (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Stock-based compensation expense $ 14,315 $ 11,085 $ 5,386
Cost of Sales [Member]      
Stock-based compensation expense 820 716 719
Research and Development Expense [Member]      
Stock-based compensation expense 1,646 1,233 713
Selling, General and Administrative Expenses [Member]      
Stock-based compensation expense $ 11,849 $ 9,136 $ 3,954
XML 84 R69.htm IDEA: XBRL DOCUMENT v3.22.4
Note 14 - Equity Incentive Plan - Stock Options (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Outstanding, shares (in shares) 1,175,993    
Outstanding, Weighted Average Exercise (in dollars per share) $ 39.56    
Granted, shares (in shares) 553,827    
Granted, Weighted Average Exercise Price (in dollars per share) $ 28.07    
Exercised, shares (in shares) (433)    
Exercised, Weighted Average Exercise Price (in dollars per share) $ 8.83    
Exercised, Aggregate Intrinsic Value $ 10 $ 300 $ 2,800
Forfeited and canceled, shares (in shares) (198,684)    
Forfeited and canceled, Weighted Average Exercise Price (in dollars per share) $ 43.24    
Outstanding, shares (in shares) 1,530,703 1,175,993  
Outstanding, Weighted Average Exercise Price (in dollars per share) $ 34.93    
Outstanding, Weighted Average Remaining Contractual Term (Year) 8 years 1 month 6 days    
Outstanding, Aggregate Intrinsic Value $ 1,050    
Vested, shares (in shares) 640,056    
Vested, Weighted Average Exercise Price (in dollars per share) $ 40.08    
Vested, Weighted Average Remaining Contractual Term (Year) 7 years 2 months 12 days    
Vested, Aggregate Intrinsic Value $ 12    
Vested and expected to vest, shares (in shares) 1,530,703    
Vested and expected to vest, Weighted Average Exercise Price (in dollars per share) $ 34.93    
Vested and expected to vest, Weighted Average Remaining Contractual Term (Year) 8 years 1 month 6 days    
Vested and expected to vest, Aggregate Intrinsic Value $ 1,050    
XML 85 R70.htm IDEA: XBRL DOCUMENT v3.22.4
Note 14 - Equity Incentive Plan - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Expected stock price volatility 4.50% 4.00% 4.00%
Expected dividend yield 0.00% 0.00%  
Fair value per option 0.1145 0.1480  
Minimum [Member]      
Risk-free interest rate 1.28% 0.29% 0.21%
Expected stock price volatility 53.80% 54.80% 46.48%
Maximum [Member]      
Risk-free interest rate 4.28% 1.00% 1.59%
Expected stock price volatility 55.55% 56.35% 54.06%
XML 86 R71.htm IDEA: XBRL DOCUMENT v3.22.4
Note 14 - Equity Incentive Plan - Restricted Stock Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Outstanding, shares (in shares) 412,658    
Outstanding, weighted average grant date fair value (in dollars per share) $ 36.33    
Granted (in shares) 507,524    
Granted, weighted average grant date fair value (in dollars per share) $ 25.14 $ 35.88 $ 38.20
Vested, shares (in shares) (164,167)    
Vested, weighted average grant date fair value (in dollars per share) $ 36.77    
Forfeited and cancelled, shares (in shares) (80,610)    
Forfeited and cancelled, weighted average grant date fair value (in dollars per share) $ (31.40)    
Outstanding, shares (in shares) 675,405 412,658  
Outstanding, weighted average grant date fair value (in dollars per share) $ 28.40 $ 36.33  
XML 87 R72.htm IDEA: XBRL DOCUMENT v3.22.4
Note 14 - Equity Incentive Plan - Performance Stock Units (Details) - Performance Shares [Member] - $ / shares
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Outstanding, shares (in shares) 158,297    
Outstanding, weighted average grant date fair value (in dollars per share) $ 37.44    
Granted (in shares) 2,125    
Granted, weighted average grant date fair value (in dollars per share) $ 32.53 $ 0 $ 36.93
Vested, shares (in shares) (19,125)    
Vested, weighted average grant date fair value (in dollars per share) $ 32.53    
Forfeited and cancelled, shares (in shares) (23,400)    
Forfeited and cancelled, weighted average grant date fair value (in dollars per share) $ 41.86    
Outstanding, shares (in shares) 117,897 158,297  
Outstanding, weighted average grant date fair value (in dollars per share) $ 34.98 $ 37.44  
XML 88 R73.htm IDEA: XBRL DOCUMENT v3.22.4
Note 15 - Employee Benefit Plan (Details Textual) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Defined Contribution Plan, Employer Matching Contribution, Percent of Match 140.00%    
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay 5.00%    
Defined Contribution Plan, Employer Matching Contribution, Amount $ 2.3 $ 2.0 $ 1.7
XML 89 R74.htm IDEA: XBRL DOCUMENT v3.22.4
Note 16 - Income Taxes (Details Textual) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Capitalized Costs, Research and Development $ 23,400  
Finite-Lived Intangible Asset, Useful Life (Year) 13 years 13 years
Unrecognized Tax Benefits, Ending Balance $ 0  
Open Tax Year 2019 2020 2021 2022  
Domestic Tax Authority [Member] | In Process Research and Development [Member]    
Finite-Lived Intangible Asset, Useful Life (Year) 5 years  
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]    
Operating Loss Carryforwards $ 0  
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]    
Operating Loss Carryforwards 400  
State and Local Jurisdiction [Member]    
Operating Loss Carryforwards 3,100  
State and Local Jurisdiction [Member] | Research Tax Credit Carryforward [Member]    
Operating Loss Carryforwards 500  
Foreign Tax Authority [Member]    
Deferred Tax Liabilities, Undistributed Foreign Earnings $ 500  
Foreign Tax Authority [Member] | In Process Research and Development [Member]    
Finite-Lived Intangible Asset, Useful Life (Year) 15 years  
Foreign Tax Authority [Member] | Ministry of Economic Affairs and Finance, Italy [Member]    
Operating Loss Carryforwards $ 6,100  
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount $ (900)  
XML 90 R75.htm IDEA: XBRL DOCUMENT v3.22.4
Note 16 - Income Taxes - Components of Income Before Taxes and Provision for (Benefit from) Income Taxes (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Domestic $ (19,080) $ (2,529) $ (25,722)
Foreign 334 4,956 (2,902)
(Loss) income before income taxes (18,746) 2,427 (28,624)
Federal 1,005 494 357
State 285 (635) (1,970)
Foreign 96 167 49
Total current 1,386 26 (1,564)
Federal (3,243) (553) (1,980)
State (1,256) (426) (1,070)
Foreign (774) (754) (28)
Total deferred (5,273) (1,733) (3,078)
Total benefit from income taxes $ (3,887) $ (1,707) $ (4,642)
XML 91 R76.htm IDEA: XBRL DOCUMENT v3.22.4
Note 16 - Income Taxes - Significant Components of Company's Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Lease liability $ 7,468 $ 4,684
Capitalized research expenditures 5,451 0
Stock-based compensation expense 2,795 2,782
Inventory reserves 2,763 2,453
Compensation accrual 1,635 1,236
Net operating loss carry forwards 1,551 2,822
Tax credits 741 3,022
Accrued expenses 519 491
Foreign currency exchange 221 282
Deferred tax assets 23,144 17,772
Acquisition-related intangible asset (12,075) (14,770)
Depreciation (8,804) (8,509)
Right of use asset (7,252) (4,650)
Deferred tax liabilities (28,131) (27,929)
Net deferred tax liabilities $ (4,987) $ (10,157)
XML 92 R77.htm IDEA: XBRL DOCUMENT v3.22.4
Note 16 - Income Taxes - Reconciliation Between U.S. Federal Statutory Rate and Effective Rate (Details)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Statutory federal income tax rate 21.00% 21.00% 21.00%
State tax expense, net of federal benefit 1.40% (3.20%) 1.50%
Stock compensation (4.70%) 22.30% (2.20%)
Section 162(m) limitation (8.20%) 8.70% 0.00%
Goodwill impairment 0.00% 0.00% (16.80%)
Change in fair value of contingent consideration 0.00% (36.70%) 6.70%
Change in tax rates and state apportionment 1.20% (29.80%) 4.90%
Federal, state and foreign tax credits 5.10% (28.40%) 2.20%
Valuation allowance 0.00% (35.30%) (3.00%)
Return to provision adjustments 5.00% 0.00% 0.00%
Other permanent items (0.10%) 11.00% 1.90%
Effective income tax rate 20.70% (70.40%) 16.20%
XML 93 R78.htm IDEA: XBRL DOCUMENT v3.22.4
Note 17- Earnings Per Share ("EPS") (Details Textual)
shares in Millions
 12 Months Ended
Dec. 31, 2021
shares
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) 1.1
XML 94 R79.htm IDEA: XBRL DOCUMENT v3.22.4
Note 17 - Earnings Per Share ("EPS") - Basic and Diluted Earnings Per Share (Details) - shares
shares in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Basic (in shares) 14,561 14,401 14,222
Share based awards (in shares) 0 233 0
Diluted shares used in the calculation of EPS (in shares) 14,561 14,634 14,222
XML 95 anik20221231_10k_htm.xml IDEA: XBRL DOCUMENT 0000898437 2022-01-01 2022-12-31 0000898437 2022-06-30 0000898437 2023-03-08 0000898437 2022-12-31 0000898437 2021-12-31 0000898437 2021-01-01 2021-12-31 0000898437 2020-01-01 2020-12-31 0000898437 us-gaap:CommonStockMember 2019-12-31 0000898437 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000898437 us-gaap:RetainedEarningsMember 2019-12-31 0000898437 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000898437 2019-12-31 0000898437 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0000898437 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0000898437 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0000898437 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0000898437 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2020-01-01 2020-12-31 0000898437 us-gaap:RestrictedStockUnitsRSUMember us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0000898437 us-gaap:RestrictedStockUnitsRSUMember us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0000898437 us-gaap:RestrictedStockUnitsRSUMember us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0000898437 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0000898437 us-gaap:CommonStockMember 2020-12-31 0000898437 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000898437 us-gaap:RetainedEarningsMember 2020-12-31 0000898437 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000898437 2020-12-31 0000898437 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0000898437 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0000898437 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0000898437 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0000898437 us-gaap:CommonStockMember 2021-12-31 0000898437 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000898437 us-gaap:RetainedEarningsMember 2021-12-31 0000898437 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000898437 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0000898437 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0000898437 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0000898437 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0000898437 us-gaap:CommonStockMember 2022-12-31 0000898437 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000898437 us-gaap:RetainedEarningsMember 2022-12-31 0000898437 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000898437 us-gaap:AccountingStandardsUpdate201602Member 2022-01-01 2022-12-31 0000898437 us-gaap:AccountingStandardsUpdate201602Member 2021-01-01 2021-12-31 0000898437 us-gaap:AccountingStandardsUpdate201602Member 2020-01-01 2020-12-31 0000898437 anik:DepuyMitekIncMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000898437 anik:DepuyMitekIncMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000898437 anik:DepuyMitekIncMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0000898437 anik:DepuyMitekIncMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000898437 anik:DepuyMitekIncMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0000898437 srt:MinimumMember anik:ComputerEquipmentAndSoftwareMember 2022-01-01 2022-12-31 0000898437 srt:MaximumMember anik:ComputerEquipmentAndSoftwareMember 2022-01-01 2022-12-31 0000898437 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-12-31 0000898437 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2022-01-01 2022-12-31 0000898437 srt:MinimumMember us-gaap:EquipmentMember 2022-01-01 2022-12-31 0000898437 srt:MaximumMember us-gaap:EquipmentMember 2022-01-01 2022-12-31 0000898437 2022-01-01 2022-11-30 0000898437 srt:MinimumMember 2022-01-01 2022-12-31 0000898437 srt:MaximumMember 2022-01-01 2022-12-31 0000898437 anik:ParcusMedicalMember 2020-01-24 2020-01-24 0000898437 anik:ParcusMedicalMember 2021-09-30 0000898437 anik:ParcusMedicalMember 2020-01-01 2020-03-31 0000898437 anik:ParcusMedicalMember 2020-01-24 0000898437 anik:ParcusMedicalMember us-gaap:DevelopedTechnologyRightsMember 2020-01-24 0000898437 anik:ParcusMedicalMember us-gaap:TradeNamesMember 2020-01-24 0000898437 anik:ParcusMedicalMember us-gaap:CustomerRelationshipsMember 2020-01-24 0000898437 anik:ParcusMedicalMember us-gaap:DevelopedTechnologyRightsMember 2020-01-24 2020-01-24 0000898437 anik:ParcusMedicalMember us-gaap:CustomerRelationshipsMember 2020-01-24 2020-01-24 0000898437 anik:ParcusMedicalMember us-gaap:TradeNamesMember 2020-01-24 2020-01-24 0000898437 anik:ArthrosurfaceMember 2020-02-03 2020-02-03 0000898437 anik:ArthrosurfaceMember 2020-10-01 2020-10-31 0000898437 anik:ArthrosurfaceMember 2021-07-01 2021-07-31 0000898437 anik:ArthrosurfaceMember 2020-01-01 2020-03-31 0000898437 anik:ArthrosurfaceMember 2020-02-03 0000898437 anik:ArthrosurfaceMember us-gaap:DevelopedTechnologyRightsMember 2020-02-03 0000898437 anik:ArthrosurfaceMember us-gaap:TradeNamesMember 2020-02-03 0000898437 anik:ArthrosurfaceMember us-gaap:CustomerRelationshipsMember 2020-02-03 0000898437 anik:ArthrosurfaceMember us-gaap:InProcessResearchAndDevelopmentMember 2020-02-03 0000898437 anik:ArthrosurfaceMember us-gaap:DevelopedTechnologyRightsMember 2020-02-03 2020-02-03 0000898437 anik:ArthrosurfaceMember us-gaap:CustomerRelationshipsMember 2020-02-03 2020-02-03 0000898437 anik:ArthrosurfaceMember us-gaap:TradeNamesMember 2020-02-03 2020-02-03 0000898437 anik:ArthrosurfaceMember us-gaap:InProcessResearchAndDevelopmentMember 2022-12-31 0000898437 us-gaap:MoneyMarketFundsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-12-31 0000898437 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-12-31 0000898437 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-12-31 0000898437 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-12-31 0000898437 us-gaap:MoneyMarketFundsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2022-12-31 0000898437 us-gaap:MoneyMarketFundsMember us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-12-31 0000898437 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-12-31 0000898437 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-12-31 0000898437 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-12-31 0000898437 us-gaap:MoneyMarketFundsMember us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-12-31 0000898437 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-12-31 0000898437 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-12-31 0000898437 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-12-31 0000898437 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-12-31 0000898437 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-12-31 0000898437 anik:ContingentConsiderationMember 2021-12-31 0000898437 anik:ContingentConsiderationMember 2020-12-31 0000898437 anik:ContingentConsiderationMember 2022-01-01 2022-12-31 0000898437 anik:ContingentConsiderationMember 2021-01-01 2021-12-31 0000898437 anik:ContingentConsiderationMember 2022-12-31 0000898437 anik:ParcusMedicalAndArthrosurfaceAcquisitionsMember 2022-01-01 2022-12-31 0000898437 srt:MinimumMember anik:ParcusMedicalAndArthrosurfaceAcquisitionsMember us-gaap:MeasurementInputDiscountRateMember 2022-12-31 0000898437 srt:MaximumMember anik:ParcusMedicalAndArthrosurfaceAcquisitionsMember us-gaap:MeasurementInputDiscountRateMember 2022-12-31 0000898437 anik:ParcusMedicalMember anik:MeasurementInputWeightedAverageCostOfCapitalMember 2020-12-31 0000898437 anik:ParcusMedicalMember anik:MeasurementInputWeightedAverageCostOfCapitalMember 2021-12-31 0000898437 anik:ArthrosurfaceMember anik:MeasurementInputWeightedAverageCostOfCapitalMember 2020-12-31 0000898437 anik:ParcusMedicalMember 2021-12-31 0000898437 anik:ArthrosurfaceMember 2021-06-01 2021-06-30 0000898437 anik:ArthrosurfaceMember 2021-01-01 2021-12-31 0000898437 anik:ArthrosurfaceMember 2020-01-01 2020-12-31 0000898437 anik:EquipmentAndSoftwareMember 2022-12-31 0000898437 anik:EquipmentAndSoftwareMember 2021-12-31 0000898437 us-gaap:FurnitureAndFixturesMember 2022-12-31 0000898437 us-gaap:FurnitureAndFixturesMember 2021-12-31 0000898437 us-gaap:LeaseholdImprovementsMember 2022-12-31 0000898437 us-gaap:LeaseholdImprovementsMember 2021-12-31 0000898437 us-gaap:ConstructionInProgressMember 2022-12-31 0000898437 us-gaap:ConstructionInProgressMember 2021-12-31 0000898437 us-gaap:DevelopedTechnologyRightsMember 2022-12-31 0000898437 us-gaap:DevelopedTechnologyRightsMember 2022-01-01 2022-12-31 0000898437 us-gaap:InProcessResearchAndDevelopmentMember 2022-12-31 0000898437 us-gaap:InProcessResearchAndDevelopmentMember 2022-01-01 2022-12-31 0000898437 us-gaap:CustomerRelationshipsMember 2022-12-31 0000898437 us-gaap:CustomerRelationshipsMember 2022-01-01 2022-12-31 0000898437 us-gaap:DistributionRightsMember 2022-12-31 0000898437 us-gaap:DistributionRightsMember 2022-01-01 2022-12-31 0000898437 us-gaap:PatentsMember 2022-12-31 0000898437 us-gaap:PatentsMember 2022-01-01 2022-12-31 0000898437 us-gaap:TradeNamesMember 2022-12-31 0000898437 us-gaap:TradeNamesMember 2022-01-01 2022-12-31 0000898437 us-gaap:DevelopedTechnologyRightsMember 2021-12-31 0000898437 us-gaap:DevelopedTechnologyRightsMember 2021-01-01 2021-12-31 0000898437 us-gaap:InProcessResearchAndDevelopmentMember 2021-12-31 0000898437 us-gaap:InProcessResearchAndDevelopmentMember 2021-01-01 2021-12-31 0000898437 us-gaap:CustomerRelationshipsMember 2021-12-31 0000898437 us-gaap:CustomerRelationshipsMember 2021-01-01 2021-12-31 0000898437 us-gaap:DistributionRightsMember 2021-12-31 0000898437 us-gaap:DistributionRightsMember 2021-01-01 2021-12-31 0000898437 us-gaap:PatentsMember 2021-12-31 0000898437 us-gaap:PatentsMember 2021-01-01 2021-12-31 0000898437 us-gaap:TradeNamesMember 2021-12-31 0000898437 us-gaap:TradeNamesMember 2021-01-01 2021-12-31 0000898437 anik:AcquisitionsOfParcusMedicalAndArthrosurfaceMember us-gaap:ResearchAndDevelopmentExpenseMember 2021-10-01 2021-12-31 0000898437 anik:ParcusMedicalAndArthrosurfaceMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-10-01 2020-12-31 0000898437 us-gaap:DevelopedTechnologyRightsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-12-31 0000898437 anik:ParcusMedicalAndArthrosurfaceMember 2022-01-01 2022-12-31 0000898437 anik:LegacyAnikaReportingUnitMember 2021-01-01 2021-11-30 0000898437 anik:LegacyAnikaReportingUnitMember 2020-01-01 2020-03-31 0000898437 anik:LegacyAnikaReportingUnitMember 2020-01-01 2020-12-31 0000898437 anik:ParcusMedicalAndArthrosurfaceMember 2020-01-01 2020-03-31 0000898437 anik:ParcusMedicalAndArthrosurfaceMember 2020-10-01 2020-12-31 0000898437 anik:ParcusMedicalAndArthrosurfaceMember 2020-01-01 2020-12-31 0000898437 anik:ParcusMedicalAndArthrosurfaceMember 2020-12-31 0000898437 anik:LiabilitiesMember 2022-12-31 0000898437 anik:AccruedExpensesAndOtherCurrentLiabilitiesMember 2022-12-31 0000898437 anik:AccruedExpensesAndOtherCurrentLiabilitiesMember 2021-12-31 0000898437 us-gaap:RevolvingCreditFacilityMember 2021-11-12 0000898437 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember 2021-11-12 2021-11-12 0000898437 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember 2021-11-12 2021-11-12 0000898437 us-gaap:RevolvingCreditFacilityMember 2021-11-12 2021-11-12 0000898437 us-gaap:RevolvingCreditFacilityMember 2022-12-31 0000898437 us-gaap:RevolvingCreditFacilityMember 2021-12-31 0000898437 us-gaap:RevolvingCreditFacilityMember 2020-04-08 2020-04-08 0000898437 us-gaap:RevolvingCreditFacilityMember 2020-04-08 0000898437 us-gaap:RevolvingCreditFacilityMember 2022-01-01 2022-12-31 0000898437 us-gaap:RevolvingCreditFacilityMember 2021-01-01 2021-12-31 0000898437 us-gaap:RevolvingCreditFacilityMember 2020-01-01 2020-12-31 0000898437 anik:OAPainManagementMember 2022-01-01 2022-12-31 0000898437 anik:OAPainManagementMember 2021-01-01 2021-12-31 0000898437 anik:OAPainManagementMember 2020-01-01 2020-12-31 0000898437 anik:JointPreservationAndRestorationMember 2022-01-01 2022-12-31 0000898437 anik:JointPreservationAndRestorationMember 2021-01-01 2021-12-31 0000898437 anik:JointPreservationAndRestorationMember 2020-01-01 2020-12-31 0000898437 anik:NonorthopedicMember 2022-01-01 2022-12-31 0000898437 anik:NonorthopedicMember 2021-01-01 2021-12-31 0000898437 anik:NonorthopedicMember 2020-01-01 2020-12-31 0000898437 anik:VeterinaryMember anik:OAPainManagementMember 2022-01-01 2022-12-31 0000898437 anik:VeterinaryMember anik:OAPainManagementMember 2021-01-01 2021-12-31 0000898437 anik:VeterinaryMember anik:OAPainManagementMember 2020-01-01 2020-12-31 0000898437 country:US 2022-01-01 2022-12-31 0000898437 country:US 2021-01-01 2021-12-31 0000898437 country:US 2020-01-01 2020-12-31 0000898437 srt:EuropeMember 2022-01-01 2022-12-31 0000898437 srt:EuropeMember 2021-01-01 2021-12-31 0000898437 srt:EuropeMember 2020-01-01 2020-12-31 0000898437 anik:OtherLocationMember 2022-01-01 2022-12-31 0000898437 anik:OtherLocationMember 2021-01-01 2021-12-31 0000898437 anik:OtherLocationMember 2020-01-01 2020-12-31 0000898437 country:US 2022-12-31 0000898437 country:US 2021-12-31 0000898437 country:IT 2022-12-31 0000898437 country:IT 2021-12-31 0000898437 anik:The2017PlanMember 2017-06-13 0000898437 anik:The2017PlanMember 2022-12-31 0000898437 anik:The2021InducementPlanMember 2021-11-04 0000898437 anik:The2021InducementPlanMember 2022-12-31 0000898437 srt:MinimumMember anik:The2017PlanMember 2022-01-01 2022-12-31 0000898437 srt:MaximumMember anik:The2017PlanMember 2022-01-01 2022-12-31 0000898437 anik:The2017PlanMember 2022-01-01 2022-12-31 0000898437 us-gaap:CostOfSalesMember 2022-01-01 2022-12-31 0000898437 us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0000898437 us-gaap:CostOfSalesMember 2020-01-01 2020-12-31 0000898437 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0000898437 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0000898437 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0000898437 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-12-31 0000898437 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-12-31 0000898437 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-12-31 0000898437 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-03-31 0000898437 anik:PremiumPricedEmployeeStockOptionsMember 2022-01-01 2022-12-31 0000898437 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0000898437 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0000898437 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0000898437 anik:TotalShareholderReturnTsrsOptionsMember 2022-01-01 2022-12-31 0000898437 srt:MinimumMember anik:TotalShareholderReturnTsrsOptionsMember 2022-01-01 2022-12-31 0000898437 srt:MaximumMember anik:TotalShareholderReturnTsrsOptionsMember 2022-01-01 2022-12-31 0000898437 anik:TotalShareholderReturnTsrsOptionsMember 2022-12-31 0000898437 srt:MinimumMember 2021-01-01 2021-12-31 0000898437 srt:MaximumMember 2021-01-01 2021-12-31 0000898437 srt:MinimumMember 2020-01-01 2020-12-31 0000898437 srt:MaximumMember 2020-01-01 2020-12-31 0000898437 us-gaap:EmployeeStockOptionMember 2022-12-31 0000898437 srt:MinimumMember us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0000898437 srt:MaximumMember us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0000898437 us-gaap:RestrictedStockUnitsRSUMember 2021-12-31 0000898437 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0000898437 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0000898437 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-12-31 0000898437 srt:MinimumMember us-gaap:PerformanceSharesMember 2022-01-01 2022-12-31 0000898437 anik:GrantedIn2019Member us-gaap:PerformanceSharesMember 2019-12-31 0000898437 anik:GrantedIn2019Member us-gaap:PerformanceSharesMember 2022-12-31 0000898437 anik:GrantedIn2020Member us-gaap:PerformanceSharesMember 2021-12-31 0000898437 anik:GrantedIn2020Member us-gaap:PerformanceSharesMember 2022-12-31 0000898437 us-gaap:PerformanceSharesMember 2021-12-31 0000898437 us-gaap:PerformanceSharesMember 2022-01-01 2022-12-31 0000898437 us-gaap:PerformanceSharesMember 2022-12-31 0000898437 us-gaap:PerformanceSharesMember 2021-01-01 2021-12-31 0000898437 us-gaap:PerformanceSharesMember 2020-01-01 2020-12-31 0000898437 anik:EmployeeStockPurchasePlanESPPMember 2021-03-17 0000898437 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember 2022-12-31 0000898437 us-gaap:StateAndLocalJurisdictionMember 2022-12-31 0000898437 us-gaap:ForeignCountryMember us-gaap:MinistryOfEconomicAffairsAndFinanceItalyMember 2022-12-31 0000898437 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember us-gaap:ResearchMember 2022-12-31 0000898437 us-gaap:StateAndLocalJurisdictionMember us-gaap:ResearchMember 2022-12-31 0000898437 us-gaap:InProcessResearchAndDevelopmentMember us-gaap:DomesticCountryMember 2022-01-01 2022-12-31 0000898437 us-gaap:InProcessResearchAndDevelopmentMember us-gaap:ForeignCountryMember 2022-01-01 2022-12-31 0000898437 us-gaap:ForeignCountryMember us-gaap:MinistryOfEconomicAffairsAndFinanceItalyMember 2022-01-01 2022-12-31 0000898437 us-gaap:ForeignCountryMember 2022-12-31 iso4217:USD shares thunderdome:item iso4217:USD shares pure utr:Y 0000898437 Anika Therapeutics, Inc. false --12-31 FY 2022 0.01 0.01 1250000 1250000 0 0 0 0 0.01 0.01 90000000 90000000 14625000 14625000 14441000 14441000 0 0 P5Y P16Y 1 0 0 0 0 P5Y 0 0 P1Y P4Y P10Y -500000 P3Y P4Y P10Y 0.0128 0.0428 0.0029 0.0100 0.0021 0.0159 0.000 0.000 P3Y P4Y P3Y 0 0 2019 2020 2021 2022 10-K true 2022-12-31 false 001-14027 DE 04-3145961 32 Wiggins Avenue Bedford MA 01730 781 457-9000 Common Stock, par value $0.01 per share ANIK NASDAQ No No Yes Yes Accelerated Filer false false true false 321805229 14632910 34 Deloitte & Touche LLP Boston, Massachusetts 86327000 94386000 34627000 29843000 39765000 36010000 8828000 8289000 169547000 168528000 48279000 47602000 30696000 20957000 17219000 20285000 1449000 0 74599000 82382000 7339000 7781000 349128000 347535000 9074000 7633000 18840000 17847000 0 4315000 27914000 29795000 398000 1258000 6436000 10157000 28817000 19240000 0 0 146000 144000 81141000 67081000 -6443000 -5718000 210719000 225578000 285563000 287085000 349128000 347535000 156236000 147794000 130457000 62660000 64851000 61431000 93576000 82943000 69026000 28182000 27327000 23431000 84794000 74096000 60063000 0 0 42520000 0 -21095000 -28666000 112976000 80328000 97348000 -19400000 2615000 -28322000 654000 -188000 -302000 -18746000 2427000 -28624000 -3887000 -1707000 -4642000 -14859000 4134000 -23982000 -1.02 0.29 -1.69 -1.02 0.28 -1.69 14561000 14401000 14222000 14561000 14634000 14222000 -14859000 4134000 -23982000 -725000 -1176000 1356000 -15584000 2958000 -22626000 14308000 143000 48707000 245426000 -5898000 288378000 123000 1000 1523000 0 0 1524000 54000 0 0 0 0 0 9000 -0 -0 -0 -0 -0 0 5386000 0 0 5386000 8000 -0 262000 -0 -0 262000 139000 1000 -1000 -0 -0 -0 0 0 -23982000 0 -23982000 0 0 0 1356000 1356000 14329000 143000 55355000 221444000 -4542 272400000 32000 0 1128000 0 0 1128000 92000 1000 -1000 0 0 0 0 11085000 0 0 11085000 12000 -0 486000 -0 -0 486000 0 0 4134000 0 4134000 0 0 0 -1176000 -1176000 14441000 144000 67081000 225578000 -5718000 287085000 0 16000 0 0 16000 184000 2000 -2000 0 0 0 0 665000 0 0 665000 0 14315000 0 0 14315000 -0 934000 -0 -0 934000 0 0 -14859000 0 -14859000 0 0 0 -725000 -725000 14625000 146000 81141000 210719000 -6443000 285563000 -14859000 4134000 -23982000 6704000 6480000 6083000 7783000 7837000 7381000 0 6465000 11082000 1850000 1708000 1531 0 0 42520000 0 -21095000 -28666000 -0 -993000 -265000 0 600000 2439000 14315000 11085000 5386000 -5270000 -1766000 -3543000 378000 64000 549000 5329000 6628000 5490000 -0 18000 12000 5630000 6216 -5855000 6873000 6619000 14177000 792000 -1424000 1783000 1965000 -1100000 822000 -1485000 -1626000 -1439000 -443000 3510000 -142000 1437000 -1311000 -2072000 0 -2780000 -522000 4409000 8397000 13065000 -0 476000 94601000 0 2501000 45000000 -0 -0 20035.000 7486000 5143000 1628000 -7486000 -3118000 -71264000 284000 201000 208000 0 0 50000000 -0 -0 50350000 665000 0 0 934000 486000 262000 16000 1128000 1524000 4315000 7220000 4478000 -4852000 -6779000 -3774000 -130000 69000 327000 -8059000 -1431000 -61646000 94386000 95817000 157463000 86327000 94386000 95817000 106000 1233000 993000 11703000 220000 0 108000 15000 17000 0 0 476000 0 0 69076000 <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-align: left; text-indent: 0pt;"><b><em style="font: inherit;">1.</em> Nature of Business</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Anika Therapeutics, Inc. (“the Company”) is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care, including in the areas of osteoarthritis (“OA”) pain management, regenerative solutions, sports medicine and bone preserving joint solutions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">In early <em style="font: inherit;">2020,</em> the Company expanded its overall technology platform through its strategic acquisitions of Parcus Medical, LLC (“Parcus Medical”), a sports medicine implant and instrumentation company, and Arthrosurface Inc. (“Arthrosurface”), a company specializing in less invasive, bone preserving partial and total joint replacement solutions. These acquisitions broadened the Company's product portfolio, developed over its <em style="font: inherit;">30</em> years of expertise in hyaluronic acid technology, into joint preservation and restoration, added higher-growth revenue streams, increased its commercial capabilities, diversified its revenue base, and expanded its product pipeline and research and development expertise.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Company is subject to risks common to companies in the life sciences industry including, but <em style="font: inherit;">not</em> limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with U.S. Food and Drug Administration (“FDA”) and foreign regulations and approval requirements, as well as the ability to grow the Company’s business through appropriate commercial strategies.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Since the global COVID pandemic began in <em style="font: inherit;">2020,</em> there also continues to be increased volatility and uncertainty in the global macroeconomic environment, including staffing shortages, supply chain disruption, inflation and other direct and indirect impacts of the pandemic.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-align: left; text-indent: 0pt;"><b><em style="font: inherit;">2.</em> Summary of Significant Accounting Policies</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 15pt;"><i/></p><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 15pt;"><i>Use of Estimates</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America (“US GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 15pt;"/><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 15pt;"><i/></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 15pt;"><i>Principles of Consolidation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The accompanying consolidated financial statements include the accounts of Anika Therapeutics, Inc. and its wholly owned subsidiaries, Anika Securities, Inc., Anika Therapeutics S.r.l. (“Anika S.r.l.”), Anika Therapeutics Limited, Parcus Medical and Arthrosurface. All intercompany balances and transactions have been eliminated in consolidation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 15pt;"/><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 15pt;"><i/></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 15pt;"><i>Foreign Currency Translation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The functional currency of Anika S.r.l. is the Euro, and the functional currency of Anika Therapeutics Limited is the British Pound Sterling. Assets and liabilities of the foreign subsidiaries are translated using the exchange rate existing on each respective balance sheet date. Revenues and expenses are translated using the average exchange rates for the period. The translation adjustments resulting from this process are included in stockholders’ equity as a component of accumulated other comprehensive income (loss) which resulted in a gain (loss) from foreign currency translation of ($0.7) million, ($1.2) million, and $1.3 million for the years ended <em style="font: inherit;"> December 31, 2022, </em><em style="font: inherit;">2021,</em> and <em style="font: inherit;">2020,</em> respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Gains and losses resulting from foreign currency transactions are recognized in the consolidated statements of operations. Recorded balances that are denominated in a currency other than the functional currency are remeasured to the functional currency using the exchange rate at the balance sheet date and gains or losses are recorded in the statements of operations. The Company recognized a gain (loss) from foreign currency transactions of ($0.5) million, ($0.4) million, and $0.3 million during the years ended <em style="font: inherit;"> December 31, 2022, </em><em style="font: inherit;">2021,</em> and <em style="font: inherit;">2020,</em> respectively</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 15pt;"/><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 15pt;"><i/></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 15pt;"><i>Accounts Receivable</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Company estimates an allowance for credit losses with its accounts receivable resulting from the inability of its customers to make required payments, which is included in selling, general and administrative expenses in the accompanying consolidated statements of operations. In determining the adequacy of the allowance, management specifically analyzes individual accounts receivable, historical bad debts, customer concentrations, customer creditworthiness, current and reasonable and supportable forecasts of future economic conditions, accounts receivable aging trends, and changes in the Company’s customer payment terms.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The components of the Company’s accounts receivables are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As of December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2021</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accounts Receivable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">36,235</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">31,285</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Allowance for credit losses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,608</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,442</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net balance, end of the year</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">34,627</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">29,843</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">A summary of activity in the allowance for credit losses is as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As of <b>December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance, beginning of the year</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,442</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,523</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">962</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Amounts provided</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">554</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">156</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">635</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Amounts recovered</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(180</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(92</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(86</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Amounts written off</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(158</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(73</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(78</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Translation adjustments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(72</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">90</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance, end of the year</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,608</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,442</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,523</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"/><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i/></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i>Revenue Recognition </i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Pursuant to Accounting Standard Codification <em style="font: inherit;">606,</em> <i>Revenue from Contracts with Customers</i> (“ASC <em style="font: inherit;">606”</em>), the Company recognizes revenue when a customer obtains control of promised goods or services. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following <em style="font: inherit;">five</em>-step model in order to determine this amount: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are capable of being distinct or distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"/><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i/></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i>Revenue</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Company generates sales principally through <em style="font: inherit;">three</em> types of customers: (i) commercial partnerships (ii) hospitals and ambulatory surgical centers (“ASCs”), and (iii) distributors, referred to as the distribution model.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">For commercial partnership sales, the Company sells its products directly to these partners, who perform most of the downstream sales and marketing activities to customers and end-users. These arrangements <em style="font: inherit;"> may </em>include the grant of certain licenses, performance of development services, and the supply of product. The Company’s largest such customer, DePuy Synthes Mitek Sports Medicine, a division of DePuy Orthopedics, Inc., part of the Johnson &amp; Johnson Medical Companies (“Mitek”), represented 43%, 45% and 49% of total revenues for the years-ended <em style="font: inherit;"> December 31, 2022, </em><em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> respectively. The Company completed the performance obligations related to granted licenses and development services under the agreements with Mitek prior to <em style="font: inherit;">2016</em> and has <em style="font: inherit;">no</em> remaining material performance obligations. The Company recognizes revenue from product sales when the customer obtains control of the Company’s product, which typically occurs upon shipment to the customer. Commercial partnership agreements <em style="font: inherit;"> may </em>also include sales-based royalties and milestones. As the Company considered the license to be the predominant item to which the royalties relate for these agreements, sales-based royalties and milestones are only recognized when the later of the underlying sale occurs or the performance obligation to which the sales-based royalty has been satisfied (or partially satisfied). This is generally in the same period that the Company’s licensees complete their product sales in their territory, for which the Company is contractually entitled to a percentage-based royalty. The Company records royalty revenues based on estimated net sales of licensed products as reported to the Company by its commercial partners. The differences between actual and estimated royalty revenues have <em style="font: inherit;">not</em> been material and are typically adjusted in the following quarter when the actual amounts are known. Revenue from sales-based royalties is included in revenue in the consolidated statement of operations. The Company’s certain supply agreements represent a promise to deliver products at the customer’s discretion that are considered distributor options. The Company assesses if these options provide a material right to the licensee, and if so, they are accounted for as separate performance obligations. Substantially all of the Company’s supply agreements do <em style="font: inherit;">not</em> provide options that are considered material rights.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">For sales to hospitals and ASCs, which generally pairs in-house sales representatives with local or regional distributors, the inventory is generally consigned so that products are available when needed for surgical procedures. <em style="font: inherit;">No</em> revenue is recognized upon the placement of inventory into consignment, as the Company retains the ability to control the inventory. Revenue is typically recognized as of the date of surgical implantation of the product.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">For distributor sales, the Company sells its products principally to distributors, generally outside the United States, who subsequently resell the products to sub-distributors and health care providers, among others. The Company recognizes revenue from product sales when the distributor obtains control of the Company’s product, which typically occurs upon shipment to the distributor, in return for agreed-upon, fixed-price consideration. Performance obligations are generally settled quickly after purchase order acceptance; therefore, the value of unsatisfied performance obligations at the end of any reporting period is generally insignificant. The Company sells to a diversified base of distributors and, therefore, believes there is <em style="font: inherit;">no</em> material concentration of credit risk.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Company’s payment terms are consistent with prevailing practice in the respective markets in which the Company does business. Most of the Company’s customers make payments based on contract terms, which are <em style="font: inherit;">not</em> affected by contingent events that could impact the transaction price. Payment terms fall within the <em style="font: inherit;">one</em>-year guidance for the practical expedient, which allows the Company to forgo adjustment of the contractual payment amount of consideration for the effects of a significant financing component.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Some of the Company’s distributor agreements have volume-based discounts with tiered pricing which are generally prospective in nature. These prospective discounts together with any free-of-charge sample units offered are evaluated as potential material rights. If the prospective discounts or free-of-charge sample units are considered material rights, these would be separate performance obligations and a portion of the sales transaction price is allocated to the material right. Revenue allocated to the material right is recognized when the additional goods are transferred to the customer or when the option expires. During <em style="font: inherit;">2022</em> and <em style="font: inherit;">2021,</em> the consideration allocated to material rights was <em style="font: inherit;">not</em> significant.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Company receives payments from its customers based on billing schedules established in each contract. Up-front payments and fees are recorded as deferred revenue upon receipt or when due and <em style="font: inherit;"> may </em>require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when its right to consideration is unconditional. Deferred revenue was $0 and $1.0 million as of <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Generally, customer contracts contain Free on Board (“FOB”) or Ex-Works shipping point terms where the customer pays the shipping company directly for all shipping and handling costs. In those contracts in which the Company pays for the shipping and handling, the associated costs are generally recorded along with the product sale at the time of shipment in cost of revenue when control over the products has transferred to the customer. Value-add and other taxes collected by the Company concurrently with revenue-producing activities are excluded from revenue. The Company’s general product warranty does <em style="font: inherit;">not</em> extend beyond an assurance that the product or services delivered will be consistent with stated contractual specifications, which does <em style="font: inherit;">not</em> create a separate performance obligation. The Company recognizes the incremental costs of obtaining contracts as an expense when incurred as the amortization period of the assets that the Company otherwise would have recognized is <em style="font: inherit;">one</em> year or less in accordance with the practical expedient in paragraph ASC <em style="font: inherit;">340</em>-<em style="font: inherit;">40</em>-<em style="font: inherit;">25</em>-<em style="font: inherit;">4.</em> These costs are included in selling, general and administrative expenses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i>Licensing, Milestone and Contract Revenue</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The agreements with Mitek include variable consideration such as contingent development and regulatory milestones. Since <em style="font: inherit;">2016,</em> there have been <em style="font: inherit;">no</em> remaining regulatory milestones related to the Mitek agreements. In general, variable consideration is included in the transaction price only to the extent a significant reversal in the amount of cumulative revenue recognized is <em style="font: inherit;">not</em> probable to occur.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"/><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i/></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i>Cash and Cash Equivalents </i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Company considers only those investments which are highly liquid, readily convertible to cash, and that mature within <em style="font: inherit;">90</em> days from the date of purchase to be cash equivalents. The Company’s cash equivalents consist of money market funds.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"/><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i/></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i>Investments</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">All of the Company’s investments are classified as available-for-sale which consist of U.S. treasury bills and are carried at fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income (loss), net of related income taxes. For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. Realized gains and losses on the sale of investments are recorded in interest and other income, net. Interest is recorded when earned. Investments with original maturities greater than approximately <em style="font: inherit;">three</em> months and remaining maturities less than <em style="font: inherit;">one</em> year are classified as short-term investments. Investments with remaining maturities greater than <em style="font: inherit;">one</em> year are classified as long-term investments. The Company had no investments as of <em style="font: inherit;"> December 31, 2022 </em>or <em style="font: inherit;"> December 31, 2021.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">All of the Company’s investments are subject to a periodic impairment review. For available-for-sale debt securities in an unrealized loss position, the Company <em style="font: inherit;">first</em> assesses whether (i) the Company intends to sell, or (ii) it is more likely than <em style="font: inherit;">not</em> that the Company will be required to sell the security before recovery of its amortized cost basis. If either case is affirmative, any previously recognized allowances are charged-off and the security's amortized cost is written down to fair value through earnings. If neither case is affirmative, the security is evaluated to determine whether the decline in fair value has resulted from credit losses or other factors.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Any impairment that has <em style="font: inherit;">not</em> been recorded through an allowance for credit losses is recognized in other comprehensive income. Adjustments to the allowance are reported in the consolidated statement of operations as a component of credit loss expense. Available-for-sale securities are charged-off against the allowance or, in the absence of any allowance, written down through earnings when deemed uncollectible by management or when either of the criteria regarding intent or requirement to sell is met.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">During the years ended <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2022,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> the Company did <em style="font: inherit;">not</em> record any impairment charges on its available-for-sale securities because it is <em style="font: inherit;">not</em> more likely than <em style="font: inherit;">not</em> that the Company will be required to sell these securities before the recovery of their cost basis.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"/><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i/></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i>Concentration of Credit Risk </i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Company has <em style="font: inherit;">no</em> significant off-balance sheet risks related to foreign exchange contracts, option contracts, or other foreign hedging arrangements. The Company’s cash equivalents and investments are held with <em style="font: inherit;">two</em> major international financial institutions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Company, by policy, routinely assesses the financial strength of its customers. As a result, the Company believes that its accounts receivable credit risk exposure is limited.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">As of <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2022</em> and <em style="font: inherit;">2021,</em> Mitek represented 47% and 41%, respectively, of the Company’s accounts receivable balance. <em style="font: inherit;">No</em> other single customer accounted for more than <em style="font: inherit;">10%</em> of accounts receivable in either period.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"/><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i/></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i>Inventories</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Inventories are primarily stated at the lower of standard cost and net realizable value, with cost determined using the <em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out method. Work-in-process and finished goods inventories include materials, labor, and certain manufacturing overhead. Manufacturing variances attributable to abnormally low production are expensed in the period incurred.  </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Company’s policy is to write down inventory when conditions exist that suggest inventory <em style="font: inherit;"> may </em>be in excess of anticipated demand or is obsolete based upon assumptions about future demand for the Company’s products and market conditions. The Company regularly evaluates the ability to realize the value of inventory based on a combination of factors including, but <em style="font: inherit;">not</em> limited to, historical usage rates, forecasted sales or usage, product end of life dates, and estimated current or future market values. Purchasing requirements and alternative usage avenues are explored within these processes to mitigate inventory exposure.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">When recorded, inventory write-downs are intended to reduce the carrying value of inventory to its net realizable value. If actual demand for the Company’s products deteriorates, or if market conditions are less favorable than those projected, additional inventory write-downs <em style="font: inherit;"> may </em>be required. Other long-term assets include inventory expected to remain on hand beyond <em style="font: inherit;">one</em> year.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"/><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i/></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i>Leases</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the circumstances present and evaluates whether the lease is an operating lease or a finance lease at the commencement date. Operating and finance leases with a term greater than <em style="font: inherit;">one</em> year are recognized on the consolidated balance sheet as right-of-use assets, lease liabilities, and, if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease in the lease term where it is reasonably certain that it will exercise these options. Operating and finance lease liabilities and the corresponding right-of-use assets are recorded based on the present values of lease payments over the lease terms. The Company elected an accounting policy to combine the non-lease components (which include common area maintenance, taxes and insurance) with the related lease component. The interest rate implicit in lease contracts is typically <em style="font: inherit;">not</em> readily determinable. As such, the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a similar economic environment. Variable payments that do <em style="font: inherit;">not</em> depend on a rate or index are <em style="font: inherit;">not</em> included in the lease liability and are recognized as incurred. Lease contracts do <em style="font: inherit;">not</em> include residual value guarantees nor do they include restrictions or other covenants. Certain adjustments to the right-of-use assets <em style="font: inherit;"> may </em>be required for items such as initial direct costs paid, incentives received or lease prepayments. If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure the finance and operating lease liabilities by using revised inputs as of the reassessment date, and adjust the right-of-use asset. Operating lease expense is recognized on a straight-line basis over the lease term. Finance lease expense is recognized based on the effective-interest method over the lease term.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"/><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i/></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i>Property and Equipment</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives, which are typically:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 43%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Asset</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Estimated useful life</b><br/> <b>(in years)</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Computer equipment and software</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Furniture and fixtures</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Leasehold improvements</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Shorter of useful life or term of lease</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Maintenance and repairs are charged to expense when incurred; additions and improvements are capitalized. Fully depreciated assets are retained in the accounts until they are <em style="font: inherit;">no</em> longer used and <em style="font: inherit;">no</em> further charge for depreciation is made in respect of these assets. When an item is sold, retired or removed from service, the cost and related accumulated depreciation is relieved, and the resulting gain or loss, if any, is recognized in income.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Construction-in-process assets are stated at cost, which includes the cost of construction and other direct costs attributable to the construction. Construction-in-process assets are <em style="font: inherit;">not</em> depreciated until such time as the relevant assets are completed and put into use.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"/><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i/></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i>Goodwill and IPR&amp;D Assets</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Goodwill is the amount by which the purchase price of acquired net assets in a business combination exceeded the fair values of net identifiable assets on the date of acquisition. Acquired In-Process Research and Development (“IPR&amp;D”) represents the fair value assigned to research and development assets that the Company acquires that have <em style="font: inherit;">not</em> been completed at the date of acquisition or are pending regulatory approval in certain jurisdictions. The value assigned to the acquired IPR&amp;D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenue from the projects, and discounting the net cash flows to present value.  </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Goodwill and IPR&amp;D are <em style="font: inherit;">not</em> amortized but are evaluated for impairment annually or more frequently if events or changes in circumstances indicate that the asset might be impaired. The goodwill impairment assessment is performed by reporting unit. A reporting unit is the operating segment, or a business <em style="font: inherit;">one</em> level below that operating segment (the component level) if discrete financial information is prepared and regularly reviewed by segment management. However, components are aggregated as a single reporting unit if they have similar economic characteristics. The Company has two reporting units: the legacy Anika reporting unit, which specializes in therapies based on its hyaluronic acid, or HA, technology platform, and a newly formed reporting unit established in <em style="font: inherit;">2020</em> upon the acquisitions of Parcus Medical and Arthrosurface. Factors that the Company considers important, on an overall company basis, that could trigger an impairment review include significant underperformance relative to historical or projected future operating results, significant changes in the Company’s use of the acquired assets or the strategy for its overall business, significant negative industry or economic trends, a significant decline in the Company’s stock price for a sustained period, or a reduction of its market capitalization relative to net book value.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Under U.S. GAAP, the Company has the option to perform a qualitative assessment to determine if it is necessary to perform the impairment test. If the Company concludes, based on a qualitative assessment, it is <em style="font: inherit;">not</em> more likely than <em style="font: inherit;">not</em> that the Goodwill or the IPR&amp;D asset is impaired, the Company is <em style="font: inherit;">not</em> required to perform the quantitative test. The Company has an unconditional option to bypass the qualitative assessment in any period and proceed directly to the quantitative impairment test.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">To conduct quantitative impairment tests of goodwill, the fair value of the reporting unit is compared to its carrying value. If the reporting unit’s carrying value exceeds its fair value, the Company records an impairment loss to the extent that the carrying value of goodwill exceeds its implied fair value, <em style="font: inherit;">not</em> to exceed the recorded amount of goodwill. The Company recorded a non-cash goodwill impairment charge with respect to the newly formed reporting unit amounted to $42.5 million for the year ended <em style="font: inherit;"> December 31, 2020. </em>Please see Note <em style="font: inherit;">8,</em> <i>Goodwill</i> for further details.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Company performed a qualitative annual assessment for impairment of the remaining goodwill with respect to legacy Anika reporting unit as of <em style="font: inherit;"> November 30, 2022, </em>including consideration of (i) general macroeconomic factors, (ii) industry and market conditions, and (iii) the extent of the excess of the fair value over the carrying value indicated in prior impairment testing. Accordingly, the Company determined it was <em style="font: inherit;">not</em> more likely than <em style="font: inherit;">not</em> that the fair value of the legacy Anika reporting unit is less than its carrying amount and thus goodwill was <span style="-sec-ix-hidden:c95412934">not</span> impaired as of <em style="font: inherit;"> November 30, 2022.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">To conduct impairment tests of IPR&amp;D, the fair value of the IPR&amp;D project is compared to its carrying value. If the carrying value exceeds its fair value, the Company records an impairment loss to the extent that the carrying value of the IPR&amp;D project exceeds its fair value. The Company estimates the fair value for IPR&amp;D using the income approach, which is based on the Multi-Period Excess Earnings Method (“MPEEM”). MPEEM measures economic benefit indirectly by calculating the income attributable to an asset after appropriate returns are paid to complementary assets used in conjunction with the subject asset to produce the earnings associated with the subject asset, commonly referred to as contributory asset charges. This approach incorporates significant estimates and assumptions related to the forecasted results including revenues, expenses, expected economic life of the asset, contributory asset charges and discount rates to estimate future cash flows.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"/><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i/></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i>Long-Lived Assets</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Long-lived assets primarily include property and equipment and intangible assets with finite lives. The Company’s intangible assets are comprised of purchased developed technologies, patents, trade names, customer relationships and distributor relationships. These intangible assets are carried at cost, net of accumulated amortization. Amortization is recorded on a straight-line basis over the intangible assets' useful lives, which range from approximately <span style="-sec-ix-hidden:c95412935">five</span> to <span style="-sec-ix-hidden:c95412936">sixteen</span> years. The Company reviews long-lived assets for impairment when events or changes in business circumstances indicate that the carrying amount of the assets <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be fully recoverable or that the useful lives of those assets are <em style="font: inherit;">no</em> longer appropriate. Each impairment test is based on a comparison of the undiscounted cash flows to the recorded value of the asset. If impairment is indicated, the asset is written down to its estimated fair value based on a discounted cash flow analysis.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">In determining the useful lives of intangible assets, the Company considers the expected use of the assets and the effects of obsolescence, demand, competition, anticipated technological advances, changes in surgical techniques, market influences and other economic factors. For technology-based intangible assets, the Company considers the expected life cycles of products, absent unforeseen technological advances, which incorporate the corresponding technology.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"/><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i/></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i>Fair Value Measurements</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Fair value is defined as the price that would be received from selling an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of non-performance. The accounting standard establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Three levels of inputs that <em style="font: inherit;"> may </em>be used to measure fair value are:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:2.8%;"> </td><td style="vertical-align:top;width:0.9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">•</p> </td><td style="vertical-align:top;width:43%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Level <em style="font: inherit;">1</em> – Valuation is based upon quoted prices for identical instruments traded in active markets. Level <em style="font: inherit;">1</em> instruments include securities traded on active exchange markets, such as the New York Stock Exchange.</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:2.8%;"> </td><td style="vertical-align:top;width:0.9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">•</p> </td><td style="vertical-align:top;width:43%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Level <em style="font: inherit;">2</em> – Valuation is based upon quoted prices, unadjusted, for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are <em style="font: inherit;">not</em> active and model-based valuation techniques for which all significant assumptions are directly observable in the market.</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:2.8%;"> </td><td style="vertical-align:top;width:0.9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">•</p> </td><td style="vertical-align:top;width:43%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Level <em style="font: inherit;">3</em> – Valuation is generated from model-based techniques that use significant assumptions <em style="font: inherit;">not</em> observable in the market. These unobservable assumptions reflect the Company’s own estimates of assumptions market participants would use in pricing the instrument.</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Company’s financial assets have been classified as Level <em style="font: inherit;">1.</em> The Company’s financial assets (which include cash equivalents and investments) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing <em style="font: inherit;">third</em> party pricing services. The Company’s financial liabilities have been classified as Level <em style="font: inherit;">3.</em> The Company’s financial liabilities (which include contingent considerations as discussed in Note <em style="font: inherit;">4</em> – <i>Fair Value Measurements</i>) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing a <em style="font: inherit;">third</em>-party valuation specialist.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"/><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i/></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i>Research and Development</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Research and development costs consist primarily of salaries and related expenses for personnel, clinical trial expenses and fees paid to outside consultants and outside service providers. Research and development costs are expensed as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"/><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i/></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i>Stock-Based Compensation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Company has stock-based compensation plans under which it grants various types of equity-based awards, the cost of which is based on the grant-date fair value of the underlying award and recognized over the period during which an employee is required to provide service in exchange for the award, which is generally the vesting period.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">For performance-equity awards with market-based conditions, compensation cost is measured at the date of the award and is recorded over the vesting period, regardless of the likelihood of achievement of the market-based performance criteria. For performance-based equity awards with financial and business milestone achievement targets, compensation cost is based on the probable outcome of the performance conditions. Changes to the probability assessment and the estimated shares expected to vest will result in adjustments to the related stock-based compensation expense that will be recorded in the period of the change. If the performance targets are <em style="font: inherit;">not</em> achieved, <em style="font: inherit;">no</em> compensation cost is recognized, and any previously recognized compensation cost is reversed.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">See Note <em style="font: inherit;">14,</em> <i>Equity Incentive Plan</i>, for a description of the types of stock-based awards granted, the compensation expense related to such awards, and detail of equity-based awards outstanding.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"/><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i/></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i>Income Taxes</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets, or DTAs, and deferred tax liabilities, or DTLs, for the expected future tax consequences of events that have been included in the financial statements. Under this method, we determine DTAs and DTLs based on the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on DTAs and DTLs is recognized in income in the period that includes the enactment date.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">We recognize DTAs to the extent that we believe that these assets are more likely than <em style="font: inherit;">not</em> to be realized. In making such a determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, carryback potential if permitted under the tax law, and results of recent operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">We record uncertain tax positions in accordance with ASC <em style="font: inherit;">740,</em> <i>Income Taxes</i>, on the basis of a <em style="font: inherit;">two</em>-step process in which (<em style="font: inherit;">1</em>) we determine whether it is more likely than <em style="font: inherit;">not</em> that the tax positions will be sustained on the basis of the technical merits of the position and (<em style="font: inherit;">2</em>) for those tax positions that meet the more-likely-than-<em style="font: inherit;">not</em> recognition threshold, we recognize the largest amount of tax benefit that is more than <em style="font: inherit;">50</em> percent likely to be realized upon ultimate settlement with the related tax authority. Interest and penalties associated with income tax filings are recorded in income tax expense.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"/><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i/></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i>Comprehensive Income (Loss)</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Comprehensive income (loss) consists of net income (loss) and other comprehensive income (loss), which includes foreign currency translation adjustments. For the purposes of comprehensive income (loss) disclosures, the Company does <em style="font: inherit;">not</em> record tax provisions or benefits for the net changes in the foreign currency translation adjustment, as it intends to indefinitely reinvest undistributed earnings of its foreign subsidiary. Accumulated other comprehensive income (loss) is reported as a component of stockholders' equity.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"/><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i/></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i>Segment Information</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is its President and Chief Executive Officer as of <em style="font: inherit;"> December 31, 2022. </em>Based on the criteria established by ASC <em style="font: inherit;">280,</em> <i>Segment Reportin</i>g, the Company has <span style="-sec-ix-hidden:c95412964">one</span> operating and reportable segment.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"/><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i/></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i>Contingencies</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">In the normal course of business, the Company is involved from time-to-time in various legal proceedings and other matters such as contractual disputes, which are complex in nature and have outcomes that are difficult to predict. The Company records accruals for loss contingencies to the extent that it concludes that it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. The Company considers all relevant factors when making assessments regarding these contingencies. Although the outcomes of any potential legal proceedings are inherently difficult to predict, the Company does <em style="font: inherit;">not</em> expect the resolution of any potential legal proceedings to have a material adverse effect on its financial position, results of operations, or cash flow.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"/><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i/></p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i>Recent Issued Accounting Pronouncements</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><em style="font: inherit;">No</em> new accounting pronouncements issued or effective during the period had, or are expected to have, a material impact on the consolidated financial statements.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"/> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 15pt;"><i>Use of Estimates</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America (“US GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 15pt;"/> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 15pt;"><i>Principles of Consolidation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The accompanying consolidated financial statements include the accounts of Anika Therapeutics, Inc. and its wholly owned subsidiaries, Anika Securities, Inc., Anika Therapeutics S.r.l. (“Anika S.r.l.”), Anika Therapeutics Limited, Parcus Medical and Arthrosurface. All intercompany balances and transactions have been eliminated in consolidation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 15pt;"/> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 15pt;"><i>Foreign Currency Translation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The functional currency of Anika S.r.l. is the Euro, and the functional currency of Anika Therapeutics Limited is the British Pound Sterling. Assets and liabilities of the foreign subsidiaries are translated using the exchange rate existing on each respective balance sheet date. Revenues and expenses are translated using the average exchange rates for the period. The translation adjustments resulting from this process are included in stockholders’ equity as a component of accumulated other comprehensive income (loss) which resulted in a gain (loss) from foreign currency translation of ($0.7) million, ($1.2) million, and $1.3 million for the years ended <em style="font: inherit;"> December 31, 2022, </em><em style="font: inherit;">2021,</em> and <em style="font: inherit;">2020,</em> respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Gains and losses resulting from foreign currency transactions are recognized in the consolidated statements of operations. Recorded balances that are denominated in a currency other than the functional currency are remeasured to the functional currency using the exchange rate at the balance sheet date and gains or losses are recorded in the statements of operations. The Company recognized a gain (loss) from foreign currency transactions of ($0.5) million, ($0.4) million, and $0.3 million during the years ended <em style="font: inherit;"> December 31, 2022, </em><em style="font: inherit;">2021,</em> and <em style="font: inherit;">2020,</em> respectively</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 15pt;"/> -700000 -1200000 1300000 -500000 -400000 300000 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 15pt;"><i>Accounts Receivable</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Company estimates an allowance for credit losses with its accounts receivable resulting from the inability of its customers to make required payments, which is included in selling, general and administrative expenses in the accompanying consolidated statements of operations. In determining the adequacy of the allowance, management specifically analyzes individual accounts receivable, historical bad debts, customer concentrations, customer creditworthiness, current and reasonable and supportable forecasts of future economic conditions, accounts receivable aging trends, and changes in the Company’s customer payment terms.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The components of the Company’s accounts receivables are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As of December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2021</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accounts Receivable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">36,235</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">31,285</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Allowance for credit losses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,608</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,442</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net balance, end of the year</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">34,627</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">29,843</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">A summary of activity in the allowance for credit losses is as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As of <b>December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance, beginning of the year</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,442</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,523</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">962</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Amounts provided</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">554</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">156</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">635</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Amounts recovered</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(180</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(92</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(86</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Amounts written off</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(158</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(73</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(78</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Translation adjustments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(72</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">90</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance, end of the year</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,608</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,442</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,523</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"/> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As of December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2021</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accounts Receivable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">36,235</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">31,285</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Allowance for credit losses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,608</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,442</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net balance, end of the year</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">34,627</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">29,843</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As of <b>December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance, beginning of the year</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,442</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,523</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">962</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Amounts provided</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">554</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">156</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">635</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Amounts recovered</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(180</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(92</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(86</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Amounts written off</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(158</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(73</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(78</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Translation adjustments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(72</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">90</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance, end of the year</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,608</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,442</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,523</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 36235000 31285000 1608000 1442000 34627000 29843000 1442000 1523000 962000 554000 156000 635000 180000 92000 86000 158000 73000 78000 -50000 -72000 90000 1608000 1442000 1523000 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i>Revenue Recognition </i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Pursuant to Accounting Standard Codification <em style="font: inherit;">606,</em> <i>Revenue from Contracts with Customers</i> (“ASC <em style="font: inherit;">606”</em>), the Company recognizes revenue when a customer obtains control of promised goods or services. The amount of revenue that is recorded reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following <em style="font: inherit;">five</em>-step model in order to determine this amount: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are capable of being distinct or distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"/> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i>Revenue</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Company generates sales principally through <em style="font: inherit;">three</em> types of customers: (i) commercial partnerships (ii) hospitals and ambulatory surgical centers (“ASCs”), and (iii) distributors, referred to as the distribution model.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">For commercial partnership sales, the Company sells its products directly to these partners, who perform most of the downstream sales and marketing activities to customers and end-users. These arrangements <em style="font: inherit;"> may </em>include the grant of certain licenses, performance of development services, and the supply of product. The Company’s largest such customer, DePuy Synthes Mitek Sports Medicine, a division of DePuy Orthopedics, Inc., part of the Johnson &amp; Johnson Medical Companies (“Mitek”), represented 43%, 45% and 49% of total revenues for the years-ended <em style="font: inherit;"> December 31, 2022, </em><em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> respectively. The Company completed the performance obligations related to granted licenses and development services under the agreements with Mitek prior to <em style="font: inherit;">2016</em> and has <em style="font: inherit;">no</em> remaining material performance obligations. The Company recognizes revenue from product sales when the customer obtains control of the Company’s product, which typically occurs upon shipment to the customer. Commercial partnership agreements <em style="font: inherit;"> may </em>also include sales-based royalties and milestones. As the Company considered the license to be the predominant item to which the royalties relate for these agreements, sales-based royalties and milestones are only recognized when the later of the underlying sale occurs or the performance obligation to which the sales-based royalty has been satisfied (or partially satisfied). This is generally in the same period that the Company’s licensees complete their product sales in their territory, for which the Company is contractually entitled to a percentage-based royalty. The Company records royalty revenues based on estimated net sales of licensed products as reported to the Company by its commercial partners. The differences between actual and estimated royalty revenues have <em style="font: inherit;">not</em> been material and are typically adjusted in the following quarter when the actual amounts are known. Revenue from sales-based royalties is included in revenue in the consolidated statement of operations. The Company’s certain supply agreements represent a promise to deliver products at the customer’s discretion that are considered distributor options. The Company assesses if these options provide a material right to the licensee, and if so, they are accounted for as separate performance obligations. Substantially all of the Company’s supply agreements do <em style="font: inherit;">not</em> provide options that are considered material rights.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">For sales to hospitals and ASCs, which generally pairs in-house sales representatives with local or regional distributors, the inventory is generally consigned so that products are available when needed for surgical procedures. <em style="font: inherit;">No</em> revenue is recognized upon the placement of inventory into consignment, as the Company retains the ability to control the inventory. Revenue is typically recognized as of the date of surgical implantation of the product.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">For distributor sales, the Company sells its products principally to distributors, generally outside the United States, who subsequently resell the products to sub-distributors and health care providers, among others. The Company recognizes revenue from product sales when the distributor obtains control of the Company’s product, which typically occurs upon shipment to the distributor, in return for agreed-upon, fixed-price consideration. Performance obligations are generally settled quickly after purchase order acceptance; therefore, the value of unsatisfied performance obligations at the end of any reporting period is generally insignificant. The Company sells to a diversified base of distributors and, therefore, believes there is <em style="font: inherit;">no</em> material concentration of credit risk.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Company’s payment terms are consistent with prevailing practice in the respective markets in which the Company does business. Most of the Company’s customers make payments based on contract terms, which are <em style="font: inherit;">not</em> affected by contingent events that could impact the transaction price. Payment terms fall within the <em style="font: inherit;">one</em>-year guidance for the practical expedient, which allows the Company to forgo adjustment of the contractual payment amount of consideration for the effects of a significant financing component.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Some of the Company’s distributor agreements have volume-based discounts with tiered pricing which are generally prospective in nature. These prospective discounts together with any free-of-charge sample units offered are evaluated as potential material rights. If the prospective discounts or free-of-charge sample units are considered material rights, these would be separate performance obligations and a portion of the sales transaction price is allocated to the material right. Revenue allocated to the material right is recognized when the additional goods are transferred to the customer or when the option expires. During <em style="font: inherit;">2022</em> and <em style="font: inherit;">2021,</em> the consideration allocated to material rights was <em style="font: inherit;">not</em> significant.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Company receives payments from its customers based on billing schedules established in each contract. Up-front payments and fees are recorded as deferred revenue upon receipt or when due and <em style="font: inherit;"> may </em>require deferral of revenue recognition to a future period until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when its right to consideration is unconditional. Deferred revenue was $0 and $1.0 million as of <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Generally, customer contracts contain Free on Board (“FOB”) or Ex-Works shipping point terms where the customer pays the shipping company directly for all shipping and handling costs. In those contracts in which the Company pays for the shipping and handling, the associated costs are generally recorded along with the product sale at the time of shipment in cost of revenue when control over the products has transferred to the customer. Value-add and other taxes collected by the Company concurrently with revenue-producing activities are excluded from revenue. The Company’s general product warranty does <em style="font: inherit;">not</em> extend beyond an assurance that the product or services delivered will be consistent with stated contractual specifications, which does <em style="font: inherit;">not</em> create a separate performance obligation. The Company recognizes the incremental costs of obtaining contracts as an expense when incurred as the amortization period of the assets that the Company otherwise would have recognized is <em style="font: inherit;">one</em> year or less in accordance with the practical expedient in paragraph ASC <em style="font: inherit;">340</em>-<em style="font: inherit;">40</em>-<em style="font: inherit;">25</em>-<em style="font: inherit;">4.</em> These costs are included in selling, general and administrative expenses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i>Licensing, Milestone and Contract Revenue</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The agreements with Mitek include variable consideration such as contingent development and regulatory milestones. Since <em style="font: inherit;">2016,</em> there have been <em style="font: inherit;">no</em> remaining regulatory milestones related to the Mitek agreements. In general, variable consideration is included in the transaction price only to the extent a significant reversal in the amount of cumulative revenue recognized is <em style="font: inherit;">not</em> probable to occur.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"/> 0.43 0.45 0.49 0 1000000.0 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i>Cash and Cash Equivalents </i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Company considers only those investments which are highly liquid, readily convertible to cash, and that mature within <em style="font: inherit;">90</em> days from the date of purchase to be cash equivalents. The Company’s cash equivalents consist of money market funds.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"/> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i>Investments</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">All of the Company’s investments are classified as available-for-sale which consist of U.S. treasury bills and are carried at fair value with unrealized gains and losses recorded as a component of accumulated other comprehensive income (loss), net of related income taxes. For securities sold prior to maturity, the cost of securities sold is based on the specific identification method. Realized gains and losses on the sale of investments are recorded in interest and other income, net. Interest is recorded when earned. Investments with original maturities greater than approximately <em style="font: inherit;">three</em> months and remaining maturities less than <em style="font: inherit;">one</em> year are classified as short-term investments. Investments with remaining maturities greater than <em style="font: inherit;">one</em> year are classified as long-term investments. The Company had no investments as of <em style="font: inherit;"> December 31, 2022 </em>or <em style="font: inherit;"> December 31, 2021.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">All of the Company’s investments are subject to a periodic impairment review. For available-for-sale debt securities in an unrealized loss position, the Company <em style="font: inherit;">first</em> assesses whether (i) the Company intends to sell, or (ii) it is more likely than <em style="font: inherit;">not</em> that the Company will be required to sell the security before recovery of its amortized cost basis. If either case is affirmative, any previously recognized allowances are charged-off and the security's amortized cost is written down to fair value through earnings. If neither case is affirmative, the security is evaluated to determine whether the decline in fair value has resulted from credit losses or other factors.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Any impairment that has <em style="font: inherit;">not</em> been recorded through an allowance for credit losses is recognized in other comprehensive income. Adjustments to the allowance are reported in the consolidated statement of operations as a component of credit loss expense. Available-for-sale securities are charged-off against the allowance or, in the absence of any allowance, written down through earnings when deemed uncollectible by management or when either of the criteria regarding intent or requirement to sell is met.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">During the years ended <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2022,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> the Company did <em style="font: inherit;">not</em> record any impairment charges on its available-for-sale securities because it is <em style="font: inherit;">not</em> more likely than <em style="font: inherit;">not</em> that the Company will be required to sell these securities before the recovery of their cost basis.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"/> 0 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i>Concentration of Credit Risk </i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Company has <em style="font: inherit;">no</em> significant off-balance sheet risks related to foreign exchange contracts, option contracts, or other foreign hedging arrangements. The Company’s cash equivalents and investments are held with <em style="font: inherit;">two</em> major international financial institutions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Company, by policy, routinely assesses the financial strength of its customers. As a result, the Company believes that its accounts receivable credit risk exposure is limited.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">As of <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2022</em> and <em style="font: inherit;">2021,</em> Mitek represented 47% and 41%, respectively, of the Company’s accounts receivable balance. <em style="font: inherit;">No</em> other single customer accounted for more than <em style="font: inherit;">10%</em> of accounts receivable in either period.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"/> 0.47 0.41 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i>Inventories</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Inventories are primarily stated at the lower of standard cost and net realizable value, with cost determined using the <em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out method. Work-in-process and finished goods inventories include materials, labor, and certain manufacturing overhead. Manufacturing variances attributable to abnormally low production are expensed in the period incurred.  </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Company’s policy is to write down inventory when conditions exist that suggest inventory <em style="font: inherit;"> may </em>be in excess of anticipated demand or is obsolete based upon assumptions about future demand for the Company’s products and market conditions. The Company regularly evaluates the ability to realize the value of inventory based on a combination of factors including, but <em style="font: inherit;">not</em> limited to, historical usage rates, forecasted sales or usage, product end of life dates, and estimated current or future market values. Purchasing requirements and alternative usage avenues are explored within these processes to mitigate inventory exposure.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">When recorded, inventory write-downs are intended to reduce the carrying value of inventory to its net realizable value. If actual demand for the Company’s products deteriorates, or if market conditions are less favorable than those projected, additional inventory write-downs <em style="font: inherit;"> may </em>be required. Other long-term assets include inventory expected to remain on hand beyond <em style="font: inherit;">one</em> year.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"/> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i>Leases</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the circumstances present and evaluates whether the lease is an operating lease or a finance lease at the commencement date. Operating and finance leases with a term greater than <em style="font: inherit;">one</em> year are recognized on the consolidated balance sheet as right-of-use assets, lease liabilities, and, if applicable, long-term lease liabilities. The Company includes renewal options to extend the lease in the lease term where it is reasonably certain that it will exercise these options. Operating and finance lease liabilities and the corresponding right-of-use assets are recorded based on the present values of lease payments over the lease terms. The Company elected an accounting policy to combine the non-lease components (which include common area maintenance, taxes and insurance) with the related lease component. The interest rate implicit in lease contracts is typically <em style="font: inherit;">not</em> readily determinable. As such, the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a similar economic environment. Variable payments that do <em style="font: inherit;">not</em> depend on a rate or index are <em style="font: inherit;">not</em> included in the lease liability and are recognized as incurred. Lease contracts do <em style="font: inherit;">not</em> include residual value guarantees nor do they include restrictions or other covenants. Certain adjustments to the right-of-use assets <em style="font: inherit;"> may </em>be required for items such as initial direct costs paid, incentives received or lease prepayments. If significant events, changes in circumstances, or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure the finance and operating lease liabilities by using revised inputs as of the reassessment date, and adjust the right-of-use asset. Operating lease expense is recognized on a straight-line basis over the lease term. Finance lease expense is recognized based on the effective-interest method over the lease term.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"/> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i>Property and Equipment</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Property and equipment are recorded at cost and depreciated using the straight-line method over their estimated useful lives, which are typically:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 43%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Asset</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Estimated useful life</b><br/> <b>(in years)</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Computer equipment and software</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Furniture and fixtures</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Leasehold improvements</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Shorter of useful life or term of lease</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Maintenance and repairs are charged to expense when incurred; additions and improvements are capitalized. Fully depreciated assets are retained in the accounts until they are <em style="font: inherit;">no</em> longer used and <em style="font: inherit;">no</em> further charge for depreciation is made in respect of these assets. When an item is sold, retired or removed from service, the cost and related accumulated depreciation is relieved, and the resulting gain or loss, if any, is recognized in income.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Construction-in-process assets are stated at cost, which includes the cost of construction and other direct costs attributable to the construction. Construction-in-process assets are <em style="font: inherit;">not</em> depreciated until such time as the relevant assets are completed and put into use.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"/> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 43%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Asset</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Estimated useful life</b><br/> <b>(in years)</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Computer equipment and software</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Furniture and fixtures</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Leasehold improvements</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Shorter of useful life or term of lease</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> </tbody></table> P3Y P10Y P5Y P7Y P5Y P20Y <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i>Goodwill and IPR&amp;D Assets</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Goodwill is the amount by which the purchase price of acquired net assets in a business combination exceeded the fair values of net identifiable assets on the date of acquisition. Acquired In-Process Research and Development (“IPR&amp;D”) represents the fair value assigned to research and development assets that the Company acquires that have <em style="font: inherit;">not</em> been completed at the date of acquisition or are pending regulatory approval in certain jurisdictions. The value assigned to the acquired IPR&amp;D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenue from the projects, and discounting the net cash flows to present value.  </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Goodwill and IPR&amp;D are <em style="font: inherit;">not</em> amortized but are evaluated for impairment annually or more frequently if events or changes in circumstances indicate that the asset might be impaired. The goodwill impairment assessment is performed by reporting unit. A reporting unit is the operating segment, or a business <em style="font: inherit;">one</em> level below that operating segment (the component level) if discrete financial information is prepared and regularly reviewed by segment management. However, components are aggregated as a single reporting unit if they have similar economic characteristics. The Company has two reporting units: the legacy Anika reporting unit, which specializes in therapies based on its hyaluronic acid, or HA, technology platform, and a newly formed reporting unit established in <em style="font: inherit;">2020</em> upon the acquisitions of Parcus Medical and Arthrosurface. Factors that the Company considers important, on an overall company basis, that could trigger an impairment review include significant underperformance relative to historical or projected future operating results, significant changes in the Company’s use of the acquired assets or the strategy for its overall business, significant negative industry or economic trends, a significant decline in the Company’s stock price for a sustained period, or a reduction of its market capitalization relative to net book value.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Under U.S. GAAP, the Company has the option to perform a qualitative assessment to determine if it is necessary to perform the impairment test. If the Company concludes, based on a qualitative assessment, it is <em style="font: inherit;">not</em> more likely than <em style="font: inherit;">not</em> that the Goodwill or the IPR&amp;D asset is impaired, the Company is <em style="font: inherit;">not</em> required to perform the quantitative test. The Company has an unconditional option to bypass the qualitative assessment in any period and proceed directly to the quantitative impairment test.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">To conduct quantitative impairment tests of goodwill, the fair value of the reporting unit is compared to its carrying value. If the reporting unit’s carrying value exceeds its fair value, the Company records an impairment loss to the extent that the carrying value of goodwill exceeds its implied fair value, <em style="font: inherit;">not</em> to exceed the recorded amount of goodwill. The Company recorded a non-cash goodwill impairment charge with respect to the newly formed reporting unit amounted to $42.5 million for the year ended <em style="font: inherit;"> December 31, 2020. </em>Please see Note <em style="font: inherit;">8,</em> <i>Goodwill</i> for further details.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Company performed a qualitative annual assessment for impairment of the remaining goodwill with respect to legacy Anika reporting unit as of <em style="font: inherit;"> November 30, 2022, </em>including consideration of (i) general macroeconomic factors, (ii) industry and market conditions, and (iii) the extent of the excess of the fair value over the carrying value indicated in prior impairment testing. Accordingly, the Company determined it was <em style="font: inherit;">not</em> more likely than <em style="font: inherit;">not</em> that the fair value of the legacy Anika reporting unit is less than its carrying amount and thus goodwill was <span style="-sec-ix-hidden:c95412934">not</span> impaired as of <em style="font: inherit;"> November 30, 2022.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">To conduct impairment tests of IPR&amp;D, the fair value of the IPR&amp;D project is compared to its carrying value. If the carrying value exceeds its fair value, the Company records an impairment loss to the extent that the carrying value of the IPR&amp;D project exceeds its fair value. The Company estimates the fair value for IPR&amp;D using the income approach, which is based on the Multi-Period Excess Earnings Method (“MPEEM”). MPEEM measures economic benefit indirectly by calculating the income attributable to an asset after appropriate returns are paid to complementary assets used in conjunction with the subject asset to produce the earnings associated with the subject asset, commonly referred to as contributory asset charges. This approach incorporates significant estimates and assumptions related to the forecasted results including revenues, expenses, expected economic life of the asset, contributory asset charges and discount rates to estimate future cash flows.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"/> 2 42500000 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i>Long-Lived Assets</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Long-lived assets primarily include property and equipment and intangible assets with finite lives. The Company’s intangible assets are comprised of purchased developed technologies, patents, trade names, customer relationships and distributor relationships. These intangible assets are carried at cost, net of accumulated amortization. Amortization is recorded on a straight-line basis over the intangible assets' useful lives, which range from approximately <span style="-sec-ix-hidden:c95412935">five</span> to <span style="-sec-ix-hidden:c95412936">sixteen</span> years. The Company reviews long-lived assets for impairment when events or changes in business circumstances indicate that the carrying amount of the assets <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be fully recoverable or that the useful lives of those assets are <em style="font: inherit;">no</em> longer appropriate. Each impairment test is based on a comparison of the undiscounted cash flows to the recorded value of the asset. If impairment is indicated, the asset is written down to its estimated fair value based on a discounted cash flow analysis.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">In determining the useful lives of intangible assets, the Company considers the expected use of the assets and the effects of obsolescence, demand, competition, anticipated technological advances, changes in surgical techniques, market influences and other economic factors. For technology-based intangible assets, the Company considers the expected life cycles of products, absent unforeseen technological advances, which incorporate the corresponding technology.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"/> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i>Fair Value Measurements</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Fair value is defined as the price that would be received from selling an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of non-performance. The accounting standard establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. Three levels of inputs that <em style="font: inherit;"> may </em>be used to measure fair value are:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:2.8%;"> </td><td style="vertical-align:top;width:0.9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">•</p> </td><td style="vertical-align:top;width:43%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Level <em style="font: inherit;">1</em> – Valuation is based upon quoted prices for identical instruments traded in active markets. Level <em style="font: inherit;">1</em> instruments include securities traded on active exchange markets, such as the New York Stock Exchange.</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:2.8%;"> </td><td style="vertical-align:top;width:0.9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">•</p> </td><td style="vertical-align:top;width:43%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Level <em style="font: inherit;">2</em> – Valuation is based upon quoted prices, unadjusted, for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are <em style="font: inherit;">not</em> active and model-based valuation techniques for which all significant assumptions are directly observable in the market.</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:96%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align:top;width:2.8%;"> </td><td style="vertical-align:top;width:0.9%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">•</p> </td><td style="vertical-align:top;width:43%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Level <em style="font: inherit;">3</em> – Valuation is generated from model-based techniques that use significant assumptions <em style="font: inherit;">not</em> observable in the market. These unobservable assumptions reflect the Company’s own estimates of assumptions market participants would use in pricing the instrument.</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Company’s financial assets have been classified as Level <em style="font: inherit;">1.</em> The Company’s financial assets (which include cash equivalents and investments) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing <em style="font: inherit;">third</em> party pricing services. The Company’s financial liabilities have been classified as Level <em style="font: inherit;">3.</em> The Company’s financial liabilities (which include contingent considerations as discussed in Note <em style="font: inherit;">4</em> – <i>Fair Value Measurements</i>) have been initially valued at the transaction price and subsequently valued, at the end of each reporting period, utilizing a <em style="font: inherit;">third</em>-party valuation specialist.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"/> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i>Research and Development</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Research and development costs consist primarily of salaries and related expenses for personnel, clinical trial expenses and fees paid to outside consultants and outside service providers. Research and development costs are expensed as incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"/> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i>Stock-Based Compensation</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Company has stock-based compensation plans under which it grants various types of equity-based awards, the cost of which is based on the grant-date fair value of the underlying award and recognized over the period during which an employee is required to provide service in exchange for the award, which is generally the vesting period.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">For performance-equity awards with market-based conditions, compensation cost is measured at the date of the award and is recorded over the vesting period, regardless of the likelihood of achievement of the market-based performance criteria. For performance-based equity awards with financial and business milestone achievement targets, compensation cost is based on the probable outcome of the performance conditions. Changes to the probability assessment and the estimated shares expected to vest will result in adjustments to the related stock-based compensation expense that will be recorded in the period of the change. If the performance targets are <em style="font: inherit;">not</em> achieved, <em style="font: inherit;">no</em> compensation cost is recognized, and any previously recognized compensation cost is reversed.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">See Note <em style="font: inherit;">14,</em> <i>Equity Incentive Plan</i>, for a description of the types of stock-based awards granted, the compensation expense related to such awards, and detail of equity-based awards outstanding.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"/> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i>Income Taxes</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">We account for income taxes under the asset and liability method, which requires the recognition of deferred tax assets, or DTAs, and deferred tax liabilities, or DTLs, for the expected future tax consequences of events that have been included in the financial statements. Under this method, we determine DTAs and DTLs based on the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on DTAs and DTLs is recognized in income in the period that includes the enactment date.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">We recognize DTAs to the extent that we believe that these assets are more likely than <em style="font: inherit;">not</em> to be realized. In making such a determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, carryback potential if permitted under the tax law, and results of recent operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">We record uncertain tax positions in accordance with ASC <em style="font: inherit;">740,</em> <i>Income Taxes</i>, on the basis of a <em style="font: inherit;">two</em>-step process in which (<em style="font: inherit;">1</em>) we determine whether it is more likely than <em style="font: inherit;">not</em> that the tax positions will be sustained on the basis of the technical merits of the position and (<em style="font: inherit;">2</em>) for those tax positions that meet the more-likely-than-<em style="font: inherit;">not</em> recognition threshold, we recognize the largest amount of tax benefit that is more than <em style="font: inherit;">50</em> percent likely to be realized upon ultimate settlement with the related tax authority. Interest and penalties associated with income tax filings are recorded in income tax expense.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"/> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i>Comprehensive Income (Loss)</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Comprehensive income (loss) consists of net income (loss) and other comprehensive income (loss), which includes foreign currency translation adjustments. For the purposes of comprehensive income (loss) disclosures, the Company does <em style="font: inherit;">not</em> record tax provisions or benefits for the net changes in the foreign currency translation adjustment, as it intends to indefinitely reinvest undistributed earnings of its foreign subsidiary. Accumulated other comprehensive income (loss) is reported as a component of stockholders' equity.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"/> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i>Segment Information</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Operating segments are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is its President and Chief Executive Officer as of <em style="font: inherit;"> December 31, 2022. </em>Based on the criteria established by ASC <em style="font: inherit;">280,</em> <i>Segment Reportin</i>g, the Company has <span style="-sec-ix-hidden:c95412964">one</span> operating and reportable segment.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"/> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i>Contingencies</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">In the normal course of business, the Company is involved from time-to-time in various legal proceedings and other matters such as contractual disputes, which are complex in nature and have outcomes that are difficult to predict. The Company records accruals for loss contingencies to the extent that it concludes that it is probable that a liability has been incurred and the amount of the related loss can be reasonably estimated. The Company considers all relevant factors when making assessments regarding these contingencies. Although the outcomes of any potential legal proceedings are inherently difficult to predict, the Company does <em style="font: inherit;">not</em> expect the resolution of any potential legal proceedings to have a material adverse effect on its financial position, results of operations, or cash flow.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"/> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt;"><i>Recent Issued Accounting Pronouncements</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"><em style="font: inherit;">No</em> new accounting pronouncements issued or effective during the period had, or are expected to have, a material impact on the consolidated financial statements.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-align: left; text-indent: 0pt;"><b><em style="font: inherit;">3.</em> Business Combinations</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;"><b><i>Parcus Medical, LLC</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">On <em style="font: inherit;"> January 24, 2020, </em>the Company completed the acquisition of Parcus Medical pursuant to the terms of the Agreement and Plan of Merger, dated as of <em style="font: inherit;"> January 4, 2020 (</em>the “Parcus Medical Merger Agreement”), by and among the Company, Parcus Medical, the Unitholder Representative, and Sunshine Merger Sub LLC, a Wisconsin limited liability company and a wholly owned subsidiary of the Company. At the closing date, Parcus Medical became a wholly owned subsidiary of the Company. Parcus Medical is a sports medicine implant and instrumentation solutions provider focused on surgical repair and reconstruction of soft tissue.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The acquisition of Parcus Medical has been accounted for as a business combination under ASC <em style="font: inherit;">805,</em><i> Business Combinations </i>(“ASC <em style="font: inherit;">805”</em>). Under ASC <em style="font: inherit;">805,</em> assets acquired and liabilities assumed in a business combination are recorded at their fair value as of the acquisition date. The Company’s consolidated financial statements include results of operations for Parcus Medical from the <em style="font: inherit;"> January 24, 2020 </em>acquisition date.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><i>Consideration Transferred</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Pursuant to the Parcus Medical Merger Agreement, the Company acquired all outstanding equity of Parcus Medical for estimated total purchase consideration of $75.1 million, as of <em style="font: inherit;"> January 24, 2020 </em>which consisted of:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash consideration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">32,794</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred consideration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,642</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Estimated fair value of contingent consideration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">40,700</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Estimated total purchase consideration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">75,136</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Pursuant to the Parcus Medical Merger Agreement, contingent consideration represents additional payments that the Company <em style="font: inherit;"> may </em>be required to make in the future could total up to $60.0 million depending on the level of net sales of Parcus Medical products generated from <em style="font: inherit;">2020</em> through <em style="font: inherit;">2022.</em></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:27pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 14pt; text-indent: 27pt;">The fair value of contingent consideration related to net sales as of <em style="font: inherit;"> January 24, 2020 </em>was determined based on a Monte Carlo simulation model in an option pricing framework at the acquisition date, whereby a range of possible scenarios were simulated. There also was deferred consideration related to certain purchase price holdbacks, which was resolved within <em style="font: inherit;">one</em> year of the acquisition date in accordance with the Parcus Merger. The liability for contingent and deferred consideration is included in current and long-term liabilities on the consolidated balance sheets and will be remeasured at each reporting period until the contingency is resolved. During the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> September 30, 2022, </em>the Company paid contingent consideration of $4.3 million related to net sales of Parcus Medical products earned in <em style="font: inherit;">2021</em> that was recorded in contingent consideration at <em style="font: inherit;"> December 31, 2021. </em>As of <em style="font: inherit;"> December 31, 2022, </em>there were <em style="font: inherit;">no</em> milestones remaining.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Acquisition-related costs are <em style="font: inherit;">not</em> included as a component of consideration transferred but are expensed in the periods in which the costs are incurred. The Company incurred approximately $1.9 million in transaction costs related to the Parcus Medical acquisition during the <em style="font: inherit;">three</em>-month period ending <em style="font: inherit;"> March 31, 2020. </em>The transaction costs have been included in selling, general and administrative expenses in the consolidated statements of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;"><i>Fair Value of Net Assets Acquired</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The estimate of fair value as of the acquisition date required the use of significant assumptions and estimates. Critical estimates included, but were <em style="font: inherit;">not</em> limited to, future expected cash flows, including projected revenues and expenses, and the applicable discount rates. These estimates were based on assumptions that the Company believes to be reasonable, however, actual results <em style="font: inherit;"> may </em>differ from these estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The allocation of purchase price to the identifiable assets acquired and liabilities assumed was based on estimates of fair value as of <em style="font: inherit;"> January 24, 2020, </em>and is as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Recognized identifiable assets acquired and liabilities assumed:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">196</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accounts receivable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,029</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Inventories</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,968</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">364</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,099</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Right-of-use assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">944</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Intangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">44,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accounts payable, accrued expenses and other current liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,763</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Other long-term liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(594</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(735</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Net assets acquired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">55,508</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Goodwill</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19,628</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Estimated total purchase consideration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">75,136</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:35pt;">The acquired intangible assets based on estimates of fair value as of <em style="font: inherit;"> January 24, 2020 </em>are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Developed technology</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">41,100</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Trade name</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,800</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Customer relationships</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,100</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total acquired intangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">44,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The fair value of the developed technology intangible assets has been estimated using the multi-period excess earnings method, which is based on the principle that the value of an intangible asset is equal to the present value of the incremental after-tax cash flows attributable to the asset, after charges for other assets employed by the business. The fair value of the customer relationships has been estimated using the avoided costs/lost profits method, which is based on the principle that the value of an intangible asset is based on consideration of the total costs that would be avoided by having this asset in place. The fair value of the trade name has been estimated using the relief from royalty method of the income approach, which is based on the principle that the value of an intangible asset is equal to the present value of the after-tax royalty savings attributable to owning the intangible asset. Key estimates and assumptions used in these models are projected revenues and expenses related to the asset, estimated contributory asset charges, estimated costs to recreate the asset, and a risk-adjusted discount rate used to calculate the present value of the future expected cash inflows or cash outflows avoided from the asset.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The fair value of developed technology will be amortized over a useful life of 15 years, the fair value of customer relationships over 10 years, and the fair value of the trade name over 5 years.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The excess of the purchase price over the fair value of the net assets acquired was recorded as goodwill and assigned to the reporting unit for Parcus Medical and Arthrosurface. The goodwill is attributable to the workforce of the business and the value of future technologies expected to arise after the acquisition. Goodwill will <em style="font: inherit;">not</em> be amortized and is expected to be deductible for income tax purposes as the acquisition of the limited liability company is an asset purchase for tax purposes. See Note <em style="font: inherit;">8,</em> <i>Goodwill</i>, for further discussion.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Arthrosurface, Inc.</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">On <em style="font: inherit;"> February 3, 2020, </em>the Company completed the acquisition of Arthrosurface pursuant to the terms of the Agreement and Plan of Merger, dated as of <em style="font: inherit;"> January 4, 2020 (</em>the “Arthrosurface Merger Agreement”), by and among the Company, Arthrosurface, the Stockholder Representative, and Button Merger Sub, a Delaware corporation and a wholly owned subsidiary of the Company. At the closing date, Arthrosurface became a wholly owned subsidiary of the Company. Arthrosurface is a joint preservation technology company specializing in less invasive, bone-preserving partial and total joint replacement solutions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:22pt;">The acquisition of Arthrosurface has been accounted for as a business combination under ASC <em style="font: inherit;">805.</em> Under ASC <em style="font: inherit;">805,</em> assets acquired and liabilities assumed in a business combination are recorded at their fair values as of the acquisition date. Anika’s consolidated financial statements include results of operations for Arthrosurface from the <em style="font: inherit;"> February 3, 2020 </em>acquisition date.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><i>Consideration Transferred</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Pursuant to the Arthrosurface Merger Agreement, the Company acquired all outstanding equity of Arthrosurface for estimated total purchase consideration of $90.3 million, as of <em style="font: inherit;"> February 3, 2020 </em>which consisted of:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash consideration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">61,909</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Estimated fair value of contingent consideration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">28,376</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Estimated total purchase consideration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">90,285</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Pursuant to the Arthrosurface Merger Agreement, the Company could be required to make future payments of up to $40.0 million depending on the achievement of regulatory milestones and the level of net sales of Arthrosurface products from <em style="font: inherit;">2020</em> through <em style="font: inherit;">2021.</em> The fair value of contingent consideration related to regulatory milestones as of <em style="font: inherit;"> February 3, 2020 </em>was determined through a scenario-based discounted cash flow analysis using scenario probabilities and regulatory milestone dates. The fair value of contingent consideration related to net sales achievement as of <em style="font: inherit;"> February 3, 2020 </em>was determined based upon a Monte Carlo simulation approach at acquisition date, whereby a range of possible scenarios were simulated. The Company paid $5.0 million in <em style="font: inherit;"> October 2020 </em>and $10.0 million in <em style="font: inherit;"> July 2021 </em>based upon the achievement of <em style="font: inherit;">two</em> distinct regulatory milestones. As of <em style="font: inherit;"> December 31, 2022, </em>there were <em style="font: inherit;">no</em> milestones remaining.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Acquisition-related costs are <em style="font: inherit;">not</em> included as a component of consideration transferred but are expensed in the periods in which the costs are incurred. The Company incurred approximately $2.2 million in transaction costs related to the Arthrosurface acquisition during the <em style="font: inherit;">three</em>-month period ending <em style="font: inherit;"> March 31, 2020. </em>The transaction costs have been included in selling, general and administrative expenses in the consolidated statements of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><i>Fair Value of Net Assets Acquired</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The estimate of fair value required the use of significant assumptions and estimates. Critical estimates included, but were <em style="font: inherit;">not</em> limited to, future expected cash flows, including projected revenues and expenses, and the applicable discount rates. These estimates were based on assumptions that the Company believes to be reasonable. However, actual results <em style="font: inherit;"> may </em>differ from these estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The allocation of purchase price to the identifiable assets acquired and liabilities assumed was based on estimates of fair value as of <em style="font: inherit;"> February 3, 2020, </em>as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Recognized identifiable assets acquired and liabilities assumed:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,072</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accounts receivable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,368</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Inventories</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15,652</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">535</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Property, plant and equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,394</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Other long-term assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,548</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Intangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">48,900</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accounts payable, accrued expenses and other liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3,929</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Deferred tax liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(11,147</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Net assets acquired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">67,393</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Goodwill</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">22,892</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Estimated total purchase consideration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">90,285</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Intangible assets acquired consist of:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Developed technology</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">37,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Trade name</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,400</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Customer relationships</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,900</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">IPR&amp;D</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">600</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total acquired intangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">48,900</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The fair value of the developed technology intangible assets has been estimated using the multi-period excess earnings method, which is based on the principle that the value of an intangible asset is equal to the present value of the incremental after-tax cash flow attributable to the asset, after charges for other assets employed by the business. The fair value of the customer relationships has been estimated using the avoided costs/lost profits method, which is based on the principle that the value of an intangible asset is based on consideration of the total costs that would be avoided by having this asset in place. The fair value of the trade name has been estimated using the relief from royalty method of the income approach, which is based on the principle that the value of an intangible asset is equal to the present value of the after-tax royalty savings attributable to owning the intangible asset. Key estimates and assumptions used in these models are projected revenues and expenses related to the asset, estimated contributory asset charges, estimated costs to recreate the asset, and a risk-adjusted discount rate used to calculate the present value of the future expected cash inflows or cash outflows avoided from the asset.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The fair value of developed technology that will be amortized over an estimated useful life of 15 years, the fair value of customer relationships over 10 years, and the fair value of trade names over 5 years. A total of $0.6 million represents the fair value of IPR&amp;D with an indefinite useful life which was impaired during the quarter ended <em style="font: inherit;"> December 31, 2021. </em>See Note <em style="font: inherit;">7,</em> <i>Acquired Intangible Assets, Net, </i>for further discussion<i>.</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The excess of the purchase price over the fair value of the net assets acquired was recorded as goodwill and assigned to the newly established reporting unit for Parcus Medical and Arthrosurface. The goodwill is attributable to the workforce of the business and the value of future technologies expected to arise after the acquisition. Goodwill will <em style="font: inherit;">not</em> be amortized and is <em style="font: inherit;">not</em> expected to be deductible for income tax purposes as the acquisition of the corporation is a stock purchase for tax purposes. See Note <em style="font: inherit;">8,</em> <i>Goodwill</i>, for further discussion.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 15pt;"><b><i>Pro forma Information</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Parcus Medical and Arthrosurface acquisitions were both completed in the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2020.</em> Both acquired companies have similar businesses with all of their products in the Joint Preservation and Restoration product family, serving orthopedic surgeons, ambulatory surgical centers and hospitals. The Company has combined legacy Anika, Parcus Medical and Arthrosurface pro forma supplemental information as follows.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The unaudited pro forma information for the year ended <em style="font: inherit;"> December 31, 2020 </em>was calculated after applying the Company’s accounting policies and the impact of acquisition date fair value adjustments. The pro forma financial information presents the combined results of operations of Anika, Parcus Medical and Arthrosurface as if the acquisitions had occurred on <em style="font: inherit;"> January 1, 2019 </em>after giving effect to certain pro forma adjustments. The pro forma adjustments reflected herein include only those adjustments that are factually supportable and directly attributable to the acquisitions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">These pro forma adjustments include: (i) a net increase in amortization expense to record amortization expense for the aforementioned acquired identifiable intangible assets, (ii) an adjustment to cost of revenue based on the preliminary inventory step-up and the anticipated inventory turnover, (iii) a net decrease in interest expense as a result of eliminating interest expense and interest income related to borrowings that were settled in accordance with the respective Parcus Medical Merger Agreement and Arthrosurface Merger Agreement, (iv) an adjustment to record the acquisition-related transaction costs in the period required, and (v) the tax effect of the pro forma adjustments using the anticipated effective tax rate. The effective tax rate of the combined company could be materially different from the effective rate presented in this unaudited pro forma combined financial information. As a result of the transaction, the combined company <em style="font: inherit;"> may </em>be subject to annual limitations on its ability to utilize pre-acquisition net operating loss carryforwards to offset future taxable income. The amount of the annual limitation is determined based on the value of Anika immediately prior to the acquisition. As further information becomes available, any such adjustment described above could be material to the amounts presented in the unaudited pro forma combined financial statements. The pro forma information does <em style="font: inherit;">not</em> purport to be indicative of the results of operations that actually would have resulted had the combination occurred at the beginning of each period presented, or of future results of the consolidated entities.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:9pt;">The following table presents unaudited supplemental pro forma information:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Year Ended December 31,</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><b>2020 </b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">134,410</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(22,984</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> </tbody></table> 75100000 <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash consideration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">32,794</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred consideration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,642</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Estimated fair value of contingent consideration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">40,700</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Estimated total purchase consideration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">75,136</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash consideration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">61,909</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Estimated fair value of contingent consideration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">28,376</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Estimated total purchase consideration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">90,285</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 32794000 1642000 40700000 75136000 60000000.0 4300000 1900000 <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Recognized identifiable assets acquired and liabilities assumed:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">196</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accounts receivable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,029</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Inventories</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,968</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">364</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,099</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Right-of-use assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">944</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Intangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">44,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accounts payable, accrued expenses and other current liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,763</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Other long-term liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(594</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(735</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Net assets acquired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">55,508</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Goodwill</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19,628</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Estimated total purchase consideration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">75,136</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Recognized identifiable assets acquired and liabilities assumed:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 16%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,072</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accounts receivable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,368</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Inventories</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15,652</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">535</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Property, plant and equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,394</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Other long-term assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,548</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Intangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">48,900</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accounts payable, accrued expenses and other liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3,929</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Deferred tax liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(11,147</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Net assets acquired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">67,393</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Goodwill</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">22,892</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Estimated total purchase consideration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">90,285</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 196000 2029000 10968000 364000 1099000 944000 44000000 2763000 594000 735000 55508000 19628000 75136000 <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Developed technology</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">41,100</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Trade name</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,800</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Customer relationships</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,100</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total acquired intangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">44,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Intangible assets acquired consist of:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Developed technology</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">37,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Trade name</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,400</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Customer relationships</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,900</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">IPR&amp;D</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">600</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total acquired intangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">48,900</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 41100000 1800000 1100000 44000000 P15Y P10Y P5Y 90300000 61909000 28376000 90285000 40000000.0 5000000.0 10000000.0 2200000 1072000 5368000 15652000 535000 3394000 7548000 48900000 3929000 11147000 67393000 22892000 90285000 37000000 3400000 7900000 600000 48900000 P15Y P10Y P5Y 600000 <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Year Ended December 31,</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><b>2020 </b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">134,410</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(22,984</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> </tbody></table> 134410000 -22984000 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-align: left; text-indent: 0pt;"><b><em style="font: inherit;">4.</em> Fair Value Measurements</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">There were <span style="-sec-ix-hidden:c95413103">no</span> available-for-sale securities as of <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Company’s investments are all classified within Levels <em style="font: inherit;">1</em> of the fair value hierarchy and are valued based on quoted prices in active markets. For cash, current receivables, accounts payable, and interest accrual, the carrying amounts approximate fair value, because of the short maturity of these instruments, and therefore fair value information is <em style="font: inherit;">not</em> included in the table below. Contingent consideration related to the previously described business combinations are classified within Level <em style="font: inherit;">3</em> of the fair value hierarchy as the determination of fair value uses considerable judgement and represents the Company’s best estimate of an amount that could be realized in a market exchange for the asset or liability. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The classification of the Company’s cash equivalents and investments within the fair value hierarchy is as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Active Markets</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Significant Other</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Significant</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>for Identical Assets</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Observable Inputs</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Unobservable Inputs</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>December 31, 2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>(Level 1)</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>(Level 2)</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>(Level 3)</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Amortized Cost</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash equivalents:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">67,801</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">67,801</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">67,801</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Active Markets</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Significant Other</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Significant</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>for Identical Assets</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Observable Inputs</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Unobservable Inputs</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>December 31, 2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>(Level 1)</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>(Level 2)</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>(Level 3)</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Amortized Cost</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash equivalents:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">67,046</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">67,046</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">67,046</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other current and long-term liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Contingent Consideration - Short Term</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,315</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,315</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt; text-align: justify;">There were <em style="font: inherit;">no</em> transfers between fair value levels in <em style="font: inherit;">2022</em> or <em style="font: inherit;">2021.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;"><b><i>Contingent Consideration</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The following table provides a roll forward of the contingent consideration related to business acquisitions discussed in Note <em style="font: inherit;">3,</em> <i>Business Combinations.</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Years Ended December 31</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance, beginning January 1</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,315</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">35,410</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Additions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Payments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,315</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(10,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Change in fair value</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(21,095</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance, ending December 31</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,315</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Under the Parcus Medical Merger Agreement and Arthrosurface Merger Agreement, there were earn-out milestones totaling up to $100 million payable from <em style="font: inherit;">2020</em> to <em style="font: inherit;">2022.</em> Parcus Medical had net sales earn-out milestones annually from <em style="font: inherit;">2020</em> to <em style="font: inherit;">2022,</em> while Arthrosurface had both regulatory and net sales earn-out milestones annually in <em style="font: inherit;">2020</em> and <em style="font: inherit;">2021.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">In order to determine the fair value of contingent consideration at each reporting date, the projected contingent payment amounts were discounted back to the current period using a discounted cash flow model or a Monte Carlo simulation approach. The unobservable inputs used in the fair value measurement of the Company’s contingent consideration are the probabilities of successful achievement, the net sales estimates, the weighted average cost of capital used for the Monte Carlo simulation, discount rate and the periods in which the milestones are expected to be achieved. The discount rates used for the net sales earn-out milestone ranged from 3.1% - 3.4%. The weighted average cost of capital for Parcus Medical decreased from 11.4% as of <em style="font: inherit;"> December 31, 2020 </em>to 11.3% as of <em style="font: inherit;"> December 31, 2021. </em>The weighted average cost of capital for Arthrosurface was 11.4% as of <em style="font: inherit;"> December 31, 2020. </em>Increases or decreases in the discount rate would result in a lower or higher fair value measurement, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">As of <em style="font: inherit;"> December 31, 2021, </em>a net sales growth milestone with respect to the Parcus Merger Agreement was achieved for <em style="font: inherit;">2021,</em> and a liability in the amount of $4.3 million was recorded in current liabilities. This amount was paid in <em style="font: inherit;"> September 2022. </em>In <em style="font: inherit;"> June 2021, </em>the Company received regulatory clearance for a reverse shoulder implant system, which triggered a $10.0 million regulatory milestone payment per the terms of the Arthrosurface Merger Agreement. This amount was paid in <em style="font: inherit;"> July 2021. </em>As of <em style="font: inherit;"> December 31, 2022, </em>there were <em style="font: inherit;">no</em> milestones remaining.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The overall fair value of the contingent consideration decreased by $21.1 million and $28.7 million during the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> respectively, due primarily to the decrease in the likelihood that certain contingent milestones would be achieved.</p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Active Markets</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Significant Other</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Significant</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>for Identical Assets</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Observable Inputs</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Unobservable Inputs</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>December 31, 2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>(Level 1)</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>(Level 2)</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>(Level 3)</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Amortized Cost</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash equivalents:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">67,801</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">67,801</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">67,801</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Active Markets</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Significant Other</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Significant</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>for Identical Assets</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Observable Inputs</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Unobservable Inputs</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>December 31, 2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>(Level 1)</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>(Level 2)</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>(Level 3)</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Amortized Cost</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 35%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash equivalents:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">67,046</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">67,046</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">67,046</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other current and long-term liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Contingent Consideration - Short Term</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,315</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,315</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 67801000 67801000 0 0 67801000 67046000 67046000 0 0 67046000 4315000 0 0 4315000 0 <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Years Ended December 31</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance, beginning January 1</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,315</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">35,410</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Additions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Payments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,315</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(10,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Change in fair value</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(21,095</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance, ending December 31</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,315</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 4315000 35410000 0 0 4315000 10000000 -0 21095000 0 4315000 100000000 3.1 3.4 11.4 11.3 11.4 4300000 10000000.0 21100000 28700000 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-align: left; text-indent: 0pt;"><b><em style="font: inherit;">5.</em> Inventories</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt; text-align: justify;">Total inventories included in the balance sheet consist of the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 70%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"> <tbody> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As of <b>December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Raw materials</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20,535</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,881</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Work-in-process</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,648</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,442</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Finished goods</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,306</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">26,731</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">56,489</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">55,054</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Inventories</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">39,765</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">36,010</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other long-term assets</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,724</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19,044</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Total</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 16%; border-bottom: 1px solid rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">56,489</td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 16%; border-bottom: 1px solid rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">55,054</td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> </tbody> </table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">Inventories are stated net of inventory reserves of approximately $9.9 million and $9.1 million, as of <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> respectively.</p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 70%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"> <tbody> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As of <b>December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Raw materials</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20,535</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16,881</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Work-in-process</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,648</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,442</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Finished goods</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,306</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">26,731</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">56,489</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">55,054</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Inventories</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">39,765</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">36,010</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other long-term assets</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,724</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19,044</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Total</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 16%; border-bottom: 1px solid rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">56,489</td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 16%; border-bottom: 1px solid rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">55,054</td> <td style="width: 1%; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> </tbody> </table> 20535000 16881000 10648000 11442000 25306000 26731000 56489000 55054000 39765000 36010000 16724000 19044000 56489000 55054000 9900000 9100000 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-align: left; text-indent: 0pt;"><b><em style="font: inherit;">6.</em> Property</b> <b>and Equipment</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">Property and equipment is stated at cost and consists of the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 70%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"> <tbody> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As of <b>December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Equipment and software</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">52,112</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">48,804</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Furniture and fixtures</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,413</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,389</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Leasehold improvements</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">34,916</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">34,614</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Construction in progress</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,021</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,378</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Subtotal</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">94,462</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">87,185</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less accumulated depreciation</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(46,183</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(39,583</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">48,279</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">47,602</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">Depreciation expense was $6.7 million, $6.5 million, and $6.1 million for the years ended <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2022,</em> <em style="font: inherit;">2021,</em> and <em style="font: inherit;">2020,</em> respectively.</p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 70%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"> <tbody> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As of <b>December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Equipment and software</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">52,112</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">48,804</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Furniture and fixtures</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,413</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,389</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Leasehold improvements</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">34,916</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">34,614</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Construction in progress</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,021</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,378</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Subtotal</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">94,462</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">87,185</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less accumulated depreciation</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(46,183</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(39,583</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">48,279</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">47,602</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> </tbody> </table> 52112000 48804000 2413000 2389000 34916000 34614000 5021000 1378000 94462000 87185000 46183000 39583000 48279000 47602000 6700000 6500000 6100000 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-align: left; text-indent: 0pt;"><b><em style="font: inherit;">7.</em> Acquired Intangible Assets, Net</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;">Intangible assets consist of the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b> </b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="18" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Year Ended December 31, 2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Gross Cost</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Less: Accumulated </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Currency Translation </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Adjustment</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Less: Current Period </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Impairment Charge</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Less: Accumulated </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Amortization</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Net Book Value</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Weighted </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Average Useful </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Life (in Years)</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Developed technology</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">89,580</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,608</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(23,686</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">64,286</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">15</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">IPR&amp;D</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,656</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,006</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,650</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Indefinite</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Customer relationships</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,627</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,373</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Distributor relationships</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,700</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(415</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,285</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Patents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(189</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(680</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">131</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Tradenames</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,200</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,041</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,159</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">112,136</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(3,218</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(34,319</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">74,599</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b> </b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="18" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Year Ended December 31, 2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Gross Cost</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Less: Accumulated </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Currency Translation </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Adjustment</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Less: Current Period </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Impairment Charge</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Less: Accumulated </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Amortization</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Net Book Value</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Weighted </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Average Useful </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Life</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Developed technology</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">89,580</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,608</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(17,891</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">70,081</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">IPR&amp;D</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,256</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,006</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(600</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,650</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Indefinite</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Customer relationships</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,727</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,273</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Distributor relationships</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,700</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(415</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,285</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Patents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(189</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(632</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">179</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Tradenames</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,200</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,001</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,199</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">112,736</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(3,218</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(600</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(26,536</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">82,382</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Total amortization expense with respect to the definite lived acquired intangible assets was $7.8 million for each of the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em> and $7.4 million for the year ended <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2020.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">During the <em style="font: inherit;">fourth</em> quarter of <em style="font: inherit;">2021,</em> the Company decided <em style="font: inherit;">not</em> to further invest in a joint technology IPR&amp;D project, as it is <em style="font: inherit;">no</em> longer aligned with the Company’s core strategic focus. As a result, the Company recorded an impairment charge in the amount of $0.6 million in research and development expenses in the Company’s consolidated statements of operations.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">During the <em style="font: inherit;">fourth</em> quarter of <em style="font: inherit;">2020,</em> the Company decided <em style="font: inherit;">not</em> to further invest in its Hyalobone and Hyalonect IPR&amp;D projects as they were <em style="font: inherit;">no</em> longer aligned with the Company’s core strategic focus. As a result, the Company recorded an impairment charge in the period totaling $1.4 million recorded in research and development expenses in the Company’s consolidated statements of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Company performed its annual assessment of the remaining IPR&amp;D intangible asset as of <em style="font: inherit;"> November 30, 2022. </em>The Company estimated the fair value of the IPR&amp;D intangible assets using the income approach which is based on the Multi-Period Excess Earnings Method (“MPEEM”). MPEEM measures economic benefit indirectly by calculating the income attributable to an asset after appropriate returns are paid to complementary assets used in conjunction with the subject asset to produce the earnings associated with the subject asset, commonly referred to as contributory asset charges. This approach incorporates significant estimates and assumptions related to the forecasted results including revenues, expenses, expected economic life of the asset, contributory asset charges and discount rates to estimate future cash flows. While assumptions utilized are subject to a high degree of judgment and complexity, the Company made its best estimate of future cash flows under a high degree of economic uncertainty that existed as of <em style="font: inherit;"> November 30, 2022. </em>In developing its assumptions, the Company also considered observed trends of its industry participants. No impairment existed as the estimated fair value of the remaining IPR&amp;D intangible asset was greater than its carrying value.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">During <em style="font: inherit;">2020,</em> the Company determined that it would <em style="font: inherit;">not</em> pursue CE mark renewals for certain of its legacy products, which resulted in an impairment of certain developed technology related assets in the amount of $1.0 million in <em style="font: inherit;">2020.</em> This impairment charge was recorded in selling, general and administrative expenses on the Company’s consolidated statements of operations.</p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b> </b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="18" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Year Ended December 31, 2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Gross Cost</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Less: Accumulated </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Currency Translation </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Adjustment</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Less: Current Period </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Impairment Charge</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Less: Accumulated </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Amortization</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Net Book Value</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Weighted </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Average Useful </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Life (in Years)</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Developed technology</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">89,580</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,608</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(23,686</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">64,286</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;">15</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">IPR&amp;D</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,656</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,006</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,650</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Indefinite</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Customer relationships</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,627</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,373</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Distributor relationships</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,700</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(415</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,285</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Patents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(189</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(680</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">131</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Tradenames</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,200</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,041</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,159</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">112,136</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(3,218</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(34,319</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">74,599</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b> </b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="18" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Year Ended December 31, 2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Gross Cost</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Less: Accumulated </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Currency Translation </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Adjustment</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Less: Current Period </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Impairment Charge</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Less: Accumulated </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Amortization</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Net Book Value</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Weighted </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Average Useful </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Life</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Developed technology</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">89,580</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,608</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(17,891</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">70,081</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">IPR&amp;D</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,256</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,006</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(600</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,650</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">Indefinite</em></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Customer relationships</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,727</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,273</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Distributor relationships</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,700</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(415</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,285</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Patents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(189</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(632</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">179</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">16</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Tradenames</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,200</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,001</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,199</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">112,736</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(3,218</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(600</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(26,536</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">82,382</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">13</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 89580000 1608000 -0 23686000 64286000 P15Y 2656000 1006000 -0 -0 1650000 9000000 -0 -0 2627000 6373000 P10Y 4700000 415000 -0 4285000 0 P5Y 1000000 189000 -0 680000 131000 P16Y 5200000 -0 -0 3041000 2159000 P5Y 112136000 3218000 -0 34319000 74599000 P13Y 89580000 1608000 -0 17891000 70081000 P15Y 3256000 1006000 600000 -0 1650000 9000000 -0 -0 1727000 7273000 P10Y 4700000 415000 -0 4285000 0 P5Y 1000000 189000 -0 632000 179000 P16Y 5200000 -0 -0 2001000 3199000 P5Y 112736000 3218000 600000 26536000 82382000 P13Y 7800000 7400000 600000 1400000 0 1000000.0 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-align: left; text-indent: 0pt;"><b><em style="font: inherit;">8.</em> Goodwill</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt; text-align: justify;">The following table provides a roll forward of goodwill for the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021:</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Years Ended December 31</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance, beginning January 1</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,781</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,413</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Effect of foreign currency adjustments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(442</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(632</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance, ending December 31</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,339</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,781</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">In the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2020,</em> the Company acquired Parcus Medical and Arthrosurface, as further discussed in Note <em style="font: inherit;">3,</em> <i>Business Combinations</i>. As a result of the acquisitions, the Company determined that it had two reporting units. It created a reporting unit in <em style="font: inherit;">2020</em> that included Parcus Medical and Arthrosurface, which share similar economic and qualitative characteristics. This reporting unit produces sports medicine surgical products, instruments and joint repair implants. The Company also has another reporting unit that comprises the legacy Anika business, which specializes in therapies based on its hyaluronic acid, or HA, technology platform. The Company impaired the Parcus Medical and Arthrosurface reporting unit in <em style="font: inherit;">2020.</em> The remaining goodwill balance at <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021</em> was related to the legacy Anika reporting unit.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">As part of its annual impairment testing as of <em style="font: inherit;"> November 30 </em>each year for the goodwill related to the legacy Anika reporting unit, the Company performed a qualitative assessment including consideration of (i) general macroeconomic factors, (ii) industry and market conditions, and (iii) the extent of the excess of the fair value over the carrying value indicated in prior impairment testing. The Company determined it was <em style="font: inherit;">not</em> more likely than <em style="font: inherit;">not</em> that the fair value of the legacy Anika reporting unit is less than its carrying amount and thus goodwill was <span style="-sec-ix-hidden:c95413321">not</span> impaired as of <em style="font: inherit;"> November 30, 2022.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">Government policy responses to the COVID-<em style="font: inherit;">19</em> pandemic and the resulting changes in healthcare guidelines caused a temporary suspension of global elective surgical procedures. As a result, the widespread economic volatility triggered impairment testing in the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2020,</em> and accordingly, the Company performed interim impairment testing on the goodwill balances of its reporting units. The Company also performed its annual impairment testing in the <em style="font: inherit;">fourth</em> quarter of <em style="font: inherit;">2020.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">The Company estimated the fair value of the reporting units using a discounted cash flow method, which is based on the present value of projected cash flows and a terminal value, which represents the expected normalized cash flows of the reporting units beyond the cash flows from the discrete projection period. The Company determined that a discounted cash flow model provided the best approximation of fair value of the reporting units for the purpose of performing the impairment test. This approach incorporates significant estimates and assumptions related to the forecasted results including revenues, expenses, the achievement of certain cost synergies, terminal growth rates and discount rates to estimate future cash flows. While assumptions utilized are subject to a high degree of judgment and complexity, the Company made its best estimate of future cash flows under a high degree of economic uncertainty that existed as of <em style="font: inherit;"> November 30, 2020. </em>In developing its assumptions, the Company also considered observed trends of its industry participants.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">For the legacy Anika reporting unit, the Company performed a qualitative assessment including consideration of (i) general macroeconomic factors, (ii) industry and market conditions, and (iii) the extent of the excess of the fair value over the carrying value indicated in prior impairment testing. The Company determined it was <em style="font: inherit;">not</em> more likely than <em style="font: inherit;">not</em> that the fair value of the legacy Anika reporting unit is less than its carrying amount and thus goodwill was <span style="-sec-ix-hidden:c95413330">not</span> impaired as of <em style="font: inherit;"> March 31, 2020. </em>As part of its annual impairment testing, the Company decided to perform a quantitative assessment related to the legacy Anika reporting unit as of <em style="font: inherit;"> November 30, 2020, </em>due to the expectation that the economic recovery will take longer than expected to materialize. The results of the impairment test indicated that the estimated fair value of the legacy Anika reporting unit was greater than its carrying value, therefore the Company did <span style="-sec-ix-hidden:c95413331">not</span> record any impairment charges related to the legacy Anika reporting unit for the year ended <em style="font: inherit;"> December 31, 2020.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 15pt;text-indent:27pt;">For its newly created reporting unit, which includes Parcus Medical and Arthrosurface, the Company performed an interim quantitative assessment of goodwill impairment as of <em style="font: inherit;"> March 31, 2020. </em>The Company estimated the fair value of the reporting unit using a discounted cash flow method. The results of the interim impairment test indicated that the estimated fair value of the reporting unit was less than its carrying value. This was primarily due to decreases in near term revenue and related cash flows as a result of the temporary suspension of domestic elective procedures, primarily due to the COVID-<em style="font: inherit;">19</em> pandemic which directly impacted the reporting unit. Consequently, a non-cash goodwill impairment charge was recorded in the amount of $18.1 million during the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2020.</em> As part of its annual impairment testing, the Company performed a quantitative assessment related to the newly created reporting unit as of <em style="font: inherit;"> November 30, 2020. </em>The results of the annual impairment test indicated that the estimated fair value of the reporting unit was less than its carrying value. This was primarily due to a decline in projected net cash flows as a result of the continued impact of COVID-<em style="font: inherit;">19</em> on revenue and related cash flows, the expectation that the economic recovery will take longer than expected to materialize, and additional projected investment to support future growth. Consequently, a non-cash goodwill impairment charge was recorded in the amount of $24.4 million during the <em style="font: inherit;">fourth</em> quarter of <em style="font: inherit;">2020.</em> The total non-cash goodwill impairment charge with respect to the reporting unit amounted to $42.5 million for the year ended <em style="font: inherit;"> December 31, 2020. </em>There was no remaining goodwill with respect to the newly created reporting unit as of <em style="font: inherit;"> December 31, 2020.</em></p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Years Ended December 31</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance, beginning January 1</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,781</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,413</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Effect of foreign currency adjustments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(442</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(632</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance, ending December 31</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,339</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">7,781</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 7781000 8413000 -442000 -632000 7339000 7781000 2 18100000 24400000 42500000 0 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-align: left; text-indent: 0pt;"><b><em style="font: inherit;">9.</em> Leases</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Company leases its buildings and manufacturing facilities under operating leases. As of <em style="font: inherit;"> December 31, 2022, </em>the Company had real estate leases in Bedford, Massachusetts, Franklin, Massachusetts, Sarasota, Florida, Warsaw, Indiana and Padova, Italy.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">In <em style="font: inherit;"> June 2022, </em>the Company finalized a renewal option to extend the current term for its operating headquarters and manufacturing facility in Bedford through <em style="font: inherit;">2027.</em> There are also lease renewal options into <em style="font: inherit;">2038.</em> The current term of the Padova lease extends to <em style="font: inherit;">2032,</em> with a right to terminate at the Company’s option in <em style="font: inherit;">2026</em> without penalty.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">As a result of the acquisition of Parcus Medical and Arthrosurface, the Company acquired operating and finance leases for corporate offices, manufacturing and warehouse facilities and machinery. The operating leases consist of <em style="font: inherit;">one</em> real estate lease in Franklin, Massachusetts (Franklin lease) and <em style="font: inherit;">two</em> real estate leases in Sarasota, Florida (Sarasota lease). In <em style="font: inherit;"> October 2022, </em>the Company entered into an option to extend the current term of the Franklin lease through <em style="font: inherit;">2024.</em> In <em style="font: inherit;"> June 2022, </em>the Company finalized an option to extend the current term of the <em style="font: inherit;">two</em> Sarasota leases through <em style="font: inherit;">2027.</em> The finance leases include equipment utilized in the Company’s manufacturing facility in Sarasota, Florida and were terminated in <em style="font: inherit;"> September 2022.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The significant assumptions in recognizing the right-of-use asset and lease liability are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;"><i>Incremental borrowing rate</i>. The Company derives its incremental borrowing rate from information available at the lease commencement date in determining the present value of lease payments. The incremental borrowing rate represents a collateralized rate of interest the Company would have to pay to borrow over a similar term an amount equal to the lease payments in a similar economic environment. The Company’s lease agreements do <em style="font: inherit;">not</em> provide implicit rates. As the Company did <em style="font: inherit;">not</em> have any external borrowings at either the transition or subsequent renewal dates with comparable terms to its lease agreements, the Company estimated its incremental borrowing rate based on its credit quality, line of credit agreement and by comparing interest rates available in the market for similar borrowings, and adjusting this amount based on the impact of collateral over the term of the lease. The weighted average discount rate at <em style="font: inherit;"> December 31, 2022 </em>was 3.6% for operating leases.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;"><i>Lease term.</i> The lease term begins at the lease commencement date and is determined on that date based on the non-cancelable term of the lease together with periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option, or periods covered by an option to terminate the lease if the Company is reasonably certain <em style="font: inherit;">not</em> to exercise that option.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt; text-align: justify;">The components of lease expense and other information are as follows: </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; margin-left: 15pt; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><b>Years Ended December 31</b></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><b>2022</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><b>2021</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><b><b>2020</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 43%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Finance lease amortization of right-of-use assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">121</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">143</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">185</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Interest on finance lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Finance lease expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">132</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">162</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">210</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating lease expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,839</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,468</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,383</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Short-term lease expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Variable lease expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">413</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">319</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">264</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total lease expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,401</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,951</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,857</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 70%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Years Ended December 31</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Weighted Average Remaining Lease Term (in years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Operating leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14.8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Financing leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Weighted Average Discount Rate</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Operating leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Financing leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.9</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Other information</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Operating cash flows from operating leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,471</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,392</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Operating cash flows from financing leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">121</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">136</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt; text-align: justify;">Future commitments due under these lease agreements as of <em style="font: inherit;"> December 31, 2022 </em>are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Years ended December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Operating Leases</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,170</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,055</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,066</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,760</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2027</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,643</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,230</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Present value adjustment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(9,034</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Present value of lease payments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">30,890</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less current portion included in accrued expenses and other current liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,073</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">28,817</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 0.036 <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; margin-left: 15pt; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><b><b>Years Ended December 31</b></b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><b>2022</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b><b>2021</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><b><b>2020</b></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 43%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Finance lease amortization of right-of-use assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">121</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">143</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">185</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Interest on finance lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">19</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Finance lease expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">132</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">162</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">210</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating lease expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,839</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,468</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,383</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Short-term lease expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">17</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Variable lease expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">413</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">319</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">264</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total lease expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,401</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,951</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,857</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 70%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Years Ended December 31</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Weighted Average Remaining Lease Term (in years)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Operating leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14.8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">15.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Financing leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Weighted Average Discount Rate</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Operating leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Financing leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.9</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Other information</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Operating cash flows from operating leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,471</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,392</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Operating cash flows from financing leases</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">121</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">136</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 121000 143000 185000 11000 19000 25000 132000 162000 210000 2839000 2468000 2383000 17000 2000 0 413000 319000 264000 3401000 2951000 2857000 P14Y9M18D P15Y3M18D P2Y3M18D 0.036 0.041 0 0.049 2471000 2392000 121000 136000 <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Years ended December 31,</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Operating Leases</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,170</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,055</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,066</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,760</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2027</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,643</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Thereafter</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25,230</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Present value adjustment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(9,034</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Present value of lease payments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">30,890</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less current portion included in accrued expenses and other current liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,073</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">28,817</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 3170000 3055000 3066000 2760000 2643000 25230000 9034000 30890000 2073000 28817000 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: left; margin: 0pt 0pt 0pt 15pt; text-indent: 0pt;"><b><em style="font: inherit;">10.</em> Accrued Expenses</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt; text-align: justify;">Accrued expenses consist of the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 70%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"> <tbody> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As of <b>December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Compensation and related expenses</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,303</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,523</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Professional fees</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,145</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,590</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating lease liability- current</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,073</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,526</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Clinical trial costs</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">999</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,961</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Finance lease liability - current</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">188</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Income taxes payable</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">810</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">510</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,059</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">18,840</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17,847</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> </tbody> </table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 70%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"> <tbody> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As of <b>December 31,</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Compensation and related expenses</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,303</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">9,523</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Professional fees</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,145</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,590</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating lease liability- current</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,073</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,526</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Clinical trial costs</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">999</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,961</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Finance lease liability - current</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">188</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Income taxes payable</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">810</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">510</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,059</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total</p> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">18,840</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">17,847</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td> </tr> </tbody> </table> 11303000 9523000 3145000 3590000 2073000 1526000 999000 1961000 0 188000 810000 0 510000 1059000 18840000 17847000 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-align: left; text-indent: 0pt;"><b><em style="font: inherit;">11.</em> Revolving Credit Agreement</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">On <em style="font: inherit;"> November 12, 2021, </em>the Company, entered into a “Third Amendment to Credit Agreement” amending the existing revolving line of credit agreement dated <em style="font: inherit;"> October 24, 2017 </em>with Bank of America, N.A., as administrative agent, swingline lender and issuer of letters of credit, for a $75.0 million senior revolving line of credit (the “Credit Agreement”). Subject to certain conditions, the Company <em style="font: inherit;"> may </em>request up to an additional $75.0 million in commitments for a maximum aggregate commitment of $150.0 million, which requests must be approved by the Revolving Lenders (as defined in the Credit Agreement). Loans under the Credit Agreement generally bear interest at a rate equal to (a) the Bloomberg Short-Term Bank Yield Index, (“BSBY”), rate plus (b) an additional percentage that will range from 0.25% to 1.00%, based on the Company’s consolidated leverage ratio at the time of the borrowings. The Company is required to pay a commitment fee in an amount that is equal to 0.20% to 0.30% per annum, based on the Company’s consolidated leverage ratio, on the actual daily unused amount of the credit facility and that is due and payable quarterly in arrears. Loan origination costs are included as assets on the balance sheet and are being amortized over the <span style="-sec-ix-hidden:c95413435">five</span>-year term of the Credit Agreement. As of <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> there were no outstanding borrowings under the Credit Agreement and the Company is in compliance with the terms of the Credit Agreement. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Credit Agreement contains customary representations, warranties, affirmative and negative covenants, including financial covenants, events of default, and indemnification provisions in favor of the Lenders. These include restrictive covenants that require the Company <em style="font: inherit;">not</em> to exceed certain maximum leverage and interest coverage ratios, limit its incurrence of liens and indebtedness, and its entry into certain merger and acquisition transactions or dispositions and place additional restrictions on other matters, all subject to certain exceptions. The Revolving Lenders has been granted a <em style="font: inherit;">first</em> priority lien and security interest in substantially all of the Company’s assets, except for certain intangible assets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">In <em style="font: inherit;"> April 2020, </em>the Company borrowed $50.0 million available under the previous credit facility, with an initial applicable interest rate of 2.08%, all of which were repaid during the year ended <em style="font: inherit;"> December 31, 2020. </em>Interest expense for the years ended <em style="font: inherit;"> December 31, 2022, </em><em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> was $0, $0, and $0.8 million, respectively.</p> 75000000.0 75000000.0 150000000.0 0.0025 0.0100 0.0020 0.0030 0 50000000.0 0.0208 0 0 800000 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-align: left; text-indent: 0pt;"><b><em style="font: inherit;">12.</em> Commitments and Contingencies </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">In certain of its contracts, the Company warrants to its customers that the products it manufactures conform to the product specifications as in effect at the time of delivery of the specific product. The Company <em style="font: inherit;"> may </em>also warrant that the products it manufactures do <em style="font: inherit;">not</em> infringe, violate or breach any U.S. or international patent or intellectual property rights, trade secret, or other proprietary information of any <em style="font: inherit;">third</em> party. On occasion, the Company contractually indemnifies its customers against any and all losses arising out of, or in any way connected with, any claim or claims of breach of its warranties or any actual or alleged defect in any product caused by the negligent acts or omissions of the Company. The Company maintains a products liability insurance policy that limits its exposure to these risks. Based on the Company’s historical activity, in combination with its liability insurance coverage, the Company believes the estimated fair value of these indemnification agreements is immaterial. The Company had no accrued warranties at <em style="font: inherit;"> December 31, 2022 </em>or <em style="font: inherit;">2021,</em> respectively, and has <em style="font: inherit;">no</em> history of claims paid.  </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Company is also involved from time-to-time in various legal proceedings arising in the normal course of business. Although the outcomes of these legal proceedings are inherently difficult to predict, the Company does <em style="font: inherit;">not</em> expect the resolution of these occasional legal proceedings to have a material adverse effect on its financial position, results of operations, or cash flows.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">On <em style="font: inherit;"> October 21, 2021, </em>the Company received notice that the former unitholders of Parcus Medical had filed a request for arbitration regarding the earnout provisions agreed to in the Parcus Medical Merger Agreement. The Company has engaged in the arbitration process and does <em style="font: inherit;">not</em> anticipate a resolution during the <em style="font: inherit;">first</em> half of <em style="font: inherit;">2023.</em> The Company is unable to estimate the potential liability with respect to this matter at this time. There are numerous factors that make it difficult to estimate reasonably possible loss or range of loss at this stage of the matter, including the significant number of legal and factual issues still to be resolved in the arbitration process. The Company intends to vigorously defend against the claims and believes it has strong defenses to the claims asserted.</p> 0 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: left; margin: 0pt 0pt 0pt 15pt; text-indent: 0pt;"><b><em style="font: inherit;">13.</em> Revenue and Geographic Information</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Company categorizes its product portfolio into <em style="font: inherit;">three</em> product families: OA Pain Management, Joint Preservation and Restoration, and Non-Orthopedic. Anika’s consolidated financial statements include results of operations for Parcus Medical from the <em style="font: inherit;"> January 24, 2020 </em>acquisition date and Arthrosurface from the <em style="font: inherit;"> February 3, 2020 </em>acquisition date.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Product revenue by product family is as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="22" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Years Ended December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Revenue</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Percentage of</b><br/> <b>Product</b><br/> <b>Revenue</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Revenue</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Percentage of</b><br/> <b>Product</b><br/> <b>Revenue</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Revenue</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Percentage of</b><br/> <b>Product</b><br/> <b>Revenue</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">OA Pain Management</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">97,887</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">63</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">89,503</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">61</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">83,029</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">64</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Joint Preservation and Restoration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">50,402</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">32</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">48,588</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">39,368</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Non-Orthopedic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,947</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,703</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,060</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">156,236</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">147,794</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">130,457</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Effective <em style="font: inherit;"> January 1, 2023, </em>the Company will begin to report revenue from product sales to veterinary customers within the Non-Orthopedic product family whereas such revenue had been reported within the OA Pain Management revenue product family. Revenue from product sales to veterinary customers amounted to $5.9 million, $4.4 million and $3.8 million for <em style="font: inherit;">2022,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> respectively.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;text-indent:36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Product revenue from the Company’s sole significant customer, Mitek, as a percentage of the Company’s total product revenue was 43%, 45%, and 49% for the years ended <em style="font: inherit;"> December 31, 2022, </em><em style="font: inherit;">2021,</em> and <em style="font: inherit;">2020,</em> respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt; text-align: justify;">Total revenue by geographic location based on the location of the customer in total and as a percentage of total revenue are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="22" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Years Ended December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Total</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Percentage of</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Total</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Percentage of</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Total</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Percentage of</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Revenue</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Revenue</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Revenue</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Revenue</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Revenue</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Revenue</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Geographic Location:</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">United States</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">119,151</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">76</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">113,833</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">77</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">103,182</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">79</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Europe</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20,639</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">19,580</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,179</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,446</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">14,381</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13,096</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">156,236</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">147,794</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">130,457</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Net long-lived assets, consisting primarily of net property and equipment, are subject to geographic risks because they are generally difficult to move and to effectively utilize in another geographic area in a reasonable time period and because they are relatively illiquid. Net tangible long-lived assets by principal geographic areas are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Years Ended December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">United States</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">47,068</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">46,068</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Italy</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,211</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,534</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">48,279</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">47,602</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="22" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Years Ended December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Revenue</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Percentage of</b><br/> <b>Product</b><br/> <b>Revenue</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Revenue</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Percentage of</b><br/> <b>Product</b><br/> <b>Revenue</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Revenue</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Percentage of</b><br/> <b>Product</b><br/> <b>Revenue</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">OA Pain Management</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">97,887</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">63</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">89,503</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">61</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">83,029</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">64</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Joint Preservation and Restoration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">50,402</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">32</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">48,588</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">33</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">39,368</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Non-Orthopedic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,947</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,703</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,060</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">156,236</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">147,794</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">130,457</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> </tbody></table> 97887000 0.63 89503000 0.61 83029000 0.64 50402000 0.32 48588000 0.33 39368000 0.30 7947000 0.05 9703000 0.06 8060000 0.06 156236000 1 147794000 1 130457000 1 5900000 4400000 3800000 0.43 0.45 0.49 <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="22" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Years Ended December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Total</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Percentage of</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Total</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Percentage of</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Total</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Percentage of</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Revenue</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Revenue</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Revenue</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Revenue</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Revenue</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Revenue</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Geographic Location:</b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">United States</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">119,151</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">76</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">113,833</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">77</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">103,182</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">79</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Europe</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">20,639</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">19,580</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">13</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,179</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">16,446</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">14,381</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13,096</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">156,236</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">147,794</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">130,457</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">100</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> </tbody></table> 119151000 0.76 113833000 0.77 103182000 0.79 20639000 0.13 19580000 0.13 14179000 0.11 16446000 0.11 14381000 0.10 13096000 0.10 156236000 1 147794000 1 130457000 1 <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Years Ended December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">United States</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">47,068</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">46,068</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Italy</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,211</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,534</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">48,279</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">47,602</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 47068000 46068000 1211000 1534000 48279000 47602000 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-align: left; text-indent: 0pt;"><b><em style="font: inherit;">14.</em> Equity Incentive Plan </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: left; margin: 0pt 0pt 0pt 15pt; text-indent: 0pt;"><i>Equity Incentive Plan</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Anika Therapeutics, Inc. <em style="font: inherit;">2017</em> Omnibus Incentive Plan (the <em style="font: inherit;">“2017</em> Plan”) was approved by the Company’s stockholders on <em style="font: inherit;"> June 13, 2017 </em>and subsequently amended on <em style="font: inherit;"> June 18, 2019, </em><em style="font: inherit;"> June 16, 2020 </em>and <em style="font: inherit;"> June 16, 2021. </em>The <em style="font: inherit;">2017</em> Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights (“SARs”), restricted stock awards (“RSAs”), performance restricted stock units (“PSUs”), restricted stock units (“RSUs”), total shareholder return options (“TSRs”) and performance options that <em style="font: inherit;"> may </em>be settled in cash, stock, or other property. In accordance with the <em style="font: inherit;">2017</em> Plan approved by the Company’s stockholders, including the amendments thereto, each share award other than stock options or SAR’s will reduce the number of total shares available for grant by two shares. Subject to adjustment for specified types of changes in the Company’s capitalization, <em style="font: inherit;">no</em> more than 4.6 million shares of common stock <em style="font: inherit;"> may </em>be issued under the <em style="font: inherit;">2017</em> Plan. There are 1.2 million shares available for future grant at <em style="font: inherit;"> December 31, 2022 </em>under the <em style="font: inherit;">2017</em> Plan.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Anika Therapeutics, Inc. <em style="font: inherit;">2021</em> Inducement Plan (the “Inducement Plan”) was adopted by the Company’s board of directors on <em style="font: inherit;"> November 4, 2021. </em>The Inducement Plan reserves 125,000 shares of common stock for issuance pursuant to equity-based awards granted under the Inducement Plan. Such awards <em style="font: inherit;"> may </em>be granted only to an individual who was <em style="font: inherit;">not</em> previously the Company’s employee or director with the Company. The Inducement Plan provides for the grant of awards under terms substantially similar to the <em style="font: inherit;">2017</em> Plan (as amended). There are 4,883 shares available for future grant at <em style="font: inherit;"> December 31, 2022 </em>under the Inducement Plan.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Company <em style="font: inherit;"> may </em>satisfy the awards upon exercise, or upon fulfillment of the vesting requirements for other equity-based awards, with either newly issued shares or shares reacquired by the Company. Stock-based awards are granted with an exercise price equal to or greater than the market price of the Company’s stock on the date of grant. Awards contain service conditions or service and performance conditions, and they generally become exercisable ratably over <span style="-sec-ix-hidden:c95413544">one</span> to <span style="-sec-ix-hidden:c95413545">four</span> years with a maximum contractual term of <span style="-sec-ix-hidden:c95413546">ten</span> years.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Company presents the expenses related to stock-based compensation awards in the same expense line items as cash compensation paid to each of its employees. For the year ended <em style="font: inherit;"> December 31, 2022, </em>the tax benefit associated with stock-based compensation was $1.1 million. A summary of the stock-based compensation in the Company’s statements of operations is as follows (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 93%; margin-left: 15pt; margin-right: auto;"><tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: bottom; width: 25.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years Ended December 31,</b></p> </td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: bottom; width: 25.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2021</b></p> </td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2020</b></p> </td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="vertical-align: bottom; width: 25.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cost of revenue</p> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">$</p> </td><td style="vertical-align: bottom; width: 6.2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">820</p> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">$</p> </td><td style="vertical-align: bottom; width: 6.3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">716</p> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">$</p> </td><td style="vertical-align: bottom; width: 6.3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">719</p> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="vertical-align: bottom; width: 25.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 6.2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">1,646</p> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 6.3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">1,233</p> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 6.3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">713</p> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="vertical-align: bottom; width: 25.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Selling, general and administrative</p> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6.2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">11,849</p> </td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6.3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">9,136</p> </td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6.3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">3,954</p> </td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="vertical-align: bottom; width: 25.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total stock-based compensation expense</p> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">$</p> </td><td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 6.2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">14,315</p> </td><td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">$</p> </td><td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 6.3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">11,085</p> </td><td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">$</p> </td><td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 6.3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">5,386</p> </td><td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">For the years ended <em style="font: inherit;"> December 31, 2022, </em><em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> windfall tax benefits (expense) of $(<span style="-sec-ix-hidden:c95413549">0.5</span>) million, $0.1 million and $0.2 million, respectively, are associated with the stock-based compensation expense above.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Company’s former President and Chief Executive Officer, Joseph Darling, passed away unexpectedly in <em style="font: inherit;"> January 2020. </em>According to the terms of Mr. Darling’s equity award grants and the <em style="font: inherit;">2017</em> Plan, the unvested portion of his stock-based compensation was forfeited upon his death, resulting in a <em style="font: inherit;">one</em>-time benefit of $1.8 million that was fully recognized during the <em style="font: inherit;">three</em>-month period ended <em style="font: inherit;"> March 31, 2020 </em>within selling, general and administrative expenses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 9pt;text-indent:5pt;"><i>Stock Options</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Stock options are granted to purchase common shares at prices that are equal to the fair market value of the shares on the date the options are granted or, in the case of premium options, are granted with an exercise price at 110% of the market price of the Company’s common stock on the date of grant. Options generally vest in equal annual installments over a period of <span style="-sec-ix-hidden:c95413557">three</span> to <span style="-sec-ix-hidden:c95413558">four</span> years and expire <span style="-sec-ix-hidden:c95413559">10</span> years after the date of grant. The grant-date fair value of options is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The following summarizes the activity under the Company’s stock option plans:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 18pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"><b><b>Number of Options</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 18pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 18pt; text-indent: -5pt;"><b><b>Weighted Average Exercise Price</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 6pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 6pt; text-indent: -6pt;"><b><b>Weighted Average</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 6pt; text-indent: -6pt;"><b><b>Remaining</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 6pt; text-indent: -6pt;"><b><b>Contractual</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 6pt; text-indent: -6pt;"><b><b>Term (in years)</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 27pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 27pt; text-indent: -5pt;"><b><b>Aggregate Intrinsic</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 36pt; text-indent: -14pt;"><b><b>Value</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 27pt; text-indent: -14pt;"><b><b>(in thousands)</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding as of December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,175,993</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 35pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 35pt;">39.56</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">553,827</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 35pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 35pt;">28.07</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(433</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 35pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 35pt;">8.83</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited and canceled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(198,684</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 35pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 35pt;">43.24</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding as of December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,530,703</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 35pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 35pt;">34.93</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 36pt;">8.1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,050</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Vested, December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">640,056</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 35pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 35pt;">40.08</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 36pt;">7.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Vested or expected to vest, December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,530,703</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 35pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 35pt;">34.93</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 36pt;">8.1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,050</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The aggregate intrinsic value of options exercised for the years ended December 31, <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> was $0.3 million and $2.8 million, respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Company granted 553,827 stock options during the year ended <em style="font: inherit;"> December 31, 2022, </em>of which 398,314 shares were premium-priced options.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Company uses the Black-Scholes pricing model to determine the fair value of options granted. The calculation of the fair value of stock options is affected by the stock price on the grant date, the expected volatility of the Company’s common stock over the expected term of the award, the expected life of the award, the risk-free interest rate and the dividend yield. The Company estimated the fair value of TSRs using Monte-Carlo simulation model where the expected volatility assumption is evaluated over 6.3 years. The actual number of TSR options that <em style="font: inherit;"> may </em>be earned ranges from 0% to 150% of the target number, depending on the total shareholder return of the Company relative to the peer group over the vesting period of 2.7 years. The Company completed its evaluation of the TSR award and vested 139,168 TSRs as of <em style="font: inherit;"> December 31, 2022.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt; text-align: justify;">The assumptions used in the Black-Scholes pricing model for options granted during the years ended <em style="font: inherit;"> December 31, 2022 </em><em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> along with the weighted-average grant-date fair values, were as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 95%; margin-left: 15pt; margin-right: auto;"><tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: bottom; width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="3" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td><td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="3" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2021</b></p> </td><td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="3" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2020</b></p> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="vertical-align: bottom; width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free interest rate</p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><span style="-sec-ix-hidden:c95413684">1.28%</span></p> </td><td style="vertical-align: bottom; width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">-</p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><span style="-sec-ix-hidden:c95413686">4.28%</span></p> </td><td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c95413687">0.29%</span></p> </td><td style="vertical-align: bottom; width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">-</p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><span style="-sec-ix-hidden:c95413689">1.00%</span></p> </td><td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c95413690">0.21%</span></p> </td><td style="vertical-align: bottom; width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">-</p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><span style="-sec-ix-hidden:c95413692">1.59%</span></p> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="vertical-align: bottom; width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected stock price volatility</p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">53.80%</p> </td><td style="vertical-align: bottom; width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">-</p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">55.55%</p> </td><td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">54.80%</p> </td><td style="vertical-align: bottom; width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">-</p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">56.35%</p> </td><td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">46.48%</p> </td><td style="vertical-align: bottom; width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">-</p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">54.06%</p> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="vertical-align: bottom; width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected life of options (in years)</p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="vertical-align: bottom; width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">4.5</p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="vertical-align: bottom; width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">4.0</p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="vertical-align: bottom; width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">4.0</p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td></tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="vertical-align: bottom; width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected dividend yield</p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="vertical-align: bottom; width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c95413712">0.0%</span></p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="vertical-align: bottom; width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c95413715">0.0%</span></p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="vertical-align: bottom; width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">-%</em></p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td></tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="vertical-align: bottom; width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value per option</p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="vertical-align: bottom; width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">11.45</p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="vertical-align: bottom; width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">14.80</p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="vertical-align: bottom; width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">16.31</em></p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">As of <em style="font: inherit;"> December 31, 2022, </em>there was $7.4 million of unrecognized compensation cost related to unvested stock options. This expense is expected to be recognized over a weighted average period of 1.8 years.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 9pt; text-indent: 5pt;"><i>Restricted Stock Units</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">RSUs generally vest in equal annual installments over a <span style="-sec-ix-hidden:c95413578">three</span>- or <span style="-sec-ix-hidden:c95413579">four</span>-year periods. The grant-date fair value of RSUs is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The Company determines the fair value of restricted stock units based on the closing price of its common stock on the date of grant.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">RSU activity for the year ended <em style="font: inherit;"> December 31, 2022 </em>is as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 75%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 14pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 14pt; text-indent: -5pt;"><b><b>Number of Shares</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 27pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 27pt; text-indent: -13pt;"><b><b>Weighted Average Fair Value</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding as of December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">412,658</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">36.33</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">507,524</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25.14</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(164,167</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">36.77</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited and cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(80,610</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(31.40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding as of December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">675,405</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">28.40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The weighted-average grant-date fair value per share of RSUs granted was $25.14, $35.88 and $38.20 for the years ended <em style="font: inherit;"> December 31, 2022, </em><em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> respectively. The total fair value of RSUs vested was $6.0 million, $3.7 million and $2.2 million for the years ended <em style="font: inherit;"> December 31, 2022, </em><em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> respectively.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">As of <em style="font: inherit;"> December 31, 2022, </em>there was $12.3 million of unrecognized compensation cost related to time-based RSUs, which is expected to be recognized over a weighted-average period of 1.8 years.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 9pt; text-indent: 5pt;"><i>Performance Stock Units</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">PSUs generally vest over a <span style="-sec-ix-hidden:c95413592">three</span>-year period from the grant date and include both a service and performance component. The PSUs granted to employees in <em style="font: inherit;">2019</em> contained performance conditions with business and financial targets. The business target, amounting to 30% of the total performance condition awards, was measured and achieved in the <em style="font: inherit;">2019</em> fiscal year. One of the financial targets, amounting to 55% of the total performance condition awards, was measured and achieved in the <em style="font: inherit;">2022</em> fiscal year, while the remaining financial target, amounting to 15% of the total performance condition awards, was <em style="font: inherit;">not</em> achieved. The PSUs granted to employees in <em style="font: inherit;">2020</em> contained performance conditions with business and financial targets. One of the business targets, amounting to 20% of the total performance condition awards, was <em style="font: inherit;">not</em> achieved in the <em style="font: inherit;">2021</em> fiscal year, while the remaining business target related to a certain timely regulatory approval, amounting to 20% of the total performance condition awards, was <em style="font: inherit;">not</em> achieved in the <em style="font: inherit;">2022</em> fiscal year. The financial targets, amounting to 60% of the total performance condition awards, were <em style="font: inherit;">not</em> achieved in the <em style="font: inherit;">2022</em> fiscal year.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">PSU activity for the year ended <em style="font: inherit;"> December 31, 2022 </em>is as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 75%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 27pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -13pt; text-align: center;"><b><b>Number of Shares</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 27pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 27pt; text-indent: -13pt;"><b><b>Weighted Average Fair Value</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding as of December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">158,297</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">37.44</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,125</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">32.53</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(19,125</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">32.53</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited and cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(23,400</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">41.86</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding as of December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">117,897</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">34.98</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The weighted-average grant-date fair value per share of PSUs granted was $32.53, $0 and $36.93 for the years ended <em style="font: inherit;"> December 31, 2022, </em><em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> respectively. The total fair value of PSUs vested was $0.6 million, <span style="-sec-ix-hidden:c95413616">$0</span> and <span style="-sec-ix-hidden:c95413617">$0</span> for the years ended <em style="font: inherit;"> December 31, 2022, </em><em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> respectively. As of <em style="font: inherit;"> December 31, 2022, </em>there was <em style="font: inherit;">no</em> unrecognized compensation cost related to PSUs in which milestones are expected to be achieved.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 9pt; text-indent: 5pt;"><i>Employee Stock Purchase Plan</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">On <em style="font: inherit;"> March 17, 2021, </em>the Company adopted the <em style="font: inherit;">2021</em> Employee Stock Purchase Plan (“ESPP”). The ESPP is authorized to issue up to 200,000 shares of common stock to participating employees. Employees that participate in the Company’s ESPP <em style="font: inherit;"> may </em>purchase up to a maximum of 800 shares per <em style="font: inherit;">six</em>-month offering period or $25,000 worth of common stock per calendar year by authorizing payroll deductions of up to 10% of their base salary. The purchase price for each share purchased is 85% of the lower of the fair market value of the common stock on the <em style="font: inherit;">first</em> or last day of the offering period.</p> 2 4600000 1200000 125000 4883 1100000 <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 93%; margin-left: 15pt; margin-right: auto;"><tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: bottom; width: 25.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Years Ended December 31,</b></p> </td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: bottom; width: 25.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2021</b></p> </td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2020</b></p> </td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="vertical-align: bottom; width: 25.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cost of revenue</p> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">$</p> </td><td style="vertical-align: bottom; width: 6.2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">820</p> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">$</p> </td><td style="vertical-align: bottom; width: 6.3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">716</p> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">$</p> </td><td style="vertical-align: bottom; width: 6.3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">719</p> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="vertical-align: bottom; width: 25.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development</p> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 6.2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">1,646</p> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 6.3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">1,233</p> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 6.3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">713</p> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="vertical-align: bottom; width: 25.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Selling, general and administrative</p> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6.2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">11,849</p> </td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6.3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">9,136</p> </td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 6.3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">3,954</p> </td><td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="vertical-align: bottom; width: 25.1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Total stock-based compensation expense</p> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">$</p> </td><td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 6.2%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">14,315</p> </td><td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">$</p> </td><td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 6.3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">11,085</p> </td><td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">$</p> </td><td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 6.3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: right; margin: 0pt;">5,386</p> </td><td style="border-bottom: 3px double rgb(0, 0, 0); vertical-align: bottom; width: 0.5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> </tbody></table> 820000 716000 719000 1646000 1233000 713000 11849000 9136000 3954000 14315000 11085000 5386000 100000 200000 1800000 1.10 <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 18pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;"><b><b>Number of Options</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 18pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 18pt; text-indent: -5pt;"><b><b>Weighted Average Exercise Price</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 6pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 6pt; text-indent: -6pt;"><b><b>Weighted Average</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 6pt; text-indent: -6pt;"><b><b>Remaining</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 6pt; text-indent: -6pt;"><b><b>Contractual</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 6pt; text-indent: -6pt;"><b><b>Term (in years)</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 27pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 27pt; text-indent: -5pt;"><b><b>Aggregate Intrinsic</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 36pt; text-indent: -14pt;"><b><b>Value</b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 27pt; text-indent: -14pt;"><b><b>(in thousands)</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 48%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding as of December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,175,993</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 35pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 35pt;">39.56</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">553,827</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 35pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 35pt;">28.07</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(433</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 35pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 35pt;">8.83</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited and canceled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(198,684</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 35pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 35pt;">43.24</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding as of December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,530,703</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 35pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 35pt;">34.93</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 36pt;">8.1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,050</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Vested, December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">640,056</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 35pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 35pt;">40.08</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 36pt;">7.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">12</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Vested or expected to vest, December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,530,703</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 35pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 35pt;">34.93</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 36pt;">8.1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,050</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 1175993 39.56 553827 28.07 433 8.83 10000 198684 43.24 1530703 34.93 P8Y1M6D 1050000 640056 40.08 P7Y2M12D 12000 1530703 34.93 P8Y1M6D 1050000 300000 2800000 553827 398314 P6Y3M18D 0 1.50 P2Y8M12D 139168 <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 95%; margin-left: 15pt; margin-right: auto;"><tbody><tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="vertical-align: bottom; width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="3" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2022</b></p> </td><td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="3" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2021</b></p> </td><td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="3" style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 14%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>2020</b></p> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="vertical-align: bottom; width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Risk-free interest rate</p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><span style="-sec-ix-hidden:c95413684">1.28%</span></p> </td><td style="vertical-align: bottom; width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">-</p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><span style="-sec-ix-hidden:c95413686">4.28%</span></p> </td><td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c95413687">0.29%</span></p> </td><td style="vertical-align: bottom; width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">-</p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><span style="-sec-ix-hidden:c95413689">1.00%</span></p> </td><td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c95413690">0.21%</span></p> </td><td style="vertical-align: bottom; width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">-</p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><span style="-sec-ix-hidden:c95413692">1.59%</span></p> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="vertical-align: bottom; width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected stock price volatility</p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">53.80%</p> </td><td style="vertical-align: bottom; width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">-</p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">55.55%</p> </td><td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">54.80%</p> </td><td style="vertical-align: bottom; width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">-</p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">56.35%</p> </td><td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">46.48%</p> </td><td style="vertical-align: bottom; width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">-</p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">54.06%</p> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="vertical-align: bottom; width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected life of options (in years)</p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="vertical-align: bottom; width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">4.5</p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="vertical-align: bottom; width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">4.0</p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="vertical-align: bottom; width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">4.0</p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td></tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"><td style="vertical-align: bottom; width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Expected dividend yield</p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="vertical-align: bottom; width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c95413712">0.0%</span></p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="vertical-align: bottom; width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><span style="-sec-ix-hidden:c95413715">0.0%</span></p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="vertical-align: bottom; width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">-%</em></p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td></tr> <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"><td style="vertical-align: bottom; width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Fair value per option</p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="vertical-align: bottom; width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">11.45</p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="vertical-align: bottom; width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">14.80</p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="vertical-align: bottom; width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">16.31</em></p> </td><td style="vertical-align: bottom; width: 8%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em style="font: inherit;"> </em></td></tr> </tbody></table> 0.5380 0.5555 0.5480 0.5635 0.4648 0.5406 0.045 0.040 0.040 0.1145 0.1480 7400000 P1Y9M18D <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 75%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 14pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 14pt; text-indent: -5pt;"><b><b>Number of Shares</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 27pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 27pt; text-indent: -13pt;"><b><b>Weighted Average Fair Value</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding as of December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">412,658</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">36.33</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">507,524</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">25.14</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(164,167</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">36.77</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited and cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(80,610</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(31.40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding as of December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">675,405</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">28.40</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 412658 36.33 507524 25.14 164167 36.77 80610 31.40 675405 28.40 25.14 35.88 38.20 6000000.0 3700000 2200000 12300000 P1Y9M18D 0.30 0.55 0.15 0.20 0.20 0.60 <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 75%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 27pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -13pt; text-align: center;"><b><b>Number of Shares</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 27pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt 0pt 0pt 27pt; text-indent: -13pt;"><b><b>Weighted Average Fair Value</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding as of December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">158,297</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">37.44</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,125</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">32.53</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(19,125</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">32.53</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited and cancelled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(23,400</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">41.86</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding as of December 31, 2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">117,897</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">34.98</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 158297 37.44 2125 32.53 19125 32.53 23400 41.86 117897 34.98 32.53 0 36.93 600000 200000 800 25000 0.10 0.85 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-align: justify; text-indent: 5pt;"><b><em style="font: inherit;">15.</em> Employee Benefit Plan</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Company’s U.S. employees are eligible to participate in the Company’s <em style="font: inherit;">401</em>(k) savings plan. Employees <em style="font: inherit;"> may </em>elect to contribute a percentage of their compensation to the plan, and the Company will make 140% matching contributions up to a limit of 5% of an employee’s eligible compensation. In addition, the Company <em style="font: inherit;"> may </em>make annual discretionary contributions. The Company made matching contributions of $2.3 million, $2.0 million, and $1.7 million for the years ended <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2022,</em> <em style="font: inherit;">2021,</em> and <em style="font: inherit;">2020,</em> respectively.</p> 1.40 0.05 2300000 2000000.0 1700000 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-align: justify; text-indent: 5pt;"><b><em style="font: inherit;">16.</em> Income Taxes</b> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 9pt; text-indent: 5pt;"><i>Income Tax Expense</i></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-align: justify; text-indent: 27pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The components of the Company’s income (loss) before income taxes and its provision for (benefit from) income taxes consist of the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Years ended December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">(Loss) income before income taxes</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Domestic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(19,080</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,529</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(25,722</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">334</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,956</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,902</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(18,746</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,427</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(28,624</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Years ended December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Provision for (benefit from) income taxes:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Federal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,005</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">494</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">357</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">State</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">285</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(635</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,970</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">96</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">167</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">49</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total current</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,386</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">26</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,564</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Federal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3,243</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(553</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,980</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">State</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,256</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(426</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,070</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(774</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(754</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(28</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total deferred</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,273</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,733</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,078</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total benefit from income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(3,887</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1,707</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(4,642</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-align: justify; text-indent: 5pt;"><i>Deferred Tax Assets and Liabilities</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt; text-align: justify;">Significant components of the Company’s deferred tax assets and liabilities consist of the following:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As of <b>December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b> </b></td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Lease liability</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,468</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,684</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Capitalized research expenditures</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,451</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,795</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,782</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Inventory reserves</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,763</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,453</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Compensation accrual</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,635</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,236</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Net operating loss carry forwards</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,551</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,822</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Tax credits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">741</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,022</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">519</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">491</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Foreign currency exchange</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">221</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">282</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">23,144</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,772</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As of <b>December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Acquisition-related intangible asset</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(12,075</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(14,770</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Depreciation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(8,804</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(8,509</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Right of use asset</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(7,252</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,650</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Deferred tax liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(28,131</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(27,929</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net deferred tax liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(4,987</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(10,157</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">As of <em style="font: inherit;"> December 31, 2022, </em>the Company had no Federal net operating loss (“NOL”) carryforwards and state net NOL carryforwards of $3.1 million that will begin to expire in <em style="font: inherit;">2026.</em> The Company also had NOL carryforwards in Italy of $6.1 million that do <em style="font: inherit;">not</em> expire but are limited to <em style="font: inherit;">80%</em> of taxable income. As of <em style="font: inherit;"> December 31, 2022, </em>the Company had federal and state research and development tax credit carryforwards of $0.4 million and $0.5 million, respectively, that will begin expiring in <em style="font: inherit;">2023.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Tax Cuts and Jobs Act (“TCJA”) requires taxpayers to capitalize and amortize research and experimental (“R&amp;D”) expenditures for tax years beginning after <em style="font: inherit;"> December 31, 2021. </em>This rule became effective for the Company during the year ended <em style="font: inherit;"> December 31, 2022 </em>and resulted in the capitalization of R&amp;D costs of $23.4 million. The Company will amortize these costs for tax purposes over 5 years if the R&amp;D was performed in the U.S. and over 15 years if the R&amp;D was performed outside the U.S.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Company recognizes deferred tax assets to the extent that it believes that these assets are more likely than <em style="font: inherit;">not</em> to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, carryback potential if permitted under the tax law, and results of recent operations. Based upon future reversals of existing taxable temporary differences, the Company believes it is more likely than <em style="font: inherit;">not</em> that it will realize its domestic deferred tax assets. Based upon future reversals of existing taxable temporary differences and projected future taxable income, the Company believes it is more likely than <em style="font: inherit;">not</em> it will realize its foreign deferred tax assets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">During the year ended <em style="font: inherit;"> December 31, 2021, </em>the Company released the valuation allowance recorded related to the net deferred tax assets in Italy in the amount of $0.9 million. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Undistributed earnings of certain of the Company’s foreign subsidiaries amounted to approximately $0.5 million at <em style="font: inherit;"> December 31, 2022. </em>The Company expects to be able to take a <em style="font: inherit;">100%</em> dividend received deduction to offset any U.S. federal income tax liability on the undistributed earnings. Determination of the amount of unrecognized state and local deferred income tax liability is <em style="font: inherit;">not</em> practicable due to the complexities associated with its hypothetical calculation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 9pt; text-indent: 5pt;"><i>Effective Tax Rate</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt; text-align: justify;">The reconciliation between the U.S. federal statutory rate and the Company’s effective rate is summarized as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Years ended December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Statutory federal income tax rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">State tax expense, net of federal benefit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4.7%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">22.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Section 162(m) limitation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(8.2%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8.7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Goodwill impairment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(16.8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Change in fair value of contingent consideration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(36.7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Change in tax rates and state apportionment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(29.8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.9</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Federal, state and foreign tax credits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(28.4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(35.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Return to provision adjustments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other permanent items</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(0.1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1.9</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Effective income tax rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20.7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(70.4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">16.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-align: justify; text-indent: 5pt;"><i>Accounting for Uncertainty in Income Taxes</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The Company had no unrecognized tax benefits for the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2021,</em> respectively. The Company does <em style="font: inherit;">not</em> anticipate experiencing any significant increase or decrease in its unrecognized tax benefits within the <em style="font: inherit;">twelve</em> months following <em style="font: inherit;"> December 31, 2022.</em></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 8pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">In the normal course of business, Anika and its subsidiaries <em style="font: inherit;"> may </em>be periodically examined by various taxing authorities. The Company files income tax returns in the United States on a federal basis, in certain U.S. states, and in certain foreign jurisdictions. The associated tax filings remain subject to examination by applicable tax authorities for a certain length of time following the tax year to which those filings relate. With a few exceptions, the Company is <em style="font: inherit;">no</em> longer subject to income tax examinations for years prior to <span style="-sec-ix-hidden:c95413787">2019.</span></p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Years ended December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">(Loss) income before income taxes</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Domestic</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(19,080</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,529</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(25,722</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">334</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,956</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,902</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(18,746</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,427</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(28,624</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td></tr> </tbody></table> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Years ended December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Provision for (benefit from) income taxes:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Federal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,005</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">494</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">357</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">State</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">285</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(635</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,970</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">96</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">167</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">49</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total current</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,386</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">26</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,564</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Federal</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3,243</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(553</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,980</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">State</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,256</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(426</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(1,070</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(774</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(754</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(28</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total deferred</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(5,273</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,733</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,078</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total benefit from income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(3,887</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1,707</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(4,642</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td></tr> </tbody></table> -19080000 -2529000 -25722000 334000 4956000 -2902000 -18746000 2427000 -28624000 1005000 494000 357000 285000 -635000 -1970000 96000 167000 49000 1386000 26000 -1564000 -3243000 -553000 -1980000 -1256000 -426000 -1070000 -774000 -754000 -28000 -5273000 -1733000 -3078000 -3887000 -1707000 -4642000 <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As of <b>December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b> </b></td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Lease liability</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,468</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4,684</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Capitalized research expenditures</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,451</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,795</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,782</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Inventory reserves</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,763</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,453</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Compensation accrual</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,635</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,236</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Net operating loss carry forwards</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1,551</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2,822</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Tax credits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">741</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3,022</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">519</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">491</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Foreign currency exchange</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">221</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">282</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">23,144</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,772</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>As of <b>December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Acquisition-related intangible asset</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(12,075</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(14,770</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Depreciation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(8,804</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(8,509</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Right of use asset</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(7,252</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,650</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Deferred tax liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(28,131</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(27,929</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net deferred tax liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(4,987</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(10,157</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)</p> </td></tr> </tbody></table> 7468000 4684000 5451000 0 2795000 2782000 2763000 2453000 1635000 1236000 1551000 2822000 741000 3022000 519000 491000 221000 282000 23144000 17772000 12075000 14770000 8804000 8509000 7252000 4650000 28131000 27929000 4987000 10157000 0 3100000 6100000 400000 500000 23400000 P5Y P15Y -900000 500000 <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Years ended December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 49%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Statutory federal income tax rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">21.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">State tax expense, net of federal benefit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4.7%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">22.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Section 162(m) limitation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(8.2%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8.7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Goodwill impairment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(16.8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Change in fair value of contingent consideration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(36.7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6.7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Change in tax rates and state apportionment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">1.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(29.8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">4.9</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Federal, state and foreign tax credits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(28.4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">2.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(35.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(3.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%)</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Return to provision adjustments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other permanent items</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(0.1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">)%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1.9</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Effective income tax rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">20.7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(70.4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">16.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">%</p> </td></tr> </tbody></table> 0.210 0.210 0.210 0.014 -0.032 0.015 -0.047 0.223 -0.022 -0.082 0.087 0 0 0 -0.168 0 -0.367 0.067 0.012 -0.298 0.049 -0.051 0.284 -0.022 0 -0.353 -0.030 0.050 0 0 -0.001 0.110 0.019 0.207 -0.704 0.162 0 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt; text-align: justify; text-indent: 5pt;"><b><em style="font: inherit;">17.</em> Earnings per Share (</b>“<b>EPS</b>”<b>) </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Basic EPS is calculated by dividing net income (loss) by the weighted average number of shares outstanding during the period. Unvested restricted shares, although legally issued and outstanding, are <em style="font: inherit;">not</em> considered outstanding for purposes of calculating basic EPS. Diluted EPS is calculated by dividing net income by the weighted average number of shares outstanding plus the dilutive effect, if any, of outstanding share-based awards using the treasury stock method.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">The following table provides share information used in the calculation of the Company's basic and diluted EPS (in thousands):</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Years Ended December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Shares used in the calculation of basic EPS</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,561</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,401</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,222</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Effect of dilutive securities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Share based awards</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">233</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Diluted shares used in the calculation of EPS</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,561</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,634</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,222</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 15pt; text-indent: 27pt;">Stock options of 1.1 million shares were outstanding for the year ended <em style="font: inherit;"> December 31, 2021 </em>and were <em style="font: inherit;">not</em> included in the computation of diluted EPS because the awards’ impact on EPS would have been anti-dilutive. The Company was in a loss position during the years ended <em style="font: inherit;"> December 31, 2022 </em>and <em style="font: inherit;">2020,</em> therefore all potential common shares would have been anti-dilutive and accordingly were excluded from the computation of diluted EPS.</p> <table cellpadding="0" cellspacing="0" class="finTable" style="margin-right: auto; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 15pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Years Ended December 31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2022</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Shares used in the calculation of basic EPS</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,561</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,401</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">14,222</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Effect of dilutive securities:</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Share based awards</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">233</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Diluted shares used in the calculation of EPS</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,561</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,634</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,222</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"> </td></tr> </tbody></table> 14561000 14401000 14222000 0 233000 0 14561000 14634000 14222000 1100000 EXCEL 96 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( +E\<%8'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " "Y?'!6ZO&<:NX K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>*(ZA8R;UI:.G#@8K;.QF;+4UBQ-C:R1]^SE9FS*V!]C1TN]/ MGT"-"=+T$9]C'S"2PW0W^K9+TH0U.Q$%"9#,";U.94YTN7GHH]>4G_$(09L/ M?42HJVH%'DE;31HF8!$6(E.--=)$U-3'"]Z:!1\^8SO#K %LT6-'"7C)@:EI M8CB/;0,WP 0CC#Y]%] NQ+GZ)W;N +LDQ^26U# ,Y2#F7-Z!P]O3[F5>MW!= M(MT9S+^2DW0.N&;7R:]B\[C?,E57M2@J4?#5GC](<2\%?Y]621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M +E\<%9*1+L"= < ,@P 8 >&PO=V]R:W-H965T&UL MM9MK;]LV%(;_"N$510LDL40Y%[>) <=N-J])ZL5IBV[8!T:B;2&2Z)%4+O]^ M1[)L60%U; %T/R2^Z+P2GY#4^U+L^;.0CVK.N28O<92HB]90LR(OBJ$T=YZ0=LS!I]<[SS\:R=RY2'84)'TNB MTCAF\O621^+YHN6V5A_AU\T*\B-^A/Q9;;PF65,>A'C,WHR"BY:371&/N*\S"0:_GOB 1U&F M!-?Q7R':6I\S*]Q\O5*_RAL/C7E@B@]$]#,,]/RB==8B 9^R--)WXOD/7C3H M.-/S1:3RG^1Y>6RGTR)^JK2(BV*X@CA,EK_92P%BL\"I*:!% 7U3X-:=P2L* MO%T+.D5!)R>S;$K.8<@TZYU+\4QD=C2H92]RF'DU-#],LK_[1$OX-H0ZW1L* M/X4_HR;])"!?$AWJ5S)*EOTI^[L_^;>^)\-N&R*3:T)%9!V5FC[&#JO:+C#H"F9!$ #?@+ M^RAG>"-QI&;9"/W*N(S4S0 M\/HIBY2)]0 M:TK(DEB%T.F:T"G:PD$J9PF0. 69>QDN-KA MH4L//==$#"UL2LR26(78V9K8&=K&]OVI1X5IU5@*M:@K+DE@%ENN4%L_9#=?]Z\(X_+;4N\[A M5Q,BO*PI(UMJ54@;/MC=#5(_25+H4W=\(:0VTL*%M$R-DSM>UIB6);4J+5K2 MHKO1*N8I;'+?)K4R];6N'A=H3,Z26I5<:?I=U AO#$:P72K,33_2UW"Q6B>! MUS5&M@]O[Y;FWMW)W5^%$2>W:?S I1'5-F/O'KH=AQI]/5[;&-<^G+U;6GMW M)V\/-EQ(Z%=YKCP@$PW#DPA)!B*%E 1A203FX8JK#[\8 5HU][;4J@!+>^_B M_KP >,]>R"B H1I.0W^9SI'>ATLZ'3"PG>/NB='%XL6-Z>W#^;NE]7=QMU[0 MZPM(;2_$4)KZY M\^&:-WTC-JOYP)9:=56U# @4-_AOL8V%TF"!_PX7M7>)+8J.>^HYQA5:JYG! MEEJ56YD9*&[U\U'9EYS58\(%3L^,]P.\JC&D?40%6D8%BOO[:Y&O9\Q%@KFW M+2*=X]/#KN.8NY35>&!+K4JKC <4=_3WH0:7*Z;$I1\>/I()]U,)O.4>.2Q9<$C5GTG@KQ94;$]U'>J!E>J"X\8>< M%83)C$Q>XP<1&4'B OW;D7'Y R]K3&D?H8&6H8'BMG[5TBV/QGV_S+RLIH1;*E5>949@>Z4$7[R*#I\3,"5P5!E"N:X@(R42FLF.5SS M5ABQ60T'MM2JV,IP0'<*!S]$!"&4R66HE\9EVRU*-;"LA@!;:E5890B@.X6 MU<.4Y2I1/I6!K36O=6]1_,5-50.\JC&U?60 6F8 NE,&&"6:R^6NDFQEDJTP M&JGABG74K$8 6VK5K0AE!/!VB@#Y<"0#2$TS(8VN8XM.W_L:T]I'&O#*-.#A1KZ@ M]27FG4/J?"RQM#VX?R]TOE[.STWF,S!I*$]#)>I[V%6 X M MM2JL,@!X.STU&*A#MQ+,>*O$51IO0+,:"0JUXUPMV_#ZU/.H>^8<4]H] M;S^9\)1^W]O)[U=#]20+T(I\2S4,QR1+F49D-@W\H% [V6BDVSGQ:-=UUFTL M<.S#ZGNEU?=P@[Z:K:Y"&9/1T$AFR[)_QPC JL6WI5:%5%I\#S?D*TAU87M+ M^9!'(H2[ 7G/XL5GE5@57NGP/]^0K<-GJ8G8C-,+# M)2Z%TMF3T1NF%//GJ>):&XT^KM,8G%6CW][8^IUYJGP+O2)^]I!WN0M\_>EZ MFWX_WYS>+@]?[O&_83)_Q!;Q*90Z1Z&PO=V]R:W-H965T&ULM5G;;MLX$/T5PBV*%K!CD;JG MCH$VP78+["5HVMUG1J)MH9+HBI2=[-?O4%8D6Z3H!-M]L25Y.#HS).>BCR4EQ--E)N+^=SD6Q80<4%W[(2?EGQJJ 2;JOU7&PK1M-F4)'/ MB>,$\X)FY62Y:)[=5LL%KV6>E>RV0J(N"EH]?F0YWU]-\.3IP9=LO9'JP7RY MV-(UNV/RV_:V@KMYYR7-"E:*C)>H8JNKR0=\>>TV QJ+OS*V%T?72(5RS_EW M=?,YO9HX"A'+62*5"PI?.W;-\EQY AP_6J>3[IUJX/'UD_=?FN AF'LJV#7/ M_\Y2N;F:1!.4LA6M<_F%[W]E;4"^\I?P7#2?:-_:.A.4U$+RHAT,"(JL/'S3 MAS811P.P-S* M /(

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�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ϖ&;HRQ#XI]3D1MR97D.H7]^$FV:V?0RFEPOR22K7ONN4F DA8&"6QZWO>P$T( M9('A5SNC)$)9<7YG9E\#2>.9QA!#($R M$$3_/< %Q+%!TCSN*U"G]FD,=\=/Z-=%\#J8%9%PP>.?-%2;B3-R4 @1R6)U MP_,O4 74-W@!CV7QB_)JK>>@().*)Y6Q9I!05OZ3;27$C@$>O&#@5P9^P;MT M5+"\)(I,QX+G2)C5<,BE +:TV.,K,K2R7T6ZKMU/0[5X!\] DMRVU!/$)+ MNF8TH@%A"IT' <^8HFR-%CRF 06I%U])1;4B$*);"5$6HV]:6FEL%T(GC%"/ MB+ 07=UG--5;J-#1)2A"8_EA["K-VOAV@XKAK&3HO\ 0^VC.F=I(=,5""/\' M<'6X=R;=7-BG"@;H.:WZ!3W>QH>- JW+ F-K1"7? D MS12(G0-FCMN21RHG FI!T5^T3VY:G1VH\:@.9=2IQG:T7JO$IS6OT\XDWB.- MKQYGYX M;WIZ7=)\L?8M*AIM2AKNM92UPON6:=7>^ M^!,0ZZ*OD:CX5B\__NNG=>]T7G8,S?*R\9H3L:9,HA@B;>H=#W5>BK*7*2>* MIT7_L.)*=R/%<*/[/Q!F@7X?<=U#5!/CH.XHI_\ 4$L#!!0 ( +E\<%;+ MG!BN[ D ": 9 >&PO=V]R:W-H965TKW1<;L.?\SHPSSQY@GO54:^SL(HO6Q-LVQ^WFZGPRF? M^>EQ/.>1>&<<)S,_$Z?)I)W.$^Z/BJ!9V-8[G7Y[Y@=1Z^JB>.TNN;J(%UD8 M1/PN(>EB-O.3EQL>QL^7+:WU^L)],)EF^0OMJXNY/^&?>/9Y?I>(L_:*,@IF M/$J#."()'U^VKK5SSSC) XH6OP?\.5T[)OE0'N/X2W[BC"Y;G;Q'/.3#+$?X MXL<3'_ PS$FB'W^6T-8J9QZX?OQ*I\7@Q6 >_90/XO"/8)1-+UNG+3+B8W\1 M9O?Q,^/E@'HY;QB':?$W>2[;=EIDN$BS>%8&BQ[,@FCYT_]:?A!K 5IW2X!> M!NC[!AAE@/$VH+OL&],N _KY=.BD#3MX&]+<$G)8!I_MV MZ:P,.-LW0.N\_N8Z>X>L?MG+2;><)<44,_W,O[I(XF>2Y.T%+S\HYFD1+V96 M$.62^I0EXMU Q&57O\89)P;YB=PL4O%6FI)!/'L,(C^?\"GY8/+,#\*4//"O MV<(//XJ6GS^9Y,,/'\D/)(C(PS1>I'XT2B_:F>A.#FT/R]3F,K6^);5&;N,H MFZ;$BD9\5!-OJ^.-7?%L1WY= 6B+SW'U8>JO'^:-KB12_GA,.L81T3MZIZ9# M W6XZT?'1.]N#3=WA"_"8V)H1;A6$V[M"A?9C<[6<*H._VV8K;+7==Y6A]_Z MB3*6D:&BM-&P6ONX57)^4C M<1)E033A498?IL&()^4[OP3^8Q &V8MHM$@2T:)F##?*G'GE/T_G_I!?MD1I M3WGRQ%M7/_Y'ZW=^KA,"$F8B81821I$P&PEC2UBO@.6774]78N(^K2MFLT77 MT'IR(Q?9)P\$DS3376FFJ]0,#:(@XS_](J[O1L2),C^:!(\A)]=IRK,C\CGE MXT4HE#+FY,-_N9]\K).(,D53B2!A)A)F(6$4";.1,*:>,)I!7L0\J+ON<0Z. M=)$#\$ P24^]E9YZRD'>^2^SO-2(F[ZME6>]\ C]^=%0M"+7^4U6D 6\[@.Z M469M*C$DS$3"+"2,(F$V$L9Z>]089[/1B:Z_J59N#:E[^3)_^LFO)+:=,(C82829B%A M% FSD3"&A#E(F(N$>2"8)+23E=!.WO]*3IFBJ>J0,!,)LY PBH392!A33QBM MM_U*[N!(%SD #P23]'2ZTM.I*&ZX M#HYTH2/P4#1967JE+'W'X_-DN$C)+1\%0S]45S EJ;%^D#032K.@- JEV5 : M@](<*,V%TCP43=99Y930#K1*K*U2B4O)*!WS).&C(_(09WY8*T.H/T+;7'T_ MZ6E&7U[0,*%)+2B-0FDVE,:@- =*$Q^6V3#6-S3[6EG^MT/%_R(L& RK=4LU+!1TOIKFNUW MQ)^WFH5Z,: T"J794!J#TAPHS872/!1-UFSEW-#4UHWWL0^JDS;6&M2Z :59 M4!J%TFPHC4%ICE;G!GG[SZ<+S>GMRBE+J/)Z:&JS1[V$KH=_+H(T*"I=L9C& M1Z)!FM4:G=09&NL%ZOR TBPHC4)I=DE;GQ_:V=LYR: Y'2C-A=(\%$W6567M MT-0+[O6ZNN?#>!(%?^4/(4>B_ 1C49%>'T.F2]F)FS?B1Z-5L0IXFK^_F.4W M=5N>8];K$FH-*6FR;ZWFFA'J^H#2*)1F0VD,2G.@-!=*\U T69B51T13FT2V M/*\D?Y-#?8_JA(UU!G610&D6E$:A-!M*8U": Z6Y4)J'HLERK.PDVC?PDZAS M-%;@#EO"]I4=$]H1"TJC4)H-I3$HS8'27"C-0]'D__5;F4UTM=ED>_4[P#RI MSM54=E":":594!J%TFPHC4%I#I3F0FD>BB8KL7*DZ-_ D:+.T5B!ZAXK_'@F MM",6E$:A-!M*8U": Z6Y4)J'HLERJVPJ^D$V%5'X]O5?JA,TUAK4O0*E65 : MA=)L*(U!:0Z4YD)I'HHFRZ]RK^AJ]PJFVD&-*SMZK+C+@_;#@M(HE&9#:0Q* ME._%DEEV?MU$V=TT40[48VRL6:B?!4JC4)H- MI3$HS8'27"C-0]%DS5:^%_T0WTLC/YDZ0^-K4NAWFD!I%I1&H31;W_3[Z/J& MGPR:TX'27"C-0]%D756V%7V7;>5]OJ5.G;:QV*#FE9(F61HW*ZRU7S-:TZRW MTAJ4\9W8+R@9)$\W'+@#]4 :2P1J.('2 M*)1F0VD,2G.@-!=*\U T^?N]*\.)H3:\ LZ4Z5>.Z![6?0&D6E$:A-!M*8U": Z6Y4)J' MHLE"7-MFYAO83W;D4-@C!^K0QG+#;B.#W4<&NY$,=B<9J/\$2G.A- ]%D^56 M^4^,0_PG#;R6:G[C8@>UI4!I%I1&H30;2F-0F@.EN5":AZ+)ZJML*8;:EH(I M=NH\612;#B?DF&\B++E)L"K5U>;VE\76[F_>=W4SJE6\SK3SMWE[N$5_NIB M[D_XK9],@B@E(1^+5)WC$_$[29:;TB]/LGA>["7^&&=9/"L.IUS&PO=V]R:W-H965T\%O): M)0":W&1IKB96HG5Q9-LJ3"!CJB<*R'$F%C)C&KMR::M" HLJ49;:+J6!G3&> M6]-Q-3:7T[$H=(9Y(J+G$B()]:Q=+-+&HB0A2"+6Q M8/A9P0S2U#AA'']J4ZO9TPBWV[?N9Q4\PBR8@IE(?_)()Q-K:)$(8E:F^D*L M/T,-U#=^H4A5]4O6]5IJD;!46F2U&"/(>+[YLILZ$5L"QW] X-8"]ZD"KQ9X M%>@FL@KKE&DV'4NQ)M*L1C?3J')3J9&&Y^88+[7$68XZ/?TF-!"/?" GI<(I MI,Y-DA>,S_/ (9#5 ODN6JQBDA(@H]YZXU*4M\EFW_"O+>\3UV^0V M)J;)CMMDQZW\_ ?\YDSB&9!SB'C(4O+K'+(%R-]M7)U&YC(>J8*%,+'PMBF0 M*["F;]\X ?W81OE"9G>8O8;9ZV2>,960-N*4H8)OM"/ MLW7Z[LL6[/P9!WW'"]K9!@W;H)/M6.I$"E7*&./H?$2&S.\C#!GGX M N_(<"?;@3.BHR;;&X[.G9[),6HX1J]^^48[]\4=>H/@'F5G',^D=.C_0H"^ MTO6KC;7O?^^_+96S6/*3C/F5QRK%A2B-&>]@88CMS4<)N.%D55 M!BV$QJ*J:B98]X(T"W ^%E@*U1U36365]/0?4$L#!!0 ( +E\<%8%,$WW M?@8 $4U 9 >&PO=V]R:W-H965T=/X!\]'6)\BQ%=P<2_D%[7A7*.'/"O4Y62C]?;U=*J2#<^9.A=;7IAOUD+F M3)NW\G:JMI*S55649U/B.,$T9VDQ65Q4G]W(Q878Z2PM^(U$:I?G3'Y[PS-Q M?SG!D^\??$AO-[K\8+JXV+);_I'K3]L;:=Y-#Y15FO-"I:) DJ\O)U?X=4S" MLJ#:XG/*[U7K-2I_RE*(+^6;MZO+B5/N$<]XHDL$,W_N^#7/LI)D]N-K#9T< MVBP+VZ^_T^/JQYL?LV2*7XOLKW2E-Y>3^02M^)KM,OU!W/_*ZQ_DE[Q$9*KZ M%]W7VSH3E.R4%GE=;/8@3XO]7_90=T2K 'M'"DA=0$XM<.L"]]0"KR[P3BWP MZP+_U(*@+@BJOM]W5M73$=-L<2'%/9+EUH96OJAT5=6F@].B_)_U44OS;6KJ M].*]T!RYZ R]V2GSE5+H6N3+M&"E=V4^CUDJT6>6[3@2:_3>_%^_4HIKA:Z2 MK[M4\A5Z&7'-TDS]9+;^]#%"+U_\A%Z@M$!_;L1.L6*E+J;:[&K9X#2I=^O- M?K?(D=V*>'*.7/P*$8>0@?+KT\OQ0'ET>KDS4$[MY3%?GB/'/5H>V\M_8\4Y M(MY0^=38/2@F!\6DXGE'>+\(L;I/LVS(PK[2KRK+0>AN,7/=\&)ZU^[K@8UF M<]S=*.IO-/>PV]V(6G>T'$1?JRU+^.7$C)**RSL^6?SX PZNM4]OF#0')WK'5VG",O3W.YXON?QGJ(NMH)&_^1H2%D'"*"0L!H)UU'H' MM9Y5[353&V1&+924+[@9Y.Y8Q@L].(I946/E0L(B2!B%A,5>;Z3 87 8*#K. M_(,SW^KL*DG$SB@R4D"D?/*BLQ6,U0<(B2!B%A,5!3Q-VPF ^[&EV\#2SG^4DW[)T MA?B#N9!17%7#HM ;+LW45$KC$+%J,CADT8H>:Q$2%D'"*"0LGO4LNH$W['!^ M<#A_PJ&Y"I7Z6^6N/)MMS76A?H4*KH>L66%CK4'"(D@8A83%\Z%C[\@0&1ZT MA59MU27^F5B?[12W'&16R%A=D+ ($D8A87'8TQ5Z1PXR[#27TV9 MYC)_4A]D1'$-2HM :124%M>TCCX_/#:L-C$+MN@M B41D%I<4UK6_-] MWSERJ8>;" 7;,Q1;3&PO'>T*-#H!I5%06HS[Z0D. W+,59.?8'N 0I5.M8Q<:[#31LL#S5I :93T MTQ'7;:4CM;WGN*.%-%D+L6U5( M$[80>]CR'!&VO][R>+W/ M,I4!#5M :1$HC9+^'2HSWWM\V0[59E=<$[80>]@2\367Y?,$FCT\.4,!35Q M:1$HC=:T=DYVAC'V9H_E@68NT]8#)>4#1N^8O$T+A3*^-GCG?&;V1^Z?V=F_ MT6);/6.R%%J+O'JYXY+H# B% &0 'AL+W=O1. (FRH(1Y@>^/O(30U%G,LFLKL9CQO6(TA95 0T#0_DA]%(6H!>'@B("@"@I<&#(J 048T7UE&ZX8HLI@)?D3"S-9H MYB2K31:MV=#4R/B@A+Y+=9Q:?.(*T "]1]=[J6])B98\6=.4F")+??TV523= MTC4#="4E*(FNPN][*B!";V] $OOF'7J#:(KN*&,F?.8IO423 MR N+Y5SGRPE.+.<#K%WD#WY#@1_X+>%+>_@?)'51,&P+]W1ARNH$976"#&]X M F]%A-8 W4%$0\+07W>0K$'\W<;+"F2:\5+N2 AS1W>;!'$ 9_'K+WCD_][& MLB>P!N=!R7E@Y5P3G&2"M[&U0G1EFX-=9&#FL7-8#(6+U\N60TSKE9ZXT[+6.0MKGC-9C$H6(RN+ M&SCH-\M./UP^0QBGG/'M3Y2]6V0I(_H'=>A+:[ZN O<$UBC-N"S-^/4"6R&Z MLLW!L%__NV 7M[?FI*0QZ4/AEW>P-5U7RCV!-2HS+2LS?;W .<2H)LE@_*1_ MK5G.Y(#]RD_X5A:?!8D ?2()G-NQ]@1=%>T+K5F.FKW"KQ?5CM&9,7[>M]B= MM+"5_51?:,W*5(X*]V"I[!B=&3]W:"??N+@R5=CN MJOY;X@Y=W*NAZ@NM69C*4N$>/!5N\4'C9Z[9GNE<)I6KPG9;=9NBE>"A^8"_ MU_"Z8V-$T@@5=BN!5)VI=Z_^JB^T9I4JAX5[L%@%1KT'?7?T5.Y>7997V\ Q MNV=W1&QI*A&#C8;WW;%^+(A\0RH?*+[+]G367.G.SDYCT.]G82;H^QO.U>/ M;!.5VX*+?P%02P,$% @ N7QP5@P5M+ B @ B@0 !D !X;"]W;W)K M&UL?53;@+->*&%A/HOOT M;IKY^!#PG4-K#\[$=[+2^LT;#]4D2GQ!(*!TGH'A:P\YH2.F! MA^<]^]?0._:R8A9F6OS@E:LGT6U$*EBS1KAGW7Z#OI\;SU=J8<.3M'UL$I&R ML4[+'HP52*ZZ-WOOYW H/0$@/8 &NKN$H4JY\RQ(C>Z)<9'(YL_A%8#&HOC MRG^4I3-XRQ'GBB?M@(S)-9DV%J^L)3,M5UPQ/S.+_H71)/1/'E2G 3_,RSDX MQH6](A>$*_)2Z\8R5=D\=EB4IX[+OH!I5P ]44!*R:-6KK;DBZJ@^IL@QFZ& MENB^I2D]RSB'$=#Z,:!][L!.^+=DR@$'>@&CC6 M: >_"7"_#+LB'6=9FN3Q[DC:;$B;G4W[A)LIM#TZVNR_C->4?K[-_LD8'^A# M@MF$+;"DU(URG50&[[!H]YV^_H1W6_K(S(:C, 2L$9J,/F%RTRF_,YS>!K6M MM$/MAF.-/PLP/@#OUQH5UQL^P?#[*7X#4$L#!!0 ( +E\<%;_:JL/+P< M .)) 9 >&PO=V]R:W-H965TH6%2D#N6G80S.7#:C^XK:'1Y-))'&"D_?'KI"%MFN VTMO9F0^0 MI#[/LR&YCDJ1!0.,?5\R/ MGB\Z:N?UPIWWN.#9A>[D?$D?V3WCGY>WL3CKEI2Y%[ P\:*0Q.SAHG.IGKE: M+S/(6WSQV'.R<4RRH4RCZ%MVXLPO.DK6(^:S&<\05/QZ8M?,]S.2Z,?W MHI M?6:&F\>O=#,?O!C,E";L.O*_>G.^N.B,.V3.'FCJ\[OHV6;%@ 89;Q;Y2?Z3 M/!=ME0Z9I0F/@L)8]"#PPM5O^E)\$1L&FO:&@588:/L:] J#WKX&_<*@OZ_! MH# 8[&LP+ R&^QJ,"H/1O@;CPF"\K\%I87"ZKX&JO/[EE#R"5G_R/%YTRNGD M/(Z>29RU%[SL( ^ZW%Z$B1=F^KCGL?C4$W9\\E?$&>F38V)2+R9?J)\R])@%TQ?C++T%[_1*N-"G19-,3HO2.B*9H"OE\ MKY/W[SXT=.Q:CG%I>$*T_DZ,O@.3^B>DI^8858(Q=F%$;WK*3HPIQWR<\;(W MLD%9[;<]157XK%7BK*7<_MO=F_*R3V; MI;''/98HW]/E*RL[R[5FRI#-VT1$)-6'Q M$^M,?O]-'2I_-$4\$J8C80829B)AU@HVR&'9\\G31#GO/FT&.=*=@X2Y(%@E M[/MEV/>E87^5)N)*DI#K*)AZ(H([$28L+C[YTZ-3S_?X M#]$HC6/1HDD.4I]MY8"$Z4B8@8292)BU@@TEB>%A&<-#X*V:7,8Q%=?S M&85HMLA.LEG$91"EHG'TL,]=OBGFI;UL&_-(F(Z$&4B8B819PYTW]WJ+8TU5 M3K=O[\-:R!]KX^%PN!7TH,Y7@GY4!OUHQXT[%G-R,3V>>S/J$S'[%8'-%W$D M9LL/PJFX/W]/O<3+XC8A?]^P8,KB?YK"5NJG;=@B83H29B!A)A)F(6$V$N8@ M82X(5E'+N%3+^&>DB+O\0&2(CRF?14$V&]YK1I O91T1VWM<-"E0VO>V"D3" M="3,0,),),P:U^[WJI+]V\H>2)\.$N:"8!5MG9;:.CU )B+_DALO]((TJ%Q: MK_82)URF_(CH7C++'\SN*&?21";M9EL9(6$Z$F8@82829B%A-A+F(&$N"%81 MFZJL:R3*H1:F:NIJ4I'9DWHGZE9"@OITH#07 M1:O*9*.4J!XH*]$7:%:2][.UGI T'4HSH#032K.@-!M*O5!H=<*C9?[J MF&G$>13DAPM&A02S!N+SARCBKR>9@_*U3I/_ %!+ P04 " "Y?'!6:6<- MHO@# L& &0 'AL+W=O/E!1=:OE M6IWX)1:E<_V^8_H3,]X)^:@V )I\"X-(39R-UO&EZZK%!D*FSD4,D7FR$C)D MVBSEVE6Q!+9,G<+ ]3UOZ(:,1\YTG-Z[D].Q2'3 ([B31"5AR.33%01B-W&H M\WSCGJ\WVMYPI^.8K>$!].?X3IJ56T19\A BQ45$)*PFSJ_T91]LF\Y$!4'VC_@X.<.?EN'7N[02QO-*DO;NF::3<=2[(BTUB::O4BQ M2;U--SRR-#YH:9YRXZ>G?P@-I$_>DQO&)?G"@@3(+3"52#!D:55_(E;DAD@V8\4.^,_>>':_+VS3ORAO"(_+D1B6+14HU=;ZS]NZT[NX:D JD_ (I/XW7/Q#O*E'FCE)D M)L*Y <%.X9E91)I':P."O51\"3)_\CMG*5@-AWZ!0_\$G*(YN\*3!1NVHG]0M#TX M%OWDWXK%F?G.QXE6!@C80D H.B5H#5UA.%*P&ES# J[A":8$S=D5GN'>E'C- M(W)1]'SQ*B/BHR."UM 5@R,%J\$U*N :G6!$T)Q=X1FU'9$/1<\?7F5$>NB( MH#5TQ>!(P6IP4:^46MX)A@1/VA6A/%J[WQM:49D4;?T>8B$U+#L*#3QJY]Z. M%*V.0:D?Z2D$))ZT,T1^VUV"EEJ3XF+S5D3P1&Z9?#1OI3>)>1>H[@L_*$7Q MW)W;?PDQ2DLU2G$Y.F-J0^!KPK$!,DOE M2''I>#0R?T!8XB5VYOPEI"4MM27%Q64KSO?E72/G36:'.2^E(,6UX.MPCBM% MO,3.G+^$5J2E6*2X6FS%.:;7\BY:2SI::CJ*B[K7X1J7?'B)G;E^"='GEZ+/ MQT5?&Z[]?=&U=PJ$F=1+*T69CXLRG.O_*=GPG%W).U:T.D*5(S]Y<:"W"]'(# MS*A(:V">KX30SPM[8%S\@V#Z'U!+ P04 " "Y?'!6 8_PL:," !"!P M&0 'AL+W=O3'(@5AV;V0ZTW[ZVDV9<0C:-!^++^1__SK%]G.RX M>)8%@$(O)65R[!1*;6Y<5V8%E%@.^ :8GEEQ46*ENV+MRHT G%M12=W \X9N MB0ESTL2.+42:\$I1PF AD*S*$HO7"5"^&SN^\SYP3]:%,@-NFFSP&AY /6X6 M0O?P!^>$02-(#@61&<$ M82,(;: UF0UKAA5.$\%W2!AK[9Y -4.A_0($7!!U TW^7^STX8;LIH?47G?$WP12S#+HR M4PMC*S0W=)M&H1\G[G:?]M0HC"/?:ZT.H*(6*NJ%NLUS8G:T<\-JZ7!O1>^( MJ<_B@"=N>>)>G@5^M2>T"R<^6>RZ(TT=5KZG?]UKM')N3E&.K4XR&L-Y.Z5HQ+$VE9I MB3)>,57?R7:T?0AN;?T[&I_H!Z*NYW_N. MXAM;])9&ULC511;]HP M$/XK)ZL/K;1A$DI7JA!I!4WK0R<$:_MLD@NQZMB9[1#Z[VL[(6(22'V)[WSW M?7>?ST[2*OUN2D0+ATI(,R>EM?4#I28KL6)FI&J4+E(H73'K7+VCIM;(\@"J M!(W'XSM:,2Y)FH2]E4X3U5C!):XTF*:JF/YX1*':.8G(<6/-=Z7U&S1-:K;# M#=J7>J6=1P>6G%R5:I=^\\Y7,R]@VA MP,QZ!N:6/2Y0"$_DVOC7>VD?V7T&[T[)E!A=*O/'O&%>DO,1C")OD$\CN,S\,77X='_<.J4#_+C07X<^&XO\!U5?\ K$PT+-VN- M!O4>SXKKV&:!S3^0?3H;S1*Z/U5P+B<:T37+Q0;I"]X^_%\!M(/P%02P,$% @ MN7QP5E[A]TR. @ )P< !D !X;"]W;W)K&UL MC95=;YLP%(;_BH5ZT4I+^(:T(DAKHFJ]V%8U[7KMPDFP:FQF.Z'[][.!HC1Q MHMZ C=_W^#D'?V0M%V^R E#HO:9,SIU*J>;&=65108WEE#? ],B:BQHKW14; M5S8"<-F9:NH&GI>X-2;,R;/NVX/(,[Y5E#!X$$ANZQJ+?[= >3MW?.?CPR/9 M5,I\_^S2(U^D[PAT K]]K(9/+* M^9OIW)=SQS- 0*%0)@+6KQTL@%(32&/\'6(ZXY3&N-_^B'[7Y:YS><42%IR^ MD%)5$O5(V]_P)!/;.(5G,KNB=I!ZSFHV$K%Z\&L"6K"^C=^'^JP M9_"C$X9@, 1?-82#(>P2[5XMT>7%%;I A*&G MBF\E9J7,7*6I3&RW& AN>X+@!,$2BBD*_6\H\(+ 8E]\W>Y_MKNZ%F-!@K$@ M01ZO@H$P=2:36^/.[O9([L\\.(PSMS=/O2QRD]F,W]4?6(+1[;P M+-N+WA$3PB:-X 5(*UT?(-F?UTNBV0&=1>5'46"GBT:ZZ"S='6%$+\02;3BW M+X3H:-H@#KWD ,ZB2M+P1.GB$2X^"_?$%:8VIOAHMEC7Z_J R:**O3BR,R4C M4W*6:6]GV+YGITL'-.=;*]< MZ7.R:U;Z)@-A!'I\S?7I-G3,83G>C?E_4$L#!!0 ( +E\<%9W#ZK". ( M $T% 9 >&PO=V]R:W-H965TQ)6_X>VPG9@EK$2^++.6=\9CQ. MMDH_F1*18%<):69!251?AJ')2ZR8&:@:I=U9*5TQLE.]#DVMD16>5(DP'@ZG M8<6X#-+$KRUTFJB&!)>XT&":JF+Z98Y";6=!%+PMW/%U26XA3).:K7&)]% O MM)V%O4K!*Y2&*PD:5[/@*KK,1@[O 7\Y;LW>&)R31Z6>W.1W,0N&[D H,">G MP.QO@]4#D+O@=0X(HU@N[4 M]A=V?B9.+U?"^"]L6^S%.("\,:2JCFQ/4''9_MFNR\,>(9H>(<0=(?Y(.!9A MU!%&7R6,.\+89Z:UXO.0,6)IHM46M$-;-3?PR?1L:Y]+5_8E:;O++8_2/XH0 MIO -%MI>)4TOP&0!-\\-KVUQ"4XS),:%@7O<4QXF&>1=ZWH:.CX2.8KA5DDH#-[+ XKU :'WT9N(W,_/X4\4,\P&, MHG.(AW%\X$#77Z='!^C9U^G#3]R,^M*,O-[XJ)YMY)PSUQ_G<*^(B4-);D5^ M>!'7Y)MT.KA(PLV^[T.8R7M,=@@3]9C60;AWT2K4:]^P!G+52&K+U*_V;\*5 M;X4/ZW/[5K2M_5^F?6ANF5YS:4#@RDH.!Q>3 '3;O.V$5.VO\Z,BVQQ^6-KW M#K4#V/V5LE>ZF[@ _0N:O@)02P,$% @ N7QP5@3#43%, P 3 P !D M !X;"]W;W)K&ULM5==;YLP%/TK%JNF5FH+!D)( MET1:TU6KM$Y5/[:':0\NN4FL J:V2=I_OVM"*$D(:Z7V)=AP[^&<>VQ\TU\( M^:!F )H\)7&J!M9,Z^S$ME4T@X2I8Y%!BD\F0B9,XU1.;95)8.,B*8EMUW$" M.V$\M8;]XMZ5'/9%KF.>PI4D*D\2)I]/(1:+@46MU8UK/IUI<\,>]C,VA1O0 M=]F5Q)E=H8QY JGB(B42)@/K*ST94=:ROQ>([E((Z!B\2L2I^R:*,=2P2Y4J+I$Q&!@E/EU?V5!:BED#]'0ENF>"^ M-L$K$[Q"Z))9(>N,:3;L2[$@TD0CFAD4M2FR40U/C8TW6N)3CGEZ^%-H( $Y M(E<2EX;4SX2E8_+M,><9FJ5W/V":C(329/\,-..Q.L#0NYLSLK]W0/8(3\GM M3.0*KJ-Y:EJY%8U M<@L\?P?>J@*')(N9D8Z%@%4A#LE4"M4H[X?H*!Y7*6J/L592]5LH_0"G<(E&>Y#'3,,:5C;L\XLSLG2:N2[B@QN+(#VCH;9!M M"/-ZG5K8&EN_8NNWLKT5FL5-K/RMU_FAV^UMD&J(Z@:.V\RI4W'JM'*JK72T M^T9,]())('\N(;D'^;>);2N@^1Z?J(Q%,+#0"@5R#M;P\R<:.%^:EO@[@:UI M#RKMP8:"WX[RP]#QF^WJ5I2[K93/9@B+:;U0KX5K/>"6Q-.W5>3ESG0^PJ8>M6>'Z/!AN&-88%=,?^HK5&@;;2 M'HE4:9DONR\\WU'&5)ICILVV=LRW^O9>:.L5>&D#Z,?T 73[B.\4GMZW*B159T?_="8R]9#&?8[H,T M ?A\(K #+">FH:S^0 S_ 5!+ P04 " "Y?'!6C0E0(YX$ #F'0 &0 M 'AL+W=OV/7T,H@82XS8R[-PD8G\?'Y[4/ MV!ZO&/\J$@")GE.:B8F52+F\L&T1)9!B<"6(Y&G*>;?+X&RU<1RK9>".[)(9%%@3\=+ MO(![D%^6MUS=V34E)BED@K ,<9A/K)E[$;J#PJ"L\0>!E6AB?));) MQ#JS4 QSG%-YQU:_0]6ATL&(45'^HE55U[%0E O)TLI8>9"2;/V/GZM - P4 MI]O JPR\;8/^'H->9=#;-ACN,>A7!OVWMC"H# 9O-1A6!L,R]NM@E9'VL<33 M,6$0H^M,XFQ! M'BF@F1 @Q0GZK$;XD0\2$RK0 SS+'--C9?/EWD=''X[1!T0R])"P7. L%F-; M*L<*O!U53ERNG?#V.-%#-RR3B4!!%D/<8>_K[5U/ [!51.JP>"]AN?2T1!^B M4]1S3Y#G>&Z'0U=O-W>Z^O-VB"6.8&*IM"J /X$U_?47=^C\UJ6929B_A@U* M6)&^GZ:C,T>%ZZFI4T>E_G:ET)!;+6WZM39]K3;7Z1(3KMX4WQG!'G/Z.@EZ_=UY7:@5]4 =]H ]ZAFXY MBT (=*?Z@7F4()4XD0]/ZDV_+-7XZP;21^!_=\5<2S\TYB9AODE88!(6&H*U M]![6>@]_;I)=J[?6O#'1T%'P'-$\)MD"?6(L7A%*C[M&@K;=0T>"29@_?'7V MF6PN- 1KR3NJY1V];P[5X@]5T23,'[VJXFZ-W1QJR*66.&>U.&=:<:JJ@F)F&^25A@$A8:@K5T/J]U/G_?2:C%'RJX29A_ MOO,)LCT)7ZT1&G*H)8WK;-:8CE:<>Z"J:'&"/D$&'-/R:V<6J^4L$9+C8F\! M!<]+R 1L9B7Z%_WHY-6[+YM](E>_4?1^ZR1W M=R-FYS/U2N_=P3J;I 5&::$I6EOGS9Z3J]]T^O_R@-'=*:,TWR@M,$H+3=': MXV.S/>:^LC_V?GG Z-9916N]-G>V=WVC;09&::$IVEIHNW$,E0)?E >& D4L MS^3ZN* NK0\E9^51W%;YI7MQY7:4^\4A9GGLM<&O3T!O,%\0]95!8:Z:)H!CX$4%]7S.F'RY*1JHCW:G_P%02P,$% M @ N7QP5C--)V$A!P BS0 !D !X;"]W;W)K&ULM5M=;]LV%/TKA%<,+=#4(BE+=N882,)UZT.+H&DW#,,>%)F.M>K#I>BD MV:\?)2NF+ M+GD2Y.^R%4_5)XM,)(%4;\7],%\)'LS+H"0>$L?QADD0I8/9M-QV(V;3;"WC M*.4W N7K) G$TQ6/L\>+ 1X\;_@W[+Y=?5C5#OAEN6>93P M-(^R% F^N!AHD'*79=^*-Q_F%P.GR(C'/)0%1:#^ M/?!K'L<%D\KC>T4ZV'YG$;C[^IG]?2E>B;D+;00-G" MQ*#7C,L@BO,W"OCUEJ'7K]Z@5RA*T9=EMLZ#=)Y/AU+E6WSK,*QRN]KD1@[D MA@GZF*5RF:-?TSF?[Q,,E="M6O*L]HJ C(R'[Q#%;Q%Q"&E(Z+I[.&X(9]W# M'4 -W>X[6O*Y!_A^$UF>HX<@7O.FXFZ"1V5P."#V<\_8<_Y!1#J;H6ZH-#+,%PGZSB0ZO"\7@O! MT_ )?1%!FJMMQ>IQ.?]7G2IJ.9)-A=B0>SL*SRC!XUH=.J$8F*AE&4;;,HS M,FRD2[3B(LKF*$I6020*T2A8Y-1 ;&0?)&7'I9(O: MT^-M]7B==^MED@D9_5?NSB8=7L/><2F>U,0TP(@W,@YF,"_+O>AO5?N@ZF(Q M+?K@X1/7-XKMNZ-)7:J)&A,Z)C6E8"Z62L=;I6-0Z=><+]8QBJ,%1Z__XH%X MTZ06YL 4/:G(INYQ;1W)P$C+JDRV59F >3'^H-S62AWS7WBX3+,XNW]"I=_* MT=\?>7+'Q3]-=0)9N^>\*5V?9*PGLKUJ8D<;&.>4+EA%[YTGD]&XO@IV@S$X M%UNM.V8-OV0CK-CWED>56[T3=H,Q.%?;6A!="])[-ZPHH7;8#F%P8K;"M>O# ML.T[IFU65/L-D7KCN@ELPF%_/,%UZ2]A ['V@1@V@NV]LR+8/8\]EYAZ39CO M.&-#[DO8/:S]'H8-7[<&VD*"1X<[J'TH@T-M2Z.M(X:]XX<4W8@LY&KI_ZSH M Q$ND;K*1%5W+=VTU[96%]L^Z75_A3#!K6MH9K&4UELXP0S4934 M40S.Q%:I]J<8MHBGMM-QPZ+I.$8I.L$8G*MM+;0KQ; MM6JGD_9V:D(:+B_A MW"RU$VTA"6PAC^FH%16DN1W"X(1L!6L?26 ?V=Y'B>D!L3)*8ULZC/JVK;9ABDCJ*P4?;'M M_TJG[24]:4))S=&CZQLMLQ.*P9G8*M6^DK[H?)(V#!Y=/*I7H@N*P9G:5D*; M3MK_=)*V3R?;(0Q.S%;XSF_2_4TG:3U!PZ M&ONW%<+@-&QE:D=(^YA)MI (TGK2 9'VA9&.T8*.\8;=TD-J\K.Z$8G(FM4FTZZ8M.'6G3.'%.%<'>"4QQ76L#R*\?VG JME*U_W-A_]>M3;:08.]PG[0/97"H;6FT0W1A MAZB6NCE'GX*$P\T2ICFV6?;*QOIBVR_ASOV0L-=L:9:NZ2)'Q&B6G5 ,SL16 MJ;:;+NSW3KWULWT6V0YA<(ZV-=#.TH6=I4V;=,UAHR&\%<+@Q&R%:T_HPI[P MJ#;IFPV0.J[1.QI@ZJ"OW_@!)V8K7%M$%[:('1KEV/P5'H_J+K !17']3E(& M)V,K5KM %W:!'5LE3 )<45I',CCRV,(,=Y[22+@Z;XNG77(49NM4;AYAV&[= M/E%S63Y'4MM^A<_9YKD83;-Y3.>C6@ZB-$2.S5?DL MR%TF99:4+Y=$Q'0WTDQM M7_$8+5DB8M_(K+C M!\\HZ\H+I:]9X4LXTHS,(Q*30&0(+/^V9$KB."-)/_XOH5IE,Q,>/N_I7MYY MV9D7S,F4QC^B4*Q&FJVAD"SP)A:/=.>3LD.=C!?0F.>_:%>T[4B+P88+FI1B M64ZBM/C';^5 ' @LZX+ *@564T&K%+2:"MJEH-U4T"D%G::";BGH-A7T2D&O MJ< N!78>W2(<>2P=+/!XR.@.L:RUI&4/>4+D:AG"*,UR]TDP^3:2.C'^1@5! M-OH+S2@-=U$ WA7 )8"H,L1JX;-V@_;Q%(2'1+K#:>7<]J7!VB0OA"&Z0(]D39F(TB5Z3B-1^WTH4=GR-.!K M')"1)M,X8BZD M.>^JN=G5%OYYB[;5L=Y;'86S4X6STS"<K9Y$M;.V=QQ-*I'4>U64>TJH_J F=R/ MH3D)HP#'2&Z%T#T3*T;YABUD']&_W#[#B7JUK2#A#F0,!<2YO6N[CL@S?E L*-'U@EAR_P"@Z. ;E)1')U4M=4ER7U^-7!2/S$'4[.F MWC$';EV]EUVVY(?G[V:+FYHY9LLHY2@F"^F"<=>3_K/B\J,H"+K.C])?J! T MR1]7!(>$90WD^P6E8E_(#%174.-?4$L#!!0 ( +E\<%:P]=0+=0( T& M 9 >&PO=V]R:W-H965T8D#"=OL3:U9ZCLROM9M9( M]:A+ $.>*R[TW"N-V5SXODY+J*@^DQL0N)-+55&#IBI\O5% ,P>JN!^.1A._ MHDQXR%L!E,_<";^NX945IK,-/9AM:P!K,W>9& MH>7W+!FK0&@F!5&0S[W+X&(YMO$NX)Y!HP=K8C-YD/+1&M^SN3>R@H!#:BP# MQ<\3+(%S2X0R_G2<7G^D!0[76_8O+G?,Y8%J6$K^BV6FG'M3CV20TYJ;6]E\ M@RX?)S"57+M?TG2Q(X^DM3:RZL"HH&*B_=+GK@X#0# Y @[0+@+B \ H@X0 MN41;92ZM%34TF2G9$&6CDS ME+6F(M,SWZ!*>Y:?=HH6K:+P@*(@)-=2F%*3*Y%!]I; Q_3Z',-MCHOP0\85 MI&P0M_QT>?" GZDL>.;[X -^"9%CAV0-M_3\GY^13/ M?!JJ?1\TC8.H#WJC*>XUQ1]JNLIS["M[MS@8\.D+?'M*@4A?",U^XS/$QC5[ M+[/EG0S4G,9QN"-Y3] D"O=+'O>2Q_];QO'[,D;1YQU->X*&M6XU^8/.JD 5 M;N!HDLI:F/8!]MY^IEVZ5M[Q+W#6M:/IE:8=E-=4%4QHPB%'RM'9.4I2[?!I M#2,WKG\?I,%IX)8ESFM0-@#W&PO=V]R:W-H965T; 6 Y%1+95>T0FSN&+-Y!36W,]V B.\LKD N4&\AF9QU?3%O&8U@MAD['Y)_.#FU(H2R0<'"Z: MW2PI,?TU[!W439CD7J.[%\&LW,L%XQ-<_*#=- ?'7X[Q7Y#] U!+ P04 M" "Y?'!6\B4P MG)ESD5.%0[$PY5( C4NA/#,=R_+-G*;,F([+;W=B.N8KE:4,[@21JSRGXOD& M,KZ9&+;Q\N$^722J^&!.QTNZ@ =0WY9W D=FHR5.% M0(GXGL)&[KR3@LHCY[^*P6T\,:S"(L@@4H4*BH\US"#+"DUHQ[^U4J-9LQ#< M?7_1_K$DCV0>J809SWZDL4HF1F"0&.9TE:E[OOD$-:'2P(AGLOPEFQIK&21: M2<7S6A@MR%-6/>E3[8@= <<_(.#4 LZI FXMX+8$;.^ @%<+>*5G*BJE'T*J MZ'0L^(:( HW:BI?2F:4TTD]9L>\/2N!LBG)J^@]70$;D@OP-Z#WY\D(^/&%D MX9.RF'Q1"0ARRZHH*W;K+ 1%TTR>(_[;0TC.WIV3=R1EY&O"5Q)EY-A4:%VQ MAAG5EMQ4EC@'++$=\IDSE4CR@<40[RLPD5;#S7GA=N/T:@PANB2N_9XXEN-H M#)J=+FYKQ,/3Q:T>-FZS4VZISSN@[V/**(N 9.7^T)P+E?Y7;0>?$U'$]P6? M7ZR*22E!:;>@6F)0+E$<"6MT.W);[WI%@_';W\;ID" M 5(1)#3?XYJE]#'-4I6"EE.EUM^UI4U) QFU&'4AS@%"@X;0X!4;!E5"Z0@, MNM:Y3HN!!N.W,&$7X]B6GH/?VD[H*< MT: %"C6@8##4D["M[:5IO28M)#G["52<:R^]?DVV1YY15.(=G%>WGQV0F#[K M3KK9,5V#6I=[7%?8KZLH-Z_DDD8P,;">E"#68$S__,/VK;]Z[C)[I^RP3S@< M3_-@KZ;3+:U]V&^7\QH7_B;#]EWH;%WHG!B$9UY=6J[?RKD#.*^==OVFO]4UVU+)/J56VD:7 MEG*E(M">T#5;5\^V?5#V6_-6MMO"R>ZOG.Z[M1_ACUB@,XP%+,KA*4HHPWC M I[PUHU^I+BJE]X[0+UA^RC6H=Q1^TKLI_%6-VW+,;N_'MOF2T1E0N;8\DHR M%SROR\TCX3(XH736@=HY%/:;^5HWF#N]7PYB4?;0DI1Y7[5*S=>F3[\NN]/6 M]YNB?R][RJV:JOG_3,4B91*=,T>5UN40"8BJGZX&BB_+#O.1*^Q7R]<$: RB M .#\G&.760^*!9I_-:;_ U!+ P04 " "Y?'!6*XZD384# #'#0 &0 M 'AL+W=OI VJ#9^O$"\<)-K:TCB/+;3CO^>8.94PYE+DIK9&&9;J,MTK@789V:O*!*R!# M7H"A+Y NT^GQ[ M29X_?4&>$I:13RM>2)K%W[YB9FIDZ/4Z?'*?UY#_A#-^Y+@IM&4,6R)4E*\F-86S]^Z4?OG?7$M4-K M9*Z;XCN#Z1U[(7,:P=C +2E!K,&8/'MB!]:K#A2W1G$?0_'ZH6S]!$T4R_=; M*)W!3D3Q:A3O,12_'XIW!"4(6BB=P4Y$\6L4_S&4H!^*?X#BA$'[ >L,=B)* M4*,$CZ&$_5""0Y3 '\GW';9>B,\*) M^@>U_D&G_IEVF2FRIDD!A,8_\"#1K^]^Y1D<\)T-+==K\74J.)%O6/,-N^O# M]9E4$I"$T3E+F&(@^^$-#\LW&-AA"V]X\#ZWAXZW+_(]W;:U/VZM3N57>[7D MVS6D M_D7O8>^;#[N[^[@"*;&?W68@YZ+LX5D6)46,V<*><9=A^A ;+\:MA/%\[+Q MGG.%;7PY7.&7%@B] .\O.#;?U43W\O6WV^0W4$L#!!0 ( +E\<%8E_+4Z M+0, +\) 9 >&PO=V]R:W-H965T*T:1O65H(R-*2Q(0K;P[0'-[VV%DZM< M 9L7HE3X81#T_)3QS!L/B[$;-1[*M1$\@QM%]#I-F7H^!R$W(X]Z+P.W?+DR M=L ?#W.VA"F8^_Q&8<^OO0./S&'!UL+XVO:T+A' MW7Q1S1>U\EUEB4R!&/:$BSMGSVPFP,47->8>T&"/KVGS1O)Z-5RO%:[8G"Z: M7F.FJ$'3M*%!%+N!^C50OQ7H3AHF7$#]YF2#07H1O/''#[07?'8=6O_) MV4Y.XCHGSCDE;>RF?DW'!5Y6B:X,+291I@% MJH*3/LI5>5LH.T;F1<&=28/ENVBN\(8%RAK@]X7$HEMU; VO[VSC?U!+ P04 M " "Y?'!6#K]/]LL$ ",'@ &0 'AL+W=O67;8KJ ME(H66T*F[LP83ZE4IWQNBR4'&NF@-+$]Q^G9*8TS:S30U^[Y:,!6,HDSN.=$ MK-*4\I<;2-AF:+G6]L)#/%_(_((]&BSI'!Y!/BWON3JS*TH4IY")F&6$PVQH M7;M7H=O+ W2)[S%LQ-XQR;LR8>QG?G(;#2TG;Q$D,)4Y@JJ?-8PA27*2:L=_ M)=2JZLP#]X^W]%!W7G5F0@6,6?)W',G%T.I;)((9727R@6W^A+)#W9PW98G0 M?\FF+.M89+H2DJ5EL&I!&F?%+WTN!V(OP.V\$>"5 =ZQ >TRH'T8T'LCH%,& M=(ZMH5L&=(\-Z)4!6J9=#)8>:9]*.AIPMB$\+ZUH^8'6I:/5 ,=9/K,>)5=W M8Q4G1U^9!.*ZY#-Y@#5+UG$V)V,.42S)]9P#J$DDR9D/DL:)(-_@6:YHSY\;QA52SQ6Z5'?E2T.C;XI*NKJ2/"&N1Y==QU$-7.][,38E MS\-70E4!0TLE6@%\#=;H]]_K]$B?W5>/J)O[/!1J M;,NI0C%A 28L1(+5A/8JH3VC4!\FDMQF0O)5_HJ^4*]FGI*S'T#Y>9,Y,ZU+ M7E1@TXMY; P\U24F+,"$A4BPFLO+RN6E^>%DV?RS]E=_3)54)FG2I-,(/+'O M8TR8?_DJ11QDA^#=$B%2@VHR^I6,OE'&/6=3@$B0&6=*2*Y&;M6(G9LF*4;P MJ5+ZKT:I(=/ZF%4&F+ 0"59S^*5R^.6TY'B;*8<@)'F@$B[(HU0_$;D'/E6W MU0=TDTUC%:?:+&"NNS_I6^J_[_Z!3\Q* TQ8B 2K^72=W5>J8S1:"0R>EY ) MY3!W;$B09MZI^E!I?DDSY#2RU.V$NH5M_V8NR!CEJ:QU,MY M(< [[[ZRUM>B#SVCKL:@T@)46HA%JWO>KZ,2UCKE:,46D^*BU MI858M+K:WI"=RLSKGDQY5?E MY%YS3FX?>D9=L4&E!:BT$(M6>+;W-M%2X'.]W2G(E*TR6>PK55>K+=5KO9%X M<-W/MUKUYMP.4^S3WE$^CS-!$I@II-.Z5!.5%UN?Q8ED2[U5-V%2LE0?+E06 M )X74/=GC,GM25Y!M0$]^A]02P,$% @ N7QP5A\MP@\, @ 1 0 !D M !X;"]W;W)K&ULC51=;]LP#/PKA-&'%NCBC[3; M4#@&FJ3#]K A:-KU6;&96*@L>1(=I_]^E.P&&= .?;%$B7>Z(R7GO;'/KD8D M.#1*NUE4$[4W<>S*&AOA)J9%S3M;8QM!'-I=[%J+H@J@1L59DGR.&R%U5.1A M;66+W'2DI,:5!=K/(?'Y(^"VQ=R=S\$XVQCS[X$ MB&7\&3FCXY$>>#I_9?\6O+.7C7"X,.I)5E3/HJ\15+@5G:)[TW_'T<^UYRN- MO4.(!L!V4H= MZE*B@_,EDI#*P0,>J!/J@A&/ZR6[T\= M_B]C,!&?]-B_KY_"[J1VH'#+F&3RA<%VN+-#0*8-;=\8XDL4IC4_<[0^@?>W MAEL_!OXF'7\&ULO59K;]HP%/TK5]DT;=)&WA Z0**D>WSH MAEJV?9CVP4TN)&IB,]L!)NW'STY"QB.@5JHJ(6([YQS?BPY9(U9TYXSF1:LH7IEAR)'%)RC/3L:RNF9.4&J-! MN3;EHP$K9)92G'(019X3_N<2,[8>&K:Q7;A)%XG4"^9HL"0+O$7Y;3GE:F8V M*G&:(Q4IH\!Q/C3&]D48:'P)^)[B6NR,03NY8^Q>3S['0\/2 6&&D=0*1%U6 M.,$LTT(JC-^UIM%LJ8F[XZWZA]*[\G)'!$Y8]B.-93(T @-BG),BDS=L_0EK M/[[6BU@FRG]8UUC+@*@0DN4U6460I[2ZDDV=AQV"W3U!<&J"RWDJN[J>+)T1DMS*@.Y+(*Q#D1B.W -:,R$7!%8XSW!4SEJK'F;*U= M.F<50XPZX-IOP;$9:GM]K8'N6O<:R]Q#+ CYHS^,%1U0O'"F ")@BC]08 MV!QF3))L6[YM7JM=@IWHK([G'CAM!?D'/EM!_7:7?N/2/^ORZQBFZO4,UX2J M]ZPV"#]SS.^0_VHSO7"[EKOVYZ IQ0+GTAL M+XG=)HG=YWPZND?UW.\%0>^@9(Y10=^W#@HK;$&YEG.B:'J-W]Y9O]]1(D^I M^E##S^NJ6. O/+*4SF[QV%)Z2K'PB<3V4ALTJ0V>LY2"H^/W^Y9U4$G'(,\[ M!(7'(#?8 55FS9U60$6Z*%LJ 1$KJ*P^GM5?51+)EV7#<,:G250X3U9$BUP!U?\Y4TU%/] 9- MCSOZ!U!+ P04 " "Y?'!63Y%XK*8# "0#@ &0 'AL+W=O61L2]Z\3Z?6UA7!#5D4DL0];&%6ZAK MK:3J^+<7M89G:N+^]9/ZKZUY9>:1"+AE]=]5+LNY%5LHAQ79U/*>[7Z'WE"@ M]3)6B_8OVO58;*%L(R1K>K*JH*EH]TF^]HW8(SCA"8+;$]PQP3]!\'J"]U*" MWQ/\MC.=E;8/*9%D,>-LA[A&*S5]T3:S92O[%=7O_4%R]6VE>'+Q@4E CHOOF'7J#*HK^+-E&*$4QLZ6J5C_3SOK*;KK*W!.5.2ZZ8U26 OU"<\@/ M!6QE<_#J/GF]<2<54\@ND>?\A%SLNH:";E].=PST].5T/.'&&]ZE!T/IP63I'Z_14NVHZ(Y0M34VVL7G M!II'X/^8/$R*Z7W]2JQ)!G-+;=P"^!:LQ8\_."'^V131=A-S &(AMJC,V0W.LH=O@Q']=T:0>,$ M&T&^V4,\>(@G/?S!*N5@V;W8;GO7._\]J'\YO%M_OCL=ZDGQ[PWU.<72,XD= M-#49FIJ\-M3)41 #[&-W%(=CE!\'<3S*PS'*2[PP-@?"P<]' 7R&6/&\09M0"71T09M0,4XQ"X( M+RHJ4 TK)8DO(]5;WHT_W4*R=3L0/#*IQHOVLE0C(W -4-^OF!H*^H5^P#"$ M+OX'4$L#!!0 ( +E\<%:2#[Q8C@, 'D. 9 >&PO=V]R:W-H965T M,_Q Q@$3/69J+D15+ MN;JP;1'%D%%QSE:0JSL+QC,JU9 O;;'B0.<%*4MMUW%\.Z-);HV'Q=P#'P_9 M6J9)#@\IEX3):QU!/V>+BB2YB ?%H]<#6R:Y5YDD$N M$I8C#HN1=8DO0DPTH4#\E!:TA3 MK:3B^%F)6O4S-7'_^D7]F9E1 ='D]W.MR0>AU)H><=T*N6 MQ)38DM@KB'H;V(QQSW>)/[0W^W8-,*_?#[PF+#3 B./U^C6L$;Y7A^]UAO\ M/()<(K90F\E!)Z7&8/_9+1/_BPB[$(W0>W7HO<[0G^YOIS"*Q1MK\.FW^6PO6?UUB.,"] M]EJ;8&1 2&O!#3"'X(%K7O5^'7[_! 7;?U5LSGF__>(90?V6"R,H,'L8U!X& MG1YNUESU#^B?.\AFP/\U&>@4^-W:/:58>"*Q1N*".G'!6VLW>%5MKN.3H+7D MKU$XZ VKFNCT*%9M2!?1?OM2ZXT\AW M&0/?M1U===RM]+N%?%*U\%1JS2RZNRRZ;RWFBMFH0-_SVAN8">:10?O+:X(1 M)_ /E,&N\\'=K<^1]4RZ:["R8D2UC72#2AOV7D^> 5\69QN!(K;.9=FDUK/U M^>FR.#6TYJ_TN:KH]7JA @ M@P< !D !X;"]W;W)K&ULK55K3]LP%/TK5QF: M0 +R:@-C;:32LJT20Q4MF_;136\;"\<.MMO"OY^=A"AEH6)2OR1^W'-RSKW. M=6\KY*-*$34\9XRKOI-JG5^YKDI2S(@Z%SERL[,4,B/:3.7*5;E$LBA &7,# MSXOE:OD0P53QA6\5Z#B1KI456@8V"C/+R39ZK/#0 ?N<=0% !@H\" MP@H0%D9+986M$=$D[DFQ!6FC#9L=%+DIT,8-Y;:*4RW-+C4X'=\)C>"'< ;W MN$&^1B!\ =]1K"3)4YK F)='Q>;\#.[,N9H1OJ)SAG K^.J,F2HL8* 4:@7S M%YA(RA.:$]8D&9@#IN!XA)I0IDX,T<-T!,=')W $E,,L%6MEOJMZKC:>K#(W MJ?1?E_J#=_2/,#F'T#^%P N"%OCPXW!_%^Z:3-;I#.IT!@5?YQV^B33_E]0O M11;Q:4US<^+U*7#4;=Y*LFY!9O^W3=RY#"Z^]-Q-TT)+U$7D!774CM*P5AKN M5?IP-Y[=C& Z&\QNIFW:]L)M<[E2.4FP[YCNH5!NT(D_?_(C[VM;%0Y$MN.T M4SOM'+(F)5FTDVTONGQ3DY:HJ!FUH[1;*^WN53J>#6[_M&G:"_O?6AR(;,=A M5#N,#EF+Z)^3[P>^_Z84+4'=L/.F$FZC1=KKZ2>1*\H5,%P:F'=^8?"R;/GE M1(N\Z)ISH4T/+H:IN251V@"SOQ2FS?^"U!+ P04 " "Y?'!6 M]I:.\(8/ #6Q &0 'AL+W=O*S<1"9?)"N6 M:3.TU!QWO2]N8HO\D6P._Z)X1/+D*8J_)U.E4O)C%H3)I]8T3>I,@T"X[<=KM_-//\L'5Z4GQW%9^>1(LT M\$-U%9-D,9MY\?.Y"J*G3RVG]?+%M?\P3?,OCDY/YMZ#NE'IU_E5G'TZ6E$F M_DR%B1^%)%;WGUIGSD?9'^09BA3??/64K/U.\J;<1='W_(.[L;^Z'N=AOTCB[ MZF?YTM//4:J(TR4?"/USX:?/1(9C%>8")%>!%Y)W(Y5Z?I"06_4C77C!^RSE MUYL1>??7]R=':5:!'',T+@L[7Q;FOE)8AUQ&83I-" TG:F+(?V'/[[@6P%'6 M\E7SW9?FG[M6XJ47'Y*.?:3&J^RN(?NH?G;'D)W6SVZJ/+-G M_QP]'I)V]]72>8U_.F?P:G91N_+.L2&[M&?_QR+,2N\4V0<6(716_:!3\+JO M\&ZF7JP^G&=AL5L/RV]7CJ..W\OY.C MQW69(0NE2!A#PC@2)I P"8)ITNVNI-NU2I?>WZMBR)#'[FBF"H5>>UE_E XL#LA3Y72'RBVB6"[J\\HDV]>L% FI5IK MV%2I/;,"-W2ZG:ICTNEV,G=H$BJR!1P)$TB8!,$TH?970NW_,J'R+$>JJ93' M49*0=]DW29X_,8Z8'OTSS7Q9IDGKAQ \?#LCGQ>Q.Q0?Y,UKVF9Q[V7/D6.W2O[6R3?4_V-*_ MT^NT!^W.1@/CC70463F&A'$D3"!A$@33M#U<:7MHU?95K&;^8O;A M*O;'F6SI;!Y$STJ1FS0:?W^1+?G7IR (I$L:0,(Z$"21,@F!:1W#:U<1U M^WQ%-)8ODC:"TBB4QJ T#J4)*$VB:+K(W4KD[KY'._3'W(^7F9:AG;S[ MI_)B&I/-&1_)S M%#ZJ),TNEUJ_B)(T^S;-A)46WL]#Z/]'35Y\G -R&Z5>8%0^U+5TMFW+0==D MZ$"+I5 :@](XE":@-(FBZ3JOW$O';E\"=5Y&^/LH?OFZ"/R6B _U,7,2KSU+&[IT6T7HYMIE$P M4;FHTT6W.=M-[7FLBT%])8XDC:"$JC4!J#TCB4)J TB:+I,J^L5Z>. M]_JF07[Q@WS+;A*YX;1[G _U6GV#@(U8W>TMU]V MD$Z=<1&R8A1*8U :A]($E"91-+V#5-ZN8S=W?[,7%^RU;=Q9AMNO)'2.G?YP M\]$9:@-#:0Q*XU":@-(DBJ;WA,H,=NQN\'4VXHG](J(OWVSXFCWQ)N3=]U6:=H:2IKTD M[)I> !Y!RZ50&H/2.)0FH#2)HNE"KXQ<]XU&[AZG/^U5:RQ\>T,;3']"ZT6A M- :E<2A-0&D21=,[1F7^NG7,WS<-\U=+6K-ATB*_D) OZ53%))UZH>WMGS^* M-=)YEWM4K^V_*V MLJ;[2MM&$4-=8G?;)>ZWC<.D[82=@6E!E2&A:USZ!VT(A]($E"91-%W+E;?K MVBW/3%?%?ASY-$JA5[M79:YLKKMSM5:];8=Q ZA]NKLEBT.IS*$U :1)%TT5?&;3N MWA?'[FM C5R2]KV@&13PMOIMB2\,PF#UIU#:0)*DRB:+M_*3W7M_J)E#$+^ MNPRB2\WE&]'8AR=06Q1*&T%I%$IC4!J'T@24)E$T7>J5,^K6<49-^[L8.L&E M\I)%G*7,0O?Y(LE024)NO?A!I:9)N7-[V8W5#UT3"Z51*(U!:1Q*$R5M?9UE M^W!CH"511>JBKDQ.]^>6O.X4-?/#[)+O!5950XU0=WO=:ONPU]L<0$ -3BB- M06D<2A-0FD31].WF*H.S4\?@1,CZH#"#SL937ST:=U4\MU>EJQM+ZBQA*%K5:$T"J4Q*(U# M:0)*DRB:+O7*KNS\W%K5O<1SJ)M8TO1XWM\,Y] EJ5 :@](XE":@-(FBZ1I? MVR.WCC4)>+ZL(7'L/KH=@\3=38G72$2A]6)0&H?2!)0F431=N941V;$;D3SF-=0FU**$T"J4Q*(U# M:0)*DRB:KO3*HNS4MRC?MI&Y8;-;T_ZT%_8*-18Q=$THE,:@- ZE"2A-HFBZ MB"O+L6.W'"^SN#Q;S-8?%A$;'ME+;1R\D;01E$:A- :E<2A-0&D21=-U7WF5 MG;VO_6RX%MI>H<9=PMZ\SNM;'D'K0:$T!J5Q*$U :1)%T^5?^9<=NW]I"/N8 M33#LY396.=2[A-(HE,:@- ZE"2A-HFBZ\BN3L[/_?7VUW7J7$RWEDF9CEX : MGQV#\;DYO0)U/:$T!J5Q*$U :1)%TT\JJES/KMWU-$3XZY]>Q&POJZF$H;01 ME$:A- :E<2A-0&D21=/57MF?W3IK.W_E<-Y>H<9=PMX\RW >6@\*I3$HC4-I M DJ3*)HN_\H2[=HM44.P;[@@R%Y 8SDC:2,HC4)I#$KC4)J TB2*IDN\([C'"0XW1'[>ZP9[?#/F:>WEYN8Y5##5HHC4)I#$KC4)J TB2*IBN_ M,FB[>S=H&\[3VRO4N$L,MN;IGJC_NJ-YM@$] MU):%TAB4QJ$T :5)%$V3?Z^R97MV6_9VJO+M+P;D*O#L4S-V4%/90FDC*(U" M:0Q*XU":@-(DBJ9+N?)<>W93:C6F>FZK\S6WM[/2MWN.HMT&L7YYM([-0\U:J&T$91& MH30&I7$H34!ILJ2M:[Z[L;V:KOS*@^WM?-75T :LR6-.T<&-->MB-H ML11*8U :A]($E"91-+T+5#YLS^[#_N*#LNVU:2QU>]ML!V5#*T*A- :E<2A- M0&D21=/%7YFQO1WGI!H?7LE_R>;[9T8I0WU5*&T$I5$HC4%I'$H34)I$T71U M5UYK[W<['M5>H<9=PMZ\Y:DP1O5#_58HC4%I'$H34)I$T73U5WYKS^ZWOA[; M-^PIHY"AUBF4-H+2*)3&H#0.I0DH3:)HNKHKC[7W<_OU[C&V0XW8'E HC4%I'$H34)I$T73Y5Z9KS^Y*+H.[ZQ 9YM/QA:QW&U!0WQ1*&T%I%$IC M4!J'T@24)E$T3=7]RDOMUS^Y]/\X'6FO9=-^4M*TV=OA9VHLWQ [(A3?W5V\&)_DK9'F!RT-*V2)=Q*HP M7.LX]7BW@\S0+W\/6"O7./N@:2-H#0*I3$HC?>W+6>3XRR@I4H431=^Y9SV:SBG MI.9HG1A&ZU;=YPJB MHFAZ1ZAV]GPQ.!@!8J M431=X)61VK<[C=>JP.9GCP*TGGV,HR @H_Q-XB+O?+6NSZA[J*D*I8V@- JE M,2B-E[2-HZLV50\U4%$T7?65@=JW&ZA8U:=3M?;P&_OCY83DVCOT+U>UA:[& M#@$U9Z&T$91&H30&I?'^]GK@]N&PM]DCH*8KBK;L$4?)5*ETY*7>Z287] 5$/EF05F.A5RRIZKTI M&P_I6F0I@2E#?)WGF+U>0T:W(\,VWC;NTV4BU(8Y'J[P$F8@'E=3)E=FQ1*G M.1">4H(8+$;&E7T9!BI>!_Q*8Z<3FD FKSYI1F=QUD9QS)#G;07>4B(2C M&Q)#O$]@2J657.=-[K73RAA"=(%<^PPYEN,T)#1Y/]QN@(?OAULM:MRJ>:[F M\X[P[38EVFT*%$UIJGC!V-.,ZDS8C&W/M7M#<[-;AH8HVQK4HL+#J)X[\*N@ M/4U>I5\LI5+&_+ ME N&]656VJ7]1&G]S$?]TB59V!'97GF#JKQ!YWX)&NZ/@1?4#',8%=AN_5 Y M#'*#GE=SC+DS >7 EGJ2Y#+=-1'%=%#M5L/JE9[1:OO7G'1 [BP%2 ?+^@&ULM9E=;Z,X%(;_BL6.5AVI$["!A'232&W3W>W%[%3MM*.] M=(F;H +.V$[2_ONU@4#XB >ZY*;EPWY]_& .[XDG.\I>^8H0 =ZB,.938R7$ M^L(TN;\B$>8#NB:QO/-"682%/&5+DZ\9P8ND4Q2:R+*&9H2#V)A-DFMW;#:A M&Q$&,;EC@&^B"+/W*Q+2W=2 QO["?;!<"77!G$W6>$D>B'A,2?7-/P1+,1J:G@&6) 7O G%/=W] M3;()N4K/IR%/_H)=UM8R@+_A@D999QE!%,3I?_R6@3CH@-PC'5#6 54Z0.=( M!SOK8+?MX&0=G(1,.I6$PQP+/)LPN@-,M99JZB"!F?26TP]B]=P?!)-W ]E/ MS/ZA@@#H@"_@YN?Q]13<$R90&;MX(\P-.$FP+&H:8<; F+$782# =;G1 T!X/W&&%GS:HKOQZ M$BOQ76UI?KVAX:5?!HQ^R*IR>Q$IYACF?8#L_QI77' M K_+ AO6%ACR!E:5H#:LK@1[$BL1'.4$1UJ">TZME]BHML2^.'8U?VG'[(JG M)[$2'B_'X[7%T]\2\VI+S!MX583:N+HB[$FLA'"<(QRW17BY7#*RQ-+OW,:" M!=*Z^N )AQO21"E5=0^_E5:%4;V);57:S.MMD'?0J#0E:!6>S=).2CK>%Q*H MU2 _;L#'TK*%[=^A3+ST$L&Q-_2[;C:=0U,J_E18U!M+7 M&"FEQ"R3MS7QU8F@8"LOM\V$J%YH-#L]?2A=P?6E5@97%!I(7VAHP?67'U&] MVFBRA_I@.Z,]1;6!BFH#Z:N-;F@_E#1_$4%[NZ@7Z@S^%"4.*DH'U6M28!YMM$6'+9-.2 Y]N8I%N1N57\XW1RV0[L'+]"E[, MT^W-0B;=;?V*V5)R!"%YD9+68"1QL70#,ST1=)ULZ3U3(6B4'*X(7A"F&LC[ M+Y2*_8D:(-]&GOT'4$L#!!0 ( +E\<%9*J8-S@P, $@- 9 >&PO M=V]R:W-H965TICV8Y+:U<.Q@NRW\_6PG9&WJAFXJ#S1VSCVYY_@ZN1ZMA'Q0AJ'*YE 0=21*X.;.5,B":#.4LU"5$DCN@@H6QE$T" M">3 9 MN;EK.1F)A6:4P[5$:E$41#Z? Q.K<8"#EXD;.IMK.Q%.1B69P2WH'^6U-*.P M8:-&B>:0/7KU_8/SOQ1LP]47 AV$^:Z_DX& 8HARE9,'TC5E^@ M%M2W?)E@ROU'JQH;!2A;*"V*.MAD4%!>_9*GVHBU #S8$1#7 7$[(-D1T*L# M>OL&)'5 XIRII#@?4J+)9"3%"DF+-FSVPIGIHHU\RNVZWVII[E(3IR??A :$ M$_0173XNJ'Y&7WD&W*X%NF:$F_DS96JBM(NDT \%.=("72I-C>> /A,JT1UA M"T!BBFZUR![0]QI,>%[/G)6F)C-*W$J[TE+H70J:4*;>CT)M=-ALPJS.^;S* M.=Z1,X[1E>!ZKM ESR'?) B- 8T+\8L+YW$G8PK9$>KA#RB.XMB3T,7^X=@3 MGNX?'G6HZ35KVG-\R0Z^RZ?2["JS4LJY7TJ: 5H*9OQG9HE]AE>$N*H2^ZY8 M3J*C*.F/PN6Z#15LV$)M@M)70!N2DD92LI^DG"YI#J:RGBFPW"9!I^8KRFFQ*-"O*RCN0?[VR>UDV#^_ MRI-#DJ4'(MMP[KAQ[KC3N1NJ'CY.)0"B7(/AUTB:%[//P&/O'L=QJQ N_+@H M/FD5S"X<]F_U8:-H>.BWU]"72;_7%N:';6T$+RP9K.$V=)TTNDZZ:YP\O5KC MG0S_6N.')$L/1+;A'([^-BG1H:J\9MKZE&V5>0UL?:=PJQAVT.'^B;\:\%KC MA0]=YS5CNX+-7UN;'SCH]=OR_, D&K3DA6LM9@%RYEIUA3*QX+KJLYK9YCAP MYIK@UORY/2:XUO4O377&N")R1DW?R&!J**.C8_-%DE7;7@VT*%TC>R^T:8O= MY=P<=4!:@+D_%::9K0?V GN0, %\0 M 9 >&PO=V]R:W-H965TS'L!2.=;2(2Z9*TW7[[D92B2+*BV86&O8E)ZN[/ MNY_.-"_3/>//8@T@T;TY3F07F%!K/C5K=WP^95N9$PIW'(EM46#^_1IRMI]9KO6R<$]6:ZD7 M[/ET@U?P /)Q<\?5S*Y5,E( %811Q&$YLZ[L_T?4"44:KV4Y<+\1?O*UK%0NA62%96SBJ @M/S$WRH0 M#0L/!JQR\KD/PAH-?.?C'.@250V#(E*D8#@LL\7S*V1YQ;:W4],# --XJ M?4+U>W^07#TERD_./S$)R W0.?KP=4OD=_21ID#UNT!W.:9J_1Z$Y"25D*$' MR=)G=*5?E38]6X#$)!?O^JP>*9$"G=T_/*KG?]U"\03\;V7X,[*16&,.8FI+ ME8 .PTZK8*_+8+TW@G4]=,NH7 OT@6:0M05LE7F=OO>2_K4WJ+B =()\]SWR M',_K">CF>'>WQWUQO+LSD(U?OTS?Z 5OZ'W>2B$QS0A=O:\@HS-"J^&[/N"E M8&0$]1FQFP>N%X7)U-XU,0SNJ\^F2['!*$:OBZ3OW(F[ M' >#.Y7C2&(MCAB54@S5(\]]U)]X@:CO=4N&.IM>DVKM#NV->N2K%9 M@U$F@Q4H95LJRRZD7JV[Y"O3&W;6KW7W;#JZ5YFR];[%?$6H0#DLE:0S MB=75AI?=;#F1;&/ZNRKQJHG>H/Z?POP?4$L#!!0 M ( +E\<%:\F$ZEJ0, $T0 9 >&PO=V]R:W-H965TUNM=U>^KY(M M9$0-Q ZX>;(6,B/:3.7&5SL))'5&&?-Q$,1^1BCW%C.WMI*+F=AK1CFL)%+[ M+"/RVS4P<9Q[H?>X\(%NMMHN^(O9CFS@#O3'W4J:F5^JI#0#KJC@2,)Z[KT- MKY8AM@9NQR<*1W4R1C:4>R$>[.1].O<"ZQ$P2+25(.;C #? F%4R?GPI1+WR M3&MX.GY4_]T%;X*Y)PIN!/N'IGH[]R8>2F%-]DQ_$,<_H0AH9/42P93[BX[% MWL!#R5YID17&QH.,\OR3?"U G!B$\3,&N## =8/H&8-A83#L:A 5!I$CDX?B M."R))HN9%$ M\P2X?1=HQ0@WZRN0+KW,.KK3(GE 'SG5"KU8@B:4J9?U/5LB0:%_;R&[!_G9 M//T5^4BYU9FOC<_V9#\I_+O._05@5\$VP9,7Z,^!JW M*BXA&:!A^ KA .,&AVZZFX<-YLONYD%+-,/R_0V=7O2,WM][K33A*>6;5P5D M](+R8OBR"7@N&#M!>RT<%N%H@J?CF7\XQ=!ZKKV.KM2.)##WS'VC0![ 6_SV M2Q@';YJ@]"160125B*+NB([N(H 4D0-(<[&AC21Q"I0XA)*W 7*#\BN^#R[\& TK(',=XU.=@75'CTGA.3 M3CG1ZMRE''L2JW";<&Z@#R%"6VQF"L>]I-S],.#Z.@]@6Y:?7A M4EP]B55PA<%311=\'[#>,[%PY#05HW PB6MLV_V]%&Y?:E6Z)_5RV'?!52A6 M*JYP/#FKN)KV-51FRW8/OY< ?B* ?V(]51Q>N=ZBP7129]6P[;SN6K:'&ULO59M;]HP$/XKIZS:6JDC+X2VZR!2*=W+!R;4KMMGDUR(5NWM.N:._%/)!%8@:'DO&U< KM*XN?5^E!99$=42% MW+S)A2R)-ETG?V28RZ8NY9I3C1(*:ER613T-D M8CGP0F]EN*6S0EN#G_0K,L,[U/?51)J;W[)DM$2NJ. @,1]X5^'EJ&?]G<,/ MBDNU=@9;R52(!WOYF@V\P":$#%-M&8AY+/ :&;-$)HU?#:?7AK3 ]?.*_9.K MW=0R)0JO!?M),UT,O L/,LS)G.E;L?R"33TNP50PY7YAV?@&'J1SI479@$T& M)>7UDSPV.JP!PK,]@*@!1-N > ^@VP"Z+P7$#2!VRM2E.!U&1).D+\42I/4V M;/;@Q'1H4S[EMNUW6IJWU.!T\DUHA+ '[^&FK)AX0H0AT)'48P%EP7 M"FYXAMDF@6_J:(N)5L4,HX.,(TP[T U/(0JB:$="UR^'ASO@HY?#@P/5=-O6 M=!U?O)3MF_ L^+A+O5LX2=LY;G[I:?VUXEBAG;@DI2&UF M]>AIK>V>NW+C?&PO=V]R:W-H965TWG>B_/X;6O!Q3\IAL3RIQ.*WWV(#HMGJB(,G@02"9Q3,1K#R*^:#O8>7OP2"=3 M91ZXG=:,3& (ZGGV(/2=6V@):0Q,4LZ0@'';Z>*KOE\S NF*KQ06>@()&*Q[FP]B"F+/M/ M7O) + GXVP3\7,!_)X#K6P1JN4 :.3?S+(4U((IT6H(OD#"KM39SD<8FE=9H M*#-I'"JAWU(MISJ_<@4(-]$INF4!CP$]D1>0Z&@ BM!(HB=X40F)CO6"Y^$ M'7TY1E\09>AIRA-)6"A;KM)N&&5ND)OL92;]+2:QC^XY4U.)KED(X:H"5_M? M@/#?0/1\J\8!!&>HAD^0[_G^!H?ZGQ?'%G=J14QKJ;[Z%GU],J.*1/0?"%&? M2R5/T"-(("*8(ATR-("Y;I^9;@:U*7J9\D:JW'3AO./7ZI[7?7WD5S!V2AP-JRJGIF @$]8 MFDG=&*@'#,;4)%27+F43U",180%LPM=82^/[%%J-[YG"9@&M:87VF_X.I)!, M?C:Y;Q?W/7QIVL5+>V9KWUF5[(GPO$!X;G5QH'YGM[@OHB7>@_^?S.N5Q>YA=/4% MA%2MA,A:)78_=RV3JK2M1M4OH^I76R>9NN92G:Q3';O-?3&5; [;Z=Q0$Z''Y)!)4AS8XAULQ6Q-'R*!R"\>&2\F$[K=HYL_6US-;P>FJM1O<% M5?([;"=XGTKM=S=X13POC]@A6",N:2/^D#?N5@;-M3)HK%?!(7@B+HDBMC/% M&R[T:9]M^1)L1%4I]:M*VRK\DOQA.S4;P!B$R$\X=Y2,:$05!7W(>=:''*D$ M'25*OWX+TS413!? YG1?K'WW-Z3[$(P/EY0/VSF?/=T5G OL]G>NCD,P/[]D M?KZ=^55R-OC !K:<#NRB^\(O::)OIXD?%LN]CH_ND5?$Q^@ZX(S'FE-VQV-" MA4RK1@?0C A.T*TBD7U;L?NR:^%4I6TURU>%H,[+OIF/K=\QZ^ZF=C]U)-]BO /1$3 MRB2*8*Q5>F?G&J#(!NO9C>*S=#8]XDKQ.+V< @E!F 7Z_9AS]79C#!0_;W3^ M U!+ P04 " "Y?'!6/7O8W?CLNB+? MDQJ+)W8@5(UL&:^Q5$V^<\6!$UPTI+IRD>=%;HU+ZBSG3=\S7\[9458E)<\< MB&-=8_[OBE3LO'"@<^GX7N[V4G>XR_D![\@+D3\.SURUW-Y*4=:$BI)1P,EV MX7R!GS,8:$*#^*LD9W'S#;0K&\9^ZL;78N%X6A&I2"ZU":S^3F1-JDI;4CK^ MZ8PZ_9R:>/M]L?Y;X[QR9H,%6;/J[[*0^X63.* @6WRLY'=V_IUT#H7:7LXJ MT?R"O^(KD:+15/+O]DD@ 8@1GX2G-6 M$_"*WXA0S36K#XP2*@5@V\O@BJA,NV P+< S9Z>RR0$U !Y6A))M*<&6L_KQ MWN)#1B0N*_&H;/]XR<##IT?P"904O.[942A;8NY*Y9"6Y>:=^%4K'HV(APA\ M8U3N!?B5%J2X-^"J2/3A0)=PK-"DQ8SD3\"'OP#D(601M'X_'5KHV?OIWH0W M?K^X?F,O&+.GPB]DF=LBVS+#AJD/A]-R!E,O4=.>;OVUP%"(TGM49D7%.H(G MB_R@EQ],RE<;6VU;:E/?$J.;"7T_,*0/,4$:1H;R(6B&4F]$>-@+#R>%/_S! MA$KTLLW_3;MINI;4N\'F4CA4 I,X, 2OAS 4H-CPRF(+)1$*[&Y%O5O1]'J0 M@G!=CPI^T5B26RBXV$H$U/S$#.+ M? .464 PC3V[[*27G7PT^Y/!?*F9)D,(C,PL&6*"U*XY[36GDYI?F<25*EN< MJ\)A4YX.9?F)J7T(0N:V'4)F,(Q&\AMZUV+H?33#.^;=E#X*?$.[#1:&!BJS MH6":C&0,O"GF\&.IWO'N)T3F:;BVP8)!\*W&O+%\A^BJ'GTTXSOFW91Q;)[X M5E1H'C$V%$I&Q%]++9RNM6WJJQLG4E7\_26+3,0L,QIYY*ME@0128)=F]N?/6A.^: MMX, .3M2V=[W^M[^??*EN94;_2O];FGNTE,*GNZ&UL ME9=OC]HX$,:_BA55NE8Z-K'SEPJ0MJ#3K=2K5J6]>VT2 ]8F-K4-+/?I;QS2 MP"9.U'L#<7AF\O,XX\?,SE*]Z#UC!KU6I=!S;V_,X:/OZWS/*JH?Y($)^&4K M544-#-7.UP?%:%$'5:5/@B#Q*\J%MYC5]Y[58B:/IN2"/2NDCU5%U>43*^5Y M[F'OYXVO?+*/2YS8@%KQ M-V=G?7>-[%0V4K[8P5,Q]P)+Q$J6&YN"PM>)+5E9VDS \:-)ZK7/M('WUS^S M_U%/'B:SH9HM9?D/+\Q^[F4>*MB6'DOS59[_9,V$8ILOEZ6N/]&YT08>RH_: MR*H)!H**B^LW?6T*<1> HX$ T@207PT(FX"PGNB5K)[6BAJZF"EY1LJJ(9N] MJ&M31\-LN+#+N#8*?N409Q9?I&$()VB"GD0N*X:^T5>F8;CF.\&W/*?"H*6L M#E(P8322VWI$Q>4WC59LRY1BA0U"CUHS$%!1H,^<;GC)#8=,[U?,4%[J#Y#S M^WJ%WK_[@-XA+M"WO3QJ4.N9;V B%L?/&^A/5V@R +UB^0,*\>^(!(0XPI>_ M'H[?AOM0OK:&I*TAJ?-% _D^,WB/4-E,^N*:SS5!7">PG75:I%&2S?S3/75? M!)JH%;UA"UNV<)1M20_!5!$1-ZU:O<35SD48]")).XPZI2Y01-VS< MPL:CL$_B!/T@U:6NJCJY"QD[GIR$'3R'*(I#-U[2XB7CRWY?/YKGZDA+%V#2 M>S9.PF[]'"(2)F[ M 5,1P&_@$.!%RD@%#M42JU13A64$YSI3)5[5TC[(''O MO>R+2$8&5CMK:;-16KN_Y;#1<>/DRGJ/3*,N5E\3!D-8TQ9K.HKU:!<6NJ5I M$"?;M-_+>-IAZVNB*7:CX>!F+,$H'+@L>*@ $P.+$/D%*/,]%3MG'S>YWJP: MZ9;0)1KJ8WQG@'B4LS4Q XM,:Q-S$N+^PT,<15W&O@RG:3I$>;,8/.XQC_F/ M(]?<]O-$L9(: .;"0#WYIF17;B-R 5@R. MESFO=R(G8-]')ED6].KJDL7!= #OYCEXW'3JO:'D[7#E1^W8R(1D.>\WDTJ53,E31F_/@<>NQ.WOQ?X"3 MWK%G$DVSM,OKD.$ QVF'U[\["]L_(G]1M>-"HY)M(3!X2"&#NI[MKP,C#_7Q M>",-'+;KRSW\'V+*"N#WK80C@>@T&M9\/IVM%.J>A]%=;J#DM:AJ(#K+[F0)56Z*;=1 M74F@F34JBXC$<1*5E/'1:FG?W7CRP M[4Z9%]%J6=$M/(+Z5MU+W8HZE8R5P&LF.)*0WXX^X/<;/#$&ML=W!H?ZY!D9 ME"F,3Q]?E/_9.$US!.M M82V*'RQ3N]O1?(0RR.F^4 _B\#>T0%.CEXJBMO_1H>T;CU"ZKY4H6V/M0FLU M\V GTUIK?,9-W!^5U%^9ME.K?X0"A!/T)_K,4U$"^DI?H=;-!T@%3UG!J(W/ M':@# $??PL<0?8(,)"W0HZ)JKX3\B1ZHEJ$\0Q_S'&PHFU?!!A1E1?UN&2GM MK1DS2EO/[AK/R(!GF* O@JM=C3[R#+)S@4AC=JSDC?6.>!4WD(9HC&\0B0EQ M.+2^WAP[S#?7F\<>FG$7N;'5FPSH'2<_;\/!F@@J^HJDGGS7E#>201?J,=-P,K]UJ+C:_1C )9VZG MUU.7TX2,>\&\H$\UQ0H+R'2I8R=0@M%\JF ]%:ITX(S5/ M%F=_O2E(?E_/[LC..M:9U\&_A,@.K-#;LJPHD_JN="[;F6?4;T$?-"C72.B%%GLPVU-?%8KI+UR9QYJ9S3H4UOE%8+\/ MP3@96NZ;N3/RRU=5]OCBE:5D 9V*,(+]\%!>M1^'P*R M< 2QH78/,%FXJ7%\3 UB[YCM-7_S!JJ1=:*I,ZEF(E()&5.U\V:/G2Y-^S?- M!0<",@\G ] #0Q R0'V2$&'OH-_UHFYR'EKHK)CRU'F3MBJ^=7QAH& \#<=# M=)=,P]B_HS$Y\A*OU@.HO=01%:B2XH79A)YF_^G4TRQH=WB)X_*/IWU\1Z_> MP>7M=B7E!UM(]=[?F5+3EC]'F:9._4+EEO$:%9!KR3B&UL?53+ M;MLP$/R5!4\)D%H/-TT1R )LQT5[2&'$?9QI:641X4,E5['[]R4I17&!)!>+ M2^[,SBR7+H[&/KH6D>"DI'8+UA)UMTGBJA85=S/3H?8GC;&*DP_M(7&=15Y' MD)))GJ:?$L6%9F41][:V+$Q/4FC<6G"]4MS^7:$TQP7+V//&@SBT%#:2LNCX M 7=(/[NM]5$RL=1"H7;":+#8+-@RNUW-0WY,^"7PZ,[6$)SLC7D,P;=ZP=(@ M""56%!BX_SSA&J4,1%[&GY&3324#\'S]S/XE>O=>]MSAVLC?HJ9VP3XSJ+'A MO:0'<_R*HY_KP%<9Z>(O',??8&(!\!>=0] M%(HJ[SCQLK#F"#9D>[:PB%8CVHL3.ES*CJP_%1Y'Y7=#"-G-!]APJX4^.-BB MA5W++<(%VVQW[!(N[I"XD Y^X(EZ+B_!A7,'0L.]D-)WUQ4)>36!,ZG&RJNA MZ.I=;#1-=;_$R3>QN0E?_:RRM]EO,-J!O/L"O(TST:-[]#.IQ;- M(^W'-VB7FD0M9!_&!W98]5:0\.XWITKV7CDTUBA8&]7UQ..HF>:5=E[!4IE> M$USXM@WB+E_KVB F2Z.:\*:>RFR6%H'N. @ ,0< !D !X;"]W;W)K M&ULC55=;]HP%/TK5IY::6L^H5,%D0IAVAXZH;*/ M9S>Y$*N.S6R'=/]^UTY(*0V4E_CKG.-[KN/K22/5LRX!#'FIN-!3KS1F>^?[ M.B^AHOI&;D'@REJJBAH_6OSCMZ>:(:YI+_884II]X7CQ2PIC4WC[+Y!IT?%V NN79?TG38P"-Y MK8VL.C)&4#'1MO2ER\,!(1R?($0=(3HF)"<(<4>(+R4D'2%QF6FMN#QDU-!T MHF1#E$6CFNVX9#HVVF?"'OO**%QER#/I#VF A+?D,UE0)9C8:+($158E54"N MO,5RY5WCXHQJEA,J"I(Q7ALH!N$9&,JXM@1M9_2^88+\+&6M44!/?(-QV]W] MO(MQUL88G8@QC,B#%*;49"$**-X*^&BX=QWM7<^BLXH9Y#LD)O?9PKC#);;JOAU+<2HR=A*T%NS1,1F.,?G?H M>PB5!$>H; @5V43N!EPDO8ODK(OV'[)WN""TH:K0'UE*WH41'-EYCXCB^,C, M.94W1D:]D=%9(_L;TOW[M36$1DP))*<\KSEU%4^N"=ZNCSR.+CJV(=0X3HZ< M#J'>'YM_4$PJ4!M7E#7)92U,>\/ZV;[NW[MR=S0_P_>@+=^O,NUC\D#5A@E- M.*Q1,KBYQI,$"Z+HEOFF@+ #7UQ++5C>P&_2O9/H?4$L# M!!0 ( +E\<%90NWZ91 , @4 - >&POSKYVN'$*@OZ_JP ME@6UL>_Q.??8OB%NAY5>"W:[8$P'JUS(:D066I[V.1V1;OR> M!$YN4J1L1.[/WOY8%OKJ3>#N)^].3CKWYU?[\3,+G)/0*WKY!-&+#JYK,$PZ MWI6VPT^-D".>8K3^DQP=,(0)#SQ^K-"?B(F7V)H+=!!RO^,G=]J)._4BAG4A MC(=9(;?U$!$7,/HT9\$#%2,RH8)/%0=61G,NUB[<@\"L$(4*M"E$D[ +D>J7 M@[NN!S5:Z^1<%LKF=AG<[VD]? _8], @%Z(QV",N,!Z65&NFY+7IV,$V^ @* MZO;=NC0.YXJNN[U+LB78FTDR+53*5).F2S:A\5"P#.PH/E_ 71=E"*#616X: M*:?S0E+K8<.H&T9VQH2XA0?X>[:CO,&B4/R7R0:E,C,!IDCPP)3FLW;DIZ+E'5OI33FM,MQS[P@]_]MUGC/)%!5M MTZ;V7_,J/]MQ_<9["<_V:V7?L==DU'_]'NNW_&LW&1^#R:/8[L$QF$R.P&3_ MQ;XU#YH,ZU-&ZRBSPN>IDP^.L\8>4VG MYL^<'7TS/F4970I]UX CLFU_92E?YDDSZ@86HAZU;7^!Z77CYK1JV&9B&R5I?0-A'KNWE1S".P_P(8%@>S '&<2PLS_\TGP$Z'X=AW@9> M9(!R!BC'L7S(Q'ZP/'Y.8B[_3),DBN(86]')Q.M@@JU;',./7PWS!@PL#V3Z MN[7&=QNOD,-U@.WIH0K!9HI7(C93?*T!\:\;,)+$O]M8'F!@NX#5#N3WYX&: M\G.B"'85\X8]P3B2)!@"M>BOT3A&5B>&CW]_L*-8?20$3;8T.P6BP^0"X99K>]9!:GU+.D^)CSA?VFU]K2/[ M3];]O+?VIWBN*],ELU5U,(J6!^Z4:W7Y8?=- M#WDK[YMA3ROOKR6 '(SR"5QPIEW3#F<,UY? ^*C@Y.56U]IS7;7*GM%,Q)& MUNI@M#I%')FI.#,M!$EM+1%D1D!F&X,\D8$9+Y>R$MH&44DML6E;#NG>KCCKM%& M-?BA*0C @@$P!L";KJZE>QGNL7XP&CXO38L@=PC('0;(!"!7L1,GMK[79GDF M8MPE&'<9&%-@/)?:B3M9=4I\4[*!N]Y_$K?A$ZH1GS!@9H!Y81[A3+"MP@&, M2,&LV3 #6PYL4%! 6P@2E+T/?W5Z\3Z$E&:B-7MFP"P \Z@$- >MSP74*^:A MQQ!'7C0IT41K-LV N0.87ZR=/NFJPF"47*(UVV4 VP6PK_!X^-E'Z21:LT^6 M3?5DN*^EZ^"VGCW#Y8!P2$.,20DE8C%*KY1K]6BK1ZA9Q0DDH8;J\<$IC$EI M)>+P2M2+!9KJ6K=+-_>!!&^W&F-28HDXS!(ERV@J VUVC_A%V08 ME&=B#L]$^2#!TM9*W,IGKQV*R5X,AUZB F(HG8&GNQ%7RD$_1D+YN/7'K\ZV M?Y]A5LHQ\9H=@RK%OM6T'>0DM$=74)>7?F$14\:).8P3*G)_Q!B3,E#,8:!@ MF8L-%%,&BCD,%*IT_6A2!HHY#/2NTA5;MQ(HFC\Q).6?F,,_H9+7CR7EGYC# M/Z&2U\-,*/\D'/[!)>]G]SNAU)-PJ.>M]OV4CY)/PB*?0!'LWVAR$(VC;Q,J MVWQ,RCL)AW="99N/27DG8>GYO*^'/LU-RCL)2\\G4!CYT:2\DVQR1.U'@C$I M\R0<_6,)_D4Q;*."R$QQ%P+#N\UB6C+)1Q6 AAOKY9#2I@ M3,I"&8>%/,SS;EBN\:U?G]9A3,I"&D+)2SC,B%AKJ\FTY9*-_HB!RV4$Y9*&<9D0MAXK(XIRR4LXS( MA3!QERTG%[>QC,B%QC>]W*0LE+.L10AA>KE)62AG68L0PO1RD[)0OLFU"%YN M%I2%"A8+A3 +C$E9J&"Q4 AS!V-2%BI8+!18V>')LJ L5+!8Z.-,QFMUC#$I M"Q4L%OJ .50B"V^]?T%9J-C,O-#VZP \QJ0L5+!8Z!/,:U5:@U>K%^1":Q8+ MA::OL"P+RD(%BX7Z\83P^B/,2JFH&%0T'DYN#O>GT%X8-;V$[VE@?RFK\LJ) M_F588!>G6;_(;M95U0GL^VZ^6CE=_1]G]5^BPW\!4$L#!!0 ( +E\<%:[ M2=+?8@( +0N : >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-VDMN MHT 4A>&M6"P@N.ZKG%:<44\R;64#R"D_%-L@H-7)[MMR!O9!/>A)Q!FA G'Y M1Y]0P=.O]H=N6'RW'L?M1U\-F7T[-\-!VY7RYLFW[4S-> MEOVN[IK->[,KM2R74??W,ZKGI_N9B]?/KOS/Q':[/6S*SW;S^U3.XS\&UW_: M_GW8ES)6B]>FWY5Q7=4?Q]OIH;X>TL-E5M7_?Z@%02MY@]ZA*#'^8/2$F5<$B1-L";0.B'7 MB<#KA& G K$3DIT(S$Z(=B)0.R';B<#MA' G KD3TIT([$Z(=R+06U!O(=!; M4&\AT%LF+]L$>@OJ+01Z"^HM!'H+ZBT$>@OJ+01Z"^HM!'H+ZBT$>@OJ+01Z M*^JM!'HKZJT$>BOJK01ZZV2SA$!O1;V50&]%O95 ;T6]E4!O1;V50&]%O95 M;T6]E4!O0[V-0&]#O8U ;T.]C4!O0[V-0&^;;'83Z&VHMQ'H;:BW$>AMJ+<1 MZ&VHMQ'H;:BW$>CMJ+<3Z.VHMQ/H[:BW$^CMJ+<3Z.VHMQ/H[9./E01Z.^KM M!'H[ZNT$>COJ[01Z.^KM!'H'ZAT$>@?J'01Z!^H=!'H'ZAT$>@?J'01Z!^H= M!'K'Y&<3 KT#]0X"O0/U#@*] _4. KTSZIT)],ZH=R;0.Z/>F4#OC'IG KTS MZIT)],ZH=R;0.Z/>F4#O//E9D$#OC'IG KTSZIV_4^]A_#R6X=;SM8;GK[Z3 MZO%R;[D]_KK\.HDXKZXXU_<5P_-?4$L#!!0 ( +E\<%;=)VL+& ( (4M M 3 6T-O;G1E;G1?5'EP97-=+GAM;,W:WT[;,!0&\%>I-6MOG._&1?E>]^O$4*"T.0S^F M=;7+.5PREIH=#2[5/M!85C8^#BZ7KW'+@FOV;DM,K%:&-7[,-.9EGFI4UU>W MM'$/?5[<'=]]"&5B47Z>-S+ M2*;3RU *4GC"T@?7T'ZX"N41E!$Y2BDG#=^)+/YG]?7_\&4$L! A0#% @ N7QP5@=!36*! ML0 ! ( ! &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4 M " "Y?'!6ZO&<:NX K @ $0 @ &O 9&]C4')O M<',O8V]R92YX;6Q02P$"% ,4 " "Y?'!6F5R<(Q & "<)P $P M @ ', 0 >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( +E\ M<%9*1+L"= < ,@P 8 " @0T( !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% M @ N7QP5M2J&#>H @ 0 D !@ ("!^Q4 'AL+W=O=0 & @(&O'@ >&PO M=V]R:W-H965T&UL4$L! A0#% @ N7QP5H&PO=V]R:W-H965T&UL4$L! A0#% @ N7QP5I3VB)S3"@ ZR< !@ M ("!^5$ 'AL+W=O&UL4$L! A0#% @ N7QP5B_^;9\! P 5P8 !D M ("!^&( 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ N7QP5FO.]22-!0 0T !D ("!3FX M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ MN7QP5AEPZ?SE @ 4 8 !D ("!B7P 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ N7QP5H7P/OA1" MS!4 !D ("!+H@ 'AL+W=O&PO=V]R:W-H965T;W@0< "$1 9 " @4Z3 !X;"]W;W)K&UL4$L! A0#% @ N7QP5H[Q_?U6 P 7 < !D M ("!!IL 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ N7QP5G8Y:KK&! NPT !D ("!DKX 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ N7QP M5CKI.[?, @ W 4 !D ("!$&PO=V]R:W-H965T&UL4$L! A0#% @ N7QP5H\,J]/N P ; D M !D ("!TM, 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ N7QP5A6W\C98!0 /@X !D M ("!#=\ 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ N7QP5AXC@J4L!0 T!H !D ("!?^T 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ N7QP5LN< M&*[L"0 )H !D ("!%/H 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ N7QP5F/U'N2Z P (A0 !D M ("!(@X! 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ N7QP5FEG#:+X P +!@ !D ("! MTAL! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ N7QP5E[A]TR. @ )P< !D ("!_20! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ N7QP5HT)4".> M! YAT !D ("!M"T! 'AL+W=O&PO=V]R:W-H965T$Y 0!X;"]W;W)K&UL4$L! A0#% @ N7QP5K#UU MU @ #08 !D M ("!/SX! 'AL+W=OP! 7! &0 @('K0 $ >&PO=V]R M:W-H965T&UL M4$L! A0#% @ N7QP5BN.I$V% P QPT !D ("!BT&PO=V]R:W-H965T 9 M " @:M. 0!X;"]W;W)K&UL4$L! A0#% @ MN7QP5A\MP@\, @ 1 0 !D ("!K5,! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ N7QP5I(/O%B. P M>0X !D ("!2ET! 'AL+W=O&PO=V]R:W-H965T=C 0!X;"]W;W)K&UL4$L! A0#% @ N7QP5I5171M% P Y@L !D M ("!I',! 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ N7QP5E!NUZ>Y P 7Q !D ("!*H ! 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ N7QP M5LYL_2[X! ZA@ !D ("!YHH! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ N7QP5OZA59HR! C \ M !D ("!1I@! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ N7QP5E"[?IE$ P "!0 T M ( !TJ$! 'AL+W-T>6QE&PO=V]R:V)O;VLN M>&UL4$L! A0#% @ N7QP5KM)TM]B @ M"X !H ( ! M):P! 'AL+U]R96QS+W=O XML 97 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 98 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 99 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 250 416 1 false 69 0 false 6 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets Sheet http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets Consolidated Balance Sheets Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets-parentheticals Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss) Sheet http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss Consolidated Statements of Operations and Comprehensive Income (Loss) Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-stockholders-equity Consolidated Statements of Stockholders' Equity Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Cash Flows Sheet http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 006 - Disclosure - Note 1 - Nature of Business Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-1-nature-of-business Note 1 - Nature of Business Notes 7 false false R8.htm 007 - Disclosure - Note 2 - Summary of Significant Accounting Policies Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies Note 2 - Summary of Significant Accounting Policies Notes 8 false false R9.htm 008 - Disclosure - Note 3 - Business Combinations Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations Note 3 - Business Combinations Notes 9 false false R10.htm 009 - Disclosure - Note 4 - Fair Value Measurements Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements Note 4 - Fair Value Measurements Notes 10 false false R11.htm 010 - Disclosure - Note 5 - Inventories Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-5-inventories Note 5 - Inventories Notes 11 false false R12.htm 011 - Disclosure - Note 6 - Property and Equipment Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment- Note 6 - Property and Equipment Notes 12 false false R13.htm 012 - Disclosure - Note 7 - Acquired Intangible Assets, Net Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net Note 7 - Acquired Intangible Assets, Net Notes 13 false false R14.htm 013 - Disclosure - Note 8 - Goodwill Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill Note 8 - Goodwill Notes 14 false false R15.htm 014 - Disclosure - Note 9 - Leases Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases Note 9 - Leases Notes 15 false false R16.htm 015 - Disclosure - Note 10 - Accrued Expenses and Other Liabilities Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities Note 10 - Accrued Expenses and Other Liabilities Notes 16 false false R17.htm 016 - Disclosure - Note 11 - Revolving Credit Agreement Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement Note 11 - Revolving Credit Agreement Notes 17 false false R18.htm 017 - Disclosure - Note 12 - Commitments and Contingencies Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-12-commitments-and-contingencies Note 12 - Commitments and Contingencies Notes 18 false false R19.htm 018 - Disclosure - Note 13 - Revenue and Geographic Information Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information Note 13 - Revenue and Geographic Information Notes 19 false false R20.htm 019 - Disclosure - Note 14 - Equity Incentive Plan Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan Note 14 - Equity Incentive Plan Notes 20 false false R21.htm 020 - Disclosure - Note 15 - Employee Benefit Plan Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-15-employee-benefit-plan- Note 15 - Employee Benefit Plan Notes 21 false false R22.htm 021 - Disclosure - Note 16 - Income Taxes Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes Note 16 - Income Taxes Notes 22 false false R23.htm 022 - Disclosure - Note 17- Earnings Per Share ("EPS") Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-17-earnings-per-share-eps Note 17- Earnings Per Share ("EPS") Notes 23 false false R24.htm 023 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.anikatherapeutics.com/20221231/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies 24 false false R25.htm 024 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables Note 2 - Summary of Significant Accounting Policies (Tables) Tables http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies 25 false false R26.htm 025 - Disclosure - Note 3 - Business Combinations (Tables) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-tables Note 3 - Business Combinations (Tables) Tables http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations 26 false false R27.htm 026 - Disclosure - Note 4 - Fair Value Measurements (Tables) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-tables Note 4 - Fair Value Measurements (Tables) Tables http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements 27 false false R28.htm 027 - Disclosure - Note 5 - Inventories (Tables) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-5-inventories-tables Note 5 - Inventories (Tables) Tables http://www.anikatherapeutics.com/20221231/role/statement-note-5-inventories 28 false false R29.htm 028 - Disclosure - Note 6 - Property and Equipment (Tables) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-tables Note 6 - Property and Equipment (Tables) Tables http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment- 29 false false R30.htm 029 - Disclosure - Note 7 - Acquired Intangible Assets, Net (Tables) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-tables Note 7 - Acquired Intangible Assets, Net (Tables) Tables http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net 30 false false R31.htm 030 - Disclosure - Note 8 - Goodwill (Tables) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill-tables Note 8 - Goodwill (Tables) Tables http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill 31 false false R32.htm 031 - Disclosure - Note 9 - Leases (Tables) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-tables Note 9 - Leases (Tables) Tables http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases 32 false false R33.htm 032 - Disclosure - Note 10 - Accrued Expenses and Other Liabilities (Tables) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities-tables Note 10 - Accrued Expenses and Other Liabilities (Tables) Tables http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities 33 false false R34.htm 033 - Disclosure - Note 13 - Revenue and Geographic Information (Tables) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-tables Note 13 - Revenue and Geographic Information (Tables) Tables http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information 34 false false R35.htm 034 - Disclosure - Note 14 - Equity Incentive Plan (Tables) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-tables Note 14 - Equity Incentive Plan (Tables) Tables http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan 35 false false R36.htm 035 - Disclosure - Note 16 - Income Taxes (Tables) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-tables Note 16 - Income Taxes (Tables) Tables http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes 36 false false R37.htm 036 - Disclosure - Note 17- Earnings Per Share ("EPS") (Tables) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-17-earnings-per-share-eps-tables Note 17- Earnings Per Share ("EPS") (Tables) Tables http://www.anikatherapeutics.com/20221231/role/statement-note-17-earnings-per-share-eps 37 false false R38.htm 037 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual Note 2 - Summary of Significant Accounting Policies (Details Textual) Details http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables 38 false false R39.htm 038 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Allowance for Doubtful Accounts (Details) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details Note 2 - Summary of Significant Accounting Policies - Allowance for Doubtful Accounts (Details) Details 39 false false R40.htm 039 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Details) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-property-and-equipment-details Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Details) Details 40 false false R41.htm 040 - Disclosure - Note 3 - Business Combinations (Details Textual) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-details-textual Note 3 - Business Combinations (Details Textual) Details http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-tables 41 false false R42.htm 041 - Disclosure - Note 3 - Business Combinations - Consideration Transferred (Details) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-consideration-transferred-details Note 3 - Business Combinations - Consideration Transferred (Details) Details 42 false false R43.htm 042 - Disclosure - Note 3 - Business Combinations - Fair Value of Net Assets Acquired (Details) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details Note 3 - Business Combinations - Fair Value of Net Assets Acquired (Details) Details 43 false false R44.htm 043 - Disclosure - Note 3 - Business Combinations - Intangible Assets Acquired (Details) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-intangible-assets-acquired-details Note 3 - Business Combinations - Intangible Assets Acquired (Details) Details 44 false false R45.htm 044 - Disclosure - Note 3 - Business Combinations - Pro Forma Information (Details) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-pro-forma-information-details Note 3 - Business Combinations - Pro Forma Information (Details) Details 45 false false R46.htm 045 - Disclosure - Note 4 - Fair Value Measurements (Details Textual) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-details-textual Note 4 - Fair Value Measurements (Details Textual) Details http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-tables 46 false false R47.htm 046 - Disclosure - Note 4 - Fair Value Measurements - Fair Value of Financial Instruments (Details) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details Note 4 - Fair Value Measurements - Fair Value of Financial Instruments (Details) Details 47 false false R48.htm 047 - Disclosure - Note 4 - Fair Value Measurements - Contingent Consideration (Details) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-contingent-consideration-details Note 4 - Fair Value Measurements - Contingent Consideration (Details) Details 48 false false R49.htm 048 - Disclosure - Note 5 - Inventories (Details Textual) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-5-inventories-details-textual Note 5 - Inventories (Details Textual) Details http://www.anikatherapeutics.com/20221231/role/statement-note-5-inventories-tables 49 false false R50.htm 049 - Disclosure - Note 5 - Inventories - Summary of Inventories (Details) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-5-inventories-summary-of-inventories-details Note 5 - Inventories - Summary of Inventories (Details) Details 50 false false R51.htm 050 - Disclosure - Note 6 - Property and Equipment (Details Textual) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-details-textual Note 6 - Property and Equipment (Details Textual) Details http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-tables 51 false false R52.htm 051 - Disclosure - Note 6 - Property and Equipment - Property and Equipment at Cost (Details) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-property-and-equipment-at-cost-details Note 6 - Property and Equipment - Property and Equipment at Cost (Details) Details 52 false false R53.htm 052 - Disclosure - Note 7 - Acquired Intangible Assets, Net (Details Textual) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-details-textual Note 7 - Acquired Intangible Assets, Net (Details Textual) Details http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-tables 53 false false R54.htm 053 - Disclosure - Note 7 - Acquired Intangible Assets, Net - Summary of Intangible Assets (Details) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-summary-of-intangible-assets-details Note 7 - Acquired Intangible Assets, Net - Summary of Intangible Assets (Details) Details 54 false false R55.htm 054 - Disclosure - Note 8 - Goodwill (Details Textual) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill-details-textual Note 8 - Goodwill (Details Textual) Details http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill-tables 55 false false R56.htm 055 - Disclosure - Note 8 - Goodwill - Changes in the Carrying Value of Goodwill (Details) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill-changes-in-the-carrying-value-of-goodwill-details Note 8 - Goodwill - Changes in the Carrying Value of Goodwill (Details) Details 56 false false R57.htm 056 - Disclosure - Note 9 - Leases (Details Textual) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-details-textual Note 9 - Leases (Details Textual) Details http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-tables 57 false false R58.htm 057 - Disclosure - Note 9 - Leases - Lease Expense and Other Information (Details) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-lease-expense-and-other-information-details Note 9 - Leases - Lease Expense and Other Information (Details) Details 58 false false R59.htm 058 - Disclosure - Note 9 - Leases - Future Minimum Rental Payments for Leases (Details) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-future-minimum-rental-payments-for-leases-details Note 9 - Leases - Future Minimum Rental Payments for Leases (Details) Details 59 false false R60.htm 059 - Disclosure - Note 10 - Accrued Expenses and Other Liabilities - Summary of Accrued Expenses (Details) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details Note 10 - Accrued Expenses and Other Liabilities - Summary of Accrued Expenses (Details) Details 60 false false R61.htm 060 - Disclosure - Note 11 - Revolving Credit Agreement (Details Textual) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement-details-textual Note 11 - Revolving Credit Agreement (Details Textual) Details http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement 61 false false R62.htm 061 - Disclosure - Note 12 - Commitments and Contingencies (Details Textual) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-12-commitments-and-contingencies-details-textual Note 12 - Commitments and Contingencies (Details Textual) Details http://www.anikatherapeutics.com/20221231/role/statement-note-12-commitments-and-contingencies 62 false false R63.htm 062 - Disclosure - Note 13 - Revenue and Geographic Information (Details Textual) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-details-textual Note 13 - Revenue and Geographic Information (Details Textual) Details http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-tables 63 false false R64.htm 063 - Disclosure - Note 13 - Revenue and Geographic Information - Disaggregated Revenues (Details) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-disaggregated-revenues-details Note 13 - Revenue and Geographic Information - Disaggregated Revenues (Details) Details 64 false false R65.htm 064 - Disclosure - Note 13 - Revenue and Geographic Information - Total Revenue by Geographic Location (Details) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-total-revenue-by-geographic-location-details Note 13 - Revenue and Geographic Information - Total Revenue by Geographic Location (Details) Details 65 false false R66.htm 065 - Disclosure - Note 13 - Revenue and Geographic Information - Net Tangible Long-lived Assets by Principal Geographic Areas (Details) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-net-tangible-longlived-assets-by-principal-geographic-areas-details Note 13 - Revenue and Geographic Information - Net Tangible Long-lived Assets by Principal Geographic Areas (Details) Details 66 false false R67.htm 066 - Disclosure - Note 14 - Equity Incentive Plan (Details Textual) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual Note 14 - Equity Incentive Plan (Details Textual) Details http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-tables 67 false false R68.htm 067 - Disclosure - Note 14 - Equity Incentive Plan - Total Stock-based Compensation Expense (Details) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-total-stockbased-compensation-expense-details Note 14 - Equity Incentive Plan - Total Stock-based Compensation Expense (Details) Details 68 false false R69.htm 068 - Disclosure - Note 14 - Equity Incentive Plan - Stock Options (Details) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-stock-options-details Note 14 - Equity Incentive Plan - Stock Options (Details) Details 69 false false R70.htm 069 - Disclosure - Note 14 - Equity Incentive Plan - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details Note 14 - Equity Incentive Plan - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details) Details 70 false false R71.htm 070 - Disclosure - Note 14 - Equity Incentive Plan - Restricted Stock Activity (Details) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-restricted-stock-activity-details Note 14 - Equity Incentive Plan - Restricted Stock Activity (Details) Details 71 false false R72.htm 071 - Disclosure - Note 14 - Equity Incentive Plan - Performance Stock Units (Details) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-performance-stock-units-details Note 14 - Equity Incentive Plan - Performance Stock Units (Details) Details 72 false false R73.htm 072 - Disclosure - Note 15 - Employee Benefit Plan (Details Textual) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-15-employee-benefit-plan-details-textual Note 15 - Employee Benefit Plan (Details Textual) Details http://www.anikatherapeutics.com/20221231/role/statement-note-15-employee-benefit-plan- 73 false false R74.htm 073 - Disclosure - Note 16 - Income Taxes (Details Textual) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-details-textual Note 16 - Income Taxes (Details Textual) Details http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-tables 74 false false R75.htm 074 - Disclosure - Note 16 - Income Taxes - Components of Income Before Taxes and Provision for (Benefit from) Income Taxes (Details) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-components-of-income-before-taxes-and-provision-for-benefit-from-income-taxes-details Note 16 - Income Taxes - Components of Income Before Taxes and Provision for (Benefit from) Income Taxes (Details) Details 75 false false R76.htm 075 - Disclosure - Note 16 - Income Taxes - Significant Components of Company's Deferred Tax Assets and Liabilities (Details) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details Note 16 - Income Taxes - Significant Components of Company's Deferred Tax Assets and Liabilities (Details) Details 76 false false R77.htm 076 - Disclosure - Note 16 - Income Taxes - Reconciliation Between U.S. Federal Statutory Rate and Effective Rate (Details) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-reconciliation-between-us-federal-statutory-rate-and-effective-rate-details Note 16 - Income Taxes - Reconciliation Between U.S. Federal Statutory Rate and Effective Rate (Details) Details 77 false false R78.htm 077 - Disclosure - Note 17- Earnings Per Share ("EPS") (Details Textual) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-17-earnings-per-share-eps-details-textual Note 17- Earnings Per Share ("EPS") (Details Textual) Details http://www.anikatherapeutics.com/20221231/role/statement-note-17-earnings-per-share-eps-tables 78 false false R79.htm 078 - Disclosure - Note 17 - Earnings Per Share ("EPS") - Basic and Diluted Earnings Per Share (Details) Sheet http://www.anikatherapeutics.com/20221231/role/statement-note-17-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details Note 17 - Earnings Per Share ("EPS") - Basic and Diluted Earnings Per Share (Details) Details 79 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 50 fact(s) appearing in ix:hidden were eligible for transformation: anik:EffectiveIncomeTaxRateReconciliationSharebasedCompensationWindfallTaxBenefitAmount, dei:CurrentFiscalYearEndDate, dei:EntityRegistrantName, us-gaap:AvailableForSaleSecuritiesDebtSecurities, us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent, us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:CommonStockSharesAuthorized, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:DebtInstrumentTerm, us-gaap:GoodwillImpairmentLoss, us-gaap:LineOfCredit, us-gaap:NumberOfOperatingSegments, us-gaap:PreferredStockParOrStatedValuePerShare, us-gaap:PreferredStockSharesAuthorized, us-gaap:PreferredStockSharesIssued, us-gaap:PreferredStockSharesOutstanding, us-gaap:ProductWarrantyAccrual, us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod - anik20221231_10k.htm 8, 10, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62 anik20221231_10k.htm anik-20221231.xsd anik-20221231_cal.xml anik-20221231_def.xml anik-20221231_lab.xml anik-20221231_pre.xml ex_487320.htm ex_487324.htm ex_487325.htm ex_487326.htm ex_487327.htm ex_489365.htm ex_489371.htm overview.jpg perf.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 102 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "anik20221231_10k.htm": { "axisCustom": 0, "axisStandard": 26, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 985, "http://xbrl.sec.gov/dei/2022": 36 }, "contextCount": 250, "dts": { "calculationLink": { "local": [ "anik-20221231_cal.xml" ] }, "definitionLink": { "local": [ "anik-20221231_def.xml" ] }, "inline": { "local": [ "anik20221231_10k.htm" ] }, "labelLink": { "local": [ "anik-20221231_lab.xml" ] }, "presentationLink": { "local": [ "anik-20221231_pre.xml" ] }, "schema": { "local": [ "anik-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 603, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 50, "http://www.anikatherapeutics.com/20221231": 1, "http://xbrl.sec.gov/dei/2022": 6, "total": 57 }, "keyCustom": 50, "keyStandard": 366, "memberCustom": 25, "memberStandard": 43, "nsprefix": "anik", "nsuri": "http://www.anikatherapeutics.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Note 4 - Fair Value Measurements", "menuCat": "Notes", "order": "10", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements", "shortName": "Note 4 - Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Note 5 - Inventories", "menuCat": "Notes", "order": "11", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-5-inventories", "shortName": "Note 5 - Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Note 6 - Property and Equipment", "menuCat": "Notes", "order": "12", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-", "shortName": "Note 6 - Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Note 7 - Acquired Intangible Assets, Net", "menuCat": "Notes", "order": "13", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net", "shortName": "Note 7 - Acquired Intangible Assets, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Note 8 - Goodwill", "menuCat": "Notes", "order": "14", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill", "shortName": "Note 8 - Goodwill", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "anik:LesseeOperatingLeasesAndFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Note 9 - Leases", "menuCat": "Notes", "order": "15", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases", "shortName": "Note 9 - Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "anik:LesseeOperatingLeasesAndFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Note 10 - Accrued Expenses and Other Liabilities", "menuCat": "Notes", "order": "16", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities", "shortName": "Note 10 - Accrued Expenses and Other Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Note 11 - Revolving Credit Agreement", "menuCat": "Notes", "order": "17", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement", "shortName": "Note 11 - Revolving Credit Agreement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Note 12 - Commitments and Contingencies", "menuCat": "Notes", "order": "18", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-12-commitments-and-contingencies", "shortName": "Note 12 - Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Note 13 - Revenue and Geographic Information", "menuCat": "Notes", "order": "19", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information", "shortName": "Note 13 - Revenue and Geographic Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Note 14 - Equity Incentive Plan", "menuCat": "Notes", "order": "20", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan", "shortName": "Note 14 - Equity Incentive Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Note 15 - Employee Benefit Plan", "menuCat": "Notes", "order": "21", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-15-employee-benefit-plan-", "shortName": "Note 15 - Employee Benefit Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Note 16 - Income Taxes", "menuCat": "Notes", "order": "22", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes", "shortName": "Note 16 - Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Note 17- Earnings Per Share (\"EPS\")", "menuCat": "Notes", "order": "23", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-17-earnings-per-share-eps", "shortName": "Note 17- Earnings Per Share (\"EPS\")", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "24", "role": "http://www.anikatherapeutics.com/20221231/role/statement-significant-accounting-policies-policies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "25", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "shortName": "Note 2 - Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Note 3 - Business Combinations (Tables)", "menuCat": "Tables", "order": "26", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-tables", "shortName": "Note 3 - Business Combinations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Note 4 - Fair Value Measurements (Tables)", "menuCat": "Tables", "order": "27", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-tables", "shortName": "Note 4 - Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Note 5 - Inventories (Tables)", "menuCat": "Tables", "order": "28", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-5-inventories-tables", "shortName": "Note 5 - Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Note 6 - Property and Equipment (Tables)", "menuCat": "Tables", "order": "29", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-tables", "shortName": "Note 6 - Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)", "menuCat": "Statements", "order": "3", "role": "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets-parentheticals", "shortName": "Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "anik:ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Note 7 - Acquired Intangible Assets, Net (Tables)", "menuCat": "Tables", "order": "30", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-tables", "shortName": "Note 7 - Acquired Intangible Assets, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "anik:ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Note 8 - Goodwill (Tables)", "menuCat": "Tables", "order": "31", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill-tables", "shortName": "Note 8 - Goodwill (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "anik:LesseeOperatingLeasesAndFinanceLeasesTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Note 9 - Leases (Tables)", "menuCat": "Tables", "order": "32", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-tables", "shortName": "Note 9 - Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "anik:LesseeOperatingLeasesAndFinanceLeasesTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Note 10 - Accrued Expenses and Other Liabilities (Tables)", "menuCat": "Tables", "order": "33", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities-tables", "shortName": "Note 10 - Accrued Expenses and Other Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Note 13 - Revenue and Geographic Information (Tables)", "menuCat": "Tables", "order": "34", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-tables", "shortName": "Note 13 - Revenue and Geographic Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Note 14 - Equity Incentive Plan (Tables)", "menuCat": "Tables", "order": "35", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-tables", "shortName": "Note 14 - Equity Incentive Plan (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Note 16 - Income Taxes (Tables)", "menuCat": "Tables", "order": "36", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-tables", "shortName": "Note 16 - Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Note 17- Earnings Per Share (\"EPS\") (Tables)", "menuCat": "Tables", "order": "37", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-17-earnings-per-share-eps-tables", "shortName": "Note 17- Earnings Per Share (\"EPS\") (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)", "menuCat": "Details", "order": "38", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "shortName": "Note 2 - Summary of Significant Accounting Policies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableGrossCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Allowance for Doubtful Accounts (Details)", "menuCat": "Details", "order": "39", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details", "shortName": "Note 2 - Summary of Significant Accounting Policies - Allowance for Doubtful Accounts (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableGrossCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)", "menuCat": "Statements", "order": "4", "role": "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss", "shortName": "Consolidated Statements of Operations and Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-4", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "anik:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentAndSoftwareMember_RangeAxis-MinimumMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Details)", "menuCat": "Details", "order": "40", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-property-and-equipment-details", "shortName": "Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "anik:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentAndSoftwareMember_RangeAxis-MinimumMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Note 3 - Business Combinations (Details Textual)", "menuCat": "Details", "order": "41", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-details-textual", "shortName": "Note 3 - Business Combinations (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2020-01-01_2020-03-31_BusinessAcquisitionAxis-ParcusMedicalMember", "decimals": "-5", "lang": null, "name": "us-gaap:BusinessCombinationAcquisitionRelatedCosts", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2020-01-24_2020-01-24_BusinessAcquisitionAxis-ParcusMedicalMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Note 3 - Business Combinations - Consideration Transferred (Details)", "menuCat": "Details", "order": "42", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-consideration-transferred-details", "shortName": "Note 3 - Business Combinations - Consideration Transferred (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2020-01-24_2020-01-24_BusinessAcquisitionAxis-ParcusMedicalMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Note 3 - Business Combinations - Fair Value of Net Assets Acquired (Details)", "menuCat": "Details", "order": "43", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details", "shortName": "Note 3 - Business Combinations - Fair Value of Net Assets Acquired (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2020-01-24_BusinessAcquisitionAxis-ParcusMedicalMember", "decimals": "-3", "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2020-01-24_BusinessAcquisitionAxis-ParcusMedicalMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Note 3 - Business Combinations - Intangible Assets Acquired (Details)", "menuCat": "Details", "order": "44", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-intangible-assets-acquired-details", "shortName": "Note 3 - Business Combinations - Intangible Assets Acquired (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2020-01-24_BusinessAcquisitionAxis-ParcusMedicalMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Note 3 - Business Combinations - Pro Forma Information (Details)", "menuCat": "Details", "order": "45", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-pro-forma-information-details", "shortName": "Note 3 - Business Combinations - Pro Forma Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2020-01-01_2020-12-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Note 4 - Fair Value Measurements (Details Textual)", "menuCat": "Details", "order": "46", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-details-textual", "shortName": "Note 4 - Fair Value Measurements (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_BusinessAcquisitionAxis-ParcusMedicalAndArthrosurfaceAcquisitionsMember", "decimals": "-8", "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "046 - Disclosure - Note 4 - Fair Value Measurements - Fair Value of Financial Instruments (Details)", "menuCat": "Details", "order": "47", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details", "shortName": "Note 4 - Fair Value Measurements - Fair Value of Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2021-12-31_FairValueByMeasurementBasisAxis-EstimateOfFairValueFairValueDisclosureMember", "decimals": "-3", "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2021-12-31_FairValueByLiabilityClassAxis-ContingentConsiderationMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "047 - Disclosure - Note 4 - Fair Value Measurements - Contingent Consideration (Details)", "menuCat": "Details", "order": "48", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-contingent-consideration-details", "shortName": "Note 4 - Fair Value Measurements - Contingent Consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2020-12-31_FairValueByLiabilityClassAxis-ContingentConsiderationMember", "decimals": "-4", "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InventoryValuationReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "048 - Disclosure - Note 5 - Inventories (Details Textual)", "menuCat": "Details", "order": "49", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-5-inventories-details-textual", "shortName": "Note 5 - Inventories (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InventoryValuationReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Consolidated Statements of Stockholders' Equity", "menuCat": "Statements", "order": "5", "role": "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-stockholders-equity", "shortName": "Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "049 - Disclosure - Note 5 - Inventories - Summary of Inventories (Details)", "menuCat": "Details", "order": "50", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-5-inventories-summary-of-inventories-details", "shortName": "Note 5 - Inventories - Summary of Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "050 - Disclosure - Note 6 - Property and Equipment (Details Textual)", "menuCat": "Details", "order": "51", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-details-textual", "shortName": "Note 6 - Property and Equipment (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "051 - Disclosure - Note 6 - Property and Equipment - Property and Equipment at Cost (Details)", "menuCat": "Details", "order": "52", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-property-and-equipment-at-cost-details", "shortName": "Note 6 - Property and Equipment - Property and Equipment at Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "052 - Disclosure - Note 7 - Acquired Intangible Assets, Net (Details Textual)", "menuCat": "Details", "order": "53", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-details-textual", "shortName": "Note 7 - Acquired Intangible Assets, Net (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "anik:ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "053 - Disclosure - Note 7 - Acquired Intangible Assets, Net - Summary of Intangible Assets (Details)", "menuCat": "Details", "order": "54", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-summary-of-intangible-assets-details", "shortName": "Note 7 - Acquired Intangible Assets, Net - Summary of Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "anik:ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportingUnits", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "054 - Disclosure - Note 8 - Goodwill (Details Textual)", "menuCat": "Details", "order": "55", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill-details-textual", "shortName": "Note 8 - Goodwill (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:GoodwillDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_ReportingUnitAxis-ParcusMedicalAndArthrosurfaceMember", "decimals": "INF", "lang": null, "name": "us-gaap:NumberOfReportingUnits", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "055 - Disclosure - Note 8 - Goodwill - Changes in the Carrying Value of Goodwill (Details)", "menuCat": "Details", "order": "56", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill-changes-in-the-carrying-value-of-goodwill-details", "shortName": "Note 8 - Goodwill - Changes in the Carrying Value of Goodwill (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "anik:LesseeOperatingLeasesAndFinanceLeasesTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "056 - Disclosure - Note 9 - Leases (Details Textual)", "menuCat": "Details", "order": "57", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-details-textual", "shortName": "Note 9 - Leases (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R58": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "anik:LesseeOperatingLeasesAndFinanceLeasesTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "057 - Disclosure - Note 9 - Leases - Lease Expense and Other Information (Details)", "menuCat": "Details", "order": "58", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-lease-expense-and-other-information-details", "shortName": "Note 9 - Leases - Lease Expense and Other Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "anik:LesseeOperatingLeasesAndFinanceLeasesTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "anik:LesseeOperatingLeaseAndFinanceLeaseLiabilityMaturityTableTextBlock", "anik:LesseeOperatingLeasesAndFinanceLeasesTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "058 - Disclosure - Note 9 - Leases - Future Minimum Rental Payments for Leases (Details)", "menuCat": "Details", "order": "59", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-future-minimum-rental-payments-for-leases-details", "shortName": "Note 9 - Leases - Future Minimum Rental Payments for Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "anik:LesseeOperatingLeaseAndFinanceLeaseLiabilityMaturityTableTextBlock", "anik:LesseeOperatingLeasesAndFinanceLeasesTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "6", "role": "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "059 - Disclosure - Note 10 - Accrued Expenses and Other Liabilities - Summary of Accrued Expenses (Details)", "menuCat": "Details", "order": "60", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details", "shortName": "Note 10 - Accrued Expenses and Other Liabilities - Summary of Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2021-11-12_CreditFacilityAxis-RevolvingCreditFacilityMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060 - Disclosure - Note 11 - Revolving Credit Agreement (Details Textual)", "menuCat": "Details", "order": "61", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement-details-textual", "shortName": "Note 11 - Revolving Credit Agreement (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2021-11-12_CreditFacilityAxis-RevolvingCreditFacilityMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061 - Disclosure - Note 12 - Commitments and Contingencies (Details Textual)", "menuCat": "Details", "order": "62", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-12-commitments-and-contingencies-details-textual", "shortName": "Note 12 - Commitments and Contingencies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "062 - Disclosure - Note 13 - Revenue and Geographic Information (Details Textual)", "menuCat": "Details", "order": "63", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-details-textual", "shortName": "Note 13 - Revenue and Geographic Information (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "2", "lang": null, "name": "anik:RevenuesFromAgreementsAsPercentOfTotalRevenue", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "063 - Disclosure - Note 13 - Revenue and Geographic Information - Disaggregated Revenues (Details)", "menuCat": "Details", "order": "64", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-disaggregated-revenues-details", "shortName": "Note 13 - Revenue and Geographic Information - Disaggregated Revenues (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_ProductOrServiceAxis-OAPainManagementMember", "decimals": "2", "lang": null, "name": "anik:PercentageOfNetRevenue", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "064 - Disclosure - Note 13 - Revenue and Geographic Information - Total Revenue by Geographic Location (Details)", "menuCat": "Details", "order": "65", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-total-revenue-by-geographic-location-details", "shortName": "Note 13 - Revenue and Geographic Information - Total Revenue by Geographic Location (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "anik:ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_StatementGeographicalAxis-US", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentNet", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "065 - Disclosure - Note 13 - Revenue and Geographic Information - Net Tangible Long-lived Assets by Principal Geographic Areas (Details)", "menuCat": "Details", "order": "66", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-net-tangible-longlived-assets-by-principal-geographic-areas-details", "shortName": "Note 13 - Revenue and Geographic Information - Net Tangible Long-lived Assets by Principal Geographic Areas (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2022-12-31_StatementGeographicalAxis-US", "decimals": "-3", "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "066 - Disclosure - Note 14 - Equity Incentive Plan (Details Textual)", "menuCat": "Details", "order": "67", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual", "shortName": "Note 14 - Equity Incentive Plan (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "067 - Disclosure - Note 14 - Equity Incentive Plan - Total Stock-based Compensation Expense (Details)", "menuCat": "Details", "order": "68", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-total-stockbased-compensation-expense-details", "shortName": "Note 14 - Equity Incentive Plan - Total Stock-based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "068 - Disclosure - Note 14 - Equity Incentive Plan - Stock Options (Details)", "menuCat": "Details", "order": "69", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-stock-options-details", "shortName": "Note 14 - Equity Incentive Plan - Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2021-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "006 - Disclosure - Note 1 - Nature of Business", "menuCat": "Notes", "order": "7", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-1-nature-of-business", "shortName": "Note 1 - Nature of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "069 - Disclosure - Note 14 - Equity Incentive Plan - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details)", "menuCat": "Details", "order": "70", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details", "shortName": "Note 14 - Equity Incentive Plan - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "070 - Disclosure - Note 14 - Equity Incentive Plan - Restricted Stock Activity (Details)", "menuCat": "Details", "order": "71", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-restricted-stock-activity-details", "shortName": "Note 14 - Equity Incentive Plan - Restricted Stock Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2021-12-31_AwardTypeAxis-PerformanceSharesMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "071 - Disclosure - Note 14 - Equity Incentive Plan - Performance Stock Units (Details)", "menuCat": "Details", "order": "72", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-performance-stock-units-details", "shortName": "Note 14 - Equity Incentive Plan - Performance Stock Units (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31_AwardTypeAxis-PerformanceSharesMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "1", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "072 - Disclosure - Note 15 - Employee Benefit Plan (Details Textual)", "menuCat": "Details", "order": "73", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-15-employee-benefit-plan-details-textual", "shortName": "Note 15 - Employee Benefit Plan (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "1", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-5", "first": true, "lang": null, "name": "anik:CapitalizedCostsResearchAndDevelopment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "073 - Disclosure - Note 16 - Income Taxes (Details Textual)", "menuCat": "Details", "order": "74", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-details-textual", "shortName": "Note 16 - Income Taxes (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-5", "first": true, "lang": null, "name": "anik:CapitalizedCostsResearchAndDevelopment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "074 - Disclosure - Note 16 - Income Taxes - Components of Income Before Taxes and Provision for (Benefit from) Income Taxes (Details)", "menuCat": "Details", "order": "75", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-components-of-income-before-taxes-and-provision-for-benefit-from-income-taxes-details", "shortName": "Note 16 - Income Taxes - Components of Income Before Taxes and Provision for (Benefit from) Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-4", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "anik:DeferredTaxAssetsLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "075 - Disclosure - Note 16 - Income Taxes - Significant Components of Company's Deferred Tax Assets and Liabilities (Details)", "menuCat": "Details", "order": "76", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details", "shortName": "Note 16 - Income Taxes - Significant Components of Company's Deferred Tax Assets and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "i_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "anik:DeferredTaxAssetsLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "076 - Disclosure - Note 16 - Income Taxes - Reconciliation Between U.S. Federal Statutory Rate and Effective Rate (Details)", "menuCat": "Details", "order": "77", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-reconciliation-between-us-federal-statutory-rate-and-effective-rate-details", "shortName": "Note 16 - Income Taxes - Reconciliation Between U.S. Federal Statutory Rate and Effective Rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "077 - Disclosure - Note 17- Earnings Per Share (\"EPS\") (Details Textual)", "menuCat": "Details", "order": "78", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-17-earnings-per-share-eps-details-textual", "shortName": "Note 17- Earnings Per Share (\"EPS\") (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2021-01-01_2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "078 - Disclosure - Note 17 - Earnings Per Share (\"EPS\") - Basic and Diluted Earnings Per Share (Details)", "menuCat": "Details", "order": "79", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-17-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details", "shortName": "Note 17 - Earnings Per Share (\"EPS\") - Basic and Diluted Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": "-3", "lang": null, "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Note 2 - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "8", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "shortName": "Note 2 - Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Note 3 - Business Combinations", "menuCat": "Notes", "order": "9", "role": "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations", "shortName": "Note 3 - Business Combinations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "anik20221231_10k.htm", "contextRef": "d_2022-01-01_2022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 69, "tag": { "anik_APICSharebasedPaymentArrangementIncreaseDecreaseForCostRecognitionBenefit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) to additional paid-in capital (APIC) for recognition of cost (benefit) for award under share-based payment arrangement.", "label": "anik_APICSharebasedPaymentArrangementIncreaseDecreaseForCostRecognitionBenefit", "terseLabel": "Stock-based compensation expense" } } }, "localname": "APICSharebasedPaymentArrangementIncreaseDecreaseForCostRecognitionBenefit", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "anik_AccruedClinicalTrialCostsCurrent": { "auth_ref": [], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents accrued clinical trial costs current.", "label": "anik_AccruedClinicalTrialCostsCurrent", "verboseLabel": "Clinical trial costs" } } }, "localname": "AccruedClinicalTrialCostsCurrent", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "anik_AccruedExpensesAndOtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to accrued expenses and other current liabilities.", "label": "Accrued Expenses and Other Current Liabilities [Member]" } } }, "localname": "AccruedExpensesAndOtherCurrentLiabilitiesMember", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-future-minimum-rental-payments-for-leases-details" ], "xbrltype": "domainItemType" }, "anik_AccumulatedCurrencyTranslationAdjustment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of the accumulated currency translation adjustment.", "label": "anik_AccumulatedCurrencyTranslationAdjustment", "negatedLabel": "Accumulated Currency Translation Adjustment" } } }, "localname": "AccumulatedCurrencyTranslationAdjustment", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-summary-of-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "anik_AcquisitionRelatedContingentConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of acquisition related contingent consideration.", "label": "Contingent consideration fair value on acquisition date" } } }, "localname": "AcquisitionRelatedContingentConsideration", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "anik_AcquisitionsOfParcusMedicalAndArthrosurfaceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents acquisitions of Parcus Medical and Arthrosurface.", "label": "Acquisitions of Parcus Medical and Arthrosurface [Member]" } } }, "localname": "AcquisitionsOfParcusMedicalAndArthrosurfaceMember", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-details-textual" ], "xbrltype": "domainItemType" }, "anik_AllowanceForDoubtfulAccountsReceivableTranslationAdjustments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of translation adjustments affecting the allowance for doubtful accounts receivable.", "label": "Translation adjustments" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableTranslationAdjustments", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details" ], "xbrltype": "monetaryItemType" }, "anik_AmortizationOfAcquisitionRelatedIntangibleAssets": { "auth_ref": [], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expenses related to the acquisition related intangible assets.", "label": "Amortization of acquisition related intangible assets" } } }, "localname": "AmortizationOfAcquisitionRelatedIntangibleAssets", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "anik_AmortizationOfAcquisitionRelatedInventoryStepUp": { "auth_ref": [], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expenses related to the acquisition inventory step-up.", "label": "Amortization of acquisition related inventory step-up" } } }, "localname": "AmortizationOfAcquisitionRelatedInventoryStepUp", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "anik_ArthrosurfaceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to Arthrosurface.", "label": "Arthrosurface [Member]" } } }, "localname": "ArthrosurfaceMember", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-consideration-transferred-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-intangible-assets-acquired-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "anik_BusinessCombinationConsiderationTransferredDeferredConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred consideration by the acquirer as part of consideration transferred in a business combination.", "label": "Deferred consideration" } } }, "localname": "BusinessCombinationConsiderationTransferredDeferredConsideration", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-consideration-transferred-details" ], "xbrltype": "monetaryItemType" }, "anik_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease, right of use assets acquired at the acquisition date.", "label": "anik_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets", "verboseLabel": "Right-of-use assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details" ], "xbrltype": "monetaryItemType" }, "anik_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease right-of-use liabilities assumed at the acquisition date.", "label": "anik_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseLiabilities", "negatedLabel": "Lease liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseLiabilities", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details" ], "xbrltype": "monetaryItemType" }, "anik_CapitalizedCostsResearchAndDevelopment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represent the capitalization of research and development.", "label": "anik_CapitalizedCostsResearchAndDevelopment", "terseLabel": "Capitalized Costs, Research and Development" } } }, "localname": "CapitalizedCostsResearchAndDevelopment", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "anik_CashEquivalentsFairValueDisclosure": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the fair value disclosure for cash equivalents as of the balance sheet date.", "label": "anik_CashEquivalentsFairValueDisclosure", "verboseLabel": "Cash equivalents" } } }, "localname": "CashEquivalentsFairValueDisclosure", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details" ], "xbrltype": "monetaryItemType" }, "anik_ComputerEquipmentAndSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to computer equipment and software.", "label": "Computer Equipment and Software [Member]" } } }, "localname": "ComputerEquipmentAndSoftwareMember", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "anik_ConsiderationForAcquisitionsIncludedInAccountsPayableAndAccruedExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration for acquisitions included in accounts payable and accrued expenses.", "label": "Consideration for acquisitions included in accounts payable and accrued expenses" } } }, "localname": "ConsiderationForAcquisitionsIncludedInAccountsPayableAndAccruedExpenses", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "anik_ContingentConsiderationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to the contingent consideration.", "label": "Contingent Consideration [Member]" } } }, "localname": "ContingentConsiderationMember", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-contingent-consideration-details" ], "xbrltype": "domainItemType" }, "anik_DeferredIncomeTaxExpenseBenefitForeignAndDomesticNet": { "auth_ref": [], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-components-of-income-before-taxes-and-provision-for-benefit-from-income-taxes-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of global net deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "anik_DeferredIncomeTaxExpenseBenefitForeignAndDomesticNet", "totalLabel": "Total deferred" } } }, "localname": "DeferredIncomeTaxExpenseBenefitForeignAndDomesticNet", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-components-of-income-before-taxes-and-provision-for-benefit-from-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "anik_DeferredTaxAssetsCapitalizedResearchExpenditures": { "auth_ref": [], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research expenditures.", "label": "anik_DeferredTaxAssetsCapitalizedResearchExpenditures", "terseLabel": "Capitalized research expenditures" } } }, "localname": "DeferredTaxAssetsCapitalizedResearchExpenditures", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "anik_DeferredTaxAssetsLeaseLiability": { "auth_ref": [], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liability.", "label": "Lease liability" } } }, "localname": "DeferredTaxAssetsLeaseLiability", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "anik_DeferredTaxLiabilitiesRightOfUseAsset": { "auth_ref": [], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from right of use asset.", "label": "anik_DeferredTaxLiabilitiesRightOfUseAsset", "negatedLabel": "Right of use asset" } } }, "localname": "DeferredTaxLiabilitiesRightOfUseAsset", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "anik_DefinedContributionPlanEmployerMatchingContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of employer matching contributions made by an employer to a defined contribution plan.", "label": "anik_DefinedContributionPlanEmployerMatchingContributionAmount", "terseLabel": "Defined Contribution Plan, Employer Matching Contribution, Amount" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionAmount", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-15-employee-benefit-plan-details-textual" ], "xbrltype": "monetaryItemType" }, "anik_DepuyMitekIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The DePuy Mitek Inc.", "label": "DePuy Mitek Inc [Member]" } } }, "localname": "DepuyMitekIncMember", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "anik_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentConsiderationPercent": { "auth_ref": [], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-reconciliation-between-us-federal-statutory-rate-and-effective-rate-details": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in fair value of contingent consideration.", "label": "anik_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentConsiderationPercent", "verboseLabel": "Change in fair value of contingent consideration" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInFairValueOfContingentConsiderationPercent", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-reconciliation-between-us-federal-statutory-rate-and-effective-rate-details" ], "xbrltype": "percentItemType" }, "anik_EffectiveIncomeTaxRateReconciliationChangeInStateApportionmentPercent": { "auth_ref": [], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-reconciliation-between-us-federal-statutory-rate-and-effective-rate-details": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to change in state apportionment.", "label": "Change in tax rates and state apportionment" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInStateApportionmentPercent", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-reconciliation-between-us-federal-statutory-rate-and-effective-rate-details" ], "xbrltype": "percentItemType" }, "anik_EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent": { "auth_ref": [], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-reconciliation-between-us-federal-statutory-rate-and-effective-rate-details": { "order": 6.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to goodwill impairment.", "label": "anik_EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent", "verboseLabel": "Goodwill impairment" } } }, "localname": "EffectiveIncomeTaxRateReconciliationGoodwillImpairmentPercent", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-reconciliation-between-us-federal-statutory-rate-and-effective-rate-details" ], "xbrltype": "percentItemType" }, "anik_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsPercent": { "auth_ref": [], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-reconciliation-between-us-federal-statutory-rate-and-effective-rate-details": { "order": 7.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to returning provision adjustments.", "label": "Return to provision adjustments" } } }, "localname": "EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustmentsPercent", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-reconciliation-between-us-federal-statutory-rate-and-effective-rate-details" ], "xbrltype": "percentItemType" }, "anik_EffectiveIncomeTaxRateReconciliationShareBasedCompensationSection162mLimitationExcessTaxBenefitPercent": { "auth_ref": [], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-reconciliation-between-us-federal-statutory-rate-and-effective-rate-details": { "order": 8.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) of section 162(m) limitation computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "anik_EffectiveIncomeTaxRateReconciliationShareBasedCompensationSection162mLimitationExcessTaxBenefitPercent", "verboseLabel": "Section 162(m) limitation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationSection162mLimitationExcessTaxBenefitPercent", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-reconciliation-between-us-federal-statutory-rate-and-effective-rate-details" ], "xbrltype": "percentItemType" }, "anik_EffectiveIncomeTaxRateReconciliationSharebasedCompensationWindfallTaxBenefitAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to windfall tax benefit for share-based compensation.", "label": "anik_EffectiveIncomeTaxRateReconciliationSharebasedCompensationWindfallTaxBenefitAmount", "terseLabel": "Effective Income Tax Rate Reconciliation, Share-based Compensation, Windfall Tax Benefit, Amount" } } }, "localname": "EffectiveIncomeTaxRateReconciliationSharebasedCompensationWindfallTaxBenefitAmount", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual" ], "xbrltype": "monetaryItemType" }, "anik_EffectiveIncomeTaxReconciliationNondeductibleExpensesPermanentItemsPercent": { "auth_ref": [], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-reconciliation-between-us-federal-statutory-rate-and-effective-rate-details": { "order": 5.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent items including nondeductible expenses.", "label": "anik_EffectiveIncomeTaxReconciliationNondeductibleExpensesPermanentItemsPercent", "verboseLabel": "Other permanent items" } } }, "localname": "EffectiveIncomeTaxReconciliationNondeductibleExpensesPermanentItemsPercent", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-reconciliation-between-us-federal-statutory-rate-and-effective-rate-details" ], "xbrltype": "percentItemType" }, "anik_EmployeeStockPurchasePlanESPPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Employee Stock Purchase Plan (ESPP).", "label": "Employee Stock Purchase Plan (ESPP) [Member]" } } }, "localname": "EmployeeStockPurchasePlanESPPMember", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual" ], "xbrltype": "domainItemType" }, "anik_EquipmentAndSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents equipment and software.", "label": "Equipment and Software [Member]" } } }, "localname": "EquipmentAndSoftwareMember", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-property-and-equipment-at-cost-details" ], "xbrltype": "domainItemType" }, "anik_FinanceLeaseExpense": { "auth_ref": [], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-lease-expense-and-other-information-details": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of finance lease expense.", "label": "anik_FinanceLeaseExpense", "totalLabel": "Finance lease expense" } } }, "localname": "FinanceLeaseExpense", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-lease-expense-and-other-information-details" ], "xbrltype": "monetaryItemType" }, "anik_GrantedIn2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents granted in 2019.", "label": "Granted in 2019 [Member]" } } }, "localname": "GrantedIn2019Member", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual" ], "xbrltype": "domainItemType" }, "anik_GrantedIn2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents granted in 2020.", "label": "Granted in 2020 [Member]" } } }, "localname": "GrantedIn2020Member", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual" ], "xbrltype": "domainItemType" }, "anik_IncreaseDecreaseInContingentConsideration": { "auth_ref": [], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability.", "label": "Payments of contingent consideration" } } }, "localname": "IncreaseDecreaseInContingentConsideration", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "anik_IncreaseDecreaseInLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the lease liabilities.", "label": "anik_IncreaseDecreaseInLeaseLiabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInLeaseLiabilities", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "anik_InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of raw materials, work in process and finished goods.", "label": "anik_InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal", "terseLabel": "Total" } } }, "localname": "InventoryRawMaterialsWorkInProcessAndFinishedGoodsNetOfReserveTotal", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-5-inventories-summary-of-inventories-details" ], "xbrltype": "monetaryItemType" }, "anik_JointPreservationAndRestorationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Joint Preservation and Restoration.", "label": "Joint Preservation and Restoration [Member]" } } }, "localname": "JointPreservationAndRestorationMember", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-disaggregated-revenues-details" ], "xbrltype": "domainItemType" }, "anik_LegacyAnikaReportingUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to the legacy Anika reporting unit.", "label": "Legacy Anika Reporting Unit [Member]" } } }, "localname": "LegacyAnikaReportingUnitMember", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill", "http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill-details-textual" ], "xbrltype": "domainItemType" }, "anik_LesseeOperatingLeaseAndFinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease and finance lease liability.", "label": "Lessee, Operating Lease and Finance Lease, Liability, Maturity [Table Text Block]" } } }, "localname": "LesseeOperatingLeaseAndFinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-tables" ], "xbrltype": "textBlockItemType" }, "anik_LesseeOperatingLeasesAndFinanceLeasesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases and finance leases of lessee.", "label": "Lessee, Operating Leases and Finance Leases [Text Block]" } } }, "localname": "LesseeOperatingLeasesAndFinanceLeasesTextBlock", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases" ], "xbrltype": "textBlockItemType" }, "anik_LiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to liabilities.", "label": "Liabilities [Member]" } } }, "localname": "LiabilitiesMember", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-future-minimum-rental-payments-for-leases-details" ], "xbrltype": "domainItemType" }, "anik_LineOfCreditFacilityAdditionalBorrowingCapacity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of additional borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed.", "label": "anik_LineOfCreditFacilityAdditionalBorrowingCapacity", "terseLabel": "Line of Credit Facility, Additional Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement-details-textual" ], "xbrltype": "monetaryItemType" }, "anik_MeasurementInputWeightedAverageCostOfCapitalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to the weighted average cost of capital.", "label": "Measurement Input, Weighted Average Cost of Capital [Member]" } } }, "localname": "MeasurementInputWeightedAverageCostOfCapitalMember", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "anik_NonorthopedicMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents non-orthopedic.", "label": "Non-Orthopedic [Member]" } } }, "localname": "NonorthopedicMember", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-disaggregated-revenues-details" ], "xbrltype": "domainItemType" }, "anik_NoteToFinancialStatementDetailsTextual": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "localname": "NoteToFinancialStatementDetailsTextual", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_NotesToFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "localname": "NotesToFinancialStatementsAbstract", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_NumberOfSharesAvailableForGrantReducedByEachShareAwardIssuedOtherThanOptionsOrSARs": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of shares by which shares available for grant is reduced for each share award issued after a specified date other than options or stock appreciation rights.", "label": "anik_NumberOfSharesAvailableForGrantReducedByEachShareAwardIssuedOtherThanOptionsOrSARs", "terseLabel": "Number of Shares Available for Grant Reduced By Each Share Award Issued Other Than Options or SARs (in shares)" } } }, "localname": "NumberOfSharesAvailableForGrantReducedByEachShareAwardIssuedOtherThanOptionsOrSARs", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual" ], "xbrltype": "sharesItemType" }, "anik_OAPainManagementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents QA pain management.", "label": "OA Pain Management [member]" } } }, "localname": "OAPainManagementMember", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-disaggregated-revenues-details" ], "xbrltype": "domainItemType" }, "anik_OtherLocationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents other location.", "label": "Other Location [Member]" } } }, "localname": "OtherLocationMember", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-total-revenue-by-geographic-location-details" ], "xbrltype": "domainItemType" }, "anik_ParcusMedicalAndArthrosurfaceAcquisitionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents acquisitions of Parcus Medical and Arthrosurface.", "label": "Parcus Medical and Arthrosurface Acquisitions [Member]" } } }, "localname": "ParcusMedicalAndArthrosurfaceAcquisitionsMember", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "anik_ParcusMedicalAndArthrosurfaceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Parcus Medical and Arthrosurface.", "label": "Parcus Medical and Arthrosurface [Member]" } } }, "localname": "ParcusMedicalAndArthrosurfaceMember", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill", "http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill-details-textual" ], "xbrltype": "domainItemType" }, "anik_ParcusMedicalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to Parcus Medical.", "label": "Parcus Medical [Member]" } } }, "localname": "ParcusMedicalMember", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-consideration-transferred-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-intangible-assets-acquired-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "anik_PercentageOfNetRevenue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of net revenue.", "label": "Percent of revenue" } } }, "localname": "PercentageOfNetRevenue", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-disaggregated-revenues-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-total-revenue-by-geographic-location-details" ], "xbrltype": "percentItemType" }, "anik_PremiumPricedEmployeeStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to premium priced employee stock options.", "label": "Premium-Priced Employee Stock Options [Member]" } } }, "localname": "PremiumPricedEmployeeStockOptionsMember", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual" ], "xbrltype": "domainItemType" }, "anik_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the estimated useful lives of physical assets used in the normal conduct of business and not intended for resale.", "label": "Property, Plant and Equipment Estimated Useful Lives [Table Text Block]" } } }, "localname": "PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "anik_ProvisionForDoubtfulAccountsNetOfRecoveries": { "auth_ref": [], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense credit loss on accounts receivable, net of recoveries.", "label": "Provision for doubtful accounts" } } }, "localname": "ProvisionForDoubtfulAccountsNetOfRecoveries", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "anik_RepresentsShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents share based compensation arrangement by share based payment award, payroll deduction.", "label": "anik_RepresentsShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionPercentage", "terseLabel": "Represents Share Based Compensation Arrangement by Share Based Payment Award, Payroll Deduction percentage" } } }, "localname": "RepresentsShareBasedCompensationArrangementByShareBasedPaymentAwardPayrollDeductionPercentage", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual" ], "xbrltype": "percentItemType" }, "anik_RepresentsShareBasedCompensationArrangementByShareBasedPaymentAwardThePurchasePriceForEachSharePurchasedPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents share based compensation arrangement by share based payment award, the purchase price for each share purchased, percentage.", "label": "anik_RepresentsShareBasedCompensationArrangementByShareBasedPaymentAwardThePurchasePriceForEachSharePurchasedPercentage", "terseLabel": "Represents Share Based Compensation Arrangement by Share Based Payment Award, the Purchase Price for Each Share Purchased, Percentage" } } }, "localname": "RepresentsShareBasedCompensationArrangementByShareBasedPaymentAwardThePurchasePriceForEachSharePurchasedPercentage", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual" ], "xbrltype": "percentItemType" }, "anik_RevenuesFromAgreementsAsPercentOfTotalRevenue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percent of total revenue that revenue from agreements comprises.", "label": "anik_RevenuesFromAgreementsAsPercentOfTotalRevenue", "terseLabel": "Revenues From Agreements as Percent of Total Revenue" } } }, "localname": "RevenuesFromAgreementsAsPercentOfTotalRevenue", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-details-textual" ], "xbrltype": "percentItemType" }, "anik_ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of finite-lived and indefinite-lived intangible assets by major class.", "label": "Schedule of Finite-Lived and Indefinite-Lived Intangible Assets by Major Class [Table Text Block]" } } }, "localname": "ScheduleOfFinitelivedAndIndefinitelivedIntangibleAssetsByMajorClassTableTextBlock", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-tables" ], "xbrltype": "textBlockItemType" }, "anik_ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents schedule of revenue and operating income, by geographical areas.", "label": "Schedule of Revenue and Operating Income by Geographical Areas [Table Text Block]" } } }, "localname": "ScheduleOfRevenueAndOperatingIncomeByGeographicalAreasTableTextBlock", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-tables" ], "xbrltype": "textBlockItemType" }, "anik_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValuePerOption": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents fair value per option related to share based compensation arrangement by share based payment award.", "label": "Fair value per option" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValuePerOption", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details" ], "xbrltype": "pureItemType" }, "anik_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPerOfferingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents share based compensation arrangement by share based payment award number of shares authorized per offering period.", "label": "anik_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPerOfferingPeriod", "terseLabel": "Share Based Compensation Arrangement by Share Based Payment Award Number of Shares Authorized per Offering Period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedPerOfferingPeriod", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual" ], "xbrltype": "sharesItemType" }, "anik_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueAuthorized": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents share based compensation arrangement by share based payment award, value authorized.", "label": "anik_ShareBasedCompensationArrangementByShareBasedPaymentAwardValueAuthorized", "terseLabel": "Share Based Compensation Arrangement by Share Based Payment Award, Value Authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardValueAuthorized", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual" ], "xbrltype": "monetaryItemType" }, "anik_SharebasedCompensationArrangementBySharebasedPaymentAwardPercentageOfTargetNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents percentage of target market for actual number of shares that may be earned for share-based compensation.", "label": "anik_SharebasedCompensationArrangementBySharebasedPaymentAwardPercentageOfTargetNumber", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Target Number" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPercentageOfTargetNumber", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual" ], "xbrltype": "percentItemType" }, "anik_SharebasedCompensationArrangementBySharebasedPaymentAwardPremiumPricedOptionsExercisePriceAsPercentageOfMarketPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The exercise price of premium priced options granted during the reporting period represented as percentage of market price.", "label": "anik_SharebasedCompensationArrangementBySharebasedPaymentAwardPremiumPricedOptionsExercisePriceAsPercentageOfMarketPrice", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Premium Priced Options, Exercise Price as Percentage of Market Price" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPremiumPricedOptionsExercisePriceAsPercentageOfMarketPrice", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual" ], "xbrltype": "percentItemType" }, "anik_SharebasedCompensationPerformanceSharesMeasuredByBusinessTargets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percent of performance shares in a share based compensation arrangement measured by business targets.", "label": "anik_SharebasedCompensationPerformanceSharesMeasuredByBusinessTargets", "terseLabel": "Share-based Compensation, Performance Shares Measured by Business Targets" } } }, "localname": "SharebasedCompensationPerformanceSharesMeasuredByBusinessTargets", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual" ], "xbrltype": "percentItemType" }, "anik_SharebasedCompensationPerformanceSharesMeasuredByBusinessTargetsNotAchieved": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percent of performance shares in a share based compensation arrangement measured by financial targets that was not achieved.", "label": "anik_SharebasedCompensationPerformanceSharesMeasuredByBusinessTargetsNotAchieved", "terseLabel": "Share-based Compensation, Performance Shares Measured by Business Targets, Not Achieved" } } }, "localname": "SharebasedCompensationPerformanceSharesMeasuredByBusinessTargetsNotAchieved", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual" ], "xbrltype": "percentItemType" }, "anik_SharebasedCompensationPerformanceSharesMeasuredByFinancialTargets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percent of performance shares in a share based compensation arrangement measured by financial targets.", "label": "anik_SharebasedCompensationPerformanceSharesMeasuredByFinancialTargets", "terseLabel": "Share-based Compensation, Performance Shares Measured by Financial Targets" } } }, "localname": "SharebasedCompensationPerformanceSharesMeasuredByFinancialTargets", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual" ], "xbrltype": "percentItemType" }, "anik_SharebasedCompensationPerformanceSharesMeasuredByFinancialTargetsNotAchieved": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percent of performance shares in a share based compensation arrangement measured by financial targets not achieved.", "label": "anik_SharebasedCompensationPerformanceSharesMeasuredByFinancialTargetsNotAchieved", "terseLabel": "Share-based Compensation, Performance Shares Measured by Financial Targets, Not Achieved" } } }, "localname": "SharebasedCompensationPerformanceSharesMeasuredByFinancialTargetsNotAchieved", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual" ], "xbrltype": "percentItemType" }, "anik_The2017PlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Anika Therapeutics, Inc. Omnibus Incentive Plan (the \u201c2017 Plan\u201d).", "label": "The 2017 Plan [Member]" } } }, "localname": "The2017PlanMember", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual" ], "xbrltype": "domainItemType" }, "anik_The2021InducementPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the 2021 Inducement Plan.", "label": "The 2021 Inducement Plan [Member]" } } }, "localname": "The2021InducementPlanMember", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual" ], "xbrltype": "domainItemType" }, "anik_TotalShareholderReturnTsrsOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to total shareholder return (\"TSRs\") options.", "label": "Total Shareholder Return (\"TSRs\") Options [Member]" } } }, "localname": "TotalShareholderReturnTsrsOptionsMember", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual" ], "xbrltype": "domainItemType" }, "anik_VeterinaryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents veterinary.", "label": "Veterinary [Member]" } } }, "localname": "VeterinaryMember", "nsuri": "http://www.anikatherapeutics.com/20221231", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-details-textual" ], "xbrltype": "domainItemType" }, "anik_statement-statement-note-10-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Accrued Expenses and Other Liabilities - Summary of Accrued Expenses (Details)" } } }, "localname": "statement-statement-note-10-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-10-accrued-expenses-and-other-liabilities-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 10 - Accrued Expenses and Other Liabilities" } } }, "localname": "statement-statement-note-10-accrued-expenses-and-other-liabilities-tables", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-13-revenue-and-geographic-information-disaggregated-revenues-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 13 - Revenue and Geographic Information - Disaggregated Revenues (Details)" } } }, "localname": "statement-statement-note-13-revenue-and-geographic-information-disaggregated-revenues-details", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-13-revenue-and-geographic-information-net-tangible-longlived-assets-by-principal-geographic-areas-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 13 - Revenue and Geographic Information - Net Tangible Long-lived Assets by Principal Geographic Areas (Details)" } } }, "localname": "statement-statement-note-13-revenue-and-geographic-information-net-tangible-longlived-assets-by-principal-geographic-areas-details", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-13-revenue-and-geographic-information-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 13 - Revenue and Geographic Information" } } }, "localname": "statement-statement-note-13-revenue-and-geographic-information-tables", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-13-revenue-and-geographic-information-total-revenue-by-geographic-location-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 13 - Revenue and Geographic Information - Total Revenue by Geographic Location (Details)" } } }, "localname": "statement-statement-note-13-revenue-and-geographic-information-total-revenue-by-geographic-location-details", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-14-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 14 - Equity Incentive Plan - Assumptions Used to Estimate Fair Value of Stock Options and Stock Appreciation Rights (Details)" } } }, "localname": "statement-statement-note-14-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-14-equity-incentive-plan-performance-stock-units-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 14 - Equity Incentive Plan - Performance Stock Units (Details)" } } }, "localname": "statement-statement-note-14-equity-incentive-plan-performance-stock-units-details", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-14-equity-incentive-plan-restricted-stock-activity-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 14 - Equity Incentive Plan - Restricted Stock Activity (Details)" } } }, "localname": "statement-statement-note-14-equity-incentive-plan-restricted-stock-activity-details", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-14-equity-incentive-plan-stock-options-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 14 - Equity Incentive Plan - Stock Options (Details)" } } }, "localname": "statement-statement-note-14-equity-incentive-plan-stock-options-details", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-14-equity-incentive-plan-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 14 - Equity Incentive Plan" } } }, "localname": "statement-statement-note-14-equity-incentive-plan-tables", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-14-equity-incentive-plan-total-stockbased-compensation-expense-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 14 - Equity Incentive Plan - Total Stock-based Compensation Expense (Details)" } } }, "localname": "statement-statement-note-14-equity-incentive-plan-total-stockbased-compensation-expense-details", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-16-income-taxes-components-of-income-before-taxes-and-provision-for-benefit-from-income-taxes-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 16 - Income Taxes - Components of Income Before Taxes and Provision for (Benefit from) Income Taxes (Details)" } } }, "localname": "statement-statement-note-16-income-taxes-components-of-income-before-taxes-and-provision-for-benefit-from-income-taxes-details", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-16-income-taxes-reconciliation-between-us-federal-statutory-rate-and-effective-rate-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 16 - Income Taxes - Reconciliation Between U.S. Federal Statutory Rate and Effective Rate (Details)" } } }, "localname": "statement-statement-note-16-income-taxes-reconciliation-between-us-federal-statutory-rate-and-effective-rate-details", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-16-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 16 - Income Taxes - Significant Components of Company's Deferred Tax Assets and Liabilities (Details)" } } }, "localname": "statement-statement-note-16-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-16-income-taxes-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 16 - Income Taxes" } } }, "localname": "statement-statement-note-16-income-taxes-tables", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-17-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 17 - Earnings Per Share (\"EPS\") - Basic and Diluted Earnings Per Share (Details)" } } }, "localname": "statement-statement-note-17-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-17-earnings-per-share-eps-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 17- Earnings Per Share (\"EPS\")" } } }, "localname": "statement-statement-note-17-earnings-per-share-eps-tables", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-2-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies - Allowance for Doubtful Accounts (Details)" } } }, "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-property-and-equipment-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Details)" } } }, "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-property-and-equipment-details", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-2-summary-of-significant-accounting-policies-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Summary of Significant Accounting Policies" } } }, "localname": "statement-statement-note-2-summary-of-significant-accounting-policies-tables", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-3-business-combinations-consideration-transferred-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Business Combinations - Consideration Transferred (Details)" } } }, "localname": "statement-statement-note-3-business-combinations-consideration-transferred-details", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Business Combinations - Fair Value of Net Assets Acquired (Details)" } } }, "localname": "statement-statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-3-business-combinations-intangible-assets-acquired-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Business Combinations - Intangible Assets Acquired (Details)" } } }, "localname": "statement-statement-note-3-business-combinations-intangible-assets-acquired-details", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-3-business-combinations-pro-forma-information-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Business Combinations - Pro Forma Information (Details)" } } }, "localname": "statement-statement-note-3-business-combinations-pro-forma-information-details", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-3-business-combinations-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Business Combinations" } } }, "localname": "statement-statement-note-3-business-combinations-tables", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-4-fair-value-measurements-contingent-consideration-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Fair Value Measurements - Contingent Consideration (Details)" } } }, "localname": "statement-statement-note-4-fair-value-measurements-contingent-consideration-details", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Fair Value Measurements - Fair Value of Financial Instruments (Details)" } } }, "localname": "statement-statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-4-fair-value-measurements-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Fair Value Measurements" } } }, "localname": "statement-statement-note-4-fair-value-measurements-tables", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-5-inventories-summary-of-inventories-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Inventories - Summary of Inventories (Details)" } } }, "localname": "statement-statement-note-5-inventories-summary-of-inventories-details", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-5-inventories-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Inventories" } } }, "localname": "statement-statement-note-5-inventories-tables", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-6-property-and-equipment-property-and-equipment-at-cost-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Property and Equipment - Property and Equipment at Cost (Details)" } } }, "localname": "statement-statement-note-6-property-and-equipment-property-and-equipment-at-cost-details", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-6-property-and-equipment-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Property and Equipment" } } }, "localname": "statement-statement-note-6-property-and-equipment-tables", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-7-acquired-intangible-assets-net-summary-of-intangible-assets-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Acquired Intangible Assets, Net - Summary of Intangible Assets (Details)" } } }, "localname": "statement-statement-note-7-acquired-intangible-assets-net-summary-of-intangible-assets-details", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-7-acquired-intangible-assets-net-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 7 - Acquired Intangible Assets, Net" } } }, "localname": "statement-statement-note-7-acquired-intangible-assets-net-tables", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-8-goodwill-changes-in-the-carrying-value-of-goodwill-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Goodwill - Changes in the Carrying Value of Goodwill (Details)" } } }, "localname": "statement-statement-note-8-goodwill-changes-in-the-carrying-value-of-goodwill-details", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-8-goodwill-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 8 - Goodwill" } } }, "localname": "statement-statement-note-8-goodwill-tables", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-9-leases-future-minimum-rental-payments-for-leases-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Leases - Future Minimum Rental Payments for Leases (Details)" } } }, "localname": "statement-statement-note-9-leases-future-minimum-rental-payments-for-leases-details", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-9-leases-lease-expense-and-other-information-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Leases - Lease Expense and Other Information (Details)" } } }, "localname": "statement-statement-note-9-leases-lease-expense-and-other-information-details", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-note-9-leases-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 9 - Leases" } } }, "localname": "statement-statement-note-9-leases-tables", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "anik_statement-statement-significant-accounting-policies-policies": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "statement-statement-significant-accounting-policies-policies", "nsuri": "http://www.anikatherapeutics.com/20221231", "xbrltype": "stringItemType" }, "country_IT": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ITALY" } } }, "localname": "IT", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-net-tangible-longlived-assets-by-principal-geographic-areas-details" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-net-tangible-longlived-assets-by-principal-geographic-areas-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-total-revenue-by-geographic-location-details" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r633", "r634", "r635" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r633", "r634", "r635" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r633", "r634", "r635" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r633", "r634", "r635" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r636" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r631" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets", "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss", "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information", "http://www.anikatherapeutics.com/20221231/role/statement-note-1-nature-of-business", "http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities", "http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement", "http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-12-commitments-and-contingencies", "http://www.anikatherapeutics.com/20221231/role/statement-note-12-commitments-and-contingencies-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-disaggregated-revenues-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-net-tangible-longlived-assets-by-principal-geographic-areas-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-total-revenue-by-geographic-location-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-performance-stock-units-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-restricted-stock-activity-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-stock-options-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-total-stockbased-compensation-expense-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-15-employee-benefit-plan-", "http://www.anikatherapeutics.com/20221231/role/statement-note-15-employee-benefit-plan-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-components-of-income-before-taxes-and-provision-for-benefit-from-income-taxes-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-reconciliation-between-us-federal-statutory-rate-and-effective-rate-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-17-earnings-per-share-eps", "http://www.anikatherapeutics.com/20221231/role/statement-note-17-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-17-earnings-per-share-eps-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-17-earnings-per-share-eps-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-property-and-equipment-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-consideration-transferred-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-intangible-assets-acquired-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-pro-forma-information-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-contingent-consideration-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-5-inventories", "http://www.anikatherapeutics.com/20221231/role/statement-note-5-inventories-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-5-inventories-summary-of-inventories-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-5-inventories-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-", "http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-property-and-equipment-at-cost-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-summary-of-intangible-assets-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill", "http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill-changes-in-the-carrying-value-of-goodwill-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases", "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-future-minimum-rental-payments-for-leases-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-lease-expense-and-other-information-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-tables", "http://www.anikatherapeutics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r631" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r631" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r637" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r631" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r631" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r631" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r631" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r638" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r633", "r634", "r635" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets", "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss", "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information", "http://www.anikatherapeutics.com/20221231/role/statement-note-1-nature-of-business", "http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities", "http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement", "http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-12-commitments-and-contingencies", "http://www.anikatherapeutics.com/20221231/role/statement-note-12-commitments-and-contingencies-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-disaggregated-revenues-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-net-tangible-longlived-assets-by-principal-geographic-areas-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-total-revenue-by-geographic-location-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-performance-stock-units-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-restricted-stock-activity-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-stock-options-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-total-stockbased-compensation-expense-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-15-employee-benefit-plan-", "http://www.anikatherapeutics.com/20221231/role/statement-note-15-employee-benefit-plan-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-components-of-income-before-taxes-and-provision-for-benefit-from-income-taxes-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-reconciliation-between-us-federal-statutory-rate-and-effective-rate-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-17-earnings-per-share-eps", "http://www.anikatherapeutics.com/20221231/role/statement-note-17-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-17-earnings-per-share-eps-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-17-earnings-per-share-eps-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-property-and-equipment-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-consideration-transferred-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-intangible-assets-acquired-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-pro-forma-information-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-contingent-consideration-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-5-inventories", "http://www.anikatherapeutics.com/20221231/role/statement-note-5-inventories-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-5-inventories-summary-of-inventories-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-5-inventories-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-", "http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-property-and-equipment-at-cost-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-summary-of-intangible-assets-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill", "http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill-changes-in-the-carrying-value-of-goodwill-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases", "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-future-minimum-rental-payments-for-leases-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-lease-expense-and-other-information-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-tables", "http://www.anikatherapeutics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r632" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Europe [Member]" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-total-revenue-by-geographic-location-details" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r279", "r615", "r675", "r729" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r322", "r323", "r324", "r325", "r382", "r543", "r563", "r593", "r594", "r612", "r621", "r629", "r674", "r720", "r721", "r722", "r723", "r724", "r725" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement", "http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-property-and-equipment-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r322", "r323", "r324", "r325", "r382", "r543", "r563", "r593", "r594", "r612", "r621", "r629", "r674", "r720", "r721", "r722", "r723", "r724", "r725" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement", "http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-property-and-equipment-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r279", "r615", "r675", "r729" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r276", "r545", "r613", "r627", "r669", "r670", "r675", "r728" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-disaggregated-revenues-details" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r276", "r545", "r613", "r627", "r669", "r670", "r675", "r728" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-disaggregated-revenues-details" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r322", "r323", "r324", "r325", "r375", "r382", "r409", "r410", "r411", "r542", "r543", "r563", "r593", "r594", "r612", "r621", "r629", "r668", "r674", "r721", "r722", "r723", "r724", "r725" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement", "http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-property-and-equipment-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-details-textual" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r322", "r323", "r324", "r325", "r375", "r382", "r409", "r410", "r411", "r542", "r543", "r563", "r593", "r594", "r612", "r621", "r629", "r668", "r674", "r721", "r722", "r723", "r724", "r725" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement", "http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-property-and-equipment-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r277", "r278", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r614", "r628", "r675" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-net-tangible-longlived-assets-by-principal-geographic-areas-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-total-revenue-by-geographic-location-details" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r277", "r278", "r577", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r614", "r628", "r675" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-net-tangible-longlived-assets-by-principal-geographic-areas-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-total-revenue-by-geographic-location-details" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r15", "r626" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableGrossCurrent": { "auth_ref": [ "r194", "r280", "r281", "r597" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details": { "order": 1.0, "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable" } } }, "localname": "AccountsReceivableGrossCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r578" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r280", "r281" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "us-gaap_AccountsReceivableNetCurrent", "totalLabel": "Net balance, end of the year" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r1", "r157", "r169" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "us-gaap_AccruedIncomeTaxesCurrent", "verboseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "auth_ref": [], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.", "label": "Accrued expenses and other current liabilities", "totalLabel": "Total" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets", "http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r18" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "us-gaap_AccruedProfessionalFeesCurrent", "verboseLabel": "Professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r85", "r189" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-property-and-equipment-at-cost-details": { "order": 0.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "negatedLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-property-and-equipment-at-cost-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r28", "r29", "r30", "r195", "r558", "r571", "r575" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r27", "r30", "r140", "r538", "r566", "r567", "r642", "r643", "r644", "r649", "r650", "r651" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r7" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional paid-in-capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r418", "r419", "r420", "r649", "r650", "r651", "r713" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r177", "r178", "r179", "r180", "r181", "r224", "r225", "r226", "r227", "r236", "r283", "r284", "r288", "r289", "r290", "r291", "r292", "r293", "r418", "r419", "r420", "r442", "r443", "r444", "r445", "r461", "r462", "r463", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r511", "r512", "r514", "r515", "r516", "r517", "r533", "r534", "r535", "r536", "r537", "r538", "r547", "r548", "r549", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Accounting Standards Update [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "negatedLabel": "Retirement of common stock for minimum tax withholdings" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income (loss) to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r413" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "us-gaap_AllocatedShareBasedCompensationExpense", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-total-stockbased-compensation-expense-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r196", "r282", "r294", "r295", "r299" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "us-gaap_AllowanceForDoubtfulAccountsReceivable", "periodEndLabel": "Balance, end of the year", "periodStartLabel": "Balance, beginning of the year" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r196", "r282", "r294" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details": { "order": 0.0, "parentTag": "us-gaap_AccountsReceivableNetCurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Allowance for credit losses" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries": { "auth_ref": [ "r298" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in allowance for credit loss on accounts receivable, from recovery.", "label": "us-gaap_AllowanceForDoubtfulAccountsReceivableRecoveries", "negatedLabel": "Amounts recovered" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableRecoveries", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "auth_ref": [ "r297" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.", "label": "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs", "negatedLabel": "Amounts written off" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r50", "r76", "r81" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "us-gaap_AmortizationOfIntangibleAssets", "terseLabel": "Amortization of Intangible Assets, Total" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-17-earnings-per-share-eps-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r156", "r168", "r193", "r217", "r261", "r270", "r274", "r287", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r467", "r469", "r490", "r626", "r672", "r673", "r718" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r183", "r199", "r217", "r287", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r467", "r469", "r490", "r626", "r672", "r673", "r718" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r72", "r285", "r300", "r552" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "terseLabel": "Debt Securities, Available-for-sale, Total" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "auth_ref": [ "r71", "r187", "r300" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "terseLabel": "Debt Securities, Available-for-Sale, Noncurrent" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702" ], "lang": { "en-us": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date [Axis]" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [ "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702" ], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted.", "label": "Award Date [Domain]" } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r384", "r385", "r386", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r408", "r409", "r410", "r411", "r412" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-stockholders-equity", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-performance-stock-units-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-restricted-stock-activity-details" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-future-minimum-rental-payments-for-leases-details" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r141", "r142" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-future-minimum-rental-payments-for-leases-details" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r459", "r619", "r620" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-consideration-transferred-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-intangible-assets-acquired-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r120", "r121", "r459", "r619", "r620" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-consideration-transferred-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-intangible-assets-acquired-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "auth_ref": [ "r711", "r712" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.", "label": "Business Acquisition, Pro Forma Information [Table Text Block]" } } }, "localname": "BusinessAcquisitionProFormaInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r457", "r458" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss", "verboseLabel": "Net loss" } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-pro-forma-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r457", "r458" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "us-gaap_BusinessAcquisitionsProFormaRevenue", "verboseLabel": "Total revenue" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-pro-forma-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r119" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "us-gaap_BusinessCombinationAcquisitionRelatedCosts", "terseLabel": "Business Combination, Acquisition Related Costs" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r130", "r131", "r133" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Estimated total purchase consideration", "terseLabel": "Business Combination, Consideration Transferred, Total" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-consideration-transferred-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "auth_ref": [ "r128", "r130", "r131", "r465" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.", "label": "Estimated fair value of contingent consideration" } } }, "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-consideration-transferred-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r466", "r645" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss": { "order": 0.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Change in fair value of contingent consideration", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh": { "auth_ref": [ "r134" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the amount of any change recognized during the period in the high-end of the estimated range of outcomes (undiscounted) of a liability assumed in a business combination arising from an item of contingent consideration.", "label": "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r129", "r132" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Contingent consideration", "terseLabel": "Business Combination, Contingent Consideration, Liability, Current" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "auth_ref": [ "r485" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure contingent consideration liability from business combination.", "label": "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "terseLabel": "Business Combination, Contingent Consideration, Liability, Measurement Input" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-details-textual" ], "xbrltype": "decimalItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r135", "r460" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r123" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "auth_ref": [ "r123" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "verboseLabel": "Prepaid expenses and other current assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r123" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "verboseLabel": "Accounts receivable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r123" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "negatedLabel": "Accounts payable, accrued expenses and other current liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r123" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "negatedLabel": "Deferred tax liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r123" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "verboseLabel": "Intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r122", "r123" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "verboseLabel": "Intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-intangible-assets-acquired-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r122", "r123" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "verboseLabel": "Inventories" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r122", "r123" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "verboseLabel": "Net assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": { "auth_ref": [ "r123" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther", "negatedLabel": "Other long-term liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "auth_ref": [ "r123" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "verboseLabel": "Other long-term assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r122", "r123" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "verboseLabel": "Property and equipment, net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r123" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "verboseLabel": "Estimated total purchase consideration" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r55", "r56", "r57" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Purchases of property and equipment included in accounts payable and accrued expenses" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r150", "r151" ], "lang": { "en-us": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r52", "r186", "r595" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r47", "r52", "r58" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r47", "r154" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Decrease in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r22", "r162", "r173" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies (Note 12)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r88", "r320", "r321", "r579", "r671" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-12-commitments-and-contingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "auth_ref": [ "r89", "r580" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.", "label": "Commitments and Contingencies, Policy [Policy Text Block]" } } }, "localname": "CommitmentsAndContingenciesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance", "terseLabel": "Common Stock, Capital Shares Reserved for Future Issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r649", "r650", "r713" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r6", "r93" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r6", "r626" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $.01 par value; 90,000 shares authorized, 14,625 and 14,441 shares issued and outstanding at December 31, 2022 and 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "auth_ref": [ "r95", "r96", "r97", "r108" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.", "label": "Compensation and Employee Benefit Plans [Text Block]" } } }, "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-15-employee-benefit-plan-" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r31", "r202", "r204", "r210", "r554", "r560" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "us-gaap_ComprehensiveIncomeNetOfTax", "totalLabel": "Comprehensive (loss) income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r61", "r62", "r152", "r153", "r279", "r578" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r61", "r62", "r152", "r153", "r279", "r576", "r578" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r61", "r62", "r152", "r153", "r279", "r578", "r730" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r165", "r254" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r61", "r62", "r152", "r153", "r279" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "us-gaap_ConcentrationRiskPercentage1", "terseLabel": "Concentration Risk, Percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r61", "r62", "r152", "r153", "r279", "r578" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r138", "r601" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-property-and-equipment-at-cost-details" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r352", "r353", "r372" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "us-gaap_ContractWithCustomerLiability", "terseLabel": "Contract with Customer, Liability, Total" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r38", "r545" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss": { "order": 0.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of revenue" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-total-stockbased-compensation-expense-details" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r35" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "us-gaap_CostsAndExpenses", "totalLabel": "Total operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement", "http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement", "http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r648", "r707", "r709" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-components-of-income-before-taxes-and-provision-for-benefit-from-income-taxes-details": { "order": 0.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "us-gaap_CurrentFederalTaxExpenseBenefit", "terseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-components-of-income-before-taxes-and-provision-for-benefit-from-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r648", "r707" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-components-of-income-before-taxes-and-provision-for-benefit-from-income-taxes-details": { "order": 1.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_CurrentForeignTaxExpenseBenefit", "terseLabel": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-components-of-income-before-taxes-and-provision-for-benefit-from-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r118", "r439", "r449", "r648" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-components-of-income-before-taxes-and-provision-for-benefit-from-income-taxes-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "us-gaap_CurrentIncomeTaxExpenseBenefit", "totalLabel": "Total current" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-components-of-income-before-taxes-and-provision-for-benefit-from-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r648", "r707", "r709" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-components-of-income-before-taxes-and-provision-for-benefit-from-income-taxes-details": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "us-gaap_CurrentStateAndLocalTaxExpenseBenefit", "terseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-components-of-income-before-taxes-and-provision-for-benefit-from-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r60", "r279" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r126" ], "lang": { "en-us": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-intangible-assets-acquired-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-summary-of-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r92", "r216", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r344", "r346", "r347", "r348" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1", "terseLabel": "Debt Instrument, Basis Spread on Variable Rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r20", "r335" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "us-gaap_DebtInstrumentInterestRateStatedPercentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "us-gaap_DebtInstrumentTerm", "terseLabel": "Debt Instrument, Term (Year)" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r648", "r708", "r709" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-components-of-income-before-taxes-and-provision-for-benefit-from-income-taxes-details": { "order": 1.0, "parentTag": "anik_DeferredIncomeTaxExpenseBenefitForeignAndDomesticNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "us-gaap_DeferredFederalIncomeTaxExpenseBenefit", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-components-of-income-before-taxes-and-provision-for-benefit-from-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r118", "r648", "r708" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-components-of-income-before-taxes-and-provision-for-benefit-from-income-taxes-details": { "order": 2.0, "parentTag": "anik_DeferredIncomeTaxExpenseBenefitForeignAndDomesticNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "us-gaap_DeferredForeignIncomeTaxExpenseBenefit", "terseLabel": "Foreign" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-components-of-income-before-taxes-and-provision-for-benefit-from-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r426", "r427" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred tax assets" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r50", "r118", "r440", "r448", "r449", "r648" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r3", "r4", "r158", "r166", "r435" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "us-gaap_DeferredIncomeTaxLiabilities", "negatedTotalLabel": "Deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r426", "r427" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r648", "r708", "r709" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-components-of-income-before-taxes-and-provision-for-benefit-from-income-taxes-details": { "order": 0.0, "parentTag": "anik_DeferredIncomeTaxExpenseBenefitForeignAndDomesticNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.", "label": "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit", "terseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-components-of-income-before-taxes-and-provision-for-benefit-from-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInventory": { "auth_ref": [ "r116", "r706" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details": { "order": 8.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.", "label": "us-gaap_DeferredTaxAssetsInventory", "terseLabel": "Inventory reserves" } } }, "localname": "DeferredTaxAssetsInventory", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r705" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "us-gaap_DeferredTaxAssetsNet", "totalLabel": "Deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r116", "r706" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net operating loss carry forwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r114", "r116", "r706" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Tax credits" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": { "auth_ref": [ "r116", "r706" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.", "label": "Compensation accrual" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r116", "r706" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details": { "order": 0.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "terseLabel": "Stock-based compensation expense" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": { "auth_ref": [ "r116", "r706" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.", "label": "Accrued expenses" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses": { "auth_ref": [ "r116", "r706" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on foreign currency transactions.", "label": "Foreign currency exchange" } } }, "localname": "DeferredTaxAssetsUnrealizedCurrencyLosses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilities": { "auth_ref": [ "r110", "r705" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.", "label": "us-gaap_DeferredTaxLiabilities", "negatedTotalLabel": "Net deferred tax liabilities" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets": { "auth_ref": [ "r116", "r706" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details": { "order": 2.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.", "label": "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets", "negatedLabel": "Acquisition-related intangible asset" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r116", "r706" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details": { "order": 1.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment", "negatedLabel": "Depreciation" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": { "auth_ref": [ "r706" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.", "label": "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings", "terseLabel": "Deferred Tax Liabilities, Undistributed Foreign Earnings" } } }, "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.", "label": "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent", "terseLabel": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-15-employee-benefit-plan-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage employer matches of the employee's percentage contribution matched.", "label": "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "terseLabel": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-15-employee-benefit-plan-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r50", "r83" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "us-gaap_Depreciation", "terseLabel": "Depreciation, Total" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r50", "r83" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-intangible-assets-acquired-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-summary-of-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r383", "r414", "r415", "r417", "r422", "r622" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-1-nature-of-business", "http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities", "http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement", "http://www.anikatherapeutics.com/20221231/role/statement-note-12-commitments-and-contingencies", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan", "http://www.anikatherapeutics.com/20221231/role/statement-note-15-employee-benefit-plan-", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes", "http://www.anikatherapeutics.com/20221231/role/statement-note-17-earnings-per-share-eps", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements", "http://www.anikatherapeutics.com/20221231/role/statement-note-5-inventories", "http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net", "http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill", "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases" ], "xbrltype": "stringItemType" }, "us-gaap_DistributionRightsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Legal rights, generally of a limited duration, to distribute a product or products, often within specific geographic areas or supply channels.", "label": "Distribution Rights [Member]" } } }, "localname": "DistributionRightsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-summary-of-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r211", "r228", "r229", "r230", "r231", "r232", "r237", "r239", "r241", "r242", "r243", "r247", "r480", "r481", "r555", "r561", "r605" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "us-gaap_EarningsPerShareBasic", "terseLabel": "Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r211", "r228", "r229", "r230", "r231", "r232", "r239", "r241", "r242", "r243", "r247", "r480", "r481", "r555", "r561", "r605" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "us-gaap_EarningsPerShareDiluted", "terseLabel": "Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r244", "r245", "r246", "r248" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-17-earnings-per-share-eps" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r716" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Exchange rate impact on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r429" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-reconciliation-between-us-federal-statutory-rate-and-effective-rate-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "totalLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-reconciliation-between-us-federal-statutory-rate-and-effective-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r219", "r429", "r451" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-reconciliation-between-us-federal-statutory-rate-and-effective-rate-details": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Statutory federal income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-reconciliation-between-us-federal-statutory-rate-and-effective-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r704", "r710" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-reconciliation-between-us-federal-statutory-rate-and-effective-rate-details": { "order": 9.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "verboseLabel": "Valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-reconciliation-between-us-federal-statutory-rate-and-effective-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": { "auth_ref": [ "r703", "r704" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-reconciliation-between-us-federal-statutory-rate-and-effective-rate-details": { "order": 10.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Stock compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-reconciliation-between-us-federal-statutory-rate-and-effective-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r704", "r710" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-reconciliation-between-us-federal-statutory-rate-and-effective-rate-details": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "verboseLabel": "State tax expense, net of federal benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-reconciliation-between-us-federal-statutory-rate-and-effective-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": { "auth_ref": [ "r704", "r710" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-reconciliation-between-us-federal-statutory-rate-and-effective-rate-details": { "order": 0.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.", "label": "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits", "negatedTerseLabel": "Federal, state and foreign tax credits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-reconciliation-between-us-federal-statutory-rate-and-effective-rate-details" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r18" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "us-gaap_EmployeeRelatedLiabilitiesCurrent", "verboseLabel": "Compensation and related expenses" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r416" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r416" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "terseLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r413" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.", "label": "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "terseLabel": "Share-Based Payment Arrangement, Expense, Tax Benefit" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-property-and-equipment-details" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r93", "r179", "r206", "r207", "r208", "r221", "r222", "r223", "r225", "r233", "r235", "r250", "r291", "r351", "r418", "r419", "r420", "r444", "r445", "r479", "r503", "r504", "r505", "r506", "r507", "r509", "r538", "r566", "r567", "r568" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r343", "r489", "r608", "r609" ], "lang": { "en-us": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "auth_ref": [ "r143", "r144" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r145" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r143", "r148" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r343", "r376", "r377", "r378", "r379", "r380", "r381", "r483", "r539", "r540", "r541", "r608", "r609", "r616", "r617", "r618" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r147", "r148" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-contingent-consideration-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r143", "r149", "r343", "r608", "r609" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r487" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r343", "r376", "r381", "r483", "r539", "r616", "r617", "r618" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r343", "r376", "r381", "r483", "r540", "r608", "r609", "r616", "r617", "r618" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r343", "r376", "r377", "r378", "r379", "r380", "r381", "r483", "r541", "r608", "r609", "r616", "r617", "r618" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r145" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-contingent-consideration-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r145", "r148" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r486" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "negatedLabel": "Change in fair value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-contingent-consideration-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": { "auth_ref": [ "r146" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Additions" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-contingent-consideration-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r146" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "negatedLabel": "Payments" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-contingent-consideration-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r145" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "periodEndLabel": "Balance", "periodStartLabel": "Balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-contingent-consideration-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r343", "r376", "r377", "r378", "r379", "r380", "r381", "r539", "r540", "r541", "r608", "r609", "r616", "r617", "r618" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r520", "r523", "r625" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-lease-expense-and-other-information-details": { "order": 0.0, "parentTag": "anik_FinanceLeaseExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Interest on finance lease liabilities" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-lease-expense-and-other-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r519" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "us-gaap_FinanceLeaseLiabilityCurrent", "verboseLabel": "Finance lease liability - current" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r521", "r527" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "us-gaap_FinanceLeasePrincipalPayments", "negatedLabel": "Payments made on finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r520", "r523", "r625" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-lease-expense-and-other-information-details": { "order": 1.0, "parentTag": "anik_FinanceLeaseExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance lease amortization of right-of-use assets" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-lease-expense-and-other-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r530", "r625" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent", "terseLabel": "Financing leases" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-lease-expense-and-other-information-details" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r529", "r625" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1", "terseLabel": "Financing leases (Year)" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-lease-expense-and-other-information-details" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Useful life (Year)", "terseLabel": "Finite-Lived Intangible Asset, Useful Life (Year)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-summary-of-intangible-assets-details" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r191", "r316" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization", "negatedTerseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-summary-of-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r314", "r315", "r316", "r317", "r546", "r550" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-intangible-assets-acquired-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-summary-of-intangible-assets-details" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r77", "r80" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-intangible-assets-acquired-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-summary-of-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.", "label": "Foreign Tax Authority [Member]" } } }, "localname": "ForeignCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r499", "r500", "r501", "r502" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax", "terseLabel": "Foreign Currency Transaction Gain (Loss), before Tax, Total" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r510" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-property-and-equipment-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-property-and-equipment-at-cost-details" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r50" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "us-gaap_GainLossOnSaleOfPropertyPlantEquipment", "negatedLabel": "Loss on disposal of fixed assets" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r190", "r305", "r551", "r607", "r626", "r656", "r663" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "terseLabel": "Goodwill, Ending Balance" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill-changes-in-the-carrying-value-of-goodwill-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r82" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.", "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillDisclosureTextBlock": { "auth_ref": [ "r309", "r311", "r313", "r607" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill.", "label": "Goodwill Disclosure [Text Block]" } } }, "localname": "GoodwillDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r308" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "us-gaap_GoodwillForeignCurrencyTranslationGainLoss", "terseLabel": "Effect of foreign currency adjustments" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill-changes-in-the-carrying-value-of-goodwill-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r50", "r306", "r307", "r312", "r607" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill impairment charge", "terseLabel": "Goodwill, Impairment Loss" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r37", "r217", "r261", "r269", "r273", "r275", "r287", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r490", "r606", "r672" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "us-gaap_GrossProfit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "auth_ref": [ "r646", "r667" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "Loss on impairment of intangible asset", "negatedLabel": "Current period impairment charge", "terseLabel": "Impairment of Intangible Assets, Finite-lived" } } }, "localname": "ImpairmentOfIntangibleAssetsFinitelived", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-summary-of-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "auth_ref": [ "r646", "r667" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "terseLabel": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)" } } }, "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-intangible-assets-acquired-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-summary-of-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r218", "r450" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-components-of-income-before-taxes-and-provision-for-benefit-from-income-taxes-details": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Domestic" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-components-of-income-before-taxes-and-provision-for-benefit-from-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r33", "r155", "r163", "r175", "r261", "r269", "r273", "r275", "r556", "r606" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-components-of-income-before-taxes-and-provision-for-benefit-from-income-taxes-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "totalLabel": "(Loss) income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-components-of-income-before-taxes-and-provision-for-benefit-from-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r218", "r450" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-components-of-income-before-taxes-and-provision-for-benefit-from-income-taxes-details": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-components-of-income-before-taxes-and-provision-for-benefit-from-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r318", "r319" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-total-stockbased-compensation-expense-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-total-stockbased-compensation-expense-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority, Name [Domain]" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r219", "r430", "r433", "r438", "r446", "r452", "r454", "r455", "r456" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r220", "r234", "r235", "r260", "r428", "r447", "r453", "r562" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Benefit from for income taxes", "verboseLabel": "Total benefit from income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-components-of-income-before-taxes-and-provision-for-benefit-from-income-taxes-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r205", "r424", "r425", "r433", "r434", "r437", "r441" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r54" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Cash paid for income taxes, net of refunds" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r49" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "us-gaap_IncreaseDecreaseInAccountsPayable", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r49" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r49" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Income taxes" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r49" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Accrued expenses, other current and long-term liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r49" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "us-gaap_IncreaseDecreaseInInventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r49" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedLabel": "Prepaid expenses, other current and long-term assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsGrossExcludingGoodwill": { "auth_ref": [ "r190" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.", "label": "Gross value" } } }, "localname": "IntangibleAssetsGrossExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-summary-of-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r75", "r79" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible assets, net", "terseLabel": "Net book value" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-summary-of-intangible-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r40", "r345", "r349", "r610", "r611" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "us-gaap_InterestExpenseDebt", "terseLabel": "Interest Expense, Debt, Total" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest and other income (expense) , net" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InternalRevenueServiceIRSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.", "label": "Internal Revenue Service (IRS) [Member]" } } }, "localname": "InternalRevenueServiceIRSMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-5-inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r74", "r598" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-5-inventories-summary-of-inventories-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r198", "r596", "r626" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventories", "terseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets", "http://www.anikatherapeutics.com/20221231/role/statement-note-5-inventories-summary-of-inventories-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNoncurrent": { "auth_ref": [ "r639" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.", "label": "us-gaap_InventoryNoncurrent", "terseLabel": "Other long-term assets" } } }, "localname": "InventoryNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-5-inventories-summary-of-inventories-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r185", "r197", "r249", "r301", "r303", "r304", "r544", "r602" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r74", "r600" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-5-inventories-summary-of-inventories-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r73", "r640" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "us-gaap_InventoryValuationReserves", "terseLabel": "Inventory Valuation Reserves" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-5-inventories-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r74", "r599" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Work-in-process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-5-inventories-summary-of-inventories-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r302" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Provision for inventory" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r286", "r727" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r531", "r625" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-lease-expense-and-other-information-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "us-gaap_LeaseCost", "totalLabel": "Total lease expense" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-lease-expense-and-other-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r717" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-property-and-equipment-at-cost-details" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r522" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r532" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-future-minimum-rental-payments-for-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r532" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "terseLabel": "2023, operating leases" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-future-minimum-rental-payments-for-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r532" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "terseLabel": "2027, operating leases" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-future-minimum-rental-payments-for-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r532" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "terseLabel": "2026, operating leases" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-future-minimum-rental-payments-for-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r532" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "terseLabel": "2025, operating leases" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-future-minimum-rental-payments-for-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r532" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "terseLabel": "2024, operating leases" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-future-minimum-rental-payments-for-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r532" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "negatedLabel": "Present value adjustment, operating leases" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-future-minimum-rental-payments-for-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r11", "r160", "r171", "r626", "r647", "r655", "r715" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r19", "r184", "r217", "r287", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r468", "r469", "r470", "r490", "r626", "r672", "r718", "r719" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r2", "r159", "r167" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "us-gaap_LineOfCredit", "terseLabel": "Long-Term Line of Credit, Total" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "auth_ref": [ "r17" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.", "label": "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity", "terseLabel": "Line of Credit Facility, Current Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r17" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity", "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.", "label": "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "terseLabel": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage" } } }, "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Accounts receivable, net" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r714" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_MinistryOfEconomicAffairsAndFinanceItalyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government of Italy.", "label": "Ministry of Economic Affairs and Finance, Italy [Member]" } } }, "localname": "MinistryOfEconomicAffairsAndFinanceItalyMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r676" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r251", "r257" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-1-nature-of-business" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r214" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash used by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r214" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash (used in) provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r47", "r48", "r51" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r34", "r51", "r164", "r174", "r182", "r200", "r203", "r208", "r217", "r224", "r228", "r229", "r230", "r231", "r234", "r235", "r240", "r261", "r269", "r273", "r275", "r287", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r481", "r490", "r606", "r672" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net (loss) income", "totalLabel": "Net (loss) income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss", "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r654" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "us-gaap_NumberOfOperatingSegments", "terseLabel": "Number of Operating Segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportingUnits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.", "label": "us-gaap_NumberOfReportingUnits", "terseLabel": "Number of Reporting Units" } } }, "localname": "NumberOfReportingUnits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill-details-textual" ], "xbrltype": "integerItemType" }, "us-gaap_OpenTaxYear": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format.", "label": "us-gaap_OpenTaxYear", "terseLabel": "Open Tax Year" } } }, "localname": "OpenTaxYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-details-textual" ], "xbrltype": "gYearListItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r261", "r269", "r273", "r275", "r606" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "(Loss) income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r524", "r625" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-lease-expense-and-other-information-details": { "order": 0.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating lease expense" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-lease-expense-and-other-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r519" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "us-gaap_OperatingLeaseLiability", "verboseLabel": "Present value of lease payments, operating leases" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-future-minimum-rental-payments-for-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r519" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "us-gaap_OperatingLeaseLiabilityCurrent", "negatedLabel": "Less current portion included in Accrued expenses and other current liabilities, operating leases", "verboseLabel": "Operating lease liability- current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-future-minimum-rental-payments-for-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r519" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Lease liabilities", "terseLabel": "Total lease liabilities, operating leases" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets", "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-future-minimum-rental-payments-for-leases-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r518" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r646" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Non-cash operating lease cost" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r530", "r625" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent", "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-lease-expense-and-other-information-details" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r529", "r625" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1", "terseLabel": "Operating leases (Year)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-lease-expense-and-other-information-details" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r114" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "us-gaap_OperatingLossCarryforwards", "terseLabel": "Operating Loss Carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r18" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details": { "order": 0.0, "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "us-gaap_OtherAccruedLiabilitiesCurrent", "verboseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r192" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other long-term assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r136", "r137", "r139" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r26" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "terseLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r32", "r93", "r201", "r204", "r209", "r503", "r508", "r509", "r553", "r559", "r642", "r643" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r21" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r51" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "us-gaap_OtherNoncashIncomeExpense", "negatedTerseLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-summary-of-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "auth_ref": [ "r46" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities", "negatedLabel": "Payments of contingent consideration", "terseLabel": "Payment for Contingent Consideration Liability, Financing Activities" } } }, "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r213" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "negatedLabel": "Cash paid for tax withheld on vested restricted stock awards" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r41", "r464" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Cash consideration" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-consideration-transferred-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r41" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired", "negatedLabel": "Acquisition of Parcus Medical and Arthrosurface, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r70" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "us-gaap_PaymentsToAcquireMarketableSecurities", "negatedLabel": "Purchases of investments" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r42" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-performance-stock-units-details" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_PolicyTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "localname": "PolicyTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r488" ], "lang": { "en-us": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member] [Default]" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r5", "r350" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r5", "r350" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r5", "r626" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $0.01 par value; 1,250 shares authorized, no shares issued and outstanding at December 31, 2022 and 2021, respectively" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r641" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r44" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from long-term debt" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "auth_ref": [ "r44" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "us-gaap_ProceedsFromLongTermLinesOfCredit", "terseLabel": "Proceeds from Long-term Lines of Credit" } } }, "localname": "ProceedsFromLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds from maturities of investments" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r43", "r107" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from exercises of equity awards" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockPlans": { "auth_ref": [ "r43" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the stock plan during the period.", "label": "Proceeds from employee stock purchase program" } } }, "localname": "ProceedsFromStockPlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrual": { "auth_ref": [ "r90", "r91", "r161" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.", "label": "us-gaap_ProductWarrantyAccrual", "terseLabel": "Standard and Extended Product Warranty Accrual, Ending Balance" } } }, "localname": "ProductWarrantyAccrual", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-12-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r86" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-property-and-equipment-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-property-and-equipment-at-cost-details" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r87", "r581", "r582", "r583" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r84", "r188" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-property-and-equipment-at-cost-details": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, plant and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-property-and-equipment-at-cost-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r86", "r172", "r557", "r626" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-property-and-equipment-at-cost-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net", "totalLabel": "Total" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-net-tangible-longlived-assets-by-principal-geographic-areas-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-property-and-equipment-at-cost-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r86", "r581", "r582" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r86" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-property-and-equipment-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-property-and-equipment-at-cost-details" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Estimated useful life (Year)", "terseLabel": "Property, Plant and Equipment, Useful Life (Year)" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-property-and-equipment-details" ], "xbrltype": "durationItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r212", "r296" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "us-gaap_ProvisionForDoubtfulAccounts", "terseLabel": "Amounts provided" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": { "auth_ref": [ "r68" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.", "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]" } } }, "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r45" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "us-gaap_RepaymentsOfLongTermDebt", "negatedLabel": "Repayments of long-term debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReportingUnitAxis": { "auth_ref": [ "r310", "r312", "r607" ], "lang": { "en-us": { "role": { "documentation": "Information by reporting unit.", "label": "Reporting Unit [Axis]" } } }, "localname": "ReportingUnitAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill", "http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ReportingUnitDomain": { "auth_ref": [ "r310", "r312", "r607" ], "lang": { "en-us": { "role": { "documentation": "Level of reporting at which goodwill is tested for impairment.", "label": "Reporting Unit [Domain]" } } }, "localname": "ReportingUnitDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill", "http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r109", "r176", "r726" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research & development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-total-stockbased-compensation-expense-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r109" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchMember": { "auth_ref": [ "r115" ], "lang": { "en-us": { "role": { "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.", "label": "Research Tax Credit Carryforward [Member]" } } }, "localname": "ResearchMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-stockholders-equity", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-restricted-stock-activity-details" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r8", "r94", "r170", "r570", "r575", "r626" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r179", "r221", "r222", "r223", "r225", "r233", "r235", "r291", "r418", "r419", "r420", "r444", "r445", "r479", "r566", "r568" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r258", "r259", "r268", "r271", "r272", "r276", "r277", "r279", "r370", "r371", "r545" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue", "terseLabel": "Revenue from Contract with Customer, Excluding Assessed Tax" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-disaggregated-revenues-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-total-revenue-by-geographic-location-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r374", "r603" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r373", "r374" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r603", "r604" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement", "http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r528", "r625" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Operating cash flows from financing leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-lease-expense-and-other-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r528", "r625" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-use assets obtained in exchange for operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-lease-expense-and-other-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r279", "r653" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r120", "r121" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r113" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r652" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-17-earnings-per-share-eps-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r105" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table Text Block]" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of finite-lived intangible assets acquired as part of a business combination or through an asset purchase, by major class and in total, including the value of the asset acquired, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period.", "label": "Schedule of Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r607", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r0", "r12", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-5-inventories-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": { "auth_ref": [ "r99" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.", "label": "Schedule of Nonvested Performance-Based Units Activity [Table Text Block]" } } }, "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "auth_ref": [ "r36", "r67" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r98", "r100", "r102" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r262", "r263", "r264", "r265", "r266", "r267", "r277" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r39" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, general & administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-total-stockbased-compensation-expense-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r49" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensation", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r622" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "negatedLabel": "Forfeited and cancelled, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-performance-stock-units-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-restricted-stock-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Forfeited and cancelled, weighted average grant date fair value (in dollars per share)", "negatedLabel": "Forfeited and cancelled, weighted average grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-performance-stock-units-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-restricted-stock-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-performance-stock-units-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-restricted-stock-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Granted, weighted average grant date fair value (in dollars per share)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-performance-stock-units-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-restricted-stock-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r396", "r397" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "periodEndLabel": "Outstanding, shares (in shares)", "periodStartLabel": "Outstanding, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-performance-stock-units-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-restricted-stock-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r396", "r397" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "periodEndLabel": "Outstanding, weighted average grant date fair value (in dollars per share)", "periodStartLabel": "Outstanding, weighted average grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-performance-stock-units-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-restricted-stock-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "negatedLabel": "Vested, shares (in shares)", "negatedTerseLabel": "Vested, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-performance-stock-units-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-restricted-stock-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r403" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Vested, weighted average grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-performance-stock-units-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-restricted-stock-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r409" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected stock price volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r411" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r624" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r403" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Exercised, Aggregate Intrinsic Value", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-stock-options-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "negatedLabel": "Forfeited and canceled, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-stock-options-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r392" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Granted, shares (in shares)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-stock-options-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Granted, Weighted Average Exercise Price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-stock-options-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r106" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Outstanding, Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-stock-options-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r388", "r389" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "periodEndLabel": "Outstanding, shares (in shares)", "periodStartLabel": "Outstanding, shares (in shares)", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-stock-options-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r388", "r389" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodStartLabel": "Outstanding, Weighted Average Exercise (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-stock-options-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r404" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested and expected to vest, Aggregate Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-stock-options-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested and expected to vest, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-stock-options-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested and expected to vest, Weighted Average Exercise Price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-stock-options-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r384", "r385", "r386", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r408", "r409", "r410", "r411", "r412" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-stockholders-equity", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-performance-stock-units-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-restricted-stock-activity-details" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Exercised, Weighted Average Exercise Price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-stock-options-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Forfeited and canceled, Weighted Average Exercise Price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-stock-options-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r387", "r406", "r407", "r408", "r409", "r412", "r421", "r422" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r623" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r408" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r106" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Vested, Aggregate Intrinsic Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-stock-options-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r106" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Vested, Weighted Average Remaining Contractual Term (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-stock-options-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of non-vested options outstanding.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "periodEndLabel": "Outstanding, Weighted Average Exercise Price (in dollars per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-stock-options-details" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Outstanding, Weighted Average Remaining Contractual Term (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-stock-options-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested and expected to vest, Weighted Average Remaining Contractual Term (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-stock-options-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Vested, shares (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-stock-options-details" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Vested, Weighted Average Exercise Price (in dollars per share)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-stock-options-details" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "us-gaap_SharesOutstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation", "negatedLabel": "Retirement of common stock for minimum tax withholdings (in shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r525", "r625" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-lease-expense-and-other-information-details": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term lease expense" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-lease-expense-and-other-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r59", "r215" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r24", "r93", "r179", "r206", "r207", "r208", "r221", "r222", "r223", "r225", "r233", "r235", "r250", "r291", "r351", "r418", "r419", "r420", "r444", "r445", "r479", "r503", "r504", "r505", "r506", "r507", "r509", "r538", "r566", "r567", "r568" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets", "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss", "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-stockholders-equity", "http://www.anikatherapeutics.com/20221231/role/statement-note-1-nature-of-business", "http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities", "http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement", "http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-12-commitments-and-contingencies", "http://www.anikatherapeutics.com/20221231/role/statement-note-12-commitments-and-contingencies-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-disaggregated-revenues-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-net-tangible-longlived-assets-by-principal-geographic-areas-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-total-revenue-by-geographic-location-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-performance-stock-units-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-restricted-stock-activity-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-stock-options-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-total-stockbased-compensation-expense-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-15-employee-benefit-plan-", "http://www.anikatherapeutics.com/20221231/role/statement-note-15-employee-benefit-plan-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-components-of-income-before-taxes-and-provision-for-benefit-from-income-taxes-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-reconciliation-between-us-federal-statutory-rate-and-effective-rate-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-17-earnings-per-share-eps", "http://www.anikatherapeutics.com/20221231/role/statement-note-17-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-17-earnings-per-share-eps-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-17-earnings-per-share-eps-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-property-and-equipment-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-consideration-transferred-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-intangible-assets-acquired-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-pro-forma-information-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-contingent-consideration-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-5-inventories", "http://www.anikatherapeutics.com/20221231/role/statement-note-5-inventories-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-5-inventories-summary-of-inventories-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-5-inventories-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-", "http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-property-and-equipment-at-cost-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-summary-of-intangible-assets-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill", "http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill-changes-in-the-carrying-value-of-goodwill-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases", "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-future-minimum-rental-payments-for-leases-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-lease-expense-and-other-information-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-tables", "http://www.anikatherapeutics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r221", "r222", "r223", "r250", "r545" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets", "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets-parentheticals", "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows", "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss", "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-stockholders-equity", "http://www.anikatherapeutics.com/20221231/role/statement-note-1-nature-of-business", "http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities", "http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities-summary-of-accrued-expenses-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement", "http://www.anikatherapeutics.com/20221231/role/statement-note-11-revolving-credit-agreement-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-12-commitments-and-contingencies", "http://www.anikatherapeutics.com/20221231/role/statement-note-12-commitments-and-contingencies-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-disaggregated-revenues-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-net-tangible-longlived-assets-by-principal-geographic-areas-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-total-revenue-by-geographic-location-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-assumptions-used-to-estimate-fair-value-of-stock-options-and-stock-appreciation-rights-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-performance-stock-units-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-restricted-stock-activity-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-stock-options-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-total-stockbased-compensation-expense-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-15-employee-benefit-plan-", "http://www.anikatherapeutics.com/20221231/role/statement-note-15-employee-benefit-plan-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-components-of-income-before-taxes-and-provision-for-benefit-from-income-taxes-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-reconciliation-between-us-federal-statutory-rate-and-effective-rate-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-significant-components-of-companys-deferred-tax-assets-and-liabilities-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-17-earnings-per-share-eps", "http://www.anikatherapeutics.com/20221231/role/statement-note-17-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-17-earnings-per-share-eps-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-17-earnings-per-share-eps-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-allowance-for-doubtful-accounts-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-estimated-useful-lives-of-property-and-equipment-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-consideration-transferred-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-fair-value-of-net-assets-acquired-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-intangible-assets-acquired-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-pro-forma-information-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-contingent-consideration-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-fair-value-of-financial-instruments-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-5-inventories", "http://www.anikatherapeutics.com/20221231/role/statement-note-5-inventories-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-5-inventories-summary-of-inventories-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-5-inventories-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-", "http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-property-and-equipment-at-cost-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-summary-of-intangible-assets-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill", "http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill-changes-in-the-carrying-value-of-goodwill-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases", "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-future-minimum-rental-payments-for-leases-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-lease-expense-and-other-information-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-tables", "http://www.anikatherapeutics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": { "auth_ref": [ "r5", "r6", "r93", "r94" ], "lang": { "en-us": { "role": { "documentation": "Number of shares related to Restricted Stock Award forfeited during the period.", "label": "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "negatedLabel": "Forfeiture of restricted stock awards (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r5", "r6", "r93", "r94" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Vesting of restricted stock units (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r5", "r6", "r93", "r94" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Issuance of common stock for equity awards (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r5", "r6", "r93", "r94", "r393" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised", "negatedLabel": "Exercised, shares (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-stock-options-details" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r5", "r6", "r93", "r94" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Issuance of common stock from employee purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": { "auth_ref": [ "r5", "r6", "r93", "r94" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period.", "label": "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures", "negatedLabel": "Forfeiture of restricted stock awards" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r93", "r94" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Vesting of restricted stock units" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r5", "r6", "r94", "r101" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Issuance of common stock for equity awards" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r5", "r6", "r93", "r94" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "us-gaap_StockRepurchasedDuringPeriodShares", "negatedLabel": "Repurchase of common stock (in shares)" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r5", "r6", "r93", "r94" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "us-gaap_StockRepurchasedDuringPeriodValue", "negatedLabel": "Repurchase of common stock" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r6", "r9", "r10", "r69", "r626", "r647", "r655", "r715" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "us-gaap_StockholdersEquity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets", "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-stockholders-equity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-balance-sheets" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "stringItemType" }, "us-gaap_TableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "localname": "TableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-10-accrued-expenses-and-other-liabilities-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-13-revenue-and-geographic-information-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-14-equity-incentive-plan-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-17-earnings-per-share-eps-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-2-summary-of-significant-accounting-policies-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-4-fair-value-measurements-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-5-inventories-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-6-property-and-equipment-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-8-goodwill-tables", "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-tables" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r115" ], "lang": { "en-us": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r115" ], "lang": { "en-us": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward, Name [Domain]" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes", "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-details-textual", "http://www.anikatherapeutics.com/20221231/role/statement-note-3-business-combinations-intangible-assets-acquired-details", "http://www.anikatherapeutics.com/20221231/role/statement-note-7-acquired-intangible-assets-net-summary-of-intangible-assets-details" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r177", "r178", "r179", "r180", "r181", "r224", "r225", "r226", "r227", "r236", "r283", "r284", "r288", "r289", "r290", "r291", "r292", "r293", "r418", "r419", "r420", "r442", "r443", "r444", "r445", "r461", "r462", "r463", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r511", "r512", "r514", "r515", "r516", "r517", "r533", "r534", "r535", "r536", "r537", "r538", "r547", "r548", "r549", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Accounting Standards Update [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-cash-flows" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r423", "r432" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "us-gaap_UnrecognizedTaxBenefits", "terseLabel": "Unrecognized Tax Benefits, Ending Balance" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r63", "r64", "r65", "r252", "r253", "r255", "r256" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r436" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount", "terseLabel": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-16-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r526", "r625" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-lease-expense-and-other-information-details": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable lease expense" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-9-leases-lease-expense-and-other-information-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r652" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-17-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details": { "order": 0.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Share based awards (in shares)" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-note-17-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r238", "r243" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-17-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Diluted (in shares)", "totalLabel": "Diluted shares used in the calculation of EPS (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss", "http://www.anikatherapeutics.com/20221231/role/statement-note-17-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r237", "r243" ], "calculation": { "http://www.anikatherapeutics.com/20221231/role/statement-note-17-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.anikatherapeutics.com/20221231/role/statement-consolidated-statements-of-operations-and-comprehensive-income-loss", "http://www.anikatherapeutics.com/20221231/role/statement-note-17-earnings-per-share-eps-basic-and-diluted-earnings-per-share-details" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5333-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org/topic&trid=2303972", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(16))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org/topic&trid=2175825", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r631": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r632": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r633": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r634": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r635": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r636": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r637": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r638": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r671": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "740", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126970579&loc=d3e23163-113944", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "https://asc.fasb.org/topic&trid=2144416", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(5)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org/topic&trid=2208564", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "710", "URI": "https://asc.fasb.org/topic&trid=2127225", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "https://asc.fasb.org/topic&trid=2197446", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "https://asc.fasb.org/topic&trid=2235017", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 103 0001171843-23-001729-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-23-001729-xbrl.zip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�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